Clinical trial NCT02718716
Conditions: Thrombocytopenia
Keywords: ITP
Sponsor: UCB Biopharma SRL
Start date: 2016-03-02; Completion date: 2019-02-04
Enrollment: 66 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia.

Detailed description:

Arms: arm 1: Participants in this arm received 5 subcutaneous (sc) doses of UCB7665 (rozanolixizumab) 4 milligram per kilograms (mg/kg) at 1-week intervals. arm 2: Participants in this arm received 3 sc doses of UCB7665 (rozanolixizumab) 7 mg/kg at 1-week intervals. arm 3: Participants in this arm received 2 sc doses of UCB7665 (rozanolixizumab) 10 mg/kg at 1-week intervals. arm 4: Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 15 mg/kg. arm 5: Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 20 mg/kg.
Interventions: intervention 1: UCB7665
Intervention descriptions: intervention 1: * Intervention Type: Biological/Vaccine
* Pharmaceutical Form: Powder for solution for infusion
* Concentration: 100 mg/ml - Route of Administration:

Subcutaneous infusion

Protocol documents:
Prot_000.pdf: 
UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 1 of 353
PROTOCOL TP0001 AMENDMENT 3
A MULTICENTER, OPEN-LABEL, MULTIPLE-DOSE STUDY TO 
EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF 
UCB7665 IN SUBJECTS WITH PRIMARY IMMUNE 
THROMBOCYTOPENIA
PHASE 2
EudraCT Number: 2015-003984-12
Sponsor:
UCB Biopharma SPRL
Allée de la Recherche 60
B-1070 Brussels
BELGIUM
Protocol/Amendment number
Date
Type of 
amendment
Final Protocol
09 Nov 2015
Not applicable
Protocol Amendment 1
19 May 2016
Substantial
Protocol Amendment 2 (not 
implemented)
21 Oct 2016
Substantial –
Not 
implemented
Protocol Amendment 3
15 Feb 2017
Substantial
Confidential Material
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
REDACTED COPY 
sels
PY
sels
GIUM
CO
GIUM
mber
RED
mber
DA
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ut
ut
aut
ket
ma
nt
o
nt 2
ort
2 (no
t a
(no
an
Amend
d to
Amend
o s
ed
me


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 2 of 353
STUDY CONTACT INFORMATION
Sponsor
UCB Biopharma SPRL
Allée de la Recherche 60
B-1070 Brussels
BELGIUM
Sponsor Study Physician
Name:
, MD
Address:
UCB BIOSCIENCES Inc.
8010 Arco Corporation Drive, Suite 175
Raleigh
NC 27617, USA
Phone:
Fax:
Clinical Project Manager
Name:
Address:
UCB BioSciences GmbH
Alfred-Nobel-Strasse 10
40789 Monheim
GERMANY
Phone:
Fax:
Clinical Trial Biostatistician
Name:
Address:
UCB BIOSCIENCES GmbH
Alfred-Nobel-Straße 10
40789 Monheim 
GERMANY
Phone:
Fax:
REDACTED COPY 
OP
TE
ences 
EDA
ences 
el
R
el-
R
-S
R
S
AC
y marketing authorization application and any extensions or variations thereof.
on
en
on
ica
ap
iza
GmbH
aut
GmbH
Strasse
ting
Strasse
heim
rke
heim
ANY
ma
ANY
th
ny y
ort 
rt
ed to supp
upp
iosta
d to s
iosta
e used
:
This document cannot be 
ed
ddress
t be
ddress
e
a
rt any
pport


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 3 of 353
Clinical Monitoring Contract Research Organization
Name:
PAREXEL International GmbH
Address:
Early Product Development
Spandauer Damm 130
D-14050 Berlin
GERMANY
Phone:
+49 (0) 30 30 685 0
Fax:
+49 (0) 30 30 685 7113
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
o
ion  o


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 4 of 353
SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax
Europe and Rest of the World: +32 2 386 65 61
Email
Global: safetyreportingUCB7665@ucb.com
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
io
or


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 5 of 353
TABLE OF CONTENTS
LIST OF ABBREVIATIONS..................................................................................................12
1
SUMMARY.....................................................................................................................15
2
INTRODUCTION ...........................................................................................................18
3
STUDY OBJECTIVE(S).................................................................................................20
3.1 Primary objective.............................................................................................................20
3.2 Secondary objectives .......................................................................................................20
3.3 Exploratory objectives .....................................................................................................20
4
STUDY VARIABLES.....................................................................................................21
4.1 Primary variable...............................................................................................................21
4.2 Others and exploratory variables .....................................................................................21
4.2.1
Safety variables....................................................................................................21
4.2.2
Efficacy variables ................................................................................................21
4.2.3
Pharmacokinetic variable.....................................................................................22
4.2.4
Pharmacodynamic variables ................................................................................23
4.2.5
Other immunological variables............................................................................23
5
STUDY DESIGN.............................................................................................................23
5.1 Study description .............................................................................................................23
5.1.1
Exploratory genomic analyses.............................................................................25
5.1.2
Study duration per subject ...................................................................................26
5.1.3
Planned number of subjects and sites ..................................................................26
5.1.4
Anticipated regions and countries .......................................................................26
5.2 Schedule of study assessments.........................................................................................26
5.3 Schematic diagram...........................................................................................................55
5.4 Rationale for study design and selection of dose.............................................................56
5.4.1
Pathophysiology of ITP .......................................................................................56
5.4.2
Mechanism of action of UCB7665......................................................................56
5.4.3
Choice of study design and endpoints .................................................................56
5.4.4
Safety of UCB7665..............................................................................................56
5.4.5
Rationale for dose selection.................................................................................57
5.4.6
Justification for additional genomic analyses......................................................58
6
SELECTION AND WITHDRAWAL OF SUBJECTS...................................................58
6.1 Inclusion criteria ..............................................................................................................58
6.2 Exclusion criteria .............................................................................................................60
6.2.1
Exclusion criteria related to health status ............................................................60
6.2.2
Exclusion criteria related to medical history .......................................................61
6.2.3
Exclusion criteria related to concomitant medications/procedures .....................62
6.3 Rescreening......................................................................................................................64
REDACTED COPY 
..
Y
..
......
OP
......
.......
D C
.......
......
TE
......
......
AC
......
cts and
REDA
cts and
cou
R
cou
ment cannot be used to support any marketing authorization application and any extensions or variations thereof.
0
v
0
...20
or v
...20
...
on
........2
ons 
.....2
..........
nsio
..........
..........
exte
..........
.......
ny
.......
..........
d a
..........
.......
n a
.......
........
atio
........
....
pli
........
plic
....
.......
ap
.......
........
tio
........
.......
iz
.......
........
tho
........
d sites
g au
d sites
untries
eting
untries
........
ark
........
.......
m
.......
gn and 
t any
gn and 
ogy
port
ogy of 
ort 
of 
y
ort
y
m of ac
upp
m of ac
e of stu
to s
e of stu
fety
sed
fety of 
ed 
of 
y
ed
y
Ration
e us
Ration
Jus
be
Jus
SEL
nno
SELEC
no
EC
This documen
1
t
1 In
ca
Inc
a
c
6.2
men
6.2


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 6 of 353
6.4 Withdrawal criteria ..........................................................................................................64
6.4.1
Potential drug induced liver injury IMP discontinuation criteria ........................65
6.5 Study stopping rules.........................................................................................................66
7
STUDY TREATMENT...................................................................................................66
7.1 Description of investigational medicinal product............................................................66
7.2 Treatment to be administered...........................................................................................67
7.3 Packaging.........................................................................................................................67
7.4 Labeling ...........................................................................................................................67
7.5 Handling and storage requirements..................................................................................67
7.6 Drug accountability..........................................................................................................68
7.7 Procedures for monitoring subject compliance................................................................68
7.8 Concomitant medication/treatment..................................................................................68
7.8.1
Permitted immunosuppressant medications ........................................................68
7.8.2
Prohibited concomitant treatments (medications and therapies).........................69
7.8.3
Rescue medication...............................................................................................70
7.9 Blinding............................................................................................................................70
7.10 Randomization and numbering of subjects......................................................................70
8
STUDY PROCEDURES BY VISIT ...............................................................................70
8.1 Screening Period ..............................................................................................................71
8.1.1
Visit 1 (Day -28 to -1) Screening Visit (all Dose Arms).....................................71
8.2 Dosing Period for all Dose Arms.....................................................................................72
8.2.1
Visit 2 (Week 1/Day 1) Baseline Visit ................................................................72
8.2.2
Visit 3 (Week 1/Day 4) [UCB7665 4mg/kg, UCB7665 7mg/kg, and UCB7665 
10mg/kg]..............................................................................................................74
8.2.3
Visit 4 (Week 2/Day 8) [UCB7665 4mg/kg, UCB7665 7mg/kg and UCB7665 
10mg/kg]..............................................................................................................74
8.2.4
Visit 5 (Week 3/Day 15) [UCB7665 4mg/kg and UCB7665 7mg/kg] ...............76
8.2.5
Visit 6 for Dose Arm 1 (Week 4/Day 22) [UCB7665 4mg/kg only] ..................77
8.2.6
Visit 7 for Dose Arm 1 (Week 5/Day 29) [UCB7665 4mg/kg only] ..................78
8.3 Telephone Contacts..........................................................................................................79
8.3.1
Telephone Contact 1 (Week 1/Day 2) [UCB7665 10mg/kg, UCB7665 15mg/kg, 
UCB7665 20mg/kg].............................................................................................79
8.3.2
Telephone Contact 2 (Week 1/Day 3) [UCB7665 10mg/kg, UCB7665 15mg/kg, 
UCB7665 20mg/kg].............................................................................................79
8.3.3
Telephone Contact 3 (Week 2/Day 9) [UCB7665 10mg/kg only]......................80
8.3.4
Telephone Contact 4 (Week 2/Day 10) [UCB7665 10mg/kg only]....................80
8.4 Observation Period...........................................................................................................80
8.4.1
Visit 8 (Week 5/Day 32) [UCB7665 4mg/kg]/ 
Visit 6 (Week 3/Day 18) [UCB7665 7mg/kg]/ Visit 5 (Week 2/Day 11) 
REDACTED COPY 
......
PY
......
.........
COP
.........
......
ED
......
ing Vi
ACTE
ing Vi
.......
ED
.......
Base
RE
Base
ed to support any marketing authorization application and any extensions or variations thereof.
.67
r v
.67
.......67
ns o
.......67
..
s
..........
sion
........
..........
xten
..........
......
y e
..........
ex
....
......
d a
...........
any
.....
rapies)
and
rapies)
.......
tio
.......
........
ica
........
........
app
........
..........
on a
..........
........
za
........
isit (all
horiz
isit (all
........
au
........
eline V
ting 
eline V
UCB76
rketi
UCB76
........
ma
........
ay
ny
ay 8) [U
ny m
8) [U
y
ny
y
........
t a
........
ek 3/Da
ppor
ek 3/Da
or Dose
sup
or Dose
7 for D
d to 
7 for D
This document cannot be us
e Cont
used
e Cont
Telep
be u
Telep
UC
b
UC
3.2
an
3.2
8.3
en
8.3


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 7 of 353
[UCB7665 10mg/kg] Visit 3 (Week 1/Day 4) [UCB7665 15mg/kg and 
UCB7665 20mg/kg].............................................................................................80
8.4.2
Visit 9 (Week 6/Day 36) [UCB7665 4mg/kg ]/ 
Visit 7 (Week 4/Day 22) [UCB7665 7mg/kg]/ 
Visit 6 (Week 3/Day 15) [UCB7665 10mg/kg] Visit 4 (Week 2/Day
8) [UCB7665 15mg/kg and UCB7665 20mg/kg]................................................81
8.4.3
Visit 10 (Week 7/Day 43) [UCB7665 4mg/kg]/ 
Visit 8 (Week 5/Day 29) [UCB7665 7mg/kg]/ 
Visit 7 (Week 4/Day 22) [UCB7665 10mg/kg] Visit 5 (Week 3/Day
15) [UCB7665 15mg/kg and UCB7665 20mg/kg]..............................................82
8.4.4
Visit 11 (Week 8/Day 50) [UCB7665 4mg/kg]/ 
Visit 9 (Week 6/Day 36) [UCB7665 7mg/kg]/ 
Visit 8 (Week 5/Day 29) [UCB7665 10mg/kg] Visit 6 (Week 4/Day
22) [UCB7665 15mg/kg and UCB7665 20mg/kg]..............................................83
8.4.5
Visit 12 (Week 9/Day 57) [UCB7665 4mg/kg]/ 
Visit 10 (Week 7/Day 43) [UCB7665 7mg/kg]/ 
Visit 9 (Week 6/Day 36) [UCB7665 10mg/kg] Visit 7 (Week 5/Day
29) [UCB7665 15mg/kg and UCB7665 20mg/kg]..............................................84
8.4.6
Visit 13 (Week 10/Day 64) [UCB7665 4mg/kg]/ 
Visit 11 (Week 8/Day 50) [UCB7665 7mg/kg]/ 
Visit 10 (Week 7/Day 43) [UCB7665 10mg/kg] Visit 8 (Week 6/Day
36) [UCB7665 15mg/kg and UCB7665 20mg/kg]..............................................85
8.4.7
Visit 14 (Week 11/Day 71) [UCB7665 4mg/kg]/ 
Visit 12 (Week 9/Day 57) [UCB7665 7mg/kg]/ 
Visit 11 (Week 8/Day 50) [UCB7665 10mg/kg] Visit 9 (Week 7/Day
43) [UCB7665 15mg/kg and UCB7665 20mg/kg]..............................................86
8.4.8
End-of-Study Visit: Visit 15 (Week 13/Day 85) [UCB7665 4mg/kg]/ 
Visit 13 (Week 11/Day 71) [UCB7665 7mg/kg]/ 
Visit 12 (Week 10/Day 64) [UCB7665 10mg/kg] Visit 10 (Week 9/Day
57) [UCB7665 15mg/kg and UCB7665 20mg/kg]..............................................87
8.5 Early Withdrawal Visit ....................................................................................................88
8.6 Unscheduled Visit............................................................................................................88
9
ASSESSMENT OF EFFICACY......................................................................................88
9.1 Platelet counts ..................................................................................................................88
9.2 ITP bleeding score ...........................................................................................................90
9.3 Patient reported outcomes................................................................................................90
9.3.1
NFI-MS................................................................................................................90
9.4 Subject exit interview ......................................................................................................91
10
ASSESSMENT OF PHARMACOKINETIC/ PHARMACODYNAMIC VARIABLES91
10.1 Pharmacokinetic variables ...............................................................................................91
10.2 Pharmacodynamic variables ............................................................................................91
11
ASSESSMENT OF OTHER IMMUNOLOGICAL VARIABLES.................................91
REDACTED COPY
mg/k
PY 
mg/k
7mg/k
OPY
7mg/k
65
D
65 10m
CO
10m
B7665
TED 
B7665
UCB76
ACT
UCB76
[UCB
EDA
[UCB
0)
R
0) [UC
RED
[UC
R
d to support any marketing authorization application and any extensions or variations thereof.
.....82
s or
.....82
ay
ex
ay
........
ny
........
(Wee
tion a
(Wee
.......
cat
.......
]/ 
p
]/ 
kg]/ 
n a
kg]/ 
mg/kg] 
tion 
mg/kg] 
5
i
5 20mg
izati
20mg
665 4m
thori
665 4m
B7665
auth
B7665 7
h
7
CB766
ng a
CB766
nd UCB
keting
nd UCB
sit
a
sit 15
ark
15 (
Day
y m
Day 71)
y ma
71)
y
y m
y
0/Day
any
0/Day
15mg
ort a
15mg
Visit
uppo
Visit
isit
o s
isit..
s
..
This document cannot be used
ENT O
ed t
ENT O
counts
use
counts
bleedin
t be
bleedin
Patient 
nno
Patient 
9.3.1
t can
9.3.1
9.4
ent
9.4 S
10
m
10


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 8 of 353
12
ASSESSMENT OF SAFETY..........................................................................................92
12.1 Adverse events.................................................................................................................92
12.1.1
Definition of adverse event..................................................................................92
12.1.2
Procedures for reporting and recording adverse events.......................................93
12.1.3
Description of adverse events..............................................................................93
12.1.4
Follow up of adverse events ................................................................................93
12.1.5
Rule for repetition of an adverse event................................................................93
12.1.6
Pregnancy ............................................................................................................94
12.1.7
Suspected transmission of an infectious agent via a medicinal product..............95
12.1.8
Overdose of investigational medicinal product ...................................................95
12.1.9
Safety signal detection.........................................................................................95
12.1.10
Hypersensitivity and adverse reactions ...............................................................95
12.1.11
Management of severe headache.........................................................................96
12.1.12
Management of moderate or severe diarrhea.......................................................96
12.2 Serious adverse events .....................................................................................................96
12.2.1
Definition of serious adverse event .....................................................................96
12.2.2
Procedures for reporting serious adverse events .................................................97
12.2.3
Follow up of serious adverse events....................................................................98
12.3 Adverse events of special interest....................................................................................98
12.4 Adverse events of interest................................................................................................98
12.5 Immediate reporting of adverse events............................................................................99
12.6 Anticipated serious adverse events ..................................................................................99
12.7 Laboratory measurements................................................................................................99
12.7.1
Evaluation of PDILI ..........................................................................................101
12.7.1.1
Consultation with Medical Monitor and local hepatologist ....................104
12.7.1.2
Immediate action: determination of IMP discontinuation.......................104
12.7.1.3
Testing: identification/exclusion of alternative etiology.........................105
12.7.1.4
Follow-up evaluation...............................................................................106
12.8 Other safety measurements............................................................................................106
12.8.1
Assessment and management of TB and TB risk factors..................................106
12.8.1.1
TB Tests at Screening..............................................................................107
12.8.1.2
Monitoring for TB during the study........................................................107
12.8.1.3
TB tests at Final /End of Study Visit.......................................................107
12.8.1.4
Signs and symptoms of Tuberculosis......................................................107
12.8.2
Pregnancy testing...............................................................................................108
12.8.3
Vital signs ..........................................................................................................108
12.8.4
Body weight and height.....................................................................................109
12.8.5
Physical examination.........................................................................................109
REDACTED COPY
even
PY 
even
......
CO
......
.........
ED C
.........
......
CT
......
ents..
EDA
ents..
nts
RE
nts
sed to support any marketing authorization application and any extensions or variations thereof.
.94
r v
.94
.......95
ns o
.......95
..........
sion
..........
..........
xten
..........
..........
y ex
..........
.......
d a
.......
...........
and
...........
...
tio
.......
o
....
........
ica
........
ts .......
appl
ts .......
.......
on
.......
...........
izatio
...........
....
ho
.......
o
...
..........
auth
..........
........
ing
........
.......
ke
.......
........
ma
........
n with 
any 
n with 
ate acti
ort a
ate acti
ing: ide
uppo
ing: ide
ollow
o su
ollow
y
e
y meas
ed t
meas
y
e
y
This document cannot be u
Assessm
use
Assessm
8.1.1
t be 
8.1.1
12.8.1
nnot
12.8.1
12.
an
12.


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 9 of 353
12.8.6
12-Lead ECG.....................................................................................................110
13
STUDY MANAGEMENT AND ADMINISTRATION...............................................110
13.1 Adherence to protocol....................................................................................................110
13.2 Monitoring .....................................................................................................................110
13.2.1
Definition of source data ...................................................................................111
13.2.2
Source data verification .....................................................................................111
13.3 Data handling.................................................................................................................111
13.3.1
Case Report form completion............................................................................111
13.3.2
Database entry and reconciliation......................................................................112
13.3.3
Subject Screening and Enrollment log/Subject Identification Code list............112
13.4 Termination of the study................................................................................................112
13.5 Archiving and data retention..........................................................................................112
13.6 Audit and inspection ......................................................................................................113
13.7 Good Clinical Practice ...................................................................................................113
14
STATISTICS .................................................................................................................113
14.1 Definition of analysis sets..............................................................................................113
14.2 General statistical considerations...................................................................................114
14.3 Planned safety analyses..................................................................................................114
14.3.1
Analysis of the primary safety variable.............................................................114
14.3.2
Other safety analyses .........................................................................................115
14.4 Planned efficacy and other analyses ..............................................................................115
14.4.1
Efficacy analyses ...............................................................................................115
14.4.2
Pharmacokinetic analyses..................................................................................116
14.4.3
Pharmacodynamic analyses...............................................................................116
14.4.4
Immunologic variables ......................................................................................117
14.4.5
Other analyses....................................................................................................117
14.4.5.1
Subject disposition ..................................................................................117
14.4.5.2
Subject characteristics .............................................................................117
14.4.5.3
Baseline disease characteristics...............................................................117
14.4.5.4
Subject exit interview..............................................................................117
14.5 Handling of protocol deviations.....................................................................................117
14.6 Handling of dropouts or missing data............................................................................118
14.7 Planned interim analysis and data monitoring...............................................................118
14.8 Determination of sample size.........................................................................................119
15
ETHICS AND REGULATORY REQUIREMENTS....................................................120
15.1 Informed consent ...........................................................................................................120
15.2 Subject identification cards............................................................................................120
15.3 Institutional Review Boards and Independent Ethics Committees................................120
REDACTED COPY 
......
PY
......
......
CO
......
riable
ED C
riable
......
CT
......
s
ED
s ....
ED
....
....
R
....
be used to support any marketing authorization application and any extensions or variations thereof.
111
r v
111
.....112
ns o
.....112
...........
nsion
...........
..........
xten
..........
..........
y ex
..........
.......
d a
.......
........
an
........
.......
tio
.......
........
ica
........
........
app
........
.......
on
.......
........
za
........
.......
ho
.......
........
au
........
........
ing
........
s......
ke
......
al
m
alyses
ma
yses
ables
any 
ables
........
ort
........
ect disp
uppo
ect disp
Subject 
to su
Subject 
Base
ed to
Base
4
S
e
S
ent cannot b
dling o
t be 
dling o
Handlin
nnot
Handlin
7
c
7 Plan
can
Plan
This documen
14.8
ent
14.8 D
15
m
15


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 10 of 353
15.4 Subject privacy...............................................................................................................121
15.5 Protocol amendments.....................................................................................................122
16
FINANCE, INSURANCE, AND PUBLICATION.......................................................122
17
REFERENCES ..............................................................................................................122
18
APPENDICES ...............................................................................................................124
18.1 Karnofsky Performance Status Scale.............................................................................124
18.2 ITP – Bleeding Assessment Tool (ITP-BAT)................................................................125
18.3 Neurological Fatigue Index for Multiple Sclerosis (NFI-MS) ......................................135
18.4 Suggested management guidelines for infusion reactions.............................................137
18.5 Diagnosis of anaphylactic reactions...............................................................................138
18.6 Headache Questionnaire ................................................................................................139
18.7 Protocol Amendment 1 ..................................................................................................143
18.8 Protocol Amendment 2 (not implemented)....................................................................185
18.9 Protocol Amendment 3 ..................................................................................................247
19
DECLARATION AND SIGNATURE OF INVESTIGATOR .....................................352
20
SPONSOR DECLARATION ........................................................................................353
LIST OF TABLES
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm 
(Dose Arm 1) ...................................................................................................27
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm 
(Dose Arm 2) ...................................................................................................33
Table 5-3:
Schedule of assessments for the UCB7665 10mg/kg once weekly dose 
arm (Dose Arm 3)............................................................................................38
Table 5-4:
Schedule of assessments for the UCB7665 15mg/kg once dose arm (Dose 
Arm 4)..............................................................................................................43
Table 5-5:
Schedule of assessments for the UCB7665 20mg/kg once dose arm (Dose 
Arm 5)..............................................................................................................48
Table 5‒6:
Schedule of investigations on the dosing days ................................................53
Table 6‒1:
Washout periods for immunosuppressants, biologics and other therapies ......63
Table 7‒1:
Permitted immunosuppressant medications.....................................................69
Table 12‒1: Anticipated serious adverse events for ITP population.......................................99
Table 12‒2: Laboratory measurements..................................................................................100
Table 12-3: Required investigations and follow up for PDILI..............................................102
Table 12-4:
PDILI laboratory measurements....................................................................105
Table 12-5: PDILI information to be collected......................................................................106
REDACTED COPY 
TA
D CO
TAB
CO
B
the UC
CTE
the UC
......
DAC
......
nts for
RED
nts for
not be used to support any marketing authorization application and any extensions or variations thereof.
135
r v
135
.....137
ns o
.....137
..........
sion
..........
..........
xten
..........
........
y e
........
.......
d a
.......
........
an
........
R .........
tion 
R .........
........
ica
........
BLES
tion
BLES
CB766
horiza
CB766
....
uth
.......
th
...
or the U
ng a
or the U
........
eti
........
ments fo
mark
ments fo
3)
n
3)......
y
......
assessm
rt an
assessm
.......
po
.......
ule of 
sup
ule of 
m
d
m 5)...
d to 
5)...
Sched
use
Sched
:
t
:
W
e
W
This document canno
7
n
7‒1:
anno
‒1:
able
nt ca
able 12
a
12
Tab
me
Tab


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 11 of 353
Table 18‒1: Karnofsky Performance Status Scale Definitions Rating (%) Criteria..............124
Table 18‒2: ITP-Bleeding Assessment Tool.........................................................................125
Table 18‒3: Reporting of bleeding after hemostatic challenges or surgery°.........................134
Table 18‒4: NFI-MS..............................................................................................................135
Table 18‒5: Suggested management guidelines for infusion reactions.................................137
Table 18‒6: Headache Questionnaire ....................................................................................139
LIST OF FIGURES
Figure 5‒1:
Schematic diagram...........................................................................................55
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
..........
tens
..........


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 12 of 353
LIST OF ABBREVIATIONS
ADA
anti-drug antibodies 
ADL
activities of daily living
AE
adverse event
ALP
alkaline phosphatase
ALT
alanine aminotransferase
AST
aspartate aminotransferase
AUEC
area under the effect curve
BAFF
B cell activating factor
BP
blood pressure
CDMS
clinical data management system
CHMP
Committee for Medicinal Products for Human Use
CPM
Clinical Project Manager
CPMP
Committee for Proprietary Medicinal Products
CRO
contract research organization
CSF
cerebrospinal fluid 
CT
computed tomography
CTCAE
Common Terminology Criteria for Adverse Events
DCP
Data Cleaning Plan
DNA
deoxyribonucleic acid
DMC
Data Monitoring Committee
ECG
electrocardiogram
EDC
electronic data capture
EMA
European Medicines Agency
eCRF
electronic Case Report form
ES
Enrolled Set
EOS
End of Study
FAS
Full Analysis Set
FcRn
neonatal Fc receptor for IgG
GCP
Good Clinical Practice
GMP
Good Manufacturing Practice
REDACTED COPY 
dici
Y
dici
ion
COP
ion
aph
AC
aphy
ACT
y
minolo
REDA
minolo
P
R
P
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
n Use
an
n Use
l Produ
pplic
l Produ
ogy
g a
ogy Cri
au
Cri
y
a
y
Plan
ketin
Plan
ucleic a
mark
ucleic a
onitori
ny m
onitori
ctrocard
ort a
ctrocard
electro
upp
electro
Eu
s
Eu
AS
t c
AS
FcRn
men
FcRn
G


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 13 of 353
HbA1c
glycosylated hemoglobin 
HIV
human immunodeficiency virus
HLA
human leukocyte antigen
ICH
International Council for Harmonisation
IEC
Independent Ethics Committee
Ig
immunoglobulin 
IGRA
interferon-gamma release assay
IMP
investigational medicinal product
INR
International Normalized Ratio
IRB
Institutional Review Board
ITP
immune thrombocytopenia 
ITP-BAT
ITP-specific Bleeding Assessment Tool
iv
intravenous
IVIg
intravenous immunoglobulin
IXRS
interactive voice/web response system
LTB
latent tuberculosis
LLOQ
lower limit of quantification
LP
lumbar puncture 
MCID
minimal clinically important difference
MedDRA
Medical Dictionary for Regulatory Activities
MHC
major histocompatibility complex
MRI
magnetic resonance imaging
mRNA
messenger ribonucleic acid
miRNA
micro ribonucleic acid
NFI-MS
Neurological Fatigue Index for Multiple Sclerosis
NTMBI
nontuberculosis myobacterial infection
NOAEL
no observed adverse effect level 
PD
pharmacodynamic(s)
PDILI
potential drug-induced liver injury
PD-PPS
Pharmacodynamic Per Protocol Set
PEF
peak expiratory flow
PK
pharmacokinetic(s)
REDACTED COPY 
nse s
COP
nse s
ntificat
ACTE
ntificat
re 
RE
re 
call
R
call
nt cannot be used to support any marketing authorization application and any extensions or variations thereof.
ystem
n ap
stem
tion
thori
tion
ly
eti
ly imp
eting
imp
y
eti
y
ctionary
mark
ctionary
istocom
ny m
istocom
gnetic
ort a
gnetic r
m
up
messe
upp
esse
m
s
mi
This documen
L
n
L
PDIL
men
PDIL
P
m
P


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 14 of 353
PK-PPS
Pharmacokinetic Per Protocol Set
PLEX
plasma exchange
PPS
Per Protocol Set
PRO
Patient Reported Outcome
PS
Patient Safety
PTT
partial thromboplastin time
QTc
corrected QT interval
RNA
ribonucleic acid
SAE
serious adverse event
SAP
Statistical Analysis Plan
sc
subcutaneous
SD
standard deviation
SMOG
skin (S), visible mucosae (M), and organs (O), with gradation of severity
SOP
Standard Operating Procedure
SS
Safety Set
TB
tuberculosis
TEAE
treatment-emergent adverse event
TPO-R
thrombopoietin-receptor
ULN
upper limit of normal 
REDACTED COPY 
and
Y
and
ure
COP
ure
rgent a
REDA
rgent a
n
R
n
R
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
rgans (O
pplic
rgans (O
adverse
aut
adverse
recepto
eting
recepto
of 
a
of norm
ark
norm


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 15 of 353
1
SUMMARY
Primary immune thrombocytopenia (ITP) is a disease which is characterized by an isolated low 
platelet count (thrombocytopenia) and the absence of other causes of thrombocytopenia. It is an 
autoimmune disease which is characterized by specific autoantibodies directed against platelets. 
There is no causal treatment. Treatment options include immunosuppressive therapy, 
immunoglobulin therapy, and splenectomy. There is an unmet medical need for new treatment 
options due to significant side effects, significant risks, and significant complexity of existing
therapy.
The neonatal major histocompatibility complex (MHC)-class-I-like neonatal Fc receptor for IgG 
(FcRn) binds immunoglobulin G (IgG), thereby preventing IgG from intracellular lysosomal 
degradation. UCB7665 is a humanized IgG4 monoclonal antibody that has been specifically 
designed to inhibit IgG binding to FcRn with the aim to reduce the concentration of pathogenic 
IgG in patients with IgG autoantibody mediated diseases, including ITP. Thereby, it represents a 
potential new mode of action to target the underlying pathomechanism of ITP and could enhance 
the still limited treatment options.
TP0001 is a Phase 2, multicenter, open-label, multiple-dose, multiple-arm study to evaluate the 
safety, tolerability, and efficacy of UCB7665 administered as subcutaneous (sc) doses of 
4mg/kg, 7mg/kg, 10mg/kg, 15mg/kg, and 20mg/kg (resulting in cumulative doses of 20mg/kg, 
21mg/kg, 20mg/kg, 15 mg/kg and 20mg/kg respectively), in subjects ≥18 years of age with 
persistent (>3 months up to 12 months after diagnosis) or chronic (more than 12 months after
diagnosis) primary ITP. 
The study is planned to be conducted at up to approximately 45 sites in Europe and Australia. A 
total of approximately 48 to 66 subjects (dependent on emerging safety data and corresponding 
DMC recommendation) are planned to enter the Dosing Period in the study. The maximum study
duration for study participation for an individual subject is approximately 16 weeks.
The study is intended to evaluate 5 dose arms of UCB7665. Subjects in Dose Arm 1 will receive 
5 doses of UCB7665 4mg/kg sc at 1 week intervals, subjects in Dose Arm 2 will receive 3 doses 
of UCB7665 7mg/kg sc at 1 week intervals, subjects in Dose Arm 3 will receive 2 doses of 
UCB7665 10mg/kg sc at 1 week intervals, Dose Arm 4 will receive 1 dose of UCB7665
15mg/kg sc and Dose Arm 5 will receive 1 dose of UCB7665 20mg/kg sc.
The study consists of a Screening Period (up to 4 weeks), Dosing Period of 1 day to 4 weeks
where dosing arms are introduced sequentially, and an Observation Period of 8 weeks. The 
Screening Visit corresponds to Visit 1 of the study. The Dosing Period will commence at Visit 2
(Baseline Visit), with dosing visits scheduled at weekly intervals for Dose Arms 1, 2 and 3 and
only one visit scheduled for Dose Arms 4 and 5. The Observation Period will start after the last
dose administration (or only dose administration for Dose Arms 4 and 5) with a visit scheduled 3 
days after the last dosing and weekly visits thereafter (ie, weekly after last or only dose) for a 
period of 8 weeks. The End-of-Study Visit will be performed at the end of the Observation 
Period, ie, 8 weeks after the last or only dose of investigational medicinal product (IMP).
The first 6 subjects will be enrolled in Dose Arm 1 only. While recruitment is ongoing, safety
data for the first 3 subjects up to 7 days after the last dose of the third subject will be reviewed by 
the Data Monitoring Committee (DMC). During a second DMC meeting, all available safety 
data up to cut off date defined as 7 days after the last dose of the sixth subject will be reviewed. 
REDACTED COPY 
ul
Y
ul
vely
OPY
vely),
PY
),
nosis)
COP
nosis)
p to 
ACT
p to ap
CTE
ap
s (depe
EDAC
s (depe
to ent
RED
to ent
in
R
in
support any marketing authorization application and any extensions or variations thereof.
for IgG
s or 
for IgG
osomal
ons 
osomal
pecifica
nsio
pecifica
n of pa
xten
n of pa
reb
y e
reby,
ex
y, i
ITP an
any
ITP an
ple
on
ple-
n
-arm
n a
arm
ubcutan
catio
ubcutan
g in
plic
g in cum
ica
cum
in subj
app
in subj
or chro
on a
or chro
pproxim
thori
pproxim
endent 
auth
endent 
ter the 
ng a
ter the 
ndividu
keting
ndividu
dose 
mark
dose a
at 1 w
ny m
at 1 w
week in
t any
week in
week
ort 
week
not be used to
Arm
upp
Arm 5 w
ppo
5 w
of a Sc
to s
of a Sc
ms are 
ed t
ms are 
sit corr
use
sit corr
Visit)
be u
Visit)
u
e visit 
ot b
e visit 
nt can
admin
ann
admin
ay
nt
ays
t c
s afte
ca
afte
This documen
period
ment
period
Pe
m
Pe


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 16 of 353
Following this review, the DMC will make a recommendation on whether to open Dose Arm 2 
for enrollment. Once the DMC has advocated the initiation of Dose Arm 2, the subsequent 
subjects for the first 2 arms will be randomly assigned in 1:1 ratio to either Dose Arm 1 or Dose 
Arm 2 using an interactive voice/web response system (IXRS). Once 15 subjects are enrolled in 
Dose Arm 1, the subsequently enrolled subjects will be enrolled in Dose Arm 2.
After the safety data review of at least 6 subjects in Dose Arm 2 is done, the DMC will make a 
recommendation on whether to open Dose Arm 3 for enrollment. Once the DMC has advocated
the initiation of Dose Arm 3 and the enrollment of 15 subjects into Dose Arm 2 has been 
completed, the subsequent subjects will be assigned to Dose Arm 3 only. After every third 
subject has been enrolled, DMC will review all available safety data up to cut off date defined as 
7 days after the last dose of the respective subject. Depending on the emerging safety data of 
6 subjects in Dose Arm 3, the DMC will recommend whether to open Dose Arm 4 for enrollment 
or to include additional subjects in Dose Arm 3. If applicable, this procedure is planned to be 
repeated stepwise in groups of 3 subjects. A maximum of 12 subjects are planned for Dose Arm 
3. The DMC will recommend to open Dose Arm 4 for enrollment in a subsequent DMC meeting, 
if applicable.
Once the DMC has advocated the initiation of Dose Arm 4, the enrollment of Dose Arm 3 will 
be closed and all subsequently enrolled subjects will be assigned to Dose Arm 4. After every
third subject that has been enrolled, DMC will review all available safety data up to cut off date 
defined as 7 days after the last dose of the respective subject. Depending on the emerging safety 
data of 6 subjects in Dose Arm 4, the DMC will recommend whether to open Dose Arm 5 for 
enrollment or to include additional subjects in Dose Arm 4. If applicable, this procedure is 
planned to be repeated stepwise in groups of 3 subjects. A maximum of 12 subjects are planned 
for Dose Arm 4. The DMC will recommend to open Dose Arm 5 for enrollment in a subsequent 
meeting, if applicable.
Once the DMC has advocated the initiation of Dose Arm 5, the enrollment of Dose Arm 4 will 
be closed and the subsequently enrolled subjects will be assigned to Dose Arm 5. After every
third subject is enrolled, the DMC will review all available safety data up to the cutoff date 
defined as 7 days after the dosing of the third subject in Dose Arm 4. Depending on the emerging 
safety data of 6 subjects in Dose Arm 5, the DMC will recommend to include additional subjects 
in Dose Arm 5. If applicable, this procedure is planned to be done stepwise in groups of 
3 subjects. A maximum of 12 subjects may be enrolled in Dose Arm 5.
The DMC may also decide to reduce the number of doses dose arms, to stop a dose arm or not to 
open a dose arm based on review of safety data during the study. Safety data will also be 
reviewed on an ongoing basis by clinical research organization (CRO) medical monitor and UCB 
physician during the study so as to continuously evaluate the safety of subjects.
The primary objective of the study is to evaluate the safety and tolerability of UCB7665 
administered by sc infusion in subjects with ITP. 
The secondary objective of the study is to assess the clinical efficacy of UCB7665 as measured 
by the change in platelet count and to assess the pharmacodynamic (PD) effect of UCB7665 as 
measured by the change in total IgG concentrations in serum. The exploratory objectives include 
the following:
to evaluate the clinical efficacy as measured by 
REDACTED COPY 
all a
Y
all a
ve subj
COPY
ve subj
recom
D CO
recom
n Dose
TED 
n Dose
of 3 su
ACTE
of 3 su
mend t
EDAC
mend t
nnot be used to support any marketing authorization application and any extensions or variations thereof.
defined
ns o
defined
y data o
sion
y data o
4 for en
ens
4 for en
 plann
exte
plann
lanned 
ny e
lanned 
ubseque
d any
ubseque
nrollme
tion 
nrollme
ed to D
licati
ed to D
ailable
pplic
ailable
ject
n a
ject. D
ap
. D
mmend
tion
mmend
e Arm 
rizat
e Arm 
ubjects
thori
ubjects
to open
auth
to open
iation o
keti
iation o
olled
mark
olled su
k
su
C will
y m
C will
sing of
t any
sing of
n Dose 
port 
n Dose 
cable, 
uppo
cable, 
um of 
o sup
um of 
also de
ed t
also de
arm
us
arm bas
use
bas
on an o
be u
on an o
an
o
an duri
ot b
duri
This document ca
e prima
can
e prima
admini
nt c
admini
Th
me
Th


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 17 of 353
the change in ITP bleeding score; to evaluate the effect of UCB7665 on the concentrations of 
total protein, albumin, α-globulin and β-globulin, IgG subclasses, IgM, IgA, and IgE, and serum
and plasma complement levels; to evaluate the emergence of anti-drug antibodies (ADA), ie, 
anti-UCB7665 antibodies with respect to immunogenicity and pharmacokinetics (PK)/PD; to 
evaluate the relationship between changes in platelet count and total IgG, IgG subclasses, 
ITP-specific autoantibodies; and to assess the plasma concentrations of UCB7665 administered 
by sc infusion.
The primary safety variable is the occurrence of treatment-emergent adverse events (TEAEs). 
Other safety variables are TEAEs leading to withdrawal of IMP, vital signs, 12-lead 
electrocardiogram (ECG), laboratory parameters (hematology including coagulation parameters, 
clinical chemistry, and urinalysis), and concentrations of total protein, albumin, α-globulin, and 
β-globulin in serum. 
Other safety assessments are evaluation of potential drug-induced liver injury (PDILI), using 
pre-specified criteria for managing any PDILI events in accordance with the Drug 
Administration (FDA) Guidance for Industry, Drug-Induced Liver Injury: Premarketing Clinical 
Evaluation (Jul 2009).
The following efficacy variables will be assessed: Response (platelet count ≥30x109/L and at 
least 2-fold increase of the Baseline count) during the study and by visit; Complete Response
(platelet count ≥100x109/L) during the study and by visit; platelet count ≥50x109/L during the 
study and by visit; the maximum value and maximum increase from Baseline in platelet count 
during the study; value and change from Baseline in platelet count over time; Baseline-corrected 
area under the effect curve (AUEC) for platelet count; time to Response (time from starting 
treatment to achievement of Response); time to Complete Response (time from starting treatment 
to achievement of Complete Response); time to achieving platelet count ≥50x109/L; duration of 
Response (measured from achievement of Response to loss of Response [defined as platelet 
count below 30x109/L or less than 2-fold increase of Baseline platelet count]); duration of 
Complete Response (measured from achievement of Complete Response to loss of Complete 
Response [defined as platelet count below 100x109/L]); duration of platelet count ≥50x109/L
(measured from achievement of platelet count ≥50x109/L to reduction of platelet count below 
50x109/L); Clinical Response (defined as platelet count ≥30x109/L and at least 2-fold increase 
from Baseline value and absence of bleeding); time to Clinical Response (time from starting 
treatment to achievement of Clinical Response); duration of Clinical Response (measured from 
achievement of Clinical Response to loss of Clinical Response [loss of Clinical Response 
defined as platelet count <30x109/L or less than 2-fold increase from Baseline platelet count or 
presence of bleeding]); Complete Clinical Response (defined as platelet count ≥100x109/L and 
absence of bleeding); time to Complete Clinical Response (time from starting treatment to 
achievement of Complete Clinical Response); duration of Complete Clinical Response 
(measured from achievement of Complete Clinical Response to loss of Complete Clinical 
Response [loss of Complete Clinical Response defined as platelet count <100x109/L or presence 
of bleeding]); no Clinical Response (defined as platelet count <30x109/L and less than 2-fold 
increase from Baseline or presence of bleeding); ITP bleeding score over time; and Patient 
Reported Outcome (PRO), ie, Neurological Fatigue Index for Multiple Sclerosis (NFI-MS) 
summary score over time. Plasma concentration of UCB7665 over time will be assessed as the 
PK variable. The PD variables are minimum value and maximum decrease in total IgG
concentration during the study; IgG subclass concentrations; and ITP-specific autoantibody 
REDACTED COPY 
Y
visit;
OPY
visit;
mum in
COP
mum in
ine in 
ED C
ine in 
elet co
CTED
elet co
me to
ACT
me to
);
RE
); tim
EDA
tim
ent o
RE
ent o
to support any marketing authorization application and any extensions or variations thereof.
). 
v
). 
aramete
ns o
aramete
obulin
sion
obulin
y
y
y (
y
(PDIL
ext
PDIL
he
an
he Dru
any 
Dru
ry: Pre
nd a
ry: Pre
atelet
atio
atelet c
o
c
nd b
lica
nd by v
ca
y v
platele
app
platele
ncrease
on a
ncrease
platele
atio
platele
ount;
oriza
ount; ti
a
ti
o C
th
o Comp
tho
omp
me to ac
g aut
me to ac
of Resp
ting 
of Resp
old inc
keti
old inc
m achie
mark
m achie
unt bel
ny m
unt bel
of plat
t any
of plat
nse (de
port 
nse (de
d absen
uppo
d absen
ment 
o sup
ment 
This document cannot be used 
o
up
o
linical 
d to
linical 
elet co
used
elet co
bleedin
be us
bleedin
of blee
ot be
of blee
vement
nno
vement
easured
t can
easured
Respon
ent c
Respon
of b
me
of b
i


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 18 of 353
in serum over time. Other immunological variables to be 
evaluated are total IgA, IgE, and IgM levels; serum (C3 and C4) and plasma (C3a and C5a)
complement levels; ADA status (negative/positive) and relative mass units; exploratory safety
biomarkers
and B cell activating 
factor (BAFF) levels; B and T lymphocytes; and cytokines (for subjects experiencing infusion
reactions).
During this study, subjects will also have the option of providing additional informed consent for 
exploratory deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) (ie, messenger RNA 
[mRNA] and micro RNA [miRNA]) analyses. Participation in this additional portion of the study
is optional and does not preclude subject’s eligibility for participation in the main study. The 
additional genomic samples must not be collected if the subject has not consented to participate 
in this exploratory genomic substudy.
Prior to this amendment, a protocol amendment 2 with a dose arm 4mg/kg twice weekly was 
planned, however the corresponding protocol amendment 2 was not implemented. These changes 
are highlighted in Section 18.8.
2
INTRODUCTION
The neonatal MHC-class-I-like FcRn recycles immunoglobulin and albumin from most cells and 
transports it bi-directionally across epithelial barriers to affect systemic and mucosal immunity. 
It was shown that FcRn rescues both IgG and albumin from intracellular lysosomal degradation 
by recycling it from the sorting endosome to the cell surface (Anderson et al, 2006). With respect 
to IgG, this is achieved by interaction of IgG with the receptor, FcRn. Thus, in effect FcRn 
salvages IgG, saving it from degradation and returning it to circulation. Albumin is similarly
recycled by FcRn, though via a different binding site on the FcRn molecule. It has been shown 
that knockout or blockade of FcRn removes this recycling resulting in endosomal catabolism of 
IgG and a marked reduction of IgG concentrations in both the vascular and extravascular (tissue) 
compartments. In effect, blockade of FcRn accelerates removal of endogenous IgG and, if the 
albumin binding site is also blocked, potentially of albumin. 
Immune thrombocytopenia is a clinical disorder in which thrombocytopenia manifests as a 
bleeding tendency, purpura, or petechiae. Autoantibodies against platelet antigens are considered 
to be a hallmark of ITP. Production of pathogenic IgG autoantibodies by plasma cells is accepted 
as the central underlying pathophysiological mechanism in a number of IgG-mediated 
autoimmune diseases, which includes ITP. In some patients, antibodies recognize antigens 
derived from a single glycoprotein, whereas in others, antibodies recognize multiple 
glycoproteins. The spleen is the key organ in the pathophysiology of ITP, not only because 
platelet autoantibodies are formed in the white pulp, but also because mononuclear macrophages 
in the red pulp destroy immunoglobulin-coated platelets (Sandler, 2000).
Recently, new definitions for the phases of the disease were introduced (Rodeghiero et al, 2009). 
Based on the time from diagnosis, the first phase (up to 3 months) is the “newly-diagnosed ITP,” 
phase 2 (>3 months up to 12 months) is the “persistent phase,” and after 12 months the “chronic 
phase” starts. These phases also reflect the line of treatment.
The major goal for treatment of ITP is to achieve a platelet count that prevents major bleeding 
rather than correcting the platelet count to normal levels. The management of ITP should be 
REDACTED COPY
oglo
PY 
oglo
rs to a
OPY
rs to a
bumin
D CO
bumin
the ce
TED 
the ce
gG wit
ACTE
gG wit
n and 
EDAC
n and 
rent b
RED
rent b
mo
R
mo
ot be used to support any marketing authorization application and any extensions or variations thereof.
t for 
varia
t for 
A 
o
A 
f the stu
ns o
f the stu
udy
sion
udy. Th
on
. Th
d to par
tens
d to par
g twice 
any 
g twice 
plemen
nd a
plemen
ulin an
pplic
ulin an
affect s
n ap
affect s
n from 
tion
n from 
ell surfa
rizat
ell surfa
th the r
thori
th the r
return
auth
return
binding
ng a
binding
moves th
keting
moves th
concen
arke
concen
e of Fc
y ma
e of Fc
ocked, 
any 
ocked, 
a
p
a is a c
port 
is a c
pura, or
uppo
pura, or
TP.
o s
TP. P
sup
Pro
up
ro
erl
d t
erlyi
d to
ying
o
ng
iseases
used
iseases
m a sin
be us
m a sin
oteins. T
ot be
oteins. T
This document cann
et auto
nno
et auto
the red 
t can
the red 
Recen
ment
Recen
Ba
m
Ba


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 19 of 353
tailored to the individual patient and it is rarely indicated in those with platelet counts above 
50x109/L in the absence of bleeding, trauma, surgery, or high risk factors (eg, patients on 
anticoagulation therapy) (EMA/CHMP/153191/2013, 2014). However, there is general 
agreement that adults with a count of <30x109/L with bleeding at diagnosis require treatment. 
The first line of treatment for newly-diagnosed ITP is generally agreed and based on the use of 
corticosteroids and intravenous immunoglobulin (IVIg). Patients who fail to respond or who 
relapse face the options of treatment with second line drug therapy or splenectomy but there is no 
clear evidence to support the best approach. Splenectomy can provide long-term efficacy in 
around 60% of cases and recent guidelines suggest considering a splenectomy after 12 months. 
Splenectomy is an invasive procedure associated with acute complications due to 
thrombocytopenia (like bleeding events) and long-term complications from loss of splenic 
functions. Asplenic subjects are at increased risk of life-threatening infections. Splenectomy may
increase morbidity from venous thromboembolism or atherosclerosis (Ghanima et al, 2012). 
Second line drug therapies include high-dose dexamethasone or methylprednisolone; high-dose 
IVIg or anti-D Ig; vinca alkaloids; dapsone and danazol; the immunosuppressants 
cyclophosphamide, azathioprine, and cyclosporine; or mycophenolate mofetil and Helicobacter 
pylori eradication if applicable. The anti-CD20 monoclonal antibody rituximab - even if not 
licensed for the treatment of ITP - and the thrombopoietin-receptor (TPO-R) agonists are 
considered as second line as well as third line options.
Treatment-related morbidity is also a significant contributing factor; long-term courses of 
corticosteroids, other immunosuppressive medications, or splenectomy may be required to 
maintain a platelet count in a safe range in patients with chronic treatment-resistant ITP and 
morbidity and mortality can be related to treatment, reflecting the complications of therapy with 
corticosteroids or splenectomy. There thus remains a considerable unmet medical need for new 
therapeutic options in the treatment of ITP. UCB7665 may become the first targeted therapy to 
remove the autoantibodies to platelets providing a safe and tolerable alternative for patients with 
persistent or chronic ITP in acute or maintenance therapy.
UCB7665 is a humanized anti-FcRn monoclonal antibody that has been specifically designed to 
inhibit IgG binding to FcRn without inhibiting albumin binding to FcRn. UCB7665 is being 
developed as an inhibitor of FcRn activity with the aim to reduce the concentration of pathogenic 
IgG in patients with IgG autoantibody mediated diseases. UCB7665 was derived from a rat 
antibody with specificity for human FcRn by engineering the rat antibody into a humanized 
IgG4P format. The construct encoding UCB7665 was created by grafting the 
complementarity-determining region (CDRs) from the parental rat heavy and light chain variable 
regions onto a human IgG4P and kappa chain genetic background, respectively. The resulting 
UCB7665 contains only the original rat sequences that comprise the antigen binding site; all 
other sequences are human in origin.
UCB7665 is being evaluated in a study in healthy subjects (UP0018) with escalation of single 
intravenous (iv) and sc dosing. The outcomes are safety, tolerability, PK, and the PD effect on 
total IgG levels. Doses of UCB7665 1, 4, and 7mg/kg have been administered in 3 cohorts for 
the iv route and in 3 cohorts for the sc route. Preliminary information from the study is 
summarized below.
REDACTED COPY 
ntribu
COPY
ntribu
ations
D CO
ations
tients 
TED 
tients 
reatme
ACTE
reatme
hus rem
DAC
us rem
of ITP
RED
of ITP
p
R
p
used to support any marketing authorization application and any extensions or variations thereof.
o 
a
o 
nths.
or va
nths.
plenic
sion
plenic
plenect
tens
plenect
ma et al,
exte
ma et al,
dnisolon
ny e
dnisolon
pressan
d any
pressan
e mofet
and
e mofet
dy
on
dy ritux
on a
ritux
y
on
y
ptor (TP
catio
ptor (TP
uting fa
n ap
uting fa
s, or sp
tion
s, or sp
with c
rizat
with c
ent, ref
thori
ent, ref
mains 
auth
mains 
P. UCB
ng a
P. UCB
providi
keting
providi
mainte
arke
mainte
FcRn m
ny m
FcRn m
without
t any
without
of FcRn
port 
of FcRn
G autoa
uppo
G autoa
ficity
o su
ficity fo
sup
fo
y
su
y
he cons
d to
he cons
it
u
ity-
use
y-dete
sed
dete
nt cannot be
o a hum
be us
o a hum
5 conta
t be
5 conta
sequen
nno
sequen
UCB766
nt ca
UCB766
This documen
intrav
ment
intrav
tot
m
tot


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 20 of 353
In the iv cohorts, the maximum tolerated dose was reached at UCB7665 4mg/kg. The most 
common TEAEs in all iv cohorts were mild to moderate gastrointestinal disturbances (nausea, 
vomiting, and diarrhea) and mild to severe headaches. 
In the sc cohorts, a comparable tolerability profile was seen with UCB7665 7mg/kg sc and
4mg/kg iv. Adverse events of mild to moderate severity for headaches and gastrointestinal 
disturbances were observed. There were fewer cases of headache and gastrointestinal
disturbances in the overall sc cohorts compared to overall iv cohorts.
In 4-week and 13-week toxicity studies with 8-week, treatment-free recovery periods in 
Cynomolgus monkeys, UCB7665 induced the expected large decreases (75% to 90%) in plasma 
IgG in all animals which was maintained for the duration of both studies in the majority of the 
animals, with only minor effects on albumin levels. UCB7665 was well tolerated at the highest 
dose levels tested of UCB7665 150mg/kg sc and UCB7665 150mg/kg iv administered every
3 days (there was no observed adverse effect level [NOAEL]).
Further information on the PK, PD, and safety profiles for UCB7665 from nonclinical studies, 
and preliminary safety information from clinical studies (including data from this study), can be 
obtained from the current version of the UCB7665 Investigator’s Brochure.
Subjects will also have the option of providing additional informed consent for exploratory
DNA and RNA (mRNA and miRNA) analyses as described in Section 5.1.1.
3
STUDY OBJECTIVE(S)
3.1
Primary objective
The primary objective of the study is:

To evaluate the safety and tolerability of UCB7665 administered by sc infusion in subjects
with ITP
3.2
Secondary objectives
The secondary objectives of this study are:

To assess the clinical efficacy of UCB7665 as measured by the change in platelet count

To assess the PD effect of UCB7665 as measured by the change in total IgG concentration in 
serum
3.3
Exploratory objectives
The exploratory objectives of this study are:


To evaluate the clinical efficacy as measured by the change in ITP bleeding score

To evaluate the effect of UCB7665 on the concentrations of total protein, albumin, 
α-globulin and β-globulin, IgG subclasses, IgM, IgA, and IgE, and serum and plasma 
complement levels

To evaluate the emergence of ADA with respect to immunogenicity and PK/PD
REDACTED COPY 
rib
Y
rib
bility
RED
bility o
ED
o
y
ED
y
marketing authorization application and any extensions or variations thereof.
plasma
or v
plasma
ty
on
ty of th
ns 
of th
y
n
y
t the hi
nsio
t the hi
istered 
xten
istered 
m non
any
m nonc
y
c
ta from
and 
ta from
rochur
on a
rochur
med co
icatio
med co
in 
p
in Sec
plic
Sec
of UCB
g au
of UCB
ctives
mark
ctives
t be used to support any
is study
ny m
is study
fficacy
ort a
fficacy
ffect of
upp
ffect of
Explo
sed 
Explo
atory
be u
atory o
u
o
y
u
y
This document ca

e

To
nt 
To

m

not b
cann


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 21 of 353

To evaluate the relationship between changes in platelet count and total IgG, IgG subclasses, 
ITP-specific autoantibodies

To assess the plasma concentrations of UCB7665 administered by sc infusion

To evaluate the genomic components of ITP to understand the molecular etiology, 
progression, and treatment of the disease, applicable only for subjects consenting to 
participate in the optional genomic analyses substudy. 

4
STUDY VARIABLES
4.1
Primary variable
The primary safety variable is:

Occurrence of TEAEs
4.2
Others and exploratory variables
4.2.1
Safety variables
The other safety variables are:

Vital sign values and change from Baseline over time (systolic and diastolic blood pressure, 
temperature, pulse rate, respiratory rate, and body weight)

12-Lead ECG parameters and change from Baseline over time

Laboratory values and change from Baseline over time (hematology including coagulation 
parameters, clinical chemistry, and urinalysis)

Values and change from Baseline in concentrations of total protein, albumin, α-globulin, and 
β-globulin over time

Change from Baseline in exploratory safety biomarkers over time

TEAEs leading to withdrawal of IMP
4.2.2
Efficacy variables
The efficacy variables are:

Response during the study: platelet count ≥30x109/L and at least 2-fold increase of the 
Baseline count

Complete Response during the study: platelet count ≥100x109/L

Platelet count ≥50x109/L during the study

Response by visit

Complete Response by visit

Platelet count ≥50x109/L by visit
REDACTED COPY 
 over 
ED C
 over 
and bo
TED
and bo
ge from
DAC
ge from
om 
RE
om B
RE
B
ed to support any marketing authorization application and any extensions or variations thereof.
time (s
atio
time (s
od
ri
ody 
riz
y we
za
we
m 
a
m B
uth
Base
th
ase
aseline
ting 
aseline
urinal
keti
urinal
line in 
ma
line in 
in
o
in expl
ort a
expl
withdr
supp
withdr
ficacy
d to 
ficacy
This document cannot be us
ariable
used
ariable
onse
t be
onse du
e 
du
seline c
not 
seline c
Comp
t can
Comp

me

P
n
P
varia
or v


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 22 of 353

The maximum value and maximum increase from Baseline in platelet count during the study

Value and change from Baseline in platelet count over time

Baseline-corrected AUEC for platelet count

Time to Response: time from starting treatment to achievement of Response

Time to Complete Response: time from starting treatment to achievement of Complete 
Response

Time to achieving platelet count ≥50x109/L

Duration of Response: measured from achievement of Response to loss of Response (loss of 
Response defined as platelet count below 30x109/L or less than 2-fold increase of Baseline 
platelet count)

Duration of Complete Response: measured from achievement of Complete Response to loss 
of Complete Response (loss of Complete Response defined as platelet count below 
100x109/L)

Duration of platelet count ≥50x109/L: measured from achievement of platelet count 
≥50x109/L to reduction of platelet count below 50x109/L

Clinical Response: platelet count ≥30x109/L and at least 2-fold increase from Baseline value 
and absence of bleeding

Time to Clinical Response: time from starting treatment to achievement of Clinical Response

Duration of Clinical Response: measured from achievement of Clinical Response to loss of 
Clinical Response (loss of Clinical Response defined as platelet count <30x109/L or less than 
2-fold increase from Baseline platelet count or presence of bleeding)

Complete Clinical Response: platelet count ≥100x109/L and absence of bleeding

Time to Complete Clinical Response: time from starting treatment to achievement of 
Complete Clinical Response

Duration of Complete Clinical Response: measured from achievement of Complete Clinical 
Response to loss of Complete Clinical Response (loss of Complete Clinical Response defined 
as platelet count <100x109/L or presence of bleeding)

No Clinical Response: platelet count <30x109/L or less than 2-fold increase from Baseline or 
presence of bleeding

ITP bleeding score over time

Value and change from Baseline in NFI-MS summary score over time
4.2.3
Pharmacokinetic variable
The PK variable is:

Plasma concentration of UCB7665 over time
REDACTED COPY
at lea
PY 
at lea
rting tr
TED 
rting tr
ured fr
DACT
ured fr
l Re
REDA
l Resp
DA
sp
telet
RE
telet
g authorization application and any extensions or variations thereof.
nse
on
nse (l
ns
(los
s 
os
of 
nsi
of B
sio
Bas
o
as
lete Re
ny e
lete Re
et coun
d any
et coun
ment o
tion 
ment o
st 2
app
st 2-
pp
-fo
pp
fo
treatme
izat
treatme
rom ac
utho
rom ac
ponse d
g aut
ponse d
ed to support any marketin
t count
ting 
t count
atelet co
arke
atelet co
Respons
y m
Respons
nse
t a
nse
e Clinic
ppor
e Clinic
of Comp
supp
of Comp
nt <1
to s
nt <100
s
00
nt cannot be us
l Respo
sed
l Respo
e of ble
be us
e of ble
bleedi
not b
bleedi
Value 
can
Value 
This documen
4.2.3
ent 
4.2.3
Th
m
Th


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 23 of 353
4.2.4
Pharmacodynamic variables
The PD variables are:

Minimum value and maximum decrease from Baseline in total IgG concentration during the 
study

Value and change from Baseline in total IgG concentrations over time

Change from Baseline in ITP-specific autoantibody in serum over time:

Change from Baseline in IgG subclass concentrations over time
4.2.5
Other immunological variables
Other immunological variables are:

Change from Baseline in serum immunoglobulin concentrations (total IgA, IgE, and IgM) 
over time

Change from Baseline in serum (C3 and C4) and plasma (C3a and C5a) complement levels 
over time

Change from Baseline in exploratory biomarkers relating to mechanism of action, disease 
activity, treatment response, and clinical outcome

ADA (anti-UCB7665 antibodies) status (negative/positive) and change from Baseline in
relative mass units over time

Change from Baseline in cytokines over time (for subjects experiencing infusion reactions)

Change from Baseline in serum BAFF levels over time

Lymphocyte counts (B and T)
5
STUDY DESIGN
5.1
Study description
This is a Phase 2, multicenter, open-label, multiple-dose, multiple-arm study to evaluate the 
safety, tolerability, and efficacy of UCB7665 in subjects with primary persistent or chronic ITP.
Dose Arm 1 (15 subjects): UCB7665 4mg/kg sc (5 doses at an interval of 1 week)
Dose Arm 2 (15 subjects): UCB7665 7mg/kg sc (3 doses at an interval of 1 week)
Dose Arm 3 (6 to 12 subjects): UCB7665 10mg/kg sc (2 doses at an interval of 1 week)
Dose Arm 4 (6 to 12 subjects): UCB7665 15mg/kg sc (1 dose)
Dose Arm 5 (6 to 12 subjects): UCB7665 20mg/kg sc (1 dose)
The maximum duration of the study per subject is approximately 16 weeks, consisting of a 
Screening Period (1 to 28 days), a Dosing Period of 1 to 4 weeks, and an Observation Period of 
8 weeks.
Screening Period: The purpose of the Screening Period is to evaluate and confirm the subject’s 
eligibility. During the Screening Visit (Visit 1), subjects will sign a written Informed Consent 
REDACTED COPY 
elat
Y
elat
me
O
me
gative/
D CO
gative/
ver
DAC
ver tim
AC
tim
BAFF
RE
BAFF
not be used to support any marketing authorization application and any extensions or variations thereof.
IgA, Ig
any e
IgA, Ig
nd C5a
n an
nd C5a
g to me
pplic
g to me
e/positiv
ation
e/positiv
me (fo
utho
me (fo
F levels
ng a
F levels
GN
y m
GN
criptio
rt any
criptio
center,
ppo
center,
nd effic
sup
nd effic
subject
ed to
subject
(15 sub
e use
(15 sub
m 3 (6 
ot be
m 3 (6 
This document can
e Arm 4
ann
e Arm 4
Dose A
ent c
Dose A
Th
me
Th
aria


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 24 of 353
form prior to the conduct of any study-related procedures. The use of concomitant medication 
while in the study will be discussed, and the subject’s eligibility will be determined on the basis 
of the inclusion/exclusion criteria. The Screening Period should not exceed 28 days.
Dosing Period: The first 6 subjects in the study will receive UCB7665 4mg/kg. These subjects in 
the Dose Arm 1 will not be randomized. While recruitment is still ongoing, safety data for the
first 3 subjects up to 7 days after the last dose of the third subject in Dose Arm 1 will be 
reviewed by the DMC. During a second DMC meeting, all available safety data up to cut off date 
defined as 7 days after the last dose of the sixth subject in Dose Arm 1 will be reviewed. During 
these reviews recruitment in the dose arm will not be stopped. Following this review, the DMC 
will make a decision on whether to open Dose Arm 2 for enrollment. Once DMC has advocated 
the initiation of Dose Arm 2, the subsequent subjects will be randomly assigned in 1:1 ratio to 
either Dose Arm 1 or Dose Arm 2 using an IXRS. Once 15 subjects are enrolled in the Dose 
Arm 1, the remaining subjects will be enrolled in Dose Arm 2.
After the safety data review of at least 6 subjects in Dose Arm 2 is done, the DMC will make a 
recommendation on whether to open Dose Arm 3 for enrollment. Once the DMC has advocated 
the initiation of Dose Arm 3 and the enrollment of 15 subjects in Dose Arm 2 has been 
completed, the subsequent subjects will be assigned to Dose Arm 3 only. After every third 
subject has been enrolled, the DMC will review all available safety data up to cut off date 
defined as 7 days after the dosing. Depending on the emerging safety data of 6 subjects in Dose 
Arm 3, the DMC will recommend whether to open Dose Arm 4 for enrollment or to include 
additional subjects in Dose Arm 3. If applicable, this step is planned to be done stepwise in 
groups of 3 subjects. A maximum, 12 subjects will be enrolled in Dose Arm 3. The DMC will 
recommend to open Dose Arm 4 for enrollment in a subsequent DMC meeting, if applicable.
Once the DMC has advocated the initiation of Dose Arm 4, the enrollment of Dose Arm 3 will 
be closed and all subsequent subjects will be assigned to Dose Arm 4. After every third subject is 
enrolled, the DMC will review all available safety data up to the cutoff date defined as 7 days 
after the dosing. Depending on the emerging safety data of 6 subjects in Dose Arm 4, the DMC 
will recommend to include additional subjects in Dose Arm 4 or not. If applicable, this step is 
planned to be done stepwise in groups of 3 subjects. A maximum of 12 subjects may be enrolled 
in Dose Arm 4. The DMC will recommend to open Dose Arm 5 for enrollment in a subsequent 
meeting, if applicable.
Once the DMC has advocated the initiation of Dose Arm 5, the enrollment of Dose Arm 4 will 
be closed and all subsequent subjects will be assigned to Dose Arm 5. After every third subject is 
enrolled, the DMC will review all available safety data up to the cutoff date defined as 7 days 
after the dosing. Depending on the emerging safety data of 6 subjects in Dose Arm 5, the DMC 
will recommend to include additional subjects in Dose Arm 5. If applicable, this step is planned 
to be done stepwise in groups of 3 subjects. A maximum of 12 subjects may be enrolled in Dose 
Arm 5.
At least 11 interim analyses will be performed. Based on the interim analyses, the DMC will 
assess the safety of UCB7665, determine whether to initiate subsequent dose arms and may
decide to adapt the dose regimen. Planned dosing may be discontinued for all subjects in a dose 
arm (see Section 6.5). Refer to Section 14.7 for details. 
REDACTED COPY
mer
PY 
mer
Dose 
COPY
Dose 
D
this s
D CO
this s
s will 
TED 
s will 
lment 
ACTE
lment 
ation 
REDA
ation 
will
RE
will
support any marketing authorization application and any extensions or variations thereof.
e
a
e
ing
vari
ing
DMC 
or va
DMC 
dvocate
s o
dvocate
:1 ratio
ion
:1 ratio
n the D
ens
n the D
he DM
any 
he DM
the DM
nd a
the DM
se Arm
an
se Arm
3 only
tion 
3 only
afety
licati
afety d
ati
d
y
ati
y
ing
ppl
ing saf
plic
saf
Arm 4
n ap
Arm 4
step
tion
step is 
on
is 
be enr
rizat
be enr
in a su
thori
in a su
of Dos
aut
of Dos
ll be as
ting 
ll be as
ila
ke
ilable s
keti
ble s
b
ke
b
emergi
mark
emergi
tional s
ny m
tional s
in grou
t any
in grou
will re
port 
will re
This document cannot be used to
advoc
to s
advoc
l subse
ed t
l subse
DMC w
use
DMC w
osing. D
be u
osing. D
ommen
ot b
ommen
done 
ann
done 
rm
t c
rm 5.
ca
5.
At le
men
At le
a
m
a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 25 of 353
In case the DMC recommends reducing the number of doses (infusions) for any of the
predefined dose arms (as applicable) based on review of safety data, then the additional dose 
arms receiving a reduced number of doses will be considered as additional new dose arms for the 
study.
Observation Period: Following the last dose (or only dose administration for Dose Arms 4 and 
5), a visit will be scheduled 3 days postdose and weekly thereafter for 8 weeks to collect safety
and efficacy data.
5.1.1
Exploratory genomic analyses
During this study, subjects will also have the option of providing additional informed consent for 
exploratory DNA and RNA analyses. Participation in this additional portion of the study is 
optional and does not preclude subject’s eligibility for participation in the main study. The 
additional genomic samples must not be collected if the subject has not consented to participate 
in this exploratory genomic substudy.
Once subject provides consent, through a separate informed consent form, blood samples will be 
drawn as follows:
For DNA: Blood samples will be collected at Baseline (Visit 2) for all dose arms. Subsequent 
blood sample will be collected prior to the last dose (ie, Visit 7 for Dose Arm 1, Visit 5 for Dose 
Arm 2, and Visit 4 for Dose Arm 3).
For RNA: Blood samples will be collected at the following time points for different dose arms: 

Dose Arm 1: Baseline (Visit 2), 3 days after dose 1 (Visit 3), prior to the last dose (Visit 7),
and End of Study Visit (Visit 15).

Dose Arm 2: Baseline (Visit 2), 3 days after dose 1 (Visit 3), prior to the last dose (Visit 5), 
and End of Study Visit (Visit 13).

Dose Arm 3: Baseline (Visit 2), 3 days after dose 1 (Visit 3), prior to the last dose (Visit 4), 
and End of Study Visit (Visit 12).

Dose Arm 4: Baseline (Visit 2), 3 days after dosing (Visit 3) and End of Study Visit
(Visit 10).

Dose Arm 5: Baseline (Visit 2), 3 days after dosing (Visit 3) and End of Study Visit 
(Visit 10). 
For each DNA blood sample a volume of 6mL whole blood is needed and for each RNA sample 
a volume of 2.5mL whole blood is needed.
Failure to provide consent to participate in this substudy will not impact subject’s eligibility to 
participate in the main study.
Any exploratory biomarker or genomic analysis will only ever be related to the exploration of 
the underlying causes of ITP in patients, related biology, and drug response. Justification for 
additional genomic analyses is detailed in Section 5.4.6.
Details on the collection, storage, preparation, and shipping of samples will be presented in the 
Laboratory Manual provided separately.
REDACTED COPY 
follow
CO
follow
fter do
TED
fter do
d
RE
day
RED
ays a
D
s a
R
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
onsent 
s or
onsent 
tudy
ion
tudy is
ns
is
y
n
y
udy
ens
udy. Th
nsi
. Th
ted to p
exte
ted to p
m, bloo
nd a
m, bloo
for all d
ation
for all d
7 for D
lica
7 for D
wing tim
tion a
wing tim
ose 1 (
riza
ose 1 (V
after d
g au
after d
3 day
arke
3 days
e
s
12
m
2).
ma
).
Visit 2)
t any
Visit 2)
y
eline (V
sup
eline (V
A blood
used
A blood
f 2.5mL
be u
f 2.5mL
to prov
not b
to prov
icipate 
ann
icipate 
Any
ent c
Any ex
t c
ex
y
t c
y
the u
me
the u
a
m
a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 26 of 353
Any results from this analysis will be reported separately and will not form a part of the main 
clinical study report.
5.1.2
Study duration per subject
The maximum duration of the study per subject is approximately 16 weeks.
Screening Period: 1 to 28 days (4 weeks)
Dosing Period: up to 4 weeks
Observation Period: 8 weeks
The end of the study is defined as the date of the last visit of the last subject in the study.
5.1.3
Planned number of subjects and sites
A total of up to approximately 48 to 66 subjects are planned to enter the Dosing Periods in the 
study (15 subjects in each of Dose Arms 1 and 2, and 6 to 12 subjects in Dose Arms 3, 4, and 5). 
To achieve the required number of eligible subjects to enter the Dosing Period, it is anticipated 
that approximately 90 subjects will need to be screened. These subjects will be enrolled at 
approximately 45 sites. First subject first visit is planned for Q1 2016, last subject last visit for 
Q2 2018.
5.1.4
Anticipated regions and countries
It is planned to recruit subjects in Europe and Australia for the study.
5.2
Schedule of study assessments
Table 5‒1 presents the tabular scheme of study assessments for the weekly UCB7665 4mg/kg 
dose arm (Dose Arm 1), Table 5‒2 presents the tabular scheme of study assessments for the 
weekly UCB7665 7mg/kg dose arm (Dose Arm 2), Table 5-3 presents the tabular scheme of 
study assessments for the weekly UCB7665 10mg/kg dose arm (Dose Arm 3), Table 5-4 presents 
the tabular scheme of study assessments for the one dose of UCB7665 15mg/kg, Table 5-5
presents the tabular scheme of study assessments for the one dose of UCB7665 20mg/kg and
Table 5‒6 presents the assessments to be performed on dosing days.
DACTED COPY 
s
PY
s
tralia
COP
tralia
ssme
ED 
ssme
study
ACT
study
RED
T
sents 
EDA
sents 
(Dos
RE
(Dos
horization application and any extensions or variations thereof.
dy
n
dy.
n
.
ng Perio
exte
ng Perio
ose Arm
ny e
ose Arm
Period
d any
Period
y
ts will 
and
ts will 
016,
on
016, l
n a
las
a
as
for the
on ap
for the
ents
zati
ents
ny marketing auth
assess
tho
assess
the tab
aut
the tab
se Arm
ting a
se Arm
B7665 
ketin
B7665 
ments fo
ark
ments fo
tudy
y m
tudy as
m
as
y
m
y
This document cannot be used to support a
ments t
t any
ments t


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 27 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consent f
X
Demographic data
X
Verification of 
inclusion/exclusion 
criteria
X
X
Platelets for inclusion/
withdrawal check (local 
laboratory)g
X
X
X
X
X
Randomizationh
X
Withdrawal criteriai
X
X
X
X
X
X
General 
medical/procedures 
history
X
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
PY
CO
C
TE
R
AC
RE
R
any marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
ap
 a
io
iz
g
ori
X
eting
X
ng
ma
g
m
rt a
X
rt a
X
port
X
ort
X
not be used to suppo
an
rt
po
su
d
us
X
be 
X
u
This document canno
no
u


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 28 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationj
X
X
X
X
X
X
X
X
X
X
12-lead ECGk
X
X
X
X
X
X
X
X 
Karnofsky Performance 
Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xl
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serology test for HIV, 
hepatitis B, and hepatitis 
C
X
IGRA TB testm
X
REDACTED COPY 
X
COP
X
PY
CO
X
TE
X
ED
CT
AC
ED
R
rketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
X
n a
X
X
ap
 a
X
riza
X
at
ori
ho
au
g
X
keti
X
ting
mark
X
mar
X
ma
ma
sed to support any m rk
ma
X
any 
X
y m
a
u
rt
X
o su
X
u
sup
X
su
X
nnot be used
up
s
su
se
us
This document cann
nn
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 29 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
TB signs and symptoms 
questionnaire
X
X
Blood sample for 
cytokines
X
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Whole blood sample for 
DNA (optional)
X
X
Whole blood sample for 
RNA (optional)
X
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
X
X
Call to IXRS for treatment 
kit number
X
X
X
X
X
Administration of IMP
X
X
X
X
X
Blood sampling for 
plasma concentration of 
UCB7665
X
X
X
X
X
X
X
X
Anti-UCB7665 antibodies
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
PY
CO
X
TE
Xn
ED
n
ED
AC
DA
R
any marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
ap
 a
X
at
ori
ut
g
ti
ma
m
rt an
X
a
X
ot be used to support an
rt
po
su
X
d to
X
o
This document cannot be used
ed
us
no
ca


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 30 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Serum complements (C3
and C4) and plasma 
complements (C3a and 
C5a)
X
X
X
X
Blood collection for 
exploratory safety 
biomarkers 
X
Xo
X
X
X
X
Xo
Xo
Xo
Xo
Xo
Xo
Xo
Serum BAFF levels
X
X
X
X
X
X
X
Blood collection for 
exploratory biomarker 
analysis
X
X
X
X
X
X
X
Immunoglobulins (total 
IgG, IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X 
IgA, IgM, IgEp
X
X
X
X
ITP-specific 
autoantibodies q
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
REDACTED COPY 
PY
AC
CO
X
DA
X
AC
AC
AC
R
AC
nnot be used to support any marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
ap
ori
 a
X
auth
X
tho
g
o
X
arke
X
ket
ma
X
y m
X
ma
ma
ma
rt
ma
X
ppo
X
or
su
r
X
d to
X
o s
X
ed
us
X
ot 
X
t b
This document cann
nn
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 31 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Headache questionnairer
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviews
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring; 
DNA=deoxyribonucleic acid; Committee; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
 HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IMP=investigational medicinal product; ITP=immune thrombocytopenia; IXRS= interactive voice/web response 
system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
TB=tuberculosis.
a   Frequency of assessments on dosing days is detailed in Table 5‒6.  
b Visits 10, 12, and 14 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the final dose.
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose. 
e The visit windows in the Observation Period are relative to the final dosing visit date.
f Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
g Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h The first 6 subjects will be enrolled in the Dose Arm 1 group only. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the 
DMC. Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, the subsequent subjects will be 
randomly assigned in 1:1 ratio to either Dose Arm 1 or Dose Arm 2 using an IXRS. Once 15 subjects are enrolled in Dose Arm 1 and safety data review of at 
least 6 subjects in Dose Arm 2 is done, the subsequently enrolled subjects will be enrolled in Dose Arm 2 until a planned number of 15 subjects are enrolled.
i Subjects can withdraw at any time during the study, based on the criteria in Section 6.4 .
REDACTED COPY 
X
COP
X
PY
CO
C
TE
C
rebrosp
ACTE
rebrosp
OS=En
DAC
OS=En
medici
REDA
medici
etic re
RE
etic re
ny marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
X
n a
X
X
ap
 a
io
ririririz
pinal flu
horiz
pinal flu
d of Stu
utho
d of Stu
inal pro
g au
inal pro
esonance
ting 
esonance
6
a
6.  
ark
.  
care pro
ma
care pro
used to support a
.
n
.
its. The 
t any
its. The 
f 9 days
ort a
f 9 days
elative t
ppo
elative t
icipation
supp
icipation
will be 
to s
will be 
laborato
d to
laborato
>350x10
sed
>350x10
not be 
in the D
e us
in the D
DMC w
t be 
DMC w
o to eith
not b
o to eith
This document can
m 2 is d
anno
m 2 is d
at any tim
t can
at any tim


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 32 of 353
j A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
k The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
l At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
m The IGRA test will be performed in a central laboratory. Any IGRA-positive subjects will be withdrawn from the study.
n Blood sample for cytokines will be obtained and analyzed at baseline for all subjects and at subsequent visits only in subjects with infusion reactions.
o Exploratory safety biomarker samples to be obtained on dosing days for all subjects. During non-dosing visits and during the visits in the Observation Period, 
the samples should be obtained only from subjects experiencing severe headaches or GI disturbances (only in case of Adverse Events of Interest, see 
Section 12.4).
p In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 7 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
q
r This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
s A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only. 
OPY 
ollec
Y
ollec
REDACTED CO
d. In ca
COP
d. In ca
extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
perform
atio
perform
e recor
var
e recor
ubjects w
ensi
ubjects w
uring th
xten
uring th
ation and any e
e of Ad
y ex
e of Ad
cheduled
d an
cheduled
d daily u
tion
d daily u
lica
app
l assess
icat
l assess
n to be 
pplic
n to be 
This document cannot be used to support any marketing authorization
ase of ea
on a
ase of ea


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 33 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consentf
X
Demographic data
X
Verification of inclusion/exclusion 
criteria
X
X
Platelets for inclusion/withdrawal 
check (local laboratory)g
X
X
X
Randomizationh
X
Withdrawal criteriai
X
X
X
X
General medical/procedures history
X
ITP history
X
Prior and concomitant medication
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical procedures
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
O
D C
D
AC
D
AC
AC
R DAC
t any marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
n
pl
n a
on
at
ho
X
aut
X
th
in
h
tininin
a
in
X
ma
X
ark
ma
y m
be used to support a
m
t a
p
uppo
pp
su
X
d
X
d
u
t cannot be us
us
u
t b
nn
This document c
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 34 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Physical examinationj
X
X
X
X
X
X
X
X
12-lead ECGk
X
X
X
X
X
X
Karnofsky Performance Status
X
Laboratory parameters (hematology, 
chemistry, urinalysis)
Xl
X
X
X
X
X
X
X
X
X
X
X
X
Serology test for HIV, hepatitis B, and 
hepatitis C
X
IGRA TB testm
X
TB signs and symptoms questionnaire
X
X
Blood sample for cytokines
X
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Whole blood sample for DNA 
(optional)
X
X
Whole blood sample for RNA 
(optional)
X
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
Call to IXRS for treatment kit number
X
X
X
REDACTED COPY
X
OPY
X
Y 
X
D CO
X
O
D C
D
X
DAC
X
CT
DAC
RE
R
t any marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
n
pl
X
t
X
n a
on
at
o
X
tho
X
or
ho
g
in
ark
ma
y m
ot be used to support a
m
X
t a
p
pp
pp
pp
pp
to
u
e u
This document cannot 
ot
nt kit nu
t ca
nt kit nu
an
nt 


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 35 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Administration of IMP
X
X
X
Blood sampling for plasma 
concentration of UCB7665
X
X
X
X
X
X
Anti-UCB7665 antibodies
X
X
X
X
X
X
X
X
X
X
Serum complements (C3 and C4) and 
plasma complements (C3a and C5a)
X
X
X
X
Blood collection for exploratory safety
biomarkers
X
Xo
X
X
Xo
Xo
Xo
Xo
Xo
Xo
Xo
Serum BAFF levels
X
X
X
X
X
Blood collection for exploratory 
biomarker analysis
X
X
X
X
X
Immunoglobulins (total IgG, IgG 
subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgEp
X
X
X
X
ITP-specific autoantibodiesq
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
REDACTED COPY
X
OPY
X
Y 
X
D CO
X
O
D C
X
ACT
X
TE
AC
AC
AC
R DAC
R
ny marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
n
pl
X
tion
X
n a
on
X
hor
X
riz
ho
th
in
h
X
ke
Xo
ket
o
tininin
ma
in
X
n
X
ma
ma
ma
m
not be used to support any
X
a
X
any
pp
supp
pp
pp
pp
d t
us
u
b
t cann
nn
This document c
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 36 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Headache questionnairer
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviews
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
 HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IGRA= interferon-gamma release assay; IMP=investigational medicinal product; ITP=immune thrombocytopenia; 
IXRS= interactive voice/web response system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue 
Index for multiple sclerosis; TB=tuberculosis.
a Frequency of assessments on dosing days is detailed in Table 5‒6.
b Visits 8, 10, and 12 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the last dose.
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose.
e The visit windows in the Observation Period are relative to the final dosing visit date. 
f Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
g Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h The first 6 subjects will be enrolled in the Dose Arm 1 group. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the DMC. 
Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, the subsequent subjects will be randomly 
assigned in 1:1 ratio to either Dose Arm 1 or Dose Arm 2 using an IXRS. Once 15 subjects are enrolled in Dose Arm 1 and safety data review of at least 
6 subjects in Dose Arm 2 is done, the subsequently enrolled subjects will be enrolled in Dose Arm 2 until a planned number of 15 subjects are enrolled.
i Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
ED COPY
X
OPY
X
Y 
CO
REDACTED C
D
brospin
TED
brospin
=End o
ACT
=End o
ma rele
DAC
ma rele
e; RNA
RED
e; RNA
ation application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
X
app
X
plplpl
n
pl
n
port any marketing authorization 
n a
at on
nal fluid
riza
nal fluid
of Study
thori
of Study
ease ass
auth
ease ass
A=
g
A=ribonu
g au
ribonu
profess
arke
profess
. The vi
ny m
. The vi
9 days as
t any
9 days as
ative to t
ort 
ative to t
not be used to supp
pation in
ppo
pation in
ill be tak
sup
ill be tak
boratory
to s
boratory
50x109/
ed to
50x109/
the Dos
used
the Dos
ll make 
be us
ll make 
ose Arm
t be
ose Arm
one, the
not 
one, the
This document can
any time
ann
any time


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 37 of 353
j A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
k The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
l At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
m The IGRA test will be performed in a central laboratory. Any IGRA-positive subjects will be withdrawn from the study.
n Blood sample for cytokines will be obtained and analyzed at baseline for all subjects and at subsequent visits only in subjects with infusion reactions.
o Exploratory safety biomarker samples to be obtained on dosing days for all subjects. During non-dosing visits and during the visits in the Observation Period, 
the samples should be obtained only from subjects experiencing severe headaches or GI disturbances (only in case of Adverse Events of Interest, see 
Section 12.4).
p In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 5 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
q
r This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
s A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
Y
REDACTED COPY
collec
PY 
collec
ed. In 
D CO
ed. In 
extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
perform
atio
perform
e recor
var
e recor
ubjects w
tens
ubjects w
during t
exte
during t
plication and any
ase of A
ny e
ase of A
schedul
nd a
schedul
med daily
atio
med daily
cal asses
plica
cal asses
This document cannot be used to support any marketing authorization app
ion to be
appl
ion to be
case of 
tion 
case of 


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 38 of 353
Table 5-3:
Schedule of assessments for the UCB7665 10mg/kg once weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Visit 
1
2a
3
4a
5
6
7b
8
9b
10
11b
12
BL 
Visit
EOS/EW
c
Telephone 
Contact
1
2d
3
4d
Day
-28 to -1
1
2
3
4
8
9
10
11
15
22
29
36
43
50
64
Week
1
1
1
1
2
2
2
2
3
4
5
6
7
8
10
Visit 
Window
±1d
±2de
±1d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d f
Written informed consentg
X
Demographic data
X
Verification of 
inclusion/exclusion criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory) h
X
X
Withdrawal criteriai
X
X
X
General medical/procedures 
history
X
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
OP
CO
ED
AC
AC
AC
AC
RE AC
R
y marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
Arm 3)
riati
rm 3)
tion Pe
or v
tion Pe
va
o
ns
8
sio
8
on
e
n
e
ny
te
ny
ny
a
ny
11
n a
11
an
a
2
cati
2
io
ca
lic
 a
c
on
za
za
za
za
ho
g
ng
ark
g
used to support any m
y m
an
t a
pp
a
up
X
ed 
X
to
sed
This document cannot be u
e u
n
t ca
c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 39 of 353
Table 5-3:
Schedule of assessments for the UCB7665 10mg/kg once weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Visit 
1
2a
3
4a
5
6
7b
8
9b
10
11b
12
BL 
Visit
EOS/EW
c
Telephone 
Contact
1
2d
3
4d
Day
-28 to -1
1
2
3
4
8
9
10
11
15
22
29
36
43
50
64
Week
1
1
1
1
2
2
2
2
3
4
5
6
7
8
10
Visit 
Window
±1d
±2de
±1d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d f
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationj
X
X
X
X
X
X
X
12-lead ECGk
X
X
X
X
X
Karnofsky Performance 
Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xl
X
X
X
X
X
X
X
X
X
X
X
Serology test for HIV, 
hepatitis B, and hepatitis C
X
IGRA TB testm
X
TB signs and symptoms 
questionnaire
X
X
Blood sample for cytokines
X
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
REDACTED COPY 
OP
CO
ED
C
X
DAC
X
AC
AC
AC
AC
ED
RE
arketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
Arm 3)
riati
rm 3)
tion Pe
or v
tion Pe
va
o
ns
8
sio
8
on
e
n
e
ny
te
ny
ny
a
ny
11
n a
11
an
a
2
cati
2
io
ca
lic
 a
c
on
za
za
za
za
X
uth
X
ho
au
g
This document cannot be used to support any marketin
tin
ark
ar
ar
ar
an
ar
an
an
an
pp
an
su
sed
se
se
se
X
t b
X
be
nes
t
nes
an
nt ca


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 40 of 353
Table 5-3:
Schedule of assessments for the UCB7665 10mg/kg once weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Visit 
1
2a
3
4a
5
6
7b
8
9b
10
11b
12
BL 
Visit
EOS/EW
c
Telephone 
Contact
1
2d
3
4d
Day
-28 to -1
1
2
3
4
8
9
10
11
15
22
29
36
43
50
64
Week
1
1
1
1
2
2
2
2
3
4
5
6
7
8
10
Visit 
Window
±1d
±2de
±1d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d f
Whole blood sample for 
DNA (optional)
X
X
Whole blood sample for 
RNA (optional)
X
X
X
X
Serum pregnancy test
X
  
Urine pregnancy test
X
X
X
Call to IXRS for treatment 
kit number
X
X
Administration of IMP
X
X
Blood sampling for plasma 
concentration of UCB7665
X
X
X
X
X
Anti-UCB7665 antibodies
X
X
X
X
X
X
X
X
X
Serum complements (C3 
and C4) and plasma 
complements (C3a and C5a)
X
X
X
REDACTED COPY 
OP
X
D
X
CO
C
O
X
ACT
X
CT
RE AC
RE
RE
RE
eting authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
Arm 3)
riati
rm 3)
tion Pe
or v
tion Pe
va
o
ns
8
sio
8
on
e
n
e
ny
te
ny
ny
a
ny
11
n a
11
an
a
2
cati
2
io
ca
lic
 a
c
on
za
X
th
X
ori
g a
g
to support any market
eti
ark
ar
ar
ar
an
a
a
p
a
p
not be used to suppo
po
pp
X
to
X
to 
ed
ed
ed
This document cannot be used
no
se


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 41 of 353
Table 5-3:
Schedule of assessments for the UCB7665 10mg/kg once weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Visit 
1
2a
3
4a
5
6
7b
8
9b
10
11b
12
BL 
Visit
EOS/EW
c
Telephone 
Contact
1
2d
3
4d
Day
-28 to -1
1
2
3
4
8
9
10
11
15
22
29
36
43
50
64
Week
1
1
1
1
2
2
2
2
3
4
5
6
7
8
10
Visit 
Window
±1d
±2de
±1d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d f
Blood collection for 
exploratory safety
biomarkers
X
Xo
Xo
Xo
Xo
Xo
Xo
Xo
Xo
Xo
Serum BAFF levels
X
X
X
X
Blood collection for 
exploratory biomarker 
analysis
X
X
X
X
Immunoglobulins (total 
IgG, IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgEp
X
X
X
X
ITP-specific autoantibodiesq
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
Headache questionnairer
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviews
X
REDACTED COPY 
OP
X
D
Xo
D C
o
CO
AC
O
AC
AC
AC
RE AC
RE
RE
RE
any marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
Arm 3)
riati
rm 3)
tion Pe
or v
tion Pe
va
o
ns
8
sio
8
on
e
n
e
ny
te
ny
ny
a
ny
11
n a
11
an
a
2
cati
2
io
ca
lic
 a
c
on
za
X
ut
X
th
g a
ark
g
ma
used to support any ma
an
a
t a
pp
a
X
s
X
pp
pp
pp
pp
X
d to
X
o s
ed
This document cannot be used
ed
ed
ed
sed
u
ot
an


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 42 of 353
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IGRA= interferon-gamma release assay; IMP=investigational medicinal product; ITP=immune 
thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; 
NFI-MS=Neurological Fatigue Index for multiple sclerosis; TB=tuberculosis.
a Frequency of assessments on dosing days is detailed in Table 5‒6.
b Visits 7, 9, and 11 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the last dose.
d If the TC is on the same day as an on-site visit, the TC may be skipped.
e A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose.
f The visit windows in the Observation Period are relative to the final dosing visit date. 
g Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
h Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
i Subjects can withdraw at any time during the study, based on the criteria in Section 6.4. 
j A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
k The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
l At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
m The IGRA test will be performed in a central laboratory. Any IGRA-positive subjects will be withdrawn from the study.
n Blood sample for cytokines will be obtained and analyzed at baseline for all subjects and at subsequent visits only in subjects with infusion reactions.
o Exploratory safety biomarker samples to be obtained on dosing days for all subjects. During non-dosing visits and during the visits in the Observation Period, 
the samples should be obtained only from subjects experiencing severe headaches or GI disturbances (only in case of Adverse Events of Interest, see
Section 12.4).
p In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 6 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
q
r This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
s A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
REDACTED COPY 
6.4
OPY
6.4. 
P
. 
Visit. A
COP
Visit. A
essme
TED
essme
D
Gs.
CT
Gs.
the sam
DAC
the sam
RA
RE
RA-
E
-posi
ED
posi
eline 
RE
eline 
to support any marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
C=Da
atio
C=Data M
o
ta M
HIV=hum
riat
HIV=hum
TP=imm
var
TP=imm
c resona
or v
c resona
dosing v
any 
dosing v
mples wi
on a
mples wi
d the val
ation
d the val
ple wi
icat
ple will
t
ll
At al
on
At all oth
n a
l oth
nt of lab
riza
nt of lab
me day f
uth
me day f
itive sub
g au
itive sub
for all s
ting 
for all s
ys for al
ketin
ys for al
severe 
arke
severe 
uced aft
ny m
uced aft
periencin
ppo
periencin
this asse
sup
this asse
ited to C
to s
ited to C
e used
rming L
ed to
rming L
l be use
used
l be use
This document cannot be 
t only.
e us
t only.


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 43 of 353
Table 5-4:
Schedule of assessments for the UCB7665 15mg/kg once dose arm (Dose Arm 4)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consentf
X
Demographic data
X
Verification of 
inclusion/exclusion criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory)g
X
Withdrawal criteriah
X
General medical/procedures 
history
X
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
REDACTED COPY 
PY
OP
C
TE
TE
TE
TE
E
TE
ED
RE
ny marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
d
o
d
va
o
o
b
nsio
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
ap
tio
za
riz
au
z
au
au
au
rk
a
a
nnot be used to support any ma
ny
an
po
su
o s
se
t b
t canno
nn
n
This document 
nt
n


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 44 of 353
Table 5-4:
Schedule of assessments for the UCB7665 15mg/kg once dose arm (Dose Arm 4)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationi
X
X
X
X
X
X
12-lead ECGj
X
X
X
X
Karnofsky Performance Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xk
X
X
X
X
X
X
X
X
X
Serology test for HIV, 
hepatitis B, and hepatitis C
X
IGRA TB testl
X
TB signs and symptoms 
questionnaire
X
X
Blood sample for cytokines
X
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Whole blood sample for DNA 
(optional)
X
REDACTED COPY 
PY
OP
X
ED 
X
C
TE
TE
TE
TE
TE
AC
RE
RE
RE
RE
RE
keting authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
d
o
d
va
o
o
b
nsio
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
ap
X
zati
X
io
za
iz
th
au
g
used to support any marketing 
ket
an
rk
an
an
any
an
pp
o s
o
This document cannot be used to 
o
us
t b
cann


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 45 of 353
Table 5-4:
Schedule of assessments for the UCB7665 15mg/kg once dose arm (Dose Arm 4)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Whole blood sample for RNA 
(optional)
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
Call to IXRS for treatment kit 
number
X
Administration of IMP
X
Blood sampling for plasma 
concentration of UCB7665
X
X
X
Anti-UCB7665 antibodies
X
X
X
X
X
X
X
Serum complements (C3 and 
C4) and plasma complements 
(C3a and C5a)
X
X
X
Blood collection for 
exploratory safety biomarkers
X
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Serum BAFF levels
X
X
X
REDACTED COPY 
P
X
C
X
PY
OP
ED
TE
CT
ED
RE
marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
d
o
d
va
o
o
b
nsio
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
a
ap
za
za
za
za
ho
au
au
au
au
k
au
k
t be used to support any marke
ke
rk
ma
an
X
po
X
t a
X
p
X
pp
o s
ed
This document cannot b
t b
nn
nn
nn
nn


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 46 of 353
Table 5-4:
Schedule of assessments for the UCB7665 15mg/kg once dose arm (Dose Arm 4)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Blood collection for 
exploratory biomarker 
analysis
X
X
X
Immunoglobulins (total IgG, 
IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgE
X
X
X
ITP-specific autoantibodieso
X
X
X
ITP bleeding scale
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
Headache questionnairep
X
X
X
X
X
X
X
X
X
Subject exit interviewq
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IGRA= interferon-gamma release assay; IMP=investigational medicinal product; ITP=immune 
thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; 
NFI-MS=Neurological Fatigue Index for multiple sclerosis; TB=tuberculosis.
a Frequency of assessments on dosing days is detailed in Table 5‒6.
b Visits 5, 7, and 9 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the dose.
REDACTED COPY 
PY
TE
OP
CTE
TE
TE
E
T
RE
RE
RED
RE
y marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
d
o
d
va
o
o
b
nsio
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
za
ap
X
ho
X
ori
au
a
eti
rk
ar
to support any y 
an
X
po
X
rt
pp
o s
o
This document cannot be used t
ng factor
d to 
ng factor
id; ECG
sed 
id; ECG
oglobul
use
oglobul
ctive voi
be u
ctive voi
e Index f
ot b
e Index f
n dosing
nno
n dosing
perform
can
perform
it is 8 w
nt c
it is 8 w


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 47 of 353
d If the TC is on the same day as an on-site visit, the TC may be skipped.
e The visit windows in the Observation Period are relative to the dosing visit date. 
f Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
g Prior to dosing at Visit 1, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
i A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
j The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
k At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
l IGRA test will be performed in a central laboratory. It is recommended that the QFT-GIT be the first test performed at Screening to reduce the number of 
screening procedures conducted for any IGRA-positive subjects that may need to be withdrawn from the study.
m Blood sample for cytokines will be obtained and analyzed at baseline for all subjects and at subsequent visits only in subjects with infusion reactions.
n Exploratory safety biomarker samples to be obtained on dosing days for all subjects. During non-dosing visits and during the visits in the Observation Period, 
the samples should be obtained only from subjects experiencing severe headaches or GI disturbances (only in case of Adverse Events of Interest, see 
Section 12.4).
o
p This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
q A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
PY 
Durin
Y
Durin
ACTED COP
r GI di
OPY
r GI di
es and 
TED
es and 
llowed
ACTE
llowed
REDA
/or LP 
DAC
/or LP 
h ITP.
REDA
h ITP.
R
will 
RE
will 
pplication and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
o dosing
var
o dosing
eck inclu
or v
eck inclu
rior to d
ns o
rior to d
ical exa
xten
ical exa
Three EC
any 
Three EC
let coun
and
let coun
test perf
n a
test perf
m the st
tion
m the st
sequent 
icat
sequent 
non
ppli
non-
pli
-dos
plic
dos
thorization ap
isturban
app
isturban
w
riz
will be 
rizat
ill be 
d by a ne
horiz
d by a ne
g aut
for CSF
utho
for CSF
This document cannot be used to support any marketing
be recor
ting 
be recor


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 48 of 353
Table 5-5:
Schedule of assessments for the UCB7665 20mg/kg once dose arm (Dose Arm 5)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consentf
X
Demographic data
X
Verification of 
inclusion/exclusion criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory)g
X
Withdrawal criteriah
X
General medical/procedures 
history
X
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
REDACTED COPY 
PY
OP
C
TE
TE
TE
TE
E
TE
ED
RE
port any marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
d
o
d
va
o
o
b
n
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
ap
tio
za
riz
au
z
au
au
au
rk
a
a
n
t cannot be used to support any
ny
an
po
su
o s
se
t b
nn
n
This document can
nt
n


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 49 of 353
Table 5-5:
Schedule of assessments for the UCB7665 20mg/kg once dose arm (Dose Arm 5)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationi
X
X
X
X
X
X
12-lead ECGj
X
X
X
X
Karnofsky Performance Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xk
X
X
X
X
X
X
X
X
X
Serology test for HIV, 
hepatitis B, and hepatitis C
X
IGRA TB testl
X
TB signs and symptoms 
questionnaire
X
X
Blood sample for cytokines
X
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Whole blood sample for DNA 
(optional)
X
ACTED COPY 
PY
OP
X
ED 
X
C
TE
TE
TE
TE
TE
REDAC
RE
RE
RE
RE
RE
thorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
d
o
d
va
o
o
b
n
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
ap
X
zati
X
io
za
iz
This document cannot be used to support any marketing auth
th
au
g
ket
an
rk
an
an
any
an
pp
o s
o
us
t b
cann


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 50 of 353
Table 5-5:
Schedule of assessments for the UCB7665 20mg/kg once dose arm (Dose Arm 5)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Whole blood sample for RNA 
(optional)
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
Call to IXRS for treatment kit 
number
X
Administration of IMP
X
Blood sampling for plasma 
concentration of UCB7665
X
X
X
Anti-UCB7665 antibodies
X
X
X
X
X
X
X
Serum complements (C3 and 
C4) and plasma complements 
(C3a and C5a)
X
X
X
Blood collection for 
exploratory safety biomarkers
X
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Serum BAFF levels
X
X
X
REDACTED COPY 
P
X
C
X
PY
OP
ED
TE
CT
ED
RE
marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
d
o
d
va
o
o
b
n
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
a
ap
za
za
za
za
ho
au
au
au
au
k
au
ke
rk
This document cannot be used to support any ma
ma
an
X
po
X
t a
X
p
X
pp
o s
ed
t b
nn
nn
nn
nn


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 51 of 353
Table 5-5:
Schedule of assessments for the UCB7665 20mg/kg once dose arm (Dose Arm 5)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Blood collection for 
exploratory biomarker 
analysis
X
X
X
Immunoglobulins (total IgG, 
IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgE
X
X
X
ITP-specific autoantibodieso
X
X
X
ITP bleeding scale
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
Headache questionnairep
X
X
X
X
X
X
X
X
X
Subject exit interviewq
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IGRA= interferon-gamma release assay; IMP=investigational medicinal product; ITP=immune 
thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; 
NFI-MS=Neurological Fatigue Index for multiple sclerosis; TB=tuberculosis.
a Frequency of assessments on dosing days is detailed in Table 5‒6.
b Visits 5, 7, and 9 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the dose.
REDACTED COPY 
PY
TE
OP
CTE
TE
TE
E
T
RE
RE
RED
RE
y marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
d
o
d
va
o
o
b
n
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
za
ap
X
ho
X
ori
au
a
eti
rk
ar
to support any mar
y 
an
X
po
X
rt
pp
o s
o
cannot be used to
ng factor
d to 
ng factor
id; ECG
sed 
id; ECG
oglobul
use
oglobul
ctive voi
be u
ctive voi
e Index f
ot b
e Index f
n dosing
nno
n dosing
perform
can
perform
This document
it is 8 w
nt c
it is 8 w


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 52 of 353
d If the TC is on the same day as an on-site visit, the TC may be skipped.
e The visit windows in the Observation Period are relative to the dosing visit date. 
f Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
g Prior to dosing at Visit 1, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
i A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
j The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
k At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
l The IGRA test will be performed in a central laboratory. Any IGRA-positive subjects will be withdrawn from the study.
m Blood sample for cytokines will be obtained and analyzed at baseline for all subjects and at subsequent visits only in subjects with infusion reactions.
n Exploratory safety biomarker samples to be obtained on dosing days for all subjects. During non-dosing visits and during the visits in the Observation Period, 
the samples should be obtained only from subjects experiencing severe headaches or GI disturbances (only in case of Adverse Events of Interest, see
Section 12.4). 
o
p This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
q A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
COPY 
GI d
Y
GI d
DACTED 
and w
D C
and wi
C
i
wed by
TED
wed by
LP for
ACTE
LP for
RE
TP.
DA
TP.
will be 
REDA
will be 
ion application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
o dosing
var
o dosing
eck inclu
or v
eck inclu
rior to d
ns o
rior to d
ical exa
xten
ical exa
Three EC
any 
Three EC
elet coun
and
elet coun
wn from
n a
wn from
uent vis
tion
uent vis
i
-
c
-dosing
icat
dosing
urbances
pplic
urbances
authorizat
ll be per
atio
ll be per
y a neuro
rizat
y a neuro
r CSF co
horiz
r CSF co
This document cannot be used to support any marketing a
recorde
g au
recorde


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 53 of 353
Table 5‒6:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of 
infusion
4h after end of 
infusion
6h after end of 
infusiona
Withdrawal criteria
X
Platelet count (local laboratory) for 
inclusion check at Visit 2 and for 
withdrawal criterion at other dosing visits
X
Prior and concomitant medications
X
Concomitant medical procedures
X
Vital signsb
X
X
X
X
X
Physical examination
X
12-lead ECGc
X
Hematology 
X
Clinical chemistry
X
Urinalysis
X
Urine pregnancy test
X
Immunoglobulinsd
X
ITP-specific autoantibodiese
X
Blood sampling for UCB7665 plasma 
concentration
X
Anti-UCB7665 antibodies
X
Serum (C3 and C4) and plasma 
complements (C3a and C5a)f
X
Blood collection for exploratory safety
biomarkersg
X
X
X
Serum BAFF levels
X
ACTED COPY 
PY
PY
PY
PY
PY
C
TE
REDAC
AC
RE
thorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
on
of 
or
of 
on
s
on
va
ns
ns
an
a
an
X
at
X
ion
ica
ap
ion
ati
iza
t be used to support any marketing authoriza
th
g a
eti
ar
y
X
upp
X
po
X
su
e
se
y
ed
nnot b
se
t b
This document cann
nn


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 54 of 353
Table 5‒6:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of 
infusion
4h after end of 
infusion
6h after end of 
infusiona
Blood collection for exploratory 
biomarker analysis
X
Blood sampling for cytokines
Xh
Xi
Whole blood sample for DNA and RNA 
(optional)j
X
ITP bleeding scale
X
AEs
X
X
X
X
X
NFI-MSk
X
AE=adverse event; BAFF=B cell activating factor; DNA=deoxyribonucleic acid; ECG=electrocardiogram; h=hours; Ig=immunoglobulin; IMP=investigational 
medicinal product; ITP=immune thrombocytopenia; NFI-MS=Neurological Fatigue Index for multiple sclerosis; PRO=Patient Reported Outcomes; 
RNA=ribonucleic acid; 
a For Dose Arms 3, 4 and 5 only
b In addition to time points mentioned, vital signs will be evaluated every 15 minutes during infusion. Respiratory rate will be assessed only once predose.
c The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
d Total IgG and IgG subclasses. 
e Evaluation of ITP-specific autoantibodies will be performed prior to dose 1 only. 
f Serum and plasma complements (C3a and C5a) will be assessed prior to dose 1 and dose 3 only.
g
h Blood sample for Baseline cytokine values will be obtained and analyzed at Baseline (Visit 2) pre-dose for all subjects. Also for all subjects on Dose Arm 3, the 
blood sample for cytokine values will be obtained and analyzed at Visit 4 pre-dose.
i Additional cytokine blood sample to be taken at 4h after end of infusion only in subjects with infusion reaction.
j For DNA, samples are taken at Baseline (Visit 2) and last dose only. For RNA, samples are taken at Baseline (Visit 2), Visit 3, at last dose, and End of Study 
Visit. All samples collected prior to dosing (if applicable for visit).
k PRO endpoint (NFI-MS) will be assessed prior to dose 1 only.
REDACTED COPY 
OPY
P
ECG=
COP
ECG=
atigue I
D C
atigue I
ry 15 m
DAC
ry 15 m
n for as
REDA
n for as
the E
RE
the E
marketing authorization application and any extensions or variations thereof.
15 
here
15 Fe
e
Fe
on
on
of 
or
of 
on
s
on
va
ns
xte
y
a
an
X
cat
X
tio
lic
ap
=electro
on a
=electro
Index fo
ation
Index fo
minutes 
utho
minutes 
ssessme
au
ssessme
CGs.
ng
CGs.
or t
ark
or to dos
arke
o dos
ed prior
mar
ed prior
support any
ned and
t any
ned and
d analyz
ort a
d analyz
h after e
ppo
h after e
2) and la
supp
2) and la
This document cannot be used to 
if applic
to su
if applic
prior to
d to
prior to
ny m


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 55 of 353
5.3
Schematic diagram
Figure 5‒1 presents a schematic diagram for the study design.
Figure 5‒1: Schematic diagram
DMC=Data Monitoring Committee; EOS=End of Study
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
End of S
arke
End of S
eting authorization application and any extensions or variat


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 56 of 353
5.4
Rationale for study design and selection of dose
5.4.1
Pathophysiology of ITP
Production of pathogenic autoantibodies is a major feature of a number of autoimmune diseases 
often associated with a specific pathomechanism. Autoantibodies against platelet antigens are 
considered to be a hallmark of ITP. Production of pathogenic IgG autoantibodies by plasma cells 
is accepted as the central underlying pathophysiological mechanism in a number of 
IgG-mediated autoimmune diseases, which includes ITP. In some patients, antibodies recognize 
antigens derived from a single glycoprotein; whereas in others, antibodies recognize multiple 
glycoproteins. The spleen is the key organ in the pathophysiology of ITP, not only because 
platelet autoantibodies are formed in the white pulp, but also because mononuclear macrophages 
in the red pulp destroy immunoglobulin-coated platelets.
Treatments aimed at reducing the quantity of circulating IgG autoantibodies are being used for 
primary and secondary therapy of autoimmune diseases, particularly where corticosteroid-based 
immune suppression is not or no longer effective. The therapeutic approach of these treatments is 
based on lowering levels of pathogenic autoantibodies, which represents rational and effective 
treatment modalities of autoimmune diseases.
5.4.2
Mechanism of action of UCB7665
UCB7665 is a humanized IgG4 monoclonal antibody that is being developed as an inhibitor of 
the activity of FcRn. The FcRn receptor recycles IgG and albumin and transports it 
bidirectionally across epithelial barriers. Recent studies have shown that FcRn rescues both IgG 
and albumin from intracellular lysosomal degradation by recycling it from the sorting endosome 
to the cell surface (Anderson et al, 2006). UCB7665 has been specifically designed to block IgG 
binding to FcRn without blocking the binding and recycling of albumin.
By blocking the activity of FcRn, UCB7665 accelerates the catabolism of IgG antibodies, 
including IgG autoantibodies. The aim is to reduce the concentration of pathogenic IgG in 
patients with autoimmune diseases mediated by the action of IgG autoantibodies.
5.4.3
Choice of study design and endpoints
The primary objective of the study is evaluation of safety and tolerability of UCB7665 
administered as an sc infusion in subjects with ITP. The study utilizes a sequential adaptive 
design with at least 11 interim analyses as described in Section 14.7. This design was chosen to 
permit adequate monitoring of the safety of the subjects in the study.
The study will evaluate the platelet count as a surrogate marker for clinical efficacy in ITP in 
accordance with the European Medicines Agency (EMA) guidance for clinical development of 
medicinal products for chronic ITP (EMA/CHMP/153191/2013, 2014). The platelet count 
measures treatment activity and is believed to be a reliable predictor of clinical benefit. 
Endpoints related to Response and Complete Response as defined in the guidance will be 
evaluated. In addition, a platelet response of >50x109/L will be evaluated in the study.
5.4.4
Safety of UCB7665
Safety and tolerability of UCB7665 7mg/kg sc dose has been evaluated in healthy subjects. The 
most common TEAEs were mild to moderate gastrointestinal disturbances (nausea, vomiting, 
REDACTED COPY
y that 
PY 
that 
y
gG an
COP
gG an
t studi
ED C
t studi
gradat
CTED
gradat
UCB
ACT
UCB
bindin
EDA
bindin
B7
R
B7
nnot be used to support any marketing authorization application and any extensions or variations thereof.
ze
ri
ze
le
v
le
se
o
se
acroph
ons 
acroph
e being
exte
e being
cortico
y e
cortico
ach of t
d any
ach of t
nts rati
and 
nts rati
is being
appl
is being
nd albu
on ap
nd albu
ies hav
atio
ies hav
ation by
oriza
ation by
B7665 h
thor
B7665 h
ng and 
aut
ng and 
7665 ac
eting
7665 ac
m is to
arket
m is to
s media
mar
s media
ud
an
udy 
any
y de
y
de
the stu
port 
the stud
nfusion
upp
nfusion
11
o
1 inte
o su
inte
monito
ed to
monito
ill evalu
e use
ill evalu
e with 
be 
e with 
nal pro
not 
nal pro
This document ca
asures t
cann
asures t
Endpoin
nt ca
Endpoin
evalu
men
evalu
5


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 57 of 353
and diarrhea) and headaches ranging from mild to moderate intensity. Details of AEs seen with 
UCB7665 7mg/kg administered by the iv route are presented in Section 5.4.5.
5.4.5
Rationale for dose selection
A single ascending dose study in healthy subjects (UP0018) explored the dose range of 
UCB7665 (between 1 and 7mg/kg) and characterized the PK and PD effect on total IgG. 
Preliminary data indicate that mean absolute decreases in IgG and mean percent change from 
Baseline IgG were greater in the active dose groups (n=6 each) compared to the pooled iv and sc 
placebo group (n=12) with maximum decreases of 49.3% (range: 44.6% to 55.9%) observed on 
Day 6 for a UCB7665 7mg/kg iv dose and 42.8% (range: 39.6% to 48.6%) on Day 9 for a 
UCB7665 7mg/kg sc dose.
The dose-exposure-response relationship, with total IgG as primary endpoint, was determined 
using non-linear mixed effects modeling. The derived population PK-PD (structural PK-PD 
model based on that of Lowe [Lowe et al, 2010]) was then used to guide, through simulation, the 
selection of appropriate repeat dose regimens that would mimic decreases achieved by 
plasmapheresis paradigms and result in IgG reductions of 70% or greater. 
The model-based simulations demonstrate that weekly doses of UCB7665 4mg/kg for 
5 consecutive weeks are expected to produce maximum mean IgG reductions of >70%. Similar 
reductions are predicted to be achieved following 3 consecutive weekly doses of
UCB7665 7mg/kg.
Following iv administration in UP0018, the maximum tolerated dose was identified as 
UCB7665 4mg/kg due to AEs seen at the higher dose of 7mg/kg with severe headache and 
moderate diarrhea being reported. The tolerability profile of UCB7665 7mg/kg given as an sc 
infusion was more favorable than the equivalent iv dose and similar to the UCB7665 4mg/kg iv 
dose with mild to moderate cases of gastrointestinal disturbances and headaches being reported 
at a lower incidence.
Therefore, doses of UCB7665 4mg/kg given once weekly for 5 weeks(Dose Arm 1) and 
UCB7665 7mg/kg given once weekly for 3 weeks (Dose Arm 2) have been selected as the initial 
doses to evaluate the safety, tolerability and effect on platelet count in subjects with primary 
persistent or chronic ITP. Both dose regimens have the same cumulative dose of approximately
UCB7665 20mg/kg.
Preliminary data from the current study indicates that the current dose regimens of UCB7665 
4mg/kg and UCB7665 7mg/kg have been well tolerated. Hence the additional dose regimens of 
UCB7665 10mg/kg given once weekly for 2 weeks (Dose Arm 3) and of UCB7665 20mg/kg 
given once only (Dose Arm 5) are planned to further investigate the safety, tolerability and effect 
on platelet count of the same cumulative dose of UCB7665 20mg/kg but administered in dose 
regimes with higher dosages given in less infusions. The dose of UCB7665 15mg/kg given once 
only (Dose Arm 4) has been selected in addition as a risk mitigation as it is bridging the dose of 
UCB7665 10mg/kg given once weekly for 2 weeks (Dose Arm 3) and the dose of UCB7665 
20mg/kg given once only (Dose Arm 5).
REDACTED COPY 
nse
Y
nse
ximum
D C
ximum
gher do
CTED
gher do
erabil
ACT
erabil
quiva
EDA
quiva
gastro
RE
gastro
ent cannot be used to support any marketing authorization application and any extensions or variations thereof.
sc
ria
sc
d on 
var
d on 
a
s determ
ensi
s determ
ctural P
exte
ctural P
rough s
ny ex
rough s
s achie
d any
s achie
ater. 
and
ater. 
CB766
ion 
CB766
IgG red
icatio
IgG red
tive we
plic
tive we
m toler
ation
m toler
dose of 
oriza
dose of 
lity pro
thor
lity pro
alent iv
aut
alent iv
rointest
ting a
rointest
g/kg gi
mar
g/kg gi
weekl
ny m
weekly
m
y
tolerab
rt an
tolerab
Both d
port
Both d
om
to
om the
o s
the
CB7665
sed 
CB7665
0mg/kg
e us
0mg/kg
ce onl
t be
ce only
e 
y
telet co
not 
telet co
mes w
cann
mes w
only
nt c
only (D
t c
(D
y
t c
y
This documen
UCB
men
UCB
20
m
20


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 58 of 353
5.4.6
Justification for additional genomic analyses
DNA analysis
A genetic component in ITP has long been suspected to predispose some persons to develop ITP 
when exposed to a provocative event.
Further, the hypothesis of underlying genetic risk for ITP is supported by rare anecdotal and case 
reports of familial ITP. Affected members of these families present with ITP that meets the 
clinical criteria for primary ITP, but demonstrates a convincing pattern of inheritance. A 2006 
review of the Pediatric and Adult Registry of Chronic ITP (PARC-ITP) (Johnsen, 2012) found 
that 10 of 445 (2.2%) of pediatric patients reported a positive family history of ITP. However, 
identification of susceptibility genes in ITP, via family linkage studies or genome wide 
association studies, have not yet been forthcoming, likely due to the rarity of familial ITP 
families available for study and the heterogeneity of ITP sporadic cases. Identification and 
characterization of a genetic and/or epigenetic component of familial ITP will lead to important 
clues into the pathogenesis of more common forms of ITP and possibly advance understanding 
of drug response phenotypes. 
RNA analysis
Gene expression (mRNA) analyses have identified distinct gene transcription signatures from 
whole blood associated with many autoimmune diseases including rheumatoid arthritis, systemic 
lupus erythematosus, and ITP. Such signatures have provided molecular insight into disease 
biology and can facilitate patient stratification via gene expression panels predictive of 
therapeutic response and clinical outcomes. 
Collection of blood for RNA analysis will enable identification of candidate markers for 
treatment effect and safety, and determine the feasibility of patient stratification.
MicroRNA analysis
MicroRNA are short (19-25 nucleotides) evolutionarily conserved single-stranded RNA 
molecules that regulate the expression of genes involved in diverse biological processes. The 
effect of miRNA on mRNA is mediated through the binding of the miRNA to the target mRNA 
ribonucleoprotein complex resulting in altered expression and decreased protein translation.  
Regulated miRNA in ITP significantly affect both gene and protein expression in T cells, 
indicating that they may be important regulatory molecules involved in the loss of immune 
tolerance in ITP.
In summary, the genetic, epigenetic, and genomic elements of ITP are complex and require 
further elucidation to understand the cause, progression, and appropriate treatment of ITP. 
Through the voluntary collection of blood DNA/and RNA samples from consenting subjects, this 
substudy will help enable further investigation of this complex disease.
6
SELECTION AND WITHDRAWAL OF SUBJECTS
6.1
Inclusion criteria
To be eligible to participate in this study, all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by the subject.
REDACTED COPY
ses in
PY 
ses in
ve prov
COP
ve prov
via gen
D C
via gen
ll ena
DAC
ll ena
mine t
RED
mine t
annot be used to support any marketing authorization application and any extensions or variations thereof.
ound 
or va
ound 
wever,
s or
wever,
de 
io
de 
ilial ITP
ensi
ilial ITP
fication
exte
fication
ill lead
ny ex
ill lead
dvance
any
dvance
ne tran
lica
ne tran
ncludin
appl
ncludin
vided m
on ap
vided m
ne expr
ation
ne expr
ble ide
utho
ble ide
the fea
g au
the fea
otides) 
mark
otides) 
ession 
ny m
ession 
is medi
t any
is medi
x resul
port 
x resul
ITP sig
supp
ITP sig
y
d
y may
d to 
may
y
d
y
b
s
b
y
.
y
b
y, the
be us
, the g
s
g
lucidat
ot be
lucidat
ugh the 
nno
ugh the 
nt ca
study
can
study
This documen
6
ment
6
6


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 59 of 353
2. Subject is considered reliable and capable of adhering to the protocol, visit schedule, or 
medication intake according to the judgment of the investigator.
3. Subject is male or female, ≥18 years of age at Visit 1 (Screening).
4. Subject has a diagnosis of primary ITP for a minimum of 3 months prior to Screening Visit. 
5. Subject has a platelet count <30x109/L at Screening and <35x109/L at Baseline (Visit 2).
Measured as follows: At Screening Visit, 2 separate blood collections for platelet count to be 
performed on the same day with at least 1 value below 30x109/L and both values below 
35x109/L. At Baseline Visit (Visit 2), a platelet measure will be taken locally and the value 
should be below 35x109/L.
6. Subject has a current or history of a peripheral blood smear consistent with ITP 
(thrombocytopenia with normal size or only slightly enlarged platelets and normal red and 
white blood cell morphology).
7. Female subjects of childbearing potential must have a negative serum pregnancy test at the 
Screening Visit, which is confirmed to be negative by urine testing prior to the first dose of 
IMP at Week 1 (Visit 2) and prior to further dosing at each study visit thereafter. 
Female subjects of childbearing potential must agree to use a highly effective method of birth 
control, during the study and for a period of 2 months after their final dose of IMP. Highly 
effective forms of birth control are methods which achieve a failure rate of less than 1% per 
year when used consistently and correctly. Highly effective methods of birth control include:

Combined (estrogen- and progesterone-containing) hormonal contraception (oral, 
implant, injectable) associated with inhibition of ovulation (which must be stable for at 
least 1 full month prior to Screening [Visit 1], and should remain stable during the study).

Progesterone-only hormonal contraceptives (oral, implant, injectable) associated with 
inhibition of ovulation (which must be stable for at least 1 full month prior to Screening 
[Visit 1], and should remain stable during the study).

Progesterone-releasing intrauterine systems or the TCu 380A intrauterine device.

Vasectomized partner (provided sole partner and partner has medical proof of surgical 
success).

True heterosexual sexual abstinence is an acceptable form of contraception when this is 
in line with the preferred and usual lifestyle of the person. Periodic abstinence (eg, 
calendar, ovulation, symptothermal, postovulation methods), declaration of abstinence for 
the duration of the study, and withdrawal are not acceptable methods of contraception.
Women not agreeing to use birth control must be of nonchildbearing potential, defined as 
being:

Postmenopausal (for at least 2 years before the Screening Visit), verified by serum 
follicle-stimulating hormone level >40mIU/mL at the Screening Visit, or

Permanently sterilized (eg, bilateral tubal occlusion, hysterectomy, bilateral 
salpingectomy), or

Congenitally sterile
ACTED COPY
nths 
PY 
nths 
hich ac
COP
hich ac
Highl
D CO
Highly
C
y
one
CT
one-co
TE
-co
REDA
ith inh
DAC
ith inh
eening
REDA
eening
R
horization application and any extensions or variations thereof.
e
ia
e
value
or v
value
P
e
P 
normal
exten
normal
m pregn
d an
m pregn
ng prior
and
ng prior
d
io
dy visi
ion a
y visi
e a high
licat
e a high
fter the
ppli
fter the
chieve 
n ap
chieve 
y
a
y effect
tion
effect
ontainin
horiz
ontainin
to support any marketing aut
hibition
utho
hibition
g [Visit
g au
g [Visit
ntrac
keting
ntracep
ng
ep
ch must
arke
ch must
ain stab
y ma
ain stab
ng intra
t any
ng intra
artner
ppo
artner
be used 
(p
(p
rosexu
d to
rosexu
with th
used
with th
endar, o
be u
endar, o
This document cannot 
he dura
ot be
he dura
Women
cann
Women
bein
nt ca
bein


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 60 of 353
8. Contraception methods for male subjects and their female partners:

Male subject with a partner of childbearing potential must be willing to use a condom 
when sexually active during the study and for 3 months after the final administration of 
IMP.

In addition the female partner of childbearing potential of a male subject must be willing 
to use a highly effective method of contraception (as above), during the study period and 
for 3 months after the final administration of IMP.
9. Subject has adequate peripheral venous access.
10. Subject has responded to previous ITP therapy (according to the judgment of the 
investigator).
6.2
Exclusion criteria
Subjects are not permitted to enroll in the study if any of the following criteria are met:
1. Subject has participated in another study of an IMP (or a medical device) within the previous 
30 days of Screening Visit or is currently participating in another study of an IMP (or a 
medical device).
2. Subject has a known hypersensitivity to any components of the IMP.
6.2.1
Exclusion criteria related to health status
3. Subject has a Karnofsky Performance Status (Appendix 18.1) rating <60% at Screening
Visit.
4. Subject has an IgG level ≤6g/L at Screening Visit.
5. Subject has a partial thromboplastin time (PTT) ≥1.5x upper limit of normal (ULN) or 
International Normalized Ratio (INR) ≥1.5 at Screening Visit.
6. Subject has any medical condition (acute or chronic illness) or psychiatric condition that, in 
the opinion of the investigator, could harm the subject or would compromise the subject’s 
ability to participate in this study.
7. Subject has 12-lead ECG with changes considered to be clinically significant upon medical 
review. 
8. Subject has a glycosylated hemoglobin (HbA1c) value >8% at Screening Visit.
9. Subject has renal impairment, defined as:

Serum creatinine level of ≥1.4mg/dL for females and ≥1.5mg/dL for males at 
Screening Visit. 
10. Subject has 2xULN of any of the following: alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), or alkaline phosphatase (ALP), or >ULN total bilirubin (≥1.5xULN 
total bilirubin if known Gilbert’s syndrome). If the subject has elevations only in total 
bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible
undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
REDACTED COPY 
onen
Y
onen
alth 
COP
alth 
us
ED
us (
ED
(Ap
D C
Ap
creeni
EDAC
creeni
tin t
RE
tin t
arketing authorization application and any extensions or variations thereof.
eria 
any
eria ar
y 
ar
device)
and 
device)
er stud
on an
er stud
 of the 
pplic
 of the 
status
n ap
status
ppendix
zatio
ppendix
ing
aut
ing Vis
uth
Vis
time (P
ting 
time (P
NR)
rket
NR) ≥1
eti
≥1
This document cannot be used to support any m
ition (a
ma
ition (a
ator, co
any m
ator, co
his stud
rt an
his stud
ECG w
uppo
ECG w
a gly
ed t
a glyco
t
co
has ren
e us
has ren
Serum 
ot b
Serum 
Scre
nno
Scre
0.
nt
0. Subj
nt ca
Subj
a
n
a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 61 of 353
For subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, a Baseline 
diagnosis and/or the cause of any clinically meaningful elevation must be understood and 
recorded in the electronic Case Report form (eCRF).
If subject has >ULN for ALT, AST, or ALP that does not meet the exclusion limit at 
screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject 
must be discussed with the Medical Monitor. 
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. This includes rescreening (see Section 6.3).
11. Female subject who is pregnant or lactating.
12. Subject has planned an elective surgical procedure in the coming 6 months.
6.2.2
Exclusion criteria related to medical history
13. Subject has a history of chronic alcohol or drug abuse within the previous 12 months of 
Screening Visit.
14. Subject has evidence of a secondary cause of immune thrombocytopenic purpura from the 
past medical history (eg, bacterial or viral infection, past medical history of leukemia, 
lymphoma, common variable immunodeficiency, systemic lupus erythematosus, 
auto-immune thyroid disease) or to drug treatments (eg, heparin, quinine, antimicrobials, 
anticonvulsants) or subject has a multiple immune cytopenia, eg, Evan’s syndrome.
15. Subject has a history of clinically relevant ongoing chronic infections including but not 
limited to human immunodeficiency virus (HIV), hepatitis B, hepatitis C, active or latent 
tuberculosis, or is tested positive for HIV, hepatitis B, or hepatitis C at the Screening Visit.
16. Subject has a family history of primary immunodeficiency.
17. Subject has a clinically relevant active infection (eg, sepsis, pneumonia, abscess) or has had a 
serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) 
within 6 weeks prior to the first dose of IMP.
18. Subject has active neoplastic disease or history of neoplastic disease within 5 years of 
Screening Visit (except for basal or squamous cell carcinoma of the skin or carcinoma in situ 
of the uterine cervix which has been definitively treated with standard of care approaches). 
19. Subject has a history of a major organ transplant or hematopoietic stem cell/marrow 
transplant.
20. Subject has a history of known inflammatory bowel disease, diverticular disease, or has a 
history of confirmed, duodenal, gastric or esophageal ulceration in the past 6 months.
21. Subject has experienced a clinically symptomatic gastrointestinal bleed (positive hemoccult 
tests without any signs and symptoms of gastrointestinal bleedings will not be considered as 
“clinically symptomatic”) in the last 6 months prior to Screening Visit and/or has current 
gastritis or esophagitis and/or has a known risk for clinically relevant gastrointestinal
bleeding beyond ITP.
22. Subject has experienced intracranial bleed in the last 6 months prior to Screening Visit.
REDACTED COPY
sy
PY
syste
PY 
ste
ments (
COPY
ments (
mmune
D CO
mmune
nt ong
CTE
nt ong
virus 
DAC
virus 
for HIV
REDA
for HIV
m
R
m
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
eated 
var
eated 
vious 1
d an
vious 1
bocy
ation
bocytop
on
top
yty
on
yty
medical
licat
medical
mic lup
ppli
mic lup
(eg
n
(eg,
n a
, hep
ap
hep
e cy
atio
e cytop
on
top
yty
o
yty
going c
oriza
going c
(
u
(HI
uth
HIV),
ho
V),
V, hep
g au
V, hep
mary im
keting
mary im
m
active
mark
active
n hospi
ny m
n hospi
he first 
t any
he first 
oplastic
ppor
oplastic
xcept f
supp
xcept f
ervix w
to s
ervix w
s a histo
sed
s a histo
nt.
be
nt.
ject has
ot b
ject has
istory
anno
istory o
o
o
y
o
y
1.
nt
1. Sub
nt c
Sub
t
n
t


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 62 of 353
23. Subject has a medical history of thrombosis within the past 5 years or a history of thrombosis 
with unknown cause at any time or a significant known risk for thrombosis.
24. Subject has a history of coagulopathy disorders other than ITP.
25. Subjects with known tuberculosis (TB) infection, at high risk of acquiring TB infection, or 
with latent TB (LTB) infection or current history of nontuberculous mycobacterial infection 
(NTMBI) are excluded.
a.
Known TB infection whether present or past is defined as:

Active TB infection or clinical signs and symptoms suggestive of TB (pulmonary or 
extrapulmonary).

History of active TB infection involving any organ system or findings in other organ systems 
consistent with TB infection.

Any historical evidence by radiography or other imaging modalities consistent with 
previously active TB infection.
b. High risk of acquiring TB infection is defined as:

Known exposure to another person with active TB infection within the 3 months prior to 
Screening.

Time spent in a healthcare delivery setting or institution where individuals infected with TB 
are housed and where the risk of transmission of infection is high.
c.
LTB infection (refer to Section 12.8.1 for further details and instructions).
d. NTMBI is defined as a group of lung infections caused by mycobacteria different from 
mycobacterium tuberculosis infections.
26. Subjects with known TB infection, at high risk of acquiring TB infection, or LTB infection, 
or current/history of NTMBI are excluded.
6.2.3
Exclusion criteria related to concomitant medications/procedures
27. Subject has received a live vaccination within 8 weeks prior to the Baseline Visit; or intends 
to have a live vaccination during the course of the study or within 7 weeks following the final 
dose of IMP. 
28. Subject has received any experimental biological agent within or outside of a clinical study in 
the past 3 months or within 5 half-lives prior to Baseline (whichever is longer).
29. Subject has had prior treatment with rituximab in the 6 months prior to the Baseline Visit or 
subject has had prior treatment with rituximab in the 12 months prior to Baseline and B cells 
are not within the normal range.
30. Subject has not completed the washout period for the immunosuppressants, biologics and 
other therapies as detailed in Table 6‒1. Medications as presented in Table 6‒1 are prohibited 
during the study.
Subject is currently receiving any of the prohibited medications listed in Section 7.8.2 or 
receiving immunosuppressant medications in doses higher than the maximum permissible 
dose for the study as per Section 7.8.1.
REDACTED COPY 
nstitut
COP
nstitut
on of i
D CO
on of i
or furt
CTE
or furt
ng infe
EDAC
ng infe
ctions
RED
ctions
to support any marketing authorization application and any extensions or variations thereof.
r organ 
ensio
r organ 
nsisten
any 
nsisten
n within
catio
n within
tion wh
on ap
tion wh
infectio
ation
infectio
her de
oriz
her de
ections 
auth
ections 
.
n, at hig
rketi
n, at hig
e exclu
mark
e exclu
teria r
ny m
teria r
live
ort
live va
t a
va
nation d
uppo
nation d
nnot be used
eceived
ed to
eceived
month
use
month
ct has h
t be
ct has h
bject ha
nnot 
bject ha
This document ca
are not
cann
are not
30.
ent
30. Su
nt 
Su


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 63 of 353
Table 6‒1:
Washout periods for immunosuppressants, biologics and other 
therapies
Generic name (most common commercial/trade 
names)
Washout period relative to Baseline Visit 
(regardless of route)
Immunosuppressants
Cyclophosphamide 
6 months
Pimecrolimus (Elidel®)
4 weeks
Vinca alkaloids (vincristine, vinblastine)
12 weeks
Biologics (mAbs and fusion proteins)
Abatacept (CTLA 4-Ig) (Orencia®)
6 months
Belimumab (Benlysta™)
6 months
Golimumab (Simponi™)
6 months
Natalizumab (Tysabri®)
6 months
Ofatumumab (Arzerra)
6 months
Rituximab (Rituxan®) and ocrelizumab
6 months
TACI-Ig (Atacicept)
10 months
Veltuzumab
6 months
Other biologics
3 months
Others
Intravenous immunoglobulin
4 weeks
IPP-201101 (Lupuzor™)
3 months
Plasma exchange (PLEX)
4 weeks
TPO-R agonists (eltrombopag, romiplostim)
4 weeks
Anti-D
4 weeks
Antiplatelets and Anticoagulants (Vitamin K 
antagonists)
Warfarin
2 weeks
Fenprocoumon
2 weeks
Acenocoumarol
2 weeks
Heparin
1 week
Clopidogrel
1 week
Salicylates (Aspirin)
1 week
Dipyramidole
1 week
REDACTED COPY
onths
PY 
onths
10 
CO
10 mo
CO
mo
OP
D
6
D
6
D C
ED
CT
DA
R
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
i
ati
ari
or 
on
en
ex
an
an
tio
lic
onths
ion
onths
ap
month
izat
month
tio
3 m
ho
3 m
or
uth
au
ing
rk
m
ag, romi
port 
ag, romi
t a
po
d
Antic
d to 
Antic
anta
sed 
anta
s
us
oumon
not b
oumon
be
nocoum
can
nocoum
nn
Hepari
ent 
Hepari
t c
m
Cl
m
Cl
me
um


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 64 of 353
Table 6‒1:
Washout periods for immunosuppressants, biologics and other 
therapies
Generic name (most common commercial/trade 
names)
Washout period relative to Baseline Visit 
(regardless of route)
Prasugrel
1 week
Ticagrelor
1 week
Tirofiban
1 week
Abciximab
1 week
31. Subject has undergone a splenectomy in the 3 months prior to the Baseline Visit or subject 
was splenectomized >3 months prior to Baseline but was not vaccinated following local 
recommendations. 
32. Subject has received IVIg in the 4 weeks prior to the Baseline Visit.
33. Subject has received TPO-R agonists in the 4 weeks prior to Baseline Visit.
34. Subject has received cyclophosphamide in the 6 months prior to the Baseline Visit.
35. Subject has received anti-D immunoglobulin in the 4 weeks prior to the Baseline Visit.
6.3
Rescreening
Subjects with isolated test results that are outside the specified ranges and that are deemed 
potentially as clinically non-significant can be enrolled without retesting at the discretion of the 
investigator, following discussion and agreement with the Medical Monitor/study physician, if 
appropriate. If a subject has 1 isolated test result outside the specific range which is deemed 
clinically significant, retesting may be allowed at the discretion of the investigator, following 
discussion and agreement with the Medical Monitor/study physician. If the normalization of the 
test result occurs within the Screening Period, then no other screening procedures need to be 
repeated.
6.4
Withdrawal criteria
Subjects are free to withdraw from the study at any time, without prejudice to their continued 
care.
Subjects should be withdrawn from the study if any of the following events occur:
1. Subject withdraws his/her consent.
2. Subject develops an illness or has a change in health status that would interfere with his/her 
continued participation, including but not limited to:

Subject has a serious infective episode requiring hospitalization or iv antibiotic therapy 
(including but not limited to bacteremia or sepsis, bacterial meningitis, osteomyelitis or 
septic arthritis, bacterial pneumonia, or visceral abscess).

Subject experiences a severe AE of gastrointestinal disturbance or headache which is
considered related to the IMP in the opinion of the investigator.
REDACTED COPY
e 4 w
PY 
e 4 w
side th
TED 
side th
n be en
ACTE
n be en
gr
EDA
greem
DAC
eem
d test 
RED
d test 
e a
R
e a
keting authorization application and any extensions or variations thereof.
i
ati
ari
or 
on
it
n
it or su
nsio
or su
llowing
exten
llowing
seline V
n an
seline V
or to th
catio
or to th
eeks pr
pplic
eeks pr
he spec
izat
he spec
nrolled
horiz
nrolled
ment 
auth
ment wi
th
wi
result 
ng a
result 
allowed
keting
allowed
mark
M
a
M
nnot be used to support any m
edical
arke
edical
ening P
ma
ening P
wal cr
ort 
wal cr
ithdraw
supp
ithdraw
d be wi
sed
d be wi
t withd
be u
t withd
bject 
nnot
bject d
t 
d
This document ca
continu
cann
continu

n



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 65 of 353

Subject has a severe infusion reaction requiring corticosteroid and/or epinephrine 
therapy.

Subject has an anaphylactic reaction requiring corticosteroid and/or epinephrine therapy.

Subject has a life threatening bleeding event.

Subject has a TB test that is confirmed positive or any further evidence suggestive of
potential TB infection (eg, close exposure) and further examinations result in a diagnosis 
of active TB or LTB. Refer to Section 12.8.1 for further details and instructions.

If an NTMBI infection is identified during a study, the same withdrawal procedures as 
those used for an active TB infection identified during the study should be followed.
3. Subject requires rescue therapy (Section 7.8.3).
4. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test.
5. The sponsor or a regulatory agency requests withdrawal of the subject.
Subjects MAY be withdrawn from the study if any of the following events occur:
1. Subject is noncompliant with the study procedures or medications in the opinion of the 
investigator.
2. Subject takes prohibited concomitant medications as defined in this protocol that could 
compromise subject’s safety.
Subjects MUST stop treatment with the IMP if the platelet count is >350x109/L during the 
Dosing Period. Subjects should continue in the study and attend the protocol defined visits in the 
Observation Period.
6.4.1
Potential drug induced liver injury IMP discontinuation criteria
Subjects with PDILI must be assessed to determine if IMP must be discontinued. In addition, all 
concomitant medications and herbal supplements that are not medically necessary should also be 
discontinued.
The PDILI criteria below require immediate and permanent discontinuation of IMP:

Subjects with either of the following:

ALT or AST ≥5xULN

ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
The PDILI criterion below requires immediate discontinuation of IMP:

Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
If a nondrug-related cause for the symptoms can be confirmed, these subjects may resume IMP 
administration after discussion with responsible UCB physician, but only when the requirements 
for rechallenge with IMP as provided in Section 12.7.1.2.1 are followed.
REDACTED COPY 
tions a
CO
tions a
MP if t
ACT
MP if t
ue in th
EDA
ue in th
ed to support any marketing authorization application and any extensions or variations thereof.
s
i
s
res as
s or 
res as
owed.
ons 
owed.
positiv
y ext
positiv
ject.
and
ject.
ng even
tion 
ng even
dication
licat
dication
as defin
tion a
as defin
the pla
thori
the pla
he stud
auth
he stud
ced liv
rketi
ced liv
ssed to
ma
ssed to
herbal s
any 
herbal s
w 
p
w requ
uppo
requ
annot be use
ther
to s
ther of
s
of
AST 
sed
AST ≥
T
b
T or A
be u
or A
DILI cr
not
DILI cr
This document ca
Subje
t ca
Subje
he
nt 
he


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 66 of 353
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
investigator.

Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain, or tenderness).
Evaluation of PDILI must be initiated as described in Section 12.7.1. If subjects are unable to 
comply with the applicable monitoring schedule, IMP must be discontinued immediately.

For all other withdrawal criteria, investigators should contact the Medical Monitor, whenever 
possible, to discuss the withdrawal of a subject in advance. Subjects who are withdrawn will 
not be replaced.
Subjects who decide to withdraw from the study will be encouraged to return to the clinic for all 
visits during the Observation Period and to complete the End-of-Study Visit (scheduled 8 weeks 
after final dose of IMP). If a subject is unwilling to complete the Observation Period, then 
subjects will be encouraged to complete at least 2 more study visits: Early Withdrawal Visit and 
End-of-Study Visit.
Investigators should attempt to obtain information on subjects in the case of withdrawal or 
discontinuation. For subjects considered as lost to follow up, the investigator should make an 
effort (at least 1 phone call and 1 written message to the subject), and document his/her effort 
(date and summary of the phone call and copy of the written message in the source documents), 
to complete the final evaluation. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in the source 
documents. The eCRF must document the primary reason for withdrawal or discontinuation. In
case the subject is early terminated due to withdrawal of consent, the reason why the subject
withdrew consent should be added to the eCRF.
6.5
Study stopping rules
During the clinical study, planned dosing may be discontinued for all subjects on a dose level, 
but subjects will be required to attend all visits during the Observation Period. Possible reasons 
for discontinuation of a dose level include (but are not limited to):

In the opinion of the DMC, a clinically significant event or a pattern of events occur that 
contraindicate the dosing of any more subjects.

If the DMC judges it necessary for medical, safety, regulatory, or other reasons consistent 
with applicable laws, regulations, and Good Clinical Practice (GCP).
More detailed criteria for stopping a dose arm will be defined in the DMC charter.
7
STUDY TREATMENT
7.1
Description of investigational medicinal product
UCB7665 product is supplied as a lyophilized powder in a 10mL Type I glass vial with a rubber 
stopper, sealed with an aluminum overseal and flip-off overcap. Prior to use, the lyophilized 
vials have to be reconstituted with 4mL of diluent (
).
REDACTED COPY
the su
OPY 
the su
the wr
COP
the wr
these e
ED C
these e
moving
CTED
moving
e prim
DACT
e prim
e to w
REDA
e to w
the 
RE
the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
henever
or va
henever
rawn w
ns o
rawn w
the clin
xtens
the clin
(
y
(schedu
ext
schedu
ion Per
any 
ion Per
rl
nd
rly 
nd
y Wit
d a
Wit
n the ca
ation
n the ca
the inv
plica
the inv
ubject),
appl
ubject),
ritten m
on ap
ritten m
evaluat
atio
evaluat
g the su
oriza
g the su
mary
utho
mary rea
ho
rea
y
ho
y
withdraw
aut
withdraw
eCRF.
ing 
eCRF.
ules
arke
ules
ed dosin
y m
ed dosin
to atten
t any
to atten
se leve
ort a
se leve
he DM
supp
he DM
he dosi
to s
he dosi
C judge
sed
C judge
plicable
be us
plicable
etailed 
ot b
etailed 
7.1
ent
7.1
U
m
U


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 67 of 353
7.2
Treatment to be administered
Subjects in Dose Arm 1 will receive 5 sc doses of UCB7665 4mg/kg at 1-week intervals. 
Subjects in Dose Arm 2 will receive 3 sc doses of UCB7665 7mg/kg at 1-week intervals. 
Subjects in Dose Arm 3 will receive 2 sc doses of UCB7665 10mg/kg at a 1-week interval.
Subjects in Dose Arm 4 will receive 1 sc dose of UCB7665 15mg/kg. 
Subjects in Dose Arm 5 will receive 1 sc dose of UCB7665 20mg/kg.
The IMP will be administered as a sc infusion using an infusion pump:
The perfusor will be programmed at a constant flow rate of 20mL/h for all subjects. In the case 
of any blockage of the infusion, a suitable flush (eg, 0.9% sodium chloride) is allowed.
The subject’s body weight at Screening Visit will be used for the dose calculation. The dose will 
be constant for a subject throughout the duration of the study, and will not be adjusted during the 
treatment. 
The exact procedure for dose preparation according to dose arm and body weight will be 
provided in a pharmacy manual.
The infusion rate may be reduced at any time at the discretion of the investigator. If an infusion 
is interrupted, it can be restarted if the investigator considers it appropriate to do so. The 
chronology of these events should be recorded accurately in the source data and eCRF.
In the event of a severe infusion reaction, the subject must permanently discontinue IMP (see 
Section 12.1.10).
7.3
Packaging
The IMP is manufactured, packaged, and labeled according to Good Manufacturing Practice 
(GMP) guidelines and applicable laws or regulations. The IMP is suitably packaged in such a 
way as to protect the IMP from deterioration during transport and storage.
7.4
Labeling
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (ICH) guidelines on GCP and GMP and will include any locally required
statements. If necessary, labels will be translated into the local language.
7.5
Handling and storage requirements
The investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by the investigator is to be kept in a secured area with 
limited access.
Appropriate storage conditions must be ensured either by controlled fridge temperature or by
completion of a temperature log in accordance with local requirements on a regular basis 
(eg, once a day), showing minimum and maximum temperatures reached over the time interval.
In case an out-of-range temperature is noted, it must be immediately communicated to the 
Clinical Project Manager (CPM) (or designee) before further use of the IMP.
REDACTED COPY
iscret
PY 
iscret
consi
COP
consi
ccura
D CO
ccura
he subj
CTE
he subj
to support any marketing authorization application and any extensions or variations thereof.
. In the
nsion
. In the
lowed.
xtens
lowed.
lation. 
ny ex
lation. 
ot be ad
d any
ot be ad
nd body
tion a
nd body
ion of t
appl
ion of t
iders it 
on ap
iders it 
tel
atio
tely in
tion
y in
bject mu
horiz
bject mu
and lab
rket
and lab
aws or 
mar
aws or 
deterio
ny m
deterio
will be 
uppo
will be 
H) guide
o su
H) guide
This document cannot be used
cessary
d to
cessary
Han
use
Han
stigato
ot be
stigato
tigation
nno
tigation
ited ac
can
ited ac
Appro
ment
Appro
com
m
com


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 68 of 353
The CPM (or designee) will transmit the out-of-range temperature (copy of the temperature log 
and duration of the out-of-range temperature, if available) to the Clinical Supply Manager or 
designee. Based on discussion with a UCB Quality Assurance representative, the Clinical Supply
Manager or designee will then provide the CPM (or designee) with instructions for the site 
regarding use of the IMP.
7.6
Drug accountability
A Drug Accountability form will be used to record IMP dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study. Details of 
any IMP lost (due to breakage or wastage), not used, disposed of at the study site, or returned to 
the sponsor or designee must also be recorded on the appropriate forms. All supplies and 
pharmacy documentation must be made available throughout the study for UCB (or designee) to 
review.
The investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.
The investigator may assign some of the investigator’s duties for drug accountability at the study
site to an appropriate pharmacist/designee.
The investigator must ensure that the IMP is used only in accordance with the protocol.
Periodically, and/or after completion of the clinical phase of the study, all used (including empty
containers) and unused IMP containers must be reconciled and returned to UCB (or designee), 
preferably in their original package or destroyed on site. Investigational medicinal product 
intended for the study cannot be used for any other purpose than that described in this protocol.
7.7
Procedures for monitoring subject compliance
Drug accountability is ensured by administering the IMP as sc infusion by designated personnel. 
Drug accountability must be recorded on the Drug Accountability form.
7.8
Concomitant medication/treatment
7.8.1
Permitted immunosuppressant medications
The following concomitant immunosuppressant medications are permitted during the course of 
the study at a stable dose.
DACTED COPY 
Y
phase 
OPY
phase 
econc
D CO
econc
e
TE
ed on 
ED 
d on 
n
C
ny oth
CTE
y oth
RED
onitor
EDA
onitor
min
R
min
uthorization application and any extensions or variations thereof.
a a 
ails of 
var
ails of 
urned to
or 
urned to
and
ons
and
r desig
nsio
r desig
and par
ny e
and par
ug acco
n and
ug acco
ordanc
plica
ordanc
e of the 
app
e of the 
ciled an
tion 
ciled an
site
zati
site. I
ati
. I
her purp
horiz
her purp
This document cannot be used to support any marketing a
ring s
auth
ring s
nisterin
eting
nisterin
d on the
rket
d on the
medic
y ma
medic
mmun
t any
mmun
ant 
pp
ant imm
po
imm
ose
su
ose.
u
.


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 69 of 353
Table 7‒1:
Permitted immunosuppressant medications
Permitted medications
Dose
Comment
Oral corticosteroids 
(prednisolone)
≤10mg/day
Stable dose for 2 weeks prior to Baseline
Methotrexate
≤30mg/week
Stable dose for 2 months prior to Baseline
Mycophenolate mofetil
≤3g/day
Stable dose for 2 months prior to Baseline
Cyclosporin
≤5mg/kg/day
Stable dose for 2 months prior to Baseline
Azathioprine
≤3mg/kg/day
Stable dose for 2 months prior to Baseline
Danazol
≤15mg/kg/day
Stable dose for 2 months prior to Baseline
Dapsone
100mg/day
Stable dose for 2 months prior to Baseline
In the event of a subject developing an infection during the course of the study, samples for 
culture will be taken prior to commencing antimicrobial treatment. Antimicrobial treatment may
be modified accordingly when the identity of the infective organism is known.
Vaccines (with the exception of live vaccines) and prophylactic antibiotics are permitted in 
splenectomized subjects.
7.8.2
Prohibited concomitant treatments (medications and therapies)
The following concomitant medications are prohibited during the study:

IVIg

All biologics including rituximab

Cyclophosphamide

Pimecrolimus 

IPP-201101 (Lupuzor™)

PLEX

Immunoadsorption

Anti-D 

TPO-R agonists (eltrombopag, romiplostim)

Dexamethasone

Vinca alkaloids (vincristine, vinblastine)

Anticoagulants and antiplatelets (warfarin, heparin, clopidogrel, aspirin, salicylics,
dipyramidole, prasugrel, tricagrelor, tirofiban, abciximab)
If a subject needs or takes any prohibited medication (except IVIg, PLEX, dexamethasone or 
rituximab), the investigator will (where possible) discuss with the Medical Monitor and a 
decision will be made whether the subject can continue in the study or must be withdrawn. If 
REDACTED COPY 
ments
COP
ments
rohibit
ED C
rohibit
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
tititi
ati
line
or
line
va
Baseline
ons 
Baseline
o
r to Bas
ensi
r to Bas
io
prior to
ext
prior to
te
y e
study
d any
study
y
ntimicr
and 
ntimicr
m is kn
on a
m is kn
c antibi
icati
c antibi
s (med
on ap
s (med
ted du
izatio
ted du
o
n
s
n
gonists
e use
gonists
metha
ot be
metha
Vinca a
cann
Vinca a

An
nt c
An


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 70 of 353
subject needs IVIg, PLEX, dexamethasone or rituximab, the subject must be withdrawn from the 
study.
7.8.3
Rescue medication
In the case of prolonged hypogammaglobulinemia the subject will be considered for treatment 
with prophylactic antimicrobial therapy. Subjects will be followed up until immunoglobulin 
levels return to within the normal range.
In case of lack of efficacy and/or severe bleeding events and where appropriate, platelet 
substitution or treatment with a commercially available iv immunoglobulin may be considered.
If such rescue medication must be given when the subject is still in the dosing period, the subject 
should be withdrawn from the study treatment and complete all Observation visits, if possible. 
If such rescue medication is given when the subject has completed the study treatment, the 
subject should continue the Observation Visits, as per schedule of study assessments
(Section 5.2). 
7.9
Blinding
This is an open-label study and blinding is not applicable.
7.10
Randomization and numbering of subjects
An IXRS will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by PAREXEL
Informatics. The IXRS will generate individual assignments for subject kits of IMP, as 
appropriate, according to the dose arm and subject’s weight.
The first 6 subjects (and those treated before DMC assessment after the 6 subjects) will not be 
randomized. Once the DMC has advocated the initiation of Dose Arm 2 for enrollment, 
subsequent subjects will be randomly assigned to 1 of the 2 dose arms (ie, Dose Arm 1 and Dose 
Arm 2) in a 1:1 ratio. Once 15 subjects are enrolled in the Dose Arm 1, the remaining subjects 
will be enrolled in Dose Arm 2 until Dose Arm 2 is completed with 15 subjects.
After Dose Arm 2, there will be no randomization between dose arms.
To enroll a subject (Visit 1), the investigator or designee will contact the IXRS and provide brief 
details about the subject to be enrolled. Each subject will receive a 5-digit number assigned at 
screening that serves as the subject identifier throughout the study. The subject number will be 
required in all communication between the investigator or designee and the IXRS regarding a 
particular subject. Subject numbers and kit numbers will be tracked via the IXRS. 
To randomize a subject, the investigator or designee will contact the IXRS and provide brief 
details about the subject to be randomized. The IXRS will automatically inform the investigator 
or designee of the subject’s kit number. The IXRS will allocate kit numbers to the subject based 
on the subject number or randomization during the course of the study.
8
STUDY PROCEDURES BY VISIT 
A detailed tabular schedule of study procedures is provided in Section 5.2.
REDACTED COPY 
of
Y
of
ts to a 
COPY
ts to a 
packa
D CO
packa
ual ass
TED 
ual ass
d subje
ACTE
d subje
before
REDA
before
ocate
RE
ocate
marketing authorization application and any extensions or variations thereof.
ered.
r va
ered.
the sub
ns o
the sub
if possi
sion
if possi
atment
xten
atment
essmen
y ex
essmen
ubject
plica
ubject
a treatm
n ap
a treatm
aging s
ation
aging s
signmen
rizat
signmen
ect’s w
thori
ect’s w
e DMC
g aut
e DMC
ed the 
ting 
ed the 
assign
rketi
assign
ects ar
mark
ects ar
not be used to support any 
until D
y m
until D
ll be no
rt an
ll be no
it 1), th
uppo
it 1), th
ject to b
o sup
ject to b
ves as t
d to 
ves as t
commu
sed
commu
ubject. 
be us
ubject. 
omize 
not b
omize 
This document can
ls abou
anno
ls abou
r design
t ca
r design
on the
ment
on the
8
m
8


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 71 of 353
8.1
Screening Period
8.1.1
Visit 1 (Day -28 to -1) Screening Visit (all Dose Arms)
At Visit 1, subjects will be evaluated for their suitability for enrollment. Prior to the conduct of 
any study-related procedures, a complete explanation (both verbal and written) of the nature and 
purpose of the study will be given to the subject by the investigator (or designee). The subject is 
required to sign and date the IRB/IEC-approved Informed Consent form if he/she decides to 
participate in the study.
Subjects will also have the option of providing additional voluntary informed consent for 
collection of whole blood samples for exploratory DNA and RNA analyses.
The subject’s eligibility for the study will be determined on the basis of the inclusion/exclusion 
criteria and signature of an informed consent prior to any study-related procedures or 
evaluations. The following assessments and procedures will be performed during Visit 1 of 
TP0001:

Obtain written informed consent 

Obtain informed consent for substudy involving DNA and RNA analyses

Assessment of inclusion/exclusion criteria

Demographic data (includes date of birth, gender, and race/ethnicity)

General medical and procedure history

ITP history

Prior and concomitant medications 

Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory
rate)

Body weight

Height

Physical examination (complete)

12-lead ECG (triplicate)

Karnofsky Performance Status

Recording of AEs

Urine sample for urinalysis

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry (two blood samples for assessment of platelet count to be obtained via 2 
separate blood collections)

Serum pregnancy test for women of childbearing potential

Serum total IgG and IgG subclasses concentration 
REDACTED COPY 
er, and
OPY
er, and
blo
R
blo
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
n/excl
sion
n/excl
res o
xten
res or 
en
r 
ring Vi
y ext
ring Vi
NA anal
tion 
NA anal
d race/e
n app
d race/e
ood pre
eting
ood pre
n
p
n (com
ppo
(com
iplicate
to su
iplicate
Perform
sed 
Perform
ing of 
be u
ing of A
ine sam
not 
ine sam
Blood
t can
Blood



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 72 of 353

Serum HbA1c

Serology tests for HIV, hepatitis B, and hepatitis C

IGRA TB test

ITP bleeding scale

TB signs and symptoms questionnaire
8.2
Dosing Period for all Dose Arms
8.2.1
Visit 2 (Week 1/Day 1) Baseline Visit
Visit 2 can occur at any time after Visit 1, but no later than 28 days after Visit 1. Prior to dosing
at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value 
will be used to check inclusion criterion. The other platelet sample will be sent to the central 
laboratory.
Eligible subjects will be treated with IMP at Visit 2. 
Subjects allocated to Dose Arm 1 (UCB7665 4mg/kg weekly sc) will receive a total of 5 doses of 
IMP at Visit 2 (Day 1, Week 1), Visit 4 (Week 2), Visit 5 (Week 3), Visit 6 (Week 4), and 
Visit 7 (Week 5). 
Subjects allocated to Dose Arm 2 (UCB7665 7mg/kg weekly sc) will receive a total of 3 doses of 
IMP at Visit 2 (Day 1, Week 1), Visit 4 (Week 2), and Visit 5 (Week 3). 
Subjects allocated to Dose Arm 3 (UCB7665 10mg/kg weekly sc) will receive a total of 2 doses 
of IMP at Visit 2 (Day 1, Week 1) and Visit 4 (Day 8, Week 2). 
Subjects allocated to Dose Arm 4 (UCB7665 15mg/kg) will receive 1 dose of IMP at Visit 2 
(Day 1, Week 1).
Subjects allocated to Dose Arm 5 (UCB7665 20mg/kg) will receive 1 dose of IMP at Visit 2
(Day 1, Week 1).
The following assessments will be performed at this visit (predose unless stated otherwise):

Reconfirm inclusion/exclusion criteria

Serum platelets for inclusion/exclusion check

Call IXRS to obtain treatment kit number(s)

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, and temperature) assessed prior 
to dosing, every 15 minutes during infusion, end of infusion, and 2 and 4 hours after end of 
infusion; respiratory rate to be assessed only once prior to dosing

Recording of AEs (assessed predose, at end of infusion, and at 2 and 4 hours after end of 
infusion)

Subjects in Dose Arms 1 and 2 will stay on site for 4 hours after the end of infusion for 
inpatient observation at the site.
DACTED COPY 
kg
O
kg wee
OPY
wee
), and 
CO
), and 
 10mg
TED
 10mg
sit 4 (D
ACT
sit 4 (D
RE
CB766
REDA
CB766
authorization application and any extensions or variations thereof.
r to 
ion
r to do
ns
do
nd the v
ensi
nd the v
to the 
exte
to the 
ill rece
n an
ill rece
3
t
3), Vi
ation
), Vi
kl
a
kly 
ap
y sc)
pp
sc)
Visit 5
tion 
Visit 5
g/kg w
rizat
g/kg w
Day
thor
Day 8,
or
8,
y
or
y
t be used to support any marketing 
65 15
g au
65 15m
u
m
UCB766
arke
UCB766
will be p
t any
will be p
exclus
por
exclus
or incl
sup
or incl
o obtain
ed t
o obtain
itant m
e us
itant m
This document canno
ncomita
not b
ncomita
Vital s
can
Vital s
to d
nt c
to d
i
n
i


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 73 of 353

Subjects in Dose Arms 3, 4 and 5 will stay on site for 6 hours after the end of infusion for 
inpatient observation at the site.

Physical examination (abbreviated)

12-lead ECG (triplicate)

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Blood sample for the following:

Plasma concentration of UCB7665

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration 

Serum IgA, IgM, and IgE concentration

ITP-specific autoantibodies 

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the inclusion 
criteria of platelet count <35x109/L at Baseline

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Exploratory safety biomarkers
. Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety
biomarkers

Serum BAFF levels

Exploratory biomarker analysis

Serum cytokines mandatory for all subjects at pre-dose, and only in case of infusion 
reactions at 4 hours after end of infusion

Collection of whole blood for exploratory DNA and RNA analyses

ITP bleeding scale

NFI-MS

Administration of IMP

Review withdrawal criteria

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to computed tomography (CT) scan, magnetic resonance imaging
(MRI) and/or lumbar puncture (LP) for cerebrospinal fluid (CSF) collection to be performed 
ACTED COPY 
cal lab
OPY
cal lab
seline
D CO
seline
4)
CT
4) and
TED
and
R
d 4
R
d 4
DAC
RED
horization application and any extensions or variations thereof.
ulation
atio
ulation
borator
n app
borator
d plasm
oriza
d plasm
This document cannot be used to support any marketing
4 hours
eting
4 hours
ker anal
rt an
ker anal
mand
uppo
mand
hours 
sup
hours 
f whole
ed to
f whole
ding sc
e us
ding sc
MS
ot b
MS
Admin
cann
Admin

e

Re
nt 
Re

m

n a
autho
ng au


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 74 of 353
if indicated at the discretion of the investigator, considering the local guidelines for 
performing LP in subjects with ITP.
8.2.2
Visit 3 (Week 1/Day 4) [UCB7665 4mg/kg, UCB7665 7mg/kg, and 
UCB7665 10mg/kg]
This is a nondosing visit. A visit window of ±1 day relative to Dose 1 at the Visit 2 date is 
allowed for this visit. The following assessments will be performed at this visit:

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory
rate)

Recording of AEs

Urine sample for urinalysis

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Plasma concentration of UCB7665

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration

Exploratory safety biomarkers
 only from 
subjects experiencing severe headaches or GI disturbances (only in case of Adverse 
Events of Interest, see Section 12.4)

Review withdrawal criteria

Serum cytokines, only in case of late infusion reactions visible during the visit

For Dose Arm 1, 2, and 3 collection of whole blood for exploratory RNA analyses 

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
8.2.3
Visit 4 (Week 2/Day 8) [UCB7665 4mg/kg, UCB7665 7mg/kg and 
UCB7665 10mg/kg]
This is the second dosing visit and a window of ±2 days is allowed for this visit, relative to 
Dose 1 at the Visit 2 date. However, there should be a minimum of 5 days and a maximum of 
9 days since the last dosing day. The following assessments will be performed at this visit
(predose unless stated otherwise):

Concomitant medications
ACTED COPY 
 conce
CTE
 conce
REDAC
RED
thorization application and any extensions or variations thereof.
pirator
ions
pirator
ulation 
ation
ulation 
entratio
horiz
entratio
This document cannot be used to support any marketin
eadache
ketin
eadache
on
a
on 12.4
ark
12.4
in case
ort a
in case
, and 3
upp
and 3
stionna
d to s
stionna
l asses
sed 
l asses
g but no
e us
g but no
ted at t
t be 
ted at t
in
no
in subj
not 
subj
2.3
ca
2.3
Th
m
Th
auth
ting a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 75 of 353

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, and temperature) assessed prior 
to dosing, every 15 minutes during infusion, end of infusion, and 2 and 4 hours after end of 
infusion; respiratory rate to be assessed only once prior to dosing

Recording of AEs (assessed predose, at end of infusion, and at 2 and 4 hours after end of 
infusion)

Subjects in Dose Arms 1 and 2 will stay on site for 4 hours after the end of infusion for 
inpatient observation at the site.

Subjects in Dose Arms 3, 4 and 5 will stay on site for 6 hours after the end of infusion for 
inpatient observation at the site. 

Physical examination (abbreviated)

12-lead ECG (triplicate)

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)

Blood sample for the following:

Plasma concentration of UCB7665

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Exploratory safety biomarkers
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory serum 
biomarkers

Serum BAFF levels

Exploratory biomarker analysis

Serum cytokines at pre-dose mandatory for subjects on Dose Arm 3 (10mg/kg), and at 
4 hours after end of infusion (for all dose arms)

For Dose Arm 3, only collection of whole blood for exploratory DNA and RNA analyses

ITP bleeding scale

Administration of IMP

Review withdrawal criteria
REDACTED COPY 
asses c
REDA
asses c
hem
R
hem
ort any marketing authorization application and any extensions or variations thereof.
sion fo
ons 
sion fo
concen
aut
concen
matolog
eting
matolog
le for a
y m
le for a
platele
t any
platele
This document cannot be used to
ior to d
to s
ior to d
rs
ed
rs
m
e
m BAF
e us
BAF
Explor
not b
xplor

Se
n
Se

m

ppo
y
p
y biom
port
biom
su
supp


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 76 of 353

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
8.2.4
Visit 5 (Week 3/Day 15) [UCB7665 4mg/kg and UCB7665 7mg/kg]
This is the third dosing visit and a window of ±2 days is allowed for this visit, relative to Dose 1 
at the Visit 2 date. However, there should be a minimum of 5 days and a maximum of 9 days 
since the last dosing day. The following assessments will be performed at this visit (predose 
unless stated otherwise):

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, and temperature) assessed prior 
to dosing, every 15 minutes during infusion, end of infusion, and 2 and 4 hours after end of 
infusion; respiratory rate to be assessed only once prior to dosing

Recording of AEs (assessed predose, at end of infusion, and at 2 and 4 hours after end of 
infusion)

Physical examination (abbreviated)

12-lead ECG (triplicate)

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)

Blood sample for the following:

Plasma concentration of UCB7665

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration 

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Serum IgA, IgM, and IgE concentration (UCB7665 7mg/kg only)

Exploratory safety biomarkers (may include but not limited to:
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety
biomarkers
REDACTED COPY 
hildbea
DACT
hildbea
be used to support any marketing authorization application and any extensions or variations thereof.
1
ri
1
ys
ose
s or
ose
peratur
d any
peratur
2 and 4
and 
2 and 4
ng
on
ng
d at 2 a
icati
d at 2 a
aring p
uthor
aring p
number
ketin
number
g:
m
g:
of UCB
any
of UCB
tibodie
port
tibodie
gG and
sup
gG and
safet
ed to
safety
to
y
This document cannot 
stry
use
stry
ddition
t be
ddition
withd
nnot 
withd

c

S
n
S


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 77 of 353

Serum BAFF levels

Exploratory biomarker analysis

For Dose Arm 2 only, collection of whole blood for exploratory DNA and RNA analyses 

ITP bleeding scale

Administration of IMP

Review withdrawal criteria

Serum cytokines, only in case of late infusion reactions visible during the visit

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
8.2.5
Visit 6 for Dose Arm 1 (Week 4/Day 22) [UCB7665 4mg/kg only]
This is the fourth dosing visit (UCB7665 4mg/kg only) and a window of ±2 days is allowed for 
this visit, relative to Dose 1 at the Visit 2 date. However, there should be a minimum of 5 days 
and a maximum of 9 days since the last dosing day. The following assessments will be 
performed at this visit (predose unless stated otherwise):

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, and temperature) assessed prior 
to dosing, every 15 minutes during infusion, end of infusion, and 2 and 4 hours after end of 
infusion; respiratory rate to be assessed only once prior to dosing

Recording of AEs (assessed predose, at end of infusion, and at 2 and 4 hours after end of 
infusion)

Physical examination (abbreviated)

12-lead ECG (triplicate)

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)

Blood sample for the following:

Plasma concentration of UCB7665 

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry
REDACTED COPY
,
Y
,
he f
PY
he fo
Y 
o
fo
f
Y
fo
f
rwise)
COP
rwise)
blood
RED
blood
g in
R
g in
keting authorization application and any extensions or variations thereof.
b
si
by a 
sion
y a 
ic proc
ensi
ic proc
be per
exte
be per
elines f
ny e
elines f
7665
n and
7665 4
d
4
ndow o
ation
ndow o
e shoul
plica
e shoul
ollowin
appl
ollowin
:
d pressu
g au
d pressu
infusion
eting
infusion
marke
se
rk
se
used to support any 
ssed 
arke
ssed 
predos
y ma
predos
(abbre
port
(abbre
plicate)
sup
plicate)
ancy
ed t
ancy tes
d to
tes
y
d t
y
This document cannot be 
mple fo
e us
mple fo
I
o
IXRS 
ot b
XRS 
Blood 
cann
Blood 

n



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 78 of 353

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Exploratory safety biomarkers
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety
biomarkers

Serum BAFF levels

Exploratory biomarker analysis

ITP bleeding scale

Administration of IMP

Review withdrawal criteria

Serum cytokines, only in case of late infusion reactions visible during the visit

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
8.2.6
Visit 7 for Dose Arm 1 (Week 5/Day 29) [UCB7665 4mg/kg only]
This is the fifth dosing visit (UCB7665 4mg/kg only) and a window of ±2 days is allowed for 
this dosing visit, relative to Dose 1 at the Visit 2 date. However, there should be a minimum of 5 
days and a maximum of 9 days since the last dosing day. The following assessments will be 
performed at this visit (predose unless stated otherwise):
Following assessments will be performed:

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, and temperature) assessed prior 
to dosing, every 15 minutes during infusion, end of infusion, and 2 and 4 hours after end of 
infusion; respiratory rate to be assessed only once prior to dosing

Recording of AEs (assessed predose, at end of infusion, and at 2 and 4 hours after end of 
infusion)

Physical examination (abbreviated)

12-lead ECG (triplicate)

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)

Blood sample for the following:
REDACTED COPY
ider
PY 
ider
ek
ED
ek 5/
D C
5/D
C
D
g/kg o
ACTE
g/kg o
e
D
e Visit
DAC
Visit
the la
RED
the la
s st
R
s st
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
g the v
d any
g the v
aches, 
n an
aches, 
y
t
y,
ti
, other
tion 
other
SF coll
licati
SF coll
ng the l
pplic
ng the l
Day
atio
Day 29
tio
29
y
tio
y
only
horiz
only)
riz
) a
z
a
t 2
ut
t 2 dat
uth
dat
ast dosi
g au
ast dosi
tated o
eting
tated o
ormed:
mark
ormed:
procedu
ort a
procedu
c and d
supp
c and d
y
t
y 15 mi
to su
15 mi
y
t
y
piratory
ed to
piratory
ng of 
e us
ng of A
s
A
on
t b
on)
t b
)
hy
an
hysical
nno
sical
12
t c
12 l

m



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 79 of 353

Plasma concentration of UCB7665

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration

Serum IgA, IgM, and IgE concentration

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Exploratory safety biomarkers
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety
biomarkers

Serum BAFF levels

Exploratory biomarker analysis

For Dose Arm 1 only, collection of whole blood for DNA and RNA analyses

ITP bleeding scale

Administration of IMP

Review withdrawal criteria

Serum cytokines, only in case of late infusion reactions visible during the visit

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
8.3
Telephone Contacts 
For Dose Arms 3, 4 and 5 the site must make a phone call to the subject on Day 1 and Day 2 
after dosing as a safety measure.
8.3.1
Telephone Contact 1 (Week 1/Day 2) [UCB7665 10mg/kg, UCB7665 
15mg/kg, UCB7665 20mg/kg]

Concomitant medications

Concomitant medical procedures

Recording of AEs
8.3.2
Telephone Contact 2 (Week 1/Day 3) [UCB7665 10mg/kg, UCB7665 
15mg/kg, UCB7665 20mg/kg]

Concomitant medications
REDACTED COPY 
D
Y
D
ate infu
REDA
ate infu
ubj
R
ubj
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
Blood
xten
Blood
oratory
y ext
oratory
and R
plica
and R
fusion r
aut
fusion r
jec
eti
ject ex
ting
t ex
ng fund
arke
ng fund
T scan
ma
T scan
of the in
any m
of the in
one C
uppo
one C
4 and 5 
to s
4 and 5 
safety
ed to
safety
Tele
e us
Tele
1
oncom
nno
oncom
Con
nt c
Con

m

nsion
x


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 80 of 353

Concomitant medical procedures

Recording of AEs
8.3.3
Telephone Contact 3 (Week 2/Day 9) [UCB7665 10mg/kg only]

Concomitant medications

Concomitant medical procedures

Recording of AEs
8.3.4
Telephone Contact 4 (Week 2/Day 10) [UCB7665 10mg/kg only]

Concomitant medications

Concomitant medical procedures

Recording of AEs
8.4
Observation Period
The Observation Period will last for 8 weeks following the final dose administration. The first 
visit in the Observation Period will be performed 3 days after the final dose administration and 
subsequent visits will be performed at weekly intervals (except for a 2-week interval before the 
final visit). 
For UCB7665 4mg/kg weekly dose (Dose Arm 1), the following visits will be performed: 
Visit 8, Visit 9, Visit 10, Visit 11, Visit 12, Visit 13, Visit 14, and Visit 15, corresponding to 
UCB7665 7mg/kg weekly dose (Dose Arm 2) on Visit 6, Visit 7, Visit 8, Visit 9, Visit 10, 
Visit 11, Visit 12, and Visit 13.
For the UCB7665 10mg/kg weekly dose (Dose Arm 3), the following visits will be performed: 
Visit 5, Visit 6, Visit 7, Visit 8, Visit 9, Visit 10, Visit 11, and Visit 12.
For the UCB7665 15 mg/kg dose (Dose Arm 4) and the UCB7665 20mg/kg dose (Dose Arm 5), 
the following visits will be performed: Visit 3, Visit 4, Visit 5, Visit 6, Visit 7, Visit 8, Visit 9 
and Visit 10.
8.4.1
Visit 8 (Week 5/Day 32) [UCB7665 4mg/kg]/ 
Visit 6 (Week 3/Day 18) [UCB7665 7mg/kg]/
Visit 5 (Week 2/Day 11) [UCB7665 10mg/kg]
Visit 3 (Week 1/Day 4) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the first visit in the Observation Period and will be performed 3 days after the final dose 
of the IMP. A visit window of ±1 day relative to the final dosing visit is allowed for this visit. 
The following assessments will be performed at this visit:

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory
rate)

Recording of AEs
REDACTED COPY 
), 
C
, the 
CO
the 
sit 13,
ED C
sit 13,
2) on
CTE
2) on
dose (
RE
dose (
R
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
]
se adm
n an
se adm
final d
tion
final d
pt for a
lica
pt for a
follow
tion 
follow
, Visit 
zatio
, Visit 
h
Visit 6
horiz
Visit 6
(Dose A
ng a
(Dose A
, Visit
ketin
, Visit
Dose A
mar
Dose A
ormed:
ny m
ormed:
Week 
ppor
Week 
6 (
s
6 (Wee
supp
Wee
t
t
t 5
to
5 (W
 s
(W
Visit
ed t
Visit 3
t
3
first vis
be us
first vis
P
t
P.
t b
. A v
be
A v
llowin
nnot
llowin
Conc
t ca
Conc

me

C
n
C


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 81 of 353

Urine sample for urinalysis

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Plasma concentration of UCB7665 

Anti-UCB7665 antibodies

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Exploratory safety biomarkers
only from 
subjects experiencing severe headaches or GI disturbances (only in  case of Adverse of 
Interest, see Section 12.4).

Serum total IgG and IgG subclasses concentration

Serum cytokines, only in case of late infusion reactions visible during the visit

For Dose Arm 4 and 5 collection of whole blood for exploratory RNA analyses

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
8.4.2
Visit 9 (Week 6/Day 36) [UCB7665 4mg/kg ]/ 
Visit 7 (Week 4/Day 22) [UCB7665 7mg/kg]/ 
Visit 6 (Week 3/Day 15) [UCB7665 10mg/kg]
Visit 4 (Week 2/Day 8) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the second visit in the Observation Period. A visit window of ±2 days is applicable for 
this visit relative to the day of the final dosing visit. The following assessments will be 
performed at this visit:

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory
rate)

Recording of AEs

Physical examination (abbreviated)

12-lead ECG (triplicate)

Urine sample for urinalysis
REDACTED COPY
es se
PY 
es se
)
CO
). Add
COPY
. Add
d
D C
d/or
D CO
/or
d/d
D C
d/d
L
O
L
tor, co
TED 
tor, co
36
ED
36)
EDA
) [U
DA
[U
y
R
y 22
RE
22)
E
)
s or variations thereof.
5a)
or
5a)
upport any marketing authorization application and any extensio
nly
nsi
nly from
sio
from
y
si
y
of Ad
ten
of Ad
uring t
n an
uring t
atory
atio
atory RN
io
RN
y y
io
y
ere hea
pplic
ere hea
ditiona
n app
ditiona
LP for 
tion
LP for 
onsider
izat
onsider
UCB7
aut
UCB7
)
ti
) [UCB
ting 
[UCB
15)
keti
15) [U
tin
[U
ay
ma
ay 8)
mark
 8)
y 
y
ma
y 
y
[
Observa
ny m
Observa
of the
t an
of the f
n
f
This document cannot be used to s
dication
sup
dication
medic
ed to
medic
ns (s
e us
ns (sys
s
ys
Recordin
anno
Recordin
Phy
nt c
Phy

m

ions o


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 82 of 353

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Plasma concentration of UCB7665

Anti-UCB7665 antibodies

Exploratory safety biomarkers
 only from 
subjects experiencing severe headaches or GI disturbances (only in case of Adverse 
Events of Interest, see Section 12.4).

Serum total IgG and IgG subclasses concentration

Serum IgA, IgM, and IgE concentration 

ITP-specific autoantibodies 

ITP bleeding scale

NFI-MS

Serum cytokines, only in case of late infusion reactions visible during the visit

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
8.4.3
Visit 10 (Week 7/Day 43) [UCB7665 4mg/kg]/ 
Visit 8 (Week 5/Day 29) [UCB7665 7mg/kg]/
Visit 7 (Week 4/Day 22) [UCB7665 10mg/kg]
Visit 5 (Week 3/Day 15) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the third visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. This visit can be performed at home with a 
healthcare professional visiting the subject at his/her home. The following assessments will be 
performed at this visit:

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory
rate)

Recording of AEs

Urine sample for urinalysis
REDACTED COPY 
tion
Y
tion
ences 
COP
ences 
cop
ED
copy)
D C
y)
C
RI
T
RI and
TED
and
stigato
DACT
stigato
y
R
y 4
R
4
y
R
y
ed to support any marketing authorization application and any extensions or variations thereof.
rse 
o
rse 
visible
pplic
visible
s severe
on a
s severe
 Additi
atio
 Additi
d/or
riz
/or
d/d/d
LP
za
LP
or, con
utho
or, con
43
etin
43)
tin
) [U
ng
[U
y
a
y 29
rke
29)
e
) [
Day
ma
Day 22
ar
22
3
n
3/Day
ny m
/Day
Obser
ort a
Obser
of the
ppo
of the f
nal visit
sup
nal visit
visit:
d to
visit:
This document cannot be us
ant me
use
ant me
omitant
t be
omitant
Vital sig
anno
Vital sig
rate)
t can
rate)

me

R
n
R


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 83 of 353

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Anti-UCB7665 antibodies

Exploratory safety biomarkers
, only from 
subjects experiencing severe headaches or GI disturbances (only in case of Adverse 
Events of Interest, see Section 12.4)

Serum BAFF levels

Exploratory biomarker analysis

Serum total IgG and IgG subclasses concentration

Serum cytokines, only in case of late infusion reactions visible during the visit

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
8.4.4
Visit 11 (Week 8/Day 50) [UCB7665 4mg/kg]/ 
Visit 9 (Week 6/Day 36) [UCB7665 7mg/kg]/ 
Visit 8 (Week 5/Day 29) [UCB7665 10mg/kg]
Visit 6 (Week 4/Day 22) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the fourth visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. The following assessments will be performed at 
this visit:

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory
rate)

Recording of AEs

Physical examination (abbreviated)

Urine sample for urinalysis

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Exploratory safety biomarkers
 only from 
REDACTED COPY
ider
PY 
ider
CB76
ED C
CB76
UCB7
CTED
UCB7
)
DA
) [UC
DACT
[UC
22
ED
22) [
EDA
) [U
A
U
tion
R
tion
ng authorization application and any extensions or variations thereof.
g the v
d any
g the v
aches, 
n an
aches, 
y
t
y,
ti
, other
tion 
other
SF coll
licati
SF coll
ng the l
pplic
ng the l
665 4m
atio
665 4m
7665
oriza
7665 7
a
7
CB7665
utho
CB7665
UCB7
aut
UCB7
This document cannot be used to support any market
on Perio
eting
on Perio
osing v
arke
osing v
proced
port
proced
lic and
sup
lic and
g of 
use
g of AE
se
AE
cal exa
t be
cal exa
Urine sa
anno
Urine sa
Blo
nt c
Blo


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 84 of 353
subjects experiencing severe headaches or GI disturbances (only in case of Adverse 
Events of Interest, see Section 12.4)

Serum total IgG and IgG subclasses concentration 

ITP bleeding scale

NFI-MS

Serum cytokines, only in case of late infusion reactions visible during the visit

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
8.4.5
Visit 12 (Week 9/Day 57) [UCB7665 4mg/kg]/ 
Visit 10 (Week 7/Day 43) [UCB7665 7mg/kg]/ 
Visit 9 (Week 6/Day 36) [UCB7665 10mg/kg]
Visit 7 (Week 5/Day 29) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the fifth visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. This visit can be performed at home with a 
healthcare professional visiting the subject at his/her home. The following assessments will be 
performed at this visit:

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory
rate)

Recording of AEs

Urine sample for urinalysis

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Anti-UCB7665 antibodies

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Exploratory safety biomarkers
, only from 
subjects experiencing severe headaches or GI disturbances (only in case of Adverse 
Events of Interest, see Section 12.4)

Serum total IgG and IgG subclasses concentration

Serum cytokines, only in case of late infusion reactions visible during the visit
REDACTED COPY
visit 
PY 
visit 
er
CO
er hom
COP
hom
blo
R
blo
sed to support any marketing authorization application and any extensions or variations thereof.
cedure
ns o
cedure
rforme
sions
rforme
for per
tensi
for per
and
tion
and U
w of ±2
plica
w of ±2
can be p
appl
can be p
me.
n a
me. Th
ap
Th
ood pre
eting
ood pre
ysis
rt a
ysis
e follow
ppo
e follow
et
o
ety lab
to su
y lab
This document cannot be u
y
e
y
UCB7
us
UCB7
Serum c
ot b
Serum c
Exp
ann
Exp
a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 85 of 353

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
8.4.6
Visit 13 (Week 10/Day 64) [UCB7665 4mg/kg]/ 
Visit 11 (Week 8/Day 50) [UCB7665 7mg/kg]/ 
Visit 10 (Week 7/Day 43) [UCB7665 10mg/kg]
Visit 8 (Week 6/Day 36) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the sixth visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. The following assessments will be performed at 
this visit:

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory
rate)

Recording of AEs

Physical examination (abbreviated)

Urine sample for urinalysis

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Serum total IgG and IgG subclasses concentration

Exploratory safety biomarkers
, only from 
subjects experiencing severe headaches or GI disturbances (only in case of Adverse 
Events of Interest, see Section 12.4)

ITP bleeding scale

NFI-MS

Serum cytokines, only in case of late infusion reactions visible during the visit

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
REDACTED COPY 
hemat
RED
hemat
ny marketing authorization application and any extensions or variations thereof.
/kg]
or v
/kg]
ble for t
ons 
ble for t
perform
nsio
perform
mperatu
on a
mperatu
tology
g au
tology
u
y
u
y
bclasse
mark
bclasse
markers
ny m
markers
not be used to support
cing sev
port
cing sev
est, see
supp
est, see
scale
d to
scale
m cy
t be
m cytok
be
tok
yty
be
yty
This document can
Headach
anno
Headach
neuro
t can
neuro
inc
nt 
inc
rt any


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 86 of 353
8.4.7
Visit 14 (Week 11/Day 71) [UCB7665 4mg/kg]/ 
Visit 12 (Week 9/Day 57) [UCB7665 7mg/kg]/ 
Visit 11 (Week 8/Day 50) [UCB7665 10mg/kg]
Visit 9 (Week 7/Day 43) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the seventh visit in the Observation Period. A visit window of ±2 days is applicable for 
this visit relative to the day of the final dosing visit. This visit can be performed at home with a 
healthcare professional visiting the subject at his/her home. The following assessments will be 
performed at this visit:

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory
rate)

Recording of AEs

Urine sample for urinalysis

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Anti-UCB7665 antibodies

Exploratory safety biomarkers
 only from 
subjects experiencing severe headaches or GI disturbances (only in case of Adverse 
Events of Interest, see Section 12.4)

Serum BAFF levels

Exploratory biomarker analysis

Serum total IgG and IgG subclasses concentration

Serum IgA, IgM, and IgE concentration

Serum cytokines, only in case of late infusion reactions visible during the visit

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
TED COPY
ding
PY 
ding
RED
headac
RED
headac
R
12
R
12
ACTE
EDAC
ization application and any extensions or variations thereof.
d respir
xtens
d respir
coagula
pplic
coagula
be used to support any marketing au
ches or
g au
ches or
2.4
tin
2.4)
tin
)
analy
ny m
analysi
m
si
d IgG s
ort a
d IgG s
M, and 
supp
M, and 
es, 
d to
es, onl
to 
onl
questio
used
questio
ogical a
be u
ogical a
This document canno
uding b
ot b
uding b
ndicate
anno
ndicate
LP in
t can
LP in
horiz
autho


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 87 of 353
8.4.8
End-of-Study Visit: Visit 15 (Week 13/Day 85) [UCB7665 4mg/kg]/ 
Visit 13 (Week 11/Day 71) [UCB7665 7mg/kg]/
Visit 12 (Week 10/Day 64) [UCB7665 10mg/kg]
Visit 10 (Week 9/Day 57) [UCB7665 15mg/kg and UCB7665 20mg/kg]
The End-of-Study Visit will be conducted 8 weeks after the final dose. A visit window of 
±2 days is applicable for this visit relative to the day of the final dosing visit. The following 
assessments will be performed at this visit:

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory
rate)

Body weight

Recording of AEs

Physical examination (complete)

12-lead ECG (triplicate)

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration

ITP-specific autoantibodies 

For all dose arms, collection of whole blood for exploratory RNA analyses 

ITP bleeding scale

NFI-MS

Subject exit interview

Serum cytokines, only in case of late infusion reactions visible during the visit

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.

TB signs and symptoms questionnaire
REDACTED COPY
poten
PY 
poten
matolo
DAC
matolo
be used to support any marketing authorization application and any extensions or variations thereof.
espirato
nsion
espirato
tial
ap
tial
ogy inc
utho
ogy inc
ubclass
mar
ubclass
odies
any
odies
lection
port
lection
e
exit
e u
exit
This document cannot
inte
use
inte
m cy
ot b
m cyto
b
to
yty
b
yty
Headac
cann
Headac
neur
nt ca
neur
in
n
in
y 


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 88 of 353
8.5
Early Withdrawal Visit
All subjects who withdraw early from the study treatment should attend an Early Withdrawal 
Visit which will be scheduled as close as possible to the date of the decision for the study or 
treatment withdrawal. Subjects are encouraged to return to the clinic for all visits of the
Observation Period following the Early Withdrawal Visit. The subjects will have their 
End-of-Study Visit scheduled 8 weeks after their final dose. 
In case a subject is not willing to attend the visits in the Observation Period, the subjects should 
still be strongly encouraged to attend at least the Early Withdrawal Visit and End-of-Study Visit. 
The End-of-Study Visit should be scheduled 8 weeks after their last dose of IMP.
The assessments to be done at both the Early Withdrawal Visit as well as the End-of-Study Visit 
are the same as those at Visit 15 for the UCB7665 4mg/kg weekly (Dose Arm 1) group, Visit 13 
for the UCB7665 7mg/kg weekly (Dose Arm 2) group, Visit 12 for the UCB7665 10mg/kg 
weekly (Dose Arm 3) group, or Visit 10 for the UCB7665 15mg/kg (Dose Arm 4) and UCB7665 
20mg/kg (Dose Arm 5) groups, except for the subject exit interview which will be performed at 
the End-of-Study Visit only.
8.6
Unscheduled Visit
Unscheduled visits may include the following assessments or other assessments deemed 
necessary by the investigator:

Concomitant medication

Concomitant medical procedures

Recording of AEs

Vital signs (systolic and diastolic blood pressure, pulse rate, and temperature)

Serum cytokines, only in case of late infusion reactions visible during the visit

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment. Additionally, other diagnostic procedures including but not limited 
to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion 
of the investigator, considering the local guidelines for performing LP in subjects with ITP.
Other safety assessments (eg, physical examination, 12-lead ECG, laboratory assessments) may
be performed at the discretion of the investigator.
In the event of a subject developing an infection during the course of the study, samples for 
culture will be taken prior to commencing antimicrobial treatment.
9
ASSESSMENT OF EFFICACY
9.1
Platelet counts
For assessment of platelet counts, blood samples will be collected by qualified site personnel at 
the same time that samples are collected for standard clinical laboratory assessments. The time 
and date of the blood draws will be recorded in medical source data and the eCRF. Assessment 
will be performed according to the schedule of study assessments (Section 5.2).
REDACTED COPY 
Y
bloo
RE
bloo
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
d 
r
d 
Visit. 
var
Visit. 
Study
sions
Study
group
ens
group
65
ext
65 10
te
10
Arm 4) 
ny e
Arm 4) 
ch will 
d any
ch will 
other a
plica
other a
od pres
ting 
od pres
late
rke
late inf
e
inf
y
y
y if sub
y m
if sub
y
y
y
Additio
any
Additio
r LP fo
ort a
LP fo
conside
uppo
conside
ments (
to su
ments (
he disc
ed to
he disc
of a su
e us
of a su
ill be ta
t be
ill be ta
9.1
nt
9.1
For
me
For


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 89 of 353
Platelet counts will be determined by a central laboratory and the following variables will be 
computed in the statistical database for the purpose of analysis:

Response by visit and Response at least once during the study

Complete Response by visit and Complete Response at least once during the study

Platelet count ≥50x109/L by visit and at least once during the study

Value and change from Baseline in platelet count by visit

Baseline-corrected AUEC for platelet count calculated from Baseline to the end of study visit

Maximum value and maximum increase from Baseline

Time to Response

Time to Complete Response

Time to achieving platelet count ≥50x109/L

Duration of Response

Duration of Complete Response

Duration of platelet count ≥50x109/L

Clinical Response: platelet count ≥30x109/L and at least 2-fold increase from Baseline value 
and absence of bleeding

Time to Clinical Response: time from starting treatment to achievement of Clinical Response

Duration of Clinical Response: measured from achievement of Clinical Response to loss of 
Clinical Response (loss of Clinical Response defined as platelet count <30x109/L or less than 
2-fold increase from Baseline platelet count or presence of bleeding)

Complete Clinical Response: platelet count ≥100x109/L and absence of bleeding

Time to Complete Clinical Response: time from starting treatment to achievement of 
Complete Clinical Response

Duration of Complete Clinical Response: measured from achievement of Complete Clinical 
Response to loss of Complete Clinical Response (loss of Complete Clinical Response defined 
as platelet count <100x109/L or presence of bleeding)

No Clinical Response: platelet count <30x109/L or less than 2-fold increase from Baseline or 
presence of bleeding
The clinical response variables will be assessed only for visits for which both platelet counts and 
the ITP bleeding score are assessed (with the exception of the confirmatory platelet assessments 
which may be obtained at any visit [scheduled or unscheduled] provided that they meet the 
criteria below). In order to define a clinical response, the platelet count must be confirmed on 2 
separate occasions at least 7 days apart (ie, the second assessment should be ≥168 hours after the 
first assessment). The time to response will be taken as the time to the first platelet assessment 
(obtained at the same time as the corresponding ITP bleeding score assessment). If the second 
assessment does not fulfill the required criteria for a clinical response, the subject will be 
REDACTED COPY 
n
C
nd 
CO
d at l
COP
at l
tarting
ACTE
tarting
asured
EDA
asured
al Re
RE
al Re
support any marketing authorization application and any extensions or variations thereof.
dy
or
dy visit
r va
visit
y
r
y
east 2
n ap
east 2
p
g treatm
horiz
g treatm
d from 
aut
d from 
esponse
ting a
esponse
elet cou
ketin
elet cou
platelet
mar
platelet
al Respo
any
al Respo
ponse
ort a
ponse
lete Cli
supp
lete Cli
This document cannot be used to
s of Co
to su
s of Co
unt <1
ed to
unt <1
cal Res
e us
cal Res
nce of b
t be
nce of b
clinical
anno
clinical
e ITP b
t can
e ITP b
which
ent 
which
crit
me
crit


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 90 of 353
considered as a nonresponder at the respective visits. In order to define a clinical response (or no 
clinical response), the platelet count must be confirmed on 2 separate occasions; further details 
will be provided in the SAP. Absence of bleeding is indicated by Grade 0 for all domains of the 
SMOG. Presence of bleeding is indicated by a Grade of 1 or above, for at least one domain of the 
SMOG.
Refer to Section 14 for details of statistical analysis of these variables.
9.2
ITP bleeding score
The International Working Group on ITP now proposes a consensus-based ITP-specific Bleeding 
Assessment Tool (ITP-BAT), based on a precise definition of bleeding manifestations and on the 
grading of their severity (Rodeghiero et al, 2013). The ITP bleeding score will be assessed using 
the ITP-BAT tool version 1.0. Assessment will be performed according to the schedule of study
assessments (Section 5.2).
For the ITP-BAT, bleeding manifestations were grouped into 3 major domains: skin (S), visible 
mucosae (M), and organs (O), with gradation of severity (SMOG). Each bleeding manifestation 
is assessed at the time of examination. Severity is graded from 0 to 3 or 4, with grade 5 for any
fatal bleeding. Bleeding reported by the subject without medical documentation is graded 1. 
Within each domain, the same grade is assigned to bleeding manifestations of similar clinical 
impact. The “worst” bleeding manifestation since the last Observation Period visit is graded, and 
the highest grade within each domain is recorded. The SMOG system provides a consistent 
description of the bleeding phenotype in ITP.
A standardized data collection form will be used to facilitate collection of information and 
communication among physicians and investigators. The grading of bleeding symptoms at 
presentation and at each subsequent evaluation is presented in Appendix 18.2.
9.3
Patient reported outcomes
Subjects will complete 1 questionnaire (NFI-MS) and 1 subject exit interview as per time points 
mentioned in the schedule of study assessments in Section 5.2. Administration of the 
questionnaire and the subject exit interview should be performed by study personnel other than 
the treating physician. The questionnaire and the subject exit interview should be completed in a 
quiet place and by the subject themselves.
The questionnaire and the subject exit interview should be completed in the following order:
NFI-MS followed by the subject exit interview which will be performed only at last visit. The 
questionnaire and the subject exit interview should only be checked for completeness. On dosing 
days, the NFI-MS questionnaire will be completed prior to dosing.
9.3.1
NFI-MS
The NFI-MS was developed in multiple sclerosis and consists of 23 items in 4 subscales of 
Physical (8 items), Cognitive (4 items), Relief by diurnal sleep or rest (6 items) and Abnormal 
nocturnal sleep and sleepiness (5 items). A summary score is available comprising items from 
the Physical and Cognitive subscales. The measurement properties have been established using 
Rasch analysis (Mills et al, 2013; Mills et al, 2010).
Each item has a 4 point, Likert response option. There is a single sentence instruction at the start 
of the scale asking respondents to consider their experience over the previous 2 weeks.
REDACTED COPY 
last 
PY
last 
The SM
OPY
The SM
used to
TED
used to
vestiga
DACT
vestiga
valuati
EDA
valuati
ut
R
ut
ed to support any marketing authorization application and any extensions or variations thereof.
leeding
or va
leeding
and on 
ns o
and on 
sessed
sions
sessed
edule o
ensi
edule o
mains: s
any 
mains: s
h bleed
nd a
h bleed
 or 4, w
n and
 or 4, w
docume
tion 
docume
anifesta
icati
anifesta
bservat
pplic
bservat
MOG s
n app
MOG s
o facili
riza
o facili
ators.
thor
ators. T
ion
a
ion is p
aut
is p
tcom
eting
tcom
aire
mark
aire (N
rk
(N
dy
y
dy asse
y ma
asse
exit int
any
exit int
questi
ort a
questi
ubject t
uppo
ubject t
and the 
to su
and the 
d b
ed
d by th
d to
y th
This document cannot be us
and th
use
and th
FI
be
FI-
be
-MS
e u
MS
e N
ca
e NFI
can
FI
Phy
ent
Physic
t 
sic
noc
me
noc
t


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 91 of 353
Using the interval level NFI-MS scores, the largest minimal clinically important difference 
(MCID) equated to 2.49 points on the Summary scale, 2.36 points on the Physical scale, 
0.84 points on the Cognitive scale, 0.97 on the Diurnal Sleep scale and 1.95 on the Nocturnal 
Sleep scale (Mills et al, 2013). The NFI-MS questionnaire is available as Appendix 18.3.
9.4
Subject exit interview
At the last clinic visit, subject interview will be conducted using a semi-structured interview 
guide by a study nurse/study personnel. The aim is to collect the subject's experience with living 
with ITP in terms of symptoms and impact on daily activities, and the perceived changes during 
the course of the study. In addition, the relevance of the NFI-MS in ITP will be assessed. The 
interviews will be recorded. If a subject leaves the study prematurely, he/she will also be invited 
to participate in an exit interview.
10
ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC VARIABLES
10.1
Pharmacokinetic variables
The plasma concentration of UCB7665 will be characterized. Blood samples will be drawn 
according to the schedule of study assessments Section 5.2
All blood samples will be collected before dosing with UCB7665 at the dosing visits, and will be 
drawn at the same time of the sampling for standard clinical laboratory tests. The time and date 
of collection will be recorded in the eCRF.
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study.
10.2
Pharmacodynamic variables
For all PD assessments, blood samples will be collected predose (at dosing visits) by qualified 
site personnel at the same time that samples are collected for standard clinical laboratory
assessments. Blood samples for PD analyses will be drawn according to the schedule of study
assessments (Section 5.2). The time and date of collection will be recorded in the eCRF. 
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study.

Serum IgG concentrations

Serum IgG subclass concentrations 

Serum ITP-specific autoantibody
11
ASSESSMENT OF OTHER IMMUNOLOGICAL VARIABLES
For all immunological assessments, blood samples will be collected predose (at dosing visits) by
qualified site personnel at the same time that samples are collected for standard clinical 
laboratory. The time and date of the blood draws will be recorded in the eCRF. The following 
REDACTED COPY
h UC
PY 
h UC
d 
CO
d clini
COP
clini
, proce
CTE
, proce
s stud
DAC
s stud
ic 
RE
ic v
RE
va
ED
a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ng
ri
ng
uring
var
uring
The 
or
The 
o be inv
ons 
o be inv
od samp
ion a
od samp
B7665 
appli
B7665 
ical
n a
ical lab
ap
lab
essing,
horiza
essing,
dy
ut
dy.
ut
.
ariabl
ng a
ariabl
s will b
rketi
s will b
t sampl
mark
t sampl
PD an
ny m
PD an
he time
t any
he time
sample
port 
sample
ory ma
upp
ory ma
centrat
to s
centrat
G subcla
used
G subcla
IT
be
ITP-
be 
P-s
annot
nt ca
n


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 92 of 353
immunological assessments will be performed according to the schedule of study assessments 
(Section 5.2).

Serum immunoglobulin concentration over time

IgA

IgE

IgM

Serum complement levels over time

C3

C4

Plasma complement levels over time

C3a

C5a

Exploratory safety biomarkers levels over time

Serum BAFF levels

Lymphocyte counts (B and T)

Anti-UCB7665 antibodies

Cytokines
Cytokine samples will be taken at Baseline Visit for all subjects. At subsequent visits, 
cytokine samples will be taken only when the subject experiences infusion reactions.
12
ASSESSMENT OF SAFETY
12.1
Adverse events
12.1.1
Definition of adverse event
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product.
In order to ensure complete safety data collection, all AEs occurring during the study (ie, after 
the signing of the Informed Consent form), including any pretreatment and posttreatment periods 
required by the protocol, must be reported in the eCRF even if no IMP was taken but specific 
study procedures were conducted. This includes all AEs not present prior to the initial visit and 
all AEs that recurred or worsened after the initial visit.
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
REDACTED COPY 
Basel
RED
Basel
nly
R
nly
R
y
R
y
ent cannot be used to support any marketing authorization application and any extensions or variations thereof.
line Vi
g au
line Vi
when t
eting
when t
OF S
arke
OF S
nts
ny
nts
of adv
ort a
of adv
d medi
upp
d medi
maceut
to su
maceut
n AE c
d to
n AE c
oratory
used
oratory
d
(investi
be u
(investi
rder to
cann
rder to
he sign
nt ca
he sign
This documen
requi
men
requi
stu
m
stu


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 93 of 353
increases in a clinically significant manner as compared to the clinical profile known to the 
investigator from the subject’s history or the Baseline Period.
Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2 bleeding events
should not be reported as an AE since these events will be assessed and reported during the 
ITP-BAT assessment; CTCAE grade 3 or more bleeding events should be reported as AEs. 
Treatment-emergent AEs are defined as AEs starting after the time of first IMP administration up 
to and including 8 weeks after the final dose.
12.1.2
Procedures for reporting and recording adverse events
The subject will be given the opportunity to report AEs spontaneously. A general prompt will 
also be given at each study visit to detect AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
12.1.3
Description of adverse events
When recording an AE, the investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Signs and symptoms should only be documented as 
AEs in case the underlying disease or condition is unknown or they are considered as clinically
significant independent of the underlying disease or condition in the discretion of the 
investigator. Any discrepancies between the subject’s own words on his/her own records 
(eg, diary card) and the corresponding medical terminology should be clarified in the source 
documentation.
For recording an AE, CTCAE will be used, and only if it is impossible to assess severity using
CTCAE, then AE intensity will be assessed using a scale of mild, moderate, or severe.
Details for completion of the AE eCRF (including judgment of relationship to IMP) are 
described in the CRF Completion Guidelines.
12.1.4
Follow up of adverse events
An AE should be followed until it has resolved, has a stable sequelae, the investigator determines 
that it is no longer clinically significant, or the subject is lost to follow up. 
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
investigator must provide a justification. The follow up will usually be continued for 8 weeks
after the subject has discontinued his/her IMP.
12.1.5
Rule for repetition of an adverse event
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:

The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening”

The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one
REDACTED COPY
ondit
PY 
ondit
ct’s ow
COPY
ct’s ow
ermin
D CO
ermin
ed, and
DAC
ed, and
essed 
REDA
essed 
F
R
F
any marketing authorization application and any extensions or variations thereof.
mpt wil
ons o
mpt wil
visit)?”
xten
visit)?”
is or
nd a
is or sy
sy
ptoms o
n an
ptoms o
should
tion
should
r they
licat
r they a
t
a
y
t
y
on in th
ppli
on in th
wn wor
n ap
wn wor
nology
ation
nology
nd only
utho
nd only
d using 
g au
d using 
(inclu
keting
(inclu
uidelin
arke
uidelin
dverse
y m
dverse
cannot be used to support 
until it 
rt an
until it 
ally
ppo
ally sign
port
sign
y
po
y
at the e
o sup
at the e
evel of
d to 
evel of
ficant, 
sed 
ficant, 
must p
e us
must p
subject
t be
subject
This document
5
n
5
An incr
nt ca
An incr

me



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 94 of 353
12.1.6
Pregnancy
If an investigator is notified that a subject has become pregnant after the first intake of any IMP, 
the investigator must immediately notify UCB’s Patient Safety (PS) department by providing the 
completed Pregnancy Report and Outcome form (for contact details see Serious Adverse Event 
reporting information at the beginning of this protocol). The subject should be withdrawn from 
the study as soon as pregnancy is known (by positive pregnancy test), and the following should 
be completed:

The subject should return for an Early Withdrawal Visit.

No further IMP will be administered.

An End-of-Study Visit should be scheduled 8 weeks after the subject has discontinued her 
IMP.
The investigator must inform the subject of information currently known about potential risks 
and about available treatment alternatives.
The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form in which the investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for 30 days after birth for any significant medical issues. In certain 
circumstances, UCB may request that follow up is continued for a period longer than 30 days. If 
the subject is lost to follow up and/or refuses to give information, written documentation of 
attempts to contact the subject need to be provided by the investigator and filed at the site. 
UCB’s PS department is the primary contact for any questions related to the data collection for 
the pregnancy, eventual birth, and follow up.
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
investigator or designee is asked to contact the subject to request consent of the partner via the 
Partner Pregnancy Consent form that has been approved by the responsible IRB/IEC and should 
be available in the investigator site file. In case of questions about the consent process, the 
investigator may contact the UCB/contract research organization (CRO) contract monitor for the 
study. The investigator will complete the Pregnancy Report and Outcome form and send it to 
UCB’s PS department (for contact details see Serious Adverse Event reporting information at the 
beginning of this protocol) only after the partner has agreed that additional information can be 
captured and has provided the signed Partner Pregnancy Consent form. UCB’s PS department is 
also the primary contact for any questions related to the data collection for the partner pregnancy, 
eventual birth, and follow up.
A pregnancy becomes a serious adverse event (SAE) in the following circumstances: 
miscarriage, abortion (elective or spontaneous), unintended pregnancy after hormonal 
contraceptive failure (if the hormonal contraceptive was correctly used), ectopic pregnancy, fetal 
demise, or any congenital anomaly/birth defect of the baby. Those SAEs must be additionally
reported using the Investigator SAE Report form.
REDACTED COPY 
ery
PY
ery r
Y
r
y y
Y
y y
for an
OPY
for an
is con
D CO
is con
to give
TED 
to give
rovide
ACTE
rovide
ntact f
DAC
ntact f
llow
RED
llow u
D
u
not be used to support any marketing authorization application and any extensions or variations thereof.
ntinued
nsio
ntinued
out pot
ny ex
out pot
tcome 
and
tcome 
irth (if 
tion 
irth (if 
which 
icatio
which 
asonab
pplic
asonab
ny
n a
ny sign
n app
sign
y y
n a
y y
ntinued 
tion 
ntinued 
e infor
izati
e infor
ed by
horiz
ed by t
z
t
y
z
y
for any
auth
for any
up.
g
up.
ubject e
ketin
ubject e
contac
mark
contac
that
y ma
that ha
ma
ha
or site f
any
or site f
e UCB
ort a
e UCB
will co
uppo
will co
nt
o
nt (for c
o sup
(for c
protoco
d to 
protoco
as 
s
as prov
sed
prov
mary
be us
mary co
us
co
nt can
birth
t be
birth, a
e
, a
egnanc
anno
egnanc
iscarria
t ca
iscarria
This documen
contra
ment 
contra
dem
me
dem


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 95 of 353
12.1.7
Suspected transmission of an infectious agent via a medicinal 
product
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the CRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.
12.1.8
Overdose of investigational medicinal product
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the appropriate module of the eCRF. Any SAE or nonserious AE associated with 
excessive dosing must be followed as any other SAE or nonserious AE. These events are only 
considered AEs or SAEs if there are associated clinical signs and symptoms or if the act of 
taking the excess medicine itself is an AE or SAE (eg, suicide attempt).
12.1.9
Safety signal detection
The safety variables and ADA results available after 7 days of the final dose of 3 and 6 subjects 
in the UCB7665 4mg/kg weekly group (Dose Arm 1) will be reviewed by the DMC (interim 
analysis 1 and 2) comprising at least 1 external expert, the UCB study physician, the UCB PS
representative, and a biostatistician and will be summarized on an ongoing basis during the study 
so as to continuously evaluate the safety of subjects. The DMC will meet and reach a decision on 
whether or not the study can continue as planned, and whether or not Dose Arm 2 can be started.
Subsequently, safety variables and ADA results available after 7 days of the final dose of 3 and 
6 subjects in the UCB7665 7mg/kg weekly (Dose Arm 2) (together with all available data from 
Dose Arm 1 and 2) will be reviewed by the DMC (interim analysis 3 and 4). The DMC will also 
meet and review safety data to add additional subjects to subsequent dose arms or to open 
subsequent dose arms. Further details are described in Section 5.1.
The DMC may also decide to reduce the number of doses in each of the dose arms, to stop a dose 
arm or not to open a dose arm based on review of data during the study.
Thus, selected data from this study will be reviewed periodically to detect as early as possible 
any safety concern(s) related to the IMP so that investigators, clinical study subjects, regulatory
authorities, and IRBs/IECs will be informed appropriately and as early as possible.
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
of the study.
12.1.10
Hypersensitivity and adverse reactions
In the event of a severe infusion reaction, the subject must permanently discontinue IMP and be 
managed as described in Appendix 18.4.
REDACTED COPY
marize
PY 
marize
s. The
COP
s. The
d, and
D C
d, and
ults 
TE
ults av
ED
av
y
A
y (D
ACT
(D
y
A
y
o
CT
o
y the D
EDA
y the D
dditio
RE
dditio
nnot be used to support any marketing authorization application and any extensions or variations thereof.
d be
s or
d be
ted wit
ions
ted wit
ents are
ensio
ents are
if the a
exte
if the a
nal 
n a
nal do
an
do
iewed 
tion
iewed 
CB stud
licat
CB stud
d on an
appl
d on an
e DMC
on ap
e DMC
d wheth
ation
d wheth
ailable
riza
ailable
se 
th
se A
hor
Arm
o
rm
DMC (
aut
DMC (
onal su
ing a
onal su
are des
ketin
are des
ce the 
mar
ce the 
based o
ny m
based o
is study
ort a
is study
lated to
ppo
lated to
/IECs w
sup
/IECs w
cian or 
d to
cian or 
perform
used
perform
priate fo
t be 
priate fo
lly
no
lly
This document ca
qua
not b
qua
y
no
y
s, labor
ann
s, labor
f the st
nt ca
f the st
12.1
me
12.1


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 96 of 353
In case of occurrence of a hypersensitivity reaction (except for local injection site reaction) and 
depending upon its severity, appropriate countermeasures will immediately be taken by the 
investigator. The cytokine samples must be taken for infusion reactions.
If the investigator does not initially choose to discontinue the infusion of IMP and symptoms 
persist or escalate during continued infusion, the infusion should be stopped. In case of any 
severe infusion reaction(s), the infusion of IMP must be stopped immediately and appropriate 
treatment initiated, as necessary, at the discretion of the investigator and in accordance with the 
standard of care.
Suspected anaphylactic reactions should be diagnosed using Sampson’s Criteria (Sampson et al, 
2006) as described in Appendix 18.5. In the event of an anaphylactic reaction the infusion must
be discontinued immediately and emergency resuscitation measures implemented. 
12.1.11
Management of severe headache
Severe headache is defined as severe pain limiting self-care activities of daily living (ADL) or 
new/prolonged hospitalization for management of headache or life-threatening consequences 
requiring urgent medical intervention. Self-care ADL refer to bathing, dressing and undressing, 
feeding self, using the toilet, taking medications. Treatment of headache will be provided as 
clinically indicated according to the local guidelines.
Subjects experiencing severe headache will complete the Headache Questionnaire and will 
complete the questionnaire daily until resolution (ie, if headache becomes moderate or mild, 
normal collection of AEs should apply); this assessment will be followed by a neurological 
assessment (including fundoscopy). Further workup will be performed at the discretion of the 
investigator and may include eg, a CT scan, MRI and/or a LP for CSF collection, considering the 
local guidelines for performing LP in patients with ITP. These investigations will be performed 
in order to further understand the mechanism of headache in these subjects.
Details of neurological examination to be performed are provided in Section 12.8.5. The 
Headache Questionnaire is available in Appendix 18.6.
12.1.12
Management of moderate or severe diarrhea
Moderate or severe diarrhea is defined as an increase of ≥4 stools per day over Baseline or 
incontinence due to urgency of diarrhea or new/prolonged hospitalization for management of 
diarrhea or limiting self-care ADL or life-threatening consequences requiring urgent medical 
intervention.
Stool collection and analysis will be performed for subjects reporting moderate or severe 
diarrhea. The frequency of stool sampling will be as clinically indicated in the opinion of the 
investigator. Analysis of stool samples will be performed locally. 
Treatment of diarrhea will be provided as clinically indicated according to the local guidelines.
12.2
Serious adverse events
12.2.1
Definition of serious adverse event
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria:

Death
REDACTED COPY
the H
PY 
the H
e, if h
COP
e, if h
sessme
D C
sessme
worku
CTED
worku
n
A
n,
AC
, MR
ACT
MR
patient
EDA
patient
chan
RE
chan
sed to support any marketing authorization application and any extensions or variations thereof.
on et al
or v
on et al
sion m
ns 
sion m
aily
any
aily livi
ny e
livi
y
ny
y
atening
nd a
atening
g, dress
and
g, dress
adache 
tion 
adache 
Headach
appl
Headach
headach
on ap
headach
ment wil
ation
ment wil
up will 
oriza
up will 
RI
th
RI and
hor
and/d/d/d
ts with
aut
ts with
ism
ng
ism of 
g a
of 
to be pe
rket
to be pe
le in 
mar
le in A
r
A
t of mo
any 
t of mo
ea is de
port 
ea is de
gency
upp
gency o
p
o
y
p
y
annot be u
self
to s
self-
s
-f-f
s
f-f ca
su
ca
ion and
use
ion and
The fre
t be 
The fre
gator. A
not 
gator. A
This document c
eatmen
can
eatmen
12.2
ment
12.2
1
m
1


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 97 of 353

Life-threatening
(Life-threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)

Significant or persistent disability/incapacity

Congenital anomaly/birth defect (including that occurring in a fetus)

Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious
(Important medical events may include allergic bronchospasm requiring intensive treatment 
in an emergency room or at home, blood dyscrasias that do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse.)

Initial inpatient hospitalization or prolongation of hospitalization
(A subject admitted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalization. An emergency room visit that results in 
admission to the hospital would also qualify for the initial inpatient hospitalization criteria. 
However, emergency room visits that do not result in admission to the hospital would not 
qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg, life-threatening adverse experience, important medical event].
Hospitalizations for reasons not associated with the occurrence of an AE [eg, preplanned 
surgery or elective surgery for a pre-existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, 
since there is no AE upon which to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to 
be determined.)
12.2.2
Procedures for reporting serious adverse events
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information by
the site (see contact information for SAE reporting listed in the Serious Adverse Event Reporting 
section at the front of the protocol). The investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE Report form) 
provided by UCB, even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Information recorded on this form will be entered into 
the global safety database.
An Investigator SAE Report form will be provided to the investigator. The Investigator SAE 
Report form must be completed in English. 
It is important for the investigator, when completing the SAE Report form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the investigator is very important for UCB to consider in assessing the safety of the IMP 
REDACTED COPY
aluate
PY 
aluate
rse exp
COP
rse exp
d with 
TED 
d with 
isting 
ACTE
isting 
nner] 
DAC
nner] 
on his/
RED
on his/
riat
R
riat
arketing authorization application and any extensions or variations thereof.
he 
ri
he 
ther
va
ther
e treatm
sions
e treatm
ient 
ens
ient 
same d
and 
same d
om vis
n a
om vis
patient
ation
patient
mission 
plica
mission 
d for 1
appl
d for 1
perienc
on ap
perienc
h the oc
izati
h the oc
condit
horiz
condit
do not
autho
do not
/her m
g au
/her m
ate to re
eting
ate to re
to asse
arke
to asse
not be used to support any m
rsened 
mar
rsened 
an AE a
ny m
an AE a
ures fo
ppo
ures fo
ed, UCB
to su
ed, UCB
act info
ed to
act info
front
used
front o
ed
o
pleted 
be u
pleted 
ent can
d b
ot
d by UC
ot b
y UC
ed in or
anno
ed in or
e globa
t can
e globa
This documen
An In
men
An In
R
m
R


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 98 of 353
and in determining whether the SAE requires reporting to the regulatory authorities in an 
expedited manner.
Additional information (eg, autopsy or laboratory reports) received by the investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be 
summarized in the Investigator SAE Report form.
The investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each subject, and to also inform participating subjects of 
the need to inform the investigator of any SAE within this period. Serious AEs that the 
investigator thinks may be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the study.
Upon receipt of the SAE Report form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the Investigator’s 
Brochure.
12.2.3
Follow up of serious adverse events
An SAE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. 
Information on SAEs obtained after clinical database lock will be captured through the PS 
database without limitation of time.
12.3
Adverse events of special interest
An AE of special interest is any AE that a regulatory authority has mandated to be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound.
Adverse event of special interest for UCB7665 is:

Potential Hy’s law cases
Potential Hy’s law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN bilirubin in the 
absence of ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, must 
always be reported to UCB as an AE of special interest (ie, without waiting for any additional 
etiologic investigations to have been concluded). Follow-up information should then be reported 
if an alternative etiology is identified during investigation and monitoring of the subject.
12.4
Adverse events of interest
For UCB7665, AEs of interest that require immediate reporting to UCB are:

Severe headache

Moderate to severe diarrhea

Moderate to severe abdominal pain

Moderate to severe vomiting
REDACTED COPY
r the 
PY 
r the 
base lo
CO
base lo
pecial
ACT
pecial
hat a re
REDA
hat a re
ious
RE
ious
g authorization application and any extensions or variations thereof.
y 
ri
y 
p to 
va
p to 
cts of 
or v
cts of 
e
o
e
dless o
nsio
dless o
expecte
ny ex
expecte
n the
d any
n the I
y
I
y
seq
lica
sequel
ca
uel
qu
q
ca
qu
q
subject
appl
subject
ock wil
tion a
ock wil
al inter
thor
al inter
regulato
g au
regulato
sed to support any marketi
sness, e
ting
sness, e
mpound
rket
mpound
for UC
y ma
for UC
ned as 
ppor
ned as ≥
r
≥
ALP, w
supp
ALP, w
to UC
to s
to UC
gations
sed t
gations
This document cannot be u
ive etio
use
ive etio
A
e
A
UCB76
ann
UCB76
Sev
nt c
Sev

m



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 99 of 353
12.5
Immediate reporting of adverse events
The following AEs must be reported immediately using the SAE Report Form according to the 
procedure in Section 12.2.2:

SAE: AE that the investigator classifies as serious by the above definitions regardless of 
causality

Suspected transmission of an infectious agent via a medicinal product

AE of special interest (see Section 12.3)

AE of interest (see Section 12.4)

Confirmed LTB, active TB, and NTBI (see Section 12.8.1)
12.6
Anticipated serious adverse events
The following list of Anticipated SAEs has been identified, as these events are anticipated to 
occur in the population studied in this protocol at some frequency that is independent of drug 
exposure. This original list will remain in effect for the duration of the protocol.
This list does not change the investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section 12.2.2.
Table 12‒1: Anticipated serious adverse events for ITP population
Headache
Infections
Bleeding events
12.7
Laboratory measurements
Blood and urine specimens for routine assay of hematology including coagulation parameters, 
clinical chemistry, urinalysis testing, and pregnancy testing as well as serology testing will be 
performed according to the Schedule of assessments (Section 5.2) to monitor the safety of 
subjects. All clinical chemistry, hematology, and urinalysis parameters will be assessed by the 
designated central laboratory with the exception of platelet count and the urine pregnancy test 
prior to each dose. Specific details regarding the handling and processing of serum chemistry, 
hematology, and urinalysis samples are provided in the study laboratory manuals. 
Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally 
and the value will be used to check inclusion criteria. The other platelet sample will be sent to 
the central laboratory. At subsequent dosing visits, an additional platelet sample will be obtained 
prior to dosing and analyzed locally to evaluate withdrawal criterion of platelet count 
>350x109/L. The urinalysis for pregnancy testing will be performed with a dipstick.
The following laboratory parameters will be measured:
REDACTED COPY 
vents
COP
vents
D C
TE
DA
RE
any marketing authorization application and any extensions or variations thereof.
s are an
any 
s are an
s indep
nd a
s indep
he prot
n and
he prot
ll
a
ll SAE
ation
SAE
at
s for 
on ap
s for IT
p
IT
tio
riz
ut
ng
reme
ketin
reme
utine as
mar
utine as
esting
ny m
esting
d to support a
m
Schedu
t an
chedu
mistry
pport
mistry
oratory
supp
oratory
Specifi
to s
Specifi
nnot be used
d urinal
ed to
d urinal
ng at V
e us
ng at V
alue wi
t be
alue wi
ntral lab
not
ntral lab
This document ca
or to do
cann
or to do
>350x1
nt c
>350x1
The
me
The


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 100 of 353
Table 12‒2: Laboratory measurements
Hematology
Chemistry
Coagulation 
parameters
Urinalysis
Pregnancy test
Basophilsa
Calcium
INR 
pH
Urineb HCG
Eosinophilsa
Phosphate
Prothrombin time
Protein
Serum
c HCG
Neutrophilsa
Chloride
aPTT
Creatinine 
Lymphocytesa
Magnesium
Fibrinogen
Glucose
Others
Monocytesa
Potassium
Ketones
HbA1c
Hematocrit
Sodium
Urobilinogen
HIV
Hemoglobin
BUN
Bilirubin
Hepatitis B
(HBsAg, anti-HBs,
anti-HBc)
Platelet count
AST
Blood
Hepatitis C
(anti-HCV)
RBC count
ALT
Nitrite
Tuberculosisd
WBC count
GGT
Albumin
Total bilirubin 
Leucocytes
Safety Biomarkerse
Direct bilirubin (if 
indicated)
LDH
Total cholesterol
Triglycerides
ALP
Total protein
Albumin
α1-globulin, 
α2-globulin, 
β-globulin, γ-globulin
Creatinine
hs-CRP
Amylase
a Absolute as well as percentages for the differential leucocyte counts will be performed.
ALP=alkaline phosphatase; ALT=alanine aminotransferase; anti-HBc=hepatitis B core antibody; anti-HBs=hepatitis B surface 
antibody; anti-HCV=hepatitis C virus antibody; aPTT=activated partial thromboplastin time; AST=aspartate aminotransferase; 
BUN=blood urea nitrogen;GGT=gamma-glutamyltransferase; HbA1c=glycosylated hemoglobin; HBsAg=hepatitis B surface 
antigen; HCG=human chorionic gonadotropin; HIV=human immunodeficiency virus; hs-CRP=high-sensitivity C-reactive 
protein; INR=International Normalized Ratio; LDH=lactate dehydrogenase; RBC=red blood cell; WBC=white blood cell 
ACTED COPY 
OP
D C
REDAC
AC
RE
R
horization application and any extensions or variations thereof.
ari
ari
ari
ar
c
or
HIV
sio
HIV
ns
Hepat
xten
Hepat
(HBsA
y ex
(HBsA
ns
a
d a
Nitrite
cati
Nitrite
tio
Al
pl
Al
lic
ap
n a
tio
pport any marketing autho
tho
ng
rk
des
y
des
ma
LP
t a
LP
ny
Total pro
ppor
Total pro
rt 
o supp
A
up
A
This document cannot be used to 
pp
o
ed
be
no
ca
en
um
um
um
a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 101 of 353
b Urine pregnancy test will be performed predose on dosing days and at End-of-Study Visit.
c Serum pregnancy test is done at Visit 1 (Screening) and to confirm results of positive urine test if applicable.
d Interferon-gamma release assay by central laboratory.
e May include but not limited to the biomarkers listed in the table. Samples collected for safety biomarkers at Baseline (Visit 2) 
and 4 hours post dosing (Visit 2) for all subjects and during follow up only in subjects with severe headache and/or moderate to 
severe GI disturbances. The Baseline samples will only be analysed in case he subject experienced a severe headache and/or 
moderate to severe GI disturbance.
12.7.1
Evaluation of PDILI
The PDILI IMP discontinuation criteria for this study are provided in Section 6.4, with the 
accompanying required follow-up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s law must be 
reported as an AE of special interest (see Section 12.3), and, if applicable, also reported as an 
SAE (see Section 12.2.2).
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table 12-3 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 12.7.1.1). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section 12.7.1.4). 
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 2 
laboratory tests are significantly different. Data from the local and central laboratory are to be
recorded on the applicable CRF pages.
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to be hepatotoxic to a suitable alternative.
When IMP is stopped due to PDILI (as described in Section 6.4), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent alternative diagnosis fully explains the hepatic findings, and the requirements 
provided in Section 12.7.1.2.1 are met, rechallenge with IMP may be appropriate. 
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
The table below summarizes the approach to investigate PDILI.
REDACTED COPY 
orin
Y
orin
bnorm
OPY
bnorm
atory
TED
atory
D
hepatic
REDA
hepatic
be d
RE
be d
ed to support any marketing authorization application and any extensions or variations thereof.
events
r va
events
learnin
s or 
learnin
must be
ons
must be
ported a
nsio
ported a
oring in
ny e
oring in
ding s
d an
ding sy
tion
and
tion 12
nd
12
an for a
on a
an for a
e a hep
catio
e a hep
may
plic
may be
ica
be
y
ic
y
mality
app
mality is
pp
is
y
pp
y
testing
rizat
testing
c
g
c labor
g au
labor
delayed
ting 
delayed
id resu
arke
id resu
ible.
ma
ible. M
a
M
and a c
any 
and a c
antly
ort a
antly di
a
di
y
a
y
le CRF
ppor
le CRF
tinued,
o sup
tinued,
ary
d t
ary sho
d to
sho
y
d t
y
This document cannot be use
educti
sed
educti
lly
be
lly r
e u
r
y
e
y equ
us
equ
MP is s
not b
MP is s
ontinue
anno
ontinue
ubseque
nt ca
ubseque
provid
ment
provid
R
m
R


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 102 of 353
Table 12-3: Required investigations and follow up for PDILI 
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULN
b
NA
Hepatology consultc
Medical Monitor must 
be notified within 
24 hours (eg, by 
laboratory alert) and 
subject discussed with 
Medical Monitor ASAP.
Immediate, permanent 
IMP discontinuation.
Essential: Must have 
repeat liver chemistry 
values and additional 
testing completed 
ASAP (see 
Section 12.7.1.3); 
recommended to 
occur at the site with 
HCP.
Monitoring of liver 
chemistry values at least 
twice per week until 
values normalize, 
stabilize, or return to 
within Baseline values.d
≥3xULN
NA
Yes
Immediate, temporary 
or permanent, IMP 
discontinuation.
≥3xULN 
(and ≥2x 
Baseline) 
and 
<5xULN
<2xULN
No
Discussion with Medical 
Monitor required if the 
criterion that allows for 
IMP continuation is met.
Further investigation –
immediate IMP 
discontinuation not 
required (see 
Section 12.7.1.2).
Not required unless 
otherwise medically 
indicated (at 
discretion of 
investigator).
≥5xULN 
(and ≥2x 
Baseline) 
<2xULN
No
Discussion with Medical 
Monitor required.
Hepatology consult 
required if ALT or AST 
≥8xULN.
Immediate, permanent 
IMP discontinuation.
Essential: Every 
attempt must be made 
to have repeat liver 
chemistry values and 
additional testing 
completed within 
48 hours at the site 
with HCP (see 
Section 12.7.1.3).
Monitoring of liver 
chemistry values at least 
twice per week until 
values normalize, 
stabilize, or return to 
within Baseline values. d
REDACTED COPY 
for
AC
for
is met
DAC
is met
Fu
D C
Furth
 C
rth
im
ED
im
CO
TE
R
ng authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
a
o
tial: Mu
y ex
tial: Mu
peat live
any
peat live
values 
d a
values 
testi
and
testi
A
a
A
xte
a
y
o
y
P
a
P
a
n a
.
a
.
her inve
atio
her inve
mmediat
riza
mmediat
discon
hor
discon
requ
uth
requ
S
on
au
marketing
Medica
ketin
Medica
o support any m
ired.
ark
ired.
y consu
ma
y consu
d if ALT
ny m
d if ALT
ULN.
t an
ULN.
ing
This document cannot be used to s
d o s


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 103 of 353
Table 12-3: Required investigations and follow up for PDILI 
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor.
c Details provided in Section12.7.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of potential
hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
d Unless an alternative monitoring schedule is agreed by the investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
COPY
nsi
Y
nsi
ble phy
OPY 
ble phy
REDACTED CO
CO
on application and any extensions or variations thereof.
15 Fe
here
15 Fe
a
o
nsferase
ext
nsferase
=upper l
ny e
=upper l
nsi
d
nsitivity
d an
tivity
iscussed
n an
iscussed
eating ph
tion
eating ph
physici
plic
physici
sician, a
app
sician, a
xte
This document cannot be used to support any marketing authorization
on


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 104 of 353
12.7.1.1
Consultation with Medical Monitor and local hepatologist
Potential drug-induced liver injury events require notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The 
local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full 
hepatology assessment (see Section 12.7.1.3) and SAE report (if applicable).
12.7.1.2
Immediate action: determination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent discontinuation (see Section 6.4 and Table 12-3 for details).
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.
12.7.1.2.1
IMP restart/rechallenge (if applicable)
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
Subjects who are immediately discontinued from IMP due to having met certain criteria for 
PDILI (as described in Section 6.4 and Table 12-3), but for whom an alternative diagnosis is 
confirmed, can rarely restart IMP. Rechallenge with IMP can occur only if ALL of the following 
requirements are met:

The results of additional testing and monitoring described in Section 12.7.1.3 and 
Section 12.7.1.4 confirm a nondrug-related cause for the abnormal hepatic laboratory
parameters and any associated symptoms (ie, a subsequent alternative diagnosis fully
explains the hepatic findings). 

No alternative treatment options are available to the subject.

The subject has shown clear therapeutic benefit from the IMP.

Subject’s ALT or AST elevations do not exceed ≥3xULN.

Subject’s total bilirubin is < 1.5xULN.

Subject has no signs or symptoms of hypersensitivity. 

The rechallenge is approved by the UCB responsible physician, DMC, and a hepatologist. 
The hepatologist must be external to UCB but may be a member of the DMC. It is 
recommended that the hepatologist be a local hepatology expert or the hepatologist treating 
the subject.

Subject agrees to the investigator-recommended monitoring plan.
REDACTED COPY 
cable
OPY
cable
g drug
D CO
g drug
ued fro
DACT
ued fro
d d Tabl
EDA
Tabl
echa
RE
echa
g authorization application and any extensions or variations thereof.
patitis 
tens
patitis 
e inves
ext
inves
for det
any e
for det
ppleme
and a
ppleme
hould a
n an
hould a
onsider
ation
onsider
a suitab
licat
a suitab
e)
a
e)
g
a
g-
t
-induc
ation
induc
om IMP
utho
om IMP
e
d to support any marketin
12-3
au
12-3
allenge 
ting 
allenge 
ng and 
y ma
ng and 
nondru
any 
nondru
ociated
ort a
ociated
finding
ppor
finding
eatmen
o su
eatmen
This document cannot be use
has sho
sed t
has sho
’s ALT
be us
’s ALT
bject’s t
not b
bject’s t
Subjec
can
Subjec

e

T
nt
T


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 105 of 353
12.7.1.3
Testing: identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by the IMP are detailed in 
Table 12-4 (laboratory measurements) and Table 12-5 (additional information). Results of the 
laboratory measurements and information collected are to be submitted to the sponsor on the 
corresponding CRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these should be completed and submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed:
Table 12-4: PDILI laboratory measurements
Virology-related
Hematology
Hepatitis A IgM antibody
Eosinophil count
HBsAg
Urinalysis
Hepatitis E IgM antibody
Toxicology screen
HBcAb-IgM
Chemistry
Hepatitis C RNA
Amylase
Cytomegalovirus IgM antibody
If total bilirubin ≥1.5xULN, obtain fractionated 
bilirubin to obtain % direct bilirubin
Epstein-Barr viral capsid antigen IgM antibody 
(if unavailable, obtain heterophile antibody or 
monospot testing)
Serum CPK and LDH to evaluate possible 
muscle injury causing transaminase elevation
Immunology
Additional
Anti-nuclear antibody (qualitative and 
quantitative)
Prothombin time/INRa
Anti-smooth muscle antibody (qualitative and 
quantitative)
Serum pregnancy test
Type 1 anti-liver kidney microsomal antibodies 
(qualitative and quantitative)
PK sample
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb-IgM=hepatitis B core antibody-IgM; HBsAg=hepatitis 
B surface antigen; IgM=immunoglobulin; INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential 
drug-induced liver injury; PK=pharmacokinetic; RNA=ribonucleic acid; ULN=upper limit of normal
a.Measured only for subjects with ALT or AST >5 xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; 
hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative cause).
The following additional information is to be collected:
REDACTED COPY 
Y
CO
ED
ED
ED
ED
ED
M anti
RED
M anti
ib
R
ib
ED
upport any marketing authorization application and any extensions or variations thereof.
lts, a 
var
lts, a 
ology
any 
ology
e
nophil
and 
nophil
a
Urin
on 
Urin
an
Tox
icat
Tox
tio
pl
n
If tota
oriz
If tota
za
uth
ibod
ng a
ibody 
g a
y 
ibody
keting
ibody o
n
o
y
n
y
au
ma
(qualita
ort a
(qualita
ative)
ppor
ative)
any
to sup
e antib
o su
e antib
t cannot be used 
quantit
d to
quantit
upp
iver kid
use
iver kid
qualita
t be 
qualita
ed
t b
lanine am
not 
lanine am
rface ant
ann
rface ant
rug
c
rug-
ca
-indu
can
indu
This document 
Measur
nt c
Measur
hype
en
hype
hy
hy


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 106 of 353
Table 12-5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal 
remedies, vitamins); dosages and dates should be included.
Pertinent medical history, including the following:

History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other 
“fatty liver disease”)

Adverse reactions to drugs

Allergies

Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha-1 
antitrypsin deficiency)

Recent travel 

Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by 
itself, should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, 
jaundice, fever, or rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary
function
Alcohol and illicit drug use; include dates where available
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug-induced liver injury
12.7.1.4
Follow-up evaluation
Potential drug-induced liver injury events require follow-up monitoring as described in 
Table 12-3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to Baseline. Determination of stabilization is at the discretion of the investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
12.8
Other safety measurements
12.8.1
Assessment and management of TB and TB risk factors
With the currently available data, TB is not considered as an important potential or identified risk 
for treatment with UCB7665. As immunomodulation may carry a risk of new or activation of 
latent TB, UCB has conservatively developed TB detection and management procedures taking 
into account the most current recommendations of international guidelines (2010 WHO) and 
most recent literature, covering any infection by the mycobacteria tuberculosis complex. 
REDACTED COPY
ness,
PY 
ness,
ypoxem
ED C
ypoxem
CO
tes wh
EDAC
tes wh
AC
sy
RE
sy i
RE
i
ED
used to support any marketing authorization application and any extensions or variations thereof.
er 
a
er 
, alpha
xten
, alpha
tic dise
and
tic dise
AST an
ion a
AST an
ati
s
l
s or hy
licat
or hy
decreas
appli
decreas
tio
mia wit
zatio
mia wit
on
here av
auth
here av
ho
if done
ting 
if done
a
gy
ark
gy con
arke
con
y
ark
y
eti
orts
ny
orts
ma
ny
AST=as
t any
AST=as
up eva
ppor
up eva
ed live
o sup
ed live
toring 
d to 
toring 
ine. De
used
ine. De
This document cannot be
n with t
be us
n with t
8.1
ca
8.1
With t
ment 
With t
for
me
for


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 107 of 353
Appropriate rigorous precautions are being taken within this protocol to monitor for the risk of 
TB infection prior to study entry and during the study (see Section 6.2.2 (Exclusion Criterion 
#25) and Section 6.4. Following are the key considerations of these procedures:
12.8.1.1
TB Tests at Screening
The IGRA and TB questionnaire are required as indicated in Schedule of Assessments. 

TB screening is mandatory both before study entry and during the conduct of the study. The 
preferred screening test is IGRA performed at a Central Laboratory.
-
The IGRA result must be negative for subjects to enroll in this study
-
Subjects who test positive for IGRA test should be excluded from the study and 
referred for appropriate medical evaluation according to the local medical practice 
guidelines. 
-
If the result of the IGRA test is indeterminate, the particular IGRA test previously
performed may be repeated once; if positive or indeterminate on retest, the subject 
may not be randomized to study drug and, if already randomized, must undergo 
appropriate study specified withdrawal procedures. The retest must be done during 
the protocol-defined Screening window.
12.8.1.2
Monitoring for TB during the study
Subjects will be monitored for signs/symptoms of TB using routine pharmacovigilance measures 
for Adverse Events. Subjects reporting AEs related to signs/symptoms of TB will be evaluated 
for LTB and active TB according to the local medical practice guidelines. 
Subjects with confirmed LTB or active TB or NTMBI will be immediately withdrawn from the 
study as described in Withdrawal Criteria. Confirmed LTB, active TB and NTMBI must be 
reported to the Sponsor immediately regardless of seriousness using the SAE Report Form. 
Additional information received by the Investigator should be provided within 24 hours of 
awareness.
Once withdrawn from study treatment, subjects should return for the End of Study (EOS), 
complete all early withdrawal assessments, and complete the follow-up visits.
12.8.1.3
TB tests at Final /End of Study Visit
Subjects will be evaluated for signs and symptoms of latent or active TB infection and for risk 
factors of exposure to TB, using the TB questionnaire, at the Final/EOS Visit. See the ‘TB signs 
and symptoms questionnaire’ section for further instructions on using the questionnaire.
12.8.1.4
Signs and symptoms of Tuberculosis
The Investigator should consider all potential sites of infection when assessing for TB during the 
physical examination, and other evaluations, and based on the subject’s history. 
Common symptoms with which the subject may present with include cough, blood in sputum, 
night sweats, lymphadenitis, joint pain/swelling, spinal deformity, headache/confusion, 
abdominal pain mimicking inflammatory bowel disease, frequent or painful urination, scrotal 
mass in men and pelvic inflammatory disease in women as well as other symptoms, or 
REDACTED COPY 
dy
PY
dy
f TB u
COP
f TB u
lated t
ED C
lated t
al med
CTE
al med
TB or
EDAC
TB or
teri
RED
teria.
ED
a.
R
keting authorization application and any extensions or variations thereof.
dy and
ions
dy and
ical pra
ensio
ical pra
RA test
any e
RA test
e on ret
d an
e on ret
omized
and
omized
e retest
ion a
e retest
using ro
ion a
using ro
to sign
zatio
to sign
dical pr
horiz
dical pr
r 
a
r NTM
auth
NTM
Confir
g a
Confir
gardles
keting
gardles
nnot be used to support any mar
the Inv
arke
the Inv
treatme
t any
treatme
wal ass
port 
wal ass
ts at 
supp
ts at 
valuate
d to 
valuate
sure to
sed
sure to
ms que
be us
ms que
4
This document ca
Invest
cann
Invest
phy
nt
physica
nt c
sica
Com
me
Com


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 108 of 353
nonspecific symptoms. This is not an exhaustive list and unusual presentations should always be 
considered.
12.8.1.4.1
TB signs and symptoms questionnaire
The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
source document. The questionnaire will assist with the identification of subjects who may
require therapy for TB. A subject who answers “Yes” to the question 
 at Screening is excluded. A “Yes” response to any of the other questions within the 
questionnaire at Screening should trigger further careful assessment to determine if subject has 
latent or active TB (see Section 6.2.2 (Exclusion Criterion #25). A “Yes” response to any of the 
questions during/end of the study should trigger further assessments as per local medical 
guidelines to determine if the subject has either LTB or active TB infection.
12.8.1.4.2
LTB infection, active TB or other NTMBI identified during study
During the study, subjects who develop evidence of LTB infection or active TB or NTMBI must
immediately stop further administration of study drug and will be referred to an appropriate 
medical specialist for further evaluation.
Confirmed LTB or active TB or NTMBI must be reported to the Sponsor immediately as 
described above.
12.8.2
Pregnancy testing
Pregnancy testing will consist of serum testing at Screening Visit and urine testing at dosing 
visits and End-of-Study Visit as indicated in the schedule of study assessments (Section 5.2). The 
Screening Visit serum pregnancy testing results must be negative and should be confirmed by a 
negative urine pregnancy test prior to first dose of IMP. The urine pregnancy test will be 
performed locally. A negative urine pregnancy test result should be obtained prior to each dose 
of IMP. A positive urine pregnancy test must be confirmed using a serum pregnancy test. 
Pregnancy tests should be administered to all female subjects of childbearing potential, 
regardless of their use of birth control. 
12.8.3
Vital signs
Vital signs will be measured at all visits as indicated in the schedule of study assessments 
(Section 5.2).
Vital signs to be assessed are as follows:

Pulse rate

Systolic/diastolic blood pressure 

Temperature (oral preferred, ear or axillary allowed)

Respiratory rate
Subjects should be sitting for 5 minutes prior and during the collection of blood pressure, pulse 
rate, and respiration rate measurements. On dosing days, vital signs will be measured prior to 
IMP administration, every 15 minutes during the infusion, at the end of infusion, 2 hours after 
end of infusion, and 4 hours after end of infusion.
REDACTED COPY 
ng at S
TED
ng at S
in the
ACT
in the
g resu
EDA
g resu
o first
RED
o first
R
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
e
ect has 
or v
ect has 
any
ons
any of 
ns 
of 
y
ns
y
edical 
nsio
edical 
during
ny ex
during
tive TB
d an
tive TB
ferred t
and
ferred t
the Spo
licat
the Spo
Screeni
rizat
Screeni
s
h
sched
hori
ched
ults mu
auth
ults mu
t dose o
ng a
t dose o
egnanc
keting
egnanc
test mu
arke
test mu
istered 
y ma
istered 
contro
any 
contro
s
p
s
asured
supp
asured
be asses
used
be asses
ate
be
ate
ystolic/d
nnot
stolic/d
Temp
t ca
Temp

me

R
n
R
a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 109 of 353
At nondosing visits, vital signs need only be taken once during the visit. 
12.8.4
Body weight and height
Subject’s body weight will be determined at Screening and at the End-of-Study Visit. Height will 
be measured at Screening only.
12.8.5
Physical examination
Physical examination will be performed at visits as specified in the schedule of study
assessments (Section 5.2) and findings will be recorded in the eCRF. A complete physical 
examination will be performed at Screening and EOS/Early Withdrawal Visit. At all other visits 
(where physical examination is performed), an abbreviated physical examination will be 
conducted.
Clinically important abnormal changes in subsequent physical examinations will be recorded as 
AEs. Physical examinations must be documented in source documentation.
The following body systems will be examined as a part of the complete physical examination:

General appearance

Ear, nose, and throat

Eyes

Hair and skin

Respiratory

Cardiovascular

Gastrointestinal

Musculoskeletal

Hepatic

Neurological (including limb reflexes)

Mental status

Abbreviated Physical Examination

The following body systems will be examined as a part of the abbreviated physical 
examination:

General appearance

Ear, nose, and throat

Eyes

Skin

Respiratory

Gastrointestinal

Neurological (focused assessment of sensitivity and power)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
r visits
or v
r visits
be
n
be
ll be re
xten
ll be re
ph
d
physica
d an
ysica
imb ref
t any
imb ref
hysical 
o sup
hysical 
o s
ng bod
ed t
ng bod
on:
us
on:
ral app
ot be
ral app
Ear, nos
anno
Ear, nos
Ey
nt c
Ey

m



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 110 of 353

Neurological examination for severe headache
A neurological assessment will be performed only for subjects who experience severe headaches. 
This assessment will include: 1) General appearance, including posture, motor activity and 
meningeal signs and, if indicated, following assessments to be done; 2) Cranial nerves 
examination; 3) Motor system examination, including muscle tone and power and sensory
system examination – light touch; 4) Reflexes, including deep tendon reflexes; 5) Coordination, 
gait (if possible) and; 6) Fundoscopy.
12.8.6
12-Lead ECG
A standard 12-lead ECG will be performed at visits as specified in the schedule of study
assessments (Section 5.2). Care should be taken to assure proper lead placement and quality 
ECG recordings. Subjects should rest in a supine position in a controlled, calm environment for 
at least 15 minutes prior to the recording and should be motionless during the recording. 
The ECG will be performed in triplicate prior to blood collection for assessment of laboratory
parameters. Three ECGs should be recorded in a time frame of 5 minutes with at least 1 minute 
difference, 1-2 minutes between the ECGs.
The ECGs will be read at the clinical study site by an appropriately qualified physician. The PR,
RR, QRS, QT, and corrected QT (QTc) intervals and heart rate will be recorded. All ECG 
readings from an individual subject should be read by the same reader, if possible. Findings will 
be recorded in the eCRF.
For the QTc, the following correction formula will be applied:
Fridericia’s correction: QTc = QT/RR0.33
13
STUDY MANAGEMENT AND ADMINISTRATION 
13.1
Adherence to protocol
The investigator should not deviate from the protocol. However, the investigator should take any
measure necessary in deviation from or not defined by the protocol in order to protect clinical 
study subjects from any immediate hazard to their health and safety. In this case, this action 
should be taken immediately, without prior notification of the regulatory authority, IRB/IEC, or 
sponsor.
After implementation of such measure, the investigator must notify the CPM of the sponsor 
within 24 hours and follow any local regulatory requirements.
13.2
Monitoring
UCB (or designee) will monitor the study to meet the sponsor’s monitoring Standard Operating 
Procedures (SOPs), ICH-GCP guideline, and applicable regulatory requirements, and to ensure 
that study initiation, conduct, and closure are adequate. Monitoring of the study may be 
delegated by UCB to a CRO or a contract monitor.
The investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any
missing information. The investigator(s)/institution(s) will permit direct access to source 
REDACTED COPY
y
P
y the 
PY 
the 
y
P
y
will b
ED C
will b
EMEN
REDA
EMEN
R
ent cannot be used to support any marketing authorization application and any extensions or variations thereof.
y
n
y
qua
sions
qualit
ns
lit
nvironm
ensi
nvironm
recordin
exte
recordin
sment o
any 
sment o
es with
d a
es with
el
at
ely qua
ation
y qua
e 
l
e will b
lica
will b
same re
appl
same re
be appl
izatio
be appl
NT A
g au
NT A
ocol
ketin
ocol
e from 
mar
e from 
from o
ny m
from o
mediate
t any
mediate
tely
po
tely,
po
, wi
rt
wi
ion of 
d to s
ion of 
and fo
ed 
and fo
Mo
 u
Mo
or desig
not 
or desig
cedures
cann
cedures
hat stud
nt ca
hat stud
This documen
deleg
men
deleg
T


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 111 of 353
data/documents for study-related monitoring, audits, IRB/IEC review, and regulatory
inspection(s).
The investigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg, hospital and laboratory records for each study participant). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities’ regulations, and investigator’s obligations are being 
fulfilled, and resolve any inconsistencies in the study records.
13.2.1
Definition of source data 
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self-stick notes). Photocopies of CRFs are not considered acceptable source 
documents. 
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x-rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, or quality of life 
questionnaires, for example. Source documents should be kept in a secure, limited access area.
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). Once printed, these copies should be signed and dated 
by the investigator and become a permanent part of the subject’s source documents. The 
investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.
Electronic data records, such as Holter monitor records or electroencephalogram records, must 
be saved and stored as instructed by UCB (or designee).
13.2.2
Source data verification
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to being accurate, complete, and verifiable from 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory notes). All data reported on the eCRF should be supported by source 
documents, unless otherwise specified in Section 13.2.1.
13.3
Data handling
13.3.1
Case Report form completion
The study will be performed using electronic data capture (EDC). The investigator is responsible 
for prompt reporting of accurate, complete, and legible data in the eCRFs and in all required 
reports.
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.
Corrections made after the investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the investigator.
REDACTED COPY
be 
PY 
be 
d store
COP
d store
printe
D C
printe
part o
CTED
part o
enabli
ACT
enabli
puter t
EDA
puter t
er m
R
er m
keting authorization application and any extensions or variations thereof.
e of bei
ions
e of bei
ng, prin
ensi
ng, prin
ry
ex
ry attac
xte
attac
y
x
y
ed accep
ny ex
ed accep
corded. 
and
corded. 
labora
tion 
labora
eted sc
icatio
eted sc
ept in a
pplic
ept in a
ed elec
on ap
ed elec
ed, thes
ation
ed, thes
of the s
oriza
of the s
ing the
thor
ing the
to ensu
aut
to ensu
monitor
eting
monitor
sed to support any mark
UCB (o
rket
UCB (o
rificat
ma
rificat
ures acc
t any
ures acc
viewed
port 
viewed
subject
upp
subject
ory
to
ory note
o su
note
y
o
y
ss other
ed to
ss other
cannot be us
Data
use
Data
C
e
C
study
ann
study
This document 
or prom
nt ca
or prom
repor
men
repor
A
m
A


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 112 of 353
The investigator should maintain a list of personnel authorized to enter data into the eCRF.
Detailed instructions will be provided in the eCRF Completion Guidelines.
13.3.2
Database entry and reconciliation
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data. In the EDC system, the data are entered into the eCRFs once by the designated site 
personnel and are subsequently verified.
An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.
13.3.3
Subject Screening and Enrollment log/Subject Identification Code list
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log.
The investigator will keep a Subject Identification Code list. This list remains with the 
investigator and is used for unambiguous identification of each subject.
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.
13.4
Termination of the study
UCB reserves the right to temporarily suspend or prematurely discontinue this study either at a 
single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by the sponsor or by the investigator/institution, as specified by the 
applicable regulatory requirement(s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.
13.5
Archiving and data retention
The investigator will maintain adequate records for the study, including eCRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition records, safety
reports, information regarding participants who discontinued, and other pertinent data.
All essential documents are to be retained by the investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirement(s) or by an 
REDACTED COPY
ust be
OPY 
ust be
docum
COP
docum
udy
ACTE
udy
suspe
REDA
suspe
es at
RE
es at
y marketing authorization application and any extensions or variations thereof.
f f 
change
ons o
change
y loade
sion
loade
y
tificati
y ex
tificati
Screenin
d an
Screenin
s list re
tion
s list re
h subje
licat
h subje
 record
app
 record
ment the
ion a
ment the
end or p
g aut
end or p
t an
ting
t any ti
ng 
y ti
incomp
rketi
incomp
pect to 
mark
pect to 
not be used to support any
minated
any 
minated
d the re
rt an
d the re
mination
ppor
mination
RB/IEC
supp
RB/IEC
pension
to s
pension
atory
ed t
atory r
t
r
y
t
y
and oth
use
and oth
This document can
A
e
A
investi
anno
investi
borator
nt ca
borator
report
ment
report
A
m
A


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 113 of 353
agreement with UCB (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The investigator will contact 
UCB for authorization prior to the destruction of any study records or in the event of accidental 
loss or destruction of any study records. The investigator will also notify UCB should he/she 
relocate or move the study-related files to a location other than that specified in the sponsor’s 
study master file.
13.6
Audit and inspection
The investigator will permit study-related audits mandated by UCB, after reasonable notice, and 
inspections by domestic or foreign regulatory authorities.
The main purposes of an audit or inspection are to confirm that the rights and well-being of the 
subjects enrolled have been protected, that enrolled subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH-GCP, and applicable regulatory
requirements.
The investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the investigator will immediately
inform UCB (or designee).
13.7
Good Clinical Practice
Noncompliance with the protocol, ICH-GCP, or local regulatory requirements by the 
investigator, institution, institution staff, or designees of the sponsor will lead to prompt action 
by UCB to secure compliance. Continued noncompliance may result in the termination of the 
site’s involvement in the study.
14
STATISTICS
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan (SAP). Deviations from the SAP will be documented in the Clinical Study Report.
14.1
Definition of analysis sets
Enrolled Set (ES):
The ES will consist of all subjects who have given informed consent.
Safety Set (SS):
The SS will consist of all subjects who have received at least 1 infusion (full or partial infusion) 
of IMP and will be used for the demographics and analysis of safety data.
Full Analysis Set (FAS):
The FAS will consist of all subjects who have received at least 1 infusion (full infusion) of IMP
and, in addition, have a Baseline and at least 1 post-Baseline measurement for platelet count.
The analysis of the PD (excluding total IgG, and IgG subclasses), efficacy, and immunologic 
variables will be performed on the FAS. Selected outputs may be repeated for the PD Per
Protocol Set (PD-PPS). Further details will be provided in the SAP. 
REDACTED COPY 
local r
D CO
local r
signee
TED 
signee
noncom
ACTE
noncom
be used to support any marketing authorization application and any extensions or variations thereof.
nd 
ri
nd 
ng of th
ns o
ng of th
underg
sions
underg
valuati
ensi
valuati
ements,
exte
ements,
e regula
ny e
e regula
ource re
and
ource re
investig
tion 
investig
regulat
tion 
regulat
es of th
izati
es of th
mplian
horiz
mplian
follows
arke
follows
from th
ma
from th
of ana
t any
of ana
of all su
sup
of all su
consist
e use
consist
cannot b
nd will 
t be 
nd will 
Anal
nno
Analys
no
ysi
This document 
he FAS
nt ca
he FAS
and, i
ment
and, i
T
m
T


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 114 of 353
Per Protocol Set:
The PPS is a subset of the FAS, consisting of those subjects who had received all foreseen sc 
infusions, had a platelet count measurement during the Observation Period, and no important 
protocol deviations that may potentially affect the platelet count as confirmed during a 
pre-analysis review of the data prior to database lock. Protocol deviations may not necessarily
lead to total exclusion of a subject from the PPS but may lead to exclusion of specific data. 
Pharmacokinetic Per Protocol Set (PK-PPS):
The PK-PPS is a subset of the FAS, consisting of those subjects who had no important protocol 
deviations potentially affecting the plasma concentration of UCB7665, as confirmed during a 
pre-analysis review of the data prior to database lock. Protocol deviations may not necessarily
lead to total exclusion of a subject from the PK-PPS but may lead to exclusion of specific data.
Pharmacodynamic Per Protocol Set (PD-PPS)
The PD-PPS is a subset of the FAS, consisting of those subjects who had no important protocol 
deviations potentially affecting the serum concentration of total IgG, as confirmed during a 
pre-analysis review of the data prior to database lock. Protocol deviations may not necessarily
lead to total exclusion of a subject from the PD-PPS but may lead to exclusion of specific data.
The PD-PPS will be used for the analysis of the total IgG, and IgG subclasses. 
14.2
General statistical considerations
All analyses will be performed using SAS® version 9.2 or later (SAS Institute, Cary, NC, USA). 
Continuous variables will be summarized by visit (where applicable) with the statistics including 
the number of subjects (n), mean, standard deviation (SD), median, minimum, and maximum. 
Categorical variables will be summarized by visit (where applicable) with frequency counts and 
percentages. Analyses will be performed by dose arm, unless otherwise stated. In the event that 
the number of planned infusions in the dose arms are modified following review by the DMC, 
the data will be summarized based on the actual dose arms completing the study. For example, if 
the weekly 5x4mg/kg dose arm is modified such that some subjects receive only 4 infusions, 
then the data will be summarized separately for this new dose regimen.
Data listings containing all documented data and all calculated data will be generated.
Baseline will be the last non-missing data collected prior to the first dose of IMP, and 
measurement-specific Baseline values will be defined in the SAP.
14.3
Planned safety analyses
14.3.1
Analysis of the primary safety variable
All AEs will be coded using the Medical Dictionary for Regulatory Activities® (MedDRA®). 
The incidence of subjects with TEAEs will be determined and presented by dose arm and 
overall.
Only TEAEs will be included in the summary tables. As an additional analysis, the incidence of 
subjects with TEAEs will be determined and presented separately for the Dosing Period and the 
Observation Period by dose arm and overall.
REDACTED COPY 
gG,
Y
gG,
ation
COPY
ation
rsion 9
ED C
rsion 9
y
C
y visit
CTE
visit
y
C
y
rd dev
DAC
rd dev
ized b
RED
ized b
med
R
med
marketing authorization application and any extensions or variations thereof.
tocol 
or va
tocol 
ring a 
s or
ring a 
ecessar
ions
ecessar
specifi
ensi
specifi
no imp
d any
no imp
s confi
and a
s confi
ations 
n an
ations 
d to ex
ation
d to ex
d 
p
d IgG 
pplic
IgG 
ns
n
ns
9.
za
9.2 or 
zatio
2 or 
t (wher
horiz
t (wher
viation
utho
viation
by
g
by visit 
g au
visit 
y
g
y
d by
eting
d by do
ng
 do
y y
ng
y y
e
r
e d
rke
dose
ke
ose
d on the
mar
d on the
cannot be used to support any
is mod
ny m
is mod
rized se
rt any
rized se
all doc
ppo
all doc
last no
o su
last no
ecific B
d to
ecific B
Plan
use
Plan
A
e
A
AEs wi
ann
AEs wi
This document 
he inci
nt ca
he inci
overa
ment
overa
O
m
O


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 115 of 353
Adverse events starting before time of IMP administration or after 8 weeks after the final dose 
will be listed only.
14.3.2
Other safety analyses
The absolute and relative frequencies for subjects with a given TEAE with respect to the 
preferred term according to the latest available version of the MedDRA, as well as the absolute 
frequencies of the individual TEAEs that have occurred, will be determined within each system 
organ class. Additional tables will summarize TEAEs by maximum intensity and causal 
relationship with UCB7665, as judged by the investigator. Adverse events will be categorized by
severity according to the CTCAE version 4.03 grading. In case the CTCAE grading is not 
available, the intensity (mild/moderate/severe) will be utilized. For the purpose of the tabulations 
CTCAE grades will be aligned with the intensity classifications (mild/moderate/severe) to enable 
pooling of the AEs in the summaries. The TEAEs leading to discontinuation of IMP and 
treatment-emergent SAEs will also be summarized. The action taken, time of onset relative to 
dosing, and duration of each AE will be listed only.
For the continuous laboratory variables, the values and changes from Baseline will be 
summarized at each time point. For categorized values according to the reference range, shift 
tables from Baseline to each post-Baseline time point will be presented for selected variables to 
be defined in the SAP. Values outside the reference range will be flagged in the data listings. The 
number and percentage of subjects with markedly abnormal laboratory results (based on CTCAE 
grading) will be tabulated for each dose arm.
Normal versus abnormal findings with regard to the various ECG parameters and the overall 
ECG will be analyzed as required. The focus of the 12-lead ECG analysis will be the 
identification of outliers and of any trends for changes following administration of UCB7665 
with respect to QT/QTc. Descriptive statistics will be presented for ECG value and changes from 
Baseline over time based on the mean of the triplicate assessments at each time point.
Descriptive statistics will be reported for all vital sign measurements (including systolic and 
diastolic blood pressure, pulse rate, temperature, and respiratory rate). Measured values and 
changes from Baseline will be summarized by time point.
Physical examination findings and the results of any pregnancy testing will be presented in 
listings only.
Safety analyses will be presented by dose arm.
14.4
Planned efficacy and other analyses
14.4.1
Efficacy analyses
The main efficacy variable is the maximum increase from Baseline in platelet count during the 
study. The maximum increase from Baseline and maximum platelet count during the study will 
be summarized by dose arm.
In addition, all measurements of platelet count will be summarized by dose arm and time point 
using descriptive statistics (including changes from Baseline).
For dose arms with ≥10 subjects, a 1-sided t-test will be applied to assess if the average 
maximum increase from Baseline is greater than zero. In case the assumptions for the-t-test are 
not fulfilled, an alternative nonparametric method may be considered. Further details will be 
REDACTED COPY
g
Y
g
norm
OPY 
norm
to the
TED 
to the
us of t
ACTE
us of t
ds for 
DAC
ds for 
statist
RED
statist
n of
R
n of
t cannot be used to support any marketing authorization application and any extensions or variations thereof.
ed by
var
ed by
otot
tabulat
ons 
tabulat
vere) to
nsio
vere) to
MP an
ten
MP an
f onset 
y ext
f onset 
Baselin
and 
Baselin
o the
on a
o the re
a
re
esented
atio
esented
ll be fla
plica
ll be fla
al labor
app
al labor
e variou
izati
e variou
the 12
horiz
the 12
r chang
auth
r chang
tics wil
g au
tics wil
f the tr
eting
f the tr
ed for a
mark
ed for a
ate
y
ate, tem
y m
, tem
e summ
any
e summ
dings a
port
dings a
ll be
to s
ll be pr
s
pr
Plan
used
Plan
E
 
E
main 
nno
main eff
o
eff
udy
t ca
udy.
ca
.
This documen
Th
an
Th
be sum
ent c
be sum
In 
m
In 


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 116 of 353
provided in the SAP. The Response, Complete Response, and platelet count ≥50x109/L will be 
summarized (number of subjects and percentages) and presented with 90% 2-sided confidence 
intervals for the rate of responders at each time point and overall (across all time points). 
Response and Complete Response are defined in Section 4.2.2. The analysis will be repeated for 
the Clinical Response variables defined in Section 4.2.2.
Time to Response, time to Complete Response, time to platelet count ≥50x109/L, duration of 
Response, duration of Complete Response, duration of platelet count ≥50x109/L, and 
Baseline-corrected AUEC for platelet count will be calculated and summarized by dose arm. The 
time to first response will be analyzed using a log-rank test and displayed using Kaplan-Meier 
curves. The time to Response, time to Complete Response, and respective durations will be 
summarized by dose arm.
The results from the ITP bleeding scale will be summarized at each time point and will include
the grades for each of the 3 major domains: skin (S), visible mucosae (M), and organs (O). In 
addition the number and percentage of subjects with severe or clinically relevant bleeding and 
number and percentage of subjects with absence of bleeding will be summarized at each time 
point.
Results of the NFI-MS will be summarized at each time point, using summary scores where 
applicable. Changes from Baseline will be calculated and summarized.
Additional subgroup analyses may be performed as needed and further details will be provided in 
SAP regarding these analyses.
14.4.2
Pharmacokinetic analyses
Pharmacokinetic variables of UCB7665 (eg, like AUC, Cmax) cannot be derived, since blood 
sampling will be performed at 1 time point per visit only. Thus, PK is restricted to concentration 
data.
Individual concentrations of UCB7665 data will be summarized using the number of available 
observations, mean, median, SD, minimum, maximum, geometric mean, and geometric 
coefficient of variation (assuming log normally distributed data). Values below the lower limit of 
quantification (LLOQ) will be reported with a clear sign indicating that they were below the 
LLOQ. Descriptive statistics of concentrations will be calculated if at least two thirds of the 
individual data points are quantifiable (≥LLOQ). Individual concentrations of UCB7665 will 
also be displayed graphically.
Population PK analyses and PK/PD analyses may be conducted for the PD variables of interest. 
All such PK and PK/PD analyses will be described in a separate Data Analysis Plan; however,
results will not be reported in the Clinical Study Report.
14.4.3
Pharmacodynamic analyses
For all PD variables, descriptive statistics for the values and change from Baseline and/or 
percentage change from Baseline will be tabulated by time point. 
The PD variables will include ITP-specific autoantibodies
total IgG, and IgG subclasses. In addition, for total IgG, the maximum decrease from Baseline 
and minimum value will be evaluated and summarized. Figures of mean values over time and 
changes from Baseline will be presented.
REDACTED COPY 
neede
OPY
neede
s
T
s
(eg, li
DAC
(eg, li
point 
RED
point 
y marketing authorization application and any extensions or variations thereof.
The
aria
The 
eier 
or v
eier 
ll be
ns o
ll be 
nd will
ten
nd will
nd orga
y ext
nd orga
elevant 
any 
elevant 
mmariz
d a
mmariz
sing su
atio
sing su
mmariz
lica
mmariz
ed and 
n app
ed and 
ike AU
utho
ike AU
per vis
g au
per vis
665 dat
arke
665 dat
minim
y ma
minim
used to support an
ming log
any 
ming log
l be rep
ort a
l be rep
stics
ppo
stics of
o
of
s are qu
sup
s are qu
graphic
d to s
graphic
K analy
used
K analy
This document cannot be
K and P
be u
K and P
will not 
ot b
will not 
4.3
an
4.3
For all 
ent c
For all 
perc
me
perc


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 117 of 353
14.4.4
Immunologic variables
All immunologic variables including concentrations of immunoglobulins (IgA, IgE, and IgM),
serum (C3 and C4) and plasma (C3a and C5a) complement levels, serum BAFF levels, and 
lymphocyte counts (B and T) will be summarized by dose arm over time (including changes 
from Baseline) using descriptive statistics. Figures of mean values over time and changes from 
Baseline may be presented.
The ADA status (negative/positive) will be summarized by dose arm at each visit and overall; 
figures will also be presented in conjunction with PK concentrations of UCB7665.
The results of any cytokine analyses (for subjects who experience infusion reactions) will be 
summarized if appropriate.
Further details will be provided in the SAP.
14.4.5
Other analyses
14.4.5.1
Subject disposition
The number of subjects who were screened, dosed and completed/prematurely discontinued the 
study, as well as the reason for discontinuation, will be presented using frequency counts and 
percentages.
14.4.5.2
Subject characteristics
Summaries of the following will be provided:

Demographics (including gender, age, height, weight, body mass index)

Medical history

Past, prior, and concomitant medications
Concomitant medical procedures will be listed only.
14.4.5.3
Baseline disease characteristics
Summaries of the following will be provided:

Baseline disease characteristics (including disease duration) 

Baseline values of the immunological parameters (IgG, IgM, IgA, IgE, lymphocytes 
[B and T])

ITP-specific antibodies

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)
14.4.5.4
Subject exit interview
The results of the exit interview will be reported by UCB and separate to the Clinical Study
Report.
14.5
Handling of protocol deviations
Important protocol deviations are identified as part of the data cleaning process in the Data 
Cleaning Plan (DCP). Ongoing data cleaning meetings will be held throughout the duration of 
the study. Objectives of these meetings include to review and update (if necessary) the important 
REDACTED COPY 
ei
CT
eight, 
CTED
ght, 
icatio
RE
icatio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ill be 
s or
ill be 
rematur
n an
rematur
using 
tion
using 
weigh
oriza
weigh
ons
ting
ons
l be lis
arke
l be lis
se cha
y ma
se cha
will be
rt any
will be
aracteri
ppo
aracteri
of the i
to su
of the i
ific ant
e use
ific ant
m com
ot b
m com
.5.4
ann
.5.4
The res
ent c
The res
R
me
Rep
e
ep


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 118 of 353
protocol deviations in the DCP and discuss exclusion of subjects from analysis populations. 
Furthermore, overall trends in protocol deviations will be discussed at the Data Evaluation 
Meeting. Through this ongoing data cleaning and evaluation process, all decisions regarding 
important protocol deviations and exclusions from analysis populations are made on an ongoing 
basis.
14.6
Handling of dropouts or missing data
All imputation of missing or partial dates for safety assessments, as well as handling missing 
efficacy data (where applicable), will be detailed in the SAP.
14.7
Planned interim analysis and data monitoring
A DMC will be convened to monitor emergent safety data during the study. The DMC will 
comprise at least 1 external expert, the UCB study physician, the UCB PS representative, and a 
biostatistician. Safety related decisions must be made with the agreement of at least the external 
expert, the UCB study physician, and the UCB PS representative. Decisions involving reductions 
in dose regimen must also have the agreement of the UCB statistician and UCB 
pharmacometrician.
For the sequential adaptive design in this study, at least 11 interim analyses will be performed. 
Safety data from the interim analyses will be reviewed by the DMC to monitor the safety, to 
adapt the dose regimen, and to decide when and if the UCB7665 7mg/kg weekly group (Dose 
Arm 2), UCB7665 10mg/kg weekly group (Dose Arm 3), UCB7665 15mg/kg group (Dose 
Arm 4) and UCB7665 20mg/kg group (Dose Arm 5) should be opened. Planned dosing may be 
discontinued for all subjects in a dose arm (see Section 6.5).
The first interim analysis will be conducted after 3 subjects (receiving 5x4mg/kg) have attended 
the second visit of the Observation Period (ie, 7 days after final dosing). Based on this analysis,
the safety of UCB7665 will be assessed by the DMC. The DMC can either recommend to 
continue the study as planned, to reduce the number of sc infusions (eg, to 3), or to stop the 
study. If the number of infusions will be reduced, the subjects in the study already treated with 
the IMP will receive the reduced number of infusions. Subjects enrolled after the decision of the 
DMC will receive the reduced number of infusions. There will be no substitution of the subject 
with the original number of infusions; thus, the total number of subjects will not be increased. 
If the study continues without modifications, the next interim analysis will take place after data 
from 3 additional subjects are available. Based on the available combined data of the first 
6 subjects, the DMC will decide if the 3x7mg/kg dose arm can be initiated. If the new dose arm 
will be initiated and if the 5x4mg/kg will be continued, new subjects will be randomly assigned
to 1 of the 2 dose arms in an allocation ratio of 1:1.
If the decision is to open the 3x7mg/kg dose arm, the third interim analysis will be performed 
after 3 subjects (receiving 3x7mg/kg) have attended the second visit of the Observation Period 
(ie, 7 days after final dosing). The safety of UCB7665 will be assessed by the DMC. In addition, 
the DMC might recommend reducing the number of sc infusions in the UCB7665 7mg/kg dose 
arm. 
The fourth planned interim analysis and review of data by DMC will take place after safety data 
(7 days after final dose) is available for the first 6 subjects in Dose Arm 2.
REDACTED COPY
y
Y
y
e UCB
OPY 
e UCB
Arm 3
COP
Arm 3
Arm 5) 
ED C
Arm 5) 
see Se
CTED
see Se
cted af
DAC
cted af
eriod (
RED
eriod (
ed
R
ed
annot be used to support any marketing authorization application and any extensions or variations thereof.
MC wi
nsio
MC wi
sentativ
xten
sentativ
at least 
y ext
at least 
ns invo
any 
ns invo
and UC
nd a
and UC
m anal
atio
m anal
DMC 
lica
DMC 
B7665 
app
B7665 
3), 
on
3), UCB
n a
UCB
) should
atio
should
ection
oriza
ection 6
a
6
fter 3 s
auth
fter 3 s
(ie, 7 d
g au
(ie, 7 d
d b
et
d by the
eting
y the
uce the
arke
uce the
will 
ma
will be 
ma
be 
ed num
any m
ed num
ed num
rt an
ed num
of infu
ppor
of infu
s witho
o sup
s witho
subject
d to 
subject
DMC w
sed
DMC w
ated an
be us
ated an
e 2 dos
t be
e 2 dos
e decisi
anno
e decisi
This document c
fter 3 su
t ca
fter 3 su
(ie, 7 
ment 
(ie, 7 
the
me
the


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 119 of 353
All subsequent DMC meetings will be dependent on opening of Dose Arms 3, 4 and 5 and 
decisions of the previous DMC meetings. Review of data will occur after every 3 subjects. More 
details are included in the DMC charter.
During the first three interim analyses, recruitment in the Dose Arms 1 and 2 will not be stopped. 
If needed, subsequent DMC meetings may take place and the frequency will be detailed in the 
DMC charter.
The DMC will monitor data for all reported AEs, clinical findings, including vital signs (pulse 
rate, blood pressure, temperature, and respiratory rate) and safety laboratory values, and 
immunogenicity data. Pharmacokinetic data will not be required for DMC review as blood 
sampling will be performed at a single time point per visit only. Thus, PK data are restricted only
to the concentration data and can therefore make no plausible contribution to the assessment of 
safety in this particular study.
Ad hoc DMC meetings can be held for other reasons if determined appropriate by the sponsor 
and/or external expert.
The deliberations and decisions of the DMC will be formally minuted/documented.
A detailed description of the DMC composition, processes and responsibilities, criteria to 
escalate to the next dose arm, and criteria to stop, or continue a dose arm will be provided in a 
separate DMC charter.
The analyses will be described in a separate interim SAP and will include all safety data 
specified in the DMC charter, which is available at the time. For the interim analyses the data, 
subject to analysis, should be as clean as possible; however, the database will not be locked and a 
snapshot will be taken.
14.8
Determination of sample size
The sample size of 15 subjects in Dose Arms 1 and 2, is mainly based on the efficacy objective 
of the study. In addition the 15 subjects in Dose Arms 1 and 2 ensure that sufficient data are 
available to form conclusions about the safety of administering UCB7665. Based on the safety
data from dose arms 1 and 2, the sample size of 6 to 12 subjects in Dose Arms 3, 4 and 5 is 
judged to be sufficient in order to explore subjects’ safety and IgG reductions under different 
dose regimens and is not based on a formal sample size calculation. 
For Dose Arms 1 and 2, an approximate sample size calculation for the efficacy variable 
“maximum increase from Baseline in platelet count” shows that 15 subjects would be sufficient 
to show a change from Baseline with 1-sided testing at 5% and power of 80%. The anticipated 
change is based on an assumed Baseline average of 25x109/L and a clinically meaningful 
maximum value of 100x109/L. The calculation made use of platelet count data presented in a 
publication by Robak T (Robak et al, 2009), but it is approximate as maximum changes from 
Baseline for individual subjects were not available, necessitating the use of the maximum 
average platelet count instead. The SD is taken from visual inspection.
With 15 subjects, the responder endpoints will confirm a true 50% response rate, in excess of the 
maximum 15% anticipated with no treatment benefit, with power in excess of 80%.
REDACTED COPY 
im SA
CO
im SA
ble at t
ED C
ble at t
ossible
CTE
ossible
sam
RE
sam
cannot be used to support any marketing authorization application and any extensions or variations thereof.
od 
o
od 
tricted 
ons 
tricted 
ssessme
nsio
ssessme
ate by
ny ex
ate by
x
d/docu
and
d/docu
espons
ation
espons
a dose
lica
a dose
AP and 
tion 
AP and 
the tim
izatio
the tim
e;
h
e; howe
oriz
howe
mple s
ing a
mple s
e Arm
rket
e Arm
bjects 
mar
bjects inin
bout th
ny m
bout th
, the sa
rt any
, the sa
order t
port
order t
not base
supp
not base
and 2, a
d to s
and 2, a
ease fr
ed 
ease fr
ange
e use
ange fr
se
fr
based 
t be 
based 
um val
not 
um val
lication
cann
lication
This document 
aseline
nt ca
aseline
avera
men
avera
W


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 120 of 353
15
ETHICS AND REGULATORY REQUIREMENTS
15.1
Informed consent
Subject’s informed consent must be obtained and documented in accordance with local 
regulations, ICH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by the investigator (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with 
the investigator.
Prior to participation in the study, the written Informed Consent form should be signed and 
personally dated by the subject, or his/her legal representative, and by the person who conducted 
the informed consent discussion (investigator or designee). The subject or his/her legal 
representative must receive a copy of the signed and dated Informed Consent form. As part of 
the consent process, each subject must consent to direct access to his/her medical records for 
study-related monitoring, auditing, IRB/IEC review, and regulatory inspection.
If the Informed Consent form is amended during the study, the investigator (or the sponsor, if 
applicable) must follow all applicable regulatory requirements pertaining to the approval of the 
amended Informed Consent form by the IRB/IEC and use of the amended form.
The subject may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the Informed Consent form. An eCRF 
must not be started, nor may any study specific procedure be performed for a given subject, 
without having obtained his/her written consent to participate in the study.
Subjects have the right to withdraw their consent for the exploratory genomic substudy at any 
point without any impact on their care or participation in the main study. In this case, any data 
already generated on the samples will be retained and used, but no further analysis will occur.
15.2
Subject identification cards
Upon signing the Informed Consent and Assent form (as applicable), the subject or legal 
representative will be provided with a subject identification card in the language of the subject. 
The investigator will fill in the subject identifying information and medical emergency contact 
information. The investigator will instruct the subject to keep the card with him/her at all times.
15.3
Institutional Review Boards and Independent Ethics 
Committees
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.
The investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or applicable country-specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the investigator/UCB will forward copies of the protocol, Informed 
Consent form, Investigator’s Brochure, investigator’s curriculum vitae (if applicable), 
REDACTED COPY
em
Y
em
d use 
PY 
d use 
rticipa
D CO
rticipa
he has
TED 
he has
cific p
ACTE
cific p
conse
EDAC
conse
heir 
RE
heir 
nnot be used to support any marketing authorization application and any extensions or variations thereof.
i
v
with
or v
with
gned an
nsio
gned an
n who 
xten
n who 
s/her le
y ex
s/her le
sent for
any 
sent for
er med
nd a
er med
inspect
n an
inspect
nvestig
atio
nvestig
ts perta
plica
ts perta
of the 
app
of the 
ate in th
tion 
ate in th
s signe
izat
s signe
procedu
horiz
procedu
ent to p
auth
ent to p
consen
ting 
consen
 or pa
keti
 or par
will be r
mark
will be r
ntificat
any m
ntificat
d Conse
ort a
d Conse
rovided
uppo
rovided
fill in 
o sup
fill in 
investig
d to 
investig
Insti
use
Insti
Co
e u
Co
udy
nnot
udy wi
not
 wi
y y
not
y y
This document ca
H-GCP
can
-GCP
of Hels
nt c
of Hels
Th
me
Th


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 121 of 353
advertisement (if applicable), and all other subject-related documents to be used for the study to 
the IRB/IEC for its review and approval.
Before initiating a study, the investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.
The investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the investigator to obtain an expedited review by the IRB/IEC as 
allowed.
As part of the IRB/IEC requirements for continuing review of approved studies, the investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The investigator should provide a final report to the IRB/IEC following study
completion.
UCB (or its representative) will communicate safety information to the appropriate regulatory
authorities and all active investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed by the investigator or the sponsor, as specified by 
the applicable regulatory requirements in each concerned country. Where applicable, 
investigators are to provide the sponsor (or its representative) with evidence of such IRB/IEC 
notification.
15.4
Subject privacy
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number 
assigned at Screening.
The investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a subject’s study participation, and autopsy reports for deaths 
occurring during the study).
Genetic analysis data will not be shared with the subjects and will be subject to the highest level 
of data protection, as per European regulations.
Samples may be shared with collaborators working within UCB and may be analyzed at a third 
party site, but only in relation to the aims of this exploratory analysis as detailed in this study
protocol. Samples may be stored for up to 20 years and maybe used at any time up to that point. 
Samples will remain under the control of UCB at all times and may be destroyed at any point 
before the 20 year expiration date.
REDACTED COPY
inform
PY 
inform
ce wit
COP
ce wit
by th
ED C
by th
ch con
CTED
ch con
or its r
ACT
or its r
rt any marketing authorization application and any extensions or variations thereof.
cts. For
s or
cts. For
riginal
ions
riginal
the IRB
ensi
the IRB
udies, t
any 
udies, t
IEC (ba
nd a
IEC (ba
nvolved
and
nvolved
e IRB/I
tion 
e IRB/I
mation 
appl
mation 
th appl
on ap
th appl
he inves
ation
he inves
ncerned
oriza
ncerned
represe
thor
represe
and up
mark
and up
B (or de
y ma
B (or de
nnot be used to suppo
hat repr
port
hat repr
atives o
supp
atives o
edical 
o su
edical 
sult rep
ed to
sult rep
ccurring
used
ccurring
during t
be u
during t
c anal
not 
c analy
This document ca
ata pro
cann
ata pro
Sampl
ent 
Sampl
part
me
part


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 122 of 353
15.5
Protocol amendments
Protocol changes may affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its primary
objective.
Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities (if required), prior to being 
implemented.
16
FINANCE, INSURANCE, AND PUBLICATION
Insurance coverage will be handled according to local requirements.
Finance, insurance, and publication rights are addressed in the investigator and/or CRO 
agreements, as applicable.
17
REFERENCES
Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective - FcRn 
transports albumin: relevance to immunology and medicine. Trends Immunol. 2006;27(7):343-8.
CPMP/ICH/135/95. Note for guidance on Good Clinical Practice (EMEA) Jul 2002.
EMA/CHMP/153191/2013. Guideline on the clinical development of medicinal products 
intended for the treatment of chronic primary immune thrombocytopenia Sep 2014.
Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009.
Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice 
between splenectomy or a medical therapy as a second-line treatment. Blood. 2012;120(5):960-9.
Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc 
Hematol Educ Program. 2012;2012:306-12.
Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J. On setting the first dose in man: quantitating 
biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
Basic Clin Pharmacol Toxicol. 2010;106(3):195-209. 
Mills RJ, Calabresi M, Tennant A, Young CA. Perceived changes and minimum clinically
important difference of the Neurological Fatigue Index for multiple sclerosis (NFI-MS). Mult
Scler. 2013;19:502-5.
Mills RJ, Young CA, Pallant JF, Tennant A. Development of a patient reported outcome scale 
for fatigue in multiple sclerosis: The Neurological Fatigue Index (NFI-MS). Health Qual Life 
Outcomes. 2010;8:22.
Robak T, Salama A, Kovaleva L, Vyhovska Y, Davies SV, Mazzucconi MG, et al. Efficacy and 
safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and 
adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227-36.
REDACTED COPY
deve
OPY 
deve
mune th
COP
mune th
Indust
TED 
Indust
Huma
ACTE
Huma
on and
DAC
on and
Busse
RE
Busse
arketing authorization application and any extensions or variations thereof.
r CRO
ensi
r CRO
y
a
y S. 
and
S. 
y
a
y
Pe
d 
Pe
s I
on
s Immu
on a
mmu
ice (EM
icati
ice (EM
lopmen
appl
lopmen
hrombo
on ap
hrombo
try
iza
try. Dr
zati
. Dr
an Serv
horiz
an Serv
d Resea
autho
d Resea
el JB. H
ing a
el JB. H
rap
ket
rapy as
etin
y as
t be used to support any m
e throm
mar
e throm
012:30
ny m
012:30
Wu K, L
ort a
Wu K, L
et bind
ppo
et bind
l Toxic
sup
l Toxic
esi M, T
d to
esi M, T
erence 
used
erence 
;19:502
be u
;19:502
This document canno
RJ, You
not b
RJ, You
fatigue 
ann
fatigue 
ut
t
utcom
t c
com
Rob
me
Rob
s
m
s


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 123 of 353
Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, et al. 
Standardization of bleeding assessment in immune thrombocytopenia: report from the 
International Working Group. Blood. 2013;121(14):2596-606.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization 
of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults 
and children: report from an international working group. Blood. 2009;113(11):2386-93.
Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. 
Second symposium on the definition and management of anaphylaxis: summary report - Second 
National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
symposium. J Allergy Clin Immunol. 2006;117(2):391-7.
Sandler SG. The spleen and splenectomy in immune (idiopathic) thrombocytopenic purpura. 
Semin Hematol. 2000;37(1 Suppl 1):10-2.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
cond 
var
cond 
ork 
or
ork 
nic
en
nic purp
ens
purp


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 143 of 353
18.7
Protocol Amendment 1
Rationale for the amendment
The primary purpose of this substantial amendment it to include additional laboratory tests 
(serology test) at the Screening Visit in order to exclude subjects with chronic and ongoing 
infections with HIV, hepatitis B, and hepatitis C. Exclusion criteria related to medical history
were updated to define precisely and increase clarity. Withdrawal criteria for PDILI and 
evaluation of PDILI were also updated to enable the effective management and assessment of 
any PDILI cases as outlined in the Food and Drug Administration (FDA) Guidance for Industry, 
Drug-Induced Liver Injury: Premarketing Clinical Evaluation (Jul 2009), UCB has developed 
pre-specified criteria for managing any PDILI events and discontinuing IMP. In this amendment, 
a more conservative approach compared to the previous version is included. However, there have 
been no changes in the potential risk of PDILI with UCB7665 since the previous version. 
In addition, height was added in order to be able to calculate body mass index, the SAE reporting 
details were updated, and several additional exploratory biomarkers were added as 
immunological variables. Minor clarifications were added where necessary, and typographical 
errors or omissions were corrected.
Modifications and changes
Global changes
The following changes were made throughout the protocol:

Addition of HIV, hepatitis B, and hepatitis C test at the screening tests.

Addition of exploratory biomarker assessments.

Definition of complement levels for C3, C3a, C4 and C5a.
Specific changes
Change #1.
STUDY CONTACT INFORMATION
Sponsor Study Physician
Name:
, MD
Address:
UCB BIOSCIENCES GmbH
Alfred-Nobel-Straße 10
40789 Monheim 
Germany
Phone:
Fax:
Has been changed to:
Name:
, MD
REDACTED COPY 
he prot
D CO
he prot
tis C t
CTED
tis C t
ssessm
DAC
ssessm
for 
RE
for C
E
C
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ustry
r var
ustry,
a
,
loped 
s or 
loped 
amendm
ons 
amendm
ver, th
nsio
ver, th
us versi
xten
us versi
ex
ny
ex,
ny
, the
y e
the
e added
d any
e added
essary
and
essary
tocol:
tion
tocol:
test at t
oriza
test at t
ments.
auth
ments.
C3
in
C3,
ing
, C3
ng 
C3
RMAT
rt an
RMAT
n
su
su
su
su
s:
s
s:
d t
a
u


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 144 of 353
Address:
UCB BIOSCIENCES GmbH
Alfred-Nobel-Straße 10
40789 Monheim 
GERMANY
Phone:
(mobile)
Fax:
Change #2.
STUDY CONTACT INFORMATION
SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax
Europe and Rest of the World: +32 2 386 24 21
Email
Global: DSICT@ucb.com (for interventional clinical studies)
Has been changed to:
Serious adverse event reporting (24h)
Fax
Europe and Rest of the World: +32 2 386 65 61
Email
Global: safetyreportingUCB7665@ucb.com (for interventional 
clinical studies)
Change #3.
Section 1 SUMMARY
Paragraph 7
The first 6 subjects will be enrolled in Dose Arm 1 only. While recruitment is ongoing, safety
data for the first 3 subjects up to 7 days after the final dose will be reviewed by a Data 
Monitoring Committee (DMC). During a second DMC meeting, safety data for the first 6 
subjects up to 7 days after the final dose will be reviewed. Following this review, the DMC will 
make a decision on whether to open Dose Arm 2 for enrollment. Once the DMC has approved 
initiation of Dose Arm 2, subsequent subjects will be randomized to 1 of the 2 dose arms using 
an interactive voice/web response system (IXRS). The aim is to have 15 subjects in each dose 
arm. The DMC may also decide to reduce the number of doses in each of the dose arms based on 
review of data during the study. Safety data will also be reviewed on an ongoing basis during the 
study so as to continuously evaluate the safety of subjects.
REDACTED COPY 
r interv
OPY
r interv
Y
TE
adve
RE
adve
DA
marketing authorization application and any extensions or variations thereof.
o
y
4 21
on a
4 21
nd
rvention
n app
rvention
pl
iza
erse ev
ing a
erse ev
au
est of t
arke
est of t
eti
any m
afet
any
afetyr
ny
yr
t cannot be used to suppor
al studie
ort a
al studie
m
po
MARY
d to
MARY
6 subje
ot be
6 subje
or the f
nnot
or the f
onitorin
can
onitorin
This documen
subject
ent c
subject
mak
men
mak
i
m
i
m


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 145 of 353
Has been changed to:
The first 6 subjects will be enrolled in Dose Arm 1 only. While recruitment is ongoing, safety
data for the first 3 subjects up to 7 days after the final dose of the third subject will be reviewed 
by the Data Monitoring Committee (DMC). During a second DMC meeting, all available safety 
data up to cut off date defined as 7 days after the final dose of the sixth subject will be reviewed.
Following this review, the DMC will make a decision on whether to open Dose Arm 2 for 
enrollment. Once the DMC has approved initiation of Dose Arm 2, subsequent subjects will be 
randomized to 1 of the 2 dose arms using an interactive voice/web response system (IXRS). 
Once 15 subjects are in the 4mg/kg group, the remaining subjects will not be randomized. They
will be allocated to the 7mg/kg group. The aim is to have 15 subjects in each dose arm. The 
DMC may also decide to reduce the number of doses in each of the dose arms based on review 
of data during the study. Safety data will also be reviewed on an ongoing basis during the study
so as to continuously evaluate the safety of subjects.
Change #4.
Section 1 SUMMARY
Paragraph 9
The secondary objective of the study is to assess the clinical efficacy of UCB7665 as measured 
by the change in platelet count and to assess the pharmacodynamic (PD) effect of UCB7665 as 
measured by the change in total IgG concentrations in blood. The exploratory objectives
; to evaluate the clinical efficacy as measured by 
the change in ITP bleeding score; to evaluate the effect of UCB7665 on the concentrations of 
total protein, albumin, α-globulin and β-globulin, IgG subclasses, IgM, IgA, and IgE, and serum 
complement levels; to evaluate the emergence of anti-drug antibodies (ADA), ie, anti-UCB7665 
antibodies with respect to immunogenicity and pharmacokinetics (PK)/PD; to evaluate the 
relationship between changes in platelet count and total IgG, IgG subclasses, ITP-specific 
autoantibodies; and to assess the plasma concentrations of UCB7665 administered by sc 
infusion.
Has been changed to:
The secondary objective of the study is to assess the clinical efficacy of UCB7665 as measured 
by the change in platelet count and to assess the pharmacodynamic (PD) effect of UCB7665 as 
measured by the change in total IgG concentrations in serum. The exploratory objectives include 
the following:
 to evaluate the clinical efficacy as measured by 
the change in ITP bleeding score; to evaluate the effect of UCB7665 on the concentrations of 
total protein, albumin, α-globulin and β-globulin, IgG subclasses, IgM, IgA, and IgE, and serum
or plasma complement levels; to evaluate the emergence of anti-drug antibodies (ADA), ie, 
anti-UCB7665 antibodies with respect to immunogenicity and pharmacokinetics (PK)/PD; to 
evaluate the relationship between changes in platelet count and total IgG, IgG subclasses, ITP-
specific autoantibodies; and to assess the plasma concentrations of UCB7665 administered by sc 
infusion.
COPY
maco
OPY 
maco
ns in b
COP
ns in b
REDACTED
; to e
CTED
; to e
uate th
DACT
uate th
β
RE
β-
E
-glob
EDA
glob
merg
RE
merg
ED C
CT
on application and any extensions or variations thereof.
They
or va
They
The
ns o
The
on rev
sion
on rev
uring th
tens
uring th
efficacy
plica
efficacy
d
a
dyn
app
ynam
pp
am
blood. T
on a
blood. T
used to support any marketing authoriza
evaluat
oriza
evaluat
he effe
utho
he effe
bulin, I
aut
bulin, I
gence o
ting 
gence o
nicit
rket
nicity an
eti
y an
atelet c
mark
atelet c
e plasm
ny m
e plasm
to:
ppo
to:
tive of 
o sup
tive of 
platelet
d to 
platelet
he chan
sed
he chan
be
ng:
be
ng:
This document cannot
ange in
nnot
ange in
al prote
can
al prote
or plasm
ent c
or plasm
anti
me
anti
e
m
e
zation
e us
ot be


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 146 of 353
Change #5.
Section 1 SUMMARY
Paragraph 11
Description of PDILI evaluation has been added.
Change #6.
Section 1 SUMMARY
Paragraph 12
….. The PD variables are maximum change in total IgG concentration during the study; IgG 
subclass concentrations; and ITP-specific autoantibody
concentrations in blood over time. Other immunological variables to be evaluated are total IgA, 
IgE, and IgM levels; serum complement levels (C3, C3a, C4, and C5a); ADA; and cytokines (for 
subjects experiencing infusion reactions).
Has been changed to:
….. The PD variables are minimum value and maximum decrease in total IgG concentration 
during the study; IgG subclass concentrations; and ITP-specific autoantibody
in serum over time. Other immunological variables to be evaluated are 
total IgA, IgE, and IgM levels; serum (C3 and C4) and plasma (C3a and C5a) complement 
levels; ADA status (negative/positive) and relative mass units; serum biomarkers 
 B cell activating factor (BAFF) levels and the results of the 
IgG depletion assay; and cytokines (for subjects experiencing infusion reactions). Additional 
exploratory biomarkers may be investigated if needed using the samples already available.
Change #7.
Section 3.2
Secondary objectives
Bullet 2
The secondary objectives of this study are:

To assess the PD effect of UCB7665 as measured by the change in total IgG concentration in 
blood
Has been changed to:
The secondary objectives of this study are:

To assess the PD effect of UCB7665 as measured by the change in total IgG concentration in 
serum
Change #8.
Section 3.3
Exploratory objectives
Bullet 1 and 3
The exploratory objectives of this study are:
D COPY
mmu
PY 
mmu
and p
COP
and p
ive ma
D CO
ive ma
REDACT
activa
ACT
activa
r subje
EDA
r subje
R
tigate
RE
tigate
CTED 
ions or variations thereof.
d
i
dy;
ion
y; I
ons
IgG
ns
gG
ation application and any exten
ted
xt
ted are 
xten
are 
A; and 
y ex
A; and 
e in tot
ation
e in tot
ic auto
licat
ic auto
nologic
appli
nologic
plasma 
on ap
plasma 
ass uni
ation
ass uni
ensio
g author
vating
thor
vating f
ects ex
auth
ects ex
This document cannot be used to support any marketing
ted if n
ing a
ted if n
ves
y m
ves
s of thi
ppor
s of thi
D effect
o su
D effect
chang
use
chang
ndary
ot be
ndary o
e
o
y
e
y
To asse
ann
To asse
seru
t ca
seru
Cha
men
Cha
orizat


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 147 of 353


To evaluate the effect of UCB7665 on the concentrations of total protein, albumin, 
α-globulin and β-globulin, IgG subclasses, IgM, IgA, and IgE, and serum complement levels
Has been changed to:
The exploratory objectives of this study are:


To evaluate the effect of UCB7665 on the concentrations of total protein, albumin, 
α-globulin and β-globulin, IgG subclasses, IgM, IgA, and IgE, and serum or plasma 
complement levels
Change #9.
Section 4.2
Efficacy variables
Bullet 15

Value and change from Baseline in the ITP bleeding score over time
Has been changed to:

ITP bleeding score over time
Change #10.
Section 4.3.2 Pharmacodynamic variables
The PD variables are:

Maximum change from Baseline in total IgG concentration during the study

Change from Baseline in ITP-specific autoantibody concentrations in blood over time: 

Change from Baseline in IgG subclass concentrations over time

Value and change from Baseline in IgG concentrations over time
Has been changed to:

Minimum value and maximum decrease from Baseline in total IgG concentration during the 
study

Value and change from Baseline in total IgG concentrations over time

The value and change from Baseline in endogenous IgG concentrations will be measured by 
IgG depletion assay

Change from Baseline in ITP-specific autoantibody in serum over time: 

Change from Baseline in IgG subclass concentrations over time
REDACTED COPY 
g
Y
g
ables
EDA
ables
ny marketing authorization application and any extensions or variations thereof.
in
si
in, 
sio
, 
plasma 
tensi
plasma 
e over t
plica
e over t
e in tot
marke
e in tot
TP
n
TP-
y
-spec
ny m
spec
r v
This document cannot be used to support 
ne in Ig
ppo
ne in Ig
ge from
to su
ge from
hange
sed 
hange
um valu
be u
um valu
y
o
y
Value a
cann
Value a

e

Th
nt 
Th
rt any


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 148 of 353
Change #11.
Section 4.4
Other immunological variables
Other immunological variables are:

Change from Baseline in immunoglobulin concentrations (total IgA, IgE, and IgM) over time

Change from Baseline in serum complement levels (C3, C3a, C4, and C5a) over time

Value and change from Baseline in ADA (anti-UCB7665 antibodies) over time

Cytokines
Cytokine samples will be taken at Baseline for all subjects and at subsequent visits only if the 
subject experiences infusion reactions.
Has been changed to:
Other immunological variables are:

Change from Baseline in serum immunoglobulin concentrations (total IgA, IgE, and IgM) 
over time

Change from Baseline in serum (C3 and C4) and plasma (C3a and C5a) complement levels 
over time

Change from Baseline in serum biomarkers 
over time

ADA (anti-UCB7665 antibodies) status (negative/positive) and change from Baseline in
relative mass units over time

Change from Baseline in cytokines over time (for subjects experiencing infusion reactions)

Change from Baseline in serum BAFF levels over time
Cytokine samples will be taken at Baseline for all subjects and at subsequent visits only if the 
subject experiences infusion reactions. 
Additional exploratory biomarkers may be investigated if needed using the samples already
available.
Change #12.
Section 5.1
Study description
Paragraph 5
Dosing Period: The first 6 subjects in the study will receive UCB7665 4mg/kg. These subjects in 
the Dose Arm 1 will not be randomized. While recruitment is still ongoing, safety data for the 
first 3 subjects up to 7 days after the final dose will be reviewed by a DMC. During a second 
DMC meeting, safety data for the first 6 subjects up to 7 days after the final dose will be 
reviewed. During these reviews recruitment in the dose arm will not be stopped. Following this 
review, the DMC will make a decision on whether to open Dose Arm 2 for enrollment. Once the 
DMC has approved opening of Dose Arm 2 for enrollment, subjects will subsequently be 
randomized to one of the 2 dose arms using IXRS. If the new dose arm will be initiated and if the 
REDACTED COPY 
us (neg
ACT
us (neg
es o
R
es o
D COP
application and any extensions or variations thereof.
nly
ion
nly if t
ons
if t
on
(total Ig
and
(total Ig
C3a
plica
C3a an
a
an
not be used to support any marketing authorizatio
gative/
thor
gative/
over tim
eting
over tim
BAFF
marke
BAFF
at Bas
ny m
at Bas
reactio
t any
reactio
biomark
ppo
biomark
Stud
use
Stud
h 5
ot b
h 5
This document can
ng Per
anno
ng Per
he Dose
nt ca
he Dose
first 3
ent
first 3
DM
m
DM
tion a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 149 of 353
UCB7665 4mg/kg arm will be continued, new subjects will be randomized to 1 of the 2 dose 
arms in an allocation ratio of 1:1 (randomization will stop once 15 subjects are treated with 
UCB7665 4mg/kg dose).
Has been changed to:
Dosing Period: The first 6 subjects in the study will receive UCB7665 4mg/kg. These subjects in 
the Dose Arm 1 will not be randomized. While recruitment is still ongoing, safety data for the 
first 3 subjects up to 7 days after the final dose of the third subject will be reviewed by the DMC. 
During a second DMC meeting, all available safety data up to cut off date defined as 7 days after 
the final dose of the sixth subject will be reviewed. During these reviews recruitment in the dose 
arm will not be stopped. Following this review, the DMC will make a decision on whether to 
open Dose Arm 2 for enrollment. Once the DMC has approved opening of Dose Arm 2 for 
enrollment, subjects will subsequently be randomized to 1 of the 2 dose arms using IXRS. If the 
new dose arm will be initiated and if the UCB7665 4mg/kg arm will be continued, new subjects 
will be randomized to 1 of the 2 dose arms in an allocation ratio of 1:1 (Once 15 subjects are in 
the 4mg/kg group, the remaining subjects will not be randomized. They will be allocated to the 
7mg/kg group.).
Change #13.
Section 5.2
Schedule of study assessments
Assessments of height, serology test for HIV, hepatitis B, and hepatitis C and biomarkers have 
been added to the Table 5-1. Footnotes f, g, n have been updated.
Change #14.
Section 5.2
Schedule of study assessments
Assessments of height, serology test for HIV, hepatitis B, and hepatitis C and biomarkers have 
been added to the Table 5-2. Footnotes f, g, n have been updated.
Change #15.
Section 5.2
Schedule of study assessments
Assessments of biomarkers have been added to the Table 5-3. Footnote d has been updated.
REDACTED COPY 
atitis B
COP
atitis B
have be
ED C
have be
sment
EDA
sment
for
R
for
ort any marketing authorization application and any extensions or variations thereof.
MC. 
ria
MC. 
after 
var
after 
the dos
s or 
the dos
ether to
ons 
ether to
rm
nsi
rm 2 fo
sio
2 fo
sing IX
xten
sing IX
nued, n
y ex
nued, n
nce 15 
any 
nce 15 
y will b
nd a
will b
y
B, and 
on a
B, and 
een up
atio
een up
tsts
HIV, h
eting
HIV, h
es f,
arke
es f,
This document cannot be used to supp
g
e
g
tud
t a
tudy a
an
y a
ers hav
ppo
ers hav


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 150 of 353
Table 5-1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consent
X
Demographic data
X
Verification of 
inclusion/exclusion 
criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory)f
X
X
X
X
X
Randomizationg
X
Withdrawal criteriah
X
X
X
X
X
X
General 
medical/procedures 
history
X
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
PY
CO
C
TE
R
AC
RE
R
any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
ap
 a
ion
iz
g
ori
X
eting
X
g 
ma
g
d to support any m
X
ort 
X
a
rt
po
su
This document cannot be used
ed
us
X
be 
X
u
no
u


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 151 of 353
Table 5-1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationi
X
X
X
X
X
X
X
X
X
X
12-lead ECG
X
X
X
X
X
X
X
X 
Karnofsky Performance 
Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xj
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serology test for HIV, 
hepatitis B, and hepatitis 
C
X
REDACTED COPY 
X
COP
X
PY
CO
X
TE
X
ED
CT
AC
ED
R
rketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
X
n a
X
X
ap
 a
X
riza
X
at
ori
ho
au
g
X
keti
X
ting
upport any marketing
X
mar
X
rk
ma
X
any 
X
y m
sed to support a
u
rt
X
X
o su
X
X
up
nnot be us
su
s
This document cannot be use
nn
us


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 152 of 353
Table 5-1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Blood sample for 
cytokines
X
Xk
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
X
X
Call to IXRS for treatment 
kit number
X
X
X
X
X
Administration of IMP
X
X
X
X
X
Blood sampling for 
plasma concentration of 
UCB7665
X
X
X
X
X
X
X
X
Anti-UCB7665 
antibodies/IgG depletion 
assay
X
X
X
X
X
X
X
X
X
X
X
X
Serum complements (C3 
and C4) and plasma 
complements (C3a and 
C5a)
X
X
X
X
REDACTED COPY 
X
OP
X
PY
CO
ED
C
X
DAC
X
CT
AC
X
RE
X
ED
R
g authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
X
ap
 a
at
ori
X
uth
X
ho
X
g a
X
au
keting
support any marke
g
X
ark
X
ke
ma
X
y m
X
ma
ma
ma
rt
ma
X
pp
X
po
d to suppo
This document cannot be used 
su
X
d
X
d
no
us


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 153 of 353
Table 5-1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Serum biomarkers 
 
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum biomarkers 
X
X
X
X
X
X
Serum BAFF levels
X
X
X
X
X
X
X
Immunoglobulins (total 
IgG, IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X 
IgA, IgM, IgEl
X
X
X
X
ITP-specific 
autoantibodiesm
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
Headache questionnairen
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviewo
X
REDACTED COPY 
X
COP
X
PY
CO
ACTE
R
AC
R
used to support any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
X
n a
X
X
ap
ri
 a
X
tho
X
riririz
g
ori
X
ketin
X
ing
X
mar
X
rke
ma
ny
rt
ortrtrt
su
rt
X
d to
X
s
X
d
X
d
t be use
us
u
nnot b
u
t b
This document can


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 154 of 353
AE=adverse event; BAFF= B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
; HIV=human immunodeficiency virus;
Ig=immunoglobulin; IMP=investigational medicinal product; ITP=immune thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar 
puncture; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
a Frequency of assessments on dosing days is detailed in Table 5-3.  
b Visits 10, 12, and 14 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the final dose.
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose. 
e The visit windows in the Observation Period are relative to the final dosing visit date.
g Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h The first 6 subjects will be enrolled in the Dose Arm 1 group only. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the
DMC. Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, subjects subsequently enrolled will 
be randomly assigned subsequently to 1 of the 2 dose arms using an IXRS until 15 subjects are in Dose Arm 1.
Error! Reference source not found.
Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
Error! Reference source not found.
A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical 
examination is performed), an abbreviated physical examination will be conducted.
l At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
n Blood sample for cytokines will be obtained only in case of infusion reactions.
Error! Reference source not found.
In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 
7 assessment for IgA, IgM, and IgE will be performed earlier at the last dosing visit.
Error! Reference source not found.
Error! Reference source not found.
This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution 
(ie, if headache becomes moderate or mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including
fundoscopy). Additionally, other diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at 
the discretion of the investigator, considering the local guidelines for performing LP in subjects with ITP.
Error! Reference source not found.
A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the 
study, the subject exit interview should be performed at End-of-Study Visit only. 
REDACTED COPY
6
Y
6
enrol
PY 
enrol
5 subje
COP
5 subje
g the s
D CO
g the s
l be pe
ED 
l be pe
conduc
CTE
conduc
he sam
DAC
he sam
on react
EDA
on react
sions 
RE
sions 
R
variations thereof.
15 Fe
here
15 Fe
C=Data 
atio
C=Data 
y virus;
ariat
y virus;
onse sys
var
onse sys
ting authorization application and any extensions o
sing vis
y ex
sing vis
value w
n an
value w
will be a
ion 
will be a
ects up 
plica
ects up 
ment. If
app
ment. If
cts are i
n ap
cts are i
tudy, ba
tion
tudy, ba
erformed
izati
erformed
ted.
hori
ted.
me day fo
utho
me day fo
tions.
au
tions.
to be ad
ing 
to be ad
This document cannot be used to support any marke
last dos
ketin
last dos
licable o
mar
licable o
on of A
ny m
on of A
includin
t any
includin
al guidel
ort a
al guidel
ctured i
ppo
ctured i
ormed at
supp
ormed at
arke
or v


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 155 of 353
Table 5-2:
Schedule of assessments for the UCB7665 7mg/kg dose arm
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consent
X
Demographic data
X
Verification of inclusion/exclusion 
criteria
X
X
Platelets for inclusion/withdrawal 
check (local laboratory) f
X
X
X
Randomizationg
X
Withdrawal criteriah
X
X
X
X
General medical/procedures history
X
ITP history
X
Prior and concomitant medication
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical procedures
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
O
D C
D
AC
D
AC
AC
R DAC
t any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
n
pl
n a
on
at
ho
X
aut
X
th
in
h
tininin
a
in
X
ma
X
ar
ma
y
nnot be used to support a
t a
pp
supp
pp
pp
pp
s
d 
u
t b
This document cann
nn
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 156 of 353
Table 5-2:
Schedule of assessments for the UCB7665 7mg/kg dose arm
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Physical examinationi
X
X
X
X
X
X
X
X
12-lead ECG
X
X
X
X
X
X
Karnofsky Performance Status
X
Laboratory parameters (hematology, 
chemistry, urinalysis)
Xj
X
X
X
X
X
X
X
X
X
X
X
X
Serology test for HIV, hepatitis B, and 
hepatitis C
X
Blood sample for cytokines
X
Xk
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
Call to IXRS for treatment kit number
X
X
X
Administration of IMP
X
X
X
Blood sampling for plasma 
concentration of UCB7665
X
X
X
X
X
X
Anti-UCB7665 antibodies/IgG 
depletion assay
X
X
X
X
X
X
X
X
X
X
REDACTED COPY
X
OPY
X
Y 
X
D CO
X
CO
D C
D 
D
DACT
DAC
RE
R
t any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
n
pl
X
t
X
n a
on
at
o
X
utho
X
or
ho
g
a
in
X
a
X
ark
ma
y
This document cannot be used to support a
X
t a
p
pp
pp
pp
pp
s
d
u
be
an


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 157 of 353
Table 5-2:
Schedule of assessments for the UCB7665 7mg/kg dose arm
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Serum complements (C3 and C4) and 
plasma complements (C3a and C5a)
X
X
X
X
Serum biomarkers 
 
X
X
X
X
X
X
X
X
X
X
X
Serum biomarkers 
X
X
X
X
Serum BAFF levels
X
X
X
X
X
Immunoglobulins (total IgG, IgG 
subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgEl
X
X
X
X
ITP-specific autoantibodiesm
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
Headache questionnairen
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviewo
X
AE=adverse event; BAFF=B cell activating factor; BL=baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
 HIV=human immunodeficiency virus;
Ig=immunoglobulin; IMP=investigational medicinal product; ITP=immune thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar 
REDACTED COPY
X
OPY
X
Y
C
 
X
ED 
X
C
C
D C
X
DAC
X
AC
AC
R DAC
R
o support any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
X
app
X
plplpl
on
pl
X
zati
X
tio
ho
o
X
uth
X
ho
ho
ho
n
ho
ng
in
X
ark
X
ke
ma
X
an
X
y
rt
pp
X
sup
X
pp
p
ot be used to 
pp
pp
pp
pp
o
ed
u
e u
ot be u
ot
cann
B cell ac
nno
B cell ac
cardiog
can
cardiog
This document
MP=inv
nt ca
MP=inv


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 158 of 353
puncture; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
a Frequency of assessments on dosing days is detailed in Table 5‒3.
b Visits 8, 10, and 12 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the final dose.
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose. 
e The visit windows in the Observation Period are relative to the final dosing visit date. 
(local laboratory)Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion 
criteria. The other platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to 
evaluate withdrawal criterion of platelet count >350x109/L.
h The first 6 subjects will be enrolled in the Dose Arm 1 group. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the DMC. 
Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, subjects subsequently enrolled will be 
randomly assigned to one of the dose arms using an IXRS until 15 subjects are in Dose Arm 1.
i Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
j A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
l At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
n Blood sample for cytokines will be obtained only in case of infusion reactions.
Error! Reference source not found.
In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 
5 assessment for IgA, IgM, and IgE will be performed earlier at the last dosing visit.
Error! Reference source not found.
Error! Reference source not found.
This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution 
(ie, if headache becomes moderate or mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including 
fundoscopy). Additionally, other diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at 
the discretion of the investigator, considering the local guidelines for performing LP in subjects with ITP.
Error! Reference source not found.
A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the 
study, the subject exit interview should be performed at End-of-Study Visit only.
DACTED COPY
t. At al
OPY 
t. At al
day for
D CO
day for
ons.
TED
ons.
be ad
CTE
be ad
ast dosi
DAC
ast dosi
RE
ble on
RE
ble on
REDA
ations thereof.
15 Fe
here
15 Fe
uthorization application and any extensions or variat
date. H
sio
date. H
and the 
ny e
and the 
t sample
any
t sample
ays afte
n an
ays afte
rm
o
rm 2 is 
on 
 2 is 
m
o
m
l other v
app
l other v
r evalua
ation
r evalua
min
hor
minister
oriz
ister
ing visit
utho
ing visit
ting 
nly to su
ting 
nly to su
This document cannot be used to support any marke
Es shoul
ketin
Es shoul
g but no
arke
g but no
ines for 
ma
ines for 
nterview
ny m
nterview
End
t an
End-
an
-of
ny
of
g aut
n
ation


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 159 of 353
Table 5-3:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of infusion
4h after end of infusion
Withdrawal criteria
X
Platelet count (local laboratory) for inclusion check 
at Visit 2 and for withdrawal criterion at other 
dosing visits
X
Prior and concomitant medications
X
Concomitant medical procedures
X
Vital signsa
X
X
X
X
Physical examination
X
12-lead ECG
X
Hematology 
X
Clinical chemistry
X
Urinalysis
X
Urine pregnancy test
X
Immunoglobulinsb
X
ITP-specific autoantibodiesc
X
Blood sampling for UCB7665 plasma 
concentration
X
Anti-UCB7665 antibodies/IgG depletion assay
X
Serum (C3 and C4) and plasma complements (C3a 
and C5a)d
X
Serum biomarkers 
X
X
X
Serum BAFF levels
X
X
X
Blood sampling for cytokinese
X
REDACTED COPY 
Y
OP
D C
CTE
AC
DA
RE
keting authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
4h a
or v
4h a
va
o
ns
on
y e
d a
a
tio
plic
pli
pli
pli
pli
a
tio
ori
ut
g
ng
ng
This document cannot be used to support any marke ng
ke
X
ny m
X
m
rt
p
C3a
s
C3a
pp
up
d t
be 
es
a
ese
o
ca
use
e


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 160 of 353
Table 5-3:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of infusion
4h after end of infusion
ITP bleeding scale
X
AEs
X
X
X
X
NFI-MSf
X
AE=adverse event; BAFF=B cell activating factor; ECG=electrocardiogram; h=hours; Ig=immunoglobulin; IMP=investigational medicinal product; 
ITP=immune thrombocytopenia; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
 PRO=Patient Reported 
Outcomes; 
b In addition to time points mentioned, vital signs will be evaluated every 15 minutes during infusion. Respiratory rate will be assessed only once predose.
d Total IgG and IgG subclasses. 
e Evaluation of ITP-specific autoantibodies will be performed prior to dose 1 only. 
f Serum and plasma complement levels will be assessed prior to dose 1 and dose 3 only.
Error! Reference source not found.
Blood sample for Baseline cytokine values will be obtained at Visit 2 for all subjects at predose and at other visits in case 
of infusion reactions.
Error! Reference source not found.
PRO endpoint (NFI-MS) will be assessed prior to dose 1 only.
REDACTED COPY 
P
will be 
OPY
will be 
sed prio
ED C
sed prio
ny extensions or variations thereof.
15 Fe
here
15 Fe
4h a
or v
4h a
va
o
ns
on
en
e
MP=inve
ny e
MP=inve
pplication and 
Respirato
n an
Respirato
This document cannot be used to support any marketing authorization a
obtained
app
obtained
or to do
atio
or to do
d any


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 161 of 353
Change #16.
Section 6.2.1 Exclusion criteria related to health status
Number 3 and 10
3. Subject has a Karnofsky Performance Status (Appendix 18.1) rating <60 at Screening Visit.
10. Subject has liver impairment, defined as:

Subject has >2xULN alanine aminotransferase (ALT) or alkaline phosphatase (ALP), or 
>ULN bilirubin (≥1.5xULN bilirubin if known Gilbert’s syndrome) at Screening Visit. If 
the subject has isolated >ULN and <1.5xULN bilirubin, fractionate bilirubin to identify
possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
For subjects with a Baseline result >ULN, a baseline diagnosis and/or the cause of any 
clinically meaningful elevation must be understood and recorded in the medical history
section of the electronic Case Report form (eCRF).
If subject has >ULN that does not meet the exclusion limit for ALT or ALP at screening, 
repeat, if possible, prior to dosing to ensure there is no further ongoing clinically relevant 
increase. In case of a clinically relevant increase, inclusion of the subject must be discussed 
with the Medical Monitor. 
Serum ALT results up to 25% above the upper exclusion limit may be repeated once for 
confirmation. This includes rescreening (see Section 6.3).
Has been changed to:
3. Subject has a Karnofsky Performance Status (Appendix 18.1) rating <60% at Screening Visit.
10. Subject has liver impairment, defined as:

Subject has >1.5xULN of any of the following: alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), or alkaline phosphatase (ALP), or >ULN total 
bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If the subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
For subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, a Baseline 
diagnosis and/or the cause of any clinically meaningful elevation must be understood and 
recorded in the electronic Case Report form (eCRF).
If subject has >ULN for ALT, AST, or ALP that does not meet the exclusion limit at 
screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject 
must be discussed with the Medical Monitor. 
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. This includes rescreening (see Section 6.3).
Change #17.
Section 6.2.2
Exclusion criteria related to medical history
REDACTED COPY 
xclusi
OPY
xclusi
Secti
CO
Sectio
O
o
Status
DAC
Status
fined a
RED
fined a
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
or 
ar
or 
Visit. If 
or va
Visit. If 
identify
s or
identify
use of a
tens
use of a
edical h
ext
edical h
T or AL
nd a
T or AL
ngoing
n an
ngoing
f the su
ation
f the su
ion lim
app
ion lim
n
io
n 6.3
on 
6.3)
a
)
s (App
utho
s (App
as:
ng
as:
of the 
rketi
of the 
(AST),
mark
(AST),
al biliru
y m
al biliru
al biliru
t any
al biliru
ndiagn
port 
ndiagn
a a B
su
Basel
upp
asel
or the c
to s
or the c
the elec
ed t
the elec
ct has >
be us
ct has >
ning, r
ot be
ning, r
inically
nnot
inically
must b
can
must b
Te
nt
Te


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 162 of 353
14. Subject has evidence of a secondary cause of immune thrombocytopenic purpura from the 
past medical history (eg, bacterial or viral infection, past medical history of leukemia, 
lymphoma, combined variant immunodeficiency, systemic lupus erythematosus, thyroid 
disease) or to drug treatments (eg, heparin, quinine, antimicrobials, anticonvulsants) or 
subject has a multiple immune cytopenia, eg, Evan’s syndrome.
15. Subject has a history of clinically relevant ongoing chronic infections including but not 
limited to human immunodeficiency virus (HIV), hepatitis B, hepatitis C, active or latent 
tuberculosis.
20. Subject has a history of known inflammatory bowel disease, diverticular disease, and gastric 
or esophageal ulceration.
21. Subject has experienced gastrointestinal bleed in the last 6 months prior to Screening Visit 
and/or has current gastritis or esophagitis.
23. Subject has a medical history of thrombosis.
24. Subject has a history of coagulopathy disorders.
Has been changed to:
14. Subject has evidence of a secondary cause of immune thrombocytopenic purpura from the 
past medical history (eg, bacterial or viral infection, past medical history of leukemia, 
lymphoma, common variable immunodeficiency, systemic lupus erythematosus, 
auto-immune thyroid disease) or to drug treatments (eg, heparin, quinine, antimicrobials, 
anticonvulsants) or subject has a multiple immune cytopenia, eg, Evan’s syndrome.
15. Subject has a history of clinically relevant ongoing chronic infections including but not 
limited to human immunodeficiency virus (HIV), hepatitis B, hepatitis C, active or latent 
tuberculosis, or is tested positive for HIV, hepatitis B, or hepatitis C at the Screening Visit.
20. Subject has a history of known inflammatory bowel disease, diverticular disease, or has a 
history of confirmed, duodenal, gastric or esophageal ulceration in the past 6 months.
21. Subject has experienced a clinically symptomatic gastrointestinal bleed (positive hemoccult 
tests without any signs and symptoms of gastrointestinal bleedings will not be considered as 
“clinically symptomatic”) in the last 6 months prior to Screening Visit and/or has current 
gastritis or esophagitis and/or has a known risk for clincial relevant gastrointestinal bleeding 
beyond ITP.
23. Subject has a medical history of thrombosis within the past 5 years or a history of thrombosis 
with unknown cause at any time or a known significant risk for thrombosis.
24. Subject has a history of coagulopathy disorders other than ITP.
Change #18.
Section 6.2.3 Exclusion criteria related to concomitant medications/procedures
Definition of generic name was added and wording of “wash-out” changed to “washout” in 
Table 6-1.
REDACTED COPY
n, pa
PY 
n, pa
cy
CO
cy, sy
COP
, sy
P
atmen
D CO
atmen
e immu
TED
e immu
evant 
DAC
evant 
ncy
RE
ncy vir
RED
vir
y
RE
y
for
R
for
ny marketing authorization application and any extensions or variations thereof.
d gastric
or v
d gastric
reening
ensi
reening
ombocy
licat
ombocy
st medi
appl
st medi
stemic
n ap
stemic 
nts (eg, 
ation
nts (eg, 
mune cy
riza
mune cy
ongoin
utho
ongoin
rus (HI
g au
rus (HI
HIV, h
eting
HIV, h
nf
a
nflamm
arke
lamm
flf
ar
flf
al, gast
y ma
al, gast
cannot be used to support a
a clinic
t any
a clinic
s and sy
port 
s and sy
matic
upp
matic”) 
pp
”) 
hagitis 
o su
hagitis 
as a me
use
as a me
nknow
t be 
nknow
ubject h
nnot
ubject h
This document 
Chang
nt ca
Chang
Sect
men
Sect


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 163 of 353
Table 6-1:
Washout periods for immunosuppressants, biologics and other 
therapies
Generic name (most common commercial/trade 
names)
Washout period relative to Baseline Visit 
(regardless of route)
Immunosuppressants
Cyclophosphamide 
6 months
Pimecrolimus (Elidel®)
4 weeks
Vinca alkaloids (vincristine, vinblastine)
12 weeks
Biologics (mAbs and fusion proteins)
Abatacept (CTLA 4-Ig) (Orencia®)
6 months
Belimumab (Benlysta™)
6 months
Golimumab (Simponi™)
6 months
Natalizumab (Tysabri®)
6 months
Ofatumumab (Arzerra)
6 months
Rituximab (Rituxan®) and ocrelizumab
6 months
TACI-Ig (Atacicept)
10 months
Veltuzumab
6 months
Other biologics
3 months
Others
Intravenous immunoglobulin
4 weeks
IPP-201101 (Lupuzor™)
3 months
Plasma exchange (PLEX)
4 weeks
TPO-R agonists (eltrombopag, romiplostim)
4 weeks
Anti-D
4 weeks
Antiplatelets and Anticoagulants (Vitamin K 
antagonists)
Warfarin
2 weeks
Fenprocoumon
2 weeks
Acenocoumarol
2 weeks
Heparin
1 week
Clopidogrel
1 week
Salicylates (Aspirin)
1 week
Dipyramidole
1 week
REDACTED COPY
onths
PY 
onths
10 mo
CO
10 mo
OP
D
6
D
6
D C
ED
CT
DA
R
t cannot be used to support any marketing authorization application and any extensions or variations thereof.
i
ati
ari
or 
on
en
ex
an
an
tio
lic
onths
ion
onths
ap
month
izat
month
tio
3 m
ho
3 m
or
uth
au
ing
rk
m
ag,
po
ag, romi
port 
romi
t a
po
d Antic
d to 
d Antic
anta
sed 
anta
s
us
oumon
not b
oumon
be
nocoum
can
nocoum
nn
ment c
Hepari
ent 
Hepari
This docume t c
m
Cl
m
Cl
me
um


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 164 of 353
Table 6-1:
Washout periods for immunosuppressants, biologics and other 
therapies
Generic name (most common commercial/trade 
names)
Washout period relative to Baseline Visit 
(regardless of route)
Prasugrel
1 week
Ticagrelor
1 week
Tirofiban
1 week
Abciximab
1 week
Change #19.
Section 6.4
Withdrawal criteria
Number 2, bullet 5
2. Subject develops an illness or has a change in health status that would interfere with his/her 
continued participation, including but not limited to:

Subject has a clinically severe (life threatening) bleeding event (Skin [S]>2 and/or 
Mucosae [M]>1 and /or Organ [O]>1).
Has been changed to:
2. Subject develops an illness or has a change in health status that would interfere with his/her 
continued participation, including but not limited to:

Subject has a life threatening bleeding event.
Change #20.
Section 6.4
Withdrawal criteria
Subjects with potential drug-induced liver injury (PDILI) MUST stop treatment with IMP. In 
addition, all concomitant medications and herbal supplements that are not medically necessary
should also be stopped.
The below PDILI criteria require immediate and permanent discontinuation of IMP:

Subjects with any of the following:

ALT ≥8xULN

ALT ≥3xULN and co-existing total bilirubin ≥2xULN 
The below PDILI criteria requires immediate discontinuation of IMP:

Subjects with ALT ≥3xULN who exhibit a temporally associated fatigue, nausea, vomiting, 
right upper quadrant pain or tenderness, fever (without clear alternative cause), rash, or 
eosinophilia (ie, >5%) must be immediately discontinued from IMP.
If a nondrug related cause for the symptoms can be confirmed, these subjects may resume IMP 
administration after discussion with the Medical Monitor.
REDACTED COPY 
e in he
TED
e in he
not lim
ACT
not lim
bleedin
REDA
bleedin
nnot be used to support any marketing authorization application and any extensions or variations thereof.
i
ati
ari
or 
on
uld int
and
uld int
ng even
licat
ng even
ealth st
rizat
ealth st
mited t
thori
mited t
ng even
g au
ng even
nduced 
any 
nduced 
edicatio
rt an
edicatio
iteria re
o sup
iteria re
h any
ed t
h any o
t
o
y
t
y
≥8xU
e us
≥8xU
AL
ot
ALT
ot b
T ≥
b
≥
This document ca
e below
cann
e below

e

Su
nt 
Su


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 165 of 353
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
investigator.

ALT ≥3xULN (and ≥2x Baseline) and <8xULN, total bilirubin <2xULN, and no eosinophilia 
(ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, fatigue, nausea, vomiting, right 
upper quadrant pain, or tenderness).
The investigator must consult UCB Medical Monitor within 24 hours if ALT ≥3xULN (with or 
without increase in bilirubin or with/without symptoms of liver dysfunction) and further dosing 
should be withheld until after discussion with UCB medical monitor.
Has been changed to:
Subjects with PDILI must be assessed to determine if IMP must be discontinued. In addition, all 
concomitant medications and herbal supplements that are not medically necessary should also be 
discontinued.
The PDILI criteria below require immediate and permanent discontinuation of IMP:

Subjects with either of the following:

ALT or AST ≥5xULN

ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
The PDILI criterion below requires immediate discontinuation of IMP:

Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
If a nondrug-related cause for the symptoms can be confirmed, these subjects may resume IMP 
administration after discussion with responsible UCB physician, but only when the requirements 
for rechallenge with IMP as provided in Section 12.7.1.2.1 are followed.
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
investigator.

Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain, or tenderness).
Evaluation of PDILI must be initiated as described in Section 12.7.1. If subjects are unable to 
comply with the applicable monitoring schedule, IMP must be discontinued immediately.
Change #21.
Section 7.8.1 Permitted immunosuppressant medications
Dose unit for Cyclosporin was updated.
REDACTED COPY 
rubi
Y
rubi
contin
COP
contin
exhibi
ED C
exhibi
y
C
ympto
CTE
mpto
ym
y
C
ym
y
Hy
DA
Hypers
DAC
pers
yp
y
DA
yp
y
philia 
RED
philia 
R
marketing authorization application and any extensions or variations thereof.
g
n additi
nsio
n additi
ry
xt
ry shou
ten
shou
y
t
y
ation o
any
ation o
≥2xUL
pplic
≥2xUL
nuation
on ap
nuation
it temp
izatio
it temp
oms in
horiz
oms in
sensitiv
utho
sensitiv
(ie, >5
g au
(ie, >5
ptoms c
ketin
ptoms c
resp
marke
resp
be used to support any 
on
ke
on
vided in
y ma
vided in
llows f
t any
llows f
T or A
sup
T or A
no eosi
d to s
no eosi
sea, vo
sed 
sea, vo
of PDI
be u
of PDI
This document cannot
with th
ot be
with th
ange #
cann
ange #
Section
ent c
Section
Do
m
Do


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 166 of 353
Has been changed to:
Table 7‒1:
Permitted immunosuppressant medications
Permitted medications
Dose
Comment
Oral corticosteroids 
(prednisolone)
≤10mg/day
Stable dose for 2 weeks prior to Baseline
Methotrexate
≤30mg/week
Stable dose for 2 months prior to Baseline
Mycophenolate mofetil
≤3g/day
Stable dose for 2 months prior to Baseline
Cyclosporin
≤5mg/kg/day
Stable dose for 2 months prior to Baseline
Azathioprine
≤3mg/kg/day
Stable dose for 2 months prior to Baseline
Danazol
≤15mg/kg/day
Stable dose for 2 months prior to Baseline
Dapsone
100mg/day
Stable dose for 2 months prior to Baseline
Change #22.
Section 7.8.2
Prohibited concomitant treatments (medications and therapies)
Bullet 12 

Anticoagulants and antiplatelets (warfarin, heparin, clopidogrel, aspirin, salicylics, 
dipyramidole, prasugrel, ticregelor, ticofiban, abiximab)
Has been changed to:

Anticoagulants and antiplatelets (warfarin, heparin, clopidogrel, aspirin, salicylics, 
dipyramidole, prasugrel, tricagrelor, tirofiban, abciximab)
Change #23.
Section 7.10
Randomization and numbering of subjects
Paragraph 2
The first 6 subjects (and those treated before DMC assessment after the 6 subjects) will not be 
randomized. Once the DMC has approved opening of Dose Arm 2 for enrollment, subsequent 
subjects will be randomized to 1 of the 2 dose arms in a 1:1 ratio.
Has been changed to:
The first 6 subjects (and those treated before DMC assessment after the 6 subjects) will not be 
randomized. Once the DMC has approved opening of Dose Arm 2 for enrollment, subsequent 
subjects will be randomized to 1 of the 2 dose arms in a 1:1 ratio. Once 15 subjects are in the 
4mg/kg group, the remaining subjects will not be randomized. They will be allocated to the 
7mg/kg group.
Change #24.
Section 7.10
Randomization and numbering of subjects
Paragraph 4
REDACTED COPY 
parin, c
COP
parin, c
n
D
n, abix
ED C
, abix
warfari
EDA
warfari
or
RE
or,
R
, ti
E
ti
be used to support any marketing authorization application and any extensions or variations thereof.
ti
ati
ati
ati
line
or
line
va
Baselin
ons
Baselin
o
r to Bas
ens
r to Bas
io
prior to
ext
prior to
te
nths pri
d any
nths pri
y
d a
ons and
atio
ons and
clopido
on ap
clopido
iximab)
atio
iximab)
in, hep
aut
in, hep
irofiba
ing 
irofiba
nd num
y ma
nd num
those t
ppo
those t
e DMC
sup
e DMC
ndomiz
d to s
ndomiz
chang
used
chang
ent cannot b
6 subje
t be 
6 subje
mized. O
not 
mized. O
ects wi
cann
ects wi
4mg/kg 
nt ca
4mg/kg 
This documen
7mg/
men
7mg/
C


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 167 of 353
To randomize a subject, the investigator or designee will contact the IXRS and provide brief 
details about the subject to be randomized. The IXRS will automatically inform the investigator 
or designee of the subject’s randomization number. The IXRS will allocate kit numbers to the 
subject based on the subject number during the course of the study.
Has been changed to:
To randomize a subject, the investigator or designee will contact the IXRS and provide brief 
details about the subject to be randomized. The IXRS will automatically inform the investigator 
or designee of the subject’s kit number. The IXRS will allocate kit numbers to the subject based 
on the subject number or randomization during the course of the study.
Change #25.
Section 8.1.1
Visit 1 (Day -28 to -1) Screening Visit
Following assessments have been added.

Height

Serology test for HIV, hepatitis B, and hepatitis C
Change #26.
Section 8.2.1
Visit 2 (Week 1/Day 1) Baseline Visit
Paragraphs 1, 2, 3 and 4
Visit 2 can occur at any time after Visit 1, but no later than 28 days after Visit 1. Prior to 
randomization, 2 platelet samples will be taken. One sample will be analyzed locally and the 
value will be used to check inclusion criterion. The other platelet sample will be sent to the 
central laboratory.
Eligible subjects will be randomized at Visit 2 and first dose of IMP will be administered as per 
the subject’s randomization, except that the first 6 subjects will be enrolled in Dose Arm 1.
Subjects randomized to Dose Arm 1 (UCB7665 4mg/kg sc) will receive a total of 5 doses of IMP 
at Visit 2 (Day 1, Week 1), Visit 4 (Week 2), Visit 5 (Week 3), Visit 6 (Week 4), and Visit 7 
(Week 5). 
Subjects randomized to Dose Arm 2 (UCB7665 7mg/kg sc) will receive a total of 3 doses of IMP 
at Visit 2 (Day 1, Week 1), Visit 4 (Week 2), and Visit 5 (Week 3).
Has been changed to:
Visit 2 can occur at any time after Visit 1, but no later than 28 days after Visit 1. Prior to dosing 
at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value 
will be used to check inclusion criterion. The other platelet sample will be sent to the central 
laboratory.
Eligible subjects will be treated with IMP at Visit 2. The first 6 subjects will be enrolled in Dose 
Arm 1, subsequent subjects will be randomized to 1 of the 2 dose arms. Once 15 subjects are in 
Dose Arm 1, the remaining subjects will not be randomized. They will be allocated to Dose 
Arm 2.
REDACTED COPY 
Visit
PY
Visit
ut no la
TED
ut no la
taken.
ACT
taken.
riterion
EDA
riterion
annot be used to support any marketing authorization application and any extensions or variations thereof.
or 
r
or 
ased
var
ased
ater tha
rizat
ater tha
. One s
thor
. One s
on. The
auth
on. The
at Visit
rket
at Visit
pt that t
mar
pt that t
Arm 1 
any 
Arm 1 
Visit 4
ort a
Visit 4
d to Do
o sup
d to Do
Week 
d to
Week 
chang
use
chang
an occu
t be
an occu
t
n
t 2
nn
2
This document c
, 2 p
not
, 2 p
l be us
can
l be us
laborat
ent c
laborat
Eli
m
Eli


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 168 of 353
Subjects allocated to Dose Arm 1 (UCB7665 4mg/kg sc) will receive a total of 5 doses of IMP at 
Visit 2 (Day 1, Week 1), Visit 4 (Week 2), Visit 5 (Week 3), Visit 6 (Week 4), and Visit 7 (Week 
5). 
Subjects allocated to Dose Arm 2 (UCB7665 7mg/kg sc) will receive a total of 3 doses of IMP at 
Visit 2 (Day 1, Week 1), Visit 4 (Week 2), and Visit 5 (Week 3). 
Change #27.
Section 8.2.1 Visit 2 (Week 1/Day 1) Baseline Visit
Definition of complement levels were updated as:

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)
And following assessments have been added:

Serum biomarkers 
 and
serum BAFF levels. Blood samples are taken prior to dosing, 2 and 4 hours after end of 
infusion for serum biomarkers and BAFF

Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to computed tomography (CT) scan, magnetic resonance imaging 
(MRI) and/or lumbar puncture (LP) for cerebrospinal fluid (CSF) collection to be performed 
if indicated at the discretion of the investigator, considering the local guidelines for 
performing LP in subjects with ITP. 
Change #28.
Section 8.2.2 Visit 3 (Week 1/Day 4)
Following assessments have been added:

Serum biomarkers 

Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP. 
Change #29.
Section 8.2.3 Visit 4 (Week 2/Day 8)
Following assessments have been added.

Call IXRS to obtain treatment kit number(s)

Blood sample for the following laboratory parameters:
REDACTED COPY
Addi
PY 
Addi
ph
CO
phy (C
COP
y (C
ebrosp
D C
ebrosp
igator
CTED
igator
extensions or variations thereof.
and C5a
ions
and C5a
y marketing authorization application and any
nd 4 hou
d any
nd 4 hou
e heada
licat
e heada
tionally
appl
tionally
CT) sc
on ap
CT) sc
pina
atio
pinal flu
tion
l flu
r, consi
oriza
r, consi
added:
mar
added:
ny ex
This document cannot be use
ut not li
sed 
ut not li
d at the 
e use
d at the 
subject
t be 
subject
nge #
nno
nge #2
ection 
t ca
ection 
Foll
me
Foll
d to support a
che que
port 
che que
nnaire,
supp
nnaire,
ssess
d to s
ssessme
o s
me
any 


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 169 of 353

Serum biomarkers 
 and 
serum BAFF levels. Blood samples are taken prior to dosing, 2 and 4 hours after end of 
infusion for serum biomarkers and BAFF
Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/ or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
Change #30.
Section 8.2.4
Visit 5 (Week 3/Day 15)
Definition of complement levels were updated as:

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)
Following assessments have been added.

Call IXRS to obtain treatment kit number(s)

Blood sample for the following laboratory parameters:

Serum biomarkers 
and 
serum BAFF levels. Blood samples are taken prior to dosing, 2 and 4 hours after end of 
infusion for serum biomarkers and BAFF
Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/ or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
Change #31.
Section 8.2.5 Visit 6 (Week 4/Day 22) [UCB7665 4mg/kg only]
And following assessments have been added.

Call IXRS to obtain treatment kit number(s)

Blood sample for the following laboratory parameters:

Serum biomarkers 
 and 
serum BAFF levels. Blood samples are taken prior to dosing, 2 and 4 hours after end of 
infusion for serum biomarkers and BAFF

Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
OPY
eters:
PY 
eters:
REDACTED C
e taken
TED 
e taken
BAFF
CTE
BAFF
e was u
EDA
e was u
ubj
R
ubj
D COP
n application and any extensions or variations thereof.
f f 
rming
r var
rming
levels 
nd a
levels 
t be used to support any marketing authorizatio
n prior
izati
n prior
update
auth
update
ect ex
eting
ect ex
g
ng fund
rket
ng fund
T scan
mar
T scan
f th
ny
f the in
y m
e in
6 (We
to su
6 (We
assessm
sed 
assessm
RS to o
be u
RS to o
This document canno
ood sam
not 
ood sam

c

Se
n
Se
tion a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 170 of 353
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP. 
Change #32.
Section 8.2.6 Visit 7 (Week 5/Day 29) [UCB7665 4mg/kg only]
Following assessments have been added.

Call IXRS to obtain treatment kit number(s)

Blood sample for the following laboratory parameters:

Serum biomarkers 
and 
serum BAFF levels. Blood samples are taken prior to dosing, 2 and 4 hours after end of 
infusion for serum biomarkers and BAFF
Description for Headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
Change #33.
Section 8.3.1 Visit 8 (Week 5/Day 32) [UCB7665 4mg/kg]/ Visit 6 (Week 3/Day 18) 
[UCB7665 7mg/kg]
Definition of complement levels were updated as:

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)
And following assessments have been added.

Serum biomarkers 

Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to computed tomography (CT) scan, magnetic resonance imaging 
(MRI) and/or lumbar puncture (LP) for cerebrospinal fluid (CSF) collection to be performed 
if indicated at the discretion of the investigator, considering the local guidelines for 
performing LP in subjects with ITP. 
Change #34.
Section 8.3.2 Visit 9 (Week 6/Day 36) [UCB7665 4mg/kg]/ Visit 7 (Week 4/Day 22) 
[UCB7665 7mg/kg]
Following assessments have been added.

Blood sample for the following laboratory parameters:

Serum biomarkers 
REDACTED COPY 
7665 
ED C
7665 
update
EDA
update
3 an
R
3 an
ns or variations thereof.
o
marketing authorization application and any extension
after e
nsion
after e
es, 
nd
es, foll
d an
foll
iagnost
and
iagnost
collect
tion 
collect
he loc
icatio
he loca
o
a
4mg/k
izatio
4mg/k
ed as:
auth
ed as:
nd C4)
eting
nd C4)
en adde
arke
en adde
support any
he ques
ort a
he ques
naire,
upp
naire,
p
This document cannot be used to 
essmen
to su
essmen
not lim
d to
not lim
/or lum
used
/or lum
ated at 
be u
ated at 
orming 
ot be
orming 
ange #
cann
ange #
Section
ent c
Section
ons o
ny m


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 171 of 353
Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, otherdiagnostic procedures 
including but not limited to CT scan, MRI and/ or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
Change #35.
Section 8.3.3 Visit 10 (Week 7/Day 43) [UCB7665 4mg/kg]/ Visit 8 (Week 5/Day 29) 
[UCB7665 7mg/kg] 
Following assessments have been added.

Blood sample for the following laboratory parameters:

Serum biomarkers 

Serum BAFF levels
Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/ or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
Change #36.
Section 8.3.4 Visit 11 (Week 8/Day 50) [UCB7665 4mg/kg]/ Visit 9 (Week 6/Day 36) 
[UCB7665 7mg/kg]
Following assessments have been added.

Blood sample for the following laboratory parameters:

Serum biomarkers 
Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/ or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
Change #37.
Section 8.3.5 Visit 12 (Week 9/Day 57) [UCB7665 4mg/kg]/ Visit 10 (Week 7/Day 43) 
[UCB7665 7mg/kg]
Definition of complement levels were updated as:

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)
REDACTED COPY
Addi
PY 
Addi
or 
COP
or LP
OP
LP
r, con
ED C
r, con
50)
RE
50)
rt any marketing authorization application and any extensions or variations thereof.
e heada
plica
e heada
tionally
appl
tionally
P for C
on ap
P for C
nsiderin
ation
nsiderin
[UCB7
ing a
[UCB7
added.
mar
added.
wing la
any 
wing la
cannot be used to suppo
ache qu
supp
ache qu
estionn
ed to
estionn
al asse
used
al asse
ng but n
be u
ng but n
cated at
ot be
cated at
P in
nno
P in
This document
sub
no
sub
Chang
nt ca
Chang
Sec
me
Sec
port 


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 172 of 353
Following assessments have been added.

Blood sample for the following laboratory parameters:

Serum biomarkers 
Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/ or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
Change #38.
Section 8.3.6 Visit 13 (Week 10/Day 64) [UCB7665 4mg/kg]/ Visit 11 (Week 8/Day 50) 
[UCB7665 7mg/kg]
Following assessments have been added.

Blood sample for the following laboratory parameters:

Serum biomarkers 
Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/ or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
Change #39.
Section 8.3.7 Visit 14 (Week 11/Day 71) [UCB7665 4mg/kg]/ Visit 12 (Week 9/Day 57) 
[UCB7665 7mg/kg]
Following assessments have been added.

Blood sample for the following laboratory parameters:

Serum biomarkers 

Serum BAFF levels
Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/ or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
REDACTED COPY 
d as:
OPY
d as:
erienc
D CO
erienc
oscop
TED
oscop
D
MRI
ACT
MRI a
T
a
vestiga
EDA
vestiga
Y
rt any marketing authorization application and any extensions or variations thereof.
d if 
va
d if 
formin
or v
formin
ek 8/D
y ext
ek 8/D
ces sev
ation
ces sev
y). Add
riza
y). Add
nd/ or 
thor
nd/ or 
ator, co
auth
ator, co
1/Day
y ma
1/Day 7
a
7
y
a
y
cannot be used to suppo
/kg]
any
/kg]
ave bee
port 
ave bee
the fol
supp
the fol
marke
d to
marke
m BAF
use
m BAF
ion for
ot be
ion for
Headac
ann
Headac
This document ca
neur
nt ca
neur
in
nt
in
pli


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 173 of 353
Change #40.
Section 8.3.8 End-of-Study Visit: Visit 15 (Week 13/Day 85) [UCB7665 4mg/kg]/ Visit 13 
(Week 11/Day 71) [UCB7665 7mg/kg]
Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/ or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
Change #41.
Section 8.5
Unscheduled Visit
Description for headache questionnaire was updated as:

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/ or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
Change #42.
Section 10.2
Pharmacodynamic variables
Bullet 3

ITP-specific autoantibody concentration
Has been changed to:

Serum ITP-specific autoantibody
Change #43.
Section 11 ASSESSMENT OF OTHER IMMUNOLOGICAL VARIABLES
For all immunological assessments, blood samples will be collected predose (at dosing visits) by
qualified site personnel at the same time that samples are collected for standard clinical 
laboratory. The time and date of the blood draws will be recorded in the eCRF. The following 
immunological assessments will be performed according to the schedule of study assessments 
(Section 5.2).
REDACTED COPY 
Y
ntratio
RE
ntratio
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
if 
va
if 
orming
or va
orming
hes, fo
and 
hes, fo
other 
n a
other d
F colle
ation
F colle
the loc
plica
the loc
on
ng
on
to:
ppo
to:
ific aut
to su
ific aut
hange
t can
hange
Secti
men
Secti
F
m
F
be us
nnot b


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 174 of 353

Serum immunoglobulin concentration over time

IgA

IgE

IgM

Serum complement levels over time

C3

C3a

C4

C5a

Plasma anti-UCB7665 antibodies/IgG depletion assay 

Cytokines
Cytokine samples will be taken at Baseline Visit for all subjects. At subsequent visits, cytokine 
samples will be taken only when the subject experiences infusion reactions.
Has been changed to:
For all immunological assessments, blood samples will be collected predose (at dosing visits) by
qualified site personnel at the same time that samples are collected for standard clinical 
laboratory. The time and date of the blood draws will be recorded in the eCRF. The following 
immunological assessments will be performed according to the schedule of study assessments 
(Section 5.2).

Serum immunoglobulin concentration over time

IgA

IgE

IgM

Serum complement levels over time

C3

C4

Plasma complement levels over time

C3a

C5a

Serum biomarkers levels over time
REDACTED COPY 
s will b
COP
s will b
mples
ED C
mples
raws w
CTED
raws w
rmed a
ACT
rmed a
atio
R
atio
be used to support any marketing authorization application and any extensions or variations thereof.
t subse
on a
t subse
n react
ation
n react
be coll
on ap
be coll
s are co
ation
s are co
will be 
oriza
will be 
accord
thor
accord
on over
eting
on over
t levels
supp
t levels
This document cannot be
a
t
a comp
t be 
comp
C3a
nno
C3a

t c


me



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 175 of 353

Serum BAFF levels

Plasma anti-UCB7665 antibodies/IgG depletion assay 

Cytokines

Cytokine samples will be taken at Baseline Visit for all subjects. At subsequent visits, 
cytokine samples will be taken only when the subject experiences infusion reactions. 
Change #44.
Section 12.1.1
Definition of adverse event
Following wordings have been added to paragraph 4:
Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or more bleeding events 
should be reported as AEs.
Change #45.
Section 12.1.3
Description of adverse events
Information of AE evaluation was added:
For recording an AE, CTCAE will be used, and only if it is impossible to assess severity using 
CTCAE, then AE intensity will be assessed using a scale of mild, moderate, or severe.
Change #46.
Section 12.1.6 Pregnancy
Paragraph 1 and sections onward, changed the name of UCB safety reporting department and its 
abbreviation from UCB’s Drug Safety (DS) into UCB’s Patient Safety (PS). 
If an investigator is notified that a subject has become pregnant after the first intake of any IMP, 
the investigator must immediately notify UCB’s Drug Safety (DS) department by providing the 
completed Pregnancy Report and Outcome form (for contact details see Serious Adverse Event 
reporting information at the beginning of this protocol). The subject should be withdrawn from 
the study as soon as pregnancy is known (by positive pregnancy test), and the following should 
be completed:
Has been changed to:
If an investigator is notified that a subject has become pregnant after the first intake of any IMP, 
the investigator must immediately notify UCB’s Patient Safety (PS) department by providing the 
completed Pregnancy Report and Outcome form (for contact details see Serious Adverse Event 
reporting information at the beginning of this protocol). The subject should be withdrawn from 
the study as soon as pregnancy is known (by positive pregnancy test), and the following should 
be completed:
REDACTED COPY 
only
D CO
only i
CO
i
y
CO
y
using a
TED
using a
t be used to support any marketing authorization application and any extensions or variations thereof.
more b
d any
more b
if it is i
ation
if it is i
a scale 
rizat
a scale 
nged th
rketi
nged th
fet
ma
fety (D
mark
y (D
at a sub
any 
at a sub
diately
rt an
diately
n
eport an
ppor
eport an
at the b
supp
at the b
s pregn
to s
s pregn
n chan
be us
n chan
This document canno
vestiga
not b
vestiga
nvestig
ann
nvestig
omplete
nt ca
omplete
report
ment
report
the
m
the


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 176 of 353
Change #47.
Suspected transmission of an infectious agent via a medicinal product was added as Section 
12.1.7 and subsequent section numbers were changed accordingly. 
Change #48.
Section 12.1.9 Hypersensitivity and adverse reactions
Paragraph 2
In case of occurrence of a hypersensitivity reaction (not determined by the investigator to be a 
minor local reaction at the infusion site, such as minimal itching) and depending upon its 
severity, appropriate countermeasures will immediately be taken by the investigator. The 
cytokine samples must be taken for infusion reactions.
Has been changed to:
Section 12.1.10
Hypersensitivity and adverse reactions
In case of occurrence of a hypersensitivity reaction (except for local injection site reaction) and 
depending upon its severity, appropriate countermeasures will immediately be taken by the 
investigator. The cytokine samples must be taken for infusion reactions.
Change #49.
Section 12.1.10
Management of severe headache
Paragraph 2, second sentence
Further workup will be performed (if indicated) at the discretion of the investigator and may
include a CT scan and a LP for CSF collection, considering the local guidelines for performing 
LP in patients with ITP.
Has been changed to:
Section 12.1.11
Management of severe headache
Further workup will be performed at the discretion of the investigator and may include eg. a CT 
scan, MRI and/or a LP for CSF collection, considering the local guidelines for performing LP in 
patients with ITP.
Change #50.
Section 12.3
Adverse events of special interest
Paragraph 3, first sentence
Potential Hy’s law, defined as ≥3xULN ALT with co-existing ≥2xULN bilirubin in the absence 
of  ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, must always 
be reported to UCB as an AE of special interest and a serious unexpected AE (ie, without waiting 
for any additional etiologic investigations to have been concluded).
Has been changed to:
Potential Hy’s law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN bilirubin in the 
absence of  ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, must 
REDACTED COPY 
he
C
he
dicated
DAC
dicated
ollecti
REDA
ollecti
not be used to support any marketing authorization application and any extensions or variations thereof.
be
or
be a 
r v
a 
ts 
s
ts 
The 
ions
The 
injectio
and
injectio
mediate
tion a
mediate
eaction
catio
eaction
d) at th
utho
d) at th
ion, co
g au
ion, co
of sev
ny m
of sev
formed 
rt an
formed 
or CSF 
ppor
or CSF 
Adve
use
Adve
h 3
ot b
h 3, firs
be
, firs
This document can
ntial Hy
anno
ntial Hy
≥2xU
t ca
≥2xU
be rep
ment 
be rep
for
me
for


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 177 of 353
always be reported to UCB as an AE of special interest (ie, without waiting for any additional 
etiologic investigations to have been concluded).
Change #51.
Section 12.7
Laboratory measurements
Paragraphs 1 and 2, first sentence
Blood and urine specimens for routine assay of hematology including coagulation parameters, 
clinical chemistry, and urinalysis testing as well as pregnancy testing will be performed 
according to the Schedule of assessments (Section 5.2) to monitor the safety of subjects.
Prior to randomization, 2 platelet samples will be taken.
Has been changed to:
Blood and urine specimens for routine assay of hematology including coagulation parameters, 
clinical chemistry, urinalysis testing, and pregnancy testing as well as serology testing will be 
performed according to the Schedule of assessments (Section 5.2) to monitor the safety of 
subjects.
Prior to dosing at Visit 2, 2 platelet samples will be taken.
Change #52.
Section 12.7
Laboratory measurements
Table 12-2 has been updated to include serological test
REDACTED COPY 
ogical 
TED
ogical 
rization application and any extensions or variations thereof.
lation p
y ex
lation p
ology
d any
ology t
y
t
y
y
y
monitor 
nd a
monitor 
This document cannot be used to support any marketing authoriz
l test
rizat
l test


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 178 of 353
Table 12-2: Laboratory measurements
Hematology
Chemistry
Coagulation 
parameters
Urinalysis
Pregnancy test
Basophilsa
Calcium
INR 
pH
Urineb HCG
Eosinophilsa
Phosphate
Prothrombin time
Protein
Serum
c HCG
Neutrophilsa
Chloride
aPTT
Creatinine 
Lymphocytesa
Magnesium
Fibrinogen
Glucose
Others
Monocytesa
Potassium
Ketones
HbA1c
Hematocrit
Sodium
Urobilinogen
HIV
Hemoglobin
BUN
Bilirubin
Hepatitis B
(HBsAg, anti-HBs,
anti-HBc)
Platelet count
AST
Blood
Hepatitis C
(anti-HCV)
RBC count
ALT
Nitrite
WBC count
GGT
Albumin
B- and T-
Lymphocyte count
Total bilirubin 
Leucocytes
Direct bilirubin (if 
indicated)
LDH
Total cholesterol
Triglycerides
ALP
Total protein
Albumin
α1-globulin, 
α2-globulin, and 
β-globulin
Creatinine
hs-CRP
Amylase
ALP=alkaline phosphatase; ALT=alanine aminotransferase; anti-HBc=hepatitis B core antibody; anti-HBs=hepatitis B surface 
antibody; anti-HCV=hepatitis C virus antibody; aPTT=activated partial thromboplastin time; AST=aspartate aminotransferase; 
BUN=blood urea nitrogen;GGT=gamma-glutamyltransferase; HbA1c=glycosylated hemoglobin; HBsAg=hepatitis B surface 
antigen; HCG=human chorionic gonadotropin; HIV=human immunodeficiency virus; hs-CRP=high-sensitivity C-reactive 
protein; INR=International Normalized Ratio; LDH=lactate dehydrogenase; RBC=red blood cell; WBC=white blood cell 
a Absolute as well as percentages for the differential leucocyte counts will be performed.
b Urine pregnancy test will be performed predose on dosing days and at End-of-Study Visit.
c Serum pregnancy test is done at Visit 1 (Screening) and to confirm results of positive urine test if applicable.
REDACTED COPY 
Y
CO
CT
RE
RE
RE
RE
RE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ari
ar
ar
a
A1c
ns
A1c
o
HIV
nsio
HIV
ion
Hepa
exte
Hepa
(HBs
ny e
(HBs
en
a
od
n
od
nd
Nitr
ica
Nitr
at
A
p
A
pp
n a
n
ori
g a
et
rk
des
y m
des
ma
L
t
LP
t a
P
ny
Total pro
ppo
Total pro
rt
A
up
A
upp
to
ed
be
no
ca
me
AL
e
AL


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 179 of 353
Change #53.
Section 12.7.1
Section for Evaluation of PDILI was added.
Change #54.
Section 12.8.3
Body weight
Subject’s body weight will be determined at Screening and at the End-of-Study Visit. 
Has been changed to:
Section 12.8.3
Body weight and height
Subject’s body weight will be determined at Screening and at the End-of-Study Visit. Height will 
be measured at Screening only.
Change #55.
Section 14.1
Definition of analysis sets
Safety Set (SS):
The SS will consist of all randomized subjects who have received at least 1 infusion (full or 
partial infusion) of IMP and will be used for the demographics and analysis of safety data.
Has been changed to:
Safety Set (SS):
The SS will consist of all subjects who have received at least 1 infusion (full or partial infusion) 
of IMP and will be used for the demographics and analysis of safety data.
Change #56.
Section 14.2
General statistical considerations
Paragraph 1, third sentence
Analyses will be performed by dose arm and overall, unless otherwise stated. In the event that 
the number of infusions in the planned dose arms (3x7mg/kg and 5x4mg/kg) are modified 
following review by the DMC, the data will be summarized based on the actual dose arms 
completing the study. 
Has been changed to:
Analyses will be performed by dose arm, unless otherwise stated. In the event that the number of 
infusions in the planned dose arms (3x7mg/kg and 5x4mg/kg) are modified following review by 
the DMC, the data will be summarized based on the actual dose arms completing the study. 
Change #57.
Section 14.3.2
Other safety analyses
Paragraph 1, third sentence
Adverse events will be categorized by intensity (mild/moderate/severe) and severity according to 
the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grading.
REDACTED COPY 
e receiv
CTED
e receiv
phics a
DACT
phics a
annot be used to support any marketing authorization application and any extensions or variations thereof.
. Heigh
ions
. Heigh
d at lea
ation
d at lea
s and an
licat
s and an
ived at 
oriza
ived at 
and an
utho
and an
iderati
keti
iderati
y dose 
any
dose 
y
the pla
ort a
the pla
e DMC
uppo
e DMC
y.
o
y.
ange
ed to
anged
o
d
ll be pe
e us
ll be pe
in the 
t be
in the 
MC, the
nnot 
MC, the
This document c
hange
t can
hange
Secti
men
Secti
P


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 180 of 353
Has been changed to:
Adverse events will be categorized by severity according to the CTCAE version 4.03 grading. In 
case the CTCAE grading is not available, the intensity (mild/moderate/severe) will be utilized.
Change #58.
Section 14.3.2
Other safety analyses
Paragraph 2, second sentence
For categorized values according to the reference range, shift tables from Baseline to each post 
Baseline time point will be presented.
Has been changed to:
For categorized values according to the reference range, shift tables from Baseline to each post 
Baseline time point will be presented for selected variables to be defined in the SAP.
Change #59.
Section 14.3.2
Other safety analyses
Paragraph 3, last sentence
Descriptive statistics will be presented for ECG value and changes from Baseline over time.
Has been changed to:
Descriptive statistics will be presented for ECG value and changes from Baseline over time
based on the mean of the triplicate assessments at each time point.
Change #60.
Section 14.3.2
Other safety analyses
Paragraph 4, last sentence
Measured values and changes from Baseline will be summarized for all subjects by time point.
Has been changed to:
Measured values and changes from Baseline will be summarized by time point.
Change #61.
Section 14.3.2
Other safety analyses
Paragraph 6
Safety analyses will be presented by dose arms and overall.
Has been changed to:
Safety analyses will be presented by dose arm.
Change #62.
Section 14.4.1
Efficacy analyses
Paragraph 6
REDACTED COPY
and 
PY 
and 
CG val
TED
CG val
ments a
ACT
ments a
e
R
e
cannot be used to support any marketing authorization application and any extensions or variations thereof.
post 
or va
post 
line to 
exten
line to 
he SA
y ex
he SA
changes
ppli
changes
lue and
rizat
lue and
at each
thori
at each
s
from B
any m
from B
o:
o
o:
change
supp
change
O
e
O
t
6
t b
6
y anal
nno
anal
y y y
This document
y
o
y
Has be
nt ca
Has be
Safe
me
Safe


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 181 of 353
The results from the ITP bleeding score will be summarized at each time point and will include 
the scores for each of the three major domains: skin (S), visible mucosae (M), and organs (O) 
and the overall gradation of severity (SMOG).
Has been changed to:
The results from the ITP bleeding scale will be summarized at each time point and will include 
the grades for each of the 3 major domains: skin (S), visible mucosae (M), and organs (O).
Change #63.
Section 14.4.2
Pharmacokinetic analyses
Paragraph 2, third sentence
Descriptive statistics of concentrations will be calculated if at least one third of the individual 
data points are quantifiable (≥LLOQ).
Has been changed to:
Descriptive statistics of concentrations will be calculated if at least two thirds of the individual 
data points are quantifiable (≥LLOQ).
Change #64.
Section 14.4.3
Pharmacodynamic analyses
Paragraph 2
The PD variables will include ITP-specific autoantibody concentrations 
, total IgG, and IgG subclasses. In addition, for total IgG, the maximum change 
from Baseline will be evaluated and summarized. Figures of mean values over time and changes 
from Baseline will be presented.
Has been changed to:
The PD variables will include ITP-specific autoantibodies
total IgG, and IgG subclasses. In addition, for total IgG, the maximum decrease from Baseline 
and minimum value will be evaluated and summarized. Figures of mean values over time and 
changes from Baseline will be presented.
Change #65.
Section 14.4.4
Immunologic variables
Paragraphs 1 and 2
All immunologic variables including concentrations of immunoglobulins (IgA, IgE, and IgM) 
and serum complement parameters (C3, C3a, C4, and C5a) will be summarized by dose arm over 
time (including changes from Baseline) using descriptive statistics. Figures of mean values over 
time and changes from Baseline will be presented.
The results and changes from Baseline for the measurement of ADA will be summarized by dose 
arm; figures will also be presented.
REDACTED COPY 
autoan
CTE
autoan
sses. In
DAC
sses. In
umma
REDA
umma
ot be used to support any marketing authorization application and any extensions or variations thereof.
he indi
tens
he indi
wo third
and
wo third
ntibody
oriza
ntibody
n addit
utho
n addit
arized. 
g au
arized. 
TP
y
TP-
y
-spec
y m
spec
s. I
t a
s. In ad
any
n ad
be evalu
port 
be evalu
will be
uppo
will be
Im
ed
Im
1 and
be u
1 and
This document cann
mmunol
nnot
mmunol
d serum
can
d serum
time (in
ent c
time (in
time
men
time


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 182 of 353
Has been changed to:
All immunologic variables including concentrations of immunoglobulins (IgA, IgE, and IgM), 
serum (C3 and C4) and plasma (C3a and C5a) complement levels, serum biomarkers 
 
, serum BAFF levels and the results of 
the IgG depletion assay will be summarized by dose arm over time (including changes from 
Baseline) using descriptive statistics. Figures of mean values over time and changes from 
Baseline may be presented.
The ADA status (negative/positive) and changes in relative mass units from Baseline will be 
summarized by dose arm; figures will also be presented.
Change #66.
Section 14.4.5.1
Subject disposition
The number of subjects who were screened, enrolled into the study, and completed/prematurely 
discontinued the study, as well as the reason for discontinuation, will be presented using 
frequency counts and percentages.
Has been changed to:
The number of subjects who were screened, dosed and completed/prematurely discontinued the 
study, as well as the reason for discontinuation, will be presented using frequency counts and 
percentages.
Change #67.
Section 14.4.5.3
Baseline disease characteristics
Definition of complement levels were updated as:

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a).
Change #68.
Section 14.7
Planned interim analysis and data monitoring
Paragraph 1
A DMC will be convened to monitor emergent safety and immunogenicity data during the study.
The DMC will comprise at least 1 external expert, the UCB study physician, the UCB DS 
representative, and a biostatistician. Safety related decisions must be made with the agreement of 
at least the external expert, the UCB study physician, and the UCB DS representative. Decisions 
involving reductions in dose regimen must also have the agreement of the UCB statistician and 
UCB pharmacometrician.
Has been changed to:
A DMC will be convened to monitor emergent safety data during the study. The DMC will 
comprise at least 1 external expert, the UCB study physician, the UCB PS representative, and a 
biostatistician. Safety related decisions must be made with the agreement of at least the external 
expert, the UCB study physician, and the UCB PS representative. Decisions involving reductions 
in dose regimen must also have the agreement of the UCB statistician and UCB 
pharmacometrician.
REDACTED COPY
be pre
OPY 
be pre
terist
ACT
terist
e upda
RED
e upda
R
annot be used to support any marketing authorization application and any extensions or variations thereof.
e
mpleted
ny ex
mpleted
present
d any
present
eted/pr
plica
eted/pr
esented 
appl
esented 
ics
tho
ics
ated as:
g au
ated as:
and C4
ketin
and C4
m anal
any 
m analy
y
y
ened to
supp
ened to
mprise a
to s
mprise a
and a b
sed t
and a b
xternal 
use
xternal 
reducti
t be 
reducti
harmac
not 
harmac
This document c
as bee
t can
as bee
A DM
ment
A DM
co
m
co


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 183 of 353
Change #69.
Section 14.7
Planned interim analysis and data monitoring
Paragraph 4, last sentence
If the new dose arm will be initiated and if the 5x4mg/kg will be continued, new subjects will be 
randomized to 1 of the 2 dose arms in an allocation ratio of 1:1 (randomization will stop, once 15 
subjects are treated with UCB7665 4mg/kg dose).
Has been changed to:
If the new dose arm will be initiated and if the 5x4mg/kg will be continued, new subjects will be 
randomized to 1 of the 2 dose arms in an allocation ratio of 1:1 (Once 15 subjects are in the 
4mg/kg group, the remaining subjects will not be randomized. They will be allocated to the 
7mg/kg group).
Change #70.
Section 14.7
Planned interim analysis and data monitoring
Paragraph 9, second sentence
If needed, subsequent DMC meetings will take place and the frequency will be detailed in the 
DMC charter.
Has been changed to:
If needed, subsequent DMC meetings may take place and the frequency will be detailed in the 
DMC charter.
Change #71.
Section 17
REFERENCES
New reference added
Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009.
Change #72.
REDACTED COPY 
ke pla
TED
ke pla
to support any marketing authorization application and any extensions or variations thereof.
ts will 
s or
ts will 
e in the
ions
e in the
ted to 
nsi
ted to 
frequen
licat
frequen
ace and
rizat
ace and
n. Guid
any 
n. Guid
t of He
rt an
t of He
logics 
ppor
logics 
This document cannot be used t
ed to
be use


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 185 of 353
18.8
Protocol Amendment 2 (not implemented)
Rationale for the amendment
The primary purpose of this substantial amendment is to include an additional cohort to explore 
the PD effect of UCB7665 administered as an sc infusion in subjects with ITP following a more 
frequent dosing regimen (twice weekly).
During this amendment, additional exploratory genomic (DNA and RNA) analyses have been 
added as an optional substudy to evaluate the genomic components of ITP to understand the 
molecular etiology, progression, and treatment of the disease.
UCB considers that the required period for contraceptive use and pregnancy testing can be 
reduced from 3 months to 2 months after the final dose in female subjects due to nonlinear 
kinetics of UCB7665. Following single dose administration at the highest dose tested (7mg/kg) 
no drug was detectable in plasma after 5 days (target mediated disposition). Based on short 
systemic exposure of UCB7665, genotoxicity being not a class effect of monoclonal antibodies, 
and extending contraceptive and pregnancy testing by at least 30 days beyond the end of relevant 
systemic exposure, UCB considers that reducing the required period for contraceptive use and 
pregnancy testing from 3 months to 2 months after the final dose is still adequate to safeguard 
the subjects against possible effects of UCB7665 on human pregnancy.
Minor clarifications were added as necessary, and typographical errors or omissions were 
corrected.
Modifications and changes
Global changes
The following changes were made throughout the protocol:

Addition of a new dose arm 4mg/kg administered twice per week
REDACTED COPY 
ple
Y
ple
ment i
ED C
ment i
an sc i
CTE
an sc i
xplora
RED
xplora
R
ed to support any marketing authorization application and any extensions or variations thereof.
ented
plica
ented
is to 
zatio
is to in
o
in
infusio
oriz
infusio
atory
ng a
atory g
a
g
y
a
y
ate the 
keting
ate the 
d treatm
arke
d treatm
d period
ny m
d period
months
t any
months
lowing
port 
lowing
in plas
uppo
in plas
f UCB
o su
f UCB
ntracep
d to
ntracep
This document cannot be us
sure, U
used
sure, U
testing 
be us
testing 
ects aga
ot be
ects aga
or clari
ann
or clari
orrecte
t ca
orrecte
Mo
men
Mo
tion and any extensions or variations t


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 186 of 353

Additional exploratory genomic analyses added as an optional substudy
Specific changes
Change #1
STUDY CONTACT INFORMATION
Sponsor Study Physician
Name:
, MD
Address:
UCB BIOSCIENCES GmbH
Alfred-Nobel-Straße 10
40789 Monheim 
GERMANY
Phone:
 (mobile)
Fax:
Has been changed to:
Name:
, MD
Address:
UCB BIOSCIENCES Inc.
8010 Arco Corporation Drive, Suite 175
Raleigh
NC 27617, USA
Phone:
Fax:
Change #2
REDACTED COPY 
C
NCES 
ACT
NCES 
orpora
REDA
orpora
TE
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
 o
y e
a
ati
io
Inc.
thor
Inc.
rat
g
ration
aut
ion D
t
D
USA
arke
USA
riz
ma
ny
or
ny ma
ort any


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 187 of 353
STUDY CONTACT INFORMATION
Clinical Project Manager
Name:
Address:
UCB Biopharma SPRL
Allée de la Recherche 60
B-1070 Brussels
BELGIUM
Phone:
Fax:
Has been changed to:
Name:
Address:
UCB BioSciences GmbH
Alfred-Nobel-Strasse 10
40789 Monheim
GERMANY
Phone:
Fax:
Change #2
LIST OF ABBREVIATIONS
ICH
International Conference on Harmonisation
Has been changed to:
ICH
International Council for Harmonisation
Change #3
LIST OF ABBREVIATIONS
The following additions were made to the list of abbreviations:
AUEC
area under the effect curve
DNA
deoxyribonucleic acid
EOS
End of Study
IGRA
interferon-gamma release assay
LTB
latent tuberculosis
mRNA
messenger ribonucleic acid
CTED COPY 
CO
ED
E
REDAC
AC
ACTE
ort any marketing authorization application and any extensions or variations thereof.
o
 o
on
ten
ny
nd
n
za
tho
al Conf
mark
al Conf
This document cannot be used to suppo
nternati
por
nternati
REVIA
ed t
REVIA
ng add
be us
ng add
NA
ca
NA
EOS
ment
EOS
IG
m
IG


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 188 of 353
miRNA
micro ribonucleic acid
PD-PPS
Pharmacodynamic Per Protocol Set
RNA
ribonucleic acid
Change #4
Section 1 SUMMARY
Paragraph #3:
TP0001 is a Phase 2, multicenter, open-label, multiple-dose, 2-dose-arm study to evaluate the 
safety, tolerability, and efficacy of UCB7665 administered as subcutaneous (sc) doses of 4mg/kg 
or 7mg/kg, in subjects ≥18 years of age with persistent (>3 months up to 12 months after 
diagnosis) or chronic (more than 12 months after diagnosis) primary ITP. 
Has been changed to:
TP0001 is a Phase 2, multicenter, open-label, multiple-dose, multiple-arm study to evaluate the 
safety, tolerability, and efficacy of UCB7665 administered as subcutaneous (sc) doses of 4mg/kg 
or 7mg/kg, in subjects ≥18 years of age with persistent (>3 months up to 12 months after 
diagnosis) or chronic (more than 12 months after diagnosis) primary ITP.
Change #5
Section 1 SUMMARY
Paragraph #4:
The study is planned to be conducted at approximately 25 sites in Europe and Australia. A total 
of 30 subjects are planned to enter the Dosing Period in the study. The maximum study duration 
for study participation for an individual subject is approximately 16 weeks.
Has been changed to:
The study is planned to be conducted at approximately 30 sites in Europe and Australia. A total 
of 36 subjects are planned to enter the Dosing Period in the study. The maximum study duration 
for study participation for an individual subject is approximately 16 weeks.
Change #6
Section 1 SUMMARY
Paragraph #5:
The study will evaluate 2 dose arms of UCB7665. Subjects in Dose Arm 1 will receive 5 doses 
of UCB7665 4mg/kg sc at 1 week intervals and subjects in Dose Arm 2 will receive 3 doses of 
UCB7665 7mg/kg sc at 1 week intervals.
Has been changed to:
The study is intended to evaluate 3 dose arms of UCB7665. Subjects in Dose Arm 1 will receive 
5 doses of UCB7665 4mg/kg sc at 1 week intervals, subjects in Dose Arm 2 will receive 3 doses 
of UCB7665 7mg/kg sc at 1 week intervals, and subjects in Dose Arm 3 will receive 5 doses of 
UCB7665 4mg/kg sc at 3 to 4 day intervals (ie, twice per week over approximately 2 weeks). 
REDACTED COPY 
appro
DAC
appro
e Dosi
RED
e Dosi
al
R
al
be used to support any marketing authorization application and any extensions or variations thereof.
e the
or 
e the
s of 4m
ions 
s of 4m
hs after 
nsio
hs after 
arm stu
nd a
arm stu
taneou
n an
taneou
hs up to
tion
hs up to
rimary
licat
rimary
oximate
auth
oximate
sing Per
ng au
sing Per
subjec
eting
subjec
ducted 
ny m
ducted 
o enter 
rt an
o enter 
r an ind
pport
r an ind
MARY
ed to
MARY
5
e
5
annot
:
e
:
dy
ot
dy will 
ot b
will 
y
ot
y
CB7665
anno
CB7665
This document c
CB766
t can
CB766
Has
men
Has
T


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 189 of 353
Change #7
Section 1 SUMMARY
Paragraph #6:
The study consists of a Screening Period (up to 4 weeks), Dosing Period of 2 to 4 weeks, and an 
Observation Period of 8 weeks. The Screening Visit corresponds to Visit 1 of the study. The 
Dosing Period will commence at Visit 2 (Baseline Visit), with dosing visits scheduled at weekly 
intervals. The Observation Period will start after the final dose administration with a visit 
scheduled 3 days after the final dose and weekly thereafter (ie, weekly after final dose) for a 
period of 8 weeks. The End-of-Study Visit will be performed at the end of the Observation 
Period, ie, 8 weeks after the final dose of investigational medicinal product (IMP).
Has been changed to:
The study consists of a Screening Period (up to 4 weeks), Dosing Period of 2 to 4 weeks, and an 
Observation Period of 8 weeks. The Screening Visit corresponds to Visit 1 of the study. The 
Dosing Period will commence at Visit 2 (Baseline Visit), with dosing visits scheduled at weekly 
or twice weekly intervals. The Observation Period will start after the final dose administration 
with a visit scheduled 3 days after the final dose and weekly thereafter (ie, weekly after final 
dose) for a period of 8 weeks. The End-of-Study Visit will be performed at the end of the 
Observation Period, ie, 8 weeks after the final dose of investigational medicinal product (IMP).
Change #8
Section 1 SUMMARY
Paragraph #7:
The first 6 subjects will be enrolled in Dose Arm 1 only. While recruitment is ongoing, safety
data for the first 3 subjects up to 7 days after the final dose will be reviewed by a Data 
Monitoring Committee (DMC). During a second DMC meeting, safety data for the first 6 
subjects up to 7 days after the final dose will be reviewed. Following this review, the DMC will 
make a decision on whether to open Dose Arm 2 for enrollment. Once the DMC has approved 
initiation of Dose Arm 2, subsequent subjects will be randomized to 1 of the 2 dose arms using 
an interactive voice/web response system (IXRS). The aim is to have 15 subjects in each dose 
arm. The DMC may also decide to reduce the number of doses in each of the dose arms based on 
review of data during the study. Safety data will also be reviewed on an ongoing basis during the 
study so as to continuously evaluate the safety of subjects.
Has been changed to:
The first 6 subjects will be enrolled in Dose Arm 1 only. While recruitment is ongoing, safety
data for the first 3 subjects up to 7 days after the final dose of the third subject will be reviewed 
by the Data Monitoring Committee (DMC). During a second DMC meeting, all available safety 
data up to cut off date defined as 7 days after the final dose of the sixth subject will be reviewed. 
Following this review, the DMC will make a decision on whether to open Dose Arm 2 for 
enrollment. Once the DMC has approved initiation of Dose Arm 2, the subsequent subjects will 
be randomly assigned in 1:1 ratio to either Dose Arm 1 or Dose Arm 2 using an interactive 
voice/web response system (IXRS). Once 15 subjects are enrolled in Dose Arm 1 and safety data 
review of at least 3 subjects in Dose Arm 2 is done, the subsequent subjects will be randomly
REDACTED COPY
f inve
OPY 
f inve
n Do
RE
n Do
t any marketing authorization application and any extensions or variations thereof.
y
r a
or
r a
tion
ns o
tion
2 to 4 w
ny ex
2 to 4 w
1 of th
d any
1 of th
visits s
and 
visits s
he final
on a
he final
reafter 
atio
reafter 
e perfor
plica
e perfor
estigati
app
estigati
ose Arm
ing a
ose Arm
s after 
ketin
s after 
ring a s
marke
ring a s
nal dose
y ma
nal dose
o open 
any
o open 
t cannot be used to suppor
ubsequ
ort a
ubsequ
b respon
ppo
b respon
also de
sup
also de
ring the
d to 
ring the
ontinu
sed 
ontinu
n cha
be u
n cha
rst 6 su
not 
rst 6 su
a for th
cann
a for th
This document c
by
n
by the
nt c
the D
data 
men
data 
Fo
m
Fo


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 190 of 353
assigned in 1:1 ratio to either Dose Arm 2 or Dose Arm 3 using an IXRS. Once 15 subjects are 
enrolled in the Dose Arm 2 or 6 subjects are enrolled in Dose Arm 3, the respective dose arm 
will be closed. The aim is to have 15 subjects in Dose Arms 1 and 2 and 6 subjects in Dose Arm 
3. The DMC may also decide to reduce the number of doses in each of the dose arms based on 
review of data during the study. Safety data will also be reviewed on an ongoing basis during the 
study so as to continuously evaluate the safety of subjects. 
Change #9
Section 1 SUMMARY
Paragraph #13:
The following efficacy variables will be assessed: Response (platelet count ≥30x109/L and at 
least 2-fold increase of the Baseline count) during the study and by visit; Complete Response 
(platelet count ≥100x109/L) during the study and by visit; platelet count ≥50x109/L during the 
study and by visit; the maximum value and maximum increase from Baseline in platelet count 
during the study; value and change from Baseline in platelet count over time; time to Response 
(time from starting treatment to achievement of Response); time to Complete Response (time 
from starting treatment to achievement of Complete Response); time to achieving platelet count 
≥50x109/L; duration of Response (measured from achievement of Response to loss of Response 
[defined as platelet count below 30x109/L or less than 2-fold increase of Baseline platelet 
count]); duration of Complete Response (measured from achievement of Complete Response to 
loss of Complete Response [defined as platelet count below 100x109/L]); duration of platelet 
count ≥50x109/L (measured from achievement of platelet count ≥50x109/L to reduction of 
platelet count below 50x109/L); ITP bleeding score over time; and Patient Reported Outcome 
(PRO), ie, Neurological Fatigue Index for Multiple Sclerosis (NFI-MS) summary score over 
time. Plasma concentration of UCB7665 over time will be assessed as the PK variable. The PD 
variables are minimum value and maximum decrease in total IgG concentration during the study;
IgG subclass concentrations; and ITP-specific autoantibody
in serum over time. Other immunological variables to be evaluated are total IgA, IgE, and IgM 
levels; serum (C3 and C4) and plasma (C3a and C5a) complement levels; ADA status 
(negative/positive) and relative mass units; serum biomarkers 
B cell activating factor (BAFF) levels and the results of the IgG depletion assay; and cytokines 
(for subjects experiencing infusion reactions). Additional exploratory biomarkers may be 
investigated if needed using the samples already available.
Has been changed to:
The following efficacy variables will be assessed: Response (platelet count ≥30x109/L and at 
least 2-fold increase of the Baseline count) during the study and by visit; Complete Response 
(platelet count ≥100x109/L) during the study and by visit; platelet count ≥50x109/L during the 
study and by visit; the maximum value and maximum increase from Baseline in platelet count 
during the study; value and change from Baseline in platelet count over time; Baseline-corrected 
area under the effect curve (AUEC) for platelet count; time to Response (time from starting 
treatment to achievement of Response); time to Complete Response (time from starting treatment 
to achievement of Complete Response); time to achieving platelet count ≥50x109/L; duration of 
Response (measured from achievement of Response to loss of Response [defined as platelet 
REDACTED COPY
2
Y
2-
Y
-fo
Y 
fo
from 
OPY
from 
ount b
D CO
ount b
nt of pl
TED 
nt of pl
ing sco
ACTE
ing sco
for Mu
EDAC
for Mu
665 ov
RED
665 ov
xim
R
xim
ort any marketing authorization application and any extensions or variations thereof.
/L
sio
/L and
sion
and
sio
ete Res
xtens
ete Res
10
e
109
ex
9/L
ext
/L d
t
d
t
ine in p
any 
ine in p
time; t
nd a
time; t
Comple
n and
Comple
me t
tion
me to a
n 
o a
t of Res
icati
t of Res
d increa
pplic
d increa
achiev
n app
achiev
below 
tion 
below 
latelet 
izat
latelet 
ore ove
horiz
ore ove
ultiple 
auth
ultiple 
ver tim
g a
ver tim
mum
eting
mum d
g
d
P
a
P-speci
arke
speci
ologica
ma
ologica
plasma
any 
plasma
tive ma
ort a
tive ma
supp
r (BAF
supp
r (BAF
nt cannot be used to
iencing
to s
iencing
eeded u
ed t
eeded u
n chan
be us
n chan
lowing
not b
lowing
2
a
2-
n
-fold
ann
fold
platelet 
nt ca
platelet 
This documen
study
ment
study
du
m
du
pport


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 191 of 353
count below 30x109/L or less than 2-fold increase of Baseline platelet count]); duration of 
Complete Response (measured from achievement of Complete Response to loss of Complete 
Response [defined as platelet count below 100x109/L]); duration of platelet count ≥50x109/L
(measured from achievement of platelet count ≥50x109/L to reduction of platelet count below 
50x109/L); Clinical Response (defined as platelet count ≥30x109/L <100x109/L with at least 
2-fold increase from Baseline value and absence of bleeding); time to Clinical Response (time 
from starting treatment to achievement of Clinical Response); duration of Clinical Response 
(measured from achievement of Clinical Response to loss of Clinical Response [loss of Clinical 
Response defined as platelet count <30x109/L or less than 2-fold increase from Baseline platelet 
count or presence of bleeding]); Complete Clinical Response (defined as platelet count 
≥100x109/L and absence of bleeding); time to Complete Clinical Response (time from starting 
treatment to achievement of Complete Clinical Response); duration of Complete Clinical 
Response (measured from achievement of Complete Clinical Response to loss of Complete 
Clinical Response [loss of Complete Clinical Response defined as platelet count <100x109/L or 
presence of bleeding]); no Clinical Response (defined as platelet count <30x109/L and less than 
2-fold increase from Baseline or presence of bleeding); ITP bleeding score over time; and Patient 
Reported Outcome (PRO), ie, Neurological Fatigue Index for Multiple Sclerosis (NFI-MS) 
summary score over time. Plasma concentration of UCB7665 over time will be assessed as the 
PK variable. The PD variables are minimum value and maximum decrease in total IgG 
concentration during the study; IgG subclass concentrations; and ITP-specific autoantibody 
 in serum over time. Other immunological variables to be 
evaluated are total IgA, IgE, and IgM levels; serum (C3 and C4) and plasma (C3a and C5a) 
complement levels; ADA status (negative/positive) and relative mass units; serum biomarkers 
 B cell activating factor (BAFF) levels and the results of the 
IgG depletion assay; B and T lymphocytes; and cytokines (for subjects experiencing infusion 
reactions). Additional exploratory biomarkers may be investigated if needed using the samples 
already available.
Change #10
Section 1 SUMMARY
Paragraph #14:
Exploratory genomic analyses substudy details are added as follows:
During this study, subjects will also have the option of providing additional informed consent for 
exploratory deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) (ie, messenger RNA 
[mRNA] and micro RNA [miRNA]) analyses. Participation in this additional portion of the study
is optional and does not preclude subject’s eligibility for participation in the main study. The 
additional genomic samples must not be collected if the subject has not consented to participate 
in this exploratory genomic substudy.
TED COPY
ration
PY 
ration
time. 
COP
time. 
rum (C
D CO
rum (C
sitive)
TED
sitive)
REDAC
cell act
EDA
cell act
ocy
RE
ocyte
RE
te
yty
RE
yty
R
ACTE
rization application and any extensions or variations thereof.
al 
ar
al 
atelet 
r var
atelet 
m startin
ions 
m startin
Clinical
nsio
Clinical
of 
xt
of Com
xten
Com
ount <1
y ex
ount <1
30x10
any
30x109
y 
9/
y
/
core ov
nd a
core ov
ple Scl
n an
ple Scl
er time
tion
er time
um
ica
um de
at
de
s; and I
appli
s; and I
Other 
n ap
Other 
C3 and
ation
C3 and
) and r
rizat
) and r
be used to support any marketing auth
ctivatin
auth
ctivatin
s; 
n
s; and 
ng a
and 
markers
ketin
markers
mic anal
to s
mic anal
ud
s
udy, sub
sed
y, sub
de
e
deoxy
e u
oxy
t cannot 
and m
ot be
and m
ional an
nnot
ional an
ditional
can
ditional
This documen
in this 
ent c
in this 
thoriz


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 192 of 353
Change #11
Section 1 INTRODUCTION
Paragraph #13:
Exploratory genomic analyses substudy details are added as follows:
Subjects will also have the option of providing additional informed consent for exploratory
DNA and RNA (mRNA and miRNA) analyses as described in Section 5.1.1.
Change #12
Section 3.3
Exploratory objectives
NEW bullet:

To evaluate the genomic components of ITP to understand the molecular etiology, 
progression, and treatment of the disease, applicable only for subjects consenting to 
participate in the optional genomic analyses substudy.
Change #13
Section 4.2
Efficacy variables
Additional efficacy variable listed as follows:

Baseline-corrected AUEC for platelet count

Clinical Response: platelet count ≥30x109/L and <100x109/L with at least 2-fold increase 
from Baseline value and absence of bleeding

Time to Clinical Response: time from starting treatment to achievement of Clinical Response

Duration of Clinical Response: measured from achievement of Clinical Response to loss of 
Clinical Response (loss of Clinical Response defined as platelet count <30x109/L or less than 
2-fold increase from Baseline platelet count or presence of bleeding)

Complete Clinical Response: platelet count ≥100x109/L and absence of bleeding

Time to Complete Clinical Response: time from starting treatment to achievement of 
Complete Clinical Response

Duration of Complete Clinical Response: measured from achievement of Complete Clinical 
Response to loss of Complete Clinical Response (loss of Complete Clinical Response defined 
as platelet count <100x109/L or presence of bleeding)

No Clinical Response: platelet count <30x109/L and less than 2-fold increase from Baseline 
or presence of bleeding
Change #14
Section 4.4
Other immunological variables
Additional immunological variable listed as follows:

Lymphocyte counts (B and T)
REDACTED COPY 
/L
TED
/L an
ED
an
ED
eeding
ACT
eeding
rom st
REDA
rom st
R
t be used to support any marketing authorization application and any extensions or variations thereof.
etiology
exte
etiology
consent
any e
consent
d <100
izat
d <100
g
th
g
tarti
g au
tarting 
au
ng 
asured 
keting
asured 
cal Res
arke
cal Res
 platele
y ma
 platele
nse: pl
t any
nse: pl
linical R
ppor
linical R
l Respo
supp
l Respo
Complet
d to
Complet
to loss 
used
to loss 
let coun
be us
let coun
This document canno
Clinica
not b
Clinica
or prese
ann
or prese
Chan
ent c
Chan
Se
m
Se


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 193 of 353
Change #15

Section 5.1
Study description

Paragraphs #1 and #2:
This is a Phase 2, multicenter, open-label, multiple-dose, 2-dose-arm study to evaluate the safety, 
tolerability, and efficacy of UCB7665 in subjects with primary persistent or chronic ITP.
Dose Arm 1: UCB7665 4mg/kg sc (5 doses at an interval of 1 week)
Dose Arm 2: UCB7665 7mg/kg sc (3 doses at an interval of 1 week)
The maximum duration of the study per subject is approximately 16 weeks, consisting of a 
Screening Period (1 to 28 days), a Dosing Period of 2 or 4 weeks, and an Observation Period of 
8 weeks.
Has been changed to:
This is a Phase 2, multicenter, open-label, multiple-dose, multiple-arm study to evaluate the 
safety, tolerability, and efficacy of UCB7665 in subjects with primary persistent or chronic ITP.
Dose Arm 1 (15 subjects): UCB7665 4mg/kg sc (5 doses at an interval of 1 week)
Dose Arm 2 (15 subjects): UCB7665 7mg/kg sc (3 doses at an interval of 1 week)
Dose Arm 3 (6 subjects): UCB7665 4mg/kg sc (5 doses at intervals of 3 to 4 days)
The maximum duration of the study per subject is approximately 16 weeks, consisting of a 
Screening Period (1 to 28 days), a Dosing Period of 2 to 4 weeks, and an Observation Period of 
8 weeks.
Change #16
Section 5.1
Study description
Paragraph #4:
Dosing Period: The first 6 subjects in the study will receive UCB7665 4mg/kg. These subjects in 
the Dose Arm 1 will not be randomized. While recruitment is still ongoing, safety data for the 
first 3 subjects up to 7 days after the final dose of the third subject will be reviewed by the DMC. 
During a second DMC meeting, all available safety data up to cut off date defined as 7 days after 
the final dose of the sixth subject will be reviewed. During these reviews recruitment in the dose 
arm will not be stopped. Following this review, the DMC will make a decision on whether to 
open Dose Arm 2 for enrollment. Once the DMC has approved opening of Dose Arm 2 for 
enrollment, subjects will subsequently be randomized to 1 of the 2 dose arms using IXRS. If the 
new dose arm will be initiated and if the UCB7665 4mg/kg arm will be continued, new subjects 
will be randomized to 1 of the 2 dose arms in an allocation ratio of 1:1 (Once 15 subjects are in 
the 4mg/kg group, the remaining subjects will not be randomized. They will be allocated to the 
7mg/kg group.).
Has been changed to:
Dosing Period: The first 6 subjects in the study will receive UCB7665 4mg/kg. These subjects in 
the Dose Arm 1 will not be randomized. While recruitment is still ongoing, safety data for the 
first 3 subjects up to 7 days after the final dose of the third subject in Dose Arm 1 will be 
REDACTED COPY 
es 
Y
es 
doses a
COPY
doses a
t is ap
ED C
t is ap
eriod 
CTED
eriod 
be used to support any marketing authorization application and any extensions or variations thereof.
g of a
ons o
g of a
on Peri
nsion
on Peri
study to
d an
study to
y persi
and
y persi
nterval 
ation
nterval 
an inter
plica
an inter
at inter
n ap
at inter
pproxim
zatio
pproxim
of 2 to
oriza
of 2 to
bjects i
t any
bjects i
e rando
ort a
e rando
days aft
uppo
days aft
MC mee
o sup
MC mee
he sixth
d to 
he sixth
e stoppe
sed
e stoppe
Arm 2 f
be us
Arm 2 f
t cannot 
nt, subj
ot be
nt, subj
ose
no
ose arm
ot
arm
l be ran
can
l be ran
This documen
the 4m
ent c
the 4m
7mg
men
7mg


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 194 of 353
reviewed by the DMC. During a second DMC meeting, all available safety data up to cut off date 
defined as 7 days after the final dose of the sixth subject in Dose Arm 1 will be reviewed. During 
these reviews recruitment in the dose arm will not be stopped. Following this review, the DMC 
will make a decision on whether to open Dose Arm 2 for enrollment. Once DMC has approved 
initiation of Dose Arm 2, the subsequent subjects will be randomly assigned in 1:1 ratio to either 
Dose Arm 1 or Dose Arm 2 using an IXRS. Once 15 subjects are enrolled in the Dose Arm 1 and 
safety data review of at least 3 subjects in Dose Arm 2 is done, the subjects will subsequently be 
randomly assigned in 1:1 ratio to either Dose Arm 2 or Dose Arm 3 using IXRS. Once 
15 subjects are in the Dose Arm 2 or 6 subjects are enrolled in Dose Arm 3, the respective dose 
arm will be closed. 
Change #17

Section 5.1
Study description
Paragraph #5:
At least 4 interim analyses will be performed. Based on the interim analysis, the DMC will 
assess the safety of UCB7665, determine whether to initiate the UCB7665 7mg/kg dose arm and 
may decide to adapt the dose regimen. Planned dosing may be discontinued for all subjects on a 
dose arm (see Section 6.5). Refer to Section 14.7 for details.
Has been changed to:
At least 4 interim analyses will be performed. Based on the interim analyses, the DMC will 
assess the safety of UCB7665, determine whether to initiate Dose Arm 2, and may decide to 
adapt the dose regimen. Planned dosing may be discontinued for all subjects in a dose arm (see 
Section 6.5). Refer to Section 14.7 for details. 
Change #18

Section 5.1
Study description
Paragraph #6:
In case the DMC recommends reducing the number of doses (infusions) for either the 
UCB7665 4mg/kg dose or UCB7665 7mg/kg dose based on review of safety data, then the 
additional dose arms receiving a reduced number of doses will be considered as additional new 
dose arms for the study.
Has been changed to:
In case the DMC recommends reducing the number of doses (infusions) for any of the 
predefined dose arms based on review of safety data, then the additional dose arms receiving a 
reduced number of doses will be considered as additional new dose arms for the study.
Change #19

NEW Section 5.1.1
Exploratory genomic analyses
During this study, subjects will also have the option of providing additional informed consent for 
exploratory DNA and RNA analyses. Participation in this additional portion of the study is 
optional and does not preclude subject’s eligibility for participation in the main study. The 
REDACTED COPY 
ased on
D CO
ased on
ther to
TED 
ther to
ay
AC
ay be
CTE
be
y y
C
y
d
E
d
etails.
DAC
etails.
ort any marketing authorization application and any extensions or variations thereof.
dose 
r va
dose 
n
ys
nd
ysis, th
d a
is, th
B7665 
n an
B7665 
scontin
tion 
scontin
on the in
tion 
on the in
o initia
izati
o initia
discon
horiz
discon
ds redu
rt an
ds redu
cannot be used to supp
r UCB
port
r UCB
eceivin
supp
eceivin
udy
to s
udy.
hange
sed 
hange
DMC 
be u
DMC 
ned dos
ot b
ned dos
ed num
nno
ed num
This documen
Chang
nt ca
Chang

m



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 195 of 353
additional genomic samples must not be collected if the subject has not consented to participate 
in this exploratory genomic substudy.
Once subject provides consent, through a separate informed consent form, blood samples will be 
drawn as follows:
For DNA: Blood samples will be collected at Baseline (Visit 2) for all dose arms. Subsequent 
blood sample will be collected prior to the last dose (ie, Visit 7 for Dose Arm 1, Visit 5 for Dose 
Arm 2, and Visit 6 for Dose Arm 3).
For RNA: Blood samples will be collected at following time points for different dose arms: 

Dose Arm 1: Baseline (Visit 2), 3 days after dose 1 (Visit 3), prior to the last dose (Visit 7),
and End of Study Visit (Visit 15).

Dose Arm 2: Baseline (Visit 2), 3 days after dose 1 (Visit 3), prior to the last dose (Visit 5), 
and End of Study Visit (Visit 13). 

Dose Arm 3: Baseline (Visit 2), prior to second dose (Visit 3), prior to the last dose (Visit 6), 
and End of Study Visit (Visit 14).
For each DNA blood sample a volume of 6mL whole blood is needed and for each RNA sample 
a volume of 2.5mL whole blood is needed.
Failure to provide consent to participate in this substudy will not impact subject’s eligibility to 
participate in the main study.
Any exploratory biomarker or genomic analysis will only ever be related to the exploration of 
the underlying causes of ITP in patients, related biology, and drug response. Justification for 
additional genomic analyses is detailed in Section 5.4.6.
Details on the collection, storage, preparation, and shipping of samples will be presented in the 
Laboratory Manual provided separately.
Any results from this analysis will be reported separately and will not form a part of the main 
clinical study report.
Change #20
Section 5.1.3 Planned number of subjects and sites
A total of 30 subjects are planned to enter the Dosing Period in the study. This number should 
allow for an appropriate assessment of the safety and give information on efficacy of the 
treatment for planning of potential future studies. To achieve the required number of eligible 
subjects to enter the Dosing Period, it is anticipated that 40 subjects will need to be screened. 
These subjects will be enrolled at approximately 25 sites. First subject first visit is planned for 
Q1 2016, last subject last visit for Q3 2017.
Has been changed to:
A total of up to 36 subjects are planned to enter the Dosing Periods in the study (15 subjects in 
each of Dose Arms 1 and 2, and 6 subjects in Dose Arm 3). To achieve the required number of 
eligible subjects to enter the Dosing Period, it is anticipated that approximately 54 subjects will 
need to be screened. These subjects will be enrolled at approximately 30 sites. First subject first 
visit is planned for Q1 2016, last subject last visit for Q4 2017.
REDACTED COPY 
tudy
OPY
tudy w
PY
w
y
PY
y
ys
T
ysis wi
TED
is wi
elated
ACT
elated
in 
ED
in Se
DA
Se
epara
RE
epara
marketing authorization application and any extensions or variations thereof.
s: 
o
s: 
(Visit 
ons o
(Visit 
st dose
exte
st dose
to the 
nd a
to the 
eeded a
ation
eeded a
will not
app
will not
ill only
rizat
ill only
d biolog
thor
d biolog
ction
auth
ction 5
h
5
ration, a
ting
ration, a
el
r
ely.
rk
y.
nt cannot be used to support any m
ll be re
y ma
ll be re
d 
s
d numb
supp
numb
ects are
d to 
ects are
ppropria
sed
ppropria
or plann
be us
or plann
to enter
ot be
to enter
subjec
nnot
subjec
This documen
20
ca
2016, 
can
16, 
Has 
ment
Has 
A
m
A


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 196 of 353
Change #21
Section 5.2
Schedule of study assessments
Table 5‒1 presents the tabular scheme of study assessments for UCB7665 4mg/kg dose arm and 
Table 5‒2 presents the tabular scheme of study assessments for UCB7665 7mg/kg dose arm. 
Table 5‒3 presents the assessments to be performed on dosing days.
Has been changed to:
Table 5-1 presents the tabular scheme of study assessments for the weekly UCB7665 4mg/kg 
dose arm (Dose Arm 1), Table 5-2 presents the tabular scheme of study assessments for the 
weekly UCB7665 7mg/kg dose arm (Dose Arm 2), and Table 5-3 presents the tabular scheme of 
study assessments for the twice weekly UCB7665 4mg/kg dose arm (Dose Arm 3). Table 5-4
presents the assessments to be performed on dosing days.
REDACTED COPY 
ions or variations thereof.
kg
v
kg
the 
o
the 
schem
ons 
schem
This document cannot be used to support any marketing authorization application and any extensi
Table
sio
Table


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 197 of 353
Change #22
Section 5.2
Schedule of study assessments
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consent
X
Demographic data
X
Verification of 
inclusion/exclusion 
criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory)f
X
X
X
X
X
Randomizationg
X
Withdrawal criteriah
X
X
X
X
X
X
General 
medical/procedures 
history
X
ITP history
X
REDACTED COPY 
9
Y
9
5
OPY
5
Y
CO
2d
D
2dd
C
d
CO
CO
CO
CO
TE
AC
DA
RE
R
support any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
bservat
ens
bservat
sio
10
 a
10b
any
nd
n
a
n
32
plica
32
at
ca
5
app
5
pp
a
±2d
tio
±2dd
on
d
n
ri
 
riririz
ori
uth
g 
ma
g
X
ny 
X
m
rt
m
po
annot be used to sup
su
X
d to 
X
s
ed
us
X
o
X
ot 
This document can
an


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 198 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationi
X
X
X
X
X
X
X
X
X
X
12-lead ECG
X
X
X
X
X
X
X
X 
Karnofsky Performance 
Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xj
X
X
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
X
COP
X
PY
CO
X
TE
X
ED
AC
X
ED
X
DA
RE
R
keting authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
X
n a
X
X
ap
 a
X
riza
X
at
ori
X
au
X
ut
g 
g
d to support any marke
ke
ma
X
y m
X
ma
ma
ma
ma
X
an
X
ny
rt
or
u
r
u
used to sup
up
su
X
ed
This document cannot be us
ot
us


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 199 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Serology test for HIV, 
hepatitis B, and hepatitis 
C
X
Blood sample for 
cytokines
X
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
X
X
Call to IXRS for treatment 
kit number
X
X
X
X
X
Administration of IMP
X
X
X
X
X
Blood sampling for 
plasma concentration of 
UCB7665
X
X
X
X
X
X
X
X
Anti-UCB7665 
antibodies/IgG depletion 
assay
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
PY
CO
TE
AC
ED
R
marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
ap
ri
 a
X
th
Xk
h
k
riririz
ori
a
g
X
rke
X
ti
a
support any mar
X
ma
X
ar
ma
X
a
X
an
rt
X
pp
X
po
d to su
used 
su
X
d
X
d
This document cannot be us
t
us


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 200 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Serum complements (C3 
and C4) and plasma 
complements (C3a and 
C5a)
X
X
X
X
Serum biomarkers 
 
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum biomarkers 
X
X
X
X
X
X
Serum BAFF levels
X
X
X
X
X
X
X
Immunoglobulins (total 
IgG, IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X 
IgA, IgM, IgEl
X
X
X
X
ITP-specific 
autoantibodiesm
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
REDACTED COPY 
PY
AC
CO
X
DA
X
AC
AC
AC
R
AC
support any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
ap
ori
 a
X
auth
X
tho
g
o
X
arke
X
ket
ma
X
a
X
any
rt
X
ppo
X
or
be used to suppor
su
r
X
d to
X
o s
X
ed
us
nnot b
X
ot 
X
This document cann t b
nn
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 201 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Headache questionnairen
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviewo
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
 HIV=human immunodeficiency virus;
Ig=immunoglobulin; IMP=investigational medicinal product; ITP=immune thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar 
puncture; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
a Frequency of assessments on dosing days is detailed in Table 5-3.  
b Visits 10, 12, and 14 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the final dose.
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose. 
e The visit windows in the Observation Period are relative to the final dosing visit date.
f Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
g The first 6 subjects will be enrolled in the Dose Arm 1 group only. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the 
DMC. Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, subjects subsequently enrolled will 
be randomly assigned subsequently to 1 of the 2 dose arms using an IXRS until 15 subjects are in Dose Arm 1.
h Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
i A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
TED COPY 
X
COP
X
PY
CO
C
REDACTE
TE
C
erebro
CTE
erebro
Withd
DAC
Withd
=immun
EDA
=immun
gical F
RE
gical F
application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
rization applicati
1d
lic
1d
±
a
±
atio
a
ca
X
X
n a
X
X
ap
 a
ion
t any marketing autho iz
spinal f
horiz
spinal f
draw
uth
drawal; 
tho
al; 
ne throm
aut
ne throm
Fatigue I
ng a
Fatigue I
.  .  
are prof
mar
are prof
n
ts. The v
any
ts. The v
sed to suppor
f 9 days 
ort a
f 9 days 
elative to
ppor
elative to
l be tak
supp
l be tak
oratory.
to su
oratory.
0x10
d to
0x109
to
9/L
o
/L
the Dose
sed
the Dose
annot be u
MC will 
e us
MC will 
tly to 1 o
be 
tly to 1 o
time dur
ot b
time dur
nation w
nno
nation w
This document ca
minatio
can
minatio
o


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 202 of 353
j At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
k Blood sample for cytokines will be obtained only in case of infusion reactions.
l In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 7 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
m
n This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to  CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
o A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
Has been changed to:
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consentf
X
Demographic data
X
Verification of 
inclusion/exclusion 
criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory)g
X
X
X
X
X
REDACTED COPY 
Y
se 
C
se 
4
ED
4
D
O
D
OP
CO
6
T
6
TE
AC
AC
R
AC
rt any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
ment for
var
ment for
(ie
sio
(ie, if h
sion
, if h
g fundos
ensi
g fundos
ndicated 
xten
ndicated 
from th
ny 
from th
kly
ica
kly dos
cati
dos
ca
pli
a
Dose 
tion
Dose 
5
ati
5
a
i
 a
6
h
6
iz
ori
g
15
ket
15
tin
a
mark
ma
±2d
any
±2dd
y 
d
used to support a y m
rt
m
or
u
r
up
su
X
ed 
X
to
be us
This document cannot b
us
b
nt c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 203 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Randomizationh
X
Withdrawal criteriai
X
X
X
X
X
X
General 
medical/procedures 
history
X
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationj
X
X
X
X
X
X
X
X
X
X
12-lead ECGk
X
X
X
X
X
X
X
X 
REDACTED COPY 
PY
CO
X
ED 
X
C
TE
R
AC
R
keting authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
ap
 a
X
zati
X
io
ririririz
g
ori
ng
d to support any marke
g
X
ark
X
ke
ma
X
any
X
ny 
rt
X
upp
X
po
su
su
su
su
be used t
su
d t
us
be us
us
us
us
This document cannot be
X
ot b
X
be
n
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 204 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Karnofsky Performance 
Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xl
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serology test for HIV, 
hepatitis B, and hepatitis 
C
X
Blood sample for 
cytokines
X
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Whole blood sample for 
DNA (optional)
X
X
Whole blood sample for 
RNA (optional)
X
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
X
X
Call to IXRS for treatment
kit number
X
X
X
X
X
REDACTED COPY 
PY
CO
X
TE
X
ED
AC
ED
R
upport any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
ap
 a
X
riza
X
at
ori
a
ma
g
X
y
Xm
ma
ma
ma
t
ma
t
t be used to support a
t a
u
rt
X
o su
X
up
su
ed
us
u
This document cannot 
u
t
ca


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 205 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Administration of IMP
X
X
X
X
X
Blood sampling for 
plasma concentration of 
UCB7665
X
X
X
X
X
X
X
X
Anti-UCB7665 
antibodies/IgG depletion 
assay
X
X
X
X
X
X
X
X
X
X
X
X
Serum complements (C3 
and C4) and plasma 
complements (C3a and 
C5a)
X
X
X
X
Serum biomarkers 
 
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum biomarkers 
X
X
X
X
X
X
Serum BAFF levels
X
X
X
X
X
X
X
REDACTED COPY 
X
COP
X
PY
CO
X
ED C
X
C
AC
C
X
ED
X
DA
R
marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
ap
 a
X
atio
X
ion
ori
X
au
X
ut
g
X
rke
port any ma
rt
d to suppor
ma
X
ppo
X
or
su
r
used t
X
d
X
This document cannot be us d t
us
t b
nn


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 206 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Immunoglobulins (total 
IgG, IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X 
IgA, IgM, IgEn
X
X
X
X
ITP-specific 
autoantibodieso
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
Headache questionnairep
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviewq
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring; 
DNA=deoxyribonucleic acid; Committee; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
 HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IMP=investigational medicinal product; ITP=immune thrombocytopenia; IXRS= interactive voice/web response 
system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
a Frequency of assessments on dosing days is detailed in Table 5-4.  
b Visits 10, 12, and 14 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the final dose.
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose. 
REDACTED COPY 
X
COP
X
PY
CO
ED
CT
R
AC
R
keting authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
X
n a
X
X
ap
 a
X
a
X
at
ori
ho
g
o
X
etin
X
ng
port any marke
g
ke
ma
X
ny m
X
m
an
port
ed to suppo
r;r; BL=B
ppo
BL=B
G=electr
sup
G=electr
in; IMP
to s
in; IMP
nucleic 
ed to
nucleic 
t be us
g days i
e us
g days i
formed a
t be
formed a
This document canno
weeks fo
not 
weeks fo
is allow
ann
is allow
days and
t ca
days and
used


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 207 of 353
e The visit windows in the Observation Period are relative to the final dosing visit date.
f Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
g Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h The first 6 subjects will be enrolled in the Dose Arm 1 group only. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the 
DMC. Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, the subsequent subjects will be 
randomly assigned in 1:1 ratio to either Dose Arm 1 or Dose Arm 2 using an IXRS. Once 15 subjects are enrolled in Dose Arm 1 and safety data review of at 
least 3 subjects in Dose Arm 2 is done, the subsequent subjects will be randomly assigned in 1:1 ratio to either Dose Arm 2 or Dose Arm 3 using an IXRS. 
Once 15 subjects are in Dose Arm 2 or 6 subjects are enrolled in Dose Arm 3, the respective dose arm will be closed.
i Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
j A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted. 
k The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
l At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
m Blood sample for cytokines will be obtained only in case of infusion reactions.
n In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 7 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
o
p This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
q A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
ACTED COPY 
eval
Y
eval
w of saf
COP
w of saf
aches a
ACTE
aches a
REDA
follow
DAC
follow
nd/or L
REDA
nd/or L
th IT
RE
th IT
thorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
osing w
ariat
osing w
inclusio
var
inclusio
r to dosi
or v
r to dosi
st dose 
ion
st dose 
ned, the 
ensi
ned, the 
n Dose A
xten
n Dose A
ose Arm
y ex
ose Arm
closed.
any 
closed.
where p
and
where p
aramete
tion
aramete
tion of p
pplic
tion of p
fety data
on a
fety data
and w
horiz
and will 
riz
ill 
This document cannot be used to support any marketing aut
wed by a
utho
wed by a
LP for C
g au
LP for C
P.
tin
P.
ill be re
ketin
ill be re


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 208 of 353
Change #23
Section 5.2
Schedule of study assessments
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg dose arm
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consent
X
Demographic data
X
Verification of inclusion/exclusion 
criteria
X
X
Platelets for inclusion/withdrawal 
check (local laboratory) f
X
X
X
Randomizationg
X
Withdrawal criteriah
X
X
X
X
General medical/procedures history
X
ITP history
X
Prior and concomitant medication
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical procedures
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY
3
OPY
3
Y 
±
C
±
CO
D C
ED
C
AC
ACT
DAC
ED
R
rt any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
rvation
ens
rvation
sio
8
d a
8b
d a
b
an
a
8
2
plica
8
2
at
plic
3
ap
3
pp
n
p
2d
ati
2dd
tio
d
n
on
za
ho
ho
ho
ho
ho
au
in
ke
ma
X
an
X
ny
annot be used to support 
rt
pp
X
pp
pp
pp
pp
X
d to
X
o
ed
u
e u
ot
This document can
an


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 209 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg dose arm
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationi
X
X
X
X
X
X
X
X
12-lead ECG
X
X
X
X
X
X
Karnofsky Performance Status
X
Laboratory parameters (hematology, 
chemistry, urinalysis)
Xj
X
X
X
X
X
X
X
X
X
X
X
X
Serology test for HIV, hepatitis B, and 
hepatitis C
X
Blood sample for cytokines
X
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
Call to IXRS for treatment kit number
X
X
X
Administration of IMP
X
X
X
REDACTED COPY 
O
D C
X
TED
X
D
X
C
X
CT
DAC
REDA
DA
R D
R
authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
±2d
lica
d
±2d
ati
plic
plplpl
n
pl
n a
on
X
riza
X
at
o
X
tho
X
or
t be used to support any marketing au ho
X
g a
X
au
ninining
in
X
mar
X
rke
ma
ny
po
pp
X
to
X
s
d
u
ber
be
ber
us
u
This document cannot b
t b
nn


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 210 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg dose arm
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Blood sampling for plasma 
concentration of UCB7665
X
X
X
X
X
X
Anti-UCB7665 antibodies/IgG 
depletion assay
X
X
X
X
X
X
X
X
X
X
Serum complements (C3 and C4) and 
plasma complements (C3a and C5a)
X
X
X
X
Serum biomarkers 
 
X
X
X
X
X
X
X
X
X
X
X
Serum biomarkers 
X
X
X
X
Serum BAFF levels
X
X
X
X
X
Immunoglobulins (total IgG, IgG 
subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgEl
X
X
X
X
ITP-specific autoantibodiesm
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
REDACTED COPY
X
OPY
X
Y
C
 
X
ED 
X
C
C
D C
AC
AC
R DAC
R
pport any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
±2d
lica
d
±2d
ati
plic
X
app
X
plplpl
on
pl
X
zati
X
tio
ho
o
ho
ho
ho
n
ho
X
eting
X
ng
a
in
mar
ma
X
a
X
a
p
This document cannot be used to suppo
uppo
pp
to 
se
u
be 
o
ca


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 211 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg dose arm
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Headache questionnairen
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviewo
X
AE=adverse event; BAFF=B cell activating factor; BL=baseline; CSF=cerebrospinal fluid CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
 HIV=human immunodeficiency virus;
Ig=immunoglobulin; IMP=investigational medicinal product; ITP=immune thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar 
puncture; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
a Frequency of assessments on dosing days is detailed in Table 5-3.
b Visits 8, 10, and 12 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the final dose.
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose. 
e The visit windows in the Observation Period are relative to the final dosing visit date. 
f Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
g The first 6 subjects will be enrolled in the Dose Arm 1 group. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the DMC. 
Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, subjects subsequently enrolled will be 
randomly assigned to one of the dose arms using an IXRS until 15 subjects are in Dose Arm 1.
h Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
i A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
j At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
ED COPY
X
OPY
X
Y 
CO
REDACTED C
D
ebrospi
TED
ebrospi
Withdra
ACT
Withdra
mmune 
DAC
mmune 
cal Fat
RED
cal Fat
ation application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
±2d
lica
d
±2d
ati
plic
X
app
X
plplpl
n
pl
n
port any marketing authorization 
n a
at on
inal flui
riza
inal flui
wal; 
thor
wal; 
thr
aut
throm
uth
omb
h
b
mb
m
h
mb
m
igue Ind
g au
igue Ind
profess
arke
profess
. The vi
ny m
. The vi
9 days as
t any
9 days as
ative to t
ort 
ative to t
be used to supp
be taken
ppo
be taken
atory. A
sup
atory. A
x10
to
x109
o
9/L.
o s
/L.
e Dose A
ed to
e Dose A
make a d
used
make a d
se arms
be us
se arms
This document cannot b
me durin
t be
me durin
ation wil
not 
ation wil
mination 
ann
mination 
2 separa
t ca
2 separa
oriz


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 212 of 353
k Blood sample for cytokines will be obtained only in case of infusion reactions.
l In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 5 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
m
n This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
o A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
Has been changed to:
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consentf
X
Demographic data
X
Verification of inclusion/exclusion 
criteria
X
X
Platelets for inclusion/withdrawal 
check (local laboratory) g
X
X
X
Randomizationh
X
REDACTED COPY 
g w
Y
g w
PY
se 
ED
se 
2
TE
2
CO
D C
CT
DAC
D
R
ort any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
nt for Ig
ariat
nt for Ig
, if head
ns o
, if head
undosco
sion
undosco
ated at
ensi
ated at t
om the s
y ex
om the s
ekly
plica
ekly d
ca
d
ca
pp
on
Dose 
atio
Dose 
3
za
3
on
on
o
on
4
u
4a
t
a
or
ho
in
4
ark
4
ke
ma
1
y m
1
ma
ma
ma
ma
ny
not be used to suppor
or
pp
X
o
X
up
X
d t
X
to
u
t cann
u
nn
This document c
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 213 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Withdrawal criteriai
X
X
X
X
General medical/procedures history
X
ITP history
X
Prior and concomitant medication
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical procedures
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationj
X
X
X
X
X
X
X
X
12-lead ECGk
X
X
X
X
X
X
Karnofsky Performance Status
X
Laboratory parameters (hematology, 
chemistry, urinalysis)
Xl
X
X
X
X
X
X
X
X
X
X
X
X
Serology test for HIV, hepatitis B, and 
hepatitis C
X
REDACTED COPY
X
OPY
X
Y 
CO
D C
D 
D
DACT
DAC
X
RED
X
DA
DA
R D
R
any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
n
pl
n a
on
at
o
X
utho
X
or
ho
X
g a
X
au
n
X
ketin
X
inining
in
rke
ma
m
ot be used to support an
X
ort a
X
an
ppo
pp
X
to s
X
su
X
d
X
d t
u
This document cannot be us
,
b
,
us
u
itis B, an
anno
itis B, an
ot
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 214 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Blood sample for cytokines
X
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Whole blood sample for DNA 
(optional)
X
X
Whole blood sample for RNA 
(optional)
X
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
Call to IXRS for treatment kit number
X
X
X
Administration of IMP
X
X
X
Blood sampling for plasma 
concentration of UCB7665
X
X
X
X
X
X
Anti-UCB7665 antibodies/IgG 
depletion assay
X
X
X
X
X
X
X
X
X
X
Serum complements (C3 and C4) and 
plasma complements (C3a and C5a)
X
X
X
X
Serum biomarkers 
 
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY
X
OP
Xm
PY
m
Y 
X
O
X
CO
D C
TE
DAC
ED
R
arketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
X
ap
Xm
app
m
plplpl
n
pl
X
t
X
n a
on
X
riz
ho
a
in
tinin
ed to support any marketinin
a
in
ark
ma
X
an
X
y m
X
t a
pp
up
annot be used to sup
ed
u
be
This document can


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 215 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Serum biomarkers 
X
X
X
X
Serum BAFF levels
X
X
X
X
X
Immunoglobulins (total IgG, IgG 
subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgEn
X
X
X
X
ITP-specific autoantibodieso
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
Headache questionnairep
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviewq
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
 HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IMP=investigational medicinal product; ITP=immune thrombocytopenia; IXRS= interactive voice/web response 
system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
Frequency of assessments on dosing days is detailed in Table 5-4.
b Visits 8, 10, and 12 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the final dose.
REDACTED COPY
X
OPY
X
Y
C
 
X
ED 
X
C
D C
X
ACT
X
TE
DAC
ED
R
support any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
on
pl
X
zat
X
tio
X
hor
X
riz
ho
au
in
tininin
a
in
ar
ma
X
an
X
y
X
t a
pp
pp
This document cannot be used to supp
pp
pp
o s pp
factor;
d to 
factor; B
 ECG=e
ed t
 ECG=e
lobulin;
use
lobulin;
b
ribonu
be u
ribonu
n dosing
nnot
n dosing
e perfor
cann
e perfor
t is 8 w
nt ca
t is 8 w
t be
ot


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 216 of 353
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose. 
e The visit windows in the Observation Period are relative to the final dosing visit date. 
f Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
g Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h The first 6 subjects will be enrolled in the Dose Arm 1 group. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the DMC. 
Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, the subsequent subjects will be randomly 
assigned in 1:1 ratio to either Dose Arm 1 or Dose Arm 2 using an IXRS. Once 15 subjects are enrolled in Dose Arm 1 and safety data review of at least 3 
subjects in Dose Arm 2 is done, the subsequent subjects will be randomly assigned in 1:1 ratio to either Dose Arm 2 or Dose Arm 3 using an IXRS. Once 15 
subjects are in Dose Arm 2 or 6 subjects are enrolled in Dose Arm 3, the respective dose arm will be closed.
i Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
j A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
k The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
l At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
m Blood sample for cytokines will be obtained only in case of infusion reactions.
n In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 5 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
o
p This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
q A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
ED COPY 
labo
Y
labo
y for e
COP
y for e
REDACTE
review
TED
review
headac
REDA
headac
ll be 
RE
ll be 
ation application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
, there s
atio
, there s
r to dos
or v
r to dos
check in
ns o
check in
y prior t
sion
y prior t
ast d
xten
ast dose
en
ose
ed, the s
y ex
ed, the s
se Arm 
any 
se Arm 
se Arm 
d an
se Arm 
sed.
and
sed.
visits (w
tion
visits (w
tory par
pplic
tory par
valuatio
on a
valuatio
This document cannot be used to support any marketing authoriz
w of safe
rizat
w of safe
ches and
g au
ches and
followe
ting 
followe
nd/or LP
ketin
nd/or LP
ith ITP.
arke
ith ITP.
iew will
ma
iew will


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 217 of 353
Change #24
Section 5.2
Schedule of study assessments
NEW table:
Table 5-3:
Schedule of assessments for the UCB7665 4mg/kg twice weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Dose 3
Dose 4
Dose 5
Visit 
1
2a
3a
4a
5a
6a
7
8
9b
10
11b
12
13b
14
BL 
Visit
EOS/EW
c
Day
-28 to -1
1
4
8
11
15
18
22
29
36
43
50
57
71
Week
1
1
2
2
3
3
4
5
6
7
8
9
11
Visit 
Window
+1dd
+1dd
+1dd
+1dd
±1d
±2d
e
±2de
±2de
±2de
±2de
±2de
±2de
Written informed 
consentf
X
Demographic data
X
Verification of 
inclusion/exclusion 
criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory)g
X
X
X
X
X
Randomizationh
X
Withdrawal criteriai
X
X
X
X
X
General 
medical/procedures 
history
X
REDACTED COPY
15
PY 
15
3
COP
3
OPY
C
d
E
dd
D
d
C
D C
AC
DA
R
eting authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
m (Do
ensio
m (Do
Obse
ex
Obse
te
y
ny
9
nd
9b
d 
b
d a
a
ca
a
18
ppl
18
lic
a
c
on ap
 a
+1d
zati
+1dd
tio
d
tio
ho
ho
ho
ho
ho
ng
ed to support any marketi
eti
ke
an
e
X
ort 
X
t a
su
a
X
d t
X
o s
cannot be used
s
X
e
X
ed
u
X
t
X
e u
This document ca
ca


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 218 of 353
Table 5-3:
Schedule of assessments for the UCB7665 4mg/kg twice weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Dose 3
Dose 4
Dose 5
Visit 
1
2a
3a
4a
5a
6a
7
8
9b
10
11b
12
13b
14
BL 
Visit
EOS/EW
c
Day
-28 to -1
1
4
8
11
15
18
22
29
36
43
50
57
71
Week
1
1
2
2
3
3
4
5
6
7
8
9
11
Visit 
Window
+1dd
+1dd
+1dd
+1dd
±1d
±2d
e
±2de
±2de
±2de
±2de
±2de
±2de
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationj
X
X
X
X
X
X
X
X
X
X
12-lead ECGk
X
X
X
X
X
X
X
X
Karnofsky Performance 
Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xl
X
X
X
X
X
X
X
X
X
X
X
X
X
Serology test for HIV, 
X
REDACTED COPY 
Y
COP
D C
X
ACT
X
TE
DA
X
RE
X
ED
R
rketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
rm 3)
riati
rm 3)
n Period
or v
n Period
va
o
1
o
1
on
nsi
n
ny
n
29
d a
29
ny
ny
ny
4
5
an
4
5
nd
a
±2d
atio
±2d
e
on
ca
pl
a
X
tion
X
n a
 a
horiz
ho
X
ng a
X
au
tititi
not be used to support any marketin
ting
eti
rk
any y m
an
X
ort 
X
a
X
upp
X
po
su
s
se
This document cann
u
X
n
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 219 of 353
Table 5-3:
Schedule of assessments for the UCB7665 4mg/kg twice weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Dose 3
Dose 4
Dose 5
Visit 
1
2a
3a
4a
5a
6a
7
8
9b
10
11b
12
13b
14
BL 
Visit
EOS/EW
c
Day
-28 to -1
1
4
8
11
15
18
22
29
36
43
50
57
71
Week
1
1
2
2
3
3
4
5
6
7
8
9
11
Visit 
Window
+1dd
+1dd
+1dd
+1dd
±1d
±2d
e
±2de
±2de
±2de
±2de
±2de
±2de
hepatitis B, and hepatitis 
C
Blood sample for 
cytokines
X
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Whole blood sample for 
DNA (optional)
X
X
Whole blood sample for 
RNA (optional)
X
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
X
X
Call to IXRS for 
treatment kit number
X
X
X
X
X
Administration of IMP
X
X
X
X
X
Blood sampling for 
plasma concentration of 
UCB7665
X
X
X
X
X
X
X
Anti-UCB7665 
antibodies/IgG depletion 
assay
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
Y
CO
D C
CT
DA
RE
y marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
rm 3)
riati
rm 3)
n Period
or v
n Period
va
o
1
o
1
on
nsi
n
ny
n
29
d a
29
ny
ny
ny
4
5
an
4
5
nd
a
±2d
atio
±2d
e
on
ca
pl
 a
X
ati
Xm
tio
m
on
or
ho
g
eti
ark
to support any m
any m
an
X
ort 
X
t a
u
a
X
o su
X
u
sup
su
be used to up
su
X
ed t
X
to
u
This document cannot be
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 220 of 353
Table 5-3:
Schedule of assessments for the UCB7665 4mg/kg twice weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Dose 3
Dose 4
Dose 5
Visit 
1
2a
3a
4a
5a
6a
7
8
9b
10
11b
12
13b
14
BL 
Visit
EOS/EW
c
Day
-28 to -1
1
4
8
11
15
18
22
29
36
43
50
57
71
Week
1
1
2
2
3
3
4
5
6
7
8
9
11
Visit 
Window
+1dd
+1dd
+1dd
+1dd
±1d
±2d
e
±2de
±2de
±2de
±2de
±2de
±2de
Serum complements (C3 
and C4) and plasma 
complements (C3a and 
C5a)
X
X
X
X
Serum biomarkers 
X
X
X
X
X
X
X
X
X
X
X
X
Serum biomarkers 
X
X
X
X
X
Serum BAFF levels
X
X
X
X
X
X
X
Immunoglobulins (total 
IgG, IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgEn
X
X
X
X
ITP-specific 
autoantibodieso
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
REDACTED COPY 
Y
D C
X
ACT
X
CTE
DA
R
rt any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
rm 3)
riati
rm 3)
n Period
or v
n Period
va
o
1
o
1
on
nsi
n
ny
n
29
d a
29
ny
ny
ny
4
5
an
4
5
nd
a
±2d
atio
±2d
e
on
ca
X
pp
X
pl
 a
thori
i
ho
keting
eti
any
an
ot be used to support a
X
ort
X
t a
u
a
X
up
su
X
ed
X
d to
u
X
t be
X
e
annot be 
ot
This document can
an


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 221 of 353
Table 5-3:
Schedule of assessments for the UCB7665 4mg/kg twice weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Dose 3
Dose 4
Dose 5
Visit 
1
2a
3a
4a
5a
6a
7
8
9b
10
11b
12
13b
14
BL 
Visit
EOS/EW
c
Day
-28 to -1
1
4
8
11
15
18
22
29
36
43
50
57
71
Week
1
1
2
2
3
3
4
5
6
7
8
9
11
Visit 
Window
+1dd
+1dd
+1dd
+1dd
±1d
±2d
e
±2de
±2de
±2de
±2de
±2de
±2de
Headache questionnairep
X
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviewq
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; DNA=deoxyribonucleic acid ; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
 HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IMP=investigational medicinal product; ITP=immune thrombocytopenia; IXRS= interactive voice/web response 
system; LP=lumbar puncture; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue Index for multiple sclerosis;
RNA=ribonucleic acid;
a Frequency of assessments on dosing days is detailed in Table 5-4.
b Visits 9, 11, and 13 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the final dose.
d A visit window of +1 day is allowed for the dosing visits, with at least 3 days in between 2 successive doses. 
e The visit windows in the Observation Period are relative to the final dosing visit date. 
f Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
g Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h Dose Arm 3 will be opened once 15 subjects are enrolled in Dose Arm 1 and safety data review of at least 3 subjects in Dose Arm 2 is done. Subsequent 
subjects will be randomly assigned in 1:1 ratio to either Dose Arm 2 or Dose Arm 3 using an IXRS. Once 15 subjects are in Dose Arm 2 or 6 subjects are 
enrolled in Dose Arm 3, the respective dose arm will be closed.
i Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
j A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
ED COPY 
X
OPY
X
Y
O
REDACTED C
D C
ebrosp
TED
ebrosp
OS=End
ACT
OS=End
medicin
DAC
medicin
NFI
RED
NFI-
ED
-M
D
M
ED
RE
tion and any extensions or variations thereof.
15 Fe
here
15 Fe
on
rm 3)
riati
rm 3)
n Period
or v
n Period
va
o
1
o
1
on
nsi
n
ny
n
29
d a
29
ny
ny
ny
4
5
an
4
5
nd
a
ation application
±2d
atio
±2d
e
on
ca
X
app
X
pl
a
n a
rt any marketing authorization a
 a
inal flui
riza
inal flui
d of Stud
hori
d of Stud
nal prod
uth
nal prod
MS=Neu
g au
MS=Neu
at
profess
arke
profess
with at l
ny m
with at l
e to
t a
e to the 
any
the 
used to suppo
ion in th
ort 
ion in th
be taken
ppo
be taken
atory. A
sup
atory. A
x10
to
x109
o
9/L.
o s
/L.
ects are 
ed to
ects are 
1:1 ratio
used
1:1 ratio
This document cannot be 
tive dos
e us
tive dos
me durin
t be
me durin
tion wil
not 
tion wil
ination 
anno
ination 
t


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 222 of 353
k The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
l At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
m Blood sample for cytokines will be obtained only in case of infusion reactions.
n In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 6 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
o
p This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
q A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
Change #25
Section 5.2
Schedule of study assessments
Table 5-3:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of infusion
4h after end of infusion
Withdrawal criteria
X
Platelet count (local laboratory) for inclusion check 
at Visit 2 and for withdrawal criterion at other 
dosing visits
X
Prior and concomitant medications
X
Concomitant medical procedures
X
Vital signsa
X
X
X
X
Physical examination
X
12-lead ECG
X
Hematology 
X
Clinical chemistry
X
REDACTED COPY 
g day
CTED
g day
AC
AC
AC
AC
ED
o support any marketing authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
orded in
atio
orded in
ssessme
ns o
sessme
ution (i
xten
ution (i
luding f
y ex
luding f
d if indic
any 
d if indic
raw
and
rawal fr
nd
al fr
y
o
ys
o
s
End 
auth
End 
tho
a
ng
tin
X
ny
X
ny
rt
pp
ot be used to up
o
ed
e u
This document cannot 
ot
an


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 223 of 353
Table 5-3:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of infusion
4h after end of infusion
Urinalysis
X
Urine pregnancy test
X
Immunoglobulinsb
X
ITP-specific autoantibodiesc
X
Blood sampling for UCB7665 plasma 
concentration
X
Anti-UCB7665 antibodies/IgG depletion assay
X
Serum (C3 and C4) and plasma complements (C3a 
and C5a)d
X
Serum biomarkers 
X
X
X
Serum BAFF levels
X
X
X
Blood sampling for cytokinese
X
ITP bleeding scale
X
AEs
X
X
X
X
NFI-MSf
X
AE=adverse event; BAFF=B cell activating factor; ECG=electrocardiogram; h=hours; Ig=immunoglobulin; IMP=investigational medicinal product; 
ITP=immune thrombocytopenia; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
 PRO=Patient Reported 
Outcomes; 
a In addition to time points mentioned, vital signs will be evaluated every 15 minutes during infusion. Respiratory rate will be assessed only once predose.
b Total IgG and IgG subclasses. 
c Evaluation of ITP-specific autoantibodies will be performed prior to dose 1 only. 
d Serum and plasma complement levels will be assessed prior to dose 1 and dose 3 only.
e Blood sample for Baseline cytokine values will be obtained at Visit 2 for all subjects at predose and at other visits in case of infusion reactions.
f PRO endpoint (NFI-MS) will be assessed prior to dose 1 only.
REDACTED COPY 
OP
TE
AC
AC
AC
AC
AC
RE
eting authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
4h a
r v
4h a
va
o
ns
on
en
e
a
on
ca
plic
n a
iz
th
g
ny market ng
ket
X
y m
X
ma
ny
This document cannot be used to support a
G=electr
t any
G=electr
ical Fat
ort 
ical Fat
s will be
supp
s will be
s w
ed
s will be
d to
ill be
will be 
sed
will be 
e values 
e us
e values 
assesse
t be 
assesse


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 224 of 353
Has been changed to:
Table 5‒4:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of infusion
4h after end of infusion
Withdrawal criteria
X
Platelet count (local laboratory) for inclusion check 
at Visit 2 and for withdrawal criterion at other 
dosing visits
X
Prior and concomitant medications
X
Concomitant medical procedures
X
Vital signsa
X
X
X
X
Physical examination
X
12-lead ECGb
X
Hematology 
X
Clinical chemistry
X
Urinalysis
X
Urine pregnancy test
X
Immunoglobulinsc
X
ITP-specific autoantibodiesd
X
Blood sampling for UCB7665 plasma 
concentration
X
Anti-UCB7665 antibodies/IgG depletion assay
X
Serum (C3 and C4) and plasma complements (C3a 
and C5a)e
X
Serum biomarkers 
X
X
X
Serum BAFF levels
X
X
X
REDACTED COPY 
Y
OP
D
CT
AC
DA
R
keting authorization application and any extensions or variations thereof.
15 Fe
here
15 Fe
on
n
ons 
n
o
ns
io
ten
d a
a
ati
plic
pli
pli
pli
pl
a
ati
or
au
ng
ng
used to support any marketing
ng
ng
ke
X
ny m
X
m
an
pp
up
nts (C3a
d to
nts (C3a
o s
us
This document cannot be
ot
ca
be u
ot be


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 225 of 353
Table 5‒4:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of infusion
4h after end of infusion
Blood sampling for cytokinesf
X
Whole blood sample for DNA and RNA (optional)g
X
ITP bleeding scale
X
AEs
X
X
X
X
NFI-MSh
X
AE=adverse event; BAFF=B cell activating factor; DNA=deoxyribonucleic acid; ECG=electrocardiogram; h=hours; Ig=immunoglobulin; IMP=investigational 
medicinal product; ITP=immune thrombocytopenia; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
PRO=Patient Reported Outcomes; RNA=ribonucleic acid; 
a In addition to time points mentioned, vital signs will be evaluated every 15 minutes during infusion. Respiratory rate will be assessed only once predose.
b The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
c Total IgG and IgG subclasses. 
d Evaluation of ITP-specific autoantibodies will be performed prior to dose 1 only. 
e Serum and plasma complements (C3a and C5a) will be assessed prior to dose 1 and dose 3 only.
f Blood sample for Baseline cytokine values will be obtained at Visit 2 for all subjects at predose and at other visits in case of infusion reactions.
g For DNA, samples are taken at Baseline (Visit 2) and last dose only. For RNA, samples are taken at Baseline (Visit 2), Visit 3, at last dose, and End of Study 
Visit. All samples collected prior to dosing (if applicable for visit).
h PRO endpoint (NFI-MS) will be assessed prior to dose 1 only.
ACTED COPY
rin
Y
rin
of labo
OPY 
of labo
only.
TED
only.
dose 1
CTE
dose 1
REDA
for all 
DAC
for all 
y. For R
EDA
y. For R
t).
R
t).
any extensions or variations thereof.
15 Fe
here
15 Fe
on
4h a
or v
4h a
va
o
ns
on
en
X
ny
X
e
horization application and an
an
an
gram; h=
n an
gram; h=
iple scle
tion
iple scle
fusion. R
plic
fusion. R
ratory p
app
ratory p
 and do
horiz
 and do
This document cannot be used to support any marketing aut
subject
utho
subject
RNA, sa
aut
RNA, sa


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 226 of 353
Change #26
Section 5.3
Schematic diagram
Figure 5‒1: Schematic diagram
DMC=Data Monitoring Committee; EOS=End of Study; sc=subcutaneous
RED
nd of S
RED
nd of S
DACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
tudy; sc
g au
tudy; sc
authorization application and any extensions or variat


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 227 of 353
Has been changed to:
Figure 5‒1: Schematic diagram
DMC=Data Monitoring Committee; EOS=End of Study; sc=subcutaneous
Note: 2x4mg/kg refers to UCB7665 4mg/kg dose given twice weekly.
Change #27
Section 5.4.5
Rationale for dose selection
Paragraph #5:
Therefore, doses of UCB7665 4mg/kg given once weekly for 5 weeks and UCB7665 7mg/kg 
given once weekly for 3 weeks have been selected to evaluate the safety, tolerability and effect 
on platelet count in subjects with primary persistent or chronic ITP.
Has been changed to:
Therefore, doses of UCB7665 4mg/kg given once weekly for 5 weeks and UCB7665 7mg/kg 
given once weekly for 3 weeks have been selected as the initial doses to evaluate the safety, 
tolerability and effect on platelet count in subjects with primary persistent or chronic ITP. 
However, modelled data has shown a similar IgG reduction in a 4mg/kg twice weekly dosing 
regimen as in a 7mg/kg weekly dosing regimen. Therefore, a third dosing arm of UCB7665 
4mg/kg twice weekly has been integrated into the study design to explore the PD effect of 
UCB7665 administered as an sc infusion in subjects with ITP following a more frequent dosing 
regimen. This dose arm will be initiated after safety data review of at least 3 subjects in Dose 
Arm 2 is done and Dose Arm 1 has completed enrollment of 15 subjects.
REDAC
of Stu
EDA
of Stu
dose g
RED
dose g
ACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
udy; sc=
aut
udy; sc=
given tw
ng a
given tw
ose 
ma
ose sel
ma
sel
7665 4
port
7665 4
3 week
supp
3 week
subjec
to su
subjec
hange
sed 
hange
doses o
be u
doses o
nce wee
ot b
nce wee
ability
anno
ability a
o
a
y
o
y
owever
t can
owever
regime
ent 
regime
4m
me
4m
U
horization application and any extensions or variat


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 228 of 353
Change #28
NEW Section 5.4.6
Justification for additional genomic analyses
DNA analysis
A genetic component in ITP has long been suspected to predispose some persons to develop ITP 
when exposed to a provocative event.
Further, the hypothesis of underlying genetic risk for ITP is supported by rare anecdotal and case 
reports of familial ITP. Affected members of these families present with ITP that meets the 
clinical criteria for primary ITP, but demonstrates a convincing pattern of inheritance. A 2006 
review of the Pediatric and Adult Registry of Chronic ITP (PARC-ITP) (Johnsen, 2012) found 
that 10 of 445 (2.2%) of pediatric patients reported a positive family history of ITP. However, 
identification of susceptibility genes in ITP, via family linkage studies or genome wide 
association studies, have not yet been forthcoming, likely due to the rarity of familial ITP 
families available for study and the heterogeneity of ITP sporadic cases. Identification and 
characterization of a genetic and/or epigenetic component of familial ITP will lead to important 
clues into the pathogenesis of more common forms of ITP and possibly advance understanding 
of drug response phenotypes. 
RNA analysis
Gene expression (mRNA) analyses have identified distinct gene transcription signatures from 
whole blood associated with many autoimmune diseases including rheumatoid arthritis, systemic 
lupus erythematosus, and ITP. Such signatures have provided molecular insight into disease 
biology and can facilitate patient stratification via gene expression panels predictive of 
therapeutic response and clinical outcomes. 
Collection of blood for RNA analysis will enable identification of candidate markers for 
treatment effect and safety, and determine the feasibility of patient stratification.
MicroRNA analysis
MicroRNA are short (19-25 nucleotides) evolutionarily conserved single-stranded RNA 
molecules that regulate the expression of genes involved in diverse biological processes. The 
effect of miRNA on mRNA is mediated through the binding of the miRNA to the target mRNA 
ribonucleoprotein complex resulting in altered expression and decreased protein translation.  
Regulated miRNA in ITP significantly affect both gene and protein expression in T cells, 
indicating that they may be important regulatory molecules involved in the loss of immune 
tolerance in ITP.
In summary, the genetic, epigenetic, and genomic elements of ITP are complex and require 
further elucidation to understand the cause, progression, and appropriate treatment of ITP. 
Through the voluntary collection of blood DNA/and RNA samples from consenting subjects, this 
substudy will help enable further investigation of this complex disease.
REDACTED COPY 
distinc
OPY
distinc
disease
D CO
disease
s have
TED 
s have
ion via
CTE
ion via
mes.
DAC
mes.
s will
RE
s will
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ase 
ria
ase 
2006
or v
2006
2) foun
ons o
2) foun
. Howe
nsion
. Howe
me wide
xtens
me wide
familia
y ext
familia
denti
any
dentific
y 
fic
TP will 
nd a
TP will 
bly
n a
bly adv
and
adv
y
a
y
ct gene
app
ct gene
es inclu
tion 
es inclu
e provi
izati
e provi
a gene 
horiz
a gene 
 enabl
ng a
 enabl
mine the
ketin
mine the
ucleotid
any 
ucleotid
expres
ort a
expres
NA is m
ppo
NA is m
mplex r
sup
mplex r
A in IT
d to
A in IT
they
used
they m
e
m
y
e
y
ITP.
be u
ITP.
mary
not
mary, t
b
, t
er eluc
ann
er eluc
hrough
nt ca
hrough
subst
ment
subst


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 229 of 353
Change #29
Section 6.1
Inclusion criteria
7. Female subjects of childbearing potential must have a negative serum pregnancy test at the 
Screening Visit, which is confirmed to be negative by urine testing prior to the first dose of 
IMP at Week 1 (Visit 2) and prior to further dosing at each study visit thereafter. 
Female subjects of childbearing potential must agree to use a highly effective method of 
birth control, during the study and for a period of 3 months after their final dose of IMP. 
Highly effective forms of birth control are methods which achieve a failure rate of less than 
1% per year when used consistently and correctly. Highly effective methods of birth control 
include:
…
Has been changed to:
7. Female subjects of childbearing potential must have a negative serum pregnancy test at the 
Screening Visit, which is confirmed to be negative by urine testing prior to the first dose of 
IMP at Week 1 (Visit 2) and prior to further dosing at each study visit thereafter. 
Female subjects of childbearing potential must agree to use a highly effective method of 
birth control, during the study and for a period of 2 months after their final dose of IMP. 
Highly effective forms of birth control are methods which achieve a failure rate of less than 
1% per year when used consistently and correctly. Highly effective methods of birth control 
include:
…
Change #30
Section 6.5
Study stopping rules
Paragraph #2:
More detailed criteria for stopping a cohort will be defined in the DMC charter.
Has been changed to:
More detailed criteria for stopping a dose arm will be defined in the DMC charter.
Change #31
Section 7.2
Treatment to be administered
Paragraph #1: Dose Arm 3 details added as follows:
Subjects in the Dose Arm 3 will receive 5 sc doses of UCB7665 4mg/kg at 3 to 4 day intervals 
(ie, approximately twice a week).
REDACTED COPY
f 2 m
PY 
f 2 m
thods 
COP
thods 
rrectly
D C
rrectly
nnot be used to support any marketing authorization application and any extensions or variations thereof.
s than
r va
s than 
th contr
ns o
th contr
um preg
nd a
um preg
ng prio
and
ng prio
ud
tio
udy vis
ion 
y vis
se a hig
plica
se a hig
onths af
appl
onths af
which
on ap
which
y
a
y. High
ation
. High
pping a
t any
pping a
to:
ppo
to:
a for st
o sup
a for st
Tre
e us
Tre
ph #1: 
not b
ph #1: 
This document ca
bjects in
cann
bjects in
(ie,
nt
(ie, a
t c
app
c
pp
ap
a
c
ap
a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 230 of 353
Change #32
Section 7.4
Labeling
Clinical drug supplies will be labeled in accordance with the current International Conference on 
Harmonisation (ICH) guidelines on GCP and GMP and will include any locally required 
statements. If necessary, labels will be translated into the local language.
Has been changed to:
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (ICH) guidelines on GCP and GMP and will include any locally required 
statements. If necessary, labels will be translated into the local language.
Change #33
Section 7.10
Randomization and numbering of subjects
Paragraph #2:
The first 6 subjects (and those treated before DMC assessment after the 6 subjects) will not be 
randomized. Once the DMC has approved opening of Dose Arm 2 for enrollment, subsequent 
subjects will be randomized to 1 of the 2 dose arms in a 1:1 ratio. Once 15 subjects are in the 
4mg/kg group, the remaining subjects will not be randomized. They will be allocated to the 
7mg/kg group.
Has been changed to:
The first 6 subjects (and those treated before DMC assessment after the 6 subjects) will not be 
randomized. Once the DMC has approved opening of Dose Arm 2 for enrollment, subsequent 
subjects will be randomly assigned to 1 of the 2 dose arms (ie, Dose Arm 1 and Dose Arm 2) in a 
1:1 ratio. Once 15 subjects are enrolled in the Dose Arm 1 and safety data review of at least 
3 subjects in Dose Arm 2 is done, the remaining subjects will be randomly assigned in 1:1 ratio 
to either Dose Arm 2 or Dose Arm 3. Once 15 subjects are enrolled in the Dose Arm 2 or 
6 subjects are enrolled in Dose Arm 3, the respective dose arm will be closed. 
Change #34
Section 8.1.1 Visit 1 (Day -28 to -1) Screening Visit
Has been changed to:
Section 8.1.1 Visit 1 (Day -28 to -1) Screening Visit (all Dose Arms)
Detail regarding informed consent process for exploratory genomic analyses added as follows:
Subjects will also have the option of providing additional voluntary informed consent for 
collection of whole blood samples for exploratory DNA and RNA analyses.
NEW bullet:

Obtain informed consent for substudy involving DNA and RNA analyses
REDACTED COPY 
omi
Y
omi
e DM
CTE
e DM
ed ope
DAC
ed ope
1 of t
RED
1 of t
ed i
R
ed i
pport any marketing authorization application and any extensions or variations thereof.
fo
for 
v
r
the 6
and
the 6 su
d
su
2 for en
tion a
2 for en
io. Onc
catio
io. Onc
d
p
d.
p
. The
pplic
The
MC asse
horiz
MC asse
ening o
utho
ening o
the 2 d
g au
the 2 d
in the D
eting
in the D
e remai
rket
e remai
o sup
3
m
3. On
mar
. On
Arm
ny m
Arm 3
m
3
(Day
upp
(Day -
pp
-
y
pp
y
ot be used t
2
p
2
nged t
d to s
nged t
Visit 
used
Visit 
arding 
t be 
arding 
nt cann
cts will
nnot
cts will
lection
can
lection
This documen
NEW
ment
NEW


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 231 of 353
Change #35
Section 8.2
Dosing Period 
Has been changed to:
Section 8.2
Dosing Period for Dose Arms 1 and 2 (weekly dosing regimen)
Change #36
Section 8.2.1 Visit 2 (Week 1/Day 1) Baseline Visit
Paragraphs #2, #3, and #4:
Eligible subjects will be treated with IMP at Visit 2. The first 6 subjects will be enrolled in Dose 
Arm 1, subsequent subjects will be randomized to 1 of the 2 dose arms. Once 15 subjects are in 
Dose Arm 1, the remaining subjects will not be randomized. They will be allocated to Dose 
Arm 2. 
Eligible subjects will be treated with IMP at Visit 2. The first 6 subjects will be enrolled in Dose 
Arm 1, subsequent subjects will be randomized to 1 of the 2 dose arms. Once 15 subjects are in 
Dose Arm 1, the remaining subjects will not be randomized. They will be allocated to Dose 
Arm 2. 
Subjects allocated to Dose Arm 1 (UCB7665 4mg/kg sc) will receive a total of 5 doses of IMP at 
Visit 2 (Day 1, Week 1), Visit 4 (Week 2), Visit 5 (Week 3), Visit 6 (Week 4), and Visit 7 
(Week 5). 
Subjects allocated to Dose Arm 2 (UCB7665 7mg/kg sc) will receive a total of 3 doses of IMP at 
Visit 2 (Day 1, Week 1), Visit 4 (Week 2), and Visit 5 (Week 3). 
Has been changed to:
Section 8.2.1 Visit 2 (Week 1/Day 1) Baseline Visit [UCB7665 4mg/kg weekly and UCB7665 
7mg/kg weekly]
Eligible subjects will be treated with IMP at Visit 2. The first 6 subjects will be enrolled in Dose 
Arm 1; subsequent subjects will be randomly assigned to 1 of the 2 dose arms (ie, Dose Arm 1 
and Dose Arm 2). Once 15 subjects are in Dose Arm 1 and at least 3 subjects are in Dose Arm 2, 
the remaining subjects will be randomly assigned in 1:1 ratio to either Dose Arm 2 or Dose 
Arm 3. Once 15 subjects are in Dose Arm 2 or 6 subjects are enrolled in Dose Arm 3, the 
respective dose arm will be closed.
Subjects allocated to Dose Arm 1 (UCB7665 4mg/kg weekly sc) will receive a total of 5 doses of 
IMP at Visit 2 (Day 1, Week 1), Visit 4 (Week 2), Visit 5 (Week 3), Visit 6 (Week 4), and 
Visit 7 (Week 5). 
Subjects allocated to Dose Arm 2 (UCB7665 7mg/kg weekly sc) will receive a total of 3 doses of 
IMP at Visit 2 (Day 1, Week 1), Visit 4 (Week 2), and Visit 5 (Week 3). 
NEW bullet:

Collection of whole blood for exploratory DNA and RNA analyses
REDACTED COPY
sc) w
PY 
sc) w
(Week
COP
(Week
65 7mg
CTE
65 7mg
2), and
DAC
2), and
ort any marketing authorization application and any extensions or variations thereof.
lled in 
ions
lled in 
subjects
ensio
subjects
ated to
xten
ated to
will be
d an
will be
ms. Onc
and
ms. Onc
will
on a
will be
a
be
will rece
appli
will rece
k 3), V
on ap
k 3), V
g/kg sc
horiz
g/kg sc
d Visit 
utho
d Visit 
) Basel
rket
) Basel
d
a
d with 
any 
with 
will be
ort a
will be
cannot be used to supp
15 subj
ppor
15 subj
s will b
supp
s will b
ubjects 
d to s
ubjects 
arm wi
sed t
arm wi
ocated
e us
ocated
isit
t b
isit 2 (
be
2 (
7 (Wee
nno
7 (Wee
This document 
ubjects
nt ca
ubjects
IMP a
ment
IMP a
N
m
N


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 232 of 353
Change #37
Section 8.2.2 Visit 3 (Week 1/Day 4)
Has been changed to:
Section 8.2.2 Visit 3 (Week 1/Day 4) [UCB7665 4mg/kg weekly and UCB7665 7mg/kg 
weekly]
New bullet:

For Dose Arm 1 and 2, collection of whole blood for exploratory RNA analyses 
Change #38
Section 8.2.3 Visit 4 (Week 2/Day 8)
Has been changed to:
Section 8.2.3 Visit 4 (Week 2/Day 8) [UCB7665 4mg/kg weekly and UCB7665 7mg/kg 
weekly]
Change #39
Section 8.2.4 Visit 5 (Week 3/Day 15)
Has been changed to:
Section 8.2.4 Visit 5 (Week 3/Day 15) [UCB7665 4mg/kg weekly and UCB7665 7mg/kg 
weekly]
New bullet:

For Dose Arm 2 only, collection of whole blood for exploratory DNA and RNA analyses
Change #40
Section 8.2.5 Visit 6 (Week 4/Day 22) [UCB7665 4mg/kg only]
Has been changed to:
Section 8.2.5 Visit 6 for Dose Arm 1 (Week 4/Day 22) [UCB7665 4mg/kg only]
Change #41
Section 8.2.6 Visit 7 (Week 5/Day 29) [UCB7665 4mg/kg only]
Has been changed to:
Section 8.2.6 Visit 7 for Dose Arm 1 (Week 5/Day 29) [UCB7665 4mg/kg only]
New bullet:

For Dose Arm 1 only, collection of whole blood for DNA and RNA analyses
REDACTED COPY 
665 4m
D CO
665 4m
of wh
RED
of wh
ot be used to support any marketing authorization application and any extensions or variations thereof.
CB766
d any
CB766
mg/kg 
ation
mg/kg 
hole blo
ng a
hole blo
ay
y m
ay 22) 
y ma
22) 
y
y m
y
r Dose 
ppor
r Dose 
Visit 7 (
ed t
Visit 7 (
 chan
be us
 chan
This document cannot
8.2.6
ot b
8.2.6
w b
ca
w bulle
ann
ulle

e

Fo
nt 
Fo


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 233 of 353
Change #42
NEW Sections 8.3, 8.3.1, 8.3.2, 8.3.3, 8.3.4, and 8.3.5:
Section 8.3
Dosing for Dose Arm 3 (twice weekly dosing regimen)
Subjects allocated to Dose Arm 3 (UCB7665 4mg/kg twice weekly sc) will receive a total of 
5 doses of IMP at Visit 2 (Day 1, Week 1), Visit 3 (Day 4, Week 1), Visit 4 (Day 8, Week 2), 
Visit 5 (Day 11, Week 2), and Visit 6 (Day 15, Week 3). 
Section 8.3.1 Visit 2 (Week 1 Day 1) Baseline Visit [UCB7665 4mg/kg twice weekly]
The same conditions and assessments are required at this Visit as are detailed in Section 8.2.1.
Section 8.3.2 Visit 3 (Week 1/Day 4) [UCB7665 4mg/kg twice weekly]
This is the second dosing visit and a window of +1 day is allowed for this visit. However, there 
should be a minimum of 3 days (72 hours) interval between two doses. 
The assessments at this visit are identical to those detailed in Section 8.2.3. Additional to the 
assessments mentioned in Section 8.2.3, whole blood samples will be collected for RNA 
analyses.
Section 8.3.3 Visit 4 (Week 2/Day 8) [UCB7665 4mg/kg twice weekly]
This is the third dosing visit and a window of +1 day is allowed for this visit, relative to Dose 1 
at the Visit 2 date. However, there should be a minimum of 3 days (72 hours) interval between 
two doses.
The assessments at this visit are identical to those detailed in Section 8.2.4.
Section 8.3.4 Visit 5 (Week 2/Day 11) [UCB7665 4mg/kg twice weekly]
This is the fourth dosing visit and a window of +1 day is allowed for this visit, relative to Dose 1 
at the Visit 2 date. However, there should be a minimum of 3 days (72 hours) interval between 
two doses.
The assessments at this visit are identical to those detailed in Section 8.2.5.
Section 8.3.5 Visit 6 (Week 3/Day 15) [UCB7665 4mg/kg twice weekly]
This is the fifth dosing visit and a window of +1 day is allowed for this visit, relative to Dose 1 at 
the Visit 2 date. However, there should be a minimum of 3 days (72 hours) interval between two 
doses.
The assessments at this visit are identical to those detailed in Section 8.2.6. Blood samples will 
be collected for DNA and RNA analyses.
Change #43
Section 8.3
Observation Period
Paragraph #2:
For UCB7665 4mg/kg dose, the following visits will be performed: Visit 8, Visit 9, Visit 10, 
Visit 11, Visit 12, Visit 13, Visit 14, and Visit 15, corresponding to UCB7665 7mg/kg Visit 6, 
Visit 7, Visit 8, Visit 9, Visit 10, Visit 11, Visit 12, and Visit 13.
REDACTED COPY
y
O
y is all
OPY 
is all
nimum
COP
nimum
o thos
CTE
o thos
) [UC
EDA
) [UC
wind
R
wind
ny marketing authorization application and any extensions or variations thereof.
8.2.1
s or
8.2.1
Howev
xten
Howev
.3
d
.3.
d a
. Add
an
Add
collec
and
collec
ce 
lic
ce wee
cat
wee
owed f
app
owed f
m of 3 
on a
m of 3 
e detai
horiz
e detai
CB7665
aut
CB7665
dow of
eting
dow of
hould b
arket
hould b
This document cannot be used to support an
re iden
any
re iden
eek 3/D
port
eek 3/D
g visit 
sup
g visit 
owever
d to s
owever
ments a
be u
ments a
ted for
ot be
ted for
ange #
cann
ange #
Section
ent c
Section
Pa
m
Pa


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 234 of 353
Has been changed to:
Section 8.4
Observation Period
For UCB7665 4mg/kg weekly dose (Dose Arm 1), the following visits will be performed: 
Visit 8, Visit 9, Visit 10, Visit 11, Visit 12, Visit 13, Visit 14, and Visit 15, corresponding to 
UCB7665 7mg/kg weekly dose (Dose Arm 2) on Visit 6, Visit 7, Visit 8, Visit 9, Visit 10, 
Visit 11, Visit 12, and Visit 13.
For the UCB7665 4mg/kg twice weekly dose (Dose Arm 3), the following visits will be 
performed: Visit 7, Visit 8, Visit 9, Visit 10, Visit 11, Visit 12, Visit 13, and Visit 14.
Change #44
Section 8.3.1 Visit 8 (Week 5/Day 32) [UCB7665 4mg/kg]/ Visit 6 (Week 3/Day 18) 
[UCB7665 7mg/kg]
Has been changed to:
Section 8.4.1 Visit 8 (Week 5/Day 32) [UCB7665 4mg/kg weekly]/ Visit 6 (Week 3/Day 18) 
[UCB7665 7mg/kg weekly]/ Visit 7 (Week 3/Day 18) [UCB7665 4mg/kg twice weekly]
Change #45
Section 8.3.2 Visit 9 (Week 6/Day 36) [UCB7665 4mg/kg]/ Visit 7 (Week 4/Day 22) 
[UCB7665 7mg/kg]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit.
The following assessments will be performed at this visit:
…
Has been changed to:
Section 8.4.2 Visit 9 (Week 6/Day 36) [UCB7665 4mg/kg weekly]/ Visit 7 (Week 4/Day 22)
[UCB7665 7mg/kg weekly]/ Visit 8 (Week 4/Day 22) [UCB7665 4mg/kg twice weekly]
This is the second visit in the Observation Period. A visit window of ±2 days is applicable for 
this visit relative to the day of the final dosing visit. The following assessments will be 
performed at this visit:
…
Change #46
Section 8.3.3 Visit 10 (Week 7/Day 43) [UCB7665 4mg/kg]/ Visit 8 (Week 5/Day 29)
[UCB7665 7mg/kg]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit. 
This visit can be performed at home with a healthcare professional visiting the subject at his/her 
home. The following assessments will be performed at this visit:
…
REDACTED COPY
mg/k
PY 
mg/k
is visit
ED C
is visit
ed at t
CTE
ed at t
rt any marketing authorization application and any extensions or variations thereof.
y
e
y 18)
ensi
18) 
Visit
and
Visit 6
 
6
mg/kg 
on a
mg/kg 
g]/ Visi
appl
g]/ Visi
t relati
zatio
t relati
this vis
horiz
this vis
36) [U
arke
36) [U
it
y
it 8
m
8 (W
ma
(W
e Obser
t any
e Obser
nnot be used to suppo
y
p
y of the
ort 
of the
y
3.
b
3.3
be
3 Vi
e u
Vi
665
not
665 7m
t b
7m
This document ca
visit win
can
visit win
This vi
ent c
This vi
hom
men
hom


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 235 of 353
Has been changed to:
Section 8.4.3 Visit 10 (Week 7/Day 43) [UCB7665 4mg/kg weekly]/ 
Visit 8 (Week 5/Day 29) [UCB7665 7mg/kg weekly]/ 
Visit 9 (Week 5/Day 29) [UCB7665 4mg/kg twice weekly]
This is the third visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. This visit can be performed at home with a 
healthcare professional visiting the subject at his/her home. The following assessments will be 
performed at this visit:
…
Change #47
Section 8.3.4 Visit 11 (Week 8/Day 50) [UCB7665 4mg/kg]/ Visit 9 (Week 6/Day 36)
[UCB7665 7mg/kg]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit.
The following assessments will be performed at this visit:
…
Has been changed to:
Section 8.4.4 Visit 11 (Week 8/Day 50) [UCB7665 4mg/kg weekly]/ Visit 9 (Week 6/Day 36)
[UCB7665 7mg/kg weekly]/ Visit 10 (Week 6/Day 36) [UCB7665 4mg/kg twice weekly]
This is the fourth visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. The following assessments will be performed at 
this visit:
…
Change #48
Section 8.3.5 Visit 12 (Week 9/Day 57) [UCB7665 4mg/kg]/ Visit 10 (Week 7/Day 43)
[UCB7665 7mg/kg]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit. 
This visit can be performed at home with a healthcare professional visiting the subject at his/her 
home. The following assessments will be performed at this visit:
…
Has been changed to:
Section 8.4.5 Visit 12 (Week 9/Day 57) [UCB7665 4mg/kg weekly]/ Visit 10 (Week 7/Day 43) 
[UCB7665 7mg/kg weekly]/ Visit 11 (Week 7/Day 43) [UCB7665 4mg/kg twice weekly]
This is the fifth visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. This visit can be performed at home with a 
healthcare professional visiting the subject at his/her home. The following assessments will be 
performed at this visit:
…
REDACTED COPY 
65 4m
COP
65 4m
Day
D C
Day 36
CO
36
eriod. 
CTE
eriod. 
g visit
DAC
g visit
not be used to support any marketing authorization application and any extensions or variations thereof.
/Day
exte
/Day 3
of the f
nd a
of the f
mg/kg w
on ap
mg/kg w
6)
at
6) [UC
tion
[UC
A visi
horiz
A visi
t. The f
utho
t. The f
9/Day
any 
9/Day
ays is a
uppo
ays is a
formed
o sup
formed
wing ass
d to
wing ass
en ch
ot be
en ch
This document can
on 8.4
anno
on 8.4
UCB76
t ca
UCB76
This
men
This
vi
m
vi


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 236 of 353
Change #49
Section 8.3.6 Visit 13 (Week 10/Day 64) [UCB7665 4mg/kg]/ Visit 11 (Week 8/Day 50)
[UCB7665 7mg/kg]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit.
The following assessments will be performed at this visit:
…
Has been changed to:
Section 8.4.6 Visit 13 (Week 10/Day 64) [UCB7665 4mg/kg weekly]/Visit 11 (Week 8/Day 50) 
[UCB7665 7mg/kg weekly]/ Visit 12 (Week 8/Day 50) [UCB7665 4mg/kg twice weekly]
This is the sixth visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. The following assessments will be performed at 
this visit:
…
Change #50
Section 8.3.7 Visit 14 (Week 11/Day 71) [UCB7665 4mg/kg weekly]/Visit 12 (Week 9/Day 57) 
[UCB7665 7mg/kg weekly]/ Visit 13 (Week 9/Day 57) [UCB7665 4mg/kg twice weekly]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit. 
This visit can be performed at home with a healthcare professional visiting the subject at his/her 
home. The following assessments will be performed at this visit:
…
Has been changed to:
Section 8.4.7 Visit 14 (Week 11/Day 71) [UCB7665 4mg/kg weekly]/Visit 12 (Week 9/Day 57)
[UCB7665 7mg/kg weekly]/ Visit 13 (Week 9/Day 57) [UCB7665 4mg/kg twice weekly]
This is the seventh visit in the Observation Period. A visit window of ±2 days is applicable for 
this visit relative to the day of the final dosing visit. This visit can be performed at home with a 
healthcare professional visiting the subject at his/her home. The following assessments will be 
performed at this visit:
…
Change #51
Section 8.3.8 End-of-Study Visit: Visit 15 (Week 13/Day 85) [UCB7665 4mg/kg]/ 
Visit 13 (Week 11/Day 71) [UCB7665 7mg/kg]
Has been changed to:
Section 8.4.8 End-of-Study Visit: Visit 15 (Week 13/Day 85) [UCB7665 4mg/kg weekly]/ 
Visit 13 (Week 11/Day 71) [UCB7665 7mg/kg weekly]/ Visit 14 (Week 11/Day 71)
[UCB7665 4mg/kg twice weekly]
REDACTED COPY
7)
PY
7) [U
PY 
[U
isit re
CO
isit re
althcar
ED C
althcar
erform
CTE
erform
t cannot be used to support any marketing authorization application and any extensions or variations thereof.
8/Day
s or
8/Day
ekly
ions
ekly]
ns
]
plicabl
tens
plicabl
ill be p
ext
ill be p
g weekl
licat
g weekl
CB766
appl
CB766
elative t
ion a
elative t
re prof
zatio
re prof
med at t
horiz
med at t
ay
a
ay 71) 
arke
71) 
y
a
y
t 13
ma
13 (W
a
(W
e Obser
t any
e Obser
y
p
y of the
port 
of the
y
p
y
visitin
uppo
visitin
sit:
o
sit:
b
51
e
51
8.3.8
ot b
8.3.8
13
an
13 (W
nno
(W
This documen
Has b
ent c
Has b
Sec
me
Sec


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 237 of 353
NEW bullet:

For all dose arms, collection of whole blood for exploratory RNA analyses
Change #52
Section 8.4
Early Withdrawal Visit
Paragraph #3:
The assessments to be done at both the Early Withdrawal Visit as well as the End-of-Study Visit 
are the same as those at Visit 15 for the UCB7665 4mg/kg group or Visit 13 for the 
UCB7665 7mg/kg group, except for the subject exit interview which will be performed at the 
End-of-Study Visit only.
Has been changed to:
Section 8.5
Early Withdrawal Visit
The assessments to be done at both the Early Withdrawal Visit as well as the End-of-Study Visit 
are the same as those at Visit 15 for the UCB7665 4mg/kg weekly (Dose Arm 1) group, Visit 13 
for the UCB7665 7mg/kg weekly (Dose Arm 2) group, or Visit 14 for the UCB7665 4mg/kg 
twice weekly (Dose Arm 3) group, except for the subject exit interview which will be performed 
at the End-of-Study Visit only.
Change #53
Section 9.1
Platelet counts
NEW variables:

Baseline-corrected AUEC for platelet count calculated from Baseline to the end of study visit

Clinical Response: platelet count ≥30x109/L and <100x109/L with at least 2-fold increase 
from Baseline value and absence of bleeding

Time to Clinical Response: time from starting treatment to achievement of Clinical Response

Duration of Clinical Response: measured from achievement of Clinical Response to loss of 
Clinical Response (loss of Clinical Response defined as platelet count <30x109/L or less than 
2-fold increase from Baseline platelet count or presence of bleeding)

Complete Clinical Response: platelet count ≥100x109/L and absence of bleeding

Time to Complete Clinical Response: time from starting treatment to achievement of 
Complete Clinical Response

Duration of Complete Clinical Response: measured from achievement of Complete Clinical 
Response to loss of Complete Clinical Response (loss of Complete Clinical Response defined 
as platelet count <100x109/L or presence of bleeding)

No Clinical Response: platelet count <30x109/L and less than 2-fold increase from Baseline 
or presence of bleeding
REDACTED COPY 
elet 
RED
elet co
D
co
≥3
R
≥3
pport any marketing authorization application and any extensions or variations thereof.
isit 
ari
isit 
at the
s or
at the
as the E
d an
as the E
Dose Ar
and
Dose Ar
4 for the
tion a
4 for the
nterview
catio
nterview
ount 
au
ount ca
u
ca
30x10
keting
30x109
g
9
e of ble
arke
e of ble
time fr
ny m
time fr
sponse
ort a
sponse
oss of C
ppor
oss of C
This document cannot be used to s
om Bas
supp
om Bas
nical R
d to
nical R
Comple
use
Comple
lete Cli
t be 
lete Cli
uration
nno
uration
Respo
t can
Respo
as p
nt c
as p

m



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 238 of 353
Change #54
Section 11
Assessment of other immunological variables
NEW assessment:

Lymphocyte counts (B and T)
Change #55
Section 12.1.1 Definition of adverse event
Paragraph #4:
Bleeding events should not be reported as an AE since these events will be assessed and reported 
during the ITP-BAT assessment. Common Terminology Criteria for Adverse Events (CTCAE) 
grade 3 or more bleeding events should be reported as AEs.
Has been changed to:
Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2 bleeding events 
should not be reported as an AE since these events will be assessed and reported during the 
ITP-BAT assessment; CTCAE grade 3 or more bleeding events should be reported as AEs. 
Change #56
Section 12.1.9
Safety signal detection
Paragraph #1:
The safety variables and ADA results available after 7 days of the final dose of 3 and 6 subjects 
in the UCB7665 4mg/kg dose arm will be reviewed by a DMC (interim analysis 1 and 2) 
comprising at least 1 external expert, the UCB study physician, the UCB DS representative, and 
a biostatistician and will be summarized on an ongoing basis during the study so as to 
continuously evaluate the safety of subjects. The DMC will meet and reach a decision on 
whether or not the study can continue as planned, and whether or not the next dose arm can be 
started. Subsequently, safety variables and ADA results available after 7 days of the final dose of 
3 and 6 subjects in the UCB7665 7mg/kg dose arm (together with all available data from the 
UCB7665 4 mg/kg dose arm) will be reviewed by the DMC (interim analysis 3 and 4).
Has been changed to:
The safety variables and ADA results available after 7 days of the final dose of 3 and 6 subjects 
in the UCB7665 4mg/kg weekly group (Dose Arm 1) will be reviewed by the DMC (interim 
analysis 1 and 2) comprising at least 1 external expert, the UCB study physician, the UCB PS
representative, and a biostatistician and will be summarized on an ongoing basis during the study 
so as to continuously evaluate the safety of subjects. The DMC will meet and reach a decision on 
whether or not the study can continue as planned, and whether or not Dose Arm 2 can be started. 
Subsequently, safety variables and ADA results available after 7 days of the final dose of 3 and 
6 subjects in the UCB7665 7mg/kg weekly (Dose Arm 2) (together with all available data from 
Dose Arm 1 and 2) will be reviewed by the DMC (interim analysis 3 and 4).
REDACTED COPY 
lable a
ACT
lable a
be rev
EDAC
be rev
the U
RED
the U
d
R
d
ort any marketing authorization application and any extensions or variations thereof.
and rep
ions
and rep
nts
n
nts (CT
nsio
(CT
or 2 ble
and a
or 2 ble
and rep
n an
and rep
should 
ation
should 
after 7 
thori
after 7 
viewed
auth
viewed
UCB st
ng a
UCB st
d on a
eting
d on a
g
subject
arke
subject
tinue as
y ma
tinue as
a
a
ariable
any 
riable
B7665 7
ort a
B7665 7
cannot be used to supp
arm) w
ppo
arm) w
ge
to
ged to
o sup
d to
ables an
sed t
ables an
665 4m
use
665 4m
and 2)
t be 
and 2)
ntative
not 
ntative
s to con
cann
s to con
This document 
hether
t ca
hether
Subse
men
Subse
6
m
6


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 239 of 353
Change #57
Section 12.7
Laboratory measurements
Table 12-2 Laboratory measurements
Deletion of: B and T Lymphocyte count
Addition of: γ-globulin
Change #58
Section 12.7.1 Evaluation of PDILI
Table 12-3 Required investigations and follow up for PDILI
Deletion of: ≥8xULN row
Addition of: Hepatology consult required if ALT or AST ≥8xULN to≥5xULN (and ≥2x 
Baseline) row immediate consultation requirements
Change #59
Section 12.8.512-Lead ECG
Paragraph #1:
A standard 12-lead ECG will be performed at visits as specified in the schedule of study
assessments (Section 5.2). Care should be taken to assure proper lead placement and quality 
ECG recordings. Subjects should rest in a supine position in a controlled, calm environment for 
at least 15 minutes prior to the recording and should be motionless during the recording. The 
ECG will be performed in triplicate prior to blood collection for assessment of laboratory
parameters.
Has been changed to:
A standard 12-lead ECG will be performed at visits as specified in the schedule of study
assessments (Section 5.2). Care should be taken to assure proper lead placement and quality 
ECG recordings. Subjects should rest in a supine position in a controlled, calm environment for 
at least 15 minutes prior to the recording and should be motionless during the recording. 
The ECG will be performed in triplicate prior to blood collection for assessment of laboratory
parameters. Three ECGs should be recorded in a time frame of 5 minutes with at least 1 minute 
difference, 1-2 minutes between the ECGs.
Change #60
Section 14.1
Definition of analysis sets
Full Analysis Set (FAS):
The FAS will consist of all subjects who have received at least 1 infusion (full infusion) of IMP 
and, in addition, have a Baseline and at least 1 post-Baseline measurement for platelet count.
The analysis of the PD, efficacy, and immunologic variables will be performed on the FAS. 
Selected outputs may be repeated for the Per Protocol Set (PPS). Further details will be provided 
in the SAP.
REDACTED COPY 
as spe
OPY
as spe
to assu
D CO
to assu
pine po
TED 
pine po
nd sho
ACTE
nd sho
or to
EDAC
or to b
AC
b
not be used to support any marketing authorization application and any extensions or variations thereof.
N (and
y ex
N (and
pecified
n app
pecified
sure pro
tion 
sure pro
osition 
izat
osition 
ould be
horiz
ould be
blood c
auth
blood c
perform
ma
perform
e shoul
any m
e shoul
hould r
rt an
hould r
to the r
ppor
to the r
formed
o sup
formed
ECGs
d to 
ECGs
minute
sed
minute
#
b
#
This document canno
60
be u
60
n 14.1
not 
n 14.1
ll Ana
t can
ll Ana
The F
men
The F
an
m
an


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 240 of 353
Has been changed to:
The FAS will consist of all subjects who have received at least 1 infusion (full infusion) of IMP 
and, in addition, have a Baseline and at least 1 post-Baseline measurement for platelet count.
The analysis of the PD (excluding total IgG, IgG subclasses, and IgG depletion assay), efficacy, 
and immunologic variables will be performed on the FAS. Selected outputs may be repeated for 
the PD Per Protocol Set (PD-PPS). Further details will be provided in the SAP. 
Change #61
Section 14.1
Definition of analysis sets
NEW analysis set:
Pharmacodynamic Per Protocol Set (PD-PPS)
The PD-PPS is a subset of the FAS, consisting of those subjects who had no important protocol 
deviations potentially affecting the serum concentration of total IgG, as confirmed during a 
pre-analysis review of the data prior to database lock.
The PD-PPS will be used for the analysis of the total IgG, IgG subclasses, and IgG depletion 
assay. 
Change #62
Section 14.2
General statistical considerations
All analyses will be performed using SAS® version 9.2 or later (SAS Institute, Cary, NC, USA). 
Continuous variables will be summarized by visit (where applicable) with the statistics including 
the number of subjects (n), mean, standard deviation (SD), median, minimum, and maximum. 
Categorical variables will be summarized by visit (where applicable) with frequency counts and 
percentages. Analyses will be performed by dose arm, unless otherwise stated. In the event that 
the number of infusions in the planned dose arms (3x7mg/kg and 5x4mg/kg) are modified 
following review by the DMC, the data will be summarized based on the actual dose arms 
completing the study. For example, if the 5x4 mg/kg dose arm is modified such that some 
subjects receive only 4 infusions, then the data will be summarized separately for this new dose 
regimen.
Has been changed to:
All analyses will be performed using SAS® version 9.2 or later (SAS Institute, Cary, NC, USA). 
Continuous variables will be summarized by visit (where applicable) with the statistics including 
the number of subjects (n), mean, standard deviation (SD), median, minimum, and maximum. 
Categorical variables will be summarized by visit (where applicable) with frequency counts and 
percentages. Analyses will be performed by dose arm, unless otherwise stated. In the event that 
the number of planned infusions in Dose Arms 1 and 2 (5x4mg/kg and 3x7mg/kg weekly) are 
modified following review by the DMC, the data will be summarized based on the actual dose 
arms completing the study. For example, if the weekly 5x4mg/kg dose arm is modified such that 
some subjects receive only 4 infusions, then the data will be summarized separately for this new 
dose regimen.
REDACTED COPY 
ersion
TED
ersion
by
AC
by vis
ACT
vis
y
AC
y
ard de
EDAC
ard de
rized b
RED
rized b
R
support any marketing authorization application and any extensions or variations thereof.
import
y ex
import
onfirm
d any
onfirm
bclasses
ion a
bclasses
n 9.2 or
rizat
n 9.2 or
it 
h
it (whe
hori
(whe
eviation
auth
eviation
by visi
ng a
by visi
ed by d
keting
ed by d
ned dos
arke
ned dos
he data 
y ma
he data 
mple, i
any 
mple, i
usions, 
ort a
usions, 
This document cannot be used to 
ged to
to su
ged to
ll be pe
sed t
ll be pe
variable
e use
variable
er of su
t be 
er of su
rical va
not 
rical va
entage
cann
entage
he num
nt ca
he num
mo
men
modi
n
di
arm
m
arm


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 241 of 353
Change #63
Section 14.3.2 Other safety analyses
Paragraph #1 and #2:
The absolute and relative frequencies for subjects with a given TEAE with respect to the 
preferred term according to the latest available version of the MedDRA, as well as the absolute 
frequencies of the individual TEAEs that have occurred, will be determined within each system 
organ class. Additional tables will summarize TEAEs by maximum intensity and causal 
relationship with UCB7665, as judged by the investigator. Adverse events will be categorized by
severity according to the CTCAE version 4.03 grading. In case the CTCAE grading is not 
available, the intensity (mild/moderate/severe) will be utilized. The TEAEs leading to 
discontinuation of IMP and treatment-emergent SAEs will also be summarized. The action taken, 
time of onset relative to dosing, and duration of each AE will be listed only.
For the continuous laboratory variables, the values and changes from Baseline will be 
summarized at each time point. For categorized values according to the reference range, shift 
tables from Baseline to each post-Baseline time point will be presented for selected variables to 
be defined in the SAP. Values outside the reference range will be flagged in the data listings.
Has been changed to:
The absolute and relative frequencies for subjects with a given TEAE with respect to the 
preferred term according to the latest available version of the MedDRA, as well as the absolute 
frequencies of the individual TEAEs that have occurred, will be determined within each system 
organ class. Additional tables will summarize TEAEs by maximum intensity and causal 
relationship with UCB7665, as judged by the investigator. Adverse events will be categorized by
severity according to the CTCAE version 4.03 grading. In case the CTCAE grading is not 
available, the intensity (mild/moderate/severe) will be utilized. For the purpose of the tabulations 
CTCAE grades will be aligned with the intensity classifications (mild/moderate/severe) to enable 
pooling of the AEs in the summaries. The TEAEs leading to discontinuation of IMP and 
treatment-emergent SAEs will also be summarized. The action taken, time of onset relative to 
dosing, and duration of each AE will be listed only.
For the continuous laboratory variables, the values and changes from Baseline will be 
summarized at each time point. For categorized values according to the reference range, shift 
tables from Baseline to each post-Baseline time point will be presented for selected variables to
be defined in the SAP. Values outside the reference range will be flagged in the data listings. The 
number and percentage of subjects with markedly abnormal laboratory results (based on CTCAE 
grading) will be tabulated for each dose arm.
Change #64
Section 14.4.1 Efficacy analyses
The main efficacy variable is the maximum increase from Baseline in platelet count during the 
study. The maximum increase from Baseline and maximum platelet count during the study will 
be summarized by dose arm.
In addition, all measurements of platelet count will be summarized by dose arm and time point 
using descriptive statistics (including changes from Baseline).
REDACTED COPY 
with a g
OPY
with a g
ersion
D CO
ersion
e occu
TED 
e occu
ize TE
ACTE
ize TE
by
D
by the 
DAC
the 
y
D
y
rsion 4
RED
rsion 4
e/s
R
e/s
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ized by
or va
ized by
not
ns
not
to
si
to
The acti
ensi
The acti
line wi
any 
line wi
referen
nd a
referen
ted for 
n and
ted for 
flagge
tion 
flagge
given T
n app
given T
n of the
tion 
n of the
urred, w
izati
urred, w
EAEs b
horiz
EAEs b
investi
auth
investi
4.03 gr
g au
4.03 gr
severe)
eting
severe)
the inte
arke
the inte
ries.
ma
ries. Th
a
Th
also be
any m
also be
h AE w
rt an
h AE w
ratory
uppo
ratory v
o
v
y
o
y
time po
o sup
time po
ine to e
d to 
ine to e
he SAP
sed
he SAP
percen
be us
percen
will be
ot be
will be
ange #
anno
ange #
Sectio
nt c
Section
c
n
The
me
The


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 242 of 353
For each dose arm a 1-sided t-test will be applied to assess if the average maximum increase 
from Baseline is greater than zero. In case the assumptions for the-t-test are not fulfilled a 
variance-stabilizing transformation may be applied in addition and/or an alternative 
nonparametric method may be considered. Further details will be provided in the SAP.
The Response rate, Complete Response rates, and platelet count ≥50x109/L rate will be 
summarized (number of subjects and percentages) and presented with 90% 2-sided confidence 
intervals for the rate of responders at each time point and overall (across all time points).
Response and Complete Response are defined in Section 4.2.
Time to Response, time to Complete Response, time to platelet count ≥50x109/L, duration of 
Response, duration of Complete Response, and duration of platelet count ≥50x109/L will be 
calculated and summarized by dose arm.
The results from the ITP bleeding scale will be summarized at each time point and will include 
the grades for each of the 3 major domains: skin (S), visible mucosae (M), and organs (O).
Results of the NFI-MS will be summarized at each time point, using summary scores where 
applicable. Changes from Baseline will be calculated and summarized.
Has been changed to:
The main efficacy variable is the maximum increase from Baseline in platelet count during the 
study. The maximum increase from Baseline and maximum platelet count during the study will 
be summarized by dose arm.
In addition, all measurements of platelet count will be summarized by dose arm and time point 
using descriptive statistics (including changes from Baseline).
For Dose Arm 1 and 2, a 1-sided t-test will be applied to assess if the average maximum increase 
from Baseline is greater than zero. In case the assumptions for the-t-test are not fulfilled, an 
alternative nonparametric method may be considered. Further details will be provided in the 
SAP.
The Response, Complete Response, and platelet count ≥50x109/L will be summarized (number 
of subjects and percentages) and presented with 90% 2-sided confidence intervals for the rate of 
responders at each time point and overall (across all time points). Response and Complete 
Response are defined in Section 4.2. The analysis will be repeated for the Clinical Response 
variables defined in Section 4.2.
Time to Response, time to Complete Response, time to platelet count ≥50x109/L, duration of 
Response, duration of Complete Response, duration of platelet count ≥50x109/L, and 
Baseline-corrected AUEC for platelet count will be calculated and summarized by dose arm. The 
time to first response will be analyzed using a log-rank test and displayed using Kaplan-Meier 
curves. The time taken Response, time to Complete Response, and respective durations will be 
summarized by dose arm.
The results from the ITP bleeding scale will be summarized at each time point and will include 
the grades for each of the 3 major domains: skin (S), visible mucosae (M), and organs (O). In 
addition the number and percentage of subjects with severe or clinically relevant bleeding and 
number and percentage of subjects with absence of bleeding will be summarized at each time 
point.
REDACTED COPY 
om
Y
om
aximu
OPY
aximu
nt will
TED
nt will
nges fr
ACT
nges fr
t will 
RED
t will 
cas
R
cas
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
n of 
or v
n of 
will be
ns 
will be
and wi
exte
and wi
and org
ny ex
and org
mmary
nd a
mmary
d.
a
d.
aseline
pplic
aseline
um plat
app
um plat
l be su
riza
l be su
from Ba
thor
from Ba
be app
g au
be app
se the a
eting
se the a
ay
rk
ay be co
rket
be co
y
rk
y
ponse, a
any 
ponse, a
) and p
ort a
) and p
point a
ppo
point a
in Sec
sup
in Sec
n Secti
to s
Secti
onse, tim
used
onse, tim
duration
be u
duration
correc
ot be
correc
to first 
nno
to first 
rves. T
t can
rves. T
summa
ent 
summa
Th
m
Th


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 243 of 353
Results of the NFI-MS will be summarized at each time point, using summary scores where 
applicable. Changes from Baseline will be calculated and summarized.
Additional subgroup analyses may be performed as needed and further details will be provided in 
SAP regarding these analyses.
Change #65
Section 14.4.3 Pharmacodynamic analyses
For all PD variables, descriptive statistics for the values and change from Baseline and/or 
percentage change from Baseline will be tabulated by time point. If appropriate, measurements 
will be log-transformed.
The PD variables will include ITP-specific autoantibodies
total IgG, and IgG subclasses. In addition, for total IgG, the maximum decrease from Baseline 
and minimum value will be evaluated and summarized. Figures of mean values over time and 
changes from Baseline will be presented.
Has been changed to:
For all PD variables, descriptive statistics for the values and change from Baseline and/or 
percentage change from Baseline will be tabulated by time point. 
The PD variables will include ITP-specific autoantibodies
total IgG, IgG subclasses, and total and endogenous IgG measured via IgG depletion assay. In 
addition, for total IgG, the maximum decrease from Baseline and minimum value will be 
evaluated and summarized. Figures of mean values over time and changes from Baseline will be 
presented.
Change #66
Section 14.4.4 Immunologic variables
Paragraphs #1 and #2:
All immunologic variables including concentrations of immunoglobulins (IgA, IgE, and IgM),
serum (C3 and C4) and plasma (C3a and C5a) complement levels, serum biomarkers 
 
 serum BAFF levels and the results of 
the IgG depletion assay will be summarized by dose arm over time (including changes from 
Baseline) using descriptive statistics. Figures of mean values over time and changes from 
Baseline may be presented.
The ADA status (negative/positive) and changes in relative mass units from Baseline will be 
summarized by dose arm; figures will also be presented.
Has been changed to:
All immunologic variables including concentrations of immunoglobulins (IgA, IgE, and IgM), 
serum (C3 and C4) and plasma (C3a and C5a) complement levels, serum biomarkers
 
, serum BAFF levels, and lymphocyte 
counts (B and T) will be summarized by dose arm over time (including changes from Baseline) 
using descriptive statistics. Figures of mean values over time and changes from Baseline may be 
presented.
REDACTED COPY 
bod
OPY
bodies
PY
ies
ous IgG
CO
ous IgG
from 
ED C
from 
n valu
CTE
n valu
ions or variations thereof.
ments
or v
ments
pplication and any exten
from 
xten
from 
ues ove
ny ex
ues ove
nge fro
ation
nge fro
oint. 
plica
oint. 
port any marketing authorization ap
G mea
tion 
G mea
Baseli
zatio
Baseli
ues ove
horiz
ues ove
s
ncludin
t any
ncludin
asma 
port
asma (C
(C
This document cannot be used to sup
say
o s
say wil
su
wil
escript
d to
escript
be pres
used
be pres
status 
t be 
status 
rized b
not b
rized b
as bee
t can
as bee
All im
ment
All im
ser
m
ser
ensio
n app
suppo


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 244 of 353
The ADA status (negative/positive) will be summarized by dose arm at each visit and overall; 
figures will also be presented in conjunction with PK concentrations of UCB7665 and with IgG 
depletion assay results.
Change #67
Section 14.4.5.2
Subject characteristics
Bullet #3:

Prior and concomitant medications
Has been changed to:

Past, prior, and concomitant medications
Change #68
Section 14.7
Planned interim analysis and data monitoring
Paragraphs #2, #4, #6, #8, and #13:
For the sequential adaptive design in this study, at least 4 interim analyses will be performed. 
Safety data from the interim analyses will be reviewed by the DMC to monitor the safety, to 
adapt the dose regimen, and to decide when and if the UCB7665 7mg/kg dose arm should be 
opened. Planned dosing may be discontinued for all subjects on a dose arm (see Section 6.5).
If the study continues without modifications, the next interim analysis will take place after data 
from 3 additional subjects are available. Based on the available combined data of the first 
6 subjects, the DMC will decide if the 3x7mg/kg dose arm can be initiated. If the new dose arm 
will be initiated and if the 5x4mg/kg will be continued, new subjects will be randomized to 1 of 
the 2 dose arms in an allocation ratio of 1:1(Once 15 subjects are in the 4mg/kg group, the 
remaining subjects will not be randomized. They will be allocated to the 7mg/kg group).
The fourth interim analysis and review of data by DMC will take place after safety data (7 days 
after final dose) is available for the first 6 subjects in Dose Arm 2.
The potential decisions based on the fourth and subsequent interim analysis for the UCB7665 
7mg/kg cohort are in line with the decisions described above for the UCB7665 4mg/kg cohort.
A detailed description of the DMC composition, processes and responsibilities, criteria to 
escalate to the next dose arm, and criteria to stop a dose arm will be provided in a separate DMC 
charter.
Has been changed to:
For the sequential adaptive design in this study, at least 4 interim analyses will be performed. 
Safety data from the interim analyses will be reviewed by the DMC to monitor the safety, to 
adapt the dose regimen, and to decide when and if the UCB7665 7mg/kg weekly group (Dose 
Arm 2) should be opened. Planned dosing may be discontinued for all subjects in a dose arm (see 
Section 6.5).
If the study continues without modifications, the next interim analysis will take place after data 
from 3 additional subjects are available. Based on the available combined data of the first 
6 subjects, the DMC will decide if the 3x7mg/kg dose arm can be initiated. If the new dose arm 
REDACTED COPY 
UC
Y
UC
subje
OPY
subje
e next 
D CO
e next 
ed on t
TED
ed on t
7mg/kg
ACT
7mg/kg
ill be c
EDA
ill be c
of 1:
RE
of 1:
i
R
i
marketing authorization application and any extensions or variations thereof.
anal
ion
analys
n 
yse
a
e
MC to
catio
MC to
7665 7m
pplic
7665 7m
ects on 
app
ects on 
t interim
ation
t interim
the ava
rizat
the ava
kg dose
thor
kg dose
continu
auth
continu
1
n
1(Onc
ng a
(Onc
ized
ketin
ized.
t
. T
n
T
view of
mar
view of
annot be used to support any
the firs
ny m
the firs
ed on th
ort a
ed on th
e wit
ppor
e with t
or
h t
on of th
o sup
on of th
xt dose
d to
xt dose
en cha
t be u
en cha
e seque
nnot
e seque
t c
fety
ca
fety dat
can
dat
y y
ca
y
This documen
adapt t
ent c
adapt t
Arm
me
Arm
S
m
S


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 245 of 353
will be initiated and if the 5x4mg/kg will be continued, new subjects will be randomly assigned
to 1 of the 2 dose arms in an allocation ratio of 1:1.
The fourth planned interim analysis and review of data by DMC will take place after safety data 
(7 days after final dose) is available for the first 6 subjects in Dose Arm 2.
The potential decisions based on the fourth and subsequent interim analysis for the UCB7665 
7mg/kg group (Dose Arm 2) are in line with the decisions described above for the UCB7665 
4mg/kg weekly group (Dose Arm 1).
A detailed description of the DMC composition, processes and responsibilities, criteria to 
escalate to the next dose arm, and criteria to stop, or continue a dose arm will be provided in a 
separate DMC charter.
Change #69
Section 14.8
Determination of sample size
Paragraph #1:
The sample size of 15 subjects, in each dose arm, is mainly based on the efficacy objective of the 
study. In addition the 2x15 subjects ensure that sufficient data are available to form conclusions 
about the safety of administering UCB7665.
Has been changed to:
The sample size of 15 subjects in Dose Arms 1 and 2, is mainly based on the efficacy objective 
of the study. In addition the 15 subjects in Dose Arms 1 and 2 ensure that sufficient data are 
available to form conclusions about the safety of administering UCB7665. Six subjects in Dose 
Arm 3 were judged to be sufficient in order to explore IgG reductions for the 5x4mg/kg/2 weeks 
dose regimen.
Change #70
Section 15.1
Informed consent
NEW paragraph #6:
Subjects have the right to withdraw their consent for the exploratory genomic substudy at any 
point without any impact on their care or participation in the main study. In this case, any data 
already generated on the samples will be retained and used, but no further analysis will occur.
Change #71
Section 15.4
Subject privacy
NEW paragraphs #3 and #4:
Genetic analysis data will not be shared with the subjects and will be subject to the highest level 
of data protection, as per European regulations.
Samples may be shared with collaborators working within UCB and may be analyzed at a third 
party site, but only in relation to the aims of this exploratory analysis as detailed in this study
protocol. Samples may be stored for up to 20 years and maybe used at any time up to that point. 
Samples will remain under the control of UCB at all times and may be destroyed at any point 
before the 20 year expiration date.
REDACTED COPY 
and 2,
D CO
and 2,
ose Ar
TED
ose Ar
fet
AC
fety o
ACT
y o
order to
EDA
order to
ot be used to support any marketing authorization application and any extensions or variations thereof.
ed in a
s or
ed in a
n the ef
n an
n the ef
e availa
ation
e availa
, is mai
ation
, is mai
rms
riza
rms 1 a
at
1 a
of admi
thor
of admi
to explo
auth
to explo
o withd
ppor
o withd
pact on 
supp
pact on 
on the s
to s
on the s
.4
b
.4
Su
 u
Su
This document cann
paragra
nnot
paragra
enetic a
t ca
enetic a
of dat
ment 
of dat
Sa
m
Sa


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 246 of 353
Change #72
Section 17 References
NEW reference:
Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc 
Hematol Educ Program. 2012;2012:306-12.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 247 of 353
18.9
Protocol Amendment 3
Rationale for the amendment
The primary purpose of this substantial amendment is to include three additional cohorts and a 
non-mandatory genomic substudy.
The previous protocol amendment (Protocol Amendment 2) was written to introduce a third 
cohort of 4mg/kg sc twice weekly. However, based on preliminary emerging data, it was
expected that the planned inclusion of a 3rd dose arm with 4mg/kg of sc UCB7665 given twice 
per week would not create additional insight regarding the safety and the tolerability of 
UCB7665 in subjects with ITP. Therefore the planned implementation of protocol amendment 
#02 has been canceled. Instead, protocol amendment 3 will enable to further explore the safety, 
tolerability and PD effect of the same cumulative dose of UCB7665 administered with higher 
doses given in less sc infusions by integrating three new dose arms into the study.
Dose Arm 3 (10mg/kg weekly) with a cumulative dose of 20mg/kg will be opened as per DMC 
recommendation after review of the safety data of at least 6 subjects of Dose Arm 2 (7mg/kg 
weekly).
Dose Arm 4 with a single dose of 15mg/kg will be activated after review of the safety data of at 
least 6 subjects of Dose Arm 3 (10mg/kg weekly) and the DMC recommends this 4th dose 
increase.
Dose Arm 5 with a single dose of 20mg/kg will be activated after review of the safety data of at 
least 6 subjects of Dose Arm 4 (15mg/kg weekly) and the DMC recommends this 4th dose 
increase.
During this amendment, additional exploratory genomic (DNA and RNA) analyses have been 
added as an optional substudy to evaluate the genomic components of ITP to understand the 
molecular etiology, progression, and treatment of the disease.
All of the changes that were made in protocol amendment 2 that are still applicable to the current
amendment 3 will be included in this section.
Modifications and changes
Global changes

The following changes were made throughout the protocol:

Addition of a new dose arm 10mg/kg administered once per week, a total of 2 sc doses.

Addition of a new dose arm 15mg/kg administered in one sc dose.

Addition of a new dose arm 20mg/kg administered in one sc dose. 

Additional exploratory genomic analyses added as an optional substudy.

Addition of detailed tuberculosis assessment to ensure the subject safety

Study variables were rearranged into ‘primary and others and exploratory variables.’ 


Serum biomarkers were changed to exploratory safety biomarkers throughout.
REDACTED COPY 
be acti
D CO
be acti
kl
TE
kly)
TED
y) an
D 
an
plorato
EDA
plorato
R
luate 
RE
luate 
g authorization application and any extensions or variations thereof.
ce
va
ce
ndmen
s o
ndmen
the sa
ion
the sa
d with h
tens
d with h
udy
ext
udy.
ex
.
e opene
any 
e opene
Dose A
nd a
Dose A
er revie
atio
er revie
MC reco
lica
MC reco
ivated 
tion 
ivated 
nd the 
zati
nd the 
ory
au
ory
be used to support any marketing
gen
aut
gen
y
au
y
e the ge
ting a
e the ge
reatmen
ketin
reatmen
in prot
mar
in prot
n this 
ny m
n this 
anges
ort a
anges
change
d to 
change
f a
us
f a
This document cannot b
new
sed
new
ion of a
t be
ion of a
Addition
anno
Addition
Add
nt ca
Add

me



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 248 of 353

The Clinical Response upper limit of normal (<100x109/L) was deleted.

The IgG depletion assay was removed.

Clarification was added that ECG is done in triplicate.
Specific changes
Change #1
STUDY CONTACT INFORMATION
Sponsor Study Physician
Name:
, MD
Address:
UCB BIOSCIENCES GmbH
Alfred-Nobel-Straße 10
40789 Monheim 
GERMANY
Phone:
Fax:
Has been changed to:
Name:
, MD
Address:
UCB BIOSCIENCES Inc.
8010 Arco Corporation Drive, Suite 175
Raleigh
NC 27617, USA
Phone:
Fax:
Y 
Y
REDACTED CO
CO
D
A
D
TE
CIENC
RED
CIENC
o
R
o
DA
OPY
any marketing authorization application and any extensions or variations thereof.
ns
ns
n a
pp
n 
riz
CES In
g au
CES In
orporati
keting
orporati
617, U
y m
617, U
ut
ny
This document cannot be used to supp
u
support any


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 249 of 353
Change #2
Clinical Project Manager
Name:
Address:
UCB Biopharma SPRL
Allée de la Recherche 60
B-1070 Brussels
BELGIUM
Phone:
Fax:
Has been changed to:
Name:
Address:
UCB BioSciences GmbH
Alfred-Nobel-Strasse 10
40789 Monheim
Germany
Phone:
Fax:
Change #3
LIST OF ABBREVIATIONS
ICH
International Conference on Harmonisation
Has been changed to:
ICH
International Council for Harmonisation
Change #4
LIST OF ABBREVIATIONS
The following additions were made to the list of abbreviations:
AUEC
area under the effect curve
DNA
deoxyribonucleic acid
EOS
End of Study
IGRA
interferon-gamma release assay
CTED COPY 
CT
REDACT
thorization application and any extensions or variations thereof.
 o
io
xt
an
n a
at
hor
be used to support any market
rnation
rt a
rnation
d to:
supp
d to:
nt cannot 
I
4
e
4
 ABBR
ot b
 ABBR
follow
cann
follow
This documen
AUEC
ent 
AUEC
DN
m
DN
keting auth


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 250 of 353
LTB
latent tuberculosis
mRNA
messenger ribonucleic acid
miRNA
micro ribonucleic acid
NTMBI
nontuberculosis myobacterial infection
PD-PPS
Pharmacodynamic Per Protocol Set
RNA
ribonucleic acid
TB
tuberculosis
Change #5
LIST OF ABBREVIATIONS
The following abbreviation was deleted:
Change #6
Section 1 SUMMARY
Paragraph #3
TP0001 is a Phase 2, multicenter, open-label, multiple-dose, 2-dose-arm study to evaluate the 
safety, tolerability, and efficacy of UCB7665 administered as subcutaneous (sc) doses of 4mg/kg 
or 7mg/kg, in subjects ≥18 years of age with persistent (>3 months up to 12 months after 
diagnosis) or chronic (more than 12 months after diagnosis) primary ITP.
Has been changed to:
TP0001 is a Phase 2, multicenter, open-label, multiple-dose, multiple-arm study to evaluate the 
safety, tolerability, and efficacy of UCB7665 administered as subcutaneous (sc) doses of 4mg/kg, 
7mg/kg, and 10mg/kg, 15mg/kg, and 20mg/kg (resulting in cumulative doses of 20mg/kg, 
21mg/kg, 20mg/kg 15 mg/kg and 20mg/kg respectively), in subjects ≥18 years of age with 
persistent (>3 months up to 12 months after diagnosis) or chronic (more than 12 months after 
diagnosis) primary ITP.
Change #7
Section 1 SUMMARY
Paragraph #4:
The study is planned to be conducted at approximately 25 sites in Europe and Australia. A total 
of 30 subjects are planned to enter the Dosing Period in the study. The maximum study duration 
for study participation for an individual subject is approximately 16 weeks.
Has been changed to:
The study is planned to be conducted at up to approximately 45 sites in Europe and Australia. A 
total of approximately 48 to 66 subjects (dependent on emerging safety data and corresponding 
REDACTED COPY 
multipl
ED C
multipl
5 adm
CTED
5 adm
with pe
DACT
with pe
months 
REDA
months 
nnot be used to support any marketing authorization application and any extensions or variations thereof.
le
za
le-
at
-dose
atio
dose
minister
oriza
minister
ersisten
utho
ersisten
 after d
g aut
 after d
open
mark
open-
ar
-la
rk
la
of UCB
y m
of UCB
/kg, an
t any
/kg, an
/kg and
port 
/kg and
up to 12
uppo
up to 12
TP.
s
TP.
UMM
e us
UMM
ca
ph 
not
ph #
ot b
#4
t b
4:
b
:
e study
cann
e study
n
This documen
of 30 su
nt c
of 30 su
for s
men
for s


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 251 of 353
DMC recommendation) are planned to enter the Dosing Period in the study. The maximum study
duration for study participation for an individual subject is approximately 16 weeks.
Change #8
Section 1 SUMMARY
Paragraph #5:
The study will evaluate 2 dose arms of UCB7665. Subjects in Dose Arm 1 will receive 5 doses 
of UCB7665 4mg/kg sc at 1 week intervals and subjects in Dose Arm 2 will receive 3 doses of 
UCB7665 7mg/kg sc at 1 week intervals.
Has been changed to:
The study is intended to evaluate 5 dose arms of UCB7665. Subjects in Dose Arm 1 will receive 
5 doses of UCB7665 4mg/kg sc at 1 week intervals, subjects in Dose Arm 2 will receive 3 doses 
of UCB7665 7mg/kg sc at 1 week intervals, subjects in Dose Arm 3 will receive 2 doses of 
UCB7665 10mg/kg sc at 1 week intervals, Dose Arm 4 will receive 1 dose of UCB7665 
15mg/kg sc and Dose Arm 5 will receive 1 dose of UCB7665 20mg/kg sc. 
Change #9
Section 1 SUMMARY
Paragraph #6:
The study consists of a Screening Period (up to 4 weeks), Dosing Period of 2 to 4 weeks, and an 
Observation Period of 8 weeks. The Screening Visit corresponds to Visit 1 of the study. The 
Dosing Period will commence at Visit 2 (Baseline Visit), with dosing visits scheduled at weekly 
intervals. The Observation Period will start after the final dose administration with a visit 
scheduled 3 days after the final dose and weekly thereafter (ie, weekly after final dose) for a 
period of 8 weeks. The End-of-Study Visit will be performed at the end of the Observation 
Period, ie, 8 weeks after the final dose of investigational medicinal product (IMP).
Has been changed to:
The study consists of a Screening Period (up to 4 weeks), Dosing Period of 1 day to 4 weeks, and 
an Observation Period of 8 weeks. The Screening Visit corresponds to Visit 1 of the study. The 
Dosing Period will commence at Visit 2 (Baseline Visit), with dosing visits scheduled at weekly 
intervals for Dose Arms 1, 2 and 3 and only one visit scheduled for Dose Arms 4 and 5. The 
Observation Period will start after the last dose administration (or only dose administration for 
Dose Arms 4 and 5) with a visit scheduled 3 days after the last dose and weekly visits thereafter 
(ie, weekly after last or only dose) for a period of 8 weeks. The End-of-Study Visit will be 
performed at the end of the Observation Period, ie, 8 weeks after the last or only dose of 
investigational medicinal product (IMP).
Change #10
Paragraph #7:
The first 6 subjects will be enrolled in Dose Arm 1 only. While recruitment is ongoing, safety
data for the first 3 subjects up to 7 days after the final dose will be reviewed by a Data 
Monitoring Committee (DMC). During a second DMC meeting, safety data for the first 6 
REDACTED COPY 
o 4 we
ED C
o 4 we
ing Vi
CTE
ing Vi
(Base
DAC
(Base
start 
RED
start 
and
RE
and
rt any marketing authorization application and any extensions or variations thereof.
 of 
va
 of 
m
te
m 1 wi
ens
1 wi
will rec
ext
will rec
eceive 2
any 
eceive 2
ose of U
d a
ose of U
kg sc. 
and
kg sc. 
eeks), D
zatio
eeks), D
isit cor
horiz
isit cor
eline V
utho
eline V
after t
g au
after t
weekl
ting
weekl
Visit w
rket
Visit w
dose of
mar
dose of
not be used to suppo
reening
port 
reening
of 8 we
upp
of 8 we
comme
to su
comme
e Arms
d to
e Arms
eriod w
used
eriod w
4 and 
be u
4 and 
kl
o
kly 
ot
y 
This document can
afte
t b
afte
rmed a
anno
rmed a
vestigat
t can
vestigat
Cha
men
Cha
P


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 252 of 353
subjects up to 7 days after the final dose will be reviewed. Following this review, the DMC will 
make a decision on whether to open Dose Arm 2 for enrollment. Once the DMC has approved 
initiation of Dose Arm 2, subsequent subjects will be randomized to 1 of the 2 dose arms using 
an interactive voice/web response system (IXRS). The aim is to have 15 subjects in each dose 
arm. The DMC may also decide to reduce the number of doses in each of the dose arms based on 
review of data during the study. Safety data will also be reviewed on an ongoing basis during the 
study so as to continuously evaluate the safety of subjects.
Has been changed to:
The first 6 subjects will be enrolled in Dose Arm 1 only. While recruitment is ongoing, safety
data for the first 3 subjects up to 7 days after the last dose of the third subject will be reviewed by 
the Data Monitoring Committee (DMC). During a second DMC meeting, all available safety 
data up to cut off date defined as 7 days after the last dose of the sixth subject will be reviewed. 
Following this review, the DMC will make a recommendation on whether to open Dose Arm 2 
for enrollment. Once the DMC has advocated the initiation of Dose Arm 2, the subsequent 
subjects for the first 2 arms will be randomly assigned in 1:1 ratio to either Dose Arm 1 or Dose 
Arm 2 using an interactive voice/web response system (IXRS). Once 15 subjects are enrolled in 
Dose Arm 1, the subsequently enrolled subjects will be enrolled in Dose Arm 2.
Change #11
Paragraph #8 modified and NEW paragraphs #9 and #10 added:
After the safety data review of at least 6 subjects in Dose Arm 2 is done, the DMC will make a 
recommendation on whether to open Dose Arm 3 for enrollment. Once the DMC has advocated 
the initiation of Dose Arm 3 and the enrollment of 15 subjects in Dose Arm 2 has been 
completed, the subsequent subjects will be assigned to Dose Arm 3 only. After every third 
subject has been enrolled, DMC will review all available safety data up to cut off date defined as 
7 days after the last dose. Depending on the emerging safety data of 6 subjects in Dose Arm 3,
the DMC will recommend whether to open Dose Arm 4 for enrollment or to include additional 
subjects in Dose Arm 3. If applicable, this step is planned to be done stepwise in groups of 3 
subjects. A maximum of 12 subjects are planned for Dose Arm 3. The DMC will recommend to 
open Dose Arm 4 for enrollment in a subsequent DMC meeting, if applicable.
Once the DMC has advocated the initiation of Dose Arm 4, the enrollment of Dose Arm 3 will 
be closed and all subsequently enrolled subjects will be assigned to Dose Arm 4. After every
third subject that has been enrolled, DMC will review all available safety data up to cut off date 
defined as 7 days after the dosing of the third subject in Dose Arm 3. Depending on the emerging 
safety data of 6 subjects in Dose Arm 4, the DMC will recommend whether to open Dose Arm 5 
for enrollment or to include additional subjects in Dose Arm 4. If applicable, this step is planned 
to be done stepwise in groups of 3 subjects. A maximum of 12 subjects are planned for Dose 
Arm 4. The DMC will recommend to open Dose Arm 5 for enrollment in a subsequent meeting, 
if applicable.
Once the DMC has advocated the initiation of Dose Arm 5, the enrollment of Dose Arm 4 will 
be closed and the subsequently enrolled subjects will be assigned to Dose Arm 5. After every
third subject is enrolled, the DMC will review all available safety data up to the cutoff date 
defined as 7 days after the dosing of the third subject in Dose Arm 4. Depending on the emerging 
safety data of 6 subjects in Dose Arm 5, the DMC will recommend to include additional subjects 
REDACTED COPY 
d 
O
d #
OP
#10
OPY
10
ts in D
ED C
ts in D
Arm
CTE
Arm 3
ED
3
llmen
DACT
llmen
ll be a
REDA
ll be a
revi
RE
revi
not be used to support any marketing authorization application and any extensions or variations thereof.
safety
s or 
safety
reviewe
ons 
reviewe
able saf
nsio
able saf
will be r
xten
will be r
open D
y ex
open D
2, the su
any 
2, the su
ther Do
nd a
ther Do
e 15
n an
e 15 su
n
su
n Dose
tion
n Dose
added
n ap
added
Dose A
atio
Dose A
for enr
riza
for enr
nt of 15
utho
nt of 15
assigne
aut
assigne
iew all 
ting 
iew all 
on the e
rketi
on the e
to ope
mark
to ope
cable, t
ny m
cable, t
ubjects
t any
ubjects
llment 
port 
llment 
vocate
supp
vocate
ubseque
to s
ubseque
t has be
ed t
t has be
day
us
days aft
use
s aft
a of 6 su
be u
a of 6 su
ollment
not b
ollment
This document can
e done 
ann
e done 
rm
t c
rm 4. T
ca
4. T
if app
ment
if app
O
m
O


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 253 of 353
in Dose Arm 5. If applicable, this step is planned to be done stepwise in groups of 3. A 
maximum of 12 subjects are planned for Dose Arm 5.
The DMC may also decide to reduce the number of doses in each of the dose arms, to stop a dose 
arm or not to open a dose arm based on review of safety data during the study. Safety data will 
also be reviewed on an ongoing basis by CRO medical monitor and UCB physician during the 
study so as to continuously evaluate the safety of subjects.
Change #12
Section 1 SUMMARY
Paragraph #12:
The following efficacy variables will be assessed: Response (platelet count ≥30x109/L and at 
least 2-fold increase of the Baseline count) during the study and by visit; Complete Response 
(platelet count ≥100x109/L) during the study and by visit; platelet count ≥50x109/L during the 
study and by visit; the maximum value and maximum increase from Baseline in platelet count 
during the study; value and change from Baseline in platelet count over time; time to Response 
(time from starting treatment to achievement of Response); time to Complete Response (time 
from starting treatment to achievement of Complete Response); time to achieving platelet count 
≥50x109/L; duration of Response (measured from achievement of Response to loss of Response 
[defined as platelet count below 30x109/L or less than 2-fold increase of Baseline platelet 
count]); duration of Complete Response (measured from achievement of Complete Response to 
loss of Complete Response [defined as platelet count below 100x109/L]); duration of platelet 
count ≥50x109/L (measured from achievement of platelet count ≥50x109/L to reduction of 
platelet count below 50x109/L); ITP bleeding score over time; and Patient Reported Outcome 
(PRO), ie, Neurological Fatigue Index for Multiple Sclerosis (NFI-MS) summary score over 
time. Plasma concentration of UCB7665 over time will be assessed as the PK variable. The PD 
variables are minimum value and maximum decrease in total IgG concentration during the study;
IgG subclass concentrations; and ITP-specific autoantibody
in serum over time. Other immunological variables to be evaluated are total IgA, IgE, and IgM 
levels; serum (C3 and C4) and plasma (C3a and C5a) complement levels; ADA status 
(negative/positive) and relative mass units; serum biomarkers 
B cell activating factor (BAFF) levels and the results of the IgG depletion assay; and cytokines 
(for subjects experiencing infusion reactions). Additional exploratory biomarkers may be 
investigated if needed using the samples already available.
Has been changed to:
Now paragraph #13:
The following efficacy variables will be assessed: Response (platelet count ≥30x109/L and at 
least 2-fold increase of the Baseline count) during the study and by visit; Complete Response 
(platelet count ≥100x109/L) during the study and by visit; platelet count ≥50x109/L during the 
study and by visit; the maximum value and maximum increase from Baseline in platelet count 
during the study; value and change from Baseline in platelet count over time; Baseline-corrected 
area under the effect curve (AUEC) for platelet count; time to Response (time from starting 
treatment to achievement of Response); time to Complete Response (time from starting treatment 
REDACTED COPY
n 2
PY
n 2-
PY
-fo
Y 
fo
d from
COP
d from
count
ED C
count
ent of p
CTED
ent of p
ding sc
DACT
ding sc
for M
EDA
for M
665 
RE
665 
port any marketing authorization application and any extensions or variations thereof.
09/L
nsio
/L an
sio
an
sio
plete Re
exten
plete Re
x10
y e
x109
ex
9/L
ex
/L
eline in
d any
eline in
er tim
and 
er time;e;
Compl
on a
Compl
time to
ation
time to
nt of R
plica
nt of R
ld incr
appl
ld incr
m achie
on ap
m achie
t below
atio
t below
platele
oriza
platele
core ov
thor
core ov
Multiple
aut
Multiple
over ti
ing 
over ti
imum
ketin
imum
TP
ma
TP-
a
-spec
ark
spec
nologic
y m
nologic
d plasm
t any
d plasm
ative m
port a
ative m
This document cannot be used to sup
tor (BA
o sup
tor (BA
riencin
d to 
riencin
needed
sed
needed
n cha
be u
n cha
paragra
nnot
paragra
he follo
t ca
he follo
least 2
ent 
least 2
(pl
me
(pl
uppo


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 254 of 353
to achievement of Complete Response); time to achieving platelet count ≥50x109/L; duration of 
Response (measured from achievement of Response to loss of Response [defined as platelet 
count below 30x109/L or less than 2-fold increase of Baseline platelet count]); duration of 
Complete Response (measured from achievement of Complete Response to loss of Complete 
Response [defined as platelet count below 100x109/L]); duration of platelet count ≥50x109/L
(measured from achievement of platelet count ≥50x109/L to reduction of platelet count below 
50x109/L); Clinical Response (defined as platelet count ≥30x109/L with at least 2-fold increase 
from Baseline value and absence of bleeding); time to Clinical Response (time from starting 
treatment to achievement of Clinical Response); duration of Clinical Response (measured from 
achievement of Clinical Response to loss of Clinical Response [loss of Clinical Response 
defined as platelet count <30x109/L or less than 2-fold increase from Baseline platelet count or 
presence of bleeding]); Complete Clinical Response (defined as platelet count ≥100x109/L and 
absence of bleeding); time to Complete Clinical Response (time from starting treatment to 
achievement of Complete Clinical Response); duration of Complete Clinical Response 
(measured from achievement of Complete Clinical Response to loss of Complete Clinical 
Response [loss of Complete Clinical Response defined as platelet count <100x109/L or presence 
of bleeding]); no Clinical Response (defined as platelet count <30x109/L and less than 2-fold 
increase from Baseline or presence of bleeding); ITP bleeding score over time; and Patient 
Reported Outcome (PRO), ie, Neurological Fatigue Index for Multiple Sclerosis (NFI-MS) 
summary score over time. Plasma concentration of UCB7665 over time will be assessed as the 
PK variable. The PD variables are minimum value and maximum decrease in total IgG 
concentration during the study; IgG subclass concentrations; and ITP-specific autoantibody 
 in serum over time. Other immunological variables to be 
evaluated are total IgA, IgE, and IgM levels; serum (C3 and C4) and plasma (C3a and C5a) 
complement levels; ADA status (negative/positive) and relative mass units; exploratory safety 
biomarkers 
 and B cell activating factor 
(BAFF) levels; B and T lymphocytes; and cytokines (for subjects experiencing infusion 
reactions).
Change #13
Section 1 SUMMARY
Exploratory genomic analyses substudy details are added as follows:
During this study, subjects will also have the option of providing additional informed consent for 
exploratory deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) (ie, messenger RNA 
[mRNA] and micro RNA [miRNA]) analyses. Participation in this additional portion of the study
is optional and does not preclude subject’s eligibility for participation in the main study. The 
additional genomic samples must not be collected if the subject has not consented to participate 
in this exploratory genomic substudy.
Change #14
Section 1 SUMMARY
New paragraph added at the end of the summary:
EDACTED COPY
CB76
PY 
CB76
and m
COP
and m
ncentr
D CO
ncentr
m over 
TED
m over 
els; ser
ACT
els; ser
ive/po
EDA
ive/po
RED
R
authorization application and any extensions or variations thereof.
from
r va
from
e 
s
e 
t count
ons 
t count
0x10
nsio
0x109
o
9/
o
/
reatmen
xten
reatmen
Respo
y ex
Respo
omplete
any
omplete
nt <100
nd a
nt <100
10
n
109
a
9/L
n an
/L a
an
a
an
ore ove
ation
ore ove
Multip
licat
Multip
65 ove
ppli
65 ove
maximu
n ap
maximu
rations
ation
rations
time. O
rizat
time. O
rum (C
thor
rum (C
ositive)
auth
ositive)
ot be used to support any marke
es; and 
arke
es; and 
c analy
o su
c analy
y, subj
ed t
y, subj
eox
us
eoxyri
se
yri
and mic
t be 
and mic
This document canno
nal a
not b
nal and
b
nd
tional g
ann
tional g
n this ex
nt ca
n this ex
Cha
me
Cha
ing a
keting


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 255 of 353
Prior to this amendment, a protocol amendment 2 with a dose arm 4mg/kg twice weekly was 
planned, however the corresponding protocol amendment 2 was not implemented. These changes 
are highlighted in Section 18.8.
Change #15
Section 1 INTRODUCTION
Paragraph #11:
In 4-week and 13-week toxicity studies with 8-week, treatment-free recovery periods in 
Cynomolgus monkeys, UCB7665 induced the expected large decreases (75% to 90%) in plasma 
IgG in all animals which was maintained for the duration of both studies in the majority of the 
animals, with only minor effects on albumin levels. UCB7665 was well tolerated at the highest 
dose levels tested of UCB7665 150mg/kg sc and UCB7665 150mg/kg iv administered every
3 days (the no observed adverse effect level [NOAEL]).
Has been changed to:
In 4-week and 13-week toxicity studies with 8-week, treatment-free recovery periods in 
Cynomolgus monkeys, UCB7665 induced the expected large decreases (75% to 90%) in plasma 
IgG in all animals which was maintained for the duration of both studies in the majority of the 
animals, with only minor effects on albumin levels. UCB7665 was well tolerated at the highest 
dose levels tested of UCB7665 150mg/kg sc and UCB7665 150mg/kg iv administered every
3 days (there was no observed adverse effect level [NOAEL]).
Change #16
Section 1 INTRODUCTION
Paragraph #12:
Further information on the PK, PD, and safety profiles for UCB7665 from nonclinical studies, 
and preliminary safety information from clinical studies, can be obtained from the current 
version of the UCB7665 Investigator’s Brochure.
Has been changed to:
Further information on the PK, PD, and safety profiles for UCB7665 from nonclinical studies, 
and preliminary safety information from clinical studies (including data from this study), can be 
obtained from the current version of the UCB7665 Investigator’s Brochure.
Change #17
Section 1 INTRODUCTION
Paragraph #13:
Exploratory genomic analyses substudy details are added as follows:
Subjects will also have the option of providing additional informed consent for exploratory DNA 
and RNA (mRNA and miRNA) analyses as described in Section 5.1.1.
REDACTED COPY
CB7
PY 
CB7
CB766
OPY
CB766
el [NO
D CO
el [NO
port any marketing authorization application and any extensions or variations thereof.
plasma
or v
plasma
ty
on
ty of th
ns o
of th
n
t the hi
nsion
t the hi
istered 
xtens
istered 
recover
and
recover
reases (
tion 
reases (
th stud
icatio
th stud
65 was
pplic
65 was
65
n a
65 150
app
150
OAEL
tion 
OAEL]
nd safe
rket
nd safe
n from 
mar
n from 
igator’
ny m
igator’
not be used to sup
:
o
:
the PK
upp
the PK
t
o
ty info
to su
y info
e curren
d to
e curren
e
7
u
7
This document ca
IN
ot be
INT
e
T
graph #
ann
graph #
Explor
ent c
Explor
Su
me
Su


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 256 of 353
Change #18
Section 3.3
Exploratory objectives
Two additional NEW bullets:

To evaluate the genomic components of ITP to understand the molecular etiology, 
progression, and treatment of the disease, applicable only for subjects consenting to 
participate in the optional genomic analyses substudy. 

Change #19
Section 4 Study Variables sub-sections were renumbered
4.1
Safety variables 
4.1.1. Primary safety variables 
4.1.2
Other saftey variables 
4.2
Efficacy variables 
4.3
Pharmacokinetic and pharmacodynamic variables
4.3.1
Pharmacokinetic variable
4.3.2
Pharmacodynamic variables
4.4
Other immunological variables
Has been changed to:
4.1 Primary variable
4.2 Others and exploratory variables 
4.2.1
Safety variables 
4.2.2
Efficacy variables 
4.2.3
Pharmacokinetic variables 
4.2.4
Pharmacodynamic variables 
4.2.5
Other immunological variables 
Change #20
Section 4.2.2 Efficacy variables
Additional efficacy variables listed as follows:

Baseline-corrected AUEC for platelet count

Clinical Response: platelet count ≥30x109/L with at least 2-fold increase from Baseline value 
and absence of bleeding
REDACTED COPY 
riables
COPY
riables
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
s
ables
ny m
ables
les
up
les 
inetic v
to s
inetic v
acod
sed
acodyn
ed
yn
her imm
be u
her imm
nge #
nnot
nge #2
ection 4
t ca
ection 4
Add
men
Add
r vari
s or v


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 257 of 353

Time to Clinical Response: time from starting treatment to achievement of Clinical Response

Duration of Clinical Response: measured from achievement of Clinical Response to loss of 
Clinical Response (loss of Clinical Response defined as platelet count <30x109/L or less than 
2-fold increase from Baseline platelet count or presence of bleeding)

Complete Clinical Response: platelet count ≥100x109/L and absence of bleeding

Time to Complete Clinical Response: time from starting treatment to achievement of 
Complete Clinical Response

Duration of Complete Clinical Response: measured from achievement of Complete Clinical 
Response to loss of Complete Clinical Response (loss of Complete Clinical Response defined 
as platelet count <100x109/L or presence of bleeding)

No Clinical Response: platelet count <30x109/L or less than 2-fold increase from Baseline or 
presence of bleeding
Change #21
Section 4.3.2
Pharmacodynamic variables (now Section 4.2.4)
The following variable was deleted:

The value and change from Baseline in endogenous IgG concentrations will be measured by
IgG depletion assay
Change #22
Section 4.3.2 Pharmacodynamic variables (now Section 4.2.4)

Change from Baseline in serum biomarkers 
over time
Has been changed to:
Now moved to Section 4.2.1 Safety variables:

Change from Baseline in exploratory safety biomarkers over time
Change #23
Section 4.4
Other immunological variables (now Section 4.2.5)

Change from Baseline in serum biomarkers 
 over time
Has been changed to:

Change from Baseline in exploratory biomarkers relating to mechanism of action, disease 
activity, treatment response, and clinical outcome
Change #24
Section 4.4
Other immunological variables (now Section 4.2.5)
Additional immunological variable listed as follows:

Lymphocyte counts (B and T)
REDACTED COPY
ous Ig
OPY 
ous Ig
es
A
es (now
ACT
(now
iomar
RED
iomar
used to support any marketing authorization application and any extensions or variations thereof.
Clinica
s or 
Clinica
onse de
ons 
onse de
e from 
exte
e from 
)
G conc
app
G conc
ow Sect
thor
ow Sect
kers
g au
kers
fet
ny
fety va
y m
y va
in expl
ort a
in expl
her imm
d to s
her imm
om
us
om Bas
sed
Bas
au
act
nt 
act
C
m
C
This document cannot be
been c
not 
been c
Chan
t can
Chan
be us


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 258 of 353
Change #25
Section 4.2.5
Other immunological variables
The following text was deleted:
Cytokine samples will be taken at Baseline for all subjects and at subsequent visits only if the 
subject experiences infusion reactions.
Change #26
Section 5.1
Study description
Paragraphs #1, #2 and #3:
This is a Phase 2, multicenter, open-label, multiple-dose, 2-dose-arm study to evaluate the safety, 
tolerability, and efficacy of UCB7665 in subjects with primary persistent or chronic ITP.
Dose Arm 1: UCB7665 4mg/kg sc (5 doses at an interval of 1 week)
Dose Arm 2: UCB7665 7mg/kg sc (3 doses at an interval of 1 week)
The DMC will monitor emergent safety data during the study. Refer to Section 14.7 for details. 
The maximum duration of the study per subject is approximately 16 weeks, consisting of a 
Screening Period (1 to 28 days), a Dosing Period of 2 or 4 weeks, and an Observation Period of 
8 weeks.
Has been changed to:
This is a Phase 2, multicenter, open-label, multiple-dose, multiple-arm study to evaluate the 
safety, tolerability, and efficacy of UCB7665 in subjects with primary persistent or chronic ITP.
Dose Arm 1 (15 subjects): UCB7665 4mg/kg sc (5 doses at an interval of 1 week)
Dose Arm 2 (15 subjects): UCB7665 7mg/kg sc (3 doses at an interval of 1 week)
Dose Arm 3 (6 to 12 subjects): UCB7665 10mg/kg sc (2 doses at an interval of 1 week)
Dose Arm 4 (6 to 12 subjects): UCB7665 15mg/kg sc (1 dose)
Dose Arm 5 (6 to 12 subjects): UCB7665 20mg/kg sc (1 dose)
The maximum duration of the study per subject is approximately 16 weeks, consisting of a 
Screening Period (1 to 28 days), a Dosing Period of 1 to 4 weeks, and an Observation Period of 
8 weeks.
Change #27

Section 5.1
Study description
Paragraph #5:
Dosing Period: The first 6 subjects in the study will receive UCB7665 4mg/kg. These subjects in 
the Dose Arm 1 will not be randomized. While recruitment is still ongoing, safety data for the 
first 3 subjects up to 7 days after the final dose of the third subject will be reviewed by the DMC. 
During a second DMC meeting, all available safety data up to cut off date defined as 7 days after 
the final dose of the sixth subject will be reviewed. During these reviews recruitment in the dose 
arm will not be stopped. Following this review, the DMC will make a decision on whether to 
REDACTED COPY
or 4
PY 
or 4
multip
ACTE
multip
B7665 
EDAC
B7665 
4mg
RE
4mg
support any marketing authorization application and any extensions or variations thereof.
uate th
nsio
uate th
ronic IT
xten
ronic IT
er to Se
on a
er to Se
ely
lica
ely 16 w
cati
16 w
y
ca
y
weeks, 
pplic
weeks, 
ple
ho
ple-
or
-dos
oriz
dos
in subj
auth
in subj
g/kg sc
ting 
g/kg sc
a
7mg/k
arket
7mg/k
UCB766
y ma
UCB766
s): UCB
rt any
s): UCB
bjects): 
ppo
bjects): 
cannot be used to 
tion of 
o su
tion of 
(1 to 2
d to
(1 to 2
#27
t be
#27
ction 5
nno
ction 5
This document 
aragrap
nt ca
aragrap
Dos
men
Dos
th
m
th


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 259 of 353
open Dose Arm 2 for enrollment. Once the DMC has approved opening of Dose Arm 2 for 
enrollment, subjects will subsequently be randomized to 1 of the 2 dose arms using IXRS. If the 
new dose arm will be initiated and if the UCB7665 4mg/kg arm will be continued, new subjects 
will be randomized to 1 of the 2 dose arms in an allocation ratio of 1:1 (Once 15 subjects are in 
the 4mg/kg group, the remaining subjects will not be randomized. They will be allocated to the 
7mg/kg group.).
Has been changed to:
Dosing Period: The first 6 subjects in the study will receive UCB7665 4mg/kg. These subjects in 
the Dose Arm 1 will not be randomized. While recruitment is still ongoing, safety data for the 
first 3 subjects up to 7 days after the last dose of the third subject in Dose Arm 1 will be 
reviewed by the DMC. During a second DMC meeting, all available safety data up to cut off date 
defined as 7 days after the last dose of the sixth subject in Dose Arm 1 will be reviewed. During 
these reviews recruitment in the dose arm will not be stopped. Following this review, the DMC 
will make a decision on whether to open Dose Arm 2 for enrollment. Once DMC has advocated 
the initiation of Dose Arm 2, the subsequent subjects will be randomly assigned in 1:1 ratio to 
either Dose Arm 1 or Dose Arm 2 using an IXRS. Once 15 subjects are enrolled in the Dose 
Arm 1, the remaining subjects will be enrolled in Dose Arm 2.
After the safety data review of at least 6 subjects in Dose Arm 2 is done, the DMC will make a 
recommendation on whether to open Dose Arm 3 for enrollment. Once the DMC has advocated 
the initiation of Dose Arm 3 and the enrollment of 15 subjects in Dose Arm 2 has been 
completed, the subsequent subjects will be assigned to Dose Arm 3 only. After every third 
subject has been enrolled, the DMC will review all available safety data up to cut off date 
defined as 7 days after the dosing. Depending on the emerging safety data of 6 subjects in Dose 
Arm 3, the DMC will recommend whether to open Dose Arm 4 for enrollment or to include 
additional subjects in Dose Arm 3. If applicable, the latter option will be done stepwise in groups 
of 3 subjects. A maximum, 12 subjects will be enrolled in Dose Arm 3. The DMC will 
recommend to open Dose Arm 4 for enrollment in a subsequent DMC meeting, if applicable.
Once the DMC has advocated the initiation of Dose Arm 4, the enrollment of Dose Arm 3 will 
be closed and all subsequent subjects will be assigned to Dose Arm 4. After every third subject is 
enrolled, the DMC will review all available safety data up to the cutoff date defined as 7 days 
after the dosing. Depending on the emerging safety data of 6 subjects in Dose Arm 4, the DMC 
will recommend to include additional subjects in Dose Arm 4 or not. Subjects will be added 
stepwise in groups of 3, if applicable. A maximum of 12 subjects may be enrolled in Dose 
Arm 4. The DMC will recommend to open Dose Arm 5 for enrollment in a subsequent DMC 
meeting, if applicable.
Once the DMC has advocated the initiation of Dose Arm 5, the enrollment of Dose Arm 4 will 
be closed and all subsequent subjects will be assigned to Dose Arm 5. After every third subject is 
enrolled, the DMC will review all available safety data up to the cutoff date defined as 7 days 
after the dosing. Depending on the emerging safety data of 6 subjects in Dose Arm 5, the DMC 
will recommend to include additional subjects in Dose Arm 5 or not. Subjects will be added 
stepwise in groups of 3, if applicable. A maximum of 12 subjects may be enrolled in Dose 
Arm 5.
REDACTED COPY
e
Y
e
r enro
OPY 
r enro
f
C
f 15 su
COP
15 su
gned t
ED C
gned t
view al
CTED
view al
nding o
DACT
nding o
ether t
REDA
ether t
f app
RE
f app
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
cts in 
var
cts in 
or the 
s or 
or the 
be 
on
be 
p to cut 
nsio
p to cut 
eviewe
xten
eviewe
s review
y ex
s review
e DMC
any 
e DMC
assign
nd a
assign
are enr
an
are enr
m 2 is d
plica
m 2 is d
llment
app
llment
ubjects
on a
ubjects
to Dos
zatio
to Dos
all avail
oriza
all avail
on the 
utho
on the 
to open
g au
to open
plicable
ting 
plicable
ts will b
rketi
ts will b
or enro
mark
or enro
the init
any 
the init
nt subje
ort a
nt subje
eview 
ppor
eview 
ending 
supp
ending 
includ
to s
includ
ups of 3
ed t
ups of 3
DMC w
use
DMC w
f applic
t be 
f applic
he DM
nnot
he DM
closed 
can
closed 
enrolle
ent c
enrolle
after
me
after
w
m
w


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 260 of 353
Change #28
Section 5.1
Study description
Paragraph #5:
At least 4 interim analyses will be performed. Based on the interim analysis, the DMC will 
assess the safety of UCB7665, determine whether to initiate the UCB7665 7mg/kg dose arm and 
may decide to adapt the dose regimen. Planned dosing may be discontinued for all subjects on a 
dose arm (see Section 6.5). Refer to Section 14.7 for details.
Has been changed to:
At least 11 interim analyses will be performed. Based on the interim analyses, the DMC will 
assess the safety of UCB7665, determine whether to initiate subsequent dose arms and may
decide to adapt the dose regimen. Planned dosing may be discontinued for all subjects in a dose 
arm (see Section 6.5). Refer to Section 14.7 for details.
Change #29
Paragraph #6:
In case the DMC recommends reducing the number of doses (infusions) for either the 
UCB7665 4mg/kg dose or UCB7665 7mg/kg dose based on review of safety data, then the 
additional dose arms receiving a reduced number of doses will be considered as additional new 
dose arms for the study.
Has been changed to:
In case the DMC recommends reducing the number of doses (infusions) for any of the 
predefined dose arms (as applicable) based on review of safety data, then the additional dose 
arms receiving a reduced number of doses will be considered as additional new dose arms for the 
study.
Change #30
Paragraph #7:
Observation Period: Following the final dose, a visit will be scheduled 3 days postdose and 
weekly thereafter for 8 weeks to collect safety and efficacy data.
Has been changed to:
Observation Period: Following the last dose (or only dose administration for Dose Arms 4 and 
5), a visit will be scheduled 3 days postdose and weekly thereafter for 8 weeks to collect safety
and efficacy data.
Change #31
NEW Section 5.1.1
Exploratory genomic analyses
During this study, subjects will also have the option of providing additional informed consent for 
exploratory DNA and RNA analyses. Participation in this additional portion of the study is 
optional and does not preclude subject’s eligibility for participation in the main study. The 
additional genomic samples must not be collected if the subject has not consented to participate 
in this exploratory genomic substudy.
REDACTED COPY 
ed o
Y
ed o
doses
OPY
doses
the nu
DAC
the nu
based 
RED
based 
dose
R
dose
annot be used to support any marketing authorization application and any extensions or variations thereof.
MC wi
ions
MC wi
s and m
ensi
s and m
subjects
exte
subjects
nfusion
catio
nfusion
review
pplic
review
s will b
app
s will b
umber 
utho
umber 
on rev
g au
on rev
es will
eting
es will
lowing
ppo
lowing
8 week
sup
8 week
anged
ed to
anged
Period
e use
Period
will be
t be 
will be
ficacy
not 
ficacy
This document c
d
y
hange
t can
hange
NEW
ment
NEW
D
m
D


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 261 of 353
Once subject provides consent, through a separate informed consent form, blood samples will be 
drawn as follows:
For DNA: Blood samples will be collected at Baseline (Visit 2) for all dose arms. Subsequent 
blood sample will be collected prior to the last dose (ie, Visit 7 for Dose Arm 1, Visit 5 for Dose 
Arm 2, and Visit 4 for Dose Arm 3).
For RNA: Blood samples will be collected at the following time points for different dose arms: 

Dose Arm 1: Baseline (Visit 2), 3 days after dose 1 (Visit 3), prior to the last dose (Visit 7), 
and End of Study Visit (Visit 15).

Dose Arm 2: Baseline (Visit 2), 3 days after dose 1 (Visit 3), prior to the last dose (Visit 5), 
and End of Study Visit (Visit 13). 

Dose Arm 3: Baseline (Visit 2), 3 days after dose 1 (Visit 3), prior to the last dose (Visit 4), 
and End of Study Visit (Visit 12).

Dose Arm 4: Baseline (Visit 2), 3 days after dosing (Visit 3) and End of Study Visit (Visit 
10).

Dose Arm 5: Baseline (Visit 2), 3 days after dosing (Visit 3) and End of Study Visit (Visit 
10). 
For each DNA blood sample a volume of 6mL whole blood is needed and for each RNA sample 
a volume of 2.5mL whole blood is needed.
Failure to provide consent to participate in this substudy will not impact subject’s eligibility to 
participate in the main study.
Any exploratory biomarker or genomic analysis will only ever be related to the exploration of 
the underlying causes of ITP in patients, related biology, and drug response. Justification for 
additional genomic analyses is detailed in Section 5.4.6.
Details on the collection, storage, preparation, and shipping of samples will be presented in the 
Laboratory Manual provided separately.
Any results from this analysis will be reported separately and will not form a part of the main 
clinical study report.
Change #32
Section 5.1.3 Planned number of subjects and sites
A total of 30 subjects are planned to enter the Dosing Period in the study. This number should 
allow for an appropriate assessment of the safety and give information on efficacy of the 
treatment for planning of potential future studies. To achieve the required number of eligible 
subjects to enter the Dosing Period, it is anticipated that 40 subjects will need to be screened. 
These subjects will be enrolled at approximately 25 sites. First subject first visit is planned for 
Q1 2016, last subject last visit for Q3 2017.
Has been changed to:
A total of up to approximately 48 to 66 subjects are planned to enter the Dosing Periods in the 
study (15 subjects in each of Dose Arms 1 and 2, and 6 to 12 subjects in Dose Arms 3, 4, and 5). 
REDACTED COPY 
le bloo
OPY
le bloo
his sub
TED
his sub
ic ana
RED
ic ana
nts,
R
nts,
rt any marketing authorization application and any extensions or variations thereof.
7), 
a
7), 
(Visit 
ons 
(Visit 
st dose
exte
st dose
nd of St
nd a
nd of St
and En
ation
and En
od is n
n app
od is n
bstudy
riza
bstudy
al
g
alys
g a
ysis w
g au
is w
, related
eting
, related
ed in S
rket
ed in S
, prepa
y ma
, prepa
separate
any 
separate
ed to suppor
y
p
y
This document cannot be use
sis wi
port 
sis wi
Planne
used
Planne
30 subj
be 
30 subj
or an ap
not b
or an ap
me
an
ment fo
ann
nt fo
ubjects 
nt ca
ubjects 
These
ment
These
Q1
m
Q1


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 262 of 353
To achieve the required number of eligible subjects to enter the Dosing Period, it is anticipated 
that approximately 90 subjects will need to be screened. These subjects will be enrolled at 
approximately 45 sites. First subject first visit is planned for Q1 2016, last subject last visit for 
Q2 2018.
Change #33
Section 5.2
Schedule of study assessments
Table 5‒1 presents the tabular scheme of study assessments for UCB7665 4mg/kg dose arm and 
Table 5‒2 presents the tabular scheme of study assessments for UCB7665 7mg/kg dose arm. 
Table 5‒3 presents the assessments to be performed on dosing days.
Has been changed to:
Table 5‒1 presents the tabular scheme of study assessments for the weekly UCB7665 4mg/kg 
dose arm (Dose Arm 1), Table 5‒2 presents the tabular scheme of study assessments for the 
weekly UCB7665 7mg/kg dose arm (Dose Arm 2), Table 5-3 presents the tabular scheme of
study assessments for the weekly UCB7665 10mg/kg dose arm (Dose Arm 3), Table 5-4 presents 
the tabular scheme of study assessments for the one dose of UCB7665 15mg/kg, Table 5-5
presents the tabular scheme of study assessments for the one dose of UCB7665 20mg/kg and 
Table 5‒6 presents the assessments to be performed on dosing days.
REDACTED COPY 
Y
lication and any extensions or variations thereof.
and 
ari
and 
m. 
or
m. 
B7665
exte
B7665
essmen
ny ex
essmen
e tabul
d any
e tabul
Arm 3
and 
Arm 3
665
n
665 15m
a
15m
This document cannot be used to support any marketing authorization appli
e of 
atio
e of U
o
U
g day
plica
g days
a
s


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 263 of 353
Change #34
Section 5.2
Schedule of study assessments
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consent
X
Demographic data
X
Verification of 
inclusion/exclusion 
criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory)f
X
X
X
X
X
Randomizationg
X
Withdrawal criteriah
X
X
X
X
X
X
General 
medical/procedures 
history
X
ITP history
X
REDACTED COPY 
9
Y
9
5
OPY
5
Y
CO
2d
D
2dd
C
d
CO
CO
CO
CO
TE
AC
DA
RE
R
d to support any marketing authorization application and any extensions or variations thereof.
bservat
ens
bservat
sio
10
 a
10b
any
nd
n
a
n
32
plica
32
at
ca
5
app
5
pp
a
±2d
tio
±2dd
on
d
n
ri
 
riririz
ori
uth
g 
ma
g
X
ny 
X
m
rt
m
po
su
X
d to 
X
s
annot be used
s
ed
us
X
o
X
ot 
This document can
an


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 264 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationi
X
X
X
X
X
X
X
X
X
X
12-lead ECG
X
X
X
X
X
X
X
X 
Karnofsky Performance 
Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xj
X
X
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
X
COP
X
PY
CO
X
TE
X
ED
AC
X
ED
X
DA
RE
R
upport any marketing authorization application and any extensions or variations thereof.
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
X
n a
X
X
ap
 a
X
riza
X
at
ori
X
au
X
ut
g 
g
ke
ma
X
y m
X
ma
ma
ma
ma
X
an
X
ny
rt
d to suppor
or
u
r
up
su
used
X
ed
This document cannot be us
ot
us


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 265 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Serology test for HIV, 
hepatitis B, and hepatitis 
C
X
Blood sample for 
cytokines
X
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
X
X
Call to IXRS for treatment 
kit number
X
X
X
X
X
Administration of IMP
X
X
X
X
X
Blood sampling for 
plasma concentration of 
UCB7665
X
X
X
X
X
X
X
X
Anti-UCB7665 
antibodies/IgG depletion 
assay
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
PY
CO
TE
AC
ED
R
any marketing authorization application and any extensions or variations thereof.
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
ap
ri
 a
X
th
Xk
h
k
riririz
ori
a
g
X
rke
X
ti
a
X
ma
X
ar
ma
rt an
X
a
X
d to support an
rt
X
pp
X
po
su
This document cannot be used 
X
d
X
d
t
us


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 266 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Serum complements (C3 
and C4) and plasma
complements (C3a and 
C5a)
X
X
X
X
Serum biomarkers 
 
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum biomarkers 
X
X
X
X
X
X
Serum BAFF levels
X
X
X
X
X
X
X
Immunoglobulins (total 
IgG, IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X 
IgA, IgM, IgEl
X
X
X
X
ITP-specific 
autoantibodiesm
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
REDACTED COPY 
PY
AC
CO
X
DA
X
AC
AC
AC
R
AC
ed to support any marketing authorization application and any extensions or variations thereof.
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
ap
ori
 a
X
auth
X
tho
g
o
X
arke
X
ket
ma
X
a
X
any
rt
X
ppo
X
or
su
r
X
d to
X
o s
This document cannot be used
X
ed
us
X
ot 
X
t b
nn
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 267 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg dose arm
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Headache questionnairen
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviewo
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
; HIV=human immunodeficiency virus;
Ig=immunoglobulin; IMP=investigational medicinal product; ITP=immune thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar 
puncture; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
;
a Frequency of assessments on dosing days is detailed in Table 5‒3.  
b Visits 10, 12, and 14 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the final dose.
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose. 
e The visit windows in the Observation Period are relative to the final dosing visit date.
f Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
g The first 6 subjects will be enrolled in the Dose Arm 1 group only. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the
DMC. Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, subjects subsequently enrolled will 
be randomly assigned subsequently to 1 of the 2 dose arms using an IXRS until 15 subjects are in Dose Arm 1.
h Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
COPY 
X
COP
X
PY
CO
CO
DACTED CO
C
TE
C
cerebro
ACTE
cerebro
y Withd
DAC
y Withd
RE
=immu
REDA
=immu
gical F
RE
gical F
ion application and any extensions or variations thereof.
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
n a
X
ap
X
a
X
authorizatio
ap
 a
io
ririririz
ospinal f
horiz
ospinal f
draw
uth
drawal;
tho
al;
t be used to support any marketing a
une throm
g au
une throm
Fatigue 
ting 
Fatigue 
3
a
3. 
ar
. 
care pro
ma
care pro
e.
n
e.
sits. The
rt an
sits. The
of 9 day
port
of 9 day
relative
upp
relative
will be ta
o su
will be ta
aborator
d to 
aborator
350x10
sed 
350x109
t
9
n the D
use
n the D
DMC w
be u
DMC w
This document cannot
ently to 
ot b
ently to 
ny time 
nno
ny time 
o


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 268 of 353
i A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
j At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
k Blood sample for cytokines will be obtained only in case of infusion reactions.
l In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 7 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
m
n This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
o A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only. 
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg dose arm
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consent
X
Demographic data
X
Verification of inclusion/exclusion 
criteria
X
X
Platelets for inclusion/withdrawal 
check (local laboratory) f
X
X
X
REDACTED COPY 
mg/kg 
COPY
mg/kg 
iod
ED
iod
C
Dos
ACT
Dos
TE
DAC
3
RE
3
ED
R
any marketing authorization application and any extensions or variations thereof.
perform
atio
perform
assessm
ons 
assessm
olution 
exte
olution 
ncluding
ny e
ncluding
med if in
d any
med if in
hdraw
n an
hdrawal
n
al
 dose
n ap
 dose
tio
e 
h
e 
2
u
2
Do
or
Do
riz
ho
4
g a
4a
a
a
au
inin
ma
in
1
ny m
1
m
to support any m
1
a
1
an
or
pp
X
to
X
sup
sed to
X
d 
X
t cannot be used to
se
u
awal 
nno
awal 
ot
This document c
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 269 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg dose arm
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Randomizationg
X
Withdrawal criteriah
X
X
X
X
General medical/procedures history
X
ITP history
X
Prior and concomitant medication
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical procedures
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationi
X
X
X
X
X
X
X
X
12-lead ECG
X
X
X
X
X
X
Karnofsky Performance Status
X
Laboratory parameters (hematology, 
chemistry, urinalysis)
Xj
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
X
D CO
X
CO
D C
ED
CT
DAC
X
RED
X
ED
R
marketing authorization application and any extensions or variations thereof.
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
n
pl
X
t
X
n a
on
at
ho
ho
ho
ho
ho
X
g a
X
au
in
X
keti
X
inining
in
X
mar
X
rk
ma
ma
d to support any ma
m
an
p
uppo
pp
X
to s
X
su
be used t
X
d
X
d t
us
u
annot be
logy,
not b
logy,
be
This document can


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 270 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg dose arm
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Serology test for HIV, hepatitis B, and 
hepatitis C
X
Blood sample for cytokines
X
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Xk
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
Call to IXRS for treatment kit number
X
X
X
Administration of IMP
X
X
X
Blood sampling for plasma 
concentration of UCB7665
X
X
X
X
X
X
Anti-UCB7665 antibodies/IgG 
depletion assay
X
X
X
X
X
X
X
X
X
X
Serum complements (C3 and C4) and 
plasma complements (C3a and C5a)
X
X
X
X
Serum biomarkers 
 
X
X
X
X
X
X
X
X
X
X
X
Serum biomarkers 
X
X
X
X
REDACTED COPY
C
 
X
E
Xk
D
k
C
D C
TE
AC
DA
DA
DA
RE
R
marketing authorization application and any extensions or variations thereof.
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
on
pl
X
zat
Xk
ati
k
tio
riz
ho
X
au
X
uth
g
in
ed to support any market
ket
ma
y ma
ma
ma
ma
X
t a
pp
up
This document cannot be used
p
ed
u
be
annot


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 271 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg dose arm
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Serum BAFF levels
X
X
X
X
X
Immunoglobulins (total IgG, IgG 
subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgEl
X
X
X
X
ITP-specific autoantibodiesm
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
Headache questionnairen
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviewo
X
AE=adverse event; BAFF=B cell activating factor; BL=baseline; CSF=cerebrospinal fluid CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
 HIV=human immunodeficiency virus;
Ig=immunoglobulin; IMP=investigational medicinal product; ITP=immune thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar 
puncture; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
a Frequency of assessments on dosing days is detailed in Table 5‒3.
b Visits 8, 10, and 12 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the final dose.
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose. 
REDACTED COPY
X
OPY
X
Y 
X
D CO
X
O
D C
TE
AC
DA
DA
DA
RE
R
marketing authorization application and any extensions or variations thereof.
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
n
pl
X
tion
X
n a
on
X
riz
ho
uth
g
in
ke
ma
ort any ma
X
y m
X
ma
ma
ma
ma
ny
be used to suppor
or
; BL=ba
ppo
BL=ba
d of Stu
supp
d of Stu
edicinal
to su
edicinal
ing; NFI
d to
ing; NFI
g days is
e us
g days is
cannot b
rmed at 
t be
rmed at 
weeks fo
not 
weeks fo
s is
an
s is allow
ann
allow
This document c
days an
t ca
days an


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 272 of 353
e The visit windows in the Observation Period are relative to the final dosing visit date. 
f Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate
withdrawal criterion of platelet count >350x109/L.
g The first 6 subjects will be enrolled in the Dose Arm 1 group. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the DMC. 
Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, subjects subsequently enrolled will be 
randomly assigned to one of the dose arms using an IXRS until 15 subjects are in Dose Arm 1.
h Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
i A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
j At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
k Blood sample for cytokines will be obtained only in case of infusion reactions.
l In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 5 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
m
n This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
o A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
TED COPY 
ill be p
OPY
ill be p
y a neu
COP
y a neu
r CSF
D C
r CSF
REDAC
 record
ACTE
 record
pplication and any extensions or variations thereof.
nclusion
aria
nclusion
o dosing
r va
o dosing
e will be
ons 
e will be
ects sub
sion
ects sub
physical
ny e
physical
et count
nd a
et count
en the sc
tion 
en the sc
orization ap
performe
app
performe
urologic
on a
urologic
collectio
atio
collectio
This document cannot be used to support any marketing autho
ded. In
horiz
ded. In
z


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 273 of 353
Has been changed to:
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consentf
X
Demographic data
X
Verification of 
inclusion/exclusion 
criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory)g
X
X
X
X
X
Randomizationh
X
Withdrawal criteriai
X
X
X
X
X
X
General 
medical/procedures 
history
X
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
±2d
OPY
±2dd
Y
d
Y
CO
D C
TE
AC
DA
R
A
used to support any marketing authorization application and any extensions or variations thereof.
m 1)
or v
m 1)
ation P
ons 
ation P
o
0
n
0b
y
b
ex
e
nd
36
tion
36
n a
a
5
lica
5
at
ca
±1d
app
±1d
pl
 a
tio
ririririz
ori
uth
g
X
mark
X
ke
ma
a
rt
X
upp
X
po
su
su
su
t be used to su
su
us
su
X
b
X
u
This document cannot 
X
ot
X
t b
ca


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 274 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationj
X
X
X
X
X
X
X
X
X
X
12-lead ECGk
X
X
X
X
X
X
X
X 
Karnofsky Performance 
Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xl
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serology test for HIV, 
hepatitis B, and hepatitis 
C
X
IGRA TB testm
X
REDACTED COPY 
X
COP
X
PY
CO
X
TE
X
ED
CT
AC
ED
R
any marketing authorization application and any extensions or variations thereof.
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
X
n a
X
X
ap
 a
X
riza
X
at
ori
ho
au
g
X
keti
X
ting
X
mar
X
rk
ma
nnot be used to support any m
X
ny 
X
m
a
u
rt
X
su
X
up
s
This document cannot be use
su
se
us
nn
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 275 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
TB signs and symptoms 
questionnaire
X
X
Blood sample for 
cytokines
X
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Whole blood sample for 
DNA (optional)
X
X
Whole blood sample for 
RNA (optional)
X
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
X
X
Call to IXRS for treatment 
kit number
X
X
X
X
X
Administration of IMP
X
X
X
X
X
Blood sampling for 
plasma concentration of 
UCB7665
X
X
X
X
X
X
X
X
Anti-UCB7665 antibodies
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
PY
CO
X
TE
Xn
ED
n
ED
AC
DA
R
support any marketing authorization application and any extensions or variations thereof.
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
ap
 a
X
at
ori
ut
g
ti
ma
m
X
a
X
an
rt
po
This document cannot be used to suppo
su
X
d to
X
o
ed
us
no
ca


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 276 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Serum complements (C3 
and C4) and plasma 
complements (C3a and 
C5a)
X
X
X
X
Blood collection for 
exploratory safety 
biomarkers 
X
Xo
X
X
X
X
Xo
Xo
Xo
Xo
Xo
Xo
Xo
Serum BAFF levels
X
X
X
X
X
X
X
Blood collection for 
exploratory biomarker 
analysis
X
X
X
X
X
X
X
Immunoglobulins (total 
IgG, IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X 
IgA, IgM, IgEp
X
X
X
X
ITP-specific 
autoantibodies q
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
REDACTED COPY 
PY
AC
CO
X
DA
X
AC
AC
AC
R
AC
ed to support any marketing authorization application and any extensions or variations thereof.
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
ap
ori
 a
X
auth
X
tho
g
o
X
arke
X
ket
ma
X
y m
X
ma
ma
ma
rt
ma
X
ppo
X
or
su
r
X
d to
X
o s
be used
s
X
ed
us
nnot b
X
ot 
X
This document cann t b
nn
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 277 of 353
Table 5‒1:
Schedule of assessments for the UCB7665 4mg/kg weekly dose arm (Dose Arm 1)
Assessments
Screening 
Period
Dosing Period 
Observation Period
Dose 
1
Dose 
2
Dose 
3
Dose 
4
Dose 
5
Visit
1
2a
3
4a
5a
6a
7a
8
9
10b
11
12b
13
14b
15
BL 
Visit
EOS/ 
EWc
Day
-28 to -1
1
4
8
15
22
29
32
36
43
50
57
64
71
85
Week
1
1
2
3
4
5
5
6
7
8
9
10
11
13
Visit 
Window
±1d
±2dd
±2dd
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Headache questionnairer
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviews
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring; 
DNA=deoxyribonucleic acid; Committee; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal;
 HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IMP=investigational medicinal product; ITP=immune thrombocytopenia; IXRS= interactive voice/web response 
system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
TB=tuberculosis.
a Frequency of assessments on dosing days is detailed in Table 5‒6.  
b Visits 10, 12, and 14 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the final dose.
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose. 
e The visit windows in the Observation Period are relative to the final dosing visit date.
f Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
g Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h The first 6 subjects will be enrolled in the Dose Arm 1 group only. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the 
DMC. Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, the subsequent subjects will be 
randomly assigned in 1:1 ratio to either Dose Arm 1 or Dose Arm 2 using an IXRS. Once 15 subjects are enrolled in Dose Arm 1 and safety data review of at 
least 6 subjects in Dose Arm 2 is done, the subsequently enrolled subjects will be enrolled in Dose Arm 2 until a planned number of 15 subjects are enrolled.
i Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
REDACTED COPY 
X
COP
X
PY
CO
C
TE
C
rebrosp
ACTE
rebrosp
OS=En
DAC
OS=En
medici
REDA
medici
etic re
RE
etic re
t be used to support any marketing authorization application and any extensions or variations thereof.
 Period
or v
 Period
va
11
ten
11
ns
e
d
e
6
4
and
6
4
d a
nd
6
ion 
6
a
1d
lic
1d
±
a
±
atio
a
ca
X
X
n a
X
X
ap
 a
io
ririririz
pinal flu
horiz
pinal flu
d of Stu
utho
d of Stu
inal pro
g au
inal pro
esonance
ting 
esonance
.  
a
.  
care pro
ma
care pro
.
n
.
its. The 
t any
its. The 
f 9 days
ort a
f 9 days
elative t
ppo
elative t
icipation
supp
icipation
will be 
to s
will be 
la
d
laborato
d to
borato
b
d
b
>350x10
sed
>350x10
in the D
e us
in the D
DMC w
t be 
DMC w
This document canno
o to eith
not b
o to eith
m 2 
nn
m 2 is d
no
is d
at any tim
t can
at any tim


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 278 of 353
j A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
k The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
l At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
m The IGRA test will be performed in a central laboratory. Any IGRA-positive subjects will be withdrawn from the study.
o Exploratory safety biomarker samples to be obtained on dosing days for all subjects. During non-dosing visits and during the visits in the Observation Period, 
the samples should be obtained only from subjects experiencing severe headaches or GI disturbances (only in case of Adverse Events of Interest, see 
Section 12.4).
n Blood sample for cytokines will be obtained and analyzed at baseline for all subjects and at subsequent visits only in subjects with infusion reactions.
p In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 7 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
q
r This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
s A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only. 
Y
REDACTED COPY
collec
PY 
collec
ded. In 
D CO
ded. In 
plication and any extensions or variations thereof.
perform
atio
perform
e recor
var
e recor
ing the v
ens
ing the v
of Adve
exte
of Adve
only in 
any
only in 
chedule
nd a
chedule
ed daily
atio
ed daily
cal asses
plica
cal asses
This document cannot be used to support any marketing authorization app
ion to be
appl
ion to be
case of 
tion
case of 


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 279 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consentf
X
Demographic data
X
Verification of inclusion/exclusion 
criteria
X
X
Platelets for inclusion/withdrawal 
check (local laboratory)g
X
X
X
Randomizationh
X
Withdrawal criteriai
X
X
X
X
General medical/procedures history
X
ITP history
X
Prior and concomitant medication
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical procedures
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
O
D C
D
AC
D
AC
AC
R DAC
t any marketing authorization application and any extensions or variations thereof.
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
n
pl
n a
on
at
ho
X
aut
X
th
in
h
tininin
a
in
X
ma
X
ark
ma
y m
be used to support a
t a
p
uppo
pp
su
X
d
X
d
us
This document cannot b
u
t b
nn
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 280 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Physical examinationj
X
X
X
X
X
X
X
X
12-lead ECGk
X
X
X
X
X
X
Karnofsky Performance Status
X
Laboratory parameters (hematology, 
chemistry, urinalysis)
Xl
X
X
X
X
X
X
X
X
X
X
X
X
Serology test for HIV, hepatitis B, and 
hepatitis C
X
IGRA TB testm
X
TB signs and symptoms questionnaire
X
X
Blood sample for cytokines
X
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Whole blood sample for DNA 
(optional)
X
X
Whole blood sample for RNA 
(optional)
X
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
X
X
Call to IXRS for treatment kit number
X
X
X
REDACTED COPY
X
OPY
X
Y 
X
D CO
X
O
D C
D
X
DAC
X
CT
DAC
RE
R
t any marketing authorization application and any extensions or variations thereof.
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
n
pl
X
t
X
n a
on
at
o
X
tho
X
or
ho
g
in
ark
ma
y m
annot be used to support a
X
t a
p
pp
pp
pp
pp
to
u
e u
ot
nt can
nt kit nu
t ca
nt kit nu
an
This document
nt 


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 281 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Administration of IMP
X
X
X
Blood sampling for plasma 
concentration of UCB7665
X
X
X
X
X
X
Anti-UCB7665 antibodies
X
X
X
X
X
X
X
X
X
X
Serum complements (C3 and C4) and 
plasma complements (C3a and C5a)
X
X
X
X
Blood collection for exploratory safety 
biomarkers
X
Xo
X
X
Xo
Xo
Xo
Xo
Xo
Xo
Xo
Serum BAFF levels
X
X
X
X
X
Blood collection for exploratory 
biomarker analysis
X
X
X
X
X
Immunoglobulins (total IgG, IgG 
subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgEp
X
X
X
X
ITP-specific autoantibodiesq
X
X
X
ITP bleeding scale
X
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
REDACTED COPY
X
OPY
X
Y 
X
D CO
X
O
D C
X
ACT
X
TE
AC
AC
AC
R DAC
R
ny marketing authorization application and any extensions or variations thereof.
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
plplpl
n
pl
X
tion
X
n a
on
X
hor
X
riz
ho
th
in
h
X
ke
Xo
ket
o
tininin
ma
in
X
n
X
ma
ma
ma
m
pport any
X
a
X
not be used to suppor any
pp
supp
pp
pp
pp
d t
us
u
b
This document cann
nn
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 282 of 353
Table 5‒2:
Schedule of assessments for the UCB7665 7mg/kg weekly dose arm (Dose Arm 2) 
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 
2
Dose 
3
Visit
1
2a
3
4a
5a
6
7
8b
9
10b
11
12b
13
BL Visit
EOS/
EWc
Day
-28 to -1
1
4
8
15
18
22
29
36
43
50
57
71
Week
1
1
2
3
3
4
5
6
7
8
9
11
Visit Window
±1d
±2dd
±2dd
±1d
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Headache questionnairer
X
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviews
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
 HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IGRA= interferon-gamma release assay; IMP=investigational medicinal product; ITP=immune thrombocytopenia; 
IXRS= interactive voice/web response system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; NFI-MS=Neurological Fatigue 
Index for multiple sclerosis; TB=tuberculosis.
a Frequency of assessments on dosing days is detailed in Table 5‒6.
b Visits 8, 10, and 12 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the last dose.
d A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose. 
e The visit windows in the Observation Period are relative to the final dosing visit date. 
f Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
g Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h The first 6 subjects will be enrolled in the Dose Arm 1 group. Safety data for these 6 subjects up to 7 days after the last dose will be reviewed by the DMC. 
Following this review the DMC will make a decision to open Dose Arm 2 for enrollment. If Dose Arm 2 is opened, the subsequent subjects will be randomly 
assigned in 1:1 ratio to either Dose Arm 1 or Dose Arm 2 using an IXRS. Once 15 subjects are enrolled in Dose Arm 1 and safety data review of at least 
6 subjects in Dose Arm 2 is done, the subsequently enrolled subjects will be enrolled in Dose Arm 2 until a planned number of 15 subjects are enrolled.
i Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
ED COPY
X
OPY
X
Y 
CO
REDACTED C
D
brospin
TED
brospin
=End o
ACT
=End o
ma rele
DAC
ma rele
e; RNA
RED
e; RNA
ation application and any extensions or variations thereof.
eriod
or v
eriod
va
9
xte
9
ns
y
29
and
29
d
a
4
tion
4
a
d
l
d
±2
ca
±2
ati
plic
X
app
X
plplpl
n
pl
n
port any marketing authorization 
n a
at on
nal fluid
riza
nal fluid
of Study
thori
of Study
ease ass
auth
ease ass
A=
g
A=ribonu
g au
ribonu
profess
arke
profess
. The vi
ny m
. The vi
9 days a
t any
9 days a
ative to t
port 
ative to t
used to supp
pation in
ppo
pation in
ill 
s
ill be tak
sup
be tak
boratory
to s
boratory
50x10
ed t
50x109
to
9/
n the Do
use
n the Do
nnot be 
ll make
be u
l make
ose Arm
t be
ose Arm
done, the
not 
done, the
This document can
any time
ann
any time


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 283 of 353
j A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
k The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
l At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
m The IGRA test will be performed in a central laboratory. Any IGRA-positive subjects will be withdrawn from the study.
n Blood sample for cytokines will be obtained and analyzed at baseline for all subjects and at subsequent visits only in subjects with infusion reactions.
o Exploratory safety biomarker samples to be obtained on dosing days for all subjects. During non-dosing visits and during the visits in the Observation Period, 
the samples should be obtained only from subjects experiencing severe headaches or GI disturbances (only in case of Adverse Events of Interest, see 
Section 12.4).
p In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 5 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
q
r This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
s A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
Change #35
Section 5.2
Schedule of study assessments
NEW tables added:
Table 5-3:
Schedule of assessments for the UCB7665 10mg/kg once weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Visit 
1
2a
3
4a
5
6
7b
8
9b
10
11b
12
BL 
Visit
EOS/EW
c
Telephone 
Contact
1
2d
3
4d
Day
-28 to -1
1
2
3
4
8
9
10
11
15
22
29
36
43
50
64
REDACTED COPY 
euro
Y
euro
F collec
OPY
F collec
rded. In
D C
rded. In
to support any marketing authorization application and any extensions or variations thereof.
perform
atio
perform
e recor
var
e recor
ubjects 
tens
ubjects 
during 
ext
during 
ase of A
ny e
ase of A
sched
and 
schedu
med dai
icat
med dai
gical ass
pplic
gical ass
ction to 
app
ction to 
n case o
atio
n case o
he UC
y m
he UC
any
1
p
1
or
pp
2
o
2a
s
a
up
This document cannot be used to
B
t
B
to
sed
e u
-
nn
-28
n
28
o
ca
ca
ca
ca


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 284 of 353
Week
1
1
1
1
2
2
2
2
3
4
5
6
7
8
10
Visit 
Window
±1d
±2de
±1d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d f
Written informed consentg
X
Demographic data
X
Verification of 
inclusion/exclusion criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory) h
X
X
Withdrawal criteriai
X
X
X
General medical/procedures 
history
X
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationj
X
X
X
X
X
X
X
12-lead ECGk
X
X
X
X
X
Karnofsky Performance 
Status
X
Laboratory parameters 
(hematology, chemistry, 
Xl
X
X
X
X
X
X
X
X
X
X
X
REDACTED COPY 
Y
OP
C
CTE
TE
AC
X
RED
X
ED
RE
keting authorization application and any extensions or variations thereof.
7
atio
7
on
on
on
on
2d
v
2d
f
r
f
±2
ar
±2
ria
s
va
s o
ns
sio
te
te
te
ny
te
an
a
n
tio
ca
pli
 a
ion
za
X
hori
X
iza
za
z
g au
g
t be used to support any marke
X
k
X
ke
ark
ma
n
a
ny
an
X
ppo
X
ort
pp
X
s
X
upp
pp
pp
p
X
d t
X
to 
sed
se
se
se
This document cannot b
X
ot
Xl
t b
ca
ca
ca
ca


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 285 of 353
Table 5-3:
Schedule of assessments for the UCB7665 10mg/kg once weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Visit 
1
2a
3
4a
5
6
7b
8
9b
10
11b
12
BL 
Visit
EOS/EW
c
Telephone 
Contact
1
2d
3
4d
Day
-28 to -1
1
2
3
4
8
9
10
11
15
22
29
36
43
50
64
Week
1
1
1
1
2
2
2
2
3
4
5
6
7
8
10
Visit 
Window
±1d
±2de
±1d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d f
urinalysis)
Serology test for HIV, 
hepatitis B, and hepatitis C
X
IGRA TB testm
X
TB signs and symptoms 
questionnaire
X
X
Blood sample for cytokines
X
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Whole blood sample for 
DNA (optional)
X
X
Whole blood sample for 
RNA (optional)
X
X
X
X
Serum pregnancy test
X
  
Urine pregnancy test
X
X
X
Call to IXRS for treatment 
kit number
X
X
Administration of IMP
X
X
REDACTED COPY 
OP
CO
ED
AC
DA
RE
RE
RE
RE
port any marketing authorization application and any extensions or variations thereof.
Arm 3)
riati
rm 3)
tion Pe
or v
tion Pe
va
o
ns
8
sio
8
on
e
n
e
ny
te
ny
ny
a
ny
11
n a
11
an
a
2
cati
2
io
ca
lic
 a
c
on
at
za
uth
g 
ark
g
ar
ar
ar
e used to support any 
ar
y
p
an
po
pp
to
ed
ed
ed
ed
This document cannot be sed
e
nn
t ca
c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 286 of 353
Table 5-3:
Schedule of assessments for the UCB7665 10mg/kg once weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Visit 
1
2a
3
4a
5
6
7b
8
9b
10
11b
12
BL 
Visit
EOS/EW
c
Telephone 
Contact
1
2d
3
4d
Day
-28 to -1
1
2
3
4
8
9
10
11
15
22
29
36
43
50
64
Week
1
1
1
1
2
2
2
2
3
4
5
6
7
8
10
Visit 
Window
±1d
±2de
±1d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d f
Blood sampling for plasma 
concentration of UCB7665
X
X
X
X
X
Anti-UCB7665 antibodies
X
X
X
X
X
X
X
X
X
Serum complements (C3 
and C4) and plasma 
complements (C3a and C5a)
X
X
X
Blood collection for 
exploratory safety 
biomarkers
X
Xo
Xo
Xo
Xo
Xo
Xo
Xo
Xo
Xo
Serum BAFF levels
X
X
X
X
Blood collection for 
exploratory biomarker 
analysis
X
X
X
X
Immunoglobulins (total 
IgG, IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgEp
X
X
X
X
ITP-specific autoantibodiesq
X
X
X
REDACTED COPY 
OP
X
D
X
CO
C
O
X
ACT
X
CT
AC
DA
RE
pport any marketing authorization application and any extensions or variations thereof.
Arm 3)
riati
rm 3)
tion Pe
or v
tion Pe
va
o
ns
8
sio
8
on
e
n
e
ny
te
ny
ny
a
ny
11
n a
11
an
a
2
cati
2
io
ca
lic
 a
c
on
za
X
th
X
ori
ut
rk
g
rk
rk
rk
an
ark
t a
nnot be used to support a
pp
a
X
s
X
pp
pp
pp
ed
pp
used
ed
ed
sed
t b
This document cann
es
esq
c
q
nn
t ca
c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 287 of 353
Table 5-3:
Schedule of assessments for the UCB7665 10mg/kg once weekly dose arm (Dose Arm 3)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Dose 2
Visit 
1
2a
3
4a
5
6
7b
8
9b
10
11b
12
BL 
Visit
EOS/EW
c
Telephone 
Contact
1
2d
3
4d
Day
-28 to -1
1
2
3
4
8
9
10
11
15
22
29
36
43
50
64
Week
1
1
1
1
2
2
2
2
3
4
5
6
7
8
10
Visit 
Window
±1d
±2de
±1d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d
f
±2d f
ITP bleeding scale
X
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
Headache questionnairer
X
X
X
X
X
X
X
X
X
X
X
Subject exit interviews
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal;
HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IGRA= interferon-gamma release assay; IMP=investigational medicinal product; ITP=immune 
thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; 
NFI-MS=Neurological Fatigue Index for multiple sclerosis; TB=tuberculosis.
a Frequency of assessments on dosing days is detailed in Table 5‒6.
b Visits 7, 9, and 11 can be performed at home with a healthcare professional visiting the subject at his/her home.
c The End-of-Study Visit is 8 weeks following the last dose.
d If the TC is on the same day as an on-site visit, the TC may be skipped.
e A visit window of ±2 days is allowed for the dosing visits. The visit window of ±2 days is relative to the first dosing visit date. However, there should be a 
minimum interval of 5 days and maximum interval of 9 days as compared to the previous dose.
f The visit windows in the Observation Period are relative to the final dosing visit date. 
g Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
REDACTED COPY 
OP
X
D
X
CO
ED
C
X
DAC
X
AC
AC
AC
AC
ED
RE
eting authorization application and any extensions or variations thereof.
Arm 3)
riati
rm 3)
tion Pe
or v
tion Pe
va
o
ns
8
sio
8
on
e
n
e
ny
te
ny
ny
a
ny
11
n a
11
an
a
2
cati
2
io
ca
lic
 a
c
on
za
za
za
za
X
uth
X
ho
a
ting
sed to support any marke
CSF=ce
keti
CSF=ce
ram; EO
mark
ram; EO
eron
ma
eron-
m
-ga
ma
ga
e system
any 
e system
rosis
rt a
rosis;
a
; TB
n
TB
d in
po
d in Tab
ort
Tab
th a heal
upp
th a heal
the last 
o su
the last 
visit, th
d to
visit, th
or the d
sed
or the d
t be u
ximum i
e us
ximum i
ation Pe
t be 
ation Pe
This document canno
is neede
not b
is neede


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 288 of 353
h Prior to dosing at Visit 2, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
i Subjects can withdraw at any time during the study, based on the criteria in Section 6.4. 
j A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
k The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
l At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
m The IGRA test will be performed in a central laboratory. Any IGRA-positive subjects will be withdrawn from the study.
n Blood sample for cytokines will be obtained and analyzed at baseline for all subjects and at subsequent visits only in subjects with infusion reactions.
o Exploratory safety biomarker samples to be obtained on dosing days for all subjects. During non-dosing visits and during the visits in the Observation Period, 
the samples should be obtained only from subjects experiencing severe headaches or GI disturbances (only in case of Adverse Events of Interest, see 
Section 12.4).
p In case the number of infusions to be administered are reduced after DMC review of safety data, then the scheduled Visit 6 assessment for IgA, IgM, and IgE 
will be performed earlier at the last dosing visit.
q
r This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
s A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
EDACTED COPY 
fet
Y
fet
and w
D C
and wi
C
i
wed by
TED
wed by
LP for
ACT
LP for
TP.
DA
TP.
RE
will be
RED
will be
authorization application and any extensions or variations thereof.
sion cri
atio
sion cri
osing to 
aria
osing to 
minat
ons
minatio
s 
io
CGs sho
tens
CGs sho
nt.
ny
nt.
m the stu
d any
m the stu
sits only
nd 
sits only
ng visits
n an
ng visits
es (only
tion
es (only
ata, then
plic
ata, then
ill be pe
atio
ill be pe
y a neur
riza
y a neur
r CSF co
hori
r CSF co
This document cannot be used to support any marketing 
recorde
g au
recorde


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 289 of 353
Table 5-4:
Schedule of assessments for the UCB7665 15mg/kg once dose arm (Dose Arm 4)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consentf
X
Demographic data
X
Verification of 
inclusion/exclusion criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory)g
X
Withdrawal criteriah
X
General medical/procedures 
history
X
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
REDACTED COPY 
PY
OP
C
TE
TE
TE
TE
E
TE
ED
RE
port any marketing authorization application and any extensions or variations thereof.
d
o
d
va
o
o
b
nsio
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
ap
tio
za
riz
au
z
au
au
au
rk
a
a
ny
t be used to suppo
an
po
su
o s
se
t cannot t b
nn
n
This document can
nt
n


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 290 of 353
Table 5-4:
Schedule of assessments for the UCB7665 15mg/kg once dose arm (Dose Arm 4)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationi
X
X
X
X
X
X
12-lead ECGj
X
X
X
X
Karnofsky Performance Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xk
X
X
X
X
X
X
X
X
X
Serology test for HIV, 
hepatitis B, and hepatitis C
X
IGRA TB testl
X
TB signs and symptoms 
questionnaire
X
X
Blood sample for cytokines
X
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Whole blood sample for DNA 
(optional)
X
REDACTED COPY 
PY
OP
X
ED 
X
C
TE
TE
TE
TE
TE
AC
RE
RE
RE
RE
RE
pport any marketing authorization application and any extensions or variations thereof.
d
o
d
va
o
o
b
nsio
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
ap
X
zati
X
io
za
iz
th
au
g
ket
an
This document cannot be used to support an
rk
an
an
any
an
pp
o s
o
us
t b
cann


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 291 of 353
Table 5-4:
Schedule of assessments for the UCB7665 15mg/kg once dose arm (Dose Arm 4)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Whole blood sample for RNA 
(optional)
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
Call to IXRS for treatment kit 
number
X
Administration of IMP
X
Blood sampling for plasma 
concentration of UCB7665
X
X
X
Anti-UCB7665 antibodies
X
X
X
X
X
X
X
Serum complements (C3 and 
C4) and plasma complements 
(C3a and C5a)
X
X
X
Blood collection for 
exploratory safety biomarkers
X
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Serum BAFF levels
X
X
X
REDACTED COPY 
P
X
C
X
PY
OP
ED
TE
CT
ED
RE
pport any marketing authorization application and any extensions or variations thereof.
d
o
d
va
o
o
b
nsio
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
a
ap
za
za
za
za
ho
au
au
au
au
k
au
ke
rk
ma
an
ed to support a
X
po
X
t a
X
p
X
pp
o s
This document cannot be used
ed
t b
nn
nn
nn
nn


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 292 of 353
Table 5-4:
Schedule of assessments for the UCB7665 15mg/kg once dose arm (Dose Arm 4)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Blood collection for 
exploratory biomarker 
analysis
X
X
X
Immunoglobulins (total IgG, 
IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgE
X
X
X
ITP-specific autoantibodieso
X
X
X
ITP bleeding scale
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
Headache questionnairep
X
X
X
X
X
X
X
X
X
Subject exit interviewq
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal;
HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IGRA= interferon-gamma release assay; IMP=investigational medicinal product; ITP=immune 
thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; 
NFI-MS=Neurological Fatigue Index for multiple sclerosis; TB=tuberculosis.
a Frequency of assessments on dosing days is detailed in Table 5‒6.
b Visits 5, 7, and 9 can be performed at home with a healthcare professional visiting the subject at his/her home.
REDACTED COPY 
PY
TE
OP
CTE
TE
TE
E
T
RE
RE
RED
RE
rt any marketing authorization application and any extensions or variations thereof.
d
o
d
va
o
o
b
nsio
b
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
za
ap
X
ho
X
ori
au
a
eti
rk
ar
be used to support any 
an
X
po
X
rt
pp
o s
o
ng factor
d to 
ng factor
id; ECG
sed 
id; ECG
oglobul
use
oglobul
ctive voi
be u
ctive voi
nnot
e Index f
ot b
e Index f
n dosing
nno
n dosing
This document ca
perform
can
perform


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 293 of 353
c The End-of-Study Visit is 8 weeks following the dose.
d If the TC is on the same day as an on-site visit, the TC may be skipped.
e The visit windows in the Observation Period are relative to the dosing visit date. 
f Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
g Prior to dosing at Visit 1, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
i A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
j The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
k At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
l IGRA test will be performed in a central laboratory. It is recommended that the QFT-GIT be the first test performed at Screening to reduce the number of 
screening procedures conducted for any IGRA-positive subjects that may need to be withdrawn from the study.
m Blood sample for cytokines will be obtained and analyzed at baseline for all subjects and at subsequent visits only in subjects with infusion reactions.
n Exploratory safety biomarker samples to be obtained on dosing days for all subjects. During non-dosing visits and during the visits in the Observation Period, 
the samples should be obtained only from subjects experiencing severe headaches or GI disturbances (only in case of Adverse Events of Interest, see 
Section 12.4).
o
p This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
q A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
EDACTED COPY 
nd a
Y
nd a
s. Durin
OPY
s. Durin
es or G
COP
es or G
daches 
ACT
daches 
e follow
EDAC
e follow
RE
and/or 
RED
and/or 
th IT
R
th IT
authorization application and any extensions or variations thereof.
r to dos
or v
r to dos
check in
ns o
check in
y prior t
sion
y prior t
hysical e
y ex
hysical e
s. Three
d an
s. Three
latelet co
n a
latelet co
rst test p
tion
rst test p
from th
icat
from th
ubseque
pplic
ubseque
ng non
app
ng non
I disturb
on a
I disturb
and w
thor
and will
r
ill
wed by 
auth
wed by 
eting 
LP for 
g au
LP for 
TP.
tin
TP.
This document cannot be used to support any marke
will be r
rket
will be r


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 294 of 353
Table 5-5:
Schedule of assessments for the UCB7665 20mg/kg once dose arm (Dose Arm 5)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Written informed consentf
X
Demographic data
X
Verification of 
inclusion/exclusion criteria
X
X
Platelets for inclusion/ 
withdrawal check (local 
laboratory)g
X
Withdrawal criteriah
X
General medical/procedures 
history
X
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
REDACTED COPY 
PY
OP
C
TE
TE
TE
TE
E
TE
ED
RE
port any marketing authorization application and any extensions or variations thereof.
d
o
d
va
o
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
ap
tio
za
riz
au
z
au
au
au
rk
a
a
n
This document cannot be used to support any
ny
an
po
su
o s
se
t b
nn
n
nt
n


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 295 of 353
Table 5-5:
Schedule of assessments for the UCB7665 20mg/kg once dose arm (Dose Arm 5)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
Physical examinationi
X
X
X
X
X
X
12-lead ECGj
X
X
X
X
Karnofsky Performance Status
X
Laboratory parameters 
(hematology, chemistry, 
urinalysis)
Xk
X
X
X
X
X
X
X
X
X
Serology test for HIV, 
hepatitis B, and hepatitis C
X
IGRA TB testl
X
TB signs and symptoms 
questionnaire
X
X
Blood sample for cytokines
X
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Xm
Whole blood sample for DNA 
(optional)
X
REDACTED COPY 
PY
OP
X
ED 
X
C
TE
TE
TE
TE
TE
AC
RE
RE
RE
RE
RE
any marketing authorization application and any extensions or variations thereof.
d
o
d
va
o
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
ap
X
zati
X
io
za
iz
th
au
g
ket
This document cannot be used to support any
an
rk
an
an
any
an
pp
o s
o
us
t b
cann


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 296 of 353
Table 5-5:
Schedule of assessments for the UCB7665 20mg/kg once dose arm (Dose Arm 5)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Whole blood sample for RNA 
(optional)
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
Call to IXRS for treatment kit 
number
X
Administration of IMP
X
Blood sampling for plasma 
concentration of UCB7665
X
X
X
Anti-UCB7665 antibodies
X
X
X
X
X
X
X
Serum complements (C3 and 
C4) and plasma complements 
(C3a and C5a)
X
X
X
Blood collection for 
exploratory safety biomarkers
X
Xn
Xn
Xn
Xn
Xn
Xn
Xn
Serum BAFF levels
X
X
X
REDACTED COPY 
P
X
C
X
PY
OP
ED
TE
CT
ED
RE
pport any marketing authorization application and any extensions or variations thereof.
d
o
d
va
o
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
a
ap
za
za
za
za
ho
au
au
au
au
k
au
ke
rk
ma
an
o support a
X
po
X
t a
X
p
X
pp
This document cannot be used to s
o s
ed
t b
nn
nn
nn
nn


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 297 of 353
Table 5-5:
Schedule of assessments for the UCB7665 20mg/kg once dose arm (Dose Arm 5)
Assessments
Screening 
Period
Dosing Period
Observation Period
Dose 1
Visit 
1
2a
3
4
5b
6
7b
8
9b
10
BL Visit
EOS/EWc
Telephone 
Contact
1
2d
Day
-28 to -1
1
2
3
4
8
15
22
29
36
43
57
Week
1
1
1
1
2
3
4
5
6
7
9
Visit 
Window
±1de
±2de
±2de
±2de
±2de
±2de
±2de
±2de
Blood collection for 
exploratory biomarker 
analysis
X
X
X
Immunoglobulins (total IgG, 
IgG subclasses) 
X
X
X
X
X
X
X
X
X
X
IgA, IgM, IgE
X
X
X
ITP-specific autoantibodieso
X
X
X
ITP bleeding scale
X
X
X
X
X
X
NFI-MS
X
X
X
X
X
Headache questionnairep
X
X
X
X
X
X
X
X
X
Subject exit interviewq
X
AE=adverse event; BAFF=B cell activating factor; BL=Baseline; CSF=cerebrospinal fluid; CT=computed tomography; d=day(s); DMC=Data Monitoring 
Committee; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EOS=End of Study; EW=Early Withdrawal; 
HIV=human 
immunodeficiency virus; Ig=immunoglobulin; IGRA= interferon-gamma release assay; IMP=investigational medicinal product; ITP=immune 
thrombocytopenia; IXRS= interactive voice/web response system; LP=lumbar puncture; RNA=ribonucleic acid; MRI=magnetic resonance imaging; 
NFI-MS=Neurological Fatigue Index for multiple sclerosis; TB=tuberculosis.
a Frequency of assessments on dosing days is detailed in Table 5‒6.
b Visits 5, 7, and 9 can be performed at home with a healthcare professional visiting the subject at his/her home.
REDACTED COPY 
PY
TE
OP
CTE
TE
TE
E
T
RE
RE
RED
RE
rt any marketing authorization application and any extensions or variations thereof.
d
o
d
va
o
on
io
e
y
22
and
22
d
tion a
n
±2d
lica
±2de
a
e
ati
ap
ap
ap
za
ap
X
ho
X
ori
au
a
eti
rk
ar
e used to support any 
an
X
po
X
rt
pp
o s
o
ng factor
d to 
ng factor
id; ECG
sed 
id; ECG
oglobul
use
oglobul
This document cannot be
ctive voi
be u
ctive voi
e Index f
ot b
e Index f
n dosin
nno
n dosin
perform
can
perform


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 298 of 353
c The End-of-Study Visit is 8 weeks following the dose.
d If the TC is on the same day as an on-site visit, the TC may be skipped.
e The visit windows in the Observation Period are relative to the dosing visit date. 
f Additional informed consent is needed for participation in the exploratory genomic substudy. All samples will be collected prior to dosing with IMP.
g Prior to dosing at Visit 1, 2 platelet samples will be taken. One sample will be analyzed locally and the value will be used to check inclusion criteria. The other 
platelet sample will be sent to the central laboratory. At subsequent dosing visits, a platelet sample will be assessed locally prior to dosing to evaluate 
withdrawal criterion of platelet count >350x109/L.
h Subjects can withdraw at any time during the study, based on the criteria in Section 6.4.
i A complete physical examination will be performed at Screening and EOS/EW Visit. At all other visits (where physical examination is performed), an 
abbreviated physical examination will be conducted.
j The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
k At the Screening Visit, 2 separate blood samples will be obtained on the same day for evaluation of platelet count.
l The IGRA test will be performed in a central laboratory. Any IGRA-positive subjects will be withdrawn from the study.
m Blood sample for cytokines will be obtained and analyzed at baseline for all subjects and at subsequent visits only in subjects with infusion reactions.
n Exploratory safety biomarker samples to be obtained on dosing days for all subjects. During non-dosing visits and during the visits in the Observation Period, 
the samples should be obtained only from subjects experiencing severe headaches or GI disturbances (only in case of Adverse Events of Interest, see 
Section 12.4). 
o
p This assessment is applicable only to subjects experiencing severe headaches and will be performed daily until resolution (ie, if headache becomes moderate or 
mild, normal collection of AEs should apply); this assessment will be followed by a neurological assessment (including fundoscopy). Additionally, other 
diagnostic procedures including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if indicated at the discretion of the investigator, 
considering the local guidelines for performing LP in subjects with ITP.
q A semi-structured interview guide will be used and the interview will be recorded. In case of early withdrawal from the study, the subject exit interview should 
be performed at End-of-Study Visit only.
Change #36
Section 5.2
Schedule of study assessments
Table 5‒3:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of infusion
4h after end of infusion
Withdrawal criteria
X
Platelet count (local laboratory) for inclusion check 
at Visit 2 and for withdrawal criterion at other 
dosing visits
X
Prior and concomitant medications
X
ACTED COPY 
Durin
Y
Durin
or GI d
OPY
or GI d
hes and
TED
hes and
oll
AC
oll
RED
ow
ACT
owe
T
e
d/or LP
EDAC
d/or LP
h ITP.
RED
h ITP.
will
R
will
orization application and any extensions or variations thereof.
r to dos
or v
r to dos
check in
ns o
check in
y prior t
sion
y prior t
hysical e
y ex
hysical e
s. Three
d an
s. Three
latelet c
n a
latelet c
drawn fr
tion
drawn fr
sequent 
icat
sequent 
non
ppli
non-
pl
-dos
plic
dos
isturban
app
isturban
d w
riz
d will be
riza
ill be
d to support any marketing auth
d by
tho
d by a n
or
a n
y
o
y
P for CS
auth
P for CS
l be reco
ting
l be reco
ons on
ppo
ons on
sup
sed to sup
up
u
d to
nnot be us
nclusion
e us
nclusion
rion at o
t be
rion at o
se
t cann
dication
can
dication
This document c nn
t c


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 299 of 353
Table 5‒3:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of infusion
4h after end of infusion
Concomitant medical procedures
X
Vital signsa
X
X
X
X
Physical examination
X
12-lead ECG
X
Hematology 
X
Clinical chemistry
X
Urinalysis
X
Urine pregnancy test
X
Immunoglobulinsb
X
ITP-specific autoantibodiesc
X
Blood sampling for UCB7665 plasma 
concentration
X
Anti-UCB7665 antibodies/IgG depletion assay
X
Serum (C3 and C4) and plasma complements (C3a
and C5a)d
X
Serum biomarkers 
X
X
X
Serum BAFF levels
X
X
X
Blood sampling for cytokinese
X
ITP bleeding scale
X
AEs
X
X
X
X
NFI-MSf
X
AE=adverse event; BAFF=B cell activating factor; ECG=electrocardiogram; h=hours; Ig=immunoglobulin; IMP=investigational medicinal product; 
ITP=immune thrombocytopenia; NFI-MS=Neurological Fatigue Index for multiple sclerosis; 
 PRO=Patient Reported 
Outcomes; 
REDACTED COPY 
PY
C
TE
AC
ED
pport any marketing authorization application and any extensions or variations thereof.
4h a
or v
4h a
va
o
ns
on
en
e
a
an
io
ic
lic
lic
lic
plic
ap
tio
riz
a
ng
tin
X
ny
X
m
rt 
ot be used to suppo
pp
up
to
ed
e u
This document cannot
ot
B cell ac
nno
B cell ac
topenia;
can
topenia;
nt ca


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 300 of 353
a In addition to time points mentioned, vital signs will be evaluated every 15 minutes during infusion. Respiratory rate will be assessed only once predose.
b Total IgG and IgG subclasses. 
c Evaluation of ITP-specific autoantibodies will be performed prior to dose 1 only. 
d Serum and plasma complement levels will be assessed prior to dose 1 and dose 3 only.
e Blood sample for Baseline cytokine values will be obtained at Visit 2 for all subjects at predose and at other visits in case of infusion reactions.
f PRO endpoint (NFI-MS) will be assessed prior to dose 1 only.
Has been changed to:
Table 5‒6:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of 
infusion
4h after end of 
infusion
6h after end of 
infusiona
Withdrawal criteria
X
Platelet count (local laboratory) for 
inclusion check at Visit 2 and for 
withdrawal criterion at other dosing visits
X
Prior and concomitant medications
X
Concomitant medical procedures
X
Vital signsb
X
X
X
X
X
Physical examination
X
12-lead ECGc
X
Hematology 
X
Clinical chemistry
X
Urinalysis
X
Urine pregnancy test
X
Immunoglobulinsd
X
ITP-specific autoantibodiese
X
Blood sampling for UCB7665 plasma 
concentration
X
REDACTED COPY 
Y
PY
ED
CT
ED
R
port any marketing authorization application and any extensions or variations thereof.
nly once
atio
nly once
f infusio
ons
f infusio
y e
d of 
an
d of 
ion
ion
ion
nd
tio
pli
ati
at
at
at
at
ho
X
g
X
au
ing
rk
m
y
an
suppo
X
upp
X
be used to su po
X
su
d t
se
us
annot be
lasma 
ot b
lasma 
This document can
be
an


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 301 of 353
Table 5‒6:
Schedule of investigations on the dosing days
Predose
End of infusion
2h after end of 
infusion
4h after end of 
infusion
6h after end of 
infusiona
Anti-UCB7665 antibodies
X
Serum (C3 and C4) and plasma 
complements (C3a and C5a)f
X
Blood collection for exploratory safety 
biomarkersg
X
X
X
Serum BAFF levels
X
Blood collection for exploratory 
biomarker analysis
X
Blood sampling for cytokines
Xh
Xi
Whole blood sample for DNA and RNA 
(optional)j
X
ITP bleeding scale
X
AEs
X
X
X
X
X
NFI-MSk
X
AE=adverse event; BAFF=B cell activating factor; DNA=deoxyribonucleic acid; ECG=electrocardiogram; h=hours; Ig=immunoglobulin; IMP=investigational 
medicinal product; ITP=immune thrombocytopenia; NFI-MS=Neurological Fatigue Index for multiple sclerosis; PRO=Patient Reported Outcomes; 
RNA=ribonucleic acid; 
a For Dose Arms 3, 4 and 5 only
b In addition to time points mentioned, vital signs will be evaluated every 15 minutes during infusion. Respiratory rate will be assessed only once predose.
c The ECG should be performed in triplicate prior to blood collection for assessment of laboratory parameters. Three ECGs should be recorded in a time frame of 
5 minutes with at least 1 minute difference, 1-2 minutes between the ECGs.
d Total IgG and IgG subclasses. 
e Evaluation of ITP-specific autoantibodies will be performed prior to dose 1 only. 
f Serum and plasma complements (C3a and C5a) will be assessed prior to dose 1 and dose 3 only.
g
h Blood sample for Baseline cytokine values will be obtained and analyzed at Baseline (Visit 2) pre-dose for all subjects. Also for all subjects on Dose Arm 3, the 
blood sample for cytokine values will be obtained and analyzed at Visit 4 pre-dose.
i Additional cytokine blood sample to be taken at 4h after end of infusion only in subjects with infusion reaction.
REDACTED COPY 
Y
PY
CO
CT
DA
R
sed to support any marketing authorization application and any extensions or variations thereof.
on
of 
or
of 
on
s
on
va
ns
ns
y
a
an
io
pp
on
ati
or
X
g
X
ut
ng
rke
yribonu
mark
yribonu
S=Neuro
y ma
S=Neuro
ll be eva
port
ll be eva
to bloo
upp
to bloo
2 m
su
2 m
u
inu
sup
inu
es w
ed
es will b
d 
ill b
a and C
use
a and C
a
This document cannot
okine va
ot b
okine va
values w
nno
values w
od samp
can
od samp
t be u


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 302 of 353
j For DNA, samples are taken at Baseline (Visit 2) and last dose only. For RNA, samples are taken at Baseline (Visit 2), Visit 3, at last dose, and End of Study 
Visit. All samples collected prior to dosing (if applicable for visit).
k PRO endpoint (NFI-MS) will be assessed prior to dose 1 only.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ose, and 
atio
ose, and 


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 303 of 353
Change #37
Section 5.3
Schematic diagram
Figure 5‒1: Schematic diagram
RED
EDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
authorization application and any extensions or variat


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 304 of 353
Has been changed to:
Change #38
Section 5.4.3 Choice of study design endpoints
Paragraph #1:
The primary objective of the study is evaluation of safety and tolerability of UCB7665 
administered as an sc infusion in subjects with ITP. The study utilizes a sequential adaptive 
design with at least 4 interim analyses as described in Section 14.7. This design was chosen to 
permit adequate monitoring of the safety of the subjects in the study.
Has been changed to:
The primary objective of the study is evaluation of safety and tolerability of UCB7665 
administered as an sc infusion in subjects with ITP. The study utilizes a sequential adaptive 
design with at least 11 interim analyses as described in Section 14.7. This design was chosen to 
permit adequate monitoring of the safety of the subjects in the study.
Change #39
5.4.5
Rationale for dose seletion
Paragraph #5:
Therefore, doses of UCB7665 4mg/kg given once weekly for 5 weeks and UCB7665 7mg/kg 
given once weekly for 3 weeks have been selected to evaluate the safety, tolerability and effect 
on platelet count in subjects with primary persistent or chronic ITP.
REDAC
n en
R
n en
ACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ndpoin
eting
ndpoin
udy
ny
udy is e
y m
is e
y
y
y
on in su
rt any
on in su
rim ana
port
rim ana
oring o
supp
oring o
nged t
d to s
nged t
bjectiv
used
bjectiv
ed as an
be u
ed as an
with at l
ot b
with at l
it adequ
anno
it adequ
Chang
nt ca
Chang
5.4.
me
5.4.
horization application and any extensions or variat


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 305 of 353
Has been changed to:
Therefore, doses of UCB7665 4mg/kg given once weekly for 5 weeks(Dose Arm 1) and 
UCB7665 7mg/kg given once weekly for 3 weeks (Dose Arm 2) have been selected as the initial 
doses to evaluate the safety, tolerability and effect on platelet count in subjects with primary 
persistent or chronic ITP. Both dose regimens have the same cumulative dose of approximately 
UCB7665 20mg/kg.
New paragraph #6 added:
Preliminary data from the current study indicates that the current dose regimens of UCB7665 
4mg/kg and UCB7665 7mg/kg have been well tolerated. Hence the additional dose regimens of 
UCB7665 10mg/kg given once weekly for 2 weeks (Dose Arm 3) and of UCB7665 20mg/kg 
given once only (Dose Arm 5) are planned to further investigate the safety, tolerability and effect 
on platelet count of the same cumulative dose of UCB7665 20mg/kg but administered in dose 
regimes with higher dosages given in less infusions. The dose of UCB7665 15mg/kg given once 
only (Dose Arm 4) has been selected in addition as a risk mitigation as it is bridging the dose of 
UCB7665 10mg/kg given once weekly for 2 weeks (Dose Arm 3) and the dose of UCB7665 
20mg/kg given once only (Dose Arm 5).
Change #40
NEW Section 5.4.6
Justification for additional genomic analyses
DNA analysis
A genetic component in ITP has long been suspected to predispose some persons to develop ITP 
when exposed to a provocative event.
Further, the hypothesis of underlying genetic risk for ITP is supported by rare anecdotal and case 
reports of familial ITP. Affected members of these families present with ITP that meets the 
clinical criteria for primary ITP, but demonstrates a convincing pattern of inheritance. A 2006 
review of the Pediatric and Adult Registry of Chronic ITP (PARC-ITP) (Johnsen, 2012) found 
that 10 of 445 (2.2%) of pediatric patients reported a positive family history of ITP. However, 
identification of susceptibility genes in ITP, via family linkage studies or genome wide 
association studies, have not yet been forthcoming, likely due to the rarity of familial ITP 
families available for study and the heterogeneity of ITP sporadic cases. Identification and 
characterization of a genetic and/or epigenetic component of familial ITP will lead to important 
clues into the pathogenesis of more common forms of ITP and possibly advance understanding 
of drug response phenotypes. 
RNA analysis
Gene expression (mRNA) analyses have identified distinct gene transcription signatures from 
whole blood associated with many autoimmune diseases including rheumatoid arthritis, systemic 
lupus erythematosus, and ITP. Such signatures have provided molecular insight into disease 
biology and can facilitate patient stratification via gene expression panels predictive of 
therapeutic response and clinical outcomes. 
Collection of blood for RNA analysis will enable identification of candidate markers for 
treatment effect and safety, and determine the feasibility of patient stratification.
MicroRNA analysis
REDACTED COPY
nomic
OPY 
nomic
uspect
CTED
uspect
genet
RED
genet
mbe
R
mbe
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
665 
or v
665 
imens o
ns o
imens o
20mg/k
sions
20mg/k
bility
ensi
bility a
si
a
y
si
y
nistered
exte
nistered
15mg/
ny e
15mg/
is brid
d any
is brid
d the do
and 
d the do
anal
app
analys
pp
ys
ted to p
oriza
ted to p
tic risk 
g au
tic risk 
ers of th
eting
ers of th
demons
rket
demons
Registr
mar
Registr
ric pati
ny m
ric pati
ty
rt
ty gene
rt an
gene
y
rt
y
not y
port
not yet
rt
et
study
supp
study an
pp
an
y
pp
y
a genet
to su
a genet
thogene
ed to
thogene
nse phe
use
nse phe
ys
t b
ysis
be
is
expres
anno
expres
hole blo
t can
hole blo
lupus 
ent 
lupus 
bio
me
bio
t


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 306 of 353
MicroRNA are short (19-25 nucleotides) evolutionarily conserved single-stranded RNA 
molecules that regulate the expression of genes involved in diverse biological processes. The 
effect of miRNA on mRNA is mediated through the binding of the miRNA to the target mRNA 
ribonucleoprotein complex resulting in altered expression and decreased protein translation.  
Regulated miRNA in ITP significantly affect both gene and protein expression in T cells, 
indicating that they may be important regulatory molecules involved in the loss of immune 
tolerance in ITP.
In summary, the genetic, epigenetic, and genomic elements of ITP are complex and require 
further elucidation to understand the cause, progression, and appropriate treatment of ITP. 
Through the voluntary collection of blood DNA/and RNA samples from consenting subjects, this 
substudy will help enable further investigation of this complex disease.
Change #41
Section 6.1
Inclusion criteria
7. Female subjects of childbearing potential must have a negative serum pregnancy test at the 
Screening Visit, which is confirmed to be negative by urine testing prior to the first dose of 
IMP at Week 1 (Visit 2) and prior to further dosing at each study visit thereafter. 
Female subjects of childbearing potential must agree to use a highly effective method of 
birth control, during the study and for a period of 3 months after their final dose of IMP. 
Highly effective forms of birth control are methods which achieve a failure rate of less than 
1% per year when used consistently and correctly. Highly effective methods of birth control 
include:
…
Has been changed to:
7. Female subjects of childbearing potential must have a negative serum pregnancy test at the 
Screening Visit, which is confirmed to be negative by urine testing prior to the first dose of 
IMP at Week 1 (Visit 2) and prior to further dosing at each study visit thereafter. 
Female subjects of childbearing potential must agree to use a highly effective method of 
birth control, during the study and for a period of 2 months after their final dose of IMP. 
Highly effective forms of birth control are methods which achieve a failure rate of less than 
1% per year when used consistently and correctly. Highly effective methods of birth control 
include:
…
Change #42
Section 6.2.1 Exclusion criteria related to health status
9. Subject has renal impairment, defined as:
Serum creatinine level of ≥1.4 mg/dL for females and ≥1.5 mg/dL for males at 
Screening Visit.
10. Subject has liver impairment, defined as:
REDACTED COPY 
ree 
Y
ree 
of 3 m
OPY
of 3 m
method
D CO
method
correct
TED 
correct
pport any marketing authorization application and any extensions or variations thereof.
P. 
P. 
ubjects
ons 
ubjects
rum pr
and 
rum pr
ting pr
on a
ting pr
stud
atio
study v
ion
y v
use a h
pplic
use a h
months 
app
months 
ds whic
tion 
ds whic
tly
iza
tly. Hig
zati
. Hig
g poten
arke
g poten
nfirmed
y ma
nfirmed
and prio
any 
and prio
hildbear
port 
hildbear
cannot be used to sup
ng the s
upp
ng the s
e forms
to su
e forms
when u
ed to
when u
nge #4
nno
nge #4
This document 
ection 
t ca
ection 
9.
me
9. S
e
S


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 307 of 353
Subject has >1.5xULN of any of the following: alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), or alkaline phosphatase (ALP), or >ULN total bilirubin (≥1.5xULN 
total bilirubin if known Gilbert’s syndrome). If the subject has elevations only in total 
bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible 
undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
…
Has been changed to:
9. Subject has renal impairment, defined as:
Serum creatinine level of ≥1.4mg/dL for females and ≥1.5mg/dL for males at Screening 
Visit. 
10. Subject has 2xULN of any of the following: alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), or alkaline phosphatase (ALP), or >ULN total bilirubin (≥1.5xULN 
total bilirubin if known Gilbert’s syndrome). If the subject has elevations only in total bilirubin 
that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert’s 
syndrome (ie, direct bilirubin <35%).
…
Change #43
6.2.2
Exclusion criteria related to medical history
NEW exclusion criteria added:
25. Subjects with known tuberculosis (TB) infection, at high risk of acquiring TB infection, or 
with latent TB (LTB) infection or current history of nontuberculous mycobacterial infection 
(NTMBI) infection are excluded.
a. Known TB infection whether present or past is defined as:

Active TB infection or clinical signs and symptoms suggestive of TB (pulmonary or 
extrapulmonary).

History of active TB infection involving any organ system or findings in other organ systems 
consistent with TB infection.

Any historical evidence by radiography or other imaging modalities consistent with 
previously active TB infection.

b. High risk of acquiring TB infection is defined as:

Known exposure to another person with active TB infection within the 3 months prior to 
Screening.

Time spent in a healthcare delivery setting or institution where individuals infected with TB 
are housed and where the risk of transmission of infection is high.
c. LTB infection (refer to Section 12.8.1 for further details and instructions).
d. NTMBI is defined as a group of lung infections caused by mycobacteria different from 
mycobacterium tuberculosis infections.
REDACTED COPY 
ry
C
ry
B) infe
DAC
B) infe
rent
RED
rent hi
DA
hi
marketing authorization application and any extensions or variations thereof.
eening
ons o
eening
T), aspa
exten
T), aspa
rubin (
ny ex
rubin (≥
x
≥
only
d any
only in
ny
in
y
ny
y
e undia
and 
e undia
fection,
utho
fection,
stor
au
story 
au
y 
sent or 
arke
sent or 
e used to support any
cal sign
ny m
cal sign
infecti
ppor
infecti
B infect
supp
B infect
l eviden
d to
l eviden
active 
sed
active 
This document cannot b
h risk o
be 
h risk o
nown e
nnot
nown e
Screen
can
Screen

e

T
nt
T


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 308 of 353
26 Subjects with known TB infection, at high risk of acquiring TB infection, or LTB infection, 
or current/history of NTMBI are excluded.
Change #44
6.4 Withdrawal criteria
2. Subject develops an illness or has a change in health status that would interfere with 
his/her continued participation, including but not limited to:

Subject has a serious infective episode requiring hospitalization or iv antibiotic therapy 
(including but not limited to bacteremia or sepsis, bacterial meningitis, osteomyelitis or 
septic arthritis, bacterial pneumonia, or visceral abscess). 

Subject experiences a severe AE of gastrointestinal disturbance or headache which is 
considered related to the IMP in the opinion of the investigator.

Subject has a severe infusion reaction requiring corticosteroid and/or epinephrine 
therapy.

Subject has an anaphylactic reaction requiring corticosteroid and/or epinephrine therapy.

Subject has a life threatening bleeding event.
Has been changed to:
2. Subject develops an illness or has a change in health status that would interfere with his/her 
continued participation, including but not limited to:

Subject has a serious infective episode requiring hospitalization or iv antibiotic therapy 
(including but not limited to bacteremia or sepsis, bacterial meningitis, osteomyelitis or 
septic arthritis, bacterial pneumonia, or visceral abscess). 

Subject experiences a severe AE of gastrointestinal disturbance or headache which is 
considered related to the IMP in the opinion of the investigator.

Subject has a severe infusion reaction requiring corticosteroid and/or epinephrine 
therapy.

Subject has an anaphylactic reaction requiring corticosteroid and/or epinephrine therapy.

Subject has a life threatening bleeding event.

Subject has a TB test that is confirmed positive or any further evidence suggestive of
potential TB infection (eg, close exposure) and further examinations result in a diagnosis 
of active TB or LTB. Refer to Section 12.8.1 for further details and instructions.

If an NTMBI infection is identified during a study, the same withdrawal procedures as 
those used for an active TB infection identified during the study should be followed.
Change #45
6.4 Withdrawal criteria
REDACTED COPY 
health
D CO
health
ted to
TED 
ted to
sode r
ACT
sode r
cterem
EDA
cterem
mon
RE
mon
o support any marketing authorization application and any extensions or variations thereof.
ap
v
apy 
va
y 
itis or 
or v
itis or 
he whic
ensi
he whic
or epin
any 
or epin
d and/o
on a
d and/o
h status
tion 
h status
o:
i
o:
requirin
thor
requirin
mia or s
aut
mia or s
nia, or v
ting a
nia, or v
AE of 
arket
AE of 
MP in t
mar
MP in t
nfusion
any
nfusion
anaph
supp
anaph
p
This document cannot be used t
s a life 
d to 
s a life 
ct has a
use
ct has a
ential T
be u
ential T
of activ
ot b
of activ

If a
ann
If a
Ch
me
Ch


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 309 of 353
Subjects MUST stop treatment with the IMP if the platelet count is >350x109/L during the 
Dosing Period. Subjects should continue in the study and attend the protocol defined visits in the 
Observation Period.
Subjects with PDILI must be assessed to determine if IMP must be discontinued. In addition, all 
concomitant medications and herbal supplements that are not medically necessary should also be 
discontinued.
Has been changed to:
Subjects MUST stop treatment with the IMP if the platelet count is >350x109/L during the 
Dosing Period. Subjects should continue in the study and attend the protocol defined visits in the 
Observation Period.
6.4.1 Potential drug induced liver injury IMP discontinuation criteria
Subjects with PDILI must be assessed to determine if IMP must be discontinued. In addition, all 
concomitant medications and herbal supplements that are not medically necessary should also be 
discontinued.
Change #46
6.5 Study stopping rules 
More detailed criteria for stopping a cohort will be defined in the DMC charter.
Has been changed to:
More detailed criteria for stopping a dose arm will be defined in the DMC charter.
Change #47
Section 7.2 Treatment to be administered 
Subjects in Dose Arm 1 will receive 5 sc doses of UCB7665 4mg/kg at 1-week intervals. 
Subjects in Dose Arm 2 will receive 3 sc doses of UCB7665 7mg/kg at 1-week intervals.
Has been changed to:
Subjects in Dose Arm 1 will receive 5 sc doses of UCB7665 4mg/kg at 1-week intervals. 
Subjects in Dose Arm 2 will receive 3 sc doses of UCB7665 7mg/kg at 1-week intervals. 
Subjects in Dose Arm 3 will receive 2 sc doses of UCB7665 10mg/kg at a 1-week interval.
Subjects in Dose Arm 4 will receive 1 sc dose of UCB7665 15mg/kg.
Subjects in Dose Arm 5 will receive 1 sc dose of UCB7665 20mg/kg.
Change #48
Section 7.4
Labeling
Clinical drug supplies will be labeled in accordance with the current International Conference on 
Harmonisation (ICH) guidelines on GCP and GMP and will include any locally required 
statements. If necessary, labels will be translated into the local language.
Has been changed to:
REDACTED COPY 
efined
OPY
efined
rm wil
CTE
rm wil
ered
RE
ered
annot be used to support any marketing authorization application and any extensions or variations thereof.
o
sits in t
ns o
sits in t
nued. In
ny ex
nued. In
necessa
d any
necessa
d in the
app
d in the
ll be de
horiz
ll be de
d
t
d
5 sc do
arke
5 sc do
ive 3 sc
y ma
ive 3 sc
will r
ppor
will rec
r
ec
m 2 will 
supp
m 2 will 
Arm 3 w
to s
Arm 3 w
se Arm
sed
se Arm
n Dose 
be u
n Dose 
nge #4
nnot 
nge #4
This document c
ction 7
t ca
ction 7
Clini
men
Clini
H
m
H


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 310 of 353
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (ICH) guidelines on GCP and GMP and will include any locally required 
statements. If necessary, labels will be translated into the local language.
Change #49
7.8.3
Rescue medication
In the case of prolonged hypogammaglobulinemia the subject will be considered for treatment 
with prophylactic antimicrobial therapy. Subjects will be followed up until immunoglobulin 
levels return to within the normal range.
In case of lack of efficacy and/or severe bleeding events and where appropriate, platelet 
substitution or treatment with a commercially available iv immunoglobulin may be considered.
Has been changed to:
In the case of prolonged hypogammaglobulinemia the subject will be considered for treatment 
with prophylactic antimicrobial therapy. Subjects will be followed up until immunoglobulin 
levels return to within the normal range.
In case of lack of efficacy and/or severe bleeding events and where appropriate, platelet 
substitution or treatment with a commercially available iv immunoglobulin may be considered.
If such rescue medication must be given when the subject is still in the dosing period, the subject 
should be withdrawn from the study treatment and complete all Observation visits, if possible. 
If such rescue medication is given when the subject has completed the study treatment, the 
subject should continue the Observation Visits, as per schedule of study assessments 
(Section 5.2).
Change #50
Section 7.10
Randomization and numbering of subjects
Paragraph #2:
The first 6 subjects (and those treated before DMC assessment after the 6 subjects) will not be 
randomized. Once the DMC has approved opening of Dose Arm 2 for enrollment, subsequent 
subjects will be randomized to 1 of the 2 dose arms in a 1:1 ratio. Once 15 subjects are in the 
4mg/kg group, the remaining subjects will not be randomized. They will be allocated to the 
7mg/kg group.
Has been changed to:
An IXRS will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by PAREXEL 
Informatics. The IXRS will generate individual assignments for subject kits of IMP, as 
appropriate, according to the dose arm and subject’s weight.
The first 6 subjects (and those treated before DMC assessment after the 6 subjects) will not be 
randomized. Once the DMC has advocated the initiation of Dose Arm 2 for enrollment, 
subsequent subjects will be randomly assigned to 1 of the 2 dose arms (ie, Dose Arm 1 and Dose 
Arm 2) in a 1:1 ratio. Once 15 subjects are enrolled in the Dose Arm 1, the remaining subjects 
will be enrolled in Dose Arm 2 until Dose Arm 2 is completed with 15 subjects.
REDACTED COPY 
ubject 
OPY
ubject 
d com
CO
d com
subject
TED
subject
Visits, a
ACT
Visits, a
t be used to support any marketing authorization application and any extensions or variations thereof.
et 
n
et 
consid
sion
consid
idered 
any 
idered 
ntil imm
nd a
ntil imm
ere app
ation
ere app
munogl
licat
munogl
is still
app
is still
mplete a
ion a
mplete a
ct has c
rizat
ct has c
as per 
thori
as per 
number
arke
number
se treat
rt an
se treat
MC has
ppor
MC has
mized 
supp
mized 
remain
to s
remain
 chan
be us
 chan
nt canno
RS will 
not b
RS will 
etermin
anno
etermin
format
t ca
format
This documen
appro
ment
appro
T
m
T


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 311 of 353
After Dose Arm 2, there will be no randomization between dose arms.
Change #51
Section 8.1.1 Visit 1 (Day -28 to -1) Screening Visit
Has been changed to:
Section 8.1.1 Visit 1 (Day -28 to -1) Screening Visit (all Dose Arms)
Detail regarding informed consent process for exploratory genomic analyses added as follows:
Subjects will also have the option of providing additional voluntary informed consent for 
collection of whole blood samples for exploratory DNA and RNA analyses.
Change #52
Section 8.1.1
Visit (Day -28 to -1) Screening Visit 
…

12-lead ECG

Karnofsky Performance Status

Recording of AEs

Urine sample for urinalysis

Blood sample for the following laboratory parameters:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry* 

Serum pregnancy test for women of childbearing potential

Serum total IgG and IgG subclasses concentration 

Serum HbA1c 

Serology tests for HIV, hepatitis B, and hepatitis C

ITP bleeding scale
*Two blood samples for assessment of platelet count to be obtained via 2 separate blood 
collections
Has been changed to:
…

12-lead ECG (triplicate)

Karnofsky Performance Status

Recording of AEs

Urine sample for urinalysis

Blood sample for the following:
REDACTED COPY 
param
ED C
param
tology
ACT
tology
men 
RE
men 
used to support any marketing authorization application and any extensions or variations thereof.
:
a
:
meters:
zatio
meters:
y includ
thori
y includ
n of chi
ting 
n of chi
bclasses
arke
bclasses
IV, hep
ort a
IV, hep
mples f
to s
mples f
This document cannot be
 chan
be us
 chan
12
ca
12-
an
-lea
an
lea

e

K
nt
K



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 312 of 353

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry (two blood samples for assessment of platelet count to be obtained via 2 
separate blood collections)

Serum pregnancy test for women of childbearing potential

Serum total IgG and IgG subclasses concentration 

Serum HbA1c 

Serology tests for HIV, hepatitis B, and hepatitis C

ITP bleeding scale
NEW bullet points added:
…

Obtain informed consent for substudy involving DNA and RNA analyses
…

IGRA TB test

TB signs and symptoms questionnaire
Change #53
Section 8.2 Dosing Period
Has been changed to:
Section 8.2 Dosing Period for all Dose Arms 
Change #54
Section 8.2.1 Visit 2 (Week 1/Day 1) Baseline Visit
Paragraphs #2, #3, and #4:
Eligible subjects will be treated with IMP at Visit 2. The first 6 subjects will be enrolled in Dose 
Arm 1, subsequent subjects will be randomized to 1 of the 2 dose arms. Once 15 subjects are in 
Dose Arm 1, the remaining subjects will not be randomized. They will be allocated to Dose 
Arm 2. 
Eligible subjects will be treated with IMP at Visit 2. The first 6 subjects will be enrolled in Dose 
Arm 1, subsequent subjects will be randomized to 1 of the 2 dose arms. Once 15 subjects are in 
Dose Arm 1, the remaining subjects will not be randomized. They will be allocated to Dose 
Arm 2. 
Subjects allocated to Dose Arm 1 (UCB7665 4mg/kg sc) will receive a total of 5 doses of IMP at 
Visit 2 (Day 1, Week 1), Visit 4 (Week 2), Visit 5 (Week 3), Visit 6 (Week 4), and Visit 7 
(Week 5). 
Subjects allocated to Dose Arm 2 (UCB7665 7mg/kg sc) will receive a total of 3 doses of IMP at 
Visit 2 (Day 1, Week 1), Visit 4 (Week 2), and Visit 5 (Week 3).
REDACTED COPY 
Arms 
EDA
Arms 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
a
es
n
es
1) Bas
arke
1) Bas
ated
rt a
ated wi
an
wi
cts wil
ppor
cts wil
aining s
supp
aining s
ts will 
sed
ts will 
sequent
be us
sequent
m 1, the
ot be
m 1, the
.
n
.
ubjects
t ca
ubjects
Visit
ent
Visit
(W
me
(W


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 313 of 353
Has been changed to:
Eligible subjects will be treated with IMP at Visit 2. 
Subjects allocated to Dose Arm 1 (UCB7665 4mg/kg weekly sc) will receive a total of 5 doses of 
IMP at Visit 2 (Day 1, Week 1), Visit 4 (Week 2), Visit 5 (Week 3), Visit 6 (Week 4), and 
Visit 7 (Week 5). 
Subjects allocated to Dose Arm 2 (UCB7665 7mg/kg weekly sc) will receive a total of 3 doses of 
IMP at Visit 2 (Day 1, Week 1), Visit 4 (Week 2), and Visit 5 (Week 3). 
Subjects allocated to Dose Arm 3 (UCB7665 10mg/kg weekly sc) will receive a total of 2 doses 
of IMP at Visit 2 (Day 1, Week 1) and Visit 4 (Day 8, Week 2). 
Subjects allocated to Dose Arm 4 (UCB7665 15mg/kg) will receive 1 dose of IMP at Visit 2 
(Day 1, Week 1).
Subjects allocated to Dose Arm 5 (UCB7665 20mg/kg) will receive 1 dose of IMP at Visit 2 
(Day 1, Week 1).
Change #55
8.2.1
Visit 2 (Week 1/Day 1) Baseline Visit 

12-lead ECG

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Blood sample for the following laboratory parameters:

Plasma concentration of UCB7665

Anti-UCB7665 antibodies/IgG depletion assay

Serum total IgG and IgG subclasses concentration 

Serum IgA, IgM, and IgE concentration

ITP-specific autoantibodies 

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the inclusion 
criteria of platelet count <35x109/L at Baseline

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Serum biomarkers 
 and 
serum BAFF levels. Blood samples are taken prior to dosing, 2 and 4 hours after end of 
infusion for serum biomarkers and BAFF

Serum cytokines
REDACTED COPY 
ng po
CO
ng po
ratory
DAC
ratory
C
B7665
RED
B7665
support any marketing authorization application and any extensions or variations thereof.
of 
at
of 
2 d
o
2 dose
or 
ose
P at Vis
ensio
P at Vis
 of IM
any e
 of IM
otential
tion a
otential
param
utho
param
G deple
rket
G deple
subclas
y ma
subclas
Ig
t a
IgE co
any
E co
oantibod
ppor
oantibod
sed to s
et
o
et
ot be u
y labo
o su
y labo
tional p
use
tional p
teria of
t be 
teria of
This document canno
Serum
nno
Serum

t c

S


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 314 of 353
NEW bullet points:

Subjects in Dose Arms 1 and 2 will stay on site for 4 hours after the end of infusion for 
inpatient observation at the site.

Subjects in Dose Arms 3, 4 and 5 will stay on site for 6 hours after the end of infusion for 
inpatient observation at the site.
Has been changed to:

12-lead ECG (triplicate)

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Blood sample for the following:

Plasma concentration of UCB7665

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration 

Serum IgA, IgM, and IgE concentration

ITP-specific autoantibodies 

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the inclusion 
criteria of platelet count <35x109/L at Baseline

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Exploratory safety biomarkers
. Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety 
biomarkers

Serum BAFF levels

Exploratory biomarker analysis

Serum cytokines mandatory for all subjects at pre-dose, and only in case of infusion 
reactions at 4 hours after end of infusion

Collection of whole blood for exploratory DNA and RNA analyses
Change #56
8.2.2
Visit 3 (Week 1/Day 4)
…

Blood sample for the following laboratory parameters:
REDACTED COPY 
y inclu
ED C
y inclu
nal
DA
nalys
DAC
ysis
AC
is
10
RE
109
ED
9/L
ED
/L
D
COPY
marketing authorization application and any extensions or variations thereof.
luding 
atio
luding 
 in loc
utho
 in loc
at Bas
g au
at Bas
and C4
ketin
and C4
kers
ma
kers
used to support an
sing, 2 
rt an
sing, 2 
levels
sup
levels
ory
ed
ory bio
d to
bio
y
d
y
This document cannot be u
m cy
e us
m cyto
s
to
yty
s
yty
actions
t be
actions
Collecti
anno
Collecti
Chang
nt ca
Chang
8.2
me
8.2
n app
ar
any m


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 315 of 353

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Plasma concentration of UCB7665

Anti-UCB7665 antibodies/IgG depletion assay

Serum total IgG and IgG subclasses concentration

Serum biomarkers

Review withdrawal criteria

Serum cytokines, only in case of infusion reactions
…
Has been changed to:
8.2.2
Visit 3 (Week 1/Day 4) [UCB7665 4mg/kg, UCB7665 7mg/kg, and UCB7665 10mg/kg]
…

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Plasma concentration of UCB7665

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration

Exploratory safety biomarkers
 only from 
subjects experiencing severe headaches or GI disturbances (only in case of Adverse 
Events of Interest, see Section 12.4)

Review withdrawal criteria

Serum cytokines, only in case of late infusion reactions visible during the visit
For Dose Arm 1, 2, and 3 collection of whole blood for exploratory RNA analyses
…
Change #57
8.2.3
Visit 4 (Week 2/Day 8)
…

12-lead ECG

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)
REDACTED COPY 
ding
Y
ding
asses c
EDA
asses c
RE
g authorization application and any extensions or variations thereof.
nd UCB
d any
nd UCB
coagula
pplic
coagula
concen
auth
concen
This document cannot be used to support any mar
re head
mar
re head
Section 
ny m
Section 
eria
ort a
eria
nl
u
nly in 
upp
y in 
,
d
, and 3
d to s
and 3
#57
t be
#57
Visit 
nno
Visit 

me

eting 
arketi


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 316 of 353

Blood sample for the following laboratory parameters:

Plasma concentration of UCB7665

Anti-UCB7665 antibodies/IgG depletion assay

Serum total IgG and IgG subclasses concentration

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Serum biomarkers
 and 
serum BAFF levels. Blood samples are taken prior to dosing, 2 and 4 hours after end of 
infusion for serum biomarkers and BAFF
…
Has been changed to:
8.2.3
Visit 4 (Week 2/Day 8) [UCB7665 4mg/kg, UCB7665 7mg/kg and UCB7665 10mg/kg]
…

12-lead ECG (triplicate)

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)

Blood sample for the following:

Plasma concentration of UCB7665

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Exploratory safety biomarkers
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory serum 
biomarkers

Serum BAFF levels

Exploratory biomarker analysis
…
REDACTED COPY 
earing
TED 
earing
numb
RED
numb
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
urs afte
xten
urs afte
mg/kg 
ation
mg/kg 
g poten
izati
g poten
ber(s)
g au
ber(s)
CB766
mar
CB766
dies
any
dies
nd IgG
port
nd IgG
y labo
sup
y labo
onal pl
used
onal pl
hdrawa
be u
hdrawa
Explo
not 
Explo
a
nsion
ann


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 317 of 353
NEW bullet points:

Subjects in Dose Arms 1 and 2 will stay on site for 4 hours after the end of infusion for 
inpatient observation at the site.

Subjects in Dose Arms 3, 4 and 5 will stay on site for 6 hours after the end of infusion for 
inpatient observation at the site.

For Dose Arm 3, only collection of whole blood for exploratory DNA and RNA analyses
…

Serum cytokines at pre-dose mandatory for subjects on Dose Arm 3 (10mg/kg), and at 4 
hours after end of infusion (for all dose arms)
Change #58
8.2.4
Visit 5 (Week 3/Day 15)
…

12-lead ECG

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)

Blood sample for the following laboratory parameters:

Plasma concentration of UCB7665

Anti-UCB7665 antibodies/IgG depletion assay

Serum total IgG and IgG subclasses concentration 

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Serum IgA, IgM, and IgE concentration (UCB7665 7mg/kg only)

Serum biomarkers 
 and 
serum BAFF levels. Blood samples are taken prior to dosing, 2 and 4 hours after end of 
infusion for serum biomarkers and BAFF
Has been changed to:
8.2.4
Visit 5 (Week 3/Day 15) [UCB7665 4mg/kg and UCB7665 7mg/kg]
…

12-lead ECG (triplicate)

Urine pregnancy test for women of childbearing potential
REDACTED COPY 
y
T
y para
TED
para
y
T
y
5
DA
5
G dep
RE
G dep
t cannot be used to support any marketing authorization application and any extensions or variations thereof.
and at 
ns or
and at 
ameter
riza
ameter
pletion
ing a
pletion
lasses
rket
lasses
es
m
es: hem
y ma
: hem
t sampl
port 
t sampl
eria of 
upp
eria of 
mplemen
d to s
mplemen
IgA, Ig
used
IgA, Ig
rum bi
be 
rum bi
serum
not 
serum
infu
ann
infu
This documen
Has b
ent c
Has b
8.2
m
8.2


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 318 of 353

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)

Blood sample for the following:

Plasma concentration of UCB7665

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration 

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Serum IgA, IgM, and IgE concentration (UCB7665 7mg/kg only)

Exploratory safety biomarker
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety 
biomarkers

Serum BAFF levels

Exploratory biomarker analysis

For Dose Arm 2 only, collection of whole blood for exploratory DNA and RNA analyses 
…
Change #59
Visit 6 (Week 4/Day 22) [UCB7665 4mg/kg only]

12-lead ECG

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)

Blood sample for the following laboratory parameters:

Plasma concentration of UCB7665 

Anti-UCB7665 antibodies/IgG depletion assay

Serum total IgG and IgG subclasses concentration

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry
REDACTED COPY 
nd o
Y
nd o
f whol
REDA
f whol
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
cal
s o
cal 
f the 
ensi
f the 
vels (C
any 
vels (C
nly
an
nly)
and
)
nfusio
pplic
nfusio
le bloo
aut
le bloo
7665 4
ny m
7665 4
est for w
supp
est for w
for urin
d to s
for urin
S to obt
used
S to obt
d sampl
t be 
d sampl
Plasm
nno
Plasm

t c

A
a
A
tion a
licatio


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 319 of 353

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Serum biomarkers 
 and 
serum BAFF levels. Blood samples are taken prior to dosing, 2 and 4 hours after end of 
infusion for serum biomarkers and BAFF
Has been changed to:
8.2.5
Visit 6 for Dose Arm 1 (Week 4/Day 22) [UCB7665 4mg/kg only]

12-lead ECG (triplicate)

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)

Blood sample for the following:

Plasma concentration of UCB7665 

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Exploratory safety biomarkers
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety
biomarkers

Serum BAFF levels

Exploratory biomarker analysis
Change #60
8.2.6
Visit 7 (Week 5/Day 29) [UCB7665 4mg/kg only]

12-lead ECG

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)

Blood sample for the following laboratory parameters:

Plasma concentration of UCB7665

Anti-UCB7665 antibodies/IgG depletion assay
REDACTED COPY 
ation
OPY
ation
includ
D CO
includ
l
DA
lys
DAC
ysis i
ACT
is i
count >
EDA
count >
RE
ng authorization application and any extensions or variations thereof.
uding co
tion 
uding co
n loca
thor
n loca
>350x
aut
>350x
This document cannot be used to support any mar
2 and 4
ma
2 and 4
s
omarke
upp
omarke
7 (Week
use
7 (Week
d ECG
t be
d ECG
rin
nn
rine p
nn
e p
Urin
nt c
Urin

m

eting
arket


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 320 of 353

Serum total IgG and IgG subclasses concentration

Serum IgA, IgM, and IgE concentration

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Serum biomarkers 
 and 
serum BAFF levels. Blood samples are taken prior to dosing, 2 and 4 hours after end of 
infusion for serum biomarkers and BAFF
Has been changed to:

12-lead ECG (triplicate)

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Call IXRS to obtain treatment kit number(s)

Blood sample for the following:

Plasma concentration of UCB7665

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration

Serum IgA, IgM, and IgE concentration

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Additional platelet sample for analysis in local laboratory for evaluation of the 
withdrawal criteria of platelet count >350x109/L

Exploratory safety biomarkers
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety
biomarkers

Serum BAFF levels

Exploratory biomarker analysis

For Dose Arm 1 only, collection of whole blood for DNA and RNA analyses
Change #61
NEW sections added:
8.3
Telephone Contacts 
REDACTED COPY 
es con
DACT
es con
centra
RED
centra
upport any marketing authorization application and any extensions or variations thereof.
and 
var
and 
end of 
s or 
end of 
ncentra
utho
ncentra
ation
g au
ation
ematol
ketin
ematol
ple for 
any m
ple for 
of plate
rt an
of plate
ety
up
ety biom
ppo
biom
This documen
Cha
men
Cha
ent cannot be used to 
prior to
d to 
prior to
kers
sed
kers
um
be
um BA
e u
BA
E
n
Explo
not
xplo
For D
t ca
For D
o sup


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 321 of 353
For Dose Arms 3, 4 and 5 the site must make a phone call to the subject on Day 1 and Day 2 
after dosing as a safety measure.
8.3.2
Telephone Contact 1 (Week 1/Day 2) [UCB7665 10mg/kg, UCB7665 15mg/kg, 
UCB7665 20mg/kg]

Concomitant medications

Concomitant medical procedures

Recording of AEs
8.3.3
Telephone Contact 2 (Week 1/Day 3) [UCB7665 10mg/kg, UCB7665 15mg/kg, 
UCB7665 20mg/kg]

Concomitant medications

Concomitant medical procedures

Recording of AEs
8.3.4
Telephone Contact 3 (Week 2/Day 9) [UCB7665 10mg/kg only]

Concomitant medications

Concomitant medical procedures

Recording of AEs
8.3.5
Telephone Contact 4 (Week 2/Day 10) [UCB7665 10mg/kg only]

Concomitant medications

Concomitant medical procedures

Recording of AEs
Change #62
8.3 Observation Period
The Observation Period will last for 8 weeks following the final dose administration. The first 
visit in the Observation Period will be performed 3 days after the final dose administration and 
subsequent visits will be performed at weekly intervals (except for a 2-week interval before the 
final visit). 
For UCB7665 4mg/kg dose, the following visits will be performed: Visit 8, Visit 9, Visit 10, 
Visit 11, Visit 12, Visit 13, Visit 14, and Visit 15, corresponding to UCB7665 7mg/kg Visit 6, 
Visit 7, Visit 8, Visit 9, Visit 10, Visit 11, Visit 12, and Visit 13.
Has been changed to:
8.4 Observation Period 
The Observation Period will last for 8 weeks following the final dose administration. The first 
visit in the Observation Period will be performed 3 days after the final dose administration and 
subsequent visits will be performed at weekly intervals (except for a 2-week interval before the 
final visit). 
REDACTED COPY 
0) [UC
TED
0) [UC
be used to support any marketing authorization application and any extensions or variations thereof.
only
n a
only]
an
]
CB7665
rizat
CB7665
will las
ppor
will las
on Perio
supp
on Perio
will be p
to s
will be p
65 4mg
be us
65 4mg
This document cannot 
Visit 1
ot be
Visit 1
7, Visit
nnot
7, Visit
Has be
nt ca
Has be
8.4
men
8.4 O
n
O


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 322 of 353
For UCB7665 4mg/kg weekly dose (Dose Arm 1), the following visits will be performed: 
Visit 8, Visit 9, Visit 10, Visit 11, Visit 12, Visit 13, Visit 14, and Visit 15, corresponding to 
UCB7665 7mg/kg weekly dose (Dose Arm 2) on Visit 6, Visit 7, Visit 8, Visit 9, Visit 10, 
Visit 11, Visit 12, and Visit 13.
For the UCB7665 10mg/kg weekly dose (Dose Arm 3), the following visits will be performed: 
Visit 5, Visit 6, Visit 7, Visit 8, Visit 9, Visit 10, Visit 11, and Visit 12.
For the UCB7665 15 mg/kg dose (Dose Arm 4) and the UCB7665 20mg/kg dose (Dose Arm 5), 
the following visits will be performed: Visit 3, Visit 4, Visit 5, Visit 6, Visit 7, Visit 8, Visit 9 
and Visit 10.
Change #63
8.3.1
Visit 8 (Week 5/Day 32) [UCB7665 4mg/kg]/ Visit 6 (Week 3/Day 18) [UCB7665 
7mg/kg]
…

Blood sample for the following laboratory parameters:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Plasma concentration of UCB7665 

Anti-UCB7665 antibodies/IgG depletion assay

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Serum biomarkers 

Serum total IgG and IgG subclasses concentration
…
Has been changed to:
8.4.1
Visit 8 (Week 5/Day 32) [UCB7665 4mg/kg]/ Visit 6 (Week 3/Day 18) [UCB7665 
7mg/kg]]/ Visit 5 (Week 2/Day 11) [UCB7665 10mg/kg]
Visit 3 (Week 1/Day 4) [UCB7665 15mg/kg and UCB7665 20mg/kg]

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Plasma concentration of UCB7665 

Anti-UCB7665 antibodies

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Exploratory safety biomarkers
only from 
subjects experiencing severe headaches or GI disturbances (only in case of Adverse 
Events of Interest, see Section 12.4)
ACTED COPY 
n assay
D C
n assay
C4)
CT
C4) an
TE
an
RE
clas
R
clas
EDAC
thorization application and any extensions or variations thereof.
5),
ri
5),
t 9 
v
t 9 
[UCB7
xtens
[UCB7
ulation 
ation
ulation 
ay
a
ay
nd plas
horiz
nd plas
d to support any marketing a
sses con
eting
sses con
y
o
y 32) [U
ort a
32) [U
y
o
y
k 2/Day
ppo
k 2/Day
This document cannot be use
y 4) 
o s
4) 
y
[UC
su
[UC
le for th
sed t
le for th
dard sa
e us
dard sa
hemistr
ot be
hemistr
Plas
ann
Plas

nt

auth


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 323 of 353

Serum total IgG and IgG subclasses concentration
Change #64
8.3.2
Visit 9 (Week 6/Day 36) [UCB7665 4mg/kg]/ Visit 7 (Week 4/Day 22) [UCB7665 
7mg/kg]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit. 
The following assessments will be performed at this visit:
…

12-lead ECG

Urine sample for urinalysis

Blood sample for the following laboratory parameters:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Plasma concentration of UCB7665

Anti-UCB7665 antibodies/IgG depletion assay

Serum biomarkers 

Serum total IgG and IgG subclasses concentration

Serum IgA, IgM, and IgE concentration 

ITP-specific autoantibodies
Has been changed to:
8.4.2
Visit 9 (Week 6/Day 36) [UCB7665 4mg/kg ]/ Visit 7 (Week 4/Day 22) [UCB7665 
7mg/kg]]/ Visit 6 (Week 3/Day 15) [UCB7665 10mg/kg]
Visit 4 (Week 2/Day 8) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the second visit in the Observation Period. A visit window of ±2 days is applicable for 
this visit relative to the day of the final dosing visit. The following assessments will be 
performed at this visit:
…

12-lead ECG (triplicate)
…

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Plasma concentration of UCB7665

Anti-UCB7665 antibodies
REDACTED COPY
entrati
D CO
entrati
on
TE
on
DACT
OPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
rameter
any 
rameter
tion
tion
tion
B7665
rket
B7665
) [UCB
mar
) [UCB
7665 1
any 
7665 1
the Ob
port 
the Ob
day
upp
day of
pp
of
y
pp
y
it:
o
it:
ECG (
be us
ECG (
Blood
can
Blood

n

autho
appli


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 324 of 353

Exploratory safety biomarkers
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety 
biomarkers)
Change #65
8.3.3
Visit 10 (Week 7/Day 43) [UCB7665 4mg/kg]/ Visit 8 (Week 5/Day 29) [UCB7665 
7mg/kg]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit. 
This visit can be performed at home with a healthcare professional visiting the subject at his/her 
home. The following assessments will be performed at this visit:
…

Blood sample for the following laboratory parameters:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Anti-UCB7665 antibodies/IgG depletion assay

Serum biomarkers 

Serum BAFF levels

Serum total IgG and IgG subclasses concentration
…
Has been changed to:
8.4.3
Visit 10 (Week 7/Day 43) [UCB7665 4mg/kg]/ Visit 8 (Week 5/Day 29) [UCB7665 
7mg/kg]]/ Visit 7 (Week 4/Day 22) [UCB7665 10mg/kg]
Visit 5 (Week 3/Day 15) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the third visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. This visit can be performed at home with a 
healthcare professional visiting the subject at his/her home. The following assessments will be 
performed at this visi
…

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Anti-UCB7665 antibodies

Exploratory safety biomarkers
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety 
biomarkers)
REDACTED COPY
oncent
TED 
oncent
R
PY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
visit. 
or va
visit. 
at his/h
ns o
at his/h
parame
nd a
parame
tration
izati
tration
B7665 
ketin
B7665 
[UCB7
marke
[UCB7
7665 1
ny m
7665 1
Observ
ort a
Observ
of the fi
ppo
of the fi
al visit
supp
al visit
visi
d to
visi
sample
t be 
sample
Stand
nno
Stand
ch
an
ch

n

ppli


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 325 of 353

Serum BAFF levels

Exploratory biomarker analysis
…
Change #66
8.3.4
Visit 11 (Week 8/Day 50) [UCB7665 4mg/kg]/ Visit 9 (Week 6/Day 36) [UCB7665 
7mg/kg]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit. 
The following assessments will be performed at this visit:
…

Blood sample for the following laboratory parameters:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Serum biomarkers 

Serum total IgG and IgG subclasses concentration
…
Has been changed to:
8.4.4
Visit 11 (Week 8/Day 50) [UCB7665 4mg/kg]/ Visit 9 (Week 6/Day 36) [UCB7665 
7mg/kg]]/ Visit 8 (Week 5/Day 29) [UCB7665 10mg/kg]
Visit 6 (Week 4/Day 22) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the fourth visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. The following assessments will be performed at 
this visit:
…

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Exploratory safety biomarkers
Blood 
samples are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory
safety biomarkers)

Serum total IgG and IgG subclasses concentration 
REDACTED COPY 
ation
PY
ation
7665 4
DAC
7665 4
UCB76
REDA
UCB76
5m
R
5m
be used to support any marketing authorization application and any extensions or variations thereof.
sing vis
ons o
sing vis
n param
and a
n param
4mg/kg
utho
4mg/kg
665 10
g au
665 10
mg/kg
keting
mg/kg
vation 
mark
vation 
nal dos
ny m
nal dos
r the fo
o sup
r the fo
safet
ed t
safety
t
y
istry
use
istry
i
sam
an
sam
ot
xplorat
ot be
xplorat
This document canno
nnot 


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 326 of 353
Change #67
8.3.5
Visit 12 (Week 9/Day 57) [UCB7665 4mg/kg]/ Visit 10 (Week 7/Day 43) [UCB7665 
7mg/kg]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit. 
This visit can be performed at home with a healthcare professional visiting the subject at his/her 
home. The following assessments will be performed at this visit:
…

Blood sample for the following laboratory parameters:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Anti-UCB7665 antibodies/IgG depletion assay

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Serum biomarkers 

Serum total IgG and IgG subclasses concentration
Has been changed to:
8.4.5
Visit 12 (Week 9/Day 57) [UCB7665 4mg/kg]/ 
Visit 10 (Week 7/Day 43) [UCB7665 7mg/kg]/ Visit 9 (Week 6/Day 36) [UCB7665 10mg/kg]
Visit 7 (Week 5/Day 29) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the fifth visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. This visit can be performed at home with a 
healthcare professional visiting the subject at his/her home. The following assessments will be 
performed at this visit:
…

12-lead ECG (triplicate)
…

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Anti-UCB7665 antibodies

Serum complement levels (C3 and C4) and plasma complement levels (C3a and C5a)

Exploratory safety biomarkers
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety 
biomarkers)

Serum total IgG and IgG subclasses concentration

Serum cytokines, only in case of late infusion reactions visible during the visit
REDACTED COPY 
/kg]/ 
COP
/kg]/ 
Visit
D C
Visit
g and 
CTED
g and 
Period
DAC
Period
sing v
RED
sing v
ubje
R
ubje
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
clinical
ions
clinical
evels (C
d any
evels (C
9
at
9 (We
ation
(We
d UCB7
oriza
d UCB7
d. A vis
utho
d. A vis
visit. Th
g au
visit. Th
ect at h
eting
ect at h
r the fo
to su
r the fo
safet
ed t
safety
t
y
istry
e use
istry
Anti-
ot b
Anti-UC
be
UC
Seru
nn
Seru

nt



UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 327 of 353
Change #68
Visit 13 (Week 10/Day 64) [UCB7665 4mg/kg]/ Visit 11 (Week 8/Day 50) [UCB7665 7mg/kg]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit. 
The following assessments will be performed at this visit:
…

Blood sample for the following laboratory parameters:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Serum total IgG and IgG subclasses concentration

Serum biomarkers 
…
Has been changed to:
8.4.6
Visit 13 (Week 10/Day 64) [UCB7665 4mg/kg]/ Visit 11 (Week 8/Day 50) [UCB7665 
7mg/kg]]/ Visit 10 (Week 7/Day 43) [UCB7665 10mg/kg]
Visit 8 (Week 6/Day 36) [UCB7665 15mg/kg and UCB7665 20mg/kg]
This is the sixth visit in the Observation Period. A visit window of ±2 days is applicable for this 
visit relative to the day of the final dosing visit. The following assessments will be performed at 
this visit:

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Serum total IgG and IgG subclasses concentration

Exploratory safety biomarker
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety 
biomarkers)
Change #69
8.3.7
Visit 14 (Week 11/Day 71) [UCB7665 4mg/kg]/ Visit 12 (Week 9/Day 57) [UCB7665 
7mg/kg]
A visit window of ±2 days is applicable for this visit relative to the day of the final dosing visit. 
This visit can be performed at home with a healthcare professional visiting the subject at his/her 
home. The following assessments will be performed at this visit:
Has been changed to:
8.3.7
Visit 14 (Week 11/Day 71) [UCB7665 4mg/kg]/ 
Visit 12 (Week 9/Day 57) [UCB7665 7mg/kg]/ Visit 11 (Week 8/Day 50) [UCB7665 10mg/kg]
Visit 9 (Week 7/Day 43) [UCB7665 15mg/kg and UCB7665 20mg/kg]
REDACTED COPY
CB76
PY 
CB76
A visit 
CO
A visit 
t. The 
ED C
t. The 
hem
RE
hem
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
l 
o
l 
Week 
tion a
Week 
65 20m
appli
65 20m
t windo
ion a
t windo
follow
zatio
follow
matolog
ting
matolog
subc
y ma
subclas
ma
las
omarke
t any
omarke
to dosin
upp
to dosin
t 14 (W
be us
t 14 (W
sit win
ann
sit win
his visi
nt ca
his visi
home
ment
home
H
m
H
port a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 328 of 353
This is the seventh visit in the Observation Period. A visit window of ±2 days is applicable for 
this visit relative to the day of the final dosing visit. This visit can be performed at home with a 
healthcare professional visiting the subject at his/her home. The following assessments will be 
performed at this visit:

Concomitant medications

Concomitant medical procedures

Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory
rate)

Recording of AEs

Urine sample for urinalysis

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Anti-UCB7665 antibodies

Exploratory safety biomarkers
 Blood samples 
are taken prior to dosing, 2 and 4 hours after end of infusion for exploratory safety 
biomarkers)

Serum BAFF levels

Exploratory biomarker analysis
Change #70
8.3.8
End-of-Study Visit: Visit 15 (Week 13/Day 85) [UCB7665 4mg/kg]/ 
Visit 13 (Week 11/Day 71) [UCB7665 7mg/kg]
…

12-lead ECG

Urine pregnancy test for women of childbearing potential

Urine sample for urinalysis

Blood sample for the following laboratory parameters:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Anti-UCB7665 antibodies/IgG depletion assay

Serum total IgG and IgG subclasses concentration

ITP-specific autoantibodies 

ITP bleeding scale
REDACTED COP
er end
COP
er end
Y
OPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
aramet
d any
aramet
d of inf
on a
d of inf
5 (Wee
mark
5 (Wee
B7665
y m
B7665
y
t
y test fo
to su
test fo
y
t
y
le for u
sed 
le for u
sample 
be u
sample 
Standa
not 
Standa
che
ann
che

n

plicat
appl


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 329 of 353

NFI-MS

Subject exit interview 

Serum cytokines, only in case of infusion reactions

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.
Has been changed to:
8.4.8 End-of-Study Visit: Visit 15 (Week 13/Day 85) [UCB7665 4mg/kg]/ 
Visit 13 (Week 11/Day 71) [UCB7665 7mg/kg]/ 
Visit 12 (Week 10/Day 64) [UCB7665 10mg/kg]
Visit 10 (Week 9/Day 57) [UCB7665 15mg/kg and UCB7665 20mg/kg]
…

12-lead ECG (triplicate)
…

Blood sample for the following:

Standard safety laboratories: hematology including coagulation parameters, clinical 
chemistry

Anti-UCB7665 antibodies

Serum total IgG and IgG subclasses concentration

ITP-specific autoantibodies 

For all dose arms, collection of whole blood for exploratory RNA analyses

NFI-MS

Subject exit interview 

Serum cytokines, only in case of late infusion reactions visible during the visit

Headache questionnaire, only if subject experiences severe headaches, followed by a 
neurological assessment (including fundoscopy). Additionally, other diagnostic procedures 
including but not limited to CT scan, MRI and/or LP for CSF collection to be performed if 
indicated at the discretion of the investigator, considering the local guidelines for performing 
LP in subjects with ITP.

TB signs and symptoms questionnaire
Change #71
8.4 Early Withdrawal Visit
Paragraph #3
REDACTED COPY 
gy inc
TED 
gy inc
las
R
las
keting authorization application and any extensions or variations thereof.
ming
varia
ming
cluding
izati
cluding
sses co
eting
sses co
This document cannot be used to support any ma
n of wh
ny m
n of wh
iew 
sup
iew 
es, 
d to
es, onl
to s
onl
questio
used
questio
ogical a
be u
ogical a
uding b
ot b
uding b
ndicated
anno
ndicated
LP in
t can
LP in

me

T
n
T
C
marke


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 330 of 353
The assessments to be done at both the Early Withdrawal Visit as well as the End-of-Study Visit 
are the same as those at Visit 15 for the UCB7665 4mg/kg group or Visit 13 for the 
UCB7665 7mg/kg group, except for the subject exit interview which will be performed at the 
End-of-Study Visit only.
Has been changed to:
The assessments to be done at both the Early Withdrawal Visit as well as the End-of-Study Visit 
are the same as those at Visit 15 for the UCB7665 4mg/kg weekly (Dose Arm 1) group, Visit 13 
for the UCB7665 7mg/kg weekly (Dose Arm 2) group, Visit 12 for the UCB7665 10mg/kg 
weekly (Dose Arm 3) group, or Visit 10 for the UCB7665 15mg/kg (Dose Arm 4) and UCB7665 
20mg/kg (Dose Arm 5) groups, except for the subject exit interview which will be performed at 
the End-of-Study Visit only.
Change #72
9.1
Platelet counts
NEW bullet points added:

Baseline-corrected AUEC for platelet count calculated from Baseline to the end of study visit

Clinical Response: platelet count ≥30x109/L and at least 2-fold increase from Baseline value 
and absence of bleeding

Time to Clinical Response: time from starting treatment to achievement of Clinical Response

Duration of Clinical Response: measured from achievement of Clinical Response to loss of 
Clinical Response (loss of Clinical Response defined as platelet count <30x109/L or less than 
2-fold increase from Baseline platelet count or presence of bleeding)

Complete Clinical Response: platelet count ≥100x109/L and absence of bleeding

Time to Complete Clinical Response: time from starting treatment to achievement of 
Complete Clinical Response

Duration of Complete Clinical Response: measured from achievement of Complete Clinical 
Response to loss of Complete Clinical Response (loss of Complete Clinical Response defined 
as platelet count <100x109/L or presence of bleeding)

No Clinical Response: platelet count <30x109/L or less than 2-fold increase from Baseline or 
presence of bleeding
NEW paragraph added:
The clinical response variables will be assessed only for visits for which both platelet counts and 
the ITP bleeding score are assessed (with the exception of the confirmatory platelet assessments 
which may be obtained at any visit [scheduled or unscheduled] provided that they meet the 
criteria below). In order to define a clinical response, the platelet count must be confirmed on 2 
separate occasions at least 7 days apart (ie, the second assessment should be ≥168 hours after the 
first assessment). The time to response will be taken as the time to the first platelet assessment 
(obtained at the same time as the corresponding ITP bleeding score assessment). If the second 
assessment does not fulfill the required criteria for a clinical response, the subject will be 
considered as a nonresponder at the respective visits. In order to define a clinical response (or no 
REDACTED COPY 
g
D
g treat
D CO
treat
d from
CTED
d from
espons
ACT
espons
elet co
EDA
elet co
ele
R
ele
ort any marketing authorization application and any extensions or variations thereof.
3
ri
3 
UCB766
s or 
UCB766
rformed
ons 
rformed
Baseline
tion 
Baseline
-fold i
lica
-fold i
tment t
tion 
tment t
m achiev
oriza
m achiev
se defin
thor
se defin
ount or 
aut
ount or 
et coun
eting
et coun
ponse: 
mark
ponse: 
linical 
rt an
linical 
cannot be used to supp
omplet
port
omplet
100x10
supp
100x10
esponse
d to 
esponse
f bleedi
sed 
f bleedi
graph a
be u
graph a
inical r
not 
inical r
ITP ble
cann
ITP ble
This document
which m
nt ca
which m
criter
men
criter
se
m
se


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 331 of 353
clinical response), the platelet count must be confirmed on 2 separate occasions; further details 
will be provided in the SAP. Absence of bleeding is indicated by Grade 0 for all domains of the 
SMOG. Presence of bleeding is indicated by a Grade of 1 or above, for at least one domain of the 
SMOG.
Change #73
9.1
Platelet counts
Refer to Section 14 for details of statistical analysis of these parameters.
Has been changed to:
Refer to Section 14 for details of statistical analysis of these variables.
Change #74
11 Assessment of other immunological variables
…

Serum biomarkers levels over time

Serum BAFF levels

Plasma anti-UCB7665 antibodies/IgG depletion assay 

Cytokines
Cytokine samples will be taken at Baseline Visit for all subjects. At subsequent visits, cytokine 
samples will be taken only when the subject experiences infusion reactions.
Has been changed to:
…

Serum BAFF levels

Lymphocyte counts (B and T)

Anti-UCB7665 antibodies

Cytokines
Cytokine samples will be taken at Baseline Visit for all subjects. At subsequent visits, cytokine 
samples will be taken only when the subject experiences infusion reactions.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
/IgG de
rket
/IgG de
en at B
t any
en at B
y
p
y when
port 
when
y
p
y
ed to:
supp
ed to:
AFF lev
use
AFF lev
phocy
ot be
phocyte
e
te
yty
e
yty
Anti-
ann
Anti-UC
n
UC
Cy
nt c
Cy
Cy
me
Cy


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 332 of 353
Change #75
12.1.1 Definition of adverse event 
Paragraph #4:
Bleeding events should not be reported as an AE since these events will be assessed and reported 
during the ITP-BAT assessment. Common Terminology Criteria for Adverse Events (CTCAE) 
grade 3 or more bleeding events should be reported as AEs. 
Has been changed to:
Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2 bleeding events 
should not be reported as an AE since these events will be assessed and reported during the 
ITP-BAT assessment; CTCAE grade 3 or more bleeding events should be reported as AEs.
Change #76
12.1.9 Safety signal detection
Paragraph #1:
The safety variables and ADA results available after 7 days of the final dose of 3 and 6 subjects 
in the UCB7665 4mg/kg dose arm will be reviewed by the DMC (interim analysis 1 and 2) 
comprising at least 1 external expert, the UCB study physician, the UCB PS representative, and a 
biostatistician and will be summarized on an ongoing basis during the study so as to 
continuously evaluate the safety of subjects. The DMC will meet and reach a decision on 
whether or not the study can continue as planned, and whether or not the next dose arm can be 
started. Subsequently, safety variables and ADA results available after 7 days of the final dose of 
3 and 6 subjects in the UCB7665 7mg/kg dose arm (together with all available data from the 
UCB7665 4 mg/kg dose arm) will be reviewed by the DMC (interim analysis 3 and 4).
Has been changed to:
The safety variables and ADA results available after 7 days of the final dose of 3 and 6 subjects 
in the UCB7665 4mg/kg weekly group (Dose Arm 1) will be reviewed by the DMC (interim 
analysis 1 and 2) comprising at least 1 external expert, the UCB study physician, the UCB PS 
representative, and a biostatistician and will be summarized on an ongoing basis during the study 
so as to continuously evaluate the safety of subjects. The DMC will meet and reach a decision on 
whether or not the study can continue as planned, and whether or not Dose Arm 2 can be started. 
Subsequently, safety variables and ADA results available after 7 days of the final dose of 3 and 
6 subjects in the UCB7665 7mg/kg weekly (Dose Arm 2) (together with all available data from 
Dose Arm 1 and 2) will be reviewed by the DMC (interim analysis 3 and 4). The DMC will also 
meet and review safety data to add additional subjects to subsequent dose arms or to open 
subsequent dose arms. Further details are described in Section 5.1
The DMC may also decide to reduce the number of doses in each of the dose arms, to stop a dose 
arm or not to open a dose arm based on review of data during the study.
Change #77
12.5
Immediate reporting of adverse events
The following AEs must be reported immediately:
REDACTED COPY
phy
PY
physi
Y 
si
ing ba
COP
ing ba
e DM
D CO
e DM
nned, a
TED
nned, a
d ADA
ACT
d ADA
kg dos
EDA
kg dos
revie
RE
revie
t cannot be used to support any marketing authorization application and any extensions or variations thereof.
nts
s o
nts
ing the
ions
ing the
d as AE
ensi
d as AE
e final 
tion
e final 
MC 
lic
MC (int
cat
(int
cian, th
appli
cian, th
asis dur
on ap
asis dur
MC will 
ation
MC will 
and wh
riza
and wh
A resul
thor
A resul
se arm
auth
se arm
ewed b
ng a
ewed b
sults av
y ma
sults av
kl
a
kly 
an
y grou
ny 
grou
ng at lea
ort a
ng at lea
ostatisti
ppo
ostatisti
evalua
sup
evalua
stud
to s
study 
o 
y 
afet
sed
afety v
d 
y v
the UC
e us
the UC
m 1 and
t be 
m 1 and
nd revi
not 
nd revi
sequen
cann
sequen
This documen
The D
ent 
The D
arm
me
arm


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 333 of 353

SAE: AE that the investigator classifies as serious by the above definitions regardless of 
causality

Suspected transmission of an infectious agent via a medicinal product

AE of special interest (see Section 12.3)

AE of interest (see Section 12.4)
Has been changed to:
The following AEs must be reported immediately using the SAE Report Form according to the 
procedure in Section 12.2.2:

SAE: AE that the investigator classifies as serious by the above definitions regardless of 
causality

Suspected transmission of an infectious agent via a medicinal product

AE of special interest (see Section 12.3)

AE of interest (see Section 12.4)

Confirmed LTB, active TB, and NTBI (see Section 12.8.1)
Change #78
Table 12‒2: Laboratory measurements
Hematology
Chemistry
Coagulation 
parameters
Urinalysis
Pregnancy test
Basophilsa
Calcium
INR 
pH
Urineb HCG
Eosinophilsa
Phosphate
Prothrombin time
Protein
Serumc HCG
Neutrophilsa
Chloride
aPTT
Creatinine 
Lymphocytesa
Magnesium
Fibrinogen
Glucose
Others
Monocytesa
Potassium
Ketones
HbA1c
Hematocrit
Sodium
Urobilinogen
HIV
Hemoglobin
BUN
Bilirubin
Hepatitis B
(HBsAg, anti-HBs,
anti-HBc)
Platelet count
AST
Blood
Hepatitis C
(anti-HCV)
RBC count
ALT
Nitrite
WBC count
GGT
Albumin
B- and T-
Lymphocyte count
Total bilirubin 
Leucocytes
Direct bilirubin (if 
indicated)
REDACTED COPY 
O
agulat
CTED
agulat
param
ACT
param
ED
IN
ED
IN
DA
RE
R
cannot be used to support any marketing authorization application and any extensions or variations thereof.
o the
or va
o the
ardless 
nsio
ardless 
n a
tion
oriz
tion
meters
tho
meters
at
R 
g
R 
ut
Proth
ketin
Proth
ng
ke
rk
a
m
um
ort
um
an
dium
upp
dium
po
BUN
to s
BUN
su
ed
ount
ot b
ount
be
ent ca
RBC co
nt c
RBC co
This documen ca
WB
me
WB
en
um
u


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 334 of 353
Table 12‒2: Laboratory measurements
Hematology
Chemistry
Coagulation 
parameters
Urinalysis
Pregnancy test
LDH
Total cholesterol
Triglycerides
ALP
Total protein
Albumin
α1-globulin, 
α2-globulin, and 
β-globulin
Creatinine
hs-CRP
Amylase
ALP=alkaline phosphatase; ALT=alanine aminotransferase; anti-HBc=hepatitis B core antibody; anti-HBs=hepatitis 
B surface antibody; anti-HCV=hepatitis C virus antibody; aPTT=activated partial thromboplastin time; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen;GGT=gamma-glutamyltransferase; 
HbA1c=glycosylated hemoglobin; HBsAg=hepatitis B surface antigen; HCG=human chorionic gonadotropin; 
HIV=human immunodeficiency virus; hs-CRP=high-sensitivity C-reactive protein; INR=International Normalized 
Ratio; LDH=lactate dehydrogenase; RBC=red blood cell; WBC=white blood cell 
a Absolute as well as percentages for the differential leucocyte counts will be performed.
b Urine pregnancy test will be performed predose on dosing days and at End-of-Study Visit.
c Serum pregnancy test is done at Visit 1 (Screening) and to confirm results of positive urine test if applicable.
DACTED COPY
OP
-
P
-HBc
OPY 
HBc
TT=ac
COP
TT=ac
en;GG
D CO
en;GG
surfac
TED 
surfac
C
se
CT
sensit
CTE
nsit
ood cel
DAC
ood cel
RED
rential 
EDA
rential 
edose 
RE
edose 
R
uthorization application and any extensions or variations thereof.
ririri
ari
or
ns
ns
a
d a
a
ati
pl
=hepatit
app
=hepatit
ctivated 
n ap
ctivated 
GT=gam
tion
GT=gam
e antige
izat
e antige
tivity C
horiz
tivity C
ll; WBC
utho
ll; WBC
ting a
leucocy
aut
leucocy
on dosin
ng a
on dosin
This document cannot be used to support any market
ening) a
keting
ening) a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 335 of 353
Has been changed to:
Table 12‒2: Laboratory measurements
Hematology
Chemistry
Coagulation 
parameters
Urinalysis
Pregnancy test
Basophilsa
Calcium
INR 
pH
Urineb HCG
Eosinophilsa
Phosphate
Prothrombin time
Protein
Serum
c HCG
Neutrophilsa
Chloride
aPTT
Creatinine 
Lymphocytesa
Magnesium
Fibrinogen
Glucose
Others
Monocytesa
Potassium
Ketones
HbA1c
Hematocrit
Sodium
Urobilinogen
HIV
Hemoglobin
BUN
Bilirubin
Hepatitis B
(HBsAg, anti-HBs,
anti-HBc)
Platelet count
AST
Blood
Hepatitis C
(anti-HCV)
RBC count
ALT
Nitrite
Tuberculosisd
WBC count
GGT
Albumin
Total bilirubin 
Leucocytes
Safety Biomarkerse
Direct bilirubin (if 
indicated)
LDH
Total cholesterol
Triglycerides
ALP
Total protein
Albumin
α1-globulin, 
α2-globulin, 
β-globulin, γ-globulin
Creatinine
hs-CRP
Amylase
a Absolute as well as percentages for the differential leucocyte counts will be performed.
ALP=alkaline phosphatase; ALT=alanine aminotransferase; anti-HBc=hepatitis B core antibody; anti-HBs=hepatitis 
B surface antibody; anti-HCV=hepatitis C virus antibody; aPTT=activated partial thromboplastin time; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen;GGT=gamma-glutamyltransferase; 
REDACTED COPY 
Y
OP
D C
CT
RE
RE
RE
RE
RE
ny marketing authorization application and any extensions or variations thereof.
ari
ar
ar
ar
rs
ns
rs
or
HbA1c
nsio
HbA1c
on
H
e
H
en
H
e
H
(H
n
(H
ex
a
Blood
tion
Blood
n a
N
plic
a
n a
tio
or
g a
rk
rol
m
rol
not be used to support any mark
rk
rk
rk
rk
yceride
rt an
yceride
ny
ALP
ppo
ALP
ort
Tot
su
Tot
up
to
ed
se
This document cannot be use
no
ca
en
um
u


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 336 of 353
HbA1c=glycosylated hemoglobin; HBsAg=hepatitis B surface antigen; HCG=human chorionic gonadotropin; 
HIV=human immunodeficiency virus; hs-CRP=high-sensitivity C-reactive protein; INR=International Normalized 
Ratio; LDH=lactate dehydrogenase; RBC=red blood cell; WBC=white blood cell 
b Urine pregnancy test will be performed predose on dosing days and at End-of-Study Visit.
c Serum pregnancy test is done at Visit 1 (Screening) and to confirm results of positive urine test if applicable.
d Interferon-gamma release assay by central laboratory.
e May include but not limited to the biomarkers listed in the table. Samples collected for safety biomarkers at 
Baseline (Visit 2) and 4 hours post dosing (Visit 2) for all subjects and during follow up only in subjects with severe 
headache and/or moderate to severe GI disturbances. The Baseline samples will only be analysed in case he subject 
experienced a severe headache and/or moderate to severe GI disturbance
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ct
i
ct


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 337 of 353
Change #79
Table 12-3: Required investigations and follow up for PDILI 
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivit
y
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULNb
NA
Hepatology consultc
Medical Monitor 
must be notified 
within 24 hours (eg, 
by laboratory alert) 
and subject discussed 
with Medical Monitor 
ASAP.
Immediate, 
permanent IMP 
discontinuation.
Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 12.7.1.3); 
recommended to 
occur at the site 
with HCP.
Monitoring of liver 
chemistry values at 
least twice per week 
until values 
normalize, stabilize, 
or return to within 
baseline values.d
≥8xULN
NA
NA
≥3xULN
NA
Yes
Immediate, 
temporary or 
permanent, IMP 
discontinuation.
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN
<2xULN
No
Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 12.7.1.2).
Not required unless
otherwise 
medically indicated 
(at discretion of 
investigator).
REDACTED COPY 
,
C
,
rt)
DAC
rt)
scusse
REDA
scusse
l Mo
RE
l Mo
nen
Y
nen
ontinu
OPY
ontinu
E
TED
ED
TE
zation application and any extensions or variations thereof.
s 
ng
e
ng
en
n a
MP 
plic
MP 
uation.
app
uation.
n
authoriza
Immed
hori
Immed
arketing au
ed
g a
ed
onitor 
ting 
onitor 
tem
uth
tem
za
au
port any ma
ion wit
y m
ion wit
cal Mo
t any
cal Mo
quired 
port 
quired 
o supp
criteri
upp
criteri
for
su
for
a
This document cannot be used to s
se
o s


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 338 of 353
Table 12-3: Required investigations and follow up for PDILI 
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivit
y
Consultation 
requirements
Actions
Testing
Evaluation
≥5xULN 
(and ≥2x 
baseline) 
<2xULN
No
Discussion with 
Medical Monitor 
required.
Immediate, 
permanent IMP 
discontinuation.
Essential: Every
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48 hours at 
the site with HCP 
(see 
Section 12.7.1.3).
Monitoring of liver 
chemistry values at 
least twice per week 
until values 
normalize, stabilize, 
or return to within 
baseline values. d
REDACTED COPY 
TE
 and any extensions or variations thereof.
a
s 
Esse
and
Esse
a
a
a
d a
authorization application a
n.
c
n.
This document cannot be used to support any marketing au
ke
au
n a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 339 of 353
Table 12-3: Required investigations and follow up for PDILI 
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivit
y
Consultation 
requirements
Actions
Testing
Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; 
HCP=healthcare practitioner; IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; 
ULN=upper limit of normal
a
Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
include eosinophilia (>5%), rash, and fever (without clear alternative cause).
b
If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical 
Monitor.
c
Details provided in Section12.7.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment 
and management of potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
d
Unless an alternative monitoring schedule is agreed by the investigator and UCB responsible physician. Determination of 
stabilization is at the discretion of the investigator in consultation with the hepatologist (as applicable) and UCB responsible 
physician, as needed.
ACTED COPY
er qu
PY 
er qu
cause
COP
cause
ication
ED C
ication
RED
ogist i
EDAC
ogist i
ld usu
RED
ld usu
d any extensions or variations thereof.
a
s 
thorization application and a
; AST=
and
; AST=
cable; P
ion a
cable; P
adrant p
appli
adrant p
e).
n
e).
n of bi
zatio
n of bi
rketing au
is the e
auth
is the e
ually
ng a
ually be
a
be
y
a
y
by the i
rketi
by the i
ort any ma
consult
mark
consult
d a
This document cannot be used to suppo
po


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 340 of 353
Has been changed to:
Table 12-3: Required investigations and follow up for PDILI 
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULN
b
NA
Hepatology consultc
Medical Monitor must 
be notified within 
24 hours (eg, by 
laboratory alert) and 
subject discussed with 
Medical Monitor ASAP.
Immediate, permanent 
IMP discontinuation.
Essential: Must have 
repeat liver chemistry 
values and additional 
testing completed 
ASAP (see 
Section 12.7.1.3); 
recommended to 
occur at the site with 
HCP.
Monitoring of liver 
chemistry values at least 
twice per week until 
values normalize, 
stabilize, or return to 
within Baseline values.d
≥3xULN
NA
Yes
Immediate, temporary 
or permanent, IMP 
discontinuation.
≥3xULN 
(and ≥2x 
Baseline) 
and 
<5xULN
<2xULN
No
Discussion with Medical 
Monitor required if the 
criterion that allows for 
IMP continuation is met.
Further investigation –
immediate IMP 
discontinuation not 
required (see 
Section 12.7.1.2).
Not required unless 
otherwise medically 
indicated (at 
discretion of 
investigator).
≥5xULN 
(and ≥2x 
Baseline) 
<2xULN
No
Discussion with Medical 
Monitor required. 
Hepatology consult 
required if ALT or AST 
≥8xULN.
Immediate, permanent 
IMP discontinuation.
Essential: Every 
attempt must be made 
to have repeat liver 
chemistry values and 
additional testing 
completed within 
48 hours at the site 
with HCP (see 
Section 12.7.1.3).
Monitoring of liver 
chemistry values at least 
twice per week until 
values normalize, 
stabilize, or return to 
within Baseline values. d
REDACTED COPY 
mane
Y
mane
ontinu
OPY
ontinu
E
cal 
CT
cal 
f the 
DAC
f the 
ows fo
RED
ows fo
ion is
RE
ion is
TE
TE
TE
TE
o support any marketing authorization application and any extensions or variations thereof.
o
io
Essentia
d an
Essentia
repea
and
repea
va
a
va
ny
n a
porary
icati
porary
, IMP
pplic
, IMP
ation.
app
ation.
tio
or
g
or
s met.
ting
s met.
Fu
ho
Further
horiz
rther
imm
utho
imm
d
u
d
iza
au
with M
mar
with M
require
ny m
require
tology c
t any
tology c
quired if
ort a
quired if
≥8xULN
ppo
≥8xULN
rk
This document cannot be used to s
u
o s


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 341 of 353
Table 12-3: Required investigations and follow up for PDILI 
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor.
c Details provided in Section 12.7.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
d Unless an alternative monitoring schedule is agreed by the investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
Y
nsi
Y
nsi
COP
ble phy
OPY 
ble phy
REDACTED CO
CO
xtensions or variations thereof.
a
o
any ext
nsferase
ext
nsferase
=upper l
ny e
=upper l
pplication and a
nsitivity
d an
nsitivity
discussed
n an
discussed
eating p
tion
eating p
physici
plic
physici
on ap
sician, a
app
sician, a
xte
This document cannot be used to support any marketing authorization
on


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 342 of 353
Change #80
Section 12.8
Other safety measurements
NEW sections added:
12.8.1 Assessment and management of TB and TB risk factors
With the currently available data, TB is not considered as an important potential or identified risk 
for treatment with UCB7665. As immunomodulation may carry a risk of new or activation of 
latent TB, UCB has conservatively developed TB detection and management procedures taking 
into account the most current recommendations of international guidelines (2010 WHO) and 
most recent literature, covering any infection by the mycobacteria tuberculosis complex. 
Appropriate rigorous precautions are being taken within this protocol to monitor for the risk of 
TB infection prior to study entry and during the study (see Section 6.2.2 (Exclusion Criterion 
#25) and Section 6.4. Following are the key considerations of these procedures:
12.8.1.1
TB Tests at Screening
The interferon-gamma release assay (IGRA) and TB questionnaire are required as indicated in 
Schedule of Assessments. 

TB screening is mandatory both before study entry and during the conduct of the study. The 
preferred screening test is IGRA performed at a Central Laboratory. 
-
The IGRA result must be negative for subjects to enroll in this study
-
Subjects who test positive for IGRA test should be excluded from the study and 
referred for appropriate medical evaluation according to the local medical practice 
guidelines. 
-
If the result of the IGRA test is indeterminate, the particular IGRA test previously
performed may be repeated once; if positive or indeterminate on retest, the subject 
may not be randomized to study drug and, if already randomized, must undergo 
appropriate study specified withdrawal procedures. The retest must be done during 
the protocol-defined Screening window.
12.8.1.2
Monitoring for TB during the study
Subjects will be monitored for signs/symptoms of TB using routine pharmacovigilance measures 
for Adverse Events. Subjects reporting AEs related to signs/symptoms of TB will be evaluated 
for LTB and active TB according to the local medical practice guidelines. 
Subjects with confirmed LTB or active TB or NTMBI infection will be immediately withdrawn 
from the study as described in Withdrawal Criteria. Confirmed LTB, active TB and NTMBI 
must be reported to the Sponsor immediately regardless of seriousness using the SAE Report 
Form. Additional information received by the Investigator should be provided within 24 hours of 
awareness.
Once withdrawn from study treatment, subjects should return for the POET, complete all early
withdrawal assessments, and complete the follow-up visits.
12.8.1.3
TB tests at Final /End of Study Visit
REDACTED COPY 
an
Y
an
a Cen
OPY
a Cen
or subj
D CO
or subj
GRA te
CTE
GRA te
cal eva
DAC
cal eva
est
R
est
ing authorization application and any extensions or variations thereof.
king
var
king
and
or
and
ex.
on
ex.
for the r
ensio
for the r
usion C
exten
usion C
res:
ny e
res:
are requ
n an
are requ
during t
plic
during t
ntral L
app
ntral L
jects to
ation
jects to
est shou
oriza
est shou
aluatio
utho
aluatio
sed to support any market
t is ind
keting
t is ind
ed onc
arke
ed onc
ed to stu
ma
ed to stu
pecifie
any 
pecifie
ined Sc
ort a
ined Sc
for TB
uppo
for TB
onitored
to s
onitored
nts. Su
ed t
nts. Su
t cannot be u
active T
use
active T
with co
t be
with co
he stud
nnot
he stud
st be re
can
st be re
This document
Form. A
nt c
Form. A
awa
me
awa


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 343 of 353
Subjects will be evaluated for signs and symptoms of latent or active TB infection and for risk 
factors of exposure to TB, using the TB questionnaire, at the Final /End of Study (EOS) Visit. 
See the ‘TB signs and symptoms questionnaire’ section for further instructions on using the 
questionnaire.
12.8.1.4
Signs and symptoms of Tuberculosis
The Investigator should consider all potential sites of infection when assessing for TB during the 
physical examination, and other evaluations, and based on the subject’s history. 
Common symptoms with which the subject may present with include cough, blood in sputum, 
night sweats, lymphadenitis, joint pain/swelling, spinal deformity, headache/confusion, 
abdominal pain mimicking inflammatory bowel disease, frequent or painful urination, scrotal 
mass in men and pelvic inflammatory disease in women as well as other symptoms, or 
nonspecific symptoms. This is not an exhaustive list and unusual presentations should always be 
considered.
12.8.1.4.1 TB signs and symptoms questionnaire
The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
source document. The questionnaire will assist with the identification of subjects who may
require therapy for TB. A subject who answers “Yes” to the question 
 at Screening is excluded. A “Yes” response to any of the other questions within the 
questionnaire at Screening should trigger further careful assessment to determine if subject has 
latent or active TB (see Section 6.2.2 (Exclusion Criterion #25). A “Yes” response to any of the 
questions during/end of the study should trigger further assessments as per local medical 
guidelines to determine if the subject has either LTB or active TB infection.
12.8.1.4.2 LTB infection, active TB or other NTMBI identified during study
During the study, subjects who develop evidence of LTB infection or active TB or NTMBI must 
immediately stop further administration of study drug and will be referred to an appropriate 
medical specialist for further evaluation.
Confirmed LTB or active TB or NTMBI must be reported to the Sponsor immediately as 
described above.
Change #81
Section 12.8.5 12-Lead ECG
Paragraph #1:
A standard 12-lead ECG will be performed at visits as specified in the schedule of study
assessments (Section5.2). Care should be taken to assure proper lead placement and quality ECG 
recordings. Subjects should rest in a supine position in a controlled, calm environment for at 
least 15 minutes prior to the recording and should be motionless during the recording. The ECG 
will be performed in triplicate prior to blood collection for assessment of laboratory parameters.
Has been changed to:
A standard 12-lead ECG will be performed at visits as specified in the schedule of study
assessments (Section 5.2). Care should be taken to assure proper lead placement and quality 
REDACTED COPY
nse to 
COP
nse to 
er care
ED C
er care
sion C
CTED
sion C
trigger
ACT
trigger
has eith
EDA
has eith
or o
R
or o
OPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
um, 
or v
um, 
n, scrot
ions
n, scrot
ms, or 
ensi
ms, or 
shou
exte
should
e
ld
sis” sho
n an
sis” sho
ation o
ation
ation o
question
plica
question
an
on
any of
n ap
y of
eful ass
ation
eful ass
Criterio
oriza
Criterio
r furthe
thor
r furthe
her LT
aut
her LT
other N
eting
other N
elop ev
arke
elop ev
stration
y ma
stration
evaluat
any 
evaluat
TB or 
port 
TB or 
12
se
12-
se
-Le
ed
Le
#1:
t be
#1:
dard 1
nnot
dard 1
essmen
can
essmen
recordi
ent c
recordi
leas
me
leas
w
m
w
appli


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 344 of 353
ECG recordings. Subjects should rest in a supine position in a controlled, calm environment for 
at least 15 minutes prior to the recording and should be motionless during the recording. 
NEW paragraph #2 added:
The ECG will be performed in triplicate prior to blood collection for assessment of laboratory
parameters. Three ECGs should be recorded in a time frame of 5 minutes with at least 1 minute 
difference, 1-2 minutes between the ECGs.
Change #82
Section 14.1 Definition of analysis sets 
Paragraph #4:
The analysis of the PD, efficacy, and immunologic variables will be performed on the FAS. 
Selected outputs may be repeated for the Per Protocol Set (PPS). Further details will be provided 
in the SAP.
Paragraph #5 and #6:
Per Protocol Set:
The PPS is a subset of the FAS, consisting of those subjects who had received all foreseen sc 
infusions, had a platelet count measurement during the Observation Period, and no important 
protocol deviations that may potentially affect the platelet count as confirmed during a 
pre-analysis review of the data prior to database lock. Protocol deviations may not necessarily
lead to total exclusion of a subject from the PPS but may lead to exclusion of specific data. 
Pharmacokinetic Per Protocol Set (PK-PPS):
The PK-PPS is a subset of the FAS, consisting of those subjects who had no important protocol 
deviations potentially affecting the plasma concentration of UCB7665, as confirmed during a 
pre-analysis review of the data prior to database lock.
Has been changed to:
The analysis of the PD (excluding total IgG, and IgG subclasses), efficacy, and immunologic 
variables will be performed on the FAS. Selected outputs may be repeated for the PD Per 
Protocol Set (PD-PPS). Further details will be provided in the SAP.
Pharmacokinetic Per Protocol Set (PK-PPS):
The PK-PPS is a subset of the FAS, consisting of those subjects who had no important protocol 
deviations potentially affecting the plasma concentration of UCB7665, as confirmed during a 
pre-analysis review of the data prior to database lock. Protocol deviations may not necessarily
lead to total exclusion of a subject from the PK-PPS but may lead to exclusion of specific data.
Pharmacodynamic Per Protocol Set (PD-PPS)
The PD-PPS is a subset of the FAS, consisting of those subjects who had no important protocol 
deviations potentially affecting the serum concentration of total IgG, as confirmed during a 
pre-analysis review of the data prior to database lock. Protocol deviations may not necessarily
lead to total exclusion of a subject from the PD-PPS but may lead to exclusion of specific data.
The PD-PPS will be used for the analysis of the total IgG, and IgG subclasses.
REDACTED COPY
e Ob
PY 
e Ob
platele
COPY
platele
lock. 
D CO
lock. 
PS bu
TED
PS bu
PS):
DAC
PS):
consis
RED
consis
asm
R
asm
ed to support any marketing authorization application and any extensions or variations thereof.
on the F
tens
on the F
ils will
exte
ils will
ho had
licat
ho had
ervatio
pplic
ervatio
et coun
n ap
et coun
Protoc
ation
Protoc
ut may
rizat
ut may
sting of
ng a
sting of
ma con
keting
ma con
to data
arke
to data
luding 
rt an
luding 
med on t
ppor
med on t
). Furth
supp
). Furth
Per Pro
d to 
Per Pro
This document cannot be u
is a sub
use
is a sub
potenti
be u
potenti
ys
not
ysis re
ot b
is re
to total
anno
to total
harma
nt c
harma
The
me
The
d


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 345 of 353
Change #83
Section 14.3.2 Other safety analysis 
Paragraphs #1 and #2:
The absolute and relative frequencies for subjects with a given TEAE with respect to the 
preferred term according to the latest available version of the MedDRA, as well as the absolute 
frequencies of the individual TEAEs that have occurred, will be determined within each system 
organ class. Additional tables will summarize TEAEs by maximum intensity and causal 
relationship with UCB7665, as judged by the investigator. Adverse events will be categorized by
severity according to the CTCAE version 4.03 grading. In case the CTCAE grading is not 
available, the intensity (mild/moderate/severe) will be utilized. The TEAEs leading to 
discontinuation of IMP and treatment-emergent SAEs will also be summarized. The action taken, 
time of onset relative to dosing, and duration of each AE will be listed only.
For the continuous laboratory variables, the values and changes from Baseline will be 
summarized at each time point. For categorized values according to the reference range, shift 
tables from Baseline to each post-Baseline time point will be presented for selected variables to
be defined in the SAP. Values outside the reference range will be flagged in the data listings.
Has been changed to:
The absolute and relative frequencies for subjects with a given TEAE with respect to the 
preferred term according to the latest available version of the MedDRA, as well as the absolute 
frequencies of the individual TEAEs that have occurred, will be determined within each system 
organ class. Additional tables will summarize TEAEs by maximum intensity and causal 
relationship with UCB7665, as judged by the investigator. Adverse events will be categorized by 
severity according to the CTCAE version 4.03 grading. In case the CTCAE grading is not 
available, the intensity (mild/moderate/severe) will be utilized. For the purpose of the tabulations 
CTCAE grades will be aligned with the intensity classifications (mild/moderate/severe) to enable 
pooling of the AEs in the summaries. The TEAEs leading to discontinuation of IMP and 
treatment-emergent SAEs will also be summarized. The action taken, time of onset relative to 
dosing, and duration of each AE will be listed only.
For the continuous laboratory variables, the values and changes from Baseline will be 
summarized at each time point. For categorized values according to the reference range, shift 
tables from Baseline to each post-Baseline time point will be presented for selected variables to 
be defined in the SAP. Values outside the reference range will be flagged in the data listings. The 
number and percentage of subjects with markedly abnormal laboratory results (based on CTCAE 
grading) will be tabulated for each dose arm.
Change #84
Section 14.4.1 Efficacy analysis 
The main efficacy variable is the maximum increase from Baseline in platelet count during the 
study. The maximum increase from Baseline and maximum platelet count during the study will 
be summarized by dose arm.
In addition, all measurements of platelet count will be summarized by dose arm and time point 
using descriptive statistics (including changes from Baseline).
REDACTED COPY 
with a g
OPY
with a g
ersion
D CO
ersion
e occu
TED 
e occu
ize TE
ACTE
ize TE
y the 
DAC
y the 
rsion 4
RED
rsion 4
e/s
R
e/s
keting authorization application and any extensions or variations thereof.
ized by
or va
ized by
not
ns
not
to
si
to
The acti
ensi
The acti
line wi
any 
line wi
referen
nd a
referen
ted for 
n and
ted for 
flagge
tion 
flagge
given T
n app
given T
n of the
tion 
n of the
urred, w
izati
urred, w
EAEs b
horiz
EAEs b
investi
auth
investi
4.03 gr
g au
4.03 gr
severe)
eting
severe)
used to support any mar
the inte
arke
the inte
ries. Th
ma
ries. Th
also be
any m
also be
h AE w
rt an
h AE w
ratory v
uppo
ratory v
time po
o sup
time po
ine to e
d to 
ine to e
he SAP
sed
he SAP
This document cannot be 
percen
be us
percen
will be
ot be
will be
ange #
anno
ange #
Section
nt c
Section
The
me
The


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 346 of 353
For each dose arm a 1-sided t-test will be applied to assess if the average maximum increase 
from Baseline is greater than zero. In case the assumptions for the-t-test are not fulfilled a 
variance-stabilizing transformation may be applied in addition and/or an alternative 
nonparametric method may be considered. Further details will be provided in the SAP.
The Response rate, Complete Response rates, and platelet count ≥50x109/L will be summarized 
(number of subjects and percentages) and presented with 90% 2-sided confidence intervals for 
the rate of responders at each time point and overall (across all time points). Response and 
Complete Response are defined in Section 4.2.
Time to Response, time to Complete Response, time to platelet count ≥50x109/L, duration of 
Response, duration of Complete Response, and duration of platelet count ≥50x109/L will be 
calculated and summarized by dose arm.
The results from the ITP bleeding scale will be summarized at each time point and will include 
the grades for each of the 3 major domains: skin (S), visible mucosae (M), and organs (O). 
Results of the NFI-MS will be summarized at each time point, using summary scores where 
applicable. Changes from Baseline will be calculated and summarized.
Has been changed to:
The main efficacy variable is the maximum increase from Baseline in platelet count during the 
study. The maximum increase from Baseline and maximum platelet count during the study will 
be summarized by dose arm.
In addition, all measurements of platelet count will be summarized by dose arm and time point 
using descriptive statistics (including changes from Baseline).
For dose arms with ≥10 subjects, a 1-sided t-test will be applied to assess if the average 
maximum increase from Baseline is greater than zero. In case the assumptions for the-t-test are 
not fulfilled, an alternative nonparametric method may be considered. Further details will be 
provided in the SAP. The Response, Complete Response, and platelet count ≥50x109/L will be 
summarized (number of subjects and percentages) and presented with 90% 2-sided confidence 
intervals for the rate of responders at each time point and overall (across all time points). 
Response and Complete Response are defined in Section 4.3. The analysis will be repeated for 
the Clinical Response variables defined in Section 4.3.
Time to Response, time to Complete Response, time to platelet count ≥50x109/L, duration of 
Response, duration of Complete Response, duration of platelet count ≥50x109/L, and 
Baseline-corrected AUEC for platelet count will be calculated and summarized by dose arm. The 
time to first response will be analyzed using a log-rank test and displayed using Kaplan-Meier 
curves. The time to Response, time to Complete Response, and respective durations will be 
summarized by dose arm.
The results from the ITP bleeding scale will be summarized at each time point and will include 
the grades for each of the 3 major domains: skin (S), visible mucosae (M), and organs (O). In 
addition the number and percentage of subjects with severe or clinically relevant bleeding and 
number and percentage of subjects with absence of bleeding will be summarized at each time 
point.
REDACTED COPY 
om
Y
om
aximu
OPY
aximu
nt will
TED
nt will
nges fr
ACT
nges fr
sided t
RED
sided t
grea
R
grea
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
n of 
or v
n of 
will be 
ns 
will be 
and wi
exte
and wi
and org
ny ex
and org
mmary
nd a
mmary
ed.
a
ed.
aseline
pplic
aseline
um plat
app
um plat
l be su
riza
l be su
from Ba
thor
from Ba
t
g
t-test w
g au
test w
ater tha
eting
ater tha
etric m
rket
etric m
se, Com
mar
se, Com
ts and p
ny m
ts and p
onders a
rt any
onders a
Respon
port
Respon
variabl
supp
variabl
 time t
d to s
 time t
tion of 
sed 
tion of 
rected 
e use
rected 
rst resp
t be 
rst resp
. The ti
not 
. The ti
mmarize
cann
mmarize
The re
ent 
The re
the 
me
the 


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 347 of 353
Results of the NFI-MS will be summarized at each time point, using summary scores where 
applicable. Changes from Baseline will be calculated and summarized.
Additional subgroup analyses may be performed as needed and further details will be provided in 
SAP regarding these analyses.
Change #85
Section 14.4.3 Pharmacodynamic analysis 
For all PD variables, descriptive statistics for the values and change from Baseline and/or 
percentage change from Baseline will be tabulated by time point. If appropriate, measurements 
will be log-transformed.
The PD variables will include ITP-specific autoantibodies
total IgG, and IgG subclasses. In addition, for total IgG, the maximum decrease from Baseline 
and minimum value will be evaluated and summarized. Figures of mean values over time and 
changes from Baseline will be presented.
Has been changed to:
For all PD variables, descriptive statistics for the values and change from Baseline and/or 
percentage change from Baseline will be tabulated by time point. 
The PD variables will include ITP-specific autoantibodies 
total IgG, and IgG subclasses. In addition, for total IgG, the maximum decrease from Baseline 
and minimum value will be evaluated and summarized. Figures of mean values over time and 
changes from Baseline will be presented.
Change #86
Section 14.4.4 Immunologic variables 
Paragraphs #1 and #2:
All immunologic variables including concentrations of immunoglobulins (IgA, IgE, and IgM),
serum (C3 and C4) and plasma (C3a and C5a) complement levels, serum biomarkers 
 
 serum BAFF levels and the results of 
the IgG depletion assay will be summarized by dose arm over time (including changes from 
Baseline) using descriptive statistics. Figures of mean values over time and changes from 
Baseline may be presented.
The ADA status (negative/positive) and changes in relative mass units from Baseline will be 
summarized by dose arm; figures will also be presented.
Has been changed to:
All immunologic variables including concentrations of immunoglobulins (IgA, IgE, and IgM), 
serum (C3 and C4) and plasma (C3a and C5a) complement levels, serum BAFF levels, and 
lymphocyte counts (B and T) will be summarized by dose arm over time (including changes 
from Baseline) using descriptive statistics. Figures of mean values over time and changes from 
Baseline may be presented.
The ADA status (negative/positive) will be summarized by dose arm at each visit and overall; 
figures will also be presented in conjunction with PK concentrations of UCB7665.
REDACTED COPY 
bodies
OPY
bodies
al IgG
CO
al IgG
mmariz
ED C
mmariz
s
R
s
ions or variations thereof.
ments 
or v
ments 
pplication and any exten
from 
xten
from 
ues ove
ny ex
ues ove
nge fro
ation
nge fro
oint. 
plica
oint. 
t any marketing authorization ap
G, the m
tion 
G, the m
zed. Fig
izatio
zed. Fig
uding c
ny m
uding c
ma (C3a
t any
ma (C3a
ensio
n app
ly
m
ly
suppo
y will b
uppo
will b
y
This document cannot be used to 
criptive
o su
criptive
present
d to
present
atus (ne
use
atus (ne
ed by
t be 
ed by d
y
been 
nnot
been 
All imm
nt ca
All imm
serum
ment
serum
port a


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 348 of 353
Change #87
14.4.5.2
Subject characteristics 
Bullet point #3:

Prior and concomitant medications
Has been changed to:

Past, prior, and concomitant medications
Change #88
Section 14.7 Planned interim analysis and data monitoring 
Paragraph #2:
For the sequential adaptive design in this study, at least 4 interim analyses will be performed. 
Safety data from the interim analyses will be reviewed by the DMC to monitor the safety, to 
adapt the dose regimen, and to decide when and if the UCB7665 7mg/kg dose arm should be 
opened. Planned dosing may be discontinued for all subjects on a dose arm (see Section 6.5).
Paragraph #4:
If the study continues without modifications, the next interim analysis will take place after data 
from 3 additional subjects are available. Based on the available combined data of the first 6 
subjects, the DMC will decide if the 3x7mg/kg dose arm can be initiated. If the new dose arm 
will be initiated and if the 5x4mg/kg will be continued, new subjects will be randomized to 1 of 
the 2 dose arms in an allocation ratio of 1:1 (Once 15 subjects are in the 4mg/kg group, the 
remaining subjects will not be randomized. They will be allocated to the 7mg/kg group).
Paragraph #7:
The fourth interim analysis and review of data by DMC will take place after safety data (7 days 
after final dose) is available for the first 6 subjects in Dose Arm 2.
The timing of further interim analysis and review of data by DMC will be decided by the DMC 
members at the fourth DMC meeting.
Paragraph #8:
During these reviews recruitment in the dose arms will not be stopped. If needed, subsequent 
DMC meetings may take place and the frequency will be detailed in the DMC charter.
Paragraph #9:
The DMC will monitor data for all reported AEs, clinical findings, including vital signs (pulse 
rate, blood pressure, temperature, and respiratory rate) and safety laboratory values, and 
immunogenicity data. Pharmacokinetic data will not be required for DMC review as blood 
sampling will be performed at a single time point per visit only. Thus, PK data is restricted only 
to the concentration data and can therefore make no plausible contribution to the assessment of 
safety in this particular study.
Paragraph #12:
REDACTED COPY
inter
PY 
inter
the av
COP
the av
dose a
D CO
dose a
contin
TED
contin
1 (On
ACT
1 (On
zed
EDA
zed.
D
. T
A
T
keting authorization application and any extensions or variations thereof.
will be p
y ex
will be p
onitor t
any
onitor t
kg dos
and a
kg dos
ose arm
n an
ose arm
im anal
appli
im anal
vailabl
n ap
vailable
p
e
arm can
ation
arm can
nued, n
rizat
nued, n
nce 15 s
thor
nce 15 s
They
auth
They w
uth
w
y
uth
y
ot be used to support any mar
ew of d
arke
ew of d
he first 
y ma
he first 
analy
t any
analy
y
MC mee
port 
MC mee
ews rec
d to 
ews rec
may
sed
may
cann
t
#9:
be
#9:
MC wi
nnot 
MC wi
, blood
cann
, blood
This document
mmuno
nt c
mmuno
samp
men
samp
to
m
to


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 349 of 353
A detailed description of the DMC composition, processes and responsibilities, criteria to 
escalate to the next dose arm, and criteria to stop a dose arm will be provided in a separate DMC 
charter.
Has been changed to:
Paragraph #2:
For the sequential adaptive design in this study, at least 11 interim analyses will be performed. 
Safety data from the interim analyses will be reviewed by the DMC to monitor the safety, to 
adapt the dose regimen, and to decide when and if the UCB7665 7mg/kg weekly group (Dose 
Arm 2), UCB7665 10mg/kg weekly group (Dose Arm 3), UCB7665 15mg/kg group (Dose 
Arm 4) and UCB7665 20mg/kg group (Dose Arm 5) should be opened. Planned dosing may be 
discontinued for all subjects in a dose arm (see Section 6.5).
Paragraph #4:
If the study continues without modifications, the next interim analysis will take place after data 
from 3 additional subjects are available. Based on the available combined data of the first 
6 subjects, the DMC will decide if the 3x7mg/kg dose arm can be initiated. If the new dose arm 
will be initiated and if the 5x4mg/kg will be continued, new subjects will be randomly assigned 
to 1 of the 2 dose arms in an allocation ratio of 1:1
Paragraphs #6 and #7:
The fourth planned interim analysis and review of data by DMC will take place after safety data 
(7 days after final dose) is available for the first 6 subjects in Dose Arm 2.
All subsequent DMC meetings will be dependent on opening of Dose Arms 3, 4 and 5 and 
decisions of the previous DMC meetings. Review of data will occur after every 3 subjects. More 
details are included in the DMC charter.
Paragraph #8:
During the first three interim analyses, recruitment in the Dose Arms 1 and 2 will not be stopped. 
If needed, subsequent DMC meetings may take place and the frequency will be detailed in the 
DMC charter.
Paragraph #11:
A detailed description of the DMC composition, processes and responsibilities, criteria to 
escalate to the next dose arm, and criteria to stop, or continue a dose arm will be provided in a 
separate DMC charter.
Change #89
Section 14.8 Determination of sample size 
Paragraph s#1 and #2
The sample size of 15 subjects, in each dose arm, is mainly based on the efficacy objective of the 
study. In addition the 2x15 subjects ensure that sufficient data are available to form conclusions 
about the safety of administering UCB7665.
REDACTED COPY 
of dat
D CO
of dat
irst 6 s
TED
irst 6 s
epend
DAC
epend
ngs. R
RED
ngs. R
ter.
R
ter.
ny marketing authorization application and any extensions or variations thereof.
Dose
or v
Dose
Dose
ns o
Dose
ing ma
sions
ing ma
ll take 
d any
ll take 
ned dat
and 
ned dat
nitiated
n a
nitiated
jects w
ation
jects w
ta by
ation
ta by D
on
D
y
on
y
subject
riza
subject
dent on 
utho
dent on 
R
g
Review
g au
eview
aly
ny
alyses,
y m
ses,
This document cannot be used to support a
meetin
t any
meetin
ption of
d to 
ption of
next do
sed
next do
MC cha
be us
MC cha
ge #89
not b
ge #89
ction 14
can
ction 14
Paragr
ment 
Paragr
Th
m
Th


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 350 of 353
An approximate sample size calculation for the efficacy variable “maximum increase from 
Baseline in platelet count” shows that 15 subjects would be sufficient to show a change from 
Baseline with 1-sided testing at 5% and power of 80%. The anticipated change is based on an 
assumed Baseline average of 25x109/L and a clinically meaningful maximum value of 
100x109/L. The calculation made use of platelet count data presented in a publication by
Robak T (Robak et al, 2009), but it is approximate as maximum changes from Baseline for 
individual subjects were not available, necessitating the use of the maximum average platelet 
count instead. The SD is taken from visual inspection.
Has been changed to:
The sample size of 15 subjects in Dose Arms 1 and 2, is mainly based on the efficacy objective 
of the study. In addition the 15 subjects in Dose Arms 1 and 2 ensure that sufficient data are 
available to form conclusions about the safety of administering UCB7665. Based on the safety 
data from dose arms 1 and 2, the sample size of 6 to 12 subjects in Dose Arms 3, 4 and 5 is 
judged to be sufficient in order to explore subjects’ safety and IgG reductions under different 
dose regimens and is not based on a formal sample size calculation. 
For Dose Arms 1 and 2, an approximate sample size calculation for the efficacy variable 
“maximum increase from Baseline in platelet count” shows that 15 subjects would be sufficient 
to show a change from Baseline with 1-sided testing at 5% and power of 80%. The anticipated 
change is based on an assumed Baseline average of 25x109/L and a clinically meaningful 
maximum value of 100x109/L. The calculation made use of platelet count data presented in a 
publication by Robak T (Robak et al, 2009), but it is approximate as maximum changes from 
Baseline for individual subjects were not available, necessitating the use of the maximum 
average platelet count instead. The SD is taken from visual inspection.
Change #90
Section 15.1 Informed consent 
NEW paragraph added:
Subjects have the right to withdraw their consent for the exploratory genomic substudy at any 
point without any impact on their care or participation in the main study. In this case, any data 
already generated on the samples will be retained and used, but no further analysis will occur.
Change #91
Section 15.4 Subject privacy
NEW paragraphs added:
Genetic analysis data will not be shared with the subjects and will be subject to the highest level 
of data protection, as per European regulations.
Samples may be shared with collaborators working within UCB and may be analyzed at a third 
party site, but only in relation to the aims of this exploratory analysis as detailed in this study
protocol. Samples may be stored for up to 20 years and maybe used at any time up to that point. 
Samples will remain under the control of UCB at all times and may be destroyed at any point 
before the 20 year expiration date.
REDACTED COPY
5%
Y
5%
25x10
OPY 
25x10
ade us
COP
ade us
ut it is 
ED C
ut it is 
ailable
CTED
ailable
taken
DACT
taken
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
objecti
ons 
objecti
t data a
nsio
t data a
ed on th
xten
ed on th
ms 3, 4 a
y ex
ms 3, 4 a
ons un
any 
ons un
r the ef
on a
r the ef
15 sub
atio
15 sub
nd pow
plica
nd pow
/L
ap
/L and
app
and
ap
se of pl
on a
se of pl
approx
zatio
approx
e, nece
oriza
e, nece
n from 
utho
n from 
hdraw t
any
hdraw t
on their
ort a
on their
e samp
uppo
e samp
ubject p
sed 
ubject p
graphs 
be u
graphs 
c anal
not 
c analy
ata
an
ata pro
ann
pro
Sampl
ent c
Sampl
par
me
par


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 351 of 353
Change #92
Section 17 References
NEW reference:
Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc 
Hematol Educ Program. 2012;2012:306-12.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 352 of 353
19
DECLARATION AND SIGNATURE OF INVESTIGATOR
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and local 
laws and requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.
I have received and read all study-related information provided to me.
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by
UCB.
All rights of publication of the results reside with UCB, unless other agreements were made in a 
separate contract.
Investigator:
Printed name
Date/Signature
REDACTED COPY 
Date
COPY
Date
Y
plication and any extensions or variations thereof.
treated
or v
treated
ion by
ons 
ion by
ts were
exte
ts were
This document cannot be used to support any marketing authorization app
e/Signa
n ap
e/Signa
pl


UCB
15 Feb 2017
Clinical Study Protocol
UCB7665
TP0001
Confidential
Page 353 of 353
20
SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


ELECTRONIC SIGNATURES
Signed by 
Meaning of Signature 
Server Approval Date 
(dd-mon-yyyy 
(HH:mm)) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TP0001-Protocol Amendment 3 A multicenter, open-label,
multiple-dose study to evaluate the safety, tolerability, and efficacy
of UCB7665 in subjects
Clinical Approval
16-Feb-2017 15:58 GMT+01
Clinical Approval
17-Feb-2017 13:51 GMT+01
Clinical Approval
17-Feb-2017 14:34 GMT+01
D COPY 
D C
REDACTE
DA
proval
TED
proval
y marketing authorization application and any extensions or variations thereof.
n a
any e
rver A
any 
rver A
nd an
(d
a
(d
n and
y e
n a
uth
et
This document cannot be used to support any
pp
d
16
n
16
r

SAP_001.pdf: 
UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 1 of 128
STATISTICAL ANALYSIS PLAN AMENDMENT 3
Study: TP0001
Product: UCB7665
A MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO EVALUATE THE 
SAFETY, TOLERABILITY AND EFFICACY OF UCB7665 IN SUBJECTS WITH PRIMARY 
IMMUNE THROMBOCYTOPENIA
SAP/Amendment Number
Date
Final SAP
07 Oct 2016
SAP Amendment 1
14 Nov 2017
SAP Amendment 2
14 May 2018
SAP Amendment 3
28 Jan 2019
Confidentiality Statement
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
REDACTED COPY 
IPLE 
D CO
IPLE 
Y OF
ED 
Y OF
HROM
CTE
HROM
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
DOSE
tion 
DOSE
UCB7
izati
UCB7
MBOC
horiz
MBOC
Oct
ma
Oct 20
ar
20
14 No
ny m
14 No
1
an
14
an
4


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 2 of 128
TABLE OF CONTENTS
LIST OF ABBREVIATIONS....................................................................................................7
1
INTRODUCTION ...........................................................................................................12
2
PROTOCOL SUMMARY...............................................................................................13
2.1
Study objectives...........................................................................................................13
2.1.1
Primary objective.................................................................................................13
2.1.2
Secondary objectives ...........................................................................................13
2.1.3
Exploratory objectives.........................................................................................13
2.2
Study variables.............................................................................................................14
2.2.1
Safety variables....................................................................................................14
2.2.1.1
Primary safety variable..............................................................................14
2.2.1.2
Other safety variables................................................................................14
2.2.2
Efficacy variables ................................................................................................14
2.2.3
Pharmacokinetic and pharmacodynamic variables..............................................16
2.2.3.1
Pharmacokinetic variable ..........................................................................16
2.2.3.2
Pharmacodynamic variables......................................................................16
2.2.4
Other immunological variables............................................................................16
2.3
Study design and conduct ............................................................................................17
2.4
Determination of sample size.......................................................................................19
3
DATA ANALYSIS CONSIDERATIONS......................................................................19
3.1
General presentation of summaries and analyses ........................................................19
3.2
General study level definitions ....................................................................................21
3.2.1
Analysis timepoints .............................................................................................21
3.2.1.1
Relative day...............................................................................................21
3.2.1.2
Study periods.............................................................................................21
3.3
Definition of Baseline values.......................................................................................21
3.4
Protocol deviations.......................................................................................................23
3.5
Analysis sets.................................................................................................................23
3.5.1
Enrolled Set .........................................................................................................23
3.5.2
Safety Set.............................................................................................................23
3.5.3
Full Analysis Set..................................................................................................23
3.5.4
Per Protocol Set ...................................................................................................23
3.5.5
Pharmacokinetic Per Protocol Set .......................................................................24
3.5.6
Pharmacodynamic Per Protocol Set.....................................................................24
3.6
Treatment assignment and treatment groups ...............................................................24
3.7
Center pooling strategy................................................................................................24
3.8
Coding dictionaries ......................................................................................................24
3.9
Changes to protocol-defined analyses .........................................................................24
REDACTED COPY 
.
Y
.
......
OP
......
.......
D C
.......
......
TE
......
ONS
ACT
ONS
aries a
REDA
aries a
s
R
s
rt any marketing authorization application and any extensions or variations thereof.
3
v
3
...
o
...13
or v
13
........
on
........ 1
.......
ns
.......
......
ext
........
t
..
.......
ny
.......
........
d
........
........
n a
........
.......
atio
.......
........
plic
........
.......
ap
.......
........
tio
........
........
iz
........
.......
th
.......
and ana
g au
and ana
.......
tin
.......
........
ark
........
........
m
........
ods
t an
ods..
n
..
cannot be used to suppo
line va
ort 
line va
ions
upp
ions.
p
.
ts
t
ts......
to
......
rolled S
ed 
rolled S
Safety
be us
Safety
This document c
Fu
be
Fu
.4
an
.4
3.5.5
t ca
3.5.5
3.
en
3.
3
m
3


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 3 of 128
4
STATISTICAL/ANALYTICAL ISSUES.......................................................................25
4.1
Adjustments for covariates ..........................................................................................25
4.2
Handling of dropouts or missing data..........................................................................25
4.2.1
Efficacy data ........................................................................................................25
4.2.2
Safety laboratory data..........................................................................................25
4.2.3
Pharmacodynamic data........................................................................................25
4.2.4
Immunological data .............................................................................................25
4.2.5
UCB7665 concentration data...............................................................................25
4.2.6
Electrocardiogram data........................................................................................26
4.2.7
Dates and times....................................................................................................26
4.3
Handling of repeated and unscheduled measurements ................................................28
4.4
Interim analyses and data monitoring..........................................................................28
4.5
Multicenter studies.......................................................................................................29
4.6
Multiple comparisons/multiplicity...............................................................................29
4.7
Active-control studies intended to show equivalence..................................................29
4.8
Examination of subgroups ...........................................................................................29
5
STUDY POPULATION CHARACTERISTICS.............................................................30
5.1
Subject disposition.......................................................................................................30
5.2
Protocol deviations.......................................................................................................30
6
DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS ........................31
6.1
Demographics ..............................................................................................................31
6.2
Other Baseline characteristics......................................................................................31
6.3
Medical history and concomitant diseases...................................................................32
6.4
Past, prior, baseline and concomitant medications ......................................................32
6.4.1
Past medication definition ...................................................................................33
6.4.2
Prior medication definition..................................................................................33
6.4.3
Baseline medication definition ............................................................................33
6.4.4
Concomitant medication definition .....................................................................33
7
MEASUREMENTS OF TREATMENT COMPLIANCE...............................................33
8
EFFICACY ANALYSES ................................................................................................33
8.1
Platelets........................................................................................................................33
8.1.1
Definition of variables .........................................................................................34
8.1.2
Presentation of results..........................................................................................35
8.1.3
Statistical analysis of platelets.............................................................................37
8.1.3.1
Analysis of maximum increase from Baseline..........................................37
8.1.3.2
Analysis of time to response......................................................................37
8.1.3.3
Analysis of responder rate.........................................................................37
8.1.4
Rescue medication definition (after medical inspection) ....................................38
REDACTED COPY 
......
PY
......
......
CO
......
......
ED
......
ASELI
CTE
ASELI
.....
ED
.......
D
..
s
R
s....
R
....
d to support any marketing authorization application and any extensions or variations thereof.
.25
r v
25
.......
ns
.......26
o
26
.......
si
.......
..
xt
........
xte
......
........
y
........
.......
d a
.......
........
an
........
.......
tio
.......
........
ica
........
........
app
........
.......
on
.......
........
za
........
INE C
horiz
INE C
........
au
........
........
ing
........
ant dise
rket
ant dise
oncomi
mar
oncomi
efinitio
ny 
efinitio
on defi
ort a
on defi
edicati
ppo
edicati
mitant m
o su
mitant m
This document cannot be used
MENT
ed to
MENT
CY AN
use
CY AN
at
t b
atelets
t be
elets
1
n
1
8.1.2
can
8.1.2
8.1
ent
8.1


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 4 of 128
8.2
Other efficacy variables ...............................................................................................38
8.2.1
ITP bleeding score ...............................................................................................38
8.2.1.1
ITP bleeding score and platelet response ..................................................39
8.2.2
Patient reported outcomes....................................................................................41
8.2.2.1
NFI-MS .....................................................................................................41
9
PHARMACOKINETICS AND PHARMACODYNAMICS..........................................42
9.1
Pharmacokinetics .........................................................................................................42
9.2
Pharmacodynamics ......................................................................................................43
9.2.1
ITP-specific autoantibodies .................................................................................43
9.2.2
Total IgG and IgG subclasses..............................................................................44
9.3
Other immunological variables....................................................................................45
9.3.1
Serum immunoglobulins and lymphocytes .........................................................45
9.3.2
Serum and plasma complement levels.................................................................45
9.3.3
Serum biomarkers................................................................................................45
9.3.4
Anti-drug antibodies ............................................................................................46
9.3.5
Cytokines .............................................................................................................47
10
SAFETY ANALYSES.....................................................................................................47
10.1
Extent of exposure .......................................................................................................48
10.2
Adverse events.............................................................................................................48
10.3
Clinical laboratory evaluations ....................................................................................50
10.3.1
Potential drug-induced liver injury......................................................................52
10.4
Vital signs, physical findings, and other observations related to safety......................53
10.4.1
Vital signs ............................................................................................................53
10.4.2
Electrocardiograms..............................................................................................54
10.4.3
Other safety variables ..........................................................................................55
11
OTHER ANALYSES ......................................................................................................55
12
REFERENCES ................................................................................................................57
13
APPENDICES .................................................................................................................58
13.1
Corticosteroid use ........................................................................................................58
13.2
NFI-MS........................................................................................................................58
13.3
ITP bleeding score .......................................................................................................59
13.4
Cytokines .....................................................................................................................71
13.5
Classification of markedly abnormal laboratory values based on CTCAE grades......72
13.6
Treatment group assignment for the TFLs...................................................................74
14
AMENDMENTS TO THE STATISTICAL ANALYSIS PLAN....................................76
14.1
Amendment 1...............................................................................................................76
14.1.1
Rationale for the amendment...............................................................................76
14.1.2
List of changes.....................................................................................................76
REDACTED COPY 
......
PY
......
......
CO
......
......
ED
......
......
CT
......
er inju
EDA
er inju
 and
RE
 and
be used to support any marketing authorization application and any extensions or variations thereof.
.43
r v
43
.......
ns
.......43
o
43
.......
si
.......
........
xte
........
........
y
........
.......
d a
.......
...
a
........
an
.....
.......
tio
.......
.
i
........
ica
.......
........
app
........
.......
on
.......
........
za
........
.......
ho
.......
ury
au
ury....
au
....
d other 
ting 
d other 
.......
ke
.......
........
ma
........
bles
any
bles .
y
.
........
ort
........
........
pp
........
.......
o s
.......
eroid u
ed to
eroid u
This document cannot b
MS
u
MS...
us
...
P bleed
t be
P bleed
Cytok
nnot
Cytok
5
C
an
C
13.6
ent
13.6
14
m
14


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 5 of 128
14.2
Amendment 2.............................................................................................................102
14.2.1
Rationale for the amendment.............................................................................102
14.2.2
List of changes...................................................................................................102
14.3
Amendment 3.............................................................................................................114
14.3.1
Rationale for the amendment.............................................................................114
14.3.2
List of changes...................................................................................................114
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE...................................................128
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 6 of 128
LIST OF TABLES
Table 3‒1:
Definition of Baseline......................................................................................22
Table 4‒1:
Calculation rules for duration of adverse events..............................................27
Table 10‒1:
Clinical laboratory measurements....................................................................51
Table 10‒2:
TEMA/PCS criteria for vital signs...................................................................53
Table 10‒3:
TEMA/PCS criteria for ECG...........................................................................55
Table 13‒1:
ITP-BAT scoring .............................................................................................61
Table 13‒2:
Criteria for markedly abnormal laboratory tests..............................................72
Table 13‒3:
Treatment group assignment for the tabulations..............................................74
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
5
...
o
...61
or v
61
.......
on
.......
..
te
........
ten
......


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 7 of 128
LIST OF ABBREVIATIONS
ACP
above cutpoint
ADA
anti-drug antibody
ADaM
analysis data model
AE
adverse event
ALC
absolute lymphocyte count
ALD
above the limit of detection
ALP
alkaline phosphatase
ALQ
above the limit of quantification
ALT
alanine aminotransferase
ANC
absolute neutrophil count
anti-HBc
hepatitis B core antibody
anti-HBs
hepatitis B surface antibody
anti-HCV
hepatitis C virus antibody
aPTT
activated partial thromboplastin time
AST
aspartate aminotransferase
ATC
Anatomical Therapeutic Chemical
AUEC
area under the effect curve
BAFF
B cell activating factor
BCP
below cutpoint
BLQ
below the limit of quantification
BMI
body mass index
BUN
blood urea nitrogen
CI
confidence interval
REDACTED COPY 
trophil
COP
trophil
s B co
TED
s B co
patitis
EDAC
patitis
hep
R
hep
ng authorization application and any extensions or variations thereof.
ion
on
ion
e
l count
on ap
l count
ore anti
rizat
ore anti
s B sur
auth
s B sur
This document cannot be used to support any market
patitis 
eting
patitis 
acti
mar
acti
P
n
P
BLQ
nt ca
BLQ


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 8 of 128
CP
confirmed positive
CRF
case report form
CRO
contract research organization
CSF
cerebrospinal fluid
CSR
Clinical Study Report
CT
computed tomography
CTCAE
Common Terminology Criteria for Adverse Events
CV
coefficient of variation
DEM
data evaluation meeting
DMC
Data Monitoring Committee
DNA
deoxyribonucleic acid
ECG
electrocardiogram
ES
Enrolled Set
EudraCT
European Union Drug Regulating Authorities 
Clinical Trials
EOS
end of study
EW
early withdrawal
FAS
Full Analysis Set
FDA
Food and Drug Administration
FSH
follicle stimulating hormone
geoCV
geometric coefficient of variation
geoMean
geometric mean
GGT
gamma glutamyltransferase
GM-CSF
granulocyte-macrophage colony-stimulating factor
REDACTED COPY
c aci
PY 
c aci
iogram
D CO
iogram
ed Se
CTE
ed Se
Europ
RED
Europ
Cli
R
Cli
cannot be used to support any marketing authorization application and any extensions or variations thereof.
Event
tens
Event
e
a
e
a
m
ti
m
et
h
et
pean Un
g au
pean Un
nical T
ting
nical T
This document ca
end 
mar
end 
CV
not
CV
geoM
t ca
geoM


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 9 of 128
H0
null hypothesis
H1
alternative hypothesis
HA
high abundance
HbA1c
glycosylated hemoglobin
HBsAg
hepatitis B surface antigen
HCG
human chorionic gonadotropin
HIV
human immunodeficiency virus
HLT
high level term
hsCRP
high sensitivity C-reactive protein
ICAM-1
intercellular adhesion molecule-1
ICH
International Council for Harmonisation (formerly 
referred to as International Conference on 
Harmonisation)
IFN
interferon
Ig
immunoglobulin
IL
interleukin
INR
international normalized ratio
ITP
primary immune thrombocytopenia
ITP-BAT
ITP-specific Bleeding Assessment Tool
IVIg
intravenous immunoglobulin
IXRS
interactive voice/web response system
LDH
lactate dehydrogenase
LLOQ
lower limit of quantification
LP
lumbar puncture
MCP
monocyte chemotactic protein
REDACTED COPY
uncil
PY 
uncil
Intern
COP
Intern
ation)
D CO
ation)
eron
ACTE
eron
immu
RED
immu
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
n
a
n
cule
atio
cule-
o
-1
n
1
for Har
appli
for Har
nationa
n ap
nationa
unoglob
ng au
unoglob
interle
rket
interle
in
m
in
DH
ann
DH
LL
nt
LL


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 10 of 128
MDC
macrophage-derived chemokine
MedDRA
Medical Dictionary for Regulatory Activities
MIP
macrophage inflammatory protein
MRI
magnetic resonance imaging
n
number of subjects
NCP
not confirmed positive
NFI-MS
Neurological Fatigue Index for Multiple Sclerosis
OD
optical density
PCS
potentially clinically significant
PD
pharmacodynamic
PDILI
potential drug-induced liver injury
PD-PPS
Pharmacodynamic Per Protocol Set
PK
pharmacokinetic
PK-PPS
Pharmacokinetic Per Protocol Set
PPS
Per Protocol Set
PT
preferred term
QWK
every week 
QTcF
QT corrected for heart rate using Fridericia’s 
formula
RBC
red blood cells
RMU
relative mass units
RNA
ribonucleic acid
SAP
Statistical Analysis Plan
sc
subcutaneous
REDACTED COPY
nduce
PY 
nduce
dynam
D CO
dynam
macoki
CTE
macoki
Pharm
RED
Pharm
cannot be used to support any marketing authorization application and any extensions or variations thereof.
lerosis
tens
lerosis
d liver 
appli
d liver 
mic Per 
tion
mic Per 
inetic
horiz
inetic
macokin
g au
macokin
Per Pro
ket
Per Pro
This document ca
pr
m
pr
U
o
U
RNA
t ca
RNA


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 11 of 128
SD
standard deviation
SMOG
Skin (S), visible mucosae (M) and organs (O), with 
gradation of severity
SOC
system organ class
SS
Safety Set
TARC
thymus and activation-related chemokine
TB
tuberculosis
TEAE
treatment-emergent adverse event
TEMA
treatment-emergent markedly abnormal
TFLs
tables, figures and listings
TGFβ
transforming growth factor beta
TNF
tumor necrosis factor
TPO-R
thrombopoietin-receptor
ULN
upper limit of normal
VEGF
vascular endothelial growth factor
WBC
white blood cell
WHODD
World Health Organization Drug Dictionary
ACTED COPY 
Y
s fact
COP
s fact
opoieti
TED 
opoieti
RED
per lim
DAC
per lim
v
R
vas
R
as
ng authorization application and any extensions or variations thereof.
rmal
d an
rmal
tor beta
plica
tor beta
or
n
or
in
riz
in-
z
-rece
zat
rece
This document cannot be used to support any marketi
mit
aut
mit of n
uth
of n
scular e
eting
scular e
whit
mar
whit


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 12 of 128
1
INTRODUCTION
The purpose of this statistical analysis plan (SAP) amendment is to provide all information that 
is necessary to perform the required final statistical analysis of study TP0001. It also defines the 
summary tables, figures and listings (TFLs) to be included in the final clinical study report 
(CSR) according to the protocol.
This SAP is based upon, and assumes familiarity, with the following documents:

Final Protocol: 09 November 2015

Protocol Amendment 0.1 (Moldova): 18 November 2015

Protocol Amendment 0.2 (Germany): 12 January 2016

Protocol Amendment 0.3 (Poland): 23 May 2016

Protocol Amendment 0.4 (Romania): 11 August 2016

Protocol Amendment 1.0 (Global): 19 May 2016

Protocol Amendment 1.1 (Moldova): 23 May 2016

Protocol Amendment 1.3 (Poland): 09 June 2016

Protocol Amendment 2.0 (Global; not implemented): 21 October 2016

Protocol Amendment 3.0 (Global): 15 February 2017

Protocol Amendment 3.1 (Moldova): 08 March 2017

Protocol Amendment 3.3 (Poland): 07 March 2017

Protocol Amendment 3.4 (Romania): 10 March 2017

Protocol Amendment 3.5 (Georgia and Bulgaria): 23 August 2017

Protocol Amendment 3.6 (Moldova): 07 September 2017
Unless specified below, the study will be analyzed as described in the most recent version of the 
protocol (European Union Drug Regulating Authorities Clinical Trials [EudraCT]-Number: 
2015-003984-12).
If a future protocol amendment necessitates a substantial change to the statistical analysis of the 
study data, this SAP amendment will be updated accordingly. In addition, if analysis definitions 
have to be modified or updated prior to database lock, a further SAP amendment will be 
required.
This SAP amendment 3 is due to various updates and clarifications of the analysis definitions 
suggested prior to and during the Data Evaluation Meeting 3 part 1 in December 2018.
If, after database lock, additional analyses are required to supplement the planned analyses 
described in this SAP, these changes will be described in the CSR together with the associated 
rationale. The content of this SAP is compatible with the International Council for 
Harmonisation (ICH)/Food and Drug Administration (FDA) E9 Guidance documents.
UCB is the Sponsor and PAREXEL is the Contract Research Organization (CRO) for this study.
REDACTED COPY
ted
OPY
ted): 2
PY 
): 2
ary 20
D CO
ary 20
Marc
CTED
Marc
07 Ma
DAC
07 Ma
nia): 
RE
nia): 
used to support any marketing authorization application and any extensions or variations thereof.
21 Octo
app
21 Octo
t
17
tio
17
ch 2017
oriza
ch 2017
arch 20
auth
arch 20
10 Ma
ting 
10 Ma
ia and 
arke
ia and 
Moldova
y m
Moldova
study w
rt an
study w
n Drug
port
n Drug
l amen
d to s
l amen
SAP
sed
SAP a
This document cannot be 
modified
e us
modified
SAP am
nno
SAP am
ggested
t can
ggested
If, af
men
If, af
de
m
de


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 13 of 128
2
PROTOCOL SUMMARY
2.1
Study objectives
2.1.1
Primary objective
The primary objective of this study is:

To evaluate the safety and tolerability of UCB7665 administered by subcutaneous (sc) 
infusion in subjects with primary immune thrombocytopenia (ITP)
2.1.2
Secondary objectives
The secondary objectives of this study are:

To assess the clinical efficacy of UCB7665 as measured by the change in platelet count

To assess the pharmacodynamic (PD) effect of UCB7665 as measured by the change in total 
immunoglobulin (Ig) G (IgG) concentration in serum
2.1.3
Exploratory objectives
The exploratory objectives of this study are:


To evaluate the clinical efficacy as measured by the change in ITP bleeding score

To evaluate the effect of UCB7665 on the concentrations of total protein, albumin, 
α-globulin and β-globulin, IgG subclasses, IgM, IgA, IgE and serum and plasma complement 
levels

To evaluate the emergence of anti-drug antibody (ADA) with respect to immunogenicity and 
pharmacokinetics (PK)/ pharmacodynamic (PD)

To evaluate the relationship between changes in platelet count and total IgG, IgG subclasses, 
ITP-specific autoantibodies

To assess the plasma concentrations of UCB7665 administered by sc infusion

To evaluate the genomic components of ITP to understand the molecular etiology, 
progression, and treatment of the disease, applicable only for subjects consenting to 
participate in the optional genomic analyses substudy

REDACTED COPY 
by the
CO
by the
e conc
TED
e conc
sses, I
ACT
sses, I
i
R
i-
R
-dr
R
dr
Y
cation and any extensions or variations thereof.
elet cou
ensi
elet cou
the ch
y ext
the ch
d to support any marketing authorization appli
e chang
tion 
e chang
cen
riz
centrat
za
trat
IgM, Ig
thor
IgM, Ig
rug ant
eting
rug ant
odyna
rket
odynam
t
m
betwee
y ma
betwee
es
a
es
concen
port
concen
enomic
sup
enomic
nd treat
d to s
nd treat
This document cannot be use
n the o
sed 
n the o
plica
be u
ot b
anno


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 14 of 128
2.2
Study variables
2.2.1
Safety variables
2.2.1.1
Primary safety variable
The primary safety variable is:

Occurrence of treatment-emergent adverse events (TEAEs)
2.2.1.2
Other safety variables
The other safety variables are:

Vital sign values and change from Baseline (systolic and diastolic blood pressure,
temperature, pulse rate respiratory rate and body weight) to each visit in the Dosing Period
and in the Observation Period up to Day 85 in Dose Arm 1 (4mg/kg once weekly [QWK]),
up to Day 71 in Dose Arm 2 (7mg/kg QWK), up to Day 64 in Dose Arm 3 (10mg/kg QWK)
and up to Day 57 in Dose Arms 4 (15mg/kg) and 5 (20mg/kg). Body weight is measured only
at Screening and at the corresponding EOS/EW visit as outlined in the protocol

12-lead electrocardiogram (ECG) parameters and change from Baseline to each dosing visit
in the Dosing Period and to the second and the last visit in the Observation Period as outlined
in the protocol

Laboratory values and change from Baseline (hematology including coagulation parameters,
clinical chemistry, and urinalysis) to each visit in the Dosing Period and in the Observation
Period up to the corresponding EOS/EW visit as outlined in the protocol

Values and change from Baseline in concentrations of total protein, albumin, α-globulin, and
β-globulin to each visit in the Dosing Period and in the Observation Period up to the
corresponding EOS/EW visit as outlined in the protocol

TEAEs leading to withdrawal of UCB7665

Change from Baseline in serum biomarkers
 to each visit in the Dosing Period and up to the last visit prior to the 
corresponding EOS visit as outlined in the protocol
2.2.2
Efficacy variables
The efficacy variables are as follows where all variables relating to platelets refer to those 
measured by ACM Global Central Laboratory:

Response during the study: platelet count ≥30x109/L and at least 2-fold increase from the
Baseline count

Complete Response during the study: platelet count ≥100x109/L

Platelet count ≥50x109/L during the study

Response by visit

Complete Response by visit

Platelet count ≥50x109/L by visit
REDACTED COPY 
hemato
COP
hemato
isit in 
D C
isit in 
visit a
TED
visit a
conce
DAC
conce
sing Pe
RED
sing Pe
outli
R
outli
any marketing authorization application and any extensions or variations thereof.
,
i
,
osing P
ensio
osing P
weekly [
xten
weekly [
3 (
y e
3 (10
ex
10
x
weight
d any
weight
the pro
and a
the pro
m Baseli
tion a
m Baseli
he Obs
catio
he Obs
tology i
on ap
tology i
the Do
ation
the Do
as outl
riza
as outl
entratio
utho
entratio
eriod a
g au
eriod a
lined in
eting
lined in
f 
m
f UCB7
arke
UCB7
rum bi
ny m
rum bi
used to support 
h visit i
port
h visit i
S visit a
supp
S visit a
icacy 
d to s
icacy 
ariable
used
ariable
This document cannot be
y ACM
be u
y ACM
sponse 
not 
sponse 
Baselin
ann
Baselin

Co
nt c
Co

m

rt an


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 15 of 128

The maximum value and maximum increase from Baseline in platelet count during the study

Value and change from Baseline in platelet count over time

Baseline-corrected area under the effect curve (AUEC) for platelet count calculated from 
Baseline to the end of study visit (Day 85 in the Observation Period in Dose Arm 1, Day 71 
in the Observation Period in Dose Arm 2, Day 64 in the Observation Period in Dose Arm 3
and Day 57 in Observation Period in Dose Arms 4 and 5)

Time to Response: time from starting treatment to achievement of Response

Time to Complete Response: time from starting treatment to achievement of Complete 
Response

Time to achieving platelet count ≥50x109/L

Duration of Response: measured from achievement of Response to loss of Response (loss of 
Response defined as platelet count <30x109/L or less than 2-fold increase of Baseline platelet 
count)

Duration of Complete Response: measured from achievement of Complete Response to loss 
of Complete Response (loss of Complete Response defined as platelet count <100x109/L)

Duration of platelet count ≥50x109/L: measured from achievement of platelet count 
≥50x109/L to reduction of platelet count <50x109/L

Clinical Response: confirmation of platelet count ≥30x109/L and at least 2-fold increase from 
the Baseline value and absence of bleeding

Time to Clinical Response: time from starting treatment to achievement of Clinical Response

Duration of Clinical Response: measured from achievement of Clinical Response to loss of 
Clinical Response (loss of Clinical Response defined as platelet count <30x109/L or less than 
2-fold increase from Baseline platelet count or presence of bleeding)

Complete Clinical Response: confirmation of platelet count ≥100x109/L and absence of 
bleeding

Time to Complete Clinical Response: time from starting treatment to achievement of 
Complete Clinical Response

Duration of Complete Clinical Response: measured from achievement of Complete Clinical 
Response to loss of Complete Clinical Response (loss of Complete Clinical Response defined 
as platelet count <100x109/L or presence of bleeding)

No Clinical Response: confirmation of platelet count <30x109/L and less than 2-fold increase 
from Baseline or presence of bleeding

Assessment of ITP bleeding score over time at Baseline and at each dosing visit in the 
Dosing Period and to Day 36, Day 50, Day 64 and Day 85 in the Observation Period in Dose 
Arm 1, to Day 22, Day 36, Day 50 and Day 71 in the Observation Period in Dose Arm 2, to 
Day 15, Day 29, Day 43 and Day 64 in the Observation Period in Dose Arm 3 and to Day 8, 
Day 22, Day 36 and Day 57 in the Observation Period in Dose Arms 4 and 5
REDACTED COPY
om a
PY 
om a
0
O
09
O
9/L
OPY
/L
count
ED C
count
ing
CTE
ing
m star
EDAC
m star
measu
RE
measu
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
te
o
te
f Resp
y ex
f Resp
ase of 
any 
ase of 
of Com
on a
of Com
as plate
catio
as plate
chievem
pplic
chievem
t ≥30x
zatio
t ≥30x
rting tr
auth
rting tr
ured fro
ting 
ured fro
l Respo
rketi
l Respo
platelet 
mark
platelet 
se: 
an
se: conf
ny 
conf
Clinical
uppo
Clinical
al Resp
o sup
al Resp
Compl
ed t
Compl
to loss
use
to loss
elet cou
be u
elet cou
o Clinic
nnot
o Clinic
from B
can
from B

e

A
nt
A


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 16 of 128

Value and change from Baseline in Neurological Fatigue Index for Multiple Sclerosis 
(NFI-MS) summary score to Day 36, Day 50, Day 64 and Day 85 in the Observation Period 
in Dose Arm 1, to Day 22, Day 36, Day 50 and Day 71 in the Observation Period in Dose 
Arm 2, to Day 15, Day 29, Day 43 and Day 64 in the Observation Period in Dose Arm 3 and 
to Day 8, Day 22, Day 36 and Day 57 in the Observation Period in Dose Arm 4 and 5
2.2.3
Pharmacokinetic and pharmacodynamic variables
2.2.3.1
Pharmacokinetic variable
The PK variable is:

Plasma concentration of UCB7665 over time, at each visit during the Dosing Period and 3 
and 7 days following the last dose of UCB7665 in each dose arm

Additional blood samples for the optional PK/PD substudy (early blood sampling) will be 
drawn at Visit 2 (predose and 4 hours after end of infusion on Day 1), Visit 2a (24 and 36 
[optional] hours after the start of Day 1 UCB7665 infusion) and Visit 2b (48 hours after the 
start of Day 1 UCB7665 infusion).
2.2.3.2
Pharmacodynamic variables
The PD variables are:

Minimum value and maximum decrease from Baseline in total IgG concentration (absolute 
and percentage) measured by ACM Global Central Laboratory

Value and change from Baseline (absolute and percentage) in total IgG concentrations
(measured by ACM Global Central Laboratory) to each visit in the Dosing Period and in the 
Observation Period up to Day 85 in Dose Arm 1, up to Day 71 in Dose Arm 2, up to Day 64 
in Dose Arm 3 and up to Day 57 in Dose Arms 4 and 5

ITP-specific autoantibodies in serum
over time, 
measured at Day 1, Day 36 and Day 85 in Dose Arm 1, at Day 1, Day 22 and Day 71 in Dose 
Arm 2, at Day 1, Day 15, and Day 64 in Dose Arm 3 and at Day 1, Day 8 and Day 57 in 
Dose Arms 4 and 5

Change from Baseline in IgG subclass concentrations (measured by ACM Global Central 
Laboratory) to each visit in the Dosing Period and in the Observation Period up to Day 85 in 
Dose Arm 1 and up to Day 71 in Dose Arm 2, up to Day 64 in Dose Arm 3 and up to Day 57 
in Dose Arms 4 and 5
2.2.4
Other immunological variables
Other immunological variables are:

Change from Baseline in serum immunoglobulin concentrations (total IgA, IgE, and IgM) to 
the last visit in the Dosing Period and to Day 36 and Day 71 in the Observation Period in 
Dose Arm 1, to Day 22 and Day 57 in the Observation Period in Dose Arm 2, to Day 15 and
Day 50 in the Observation Period in Dose Arm 3 and to Day 8 and Day 43 in the Observation 
Period in Dose Arms 4 and 5

Change from Baseline in serum (C3 and C4) and plasma (C3a and C5a) complement levels 
to Day 15 (Dosing Period) and to Day 32 and Day 57 in the Observation Period in Dose 
REDACTED COPY 
aseline
OPY
aseline
entral 
CO
entral 
te and 
TED
te and 
aborato
ACT
aborato
E
Dose
EDA
Dose
in Do
RE
in Do
t be used to support any marketing authorization application and any extensions or variations thereof.
od and 
ons o
od and 
mpling)
exte
mpling)
isit 2a 
ny ex
isit 2a 
t 2b (48
d any
t 2b (48
ne in tot
app
ne in tot
l Labor
tion 
l Labor
d percen
riza
d percen
tory
tho
tory)
hor
) t
or
to
r
o
e Arm 
auth
e Arm 
ose Arm
ing a
ose Arm
um
rke
um
d Day 8
mar
d Day 8
nd 
ny
nd Day
ny m
Day
ne in Ig
ppo
ne in Ig
ch visit
sup
ch visit
nd up to
d to s
nd up to
ms 4 an
sed 
ms 4 an
This document canno
Ot
e u
Ot
mmuno
not 
mmuno
Chang
t can
Chang
the
nt c
the
ket


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 17 of 128
Arm 1, to Day 15 (Dosing Period) and to Day 18 and Day 43 in the Observation Period in 
Dose Arm 2, to Day 11 and Day 36 in Observation Period in Dose Arm 3 and to Day 4 and 
Day 29 in Observation Period in Dose Arms 4 and 5

Change from Baseline in exploratory biomarkers relating to mechanism of action, disease 
activity, treatment response, and clinical outcome

Value and change from Baseline in ADA relative mass units (RMU) to each visit in the 
Dosing Period and to Day 32, Day 36, Day 43, Day 57, Day 71 and Day 85 in the 
Observation Period in Dose Arm 1, and to Day 18, Day 22, Day 29, Day 43, Day 57 and 
Day 71 in the Observation Period in Dose Arm 2, to Day 11, Day 15, Day 22, Day 36, Day 
50 and Day 64 in Dose Arm 3 and to Day 4, Day 8, Day 15, Day 29, Day 43 and Day 57 in 
Dose Arms 4 and 5

Anti-drug antibody screening status (positive/negative) at each of the visits described above. 
For ADA screening positive results the confirmatory ADA result will be reported as either 
confirmed positive (CP) or not confirmed positive (NCP).

Change from Baseline in cytokines over time. Cytokines will be measured at all visits in all
dose arms for subjects who experience infusion reactions only. Further description of the 
cytokines variables can be found in Appendix 13.4. Additional exploratory biomarkers may 
be investigated if needed using the samples already available.

Change from Baseline in serum B cell activating factor (BAFF) levels to each dosing visit in 
the Dosing Period and to Day 43 and Day 71 in the Observation Period in Dose Arm 1, to 
Day 29 and Day 57 in the Observation Period in Dose Arm 2, to Day 22 and Day 50 in the 
Observation Period in Dose Arm 3 and to Day 15 and Day 43 in the Observation Period in 
Dose Arms 4 and 5

Change from Baseline in B- and T-lymphocyte concentrations to each visit in the Dosing 
Period and in the Observation Period up to Day 85 in Dose Arm 1, up to Day 71 in Dose 
Arm 2, up to Day 64 in Dose Arm 3 and up to Day 57 in Dose Arms 4 and 5
2.3
Study design and conduct
This is a Phase 2, multicenter, open-label, multiple-dose, multiple-arm study to evaluate the 
safety, tolerability, and efficacy of UCB7665 in subjects with primary persistent or chronic ITP. 
The 5 dose arms will be as follows:

Dose Arm 1 (15 subjects): UCB7665 4mg/kg sc (5 doses at an interval of 1 week)

Dose Arm 2 (15 subjects): UCB7665 7mg/kg sc (3 doses at an interval of 1 week)

Dose Arm 3 (6 to 12 subjects): UCB7665 10mg/kg sc (2 doses at intervals of 1 week)

Dose Arm 4 (6 to 12 subjects): UCB7665 15mg/kg sc (1 dose)

Dose Arm 5 (6 to 12 subjects): UCB7665 20mg/kg sc (1 dose)
The maximum duration of the study per subject is approximately 16 weeks, consisting of a 
Screening Period (1 to 28 days), a Dosing Period of 1 to 4 weeks, and an Observation Period of 8 
weeks.
REDACTED COPY
y av
PY 
y av
ing
CO
ing fac
COP
fac
71 in t
ED C
71 in t
Period 
CTE
Period 
d 
DA
d to D
ACT
to D
l
R
l
ed to support any marketing authorization application and any extensions or variations thereof.
d 
r
d 
6, Day 
s or 
6, Day 
Day 57
ons 
Day 57
descri
exte
descri
e repor
ny e
e repor
measu
n an
measu
y
t
y.
t
. Furth
tion
Furth
onal ex
licat
onal ex
ilable.
pplic
ilable.
ctor (B
ion a
ctor (B
the Obs
zatio
the Obs
d in
ori
d in Do
riza
Do
Day 15
utho
Day 15
lympho
keting
lympho
eriod up
arke
eriod up
Arm
y ma
Arm 3
a
3
gn an
t any
gn an
enter, o
ppor
enter, o
d effica
supp
d effica
ll be a
to s
ll be a
This document cannot be used
1 (15 s
used
(15 s
Arm 2
be 
Arm 2 (
ose Arm
nnot
ose Arm
Dose
nt ca
Dose

me

D
n
D


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 18 of 128
A data monitoring committee (DMC) will monitor emergent safety data during the study. The 
first 6 subjects in the study will receive UCB7665 4mg/kg. These subjects in Dose Arm 1 will 
not be randomized. While recruitment is still ongoing safety data for the first 3 subjects up to 7 
days after the final dose of the third subject in Dose Arm 1 will be reviewed by the DMC. 
During a second DMC meeting, all available safety data up to the cut off date defined as 7 days 
after the final dose of the sixth subject in Dose Arm 1 will be reviewed. During these reviews 
recruitment in the dose arm will not be stopped. Following this review, the DMC will make a 
decision on whether to open Dose Arm 2 for enrollment. Once the DMC has advocated the 
initiation of Dose Arm 2, the subsequent subjects will be randomly assigned in 1:1 ratio to either 
Dose Arm 1 or Dose Arm 2 using an interactive voice/web response system (IXRS). Once 15 
subjects are enrolled in Dose Arm 1, the remaining subjects will enrolled in Dose Arm 2.
After the safety data review of at least 6 subjects in Dose Arm 2 is done, the DMC will make a 
recommendation on whether to open Dose Arm 3 for enrollment. Once the DMC has advocated 
the initiation of Dose Arm 3 and the enrollment of 15 subjects in Dose Arm 2 has been 
completed, the subsequent subjects will be assigned to Dose Arm 3 only. After every third 
subject has been enrolled, the DMC will review all available safety data up to cut off date 
defined as 7 days after the dosing. Depending on the emerging safety data of 6 subjects in Dose 
Arm 3, the DMC will recommend whether to open Dose Arm 4 for enrollment or to include 
additional subjects in Dose Arm 3. A maximum of 12 subjects may be enrolled in Dose Arm 3.
Once the DMC has advocated the initiation of Dose Arm 4, the enrollment of Dose Arm 3 will 
be closed and all subsequent subjects will be assigned to Dose Arm 4. After every third subject is 
enrolled, the DMC will review all available safety data up to the cutoff date defined as 7 days 
after the dosing. Depending on the emerging safety data of 6 subjects in Dose Arm 4, the DMC 
will recommend to include additional subjects in Dose Arm 4 or not. A maximum of 12 subjects 
may be enrolled in Dose Arm 4. The DMC will recommend to open Dose Arm 5 for enrollment 
in a subsequent meeting, if applicable. 
Once the DMC has advocated the initiation of Dose Arm 5, the enrollment of Dose Arm 4 will 
be closed and all subsequent subjects will be assigned to Dose Arm 5. After every third subject is 
enrolled, the DMC will review all available safety data up to the cutoff date defined as 7 days 
after the dosing. Depending on the emerging safety data of 6 subjects in Dose Arm 5, the DMC 
will recommend to include additional subjects in Dose Arm 5. A maximum of 12 subjects may 
be enrolled in Dose Arm 5.
At least 11 interim analyses will be performed. Based on the interim analyses the DMC will 
assess the safety of UCB7665, determine whether to initiate subsequent dose arms and may 
decide to adapt the dose regimen. The analyses and TFLs required for the interim analyses are 
described in a separate interim SAP.
During this study, subjects will also have the option of providing additional informed consent for 
exploratory deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) analyses. Participation in 
this additional portion of the study is optional and does not preclude subject’s eligibility for 
participation in the main study. The additional genomic samples must not be collected if the 
subject has not consented to participate in this exploratory genomic substudy. Any results from 
this analysis will be reported separately and will not form a part of the main CSR. Thus, these 
analyses are not described further in this SAP.
REDACTED COPY
subj
PY 
subj
se Arm
COP
se Arm
ssigned
ED C
ssigned
safety
CTED
safety
ging sa
DACT
ging sa
subjec
REDA
subjec
DM
RE
DM
d to support any marketing authorization application and any extensions or variations thereof.
o either
or va
o either
nce 1
s o
nce 15
o
5
m 2.
ion
m 2.
MC will
xten
MC will
MC ha
ext
MC ha
m 2 has
any 
m 2 has
y. Afte
nd a
y. Afte
data up
n an
data up
fety da
tion 
fety da
4 for en
licati
4 for en
cts ma
pplic
cts ma
m 4, th
on a
m 4, th
ed to Do
atio
ed to Do
y data u
oriza
y data u
afety da
utho
afety da
cts in D
g aut
cts in D
MC will
ting 
MC will
r
initiati
ma
initiati
ubjects 
any m
ubjects 
ew all 
rt an
ew all 
ing on 
ppor
ing on 
clude a
supp
clude a
Arm 5
to s
Arm 5
This document cannot be use
erim an
sed
erim an
afety of
be us
afety of
adapt 
ot be
adapt 
bed in 
nnot
bed in 
uring th
t ca
uring th
explor
ment 
explor
thi
me
thi


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 19 of 128
During this study, subjects from Bulgaria, Georgia and Moldova who are enrolled in Dose Arm 
3, 4 or 5, will also have the option of providing additional informed consent for a PK/PD 
substudy (early blood sampling) at selected study sites. Participation in this additional portion of 
the study is optional and does not preclude subject’s eligibility for participation in the main 
study. The additional PK/PD blood samples must not be collected if the subject has not 
consented to participate in this exploratory substudy.
2.4
Determination of sample size
The sample size of 15 subjects in Dose Arms 1 and 2, is mainly based on the efficacy objective 
of the study. In addition, the inclusion of 15 subjects in Dose Arms 1 and 2 will ensure that 
sufficient data are available to form conclusions about the safety of administering UCB7665.
Based on the safety data from Dose Arms 1 and 2, the sample size of 6 to 12 subjects in Dose 
Arms 3, 4 and 5 were judged to be sufficient in order to explore subjects’ safety and IgG 
reductions under different dose regimens and is not based on a formal sample size calculation
For Dose Arms 1 and 2 an approximate sample size calculation for the efficacy variable 
“maximum increase from Baseline in platelet count” shows that 15 subjects would be sufficient 
to show a change from Baseline with 1-sided testing at 5% and power of 80%. The anticipated 
change is based on an assumed Baseline average of 25x109/L and a clinically meaningful 
maximum value of 100x109/L. The calculation made use of platelet count data presented in a 
publication by Robak (Robak et al, 2009), but it is approximate as maximum changes from 
Baseline for individual subjects were not available, necessitating the use of the maximum 
average platelet count instead. The standard deviation (SD) is taken from visual inspection.
With 15 subjects, the responder endpoints will confirm a true 50% response rate, in excess of the 
maximum 15% anticipated with no treatment benefit, with power in excess of 80%.
3
DATA ANALYSIS CONSIDERATIONS
3.1
General presentation of summaries and analyses
Statistical evaluation will be performed by PAREXEL. The datasets will follow the UCB 
analysis data model (ADaM) specifications.
All analyses will be performed using SAS version 9.3 or higher (SAS Institute, Cary, North 
Carolina, United States of America). Continuous variables will be summarized by visit (where 
applicable) including number of subjects (n), arithmetic mean, SD, median, minimum and
maximum. Categorical variables will be summarized by visit (where applicable) with frequency 
counts and percentages with 95% confidence intervals (CI) where stated. Geometric coefficient 
of variation (geoCV), geometric mean (geoMean) and 95% CI for the geoMean will also be 
presented in the descriptive statistics for the PK concentration data. 
When reporting relative frequencies or other percentage values, the following rules apply:

For values where all subjects fulfill certain criteria, the percentage value will be displayed as 
100

For values where the absolute frequency is zero, there will be no percentage displayed at all

All other percentage displays will use 1 decimal place
REDACTED COPY
se 
Y
se 
pproxi
OPY 
pproxi
e, nec
CO
e, nec
eviatio
ED C
eviatio
will c
ACT
will c
tment
EDAC
tment
S C
RE
S C
d to support any marketing authorization application and any extensions or variations thereof.
tive
va
tive
hat 
o
hat 
B7665
ons 
B7665
cts in D
nsio
cts in D
y and Ig
xten
y and Ig
e size
y ex
e size
fficacy
d an
fficacy
ubjects 
and
ubjects 
wer of 
ion a
wer of 
nd a cli
catio
nd a cli
platelet
plica
platelet
imate a
app
imate a
cessitat
ion a
cessitat
on (
zati
on (SD
atio
SD
confirm
thori
confirm
t benef
auth
t benef
CONS
ting 
CONS
ation 
arke
ation 
rformed
ny m
rformed
 specif
t any
 specif
ormed 
ppor
ormed 
es of A
supp
es of A
ng num
d to s
ng num
This document cannot be use
gorical
sed t
gorical
ercenta
e use
ercenta
on (
t be
on (geo
be
geo
ted in th
not 
ted in th
hen rep
can
hen rep

e

F
nt
F


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 20 of 128
Percentages displayed based on continuous data (eg, percentage changes from baseline) will be 
displayed to 1 decimal place.
When reporting descriptive statistics, the following rules will apply in general:

n will be an integer

Mean (arithmetic and geometric), SD and median will use 1 decimal place more than the 
original data

Minimum and maximum will be reported using the same number of decimal places as the 
original value

If no subjects have data at a given timepoint, for example, then only n=0 will be presented. If 
n<3, present the n, minimum and maximum only. If n=3, present the n, mean, median, 
minimum and maximum only. The other descriptive statistics will be left blank.
When reporting descriptive statistics for PK data, the following rules will apply with regard to 
rounding and precision:

Individual values for PK concentration data will be reported to the same level of precision as 
received from the bioanalytical laboratory

Descriptive statistics for PK concentration data will be reported to the same level of precision 
as the individual data for the minimum and maximum, and to 1 additional significant figure 
for the mean (arithmetic and geometric), median, SD and 95% CI for the geoMean

Geometric CV will be reported as a percentage to 1 decimal place
All statistical tests will be carried out 1-tailed at the 5% level of significance unless otherwise 
stated. P-values will be presented to 4 decimal places; p-values less than 0.0001 will be 
presented as “<0.0001” and p-values greater than 0.9999 will be presented as “>0.9999”. All 
statistical output will be presented in statistical appendices where appropriate.
Analyses will be performed by dose arm for all efficacy, immunological, PK, PD and safety data, 
with the exception of adverse event (AE) data which will be presented by dose arm and overall
(Section 13.6). 
In the event that the number of planned infusions in the dose arms are modified following review 
by the DMC, the data will be summarized based on the actual dose arms completing the study. 
For example, if the 5x4 mg/kg QWK dose arm is modified such that some subjects receive only 
4 infusions, then the data will be summarized separately for this new dose regimen.
In the TFLs the dose arms will be displayed as follows where applicable:

UCB7665 5x4mg/kg

UCB7665 3x7mg/kg

UCB7665 2x10mg/kg

UCB7665 1x15mg/kg

UCB7665 1x20mg/kg
REDACTED COPY
ll be
PY 
ll be
ximum
OPY
ximum
dian, S
D CO
dian, S
entage
CTED
entage
tailed 
DAC
tailed 
4 decim
RED
4 decim
gre
R
gre
keting authorization application and any extensions or variations thereof.
he 
v
he 
presen
sions
presen
media
ensi
media
lank.
exte
lank.
apply w
any 
apply w
the sam
on a
the sam
eported
pplic
eported
m, and t
n app
m, and t
SD and
tion 
SD and
e to 1 d
oriza
e to 1 d
at the 
autho
at the 
mal pla
g au
mal pla
eater th
eting
eater th
be used to support any mark
statisti
arket
statisti
ose arm
y ma
ose arm
event (
any
event (
umber o
upp
umber o
ta will 
to su
ta will 
he 5x4 
ed to
he 5x4 
hen the 
used
hen the 
This document cannot b
Ls the d
t be 
Ls the d
CB766
nno
CB766
UCB
nt ca
UCB

me



UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 21 of 128
If additional dose arms are initiated during the study these will be displayed similarly. For 
example, if the 5x4 mg/kg QWK dose arm is modified such that some subjects receive only 4 
infusions this dose arm will be displayed as UCB7665 4x4mg/kg QWK in the TFLs.
Data listings containing all documented data and all derived data will be generated.
3.2
General study level definitions
3.2.1
Analysis timepoints
3.2.1.1
Relative day
Relative day for an event will be derived with the date of the first infusion of UCB7665 as 
reference.
Relative days for an event of measurement occurring before the date of first infusion are 
calculated as follows:
Relative Day = [(Event Date – Date of First Infusion)]
The relative day for an event or measurement occurring on or after the reference date to the date 
of the last infusion is calculated as follows:
Relative Day = [(Event Date - Date of First Infusion) + 1]
For events or measurements occurring after the date of the last infusion, relative day will be 
prefixed with ‘+’ in the data listings and will be calculated as follows:
Relative Day = + [(Event Date – Date of Last Infusion)]
There is no relative Day 0. Relative day is not calculated for partial dates in cases where relative 
day is shown in a subject data listing. In such cases, relative day should be presented as ‘-‘ in the 
subject data listings.
3.2.1.2
Study periods
For each subject the duration of the study is approximately 16 weeks.

Screening Period: 1 to 28 days

Dosing Period: 1 to 4 weeks; during the Dosing Period subjects will receive weekly doses of 
UCB7665 (5 doses of 4mg/kg [QWK] in Dose Arm 1, 3 doses of 7mg/kg [QWK] in Dose
Arm 2, 2 doses of 10mg/kg [QWK] in Dose Arm 3, 1 dose of 15mg/kg in Dose Arm 4 and 1 
dose of 20mg/kg in Dose Arm 5). The dose regimen may be adapted following review by the 
DMC

Observation Period: 8 weeks; a visit will be scheduled 3 days after the final dose (or only 
dose administration for Dose Arms 4 and 5) and weekly thereafter to collect safety and 
efficacy data
The end of the study is defined as the date of the last visit of the last subject in the study.
3.3
Definition of Baseline values
Baseline will be the last available predose value prior to the first infusion of UCB7665, or if
missing, the latest non missing value prior to Baseline (screening value or unscheduled visit 
value). 
REDACTED COPY
of the
OPY 
of the
alculat
COP
alculat
Last 
ED
Last In
D 
In
s not c
ACT
s not c
In such
EDA
In such
d to support any marketing authorization application and any extensions or variations thereof.
as 
s
as 
sion ar
tens
sion ar
e refere
and
e refere
e last in
app
e last in
ated as 
on a
ated as 
nfusion
izat
nfusion
calcula
thor
calcula
h cases
aut
h cases
the stud
y ma
the stud
8 days
rt any
8 days
4 week
ppo
4 week
es of 4m
sup
es of 4m
of 
to
of 
ent cannot be use
10
o s
10
s
mg/kg in
sed 
mg/kg in
ervation
ot b
ervation
ose adm
anno
ose adm
effica
t can
effica
This documen
The e
men
The e
3


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 22 of 128
Measurement-specific Baseline timepoints (based on the scheduled or unscheduled 
measurements) are presented in Table 3‒1.
Table 3‒1:
Definition of Baseline
Measurement
Definition of Baseline
Safety data:

Clinical chemistry (including proteins)

Hematology (including platelets measured 
locally)

Coagulation

Urinalysis

Vital signs

12-lead ECG

Serum safety biomarkers 

Predose Day 1 or if missing the latest non
missing value prior to Day 1
Efficacy variables:

Platelets (measured by ACM Global 
Central Laboratory)

ITP bleeding scale

NFI-MS

Platelets: Predose Day 1 or if missing the 
latest non missing value prior to Day 1

ITP bleeding scale: Predose Day 1 or if 
missing the latest non missing value prior 
to Day 1

NFI-MS: Predose Day 1
Pharmacodynamic variables:

Total IgG

IgG subclasses


ITP-specific autoantibodies in serum 

Total IgG: Predose Day 1 or if missing the 
latest non missing value prior to Day 1

IgG subclasses: Predose Day 1 or if 
missing the latest non missing value prior 
to Day 1

ITP-specific autoantibodies: Predose Day 1
Immunological variables:

Immunoglobulins (IgA, IgE and IgM)

B- and T-lymphocytes

Serum (C3 and C4) and plasma 
complement (C3a and C5a)

ADA

Serum BAFF

Cytokines, if applicable (as outlined in the 
protocol)

Predose Day 1 (except B- and T-
lymphocytes)

B- and T-lymphocytes: Predose Day 1 or if 
missing the latest non missing value prior 
to Day 1
ADA=anti-drug antibody; BAFF= B cell activating factor; ECG=electrocardiogram; Ig=immunoglobulin; 
ITP=primary immune thrombocytopenia; NFI-MS= Neurological Fatigue Index for Multiple Sclerosis;
If a measurement is repeated at Baseline and is obtained prior to receiving the first dose of 
UCB7665, then the last available measurement will be used as the Baseline value.
REDACTED COPY 
l
Y
l

OP

ED
AC
t any marketing authorization application and any extensions or variations thereof.
ati
ets: Pre
icati
ets: Pre
est no
plic
est non
ITP bl
n ap
ITP bl
mis
on
mis
t
tio
th
dies in s
any 
dies in s
th
th
th
uth
This document cannot be used to suppo
ulins 
to s
ulins (Ig
su
(Ig
lympho
ed to
lympho
(C3 an
use
(C3 an
mpleme
be u
mpleme
ADA
not 
ADA

Ser
an
Ser

nt

or
um
um
um
A
or
ort a


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 23 of 128
For the platelet count performed at Screening (measured by ACM Global Central Laboratory 
only), 2 separate blood samples will be obtained on the same day. If the latest non missing value
prior to Baseline is to be used as Baseline (i.e., predose Day 1 is missing), the highest value for 
the platelet count obtained from the last 2 non missing measurements prior to Baseline will be 
used as the Baseline.
3.4
Protocol deviations
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct or on the primary efficacy, key safety, or PK/PD outcomes 
(if applicable) for an individual subject. The criteria for identifying such protocol deviations will 
be defined within the important protocol deviation specifications which is part of the data 
cleaning plan. Important protocol deviations will be reviewed as part of the ongoing data 
cleaning process and data evaluation. All important protocol deviations will be discussed and 
documented at the data evaluation meeting (DEM) together with any decisions regarding 
exclusion from analysis sets.
3.5
Analysis sets
3.5.1
Enrolled Set
The Enrolled Set (ES) will consist of all subjects who have given informed consent. This will 
include screening failures. Screening failures will be labeled as ‘not treated’ in any outputs based 
on the ES.
3.5.2
Safety Set
The Safety Set (SS) will consist of all subjects who have received at least 1 infusion (full or 
partial infusion) of UCB7665 and will be used for the analysis of safety data.
3.5.3
Full Analysis Set
The Full Analysis Set (FAS) will consist of all subjects who have received at least 1 infusion 
(full infusion) of UCB7665 and, in addition, have a Baseline and at least 1 post-Baseline 
measurement for platelet count (measured by ACM Global Central Laboratory).
The analysis of the PD (excluding total IgG and IgG subclasses), efficacy and immunologic 
variables will be performed on the FAS. Efficacy analyses will be repeated for the 
pharmacodynamics per protocol set (PD-PPS) where stated in the SAP.
Platelet data for subjects who have taken rescue medications (based on medical review and 
defined in Section 8.1.4) will only be utilized in the summary tables up to the start of these 
rescue medications.
3.5.4
Per Protocol Set
The Per Protocol Set (PPS) is a subset of the FAS, consisting of those subjects who had received 
all foreseen sc infusions, had a platelet count measurement (measured by ACM Global Central 
Laboratory) during the Observation Period, and no important protocol deviations that may 
potentially affect the platelet count as confirmed during a pre-analysis review of the data prior to 
database lock. Protocol deviations may not necessarily lead to total exclusion of a subject from 
the PPS but may lead to exclusion of specific data and/or timepoints from the analysis.
REDACTED COPY
label
OPY 
label
ject
ACT
jects
CT
s
T
be use
EDA
be use
nt cannot be used to support any marketing authorization application and any extensions or variations thereof.
omes 
var
omes 
ions wi
s or 
ions wi
data 
ons
data 
ng data 
nsio
ng data 
discuss
xten
discuss
ns
y
ns rega
y ex
rega
iven inf
plica
iven inf
ed as ‘n
app
ed as ‘n
who ha
thor
who ha
ed for t
aut
ed for t
onsist o
arke
onsist o
in addi
y ma
in addi
nt
a
nt (
an
(mea
any 
mea
xc
po
xcludin
port 
ludin
rmed on
upp
rmed on
per pro
to su
per pro
subjec
sed t
subjec
ction
use
ction 8
e
8
dicatio
be 
dicatio
he
t
he Per 
t ca
Per 
This documen
all for
ment
all for
La
m
La


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 24 of 128
Platelet data for subjects who have taken prohibited medications potentially affecting platelet 
counts such as IV corticosteroids, TPO-Rs, Oral corticosteroids, immunosuppressants (based on 
medical review) will only be utilised in the summary tables, up to the start date of these 
prohibited medications.
3.5.5
Pharmacokinetic Per Protocol Set
The Pharmacokinetic Per Protocol Set (PK-PPS) is a subset of the FAS, consisting of those 
subjects who had no important protocol deviations potentially affecting the plasma concentration 
of UCB7665, as confirmed during a pre-analysis review of the data prior to database lock.
3.5.6
Pharmacodynamic Per Protocol Set
The Pharmacodynamic Per Protocol Set (PD-PPS) is a subset of the FAS, consisting of those 
subjects who had no important protocol deviations potentially affecting the serum concentration 
of total IgG, as confirmed during a pre-analysis review of the data prior to database lock.
Protocol deviations may not necessarily lead to total exclusion of a subject from the PD-PPS but 
may lead to exclusion of specific data.
The PD-PPS will be used for the analysis of the total IgG and IgG subclasses.
3.6
Treatment assignment and treatment groups
Treatment (dose arm) assignment for the SS, FAS, PK-PPS, PD-PPS and the PPS will be 
according to the planned treatment regimen (reflecting the potential DMC decisions).
In the event that the number of planned infusions in the dose arms are modified following review 
by the DMC, the data will be summarized based on the actual dose arms completing the study. 
For example, if the weekly 5x4mg/kg QWK dose arm is modified such that some subjects 
receive only 4 infusions, then the data will be summarized separately for this new dose regimen.
Analyses will be performed by dose arm, unless otherwise stated. 
3.7
Center pooling strategy
The clinical study will be conducted in multiple centers in Europe and Australia. The data from 
different sites will be pooled for all analyses. There will be no analyses by site or country 
performed.
3.8
Coding dictionaries
Adverse events and medical history will be coded using the latest available version of the 
Medical Dictionary for Regulatory Activities (MedDRA®). 
Medications will be coded according to the World Health Organization Drug Dictionary 
(WHODD [September 2015]). Medical procedures will not be coded.
3.9
Changes to protocol-defined analyses
The protocol stated that changes from Baseline would be evaluated for the ITP-specific 
autoantibodies. However, as these data are semi-quantitative, changes from Baseline are not 
considered an appropriate way to present the results and would not provide any additional 
information. Thus, only absolute values over time will be reported. 
REDACTED COPY
K
P
K-
PY
-PP
PY 
PP
ting th
COP
ting th
ons in
ED C
ons in
based o
CTE
based o
WK
DAC
WK do
C
do
a will b
REDA
a will b
R
any marketing authorization application and any extensions or variations thereof.
on 
ria
on 
g of tho
sion
g of tho
m conc
tens
m conc
abase l
ext
abase l
from t
any e
from t
ubclas
n an
ubclas
g
c
grou
catio
rou
, PD
appl
, PD-
p
-P
he pote
n ap
he pote
the do
zatio
the do
on the 
horiz
on the 
ose arm
utho
ose arm
be su
g au
be sum
u
m
m, unle
keting
m, unle
s
m
strate
mark
trate
ducted i
any 
ducted i
This document cannot be used to support
d for al
ort a
d for al
ing di
o sup
ing di
and me
ed t
and me
ionary 
use
ionary 
ons wil
ot be
ons wil
ODD
nnot
ODD [S
ot
[S
9
t
9
The 
men
The 
au
m
au


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 25 of 128
4
STATISTICAL/ANALYTICAL ISSUES
4.1
Adjustments for covariates
There will be no adjustment for covariates.
4.2
Handling of dropouts or missing data
In general, there will be no imputation of missing data unless otherwise stated below.
4.2.1
Efficacy data
There will be no imputation of missing platelet data (measured by ACM Global Central 
Laboratory) or missing data for the ITP bleeding score. Missing data for the calculation of the 
NFI-MS summary score will be handled as described in Section 13.2.
4.2.2
Safety laboratory data
Measurements below the limit of quantification (BLQ) will be imputed with half of the lower 
limit of quantification (LLOQ) for the purpose of calculating change from Baseline and for 
descriptive statistics. Measurements above the limit of quantification (ALQ), if applicable, will 
be imputed to the upper quantification limit.
These rules will be applied to all safety laboratory data including coagulation parameters, clinical 
chemistry and urinalysis. 
4.2.3
Pharmacodynamic data
Measurements BLQ are not anticipated in the PD data (total IgG [measured by ACM Global 
Central Laboratory] and IgG subclasses). In the event that any BLQ measurements are received,
these will be discussed at the DEM.
For the ITP-specific autoantibodies any measurements that are above the limit of detection 
(ALD) will be imputed with the value of the upper quantification limit for the calculation of 
summary statistics.
4.2.4
Immunological data
The rules for handling BLQ or ALQ measurements for all immunological data (including IgA, 
IgE, IgM, B- and T-lymphocytes, serum and plasma complement, serum biomarkers (including 
BAFF), ADA and cytokines) will be as described in Section 4.2.2.
For all immunological data, measurements that are BLQ will be imputed with LLOQ/2 for 
individual plots.
4.2.5
UCB7665 concentration data
Measurements that are BLQ will be imputed with LLOQ/2 for the purpose of calculating the 
geoMean and its 95% CI, the geoCV, the arithmetic mean, and SD for summaries and figures.
For the individual figures, any concentrations that are BLQ will be imputed with LLOQ/2, with 
the exception of predose BLQ measurements on Day 1, which will be imputed with zero for 
linear scale plots.
Additional rules for PK data summaries are provided in Section 9.1.
REDACTED COPY 
e PD d
TED
e PD d
In the 
ACT
In the 
ny m
RE
ny m
port any marketing authorization application and any extensions or variations thereof.
on of th
ons 
on of th
th half 
any e
th half 
om Bas
nd an
om Bas
n (ALQ
and
n (ALQ
ing coa
licat
ing coa
data
riza
data (to
at
(to
event 
thor
event 
measur
ting 
measur
e of the
rket
e of the
al
an
al dat
ny 
dat
Q or A
port 
Q or A
ent cannot be used to sup
mphocy
uppo
mphocy
ytokine
o sup
ytokine
ogical
ed t
ogical
ots.
us
ots.
U
uremen
nno
uremen
oMean
t ca
oMean
This documen
For t
men
For t
th
m
th


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 26 of 128
4.2.6
Electrocardiogram data
For the ECG data, all calculations of changes from Baseline and descriptive statistics will be 
based on the mean of the triplicate assessments at each visit. In the event that there are not 3 
available measurements at a given visit, the mean will be calculated based on the number of 
measurements for which data is provided (variables analyzed will be those described in Section 
10.4.2).
4.2.7
Dates and times
Partial dates may be imputed for the following reasons:

Classification of AEs as treatment-emergent

Classification of medications as past, prior or concomitant
Imputed dates will not be shown in the listings; all dates will be displayed as reported in the 
database.
The following rules will be applied for partial start dates:

If only the month and year are specified and the month and year of first dosing is not the 
same as the month and year of the start date then use the 1st of the month, or the date of 
screening if this is later (if the latter imputation results in an end date that is earlier than the 
start date, then use the 1st of the month). If time is missing this will be imputed as 00:00 h;

If only the month and year are specified and the month and year of first dosing is the same as 
the month and year of the start date, then use the date of first dosing. If this results in an 
imputed start date that is after the specified end date, then use the 1st of the month, or the date 
of screening if this is later (if the latter imputation results in an end date that is earlier than 
the start date, then use the 1st of the month). If the imputed date is the date of first dosing then 
time will be imputed as the start time of the infusion (i.e., event will be regarded as 
treatment-emergent);

If only the year is specified, and the year of dosing is not the same as the year of the start date 
then use January 01 of the year of the start date. If time is missing this will be imputed as 
00:00 h;

If only the year is specified, and the year of dosing is the same as the year of the start date, 
then use the date of dosing. If this results in an imputed start date that is after the specified 
end date, then use January 01 of the year of start date, or the date of screening if this is later
(if the latter imputation results in an end date that is earlier than the start date, then use 
January 01). If the imputed date is the date of first dosing then time will be imputed as the 
start time of the infusion (i.e., event will be regarded as treatment-emergent);

If the start date is completely unknown, then use the date of first dosing. If this results in an 
imputed start date that is after the specified end date, then use January 01 of the year of the 
end date, or the date of screening if this is later (if the latter imputation results in an end date 
that is earlier than the start date, then use January 01). If the imputed date is the date of first 
dosing then time will be imputed as the start time of the infusion (i.e., event will be regarded 
as treatment-emergent).
REDACTED COPY 
ults
Y
ults
is mis
OPY
is mis
the m
D CO
the m
use th
TED
use th
ified e
ACT
ified e
tter im
EDA
tter im
he mo
RE
he mo
R
d to support any marketing authorization application and any extensions or variations thereof.
reporte
exte
reporte
ar of fir
ion a
ar of fir
of the 
atio
of the 
n an end
plic
n an end
ssing th
app
ssing th
month a
ation
month a
he date
riza
he date
end da
thor
end da
mputati
auth
mputati
month). 
ing a
month). 
me of th
ketin
me of th
, and th
ny m
, and th
he year 
rt any
he year 
 specif
sup
 specif
ate of d
d to s
ate of d
annot be use
en use 
sed 
en use 
tter imp
e us
tter imp
ry 01). 
t be 
ry 01). 
rt time 
not 
rt time 
This document ca
If the
t can
If the
im
nt 
im


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 27 of 128
Start and end time is not recorded for concomitant medications, thus no imputations for missing 
times will be performed. Any medication with a start date on the first dosing date, will be 
assumed to be concomitant.
The following rules will be applied for partial stop dates:

If only the month and year are specified, then use the last day of the month;

If only the year is specified, then use December 31 of the known year;

If the stop date is completely unknown, do not impute the stop date, except for ITP 
medications where end date is missing and ongoing is ticked as ‘no’, which will be imputed 
as “Past” medications.
Missing or partially missing date and/or times will be imputed as described in Table 4‒1 for the 
calculation of duration of each AE. Adverse event duration is computed and reported in day and 
time format: xx d hh:mm.
Table 4‒1:
Calculation rules for duration of adverse events
Data availability
Onset 
date/time
Outcome 
date/time
Calculation rules
Complete data
D1/T1
D2/T2
Duration = [(D2 – D1)*24 + (T2 – T1)]/24 d
End time missing
D1/T1
D2/--
End time is substituted by time 23:59h (=23.98 in 
decimal format)
Duration = <[(D2 – D1)*24 + (23.98 – T1)]/24 d
Start time missing
D1/--
D2/T2
Onset time is substituted by time 00:00h.
Duration = <[(D2 – D1)*24 + T2]/24 d
Start and end time 
missing
D1/--
D2/--
Duration = <D2 – D1 + 1
Start day and time 
missing
--/--
D2/T2
Duration = <[(D2 – D0)*24 + (T2 – T0)]/24 d
For a subject in the SS, D0 and T0 are the date and 
time of first administration of UCB7665 and for 
screen failures, D0 is the date of the screening visit 
and T0 = 00:00h
End day and time 
missing
D1/T1
--/--
For ongoing AE:
Duration = >Discharge day – D1 d
For resolved AE:
Duration = <Discharge day – D1 d
Where discharge refers to the date of the end of study 
visit or the date of discontinuation for subjects that 
were withdrawn.
For any AEs with known start date/time after the date 
of discontinuation, the date of last contact will be 
used as the discharge day.
ACTED COPY
ion =
PY 
ion =
nd tim
CO
nd tim
decim
ED C
decim
D
E
D
OP
TE
REDAC
AC
R
horization application and any extensions or variations thereof.
mputed
or v
mputed
le
en
le 4
nsi
4‒
s
‒1
ported 
exte
ported 
s
a
[(D2 
appl
[(D2 –
p
– D
lic
me is sub
ion a
me is sub
mal form
zatio
mal form
Duration
horiz
Duration
ap
autho
Ons
uth
Ons
D
ument cannot be used to support any marketing a
ho
au
-
k
-
ting
D2/T
ny m
D2/T
m
an
s
D
This docum
to
um
d


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 28 of 128
Table 4‒1:
Calculation rules for duration of adverse events
Data availability
Onset 
date/time
Outcome 
date/time
Calculation rules
Start and end date 
missing
--/--
--/--
For ongoing AE:
Duration = >Discharge day – D0 d
For resolved AE:
Duration = <Discharge day – D0 d
For a subject in the SS, D0 and T0 are the date and 
time of first administration of UCB7665 and for 
screen failures, D0 is the date of the screening visit 
and T0 = 00:00h.
Discharge refers to the date of the end of study visit 
or the date of discontinuation for subjects that were 
withdrawn.
For any AEs with known start date/time after the date 
of discontinuation, the date of last contact will be 
used as the discharge day.
4.3
Handling of repeated and unscheduled measurements
All repeated and unscheduled measurements will be presented in the listings, where applicable. 
The following general rules will apply to all repeated and unscheduled measurements:

For repeated and unscheduled measurements obtained prior to the first dose of UCB7665 the 
latest value (which may be scheduled or unscheduled) will be used in the calculation of 
descriptive statistics;

For repeated and unscheduled measurements obtained at the designated Baseline visit, the 
latest value (which may be scheduled or unscheduled) will be defined as the Baseline 
provided that this occurred prior to the first dose of UCB7665;

For repeated measurements obtained at any timepoint after the first dose of UCB7665, the 
first value of any repeated measurements will be used in the calculation of changes from 
Baseline and for the descriptive statistics. Unscheduled and repeated measurements will not 
be included in the descriptive statistics at timepoints after the first dose of UCB7665, 
however they may be included in any summaries for abnormal measurements.
The above rules are not applicable for the determination of the response variables for the platelet 
measurements; both scheduled and unscheduled measurements may be used in the calculation of 
response, time to response and duration of response (Section 8.1.1).
4.4
Interim analyses and data monitoring
For the sequential adaptive design in this study, at least 11 interim analyses will be performed.
Safety data from the interim analyses will be reviewed by the DMC to monitor the safety, to
adapt the dose regimen, and to decide when and if the UCB7665 7mg/kg weekly group (Dose 
Arm 2), UCB7665 10mg/kg weekly group (Dose Arm 3), UCB7665 15mg/kg group (Dose Arm 
REDACTED COPY
ched
PY 
ched
be pre
CO
be pre
epeated
ED C
epeated
ement
ACT
ement
ed or u
EDA
ed or u
o support any marketing authorization application and any extensions or variations thereof.
ate and 
or v
ate and 
nd for 
ns o
nd for 
reening
sion
reening
he end o
exte
he end o
for sub
ny e
for sub
wn start 
and
wn start 
he date 
on a
he date 
arge day
atio
arge day
ca
ati
duled 
appli
duled 
resented
tion a
resented
ed
z
ed and u
zatio
and u
ts obtai
thor
ts obtai
unsche
auth
unsche
asurem
rket
asurem
heduled
mar
heduled
prior to
ny m
prior to
ents ob
ort a
ents ob
peated m
ppo
peated m
the desc
sup
the desc
This document cannot be used t
the des
d to s
the des
ey may
sed 
ey may
rules ar
be u
rules ar
ments;
ot be
ments;
nse, tim
nno
nse, tim
.4
nt
.4
For 
me
For 
S


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 29 of 128
4) and UCB7665 20mg/kg group (Dose Arm 5) should be opened, as well as whether the doses 
in any of the treatment groups should be modified.
A detailed description of the DMC composition, processes and responsibilities will be provided 
in a separate DMC Charter. The data required for review as well as the timing of each interim 
analysis is described in a separate interim SAP and includes all data specified in the DMC 
Charter, which is available at the time. For the interim analyses the data, subject to analysis, 
should be as clean as possible; however, the database will not be locked and a snapshot will be 
taken.
4.5
Multicenter studies
Individual center results will not be displayed.
4.6
Multiple comparisons/multiplicity
Not applicable.
4.7
Active-control studies intended to show equivalence
Not applicable.
4.8
Examination of subgroups
The following subgroups will be defined within each dose arm:

Concomitant corticosteroid medication: Yes/No
Concomitant medication is defined in Section 6.4.4. The list of applicable Anatomical 
Therapeutic Chemical (ATC) codes to be utilized as corticosteroids is provided in
Section 13.1.

Responder at the end of past ITP therapy: No/Yes/Unknown
Responder categories will be defined utilizing the value (either Yes or No) for the last 
reported ITP therapy for each patient. If this value is unknown, the second-last reported ITP 
therapy value will be used, then the third-last, and so on, until a known response is provided. 
The Unknown responder category will only be considered in cases where the investigator has 
never reported a category (Yes or No) for any of the past ITP therapies. For the ‘Response’ 
definition, the CRF entries will be utilized.
The past ITP therapy is defined as procedure history related to ITP or past medication related 
to ITP, where past medication is defined in Section 6.4.1. For ‘related to ITP’ CRF entries 
will be utilized.
The corticosteroid medication given more than 3 months prior to screening was routinely not 
recorded and cannot be considered. Thus, some patients with an unknown response might 
have had a known response.

Past intravenous immunoglobulin (IVIg) medication: Yes/No
Past medication is defined in Section 6.4.1. The ATC Therapeutic Subgroup code (Level 2) 
‘IMMUNE SERA AND IMMUNOGLOBULINS’ will be utilized.

Number of past ITP therapies: ≤2/>2
REDACTED COPY
dose
PY 
dose
No
C
No
ction
TED
ction 6
D
6
 be ut
ACT
 be ut
ther
R
ther
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
uivale
nd a
uivale
arm
ppl
arm:
pp
:
6.4.4
riza
6.4.4. T
a
. T
tilized a
thor
tilized a
rapy
eting
rapy: N
g
: N
fined u
arke
fined u
h patien
y ma
h patien
, then t
any 
, then t
er categ
ort a
er categ
egory (Y
ppo
egory (Y
RF entri
sup
RF entri
therapy
d to
therapy
ere pas
used
ere pas
utilized
be u
utilized
e cortic
not 
e cortic
ecorde
ann
ecorde
have
nt ca
have

me



UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 30 of 128
The past ITP therapy is defined as procedure history related to ITP or past medication related 
to ITP, where past medication is defined in Section 6.4.1. For ‘related to ITP’ CRF entries 
will be utilized.
The corticosteroid medication given more than 3 months prior to screening was routinely not 
recorded and cannot be considered. Thus, some patients might have had 1 more past ITP 
therapy than utilized for subgroup determination.
The descriptive summaries for platelets and total IgG will be presented for the subgroups above. 
5
STUDY POPULATION CHARACTERISTICS
5.1
Subject disposition
The number of subjects who were enrolled, dosed, subjects included in each analysis set, and 
subjects who completed or prematurely discontinued the study, as well as the reason for 
discontinuation, will be presented by dose arm and overall. Screen failure reasons will be 
summarized, based on the ES.
In addition, the following listings will be presented by dose arm:

Subject disposition (ES)

Study discontinuation (SS)

Visit dates (SS)

Subject analysis sets (ES)
The listing of subject disposition will include the date of informed consent, date of genomic 
consent (if applicable), date of randomization (if applicable), date and time of first and last dose 
of UCB7665 (if applicable), date of premature termination and primary reason (if applicable) and 
date of final contact. 
The listing of study discontinuation will include the reason for discontinuation and the number of 
days on UCB7665.
The number of days on UCB7665 will be calculated as follows:
Number of days on UCB7665= [(Date of Last Dose Received) – (Date of First Dose Received)] 
+ 1
5.2
Protocol deviations
Important protocol deviations will be identified and classified by the deviation types identified in 
the important protocol deviations document. A listing of all important protocol deviations 
identified at the DEM will be presented for all subjects in the SS, and will include the deviation 
type and description. The number and percentage of subjects in the SS with important protocol 
deviations will be summarized by dose arm and overall. The denominator for percentages will be 
the number of subjects in the SS. 
REDACTED COPY 
ude th
ACT
ude th
ization
EDA
ization
prema
RE
prema
ot be used to support any marketing authorization application and any extensions or variations thereof.
e.
ri
e.
ysis set
ensi
ysis set
reason 
exte
reason 
easons 
ny e
easons 
he date
thor
he date
n (if ap
aut
n (if ap
mature t
ting a
mature t
n will 
mar
n will 
B7665
ort a
B7665
B7665
upp
B7665
Protoc
ed t
Protoc
protoco
be u
protoco
ortant p
ot be
ortant p
This document can
fied at 
nno
fied at 
pe and d
t can
pe and d
deviati
ent c
deviati
the 
me
the 


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 31 of 128
6
DEMOGRAPHICS AND OTHER BASELINE 
CHARACTERISTICS
6.1
Demographics
A by-subject listing of Baseline demographics will be presented by dose arm for the ES. This 
will include the year of birth (if available), age (in years), sex, race, ethnicity, height (in cm), 
weight (in kg) and body mass index (BMI). The age will be directly entered into the study 
database and will not be re-calculated for the statistical analysis.
BMI in kg/m2 is calculated based on the height (in m) and the weight (in kg) using the following 
formula:
BMI (kg/m2) = weight (kg)/[height (m)]2
BMI will be reported to 1 decimal place.
All Baseline demographic characteristics (with the exception of year of birth) will be 
summarized by dose arm and overall for the SS. Number and percentage of patients with a BMI 
equal or higher than 30 will also be summarized by dose arm.
The summary of age will include descriptive statistics and categorical summaries, the latter 
based on requirements for EudraCT and clinicaltrials.gov reporting. 
For the EudraCT reporting, the categories will include:

18 to <65 years

65 to <85 years

≥85 years
For the clinicaltrials.gov reporting, the categories will include:

≤18 years

19 to <65 years

≥65 years
Childbearing potential will be listed for the SS. 
6.2
Other Baseline characteristics
Baseline disease characteristics will be listed and summarized by dose arm for the SS including 
the following:

Duration of disease

Karnofsky Performance Scale Index

ITP bleeding scale (skin, visible mucosae and organs, with gradation of severity [SMOG])

ITP-specific autoantibodies 
expressed in terms of optical 
density (OD) for MAIPA analysis and pre-chloroquine minus post chloroquine treated scores 
for PIFT
REDACTED COPY 
ov
Y
ov
ude:
COP
ude:
e c
R
e c
ed to support any marketing authorization application and any extensions or variations thereof.
llowing
or v
llowing
rth) wi
any
rth) wi
ge of pa
nd a
ge of pa
gorical 
atio
gorical 
porting.
plica
porting.
categor
eting
categor
will be
upp
will be
her 
d to
her 
annot be us
B
 s
B
se char
used
se char
ng:
be
ng:
ration o
not 
ration o
This document ca
Karno
t can
Karno

me

IT
n
IT


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 32 of 128

Immunological variables (IgG [including total IgG and IgG subclasses measured by ACM 
Global Central Laboratory], IgM, IgA, IgE and lymphocytes [B and T])

Serum (C3 and C4) and plasma complement levels (C3a and C5a)

Platelet count (measured by ACM Global Central Laboratory)

Number of prior ITP medications received

Number of prior ITP medications received categorized

Prior ITP medications received by preferred term

Medical history of splenectomy (MedDRA v20.2, Preferred Term=”Splenectomy”)
The duration of disease will be calculated as follows, where the date of diagnosis will be 
obtained from the ITP history page of the case report form (CRF):
Duration (years) = (Date of Screening – Date of Diagnosis)
If the date of diagnosis is missing, the duration of disease will not be calculated. In the case of 
the start day being missing, the day will be imputed with the 1st of the month in the calculation of 
the disease duration. In the case of the start day and month being missing, the date will be 
imputed with 01 January in the calculation of the disease duration.
The disease duration will be presented in years to 1 decimal place in the listings.
The Karnofsky Performance Scale index is a semi-quantitative score ranging from 0 to 100% in 
intervals of 10, where 0% is death and 100% is normal (no complaints, no evidence of disease). 
Summary statistics for the Karnofsky Performance Scale will include n, median, minimum and 
maximum only.
The ITP bleeding scale will be summarized (n, median, minimum and maximum) by dose arm
for each domain (SMOG).
6.3
Medical history and concomitant diseases
Medical history will be summarized for the SS by dose arm and for all subjects by MedDRA 
system organ class (SOC), high level term (HLT) and preferred term (PT). The listing will also
include the reported condition and the start and end date (or ongoing, if applicable). Procedure 
history and history of thrombocytopenia will be listed separately by dose arm for the procedure 
reported term based on the SS.
Concomitant medical procedures performed during the study will be listed for the SS.
6.4
Past, prior, baseline and concomitant medications
Past, prior, baseline and concomitant medications will be summarized for the SS by dose arm
and for all subjects by WHODD Anatomical Main Group [Level 1], Therapeutic Subgroup 
[Level 2] and PT.
All medications will be listed and will include coding information, reported term, dose per intake 
and unit, frequency, formulation, route of administration, indication, category (past/prior and 
concomitant/concomitant) and start and end date (or ongoing, if applicable).
REDACTED COPY 
Y
decim
OPY
decim
mi
D
mi-
D C
-qu
CO
qu
is nor
TED
is nor
forman
ACT
forman
mariz
RE
mariz
cannot be used to support any marketing authorization application and any extensions or variations thereof.
o
)
o
)
will be
ensi
will be
alculat
nd 
alculat
he mon
n an
he mon
g missin
ation
g missin
ation.
plica
ation.
mal plac
app
mal plac
uantitat
ation
uantitat
rmal (n
riza
rmal (n
nce Sc
thor
nce Sc
zed (n,
ting
zed (n,
ry and
y ma
ry and
marized
t any
marized
, high l
port 
, high l
ndition
upp
ndition
of throm
to su
of throm
sed on t
ed to
sed on t
medic
e use
medic
P
, p
a
, prior
ann
rior
This document 
nd for a
nt ca
nd for a
[Leve
ment
[Leve
A
m
A


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 33 of 128
6.4.1
Past medication definition
Past medications will include any medications that started and stopped prior to the first 
administration of UCB7665.
6.4.2
Prior medication definition
Prior medications will include any medications that started prior to the first administration of 
UCB7665. This includes medications that started and stopped prior to dosing (past medications) 
as well as those that started prior to dosing and continued after (classified as prior and 
concomitant medications).
6.4.3
Baseline medication definition
Baseline medications will include any medications that started prior to dosing and continued 
after (classified as prior and concomitant medications).
6.4.4
Concomitant medication definition
Concomitant medications will include any medication that has been taken at least once (after the 
first administration of UCB7665) during the Dosing Period and/or the Observation Period.
This includes medications that started prior to the dosing and continued after (classified as prior 
and concomitant medications) as well as any medication that started after the first administration 
of UCB7665 (classified as concomitant).
Any medications with missing dates and/or times will be handled as described in Section 4.2.7 in 
order to classify them as prior and/or concomitant.
7
MEASUREMENTS OF TREATMENT COMPLIANCE
The study medication will be administered and monitored by the investigator or designee. The 
measured plasma concentrations will provide information regarding compliance. Any dosing 
deviations (eg, incomplete infusion volume administered, infusion discontinued) will be 
discussed at the DEM and any actions taken regarding the analyses will be documented 
accordingly and discussed in the CSR.
There will be no specific analysis of compliance. Exposure to UCB7665 will be presented as 
described in Section 10.1.
8
EFFICACY ANALYSES
All analyses of the efficacy variables will be performed on the FAS. Additional outputs may be 
repeated for the PPS where indicated. Treatment (dose arm) assignment for efficacy analysis will 
be according to the actual treatment regimen.
8.1
Platelets
All efficacy analyses are based on platelet count measured by ACM Global Central Laboratory. 
Measurements of platelet count obtained by the local laboratory will be listed and summarized as 
part of the safety laboratory data. These are not included in the analyses described in the sections 
below. All tabulations and mean figures will be presented for both the FAS and the PPS unless 
otherwise stated. Median figures and individual figures will be presented for the FAS only. In 
case rescue medications are taken, only the platelet data up to the start date of rescue medication
will be utilized for the summary tables (refer to Section 8.1.4). In case prohibited medications 
REDACTED COPY 
n 
Y
n 
s will 
D CO
s will 
itant.
TED
itant.
OF T
DACT
OF T
stered
RED
stered
pr
R
pr
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
contin
ensio
contin
en at l
nd a
en at l
he Obs
n an
he Obs
ntinued
atio
ntinued
started
plica
started
be han
tion
be han
TREA
tho
TREA
d and m
ng a
d and m
rovide 
keting
rovide 
volume
arke
volume
tions ta
ma
tions ta
he CSR
any 
he CSR
analysis
port 
analysis
1.
p
.
FICAC
to s
FICAC
f the ef
used
f the ef
r the PP
be us
r the PP
ding to
ot be
ding to
All
nt
All effi
nt c
effi
Mea
me
Mea
p
m
p


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 34 of 128
affecting platelets are taken, only the platelet data up to the start date of prohibited medication 
will be utilized for the summary tables for the PPS (refer to Section 3.4). Listings will contain all 
the data but a footnote will be included indicating the patients for which some data has been 
excluded from the summary tables. In case of partial dates, the imputation rules for partial dates 
described in Section 4.2.7 will be applied.
8.1.1
Definition of variables
The main efficacy variable is defined as the following:

Maximum Increase from Baseline: the Maximum Increase from Baseline (Day 1, predose) is 
defined as the highest positive change from Baseline during the study. In the event that the 
platelet count was to decrease during the study the Maximum Increase from Baseline may be 
negative and would correspond to the smallest decrease from the Baseline value
The following additional variables will be defined for the platelet count, the calculation rules for 
which are provided in the section immediately below:

Response: a platelet count ≥30x109/L and at least 2-fold increase from the Baseline value, by 
visit, and at any timepoint during the study

Time to Response: the first time that a given response is achieved during the study. Thus, in 
the event that the platelet count was to increase above the threshold level, decrease below the 
threshold level, and subsequently increase again the time to response would be to the first 
time the definition of response was achieved. The time to response will be calculated in days 
and presented to 1 decimal place in the listings.
Time to response (days) = Date/time of first response – Date/time of first dose of UCB7665

‘No’ or ‘Loss of’ Response: a platelet count <30x109/L OR >=30x109/L WITHOUT at least 
a 2-fold increase from the Baseline value, by visit

Duration of Response (including Complete Response, Response and Platelet Count 
≥50x109/L): the duration of the first time the response was achieved to first loss of response. 
The duration of response will be calculated in days and presented to 1 decimal place in the 
listings.
Duration of response (days) = Date/time of loss of first response – Date/time of first 
response, where “loss of first response” is defined as platelet count<30x109/L OR (platelet 
count ≥30x109/L WITHOUT at least a 2-fold increase from the Baseline value)
If the platelet value meets the criterion for a specific response for a second time (following a 
loss of initial response), the second response period will be added to the overall duration of 
response. This rule will be applied for any subsequent ‘response periods’. For subject in 
whom the response is maintained until the end of the study the duration of response will be 
calculated using the date of the end of study visit as the ‘end of response date’. Any such 
cases will be flagged in the data listings

Complete Response: a platelet count ≥100x109/L, by visit, and at any timepoint during the 
study

‘No’ or ‘Loss of’ Complete Response: a platelet count <100x109/L, by visit.
REDACTED COPY
ove 
PY 
ove 
n the ti
OPY
n the ti
 The t
D CO
 The t
tings.
TED
tings.
of first
ACT
of first
telet c
RED
telet c
ne v
R
ne v
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ose) is
or va
ose) is
hat the
s or
hat the
eline m
sions
eline m
ue
en
ue
alculat
ext
alculat
from th
and 
from th
hieved 
icatio
hieved 
e thres
pplic
e thres
ime to 
n app
ime to 
time to
tion 
time to
t respo
thor
t respo
count <
g au
count <
value, b
eting
value, b
g Comp
mark
g Comp
he first
y ma
he first
will be 
any
will be 
se (day
supp
se (day
 “loss o
to su
 “loss o
0
e
0 /L
d t
/L W
to
W
atelet va
e us
atelet va
f initial
t be 
f initial
ponse. 
not 
ponse. 
whom 
cann
whom 
calc
nt ca
calc
c
n
c


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 35 of 128

Time to Complete Response: the time from starting treatment (Day 1) to achievement of 
Complete Response

Platelet Count ≥50x109/L, by visit, and at any timepoint during the study

‘No’ or ‘Loss of’ Platelet Count ≥50x109/L: a platelet count <50x109/L, by visit.

Time to Platelet Count ≥50x109/L: the time to Platelet Count ≥50x109/L is defined as the 
time from starting treatment (Day 1) to achievement of Platelet Count ≥50x109/L

Maximum: the maximum value for platelet count over all visits in the study

Value and change from Baseline in platelet count over time

Baseline-corrected AUEC for platelet count calculated from Baseline to the end of study visit 
for each of the defined dose arms.
For all the above response variables the following rules will apply:

Both scheduled and unscheduled measurements may be included in the calculation of a 
response, time to response or duration of response

The Baseline-corrected AUEC will be calculated according to the following rules:

The AUEC will be calculated according to the linear trapezoidal rule using protocol 
scheduled visits

Unscheduled visits will not be included in the calculation

No imputation of any missing data will be performed

To account for differences in the timing of Baseline samples for each subject the Baseline 
measurement will be considered as time zero in the calculation

The units of the AUEC will be 109/L*day

The measurements at Baseline and at the last visit must be available

A minimum of 10 out of 14 measurements must be available for the calculation in Dose 
Arm 1; a minimum of 9 out of 12 measurements must be available for the calculation in 
Dose Arm 2; a minimum of 8 out of 11 must be available for the calculation in Dose Arm
3; a minimum of 7 out of 9 must be available for the calculation in Dose Arms 4 and 5. 
These include the Baseline and measurement at the last visit

The AUEC will not be calculated in the case of early withdrawal from the study
8.1.2
Presentation of results
The individual platelet measurements will be listed by dose arm and visit including changes from 
Baseline (Day 1, pre-dose). Descriptive summaries (including n, arithmetic mean, median, SD, 
minimum and maximum) will be presented by dose arm and scheduled visit for both absolute 
values and changes from Baseline based on the FAS only. Summary tabulations by dose arm will 
be repeated for the subgroups defined in Section 4.8 (based on the FAS only too).
In addition, a separate listing and summary will be presented (by visit, where applicable)
including the following:
REDACTED COPY
line
PY 
line
in the
D C
in the
w
AC
will b
ACTE
ill b
he timi
EDA
he timi
red a
RE
red a
port any marketing authorization application and any extensions or variations thereof.
d of stu
nsio
d of stu
the cal
nd a
the cal
to the f
atio
to the f
r trapez
pplic
r trapez
e calcu
atio
e calcu
be perfo
horiz
be perfo
ming of 
aut
ming of 
s time 
ing 
s time 
e 10
rke
e 109
et
9/L
e
/L
eline a
y m
eline a
t of 14
t an
t of 14
d to supp
m of 
port
m of 9
rt
9
minim
supp
minim
m of 
to s
m of 7
cannot be used
lude th
ed to
lude th
AUEC
e us
AUEC
individ
cann
individ
This document
Baselin
nt ca
Baselin
minim
men
minim
va
m
va


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 36 of 128

*Response by visit and over all visits

Time to Response

Duration of Response

*Complete Response by visit and over all visits

Time to Complete Response

Duration of Complete Response

*Platelet Count ≥50x109/L by visit and over all visits

Time to Platelet Count ≥50x109/L

Duration of Platelet Count ≥50x109/L

Maximum value

Maximum Increase from Baseline

Baseline-corrected AUEC
*All the above variables will be included in the listing. The number and percentage of responders
(for variables denoted with an asterisk) will be tabulated separately as described in 
Section 8.1.3.3.
Summary tabulations by dose arm will be repeated for the subgroups defined in Section 4.8
(based on the FAS only).
Mean and mean change from Baseline platelet values will be plotted versus scheduled visit by 
dose arm with all dose arms overlaid on the same plot. Similar plots will be provided for 
response rate over time (response, complete response and platelet count ≥50x109/L). Mean 
median, mean change and median change from Baseline total IgG results will be plotted over 
time by dose arm with all dose arms overlaid on the same plot.
Individual platelet and total IgG (including IgG subclasses, measured by ACM Global Central 
Laboratory) concentrations will be displayed graphically over time (Day 1 to Day 85 for Dose 
Arm 1; Day 1 to Day 71 for Dose Arm 2; Day 1 to Day 64 for Dose Arm 3 and Day 1 to Day 57 
for Dose Arms 4 and 5) for each subject (linear scale). The platelet and total IgG concentrations
will be overlaid on the same plot (discrete y-axes) with separate plots for each subject (2 lines 
per plot). Additional plots will be presented with the platelet and IgG subclasses overlaid on the 
same figure (5 lines per plot). All plots will include a vertical reference line to indicate when the 
last dose was administered for each subject. The mean (and median in a separate plot) change 
from baseline in platelet and the mean (median) change from baseline in total IgG concentrations 
will be overlaid on the same plot (discrete y-axes) with separate plots for each dose arm (2 lines 
per plot).
In addition scatter plots will be presented showing the Maximum value for platelet count versus 
the corresponding total IgG i.e., the value of total IgG at the time of the Maximum platelet value. 
All subjects will be included on the same plot with distinct symbols to distinguish the dose arms. 
This plot will be repeated for the Maximum platelet value versus percentage change in total IgG 
i.e., the percentage change from Baseline in total IgG at the time of the Maximum platelet value.
REDACTED COPY
ed s
PY 
ed s
ated fo
ED C
ated fo
latelet
DAC
latelet
on the
RED
on the
mp
R
mp
o support any marketing authorization application and any extensions or variations thereof.
mber an
icatio
mber an
parately
pplic
parately
or the s
ation
or the s
value
utho
value
e same 
g au
e same 
plete re
eting
plete re
ange fr
arket
ange fr
ms over
mar
ms over
gG (inc
any 
gG (inc
 will b
ort a
 will b
 for 
ppo
 for Do
po
Do
5) for 
sup
) for 
cannot be used t
n the sa
d to s
n the sa
tional p
sed 
tional p
(5 lines
e us
(5 lines
was ad
t be
was ad
aseline
nnot 
aseline
l be ove
cann
l be ove
This document
per plot
nt c
per plot
In a
me
In a


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 37 of 128
8.1.3
Statistical analysis of platelets
8.1.3.1
Analysis of maximum increase from Baseline
In order to investigate if the average maximum increase from Baseline in platelet count is greater 
than zero, for dose arms with ≥10 subjects, a 1-sided one sample t-test will be performed at the 
5% level. For each dose arm the following null and alternative hypotheses will be tested:

H0: Average maximum increase from Baseline within dose arm is less than or equal to zero

H1: Average maximum increase from Baseline within dose arm is greater than zero
An assessment of the distribution of the maximum increase from Baseline in platelet count will 
be performed prior to the statistical analysis in order to check the validity of the proposed 
parametric analysis method. This will be based on visual inspection of histograms and 
quantile-quantile plots for each dose arm which will be included as part of the statistical 
appendices. If the data show a departure from normality, a non-parametric Wilcoxon signed rank 
test (1-sided) will be applied in addition to the t-test.
If the data are deemed to be normally distributed a parametric analysis will be performed using a 
one sample t-test. The mean maximum increase from Baseline, the 90% CI and the p-value 
obtained from the statistical analysis will be tabulated. In order for the null hypothesis (H0) to be 
rejected the p-value must be less than 5%.
Analyses will be performed for the FAS and repeated for the PPS.
8.1.3.2
Analysis of time to response
The time to first response will be analyzed with the log-rank test and displayed using Kaplan-
Meier curves.
Kaplan-Meier curves will be presented for the variables Time to Response, Time to Complete 
Response, and Time to Platelet Count ≥50x109/L. Descriptive statistics will include the p-value 
for the log-rank test for the equality over dose arms. The point estimate for the median number of 
days to response with 90% CIs will be given if estimable. Further a summary including the 
number and percent of censored subjects, the number of responders and total subjects by dose 
arm and in total will be given.
For the purpose of the analysis subjects with no response will be censored at the end of the study 
or at the date of withdrawal.
Analyses will be performed for the FAS and repeated for the PPS.
8.1.3.3
Analysis of responder rate
The number and percentage of subjects achieving a Response, Complete Response and Platelet 
Count ≥50x109/L will be summarized by dose arm at each scheduled post-Baseline visit. The 
90% CI for the percentage of responders will be included, calculated using a Wilson 
approximation. The tabulation will also include an overall summary (across all visits) of the 
number and percentage of subjects achieving a Response, Complete Response and Platelet Count 
≥50x109/L at any time during the study. For the purpose of the tabulation the lower and upper 
90% CI for the percentage of subjects will be truncated at 0 and 100% respectively.
REDACTED COPY 
ted for
COP
ted for
s
E
se
ED
e
d with 
ACT
d with 
ed
RE
ed fo
RE
fo
pport any marketing authorization application and any extensions or variations thereof.
unt wil
s or
unt wil
osed 
ions
osed 
 and 
ensio
 and 
statistic
exte
statistic
Wilcoxo
ny ex
Wilcoxo
is will 
and
is will 
e
ti
e 9
io
90
on
0%
n 
%
for the
catio
for the
or 
o
or the P
n ap
the P
the log
thori
the log
or
ti
or the
ing 
the
≥50x1
rketi
≥50x1
y over 
mark
y over 
will be 
ny m
will be 
red sub
t any
red sub
ven.
port
ven.
This document cannot be used to su
e analys
supp
e analys
hdraw
to s
hdraw
be perf
sed
be perf
An
e u
An
umber a
nnot 
umber a
unt ≥50
cann
unt ≥50
0% CI
nt c
0% CI
appr
men
appr
nu
m
nu


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 38 of 128
In addition the percentage of subjects achieving a Response, Complete Response and Platelet 
Count ≥50x109/L will be plotted at each post-Baseline visit. Separate plots will be presented for 
each response type with all dose arms overlaid on the same plot.
Analyses will be performed for the FAS and repeated for the PPS. Summary tabulations by dose 
arm will be repeated for the subgroups defined in Section 4.8 (based on the FAS only).
Percentage of days without bleeding will also be described by dose arm for each type of response 
(response, complete response and platelet Count >=50x10/L). Percentage of days without 
bleeding is calculated using the following formula:
((N of visits with a SMOG score – N of these visits where bleeding occurred) / N of visits with a 
SMOG score) x 100
In case rescue medications are taken, only the data up to the start date of rescue medication will 
be utilized for the summary tables. Listings will contain all the data but a footnote will be 
included indicating the patients for which some data has been excluded from the summary tables.
In case of partial dates, the imputation rules for partial dates described in Section 4.2.7 will be 
applied.
8.1.4
Rescue medication definition (after medical inspection)
In the rescue medication section of the protocol, rescue medication is defined as platelet 
substitution or treatment with a commercially available IVIg. In addition, the prohibited 
medications PLEX, dexamethasone and rituximab will also be considered as a rescue medication 
for analysis.
8.2
Other efficacy variables
8.2.1
ITP bleeding score
The ITP bleeding score is a consensus-based ITP-specific Bleeding Assessment Tool (ITP-BAT) 
based on a precise definition of bleeding manifestations and on the grading of their severity 
(Rodeghiero et al, 2013). The ITP bleeding score will be assessed using the ITP-BAT tool 
version 1.0 at the visits indicated in Section 2.2.2.
Bleeding manifestations will be grouped into 3 major domains, with gradation of severity 
(SMOG):

Skin (S)

Visible mucosae (M)

Organs (O)
Each bleeding manifestation is assessed at the time of examination and each domain is 
subcategorized into different types of bleeding. Severity is graded from Grade 0 to 3 or 4, with 
Grade 5 for any fatal bleeding. Bleeding reported by the subject without medical documentation 
is graded as 1. The worst bleeding manifestation since the last visit (or in the 15 days preceding 
the first visit) is graded for each bleeding type (within each domain), and the highest grade 
within each domain is reported as part of the SMOG.
The overall SMOG index will be reported as S2M2O3 for example. Intracranial bleeding will
always be reported, irrespective of its grade. For example, if a female subject had S2 
(subcutaneous hematoma) M2 (epistaxis) O3 (menorrhagia) and an intracranial bleeding Grade 2 
REDACTED COPY
le
PY
le IV
PY 
IV
will a
COP
will a
es
ACT
es
us
R
us-
R
-ba
RE
ba
any marketing authorization application and any extensions or variations thereof.
s with 
or v
s with 
edicati
ensi
edicati
note wil
exte
note wil
m the su
ny e
m the su
Sectio
d any
Sectio
al insp
tion 
al insp
cation i
plica
cation i
Ig
ap
Ig. In a
appl
. In a
also be 
n ap
also be 
ased IT
ting
ased IT
ing ma
rket
ing ma
bleedin
mar
bleedin
d in
ny m
d in Se
m
Se
nt cannot be used to suppor
ll be gr
ort a
ll be gr
osae (M
sed t
osae (M
(O)
be u
(O)
leeding
not b
leeding
categori
ann
categori
rade 5 
nt ca
rade 5 
This documen
is gra
ment
is gra
the
m
the


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 39 of 128
(post trauma, requiring hospitalization), the SMOG index is S2M2O3 (intracranial 2). If the same 
subject also had intracranial bleeding Grade 3, the SMOG index is S2M2O3 (intracranial 3).
Further details regarding the bleeding types and scoring algorithms are provided in Section 13.3.
The individual responses for the ITP bleeding score will be listed by dose arm and visit for those 
items related to the SMOG score. A separate listing will be presented for the bleeding history 
obtained at Screening including the date and results of any platelet counts (obtained outside the 
clinical study) together with any medications taken which may interfere with hemostasis; this
information will not form part of the SMOG score. Details of bleeding after surgery, invasive 
procedures and hemostatic challenges, including platelet counts associated with such procedures
will also be listed. This information will not form part of the SMOG score.
A separate listing of the grades for each bleeding type will be presented for each domain, and 
will include the overall score (highest grade) for the specific domain which will be used in the 
derivation of the SMOG.
The results for the ITP bleeding score will be summarized (n, median, minimum and maximum) 
by dose arm and visit (absolute values only) for each domain. In addition the number and 
percentage of subjects with severe or clinically relevant bleeding will be summarized at each 
visit. Clinically relevant bleeding is defined as follows:

Skin (S) severity of Grade 3

Mucosal (M) severity of Grade 2 or higher and/or

Organ (O) severity of Grade 2 or higher
The number and percentage of subjects with absence of bleeding at each visit will also be 
included in the summary. Absence of bleeding will correspond to a Grade 0 for each domain.
Summaries will be presented for both the FAS and the PPS.
8.2.1.1
ITP bleeding score and platelet response
In addition to the platelet response variables defined in Section 8.1.1 the following variables will 
also be defined based on a combination of platelet response and information from the ITP 
bleeding score (these will be referred to as Clinical Response variables). In case rescue 
medications or prohibited medications potentially affecting platelet counts are taken, only the 
platelet data up to the start date of rescue medication will be utilized for the summary tables 
(refer to Section 8.1.4):

Clinical Response: a Clinical Response is defined as a platelet count ≥30x109/L with at least 
2-fold increase from the Baseline value AND absence of bleeding, by visit. This must be 
confirmed by a second measurement at least 5 days later (to allow for the ±2-day visit 
window), showing a platelet count ≥30x109/L and at least 2-fold increase from the Baseline.

Time to Clinical Response is defined as the time from starting treatment (Day 1) to 
achievement of Clinical Response. The will be taken as the time to the first platelet 
assessment (obtained at the same time as the corresponding ITP bleeding score assessment). 
If the second assessment does not fulfill the required criteria for a clinical response, the 
subject will be considered as a nonresponder at the respective visits.
REDACTED COPY 
nd/or
D CO
nd/or
with ab
DAC
with ab
f bleed
RED
f bleed
h
R
h
pport any marketing authorization application and any extensions or variations thereof.
ve
v
ve
cedure
or v
cedure
domain
ensi
domain
l be us
xte
l be us
minimu
nd a
minimu
tion th
and
tion th
will be 
tion 
will be 
absence
utho
absence
ding wi
g au
ding wi
the FAS
ketin
the FAS
ore and
mar
ore and
onse va
any 
onse va
combin
ort a
combin
ll be re
ppor
ll be re
ot be used to s
bited m
supp
bited m
the star
d to s
the star
8.1.4
ed t
8.1.4)
t
)
Respo
be u
Respo
d incre
ot be
d incre
This document cann
nfirme
nno
nfirme
windo
t can
windo

me

T
n
T


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 40 of 128

Duration of Clinical Response: the duration of Clinical Response is defined as the time 
between achievement of a Clinical Response to the first time a loss of Clinical Response 
occurred (defined as platelet count <30x109/L or less than 2-fold increase from Baseline OR 
presence of bleeding). Refer to Section 8.1.1 in case a subject has several clinical responses 
or the clinical response is maintained until the end of the study".

Complete Clinical Response: a Complete Clinical Response is defined as a platelet count 
≥100x109/L AND absence of bleeding, by visit. This must be confirmed by a second 
measurement at least 5 days later (to allow for the ±2-day visit window), showing a platelet 
count ≥100x109/L.

Time to Complete Clinical Response: the time to Complete Clinical Response is defined as 
the time from starting treatment (Day 1) to achievement of Complete Clinical Response

Duration of Complete Clinical Response: the duration of Complete Clinical Response is 
defined as the time between achievement of a Complete Clinical Response to the first time a 
loss of Complete Clinical Response occurred (defined as platelet count <100x109/L OR
presence of bleeding). Refer to Section 8.1.1 in case a subject has several clinical responses 
or the clinical response is maintained until the end of the study".

No Clinical Response or a loss of clinical response: the platelet count must be defined as a 
platelet count <30x109/L OR >=30x109/L WITHOUT at least a 2-fold increase from the 
Baseline value OR presence of bleeding, by visit. This must be confirmed by a second 
measurement 1 to 9 days* later, showing a platelet count <30x109/L OR >=30x109/L
WITHOUT at least a 2-fold increase from the Baseline value.
For all the above response criteria, the calculation rules included in Section 8.1.1 will apply. In 
addition the following will be applicable:

The Clinical Response variables will be assessed only for visits for which both platelet 
counts and the ITP bleeding score are assessed. The last visit cannot be a clinical response as 
no confirmation after that is available.

Absence of bleeding is indicated by Grade 0 for all domains of the SMOG, or a Skin Grade 
of 0 or 1

Presence of bleeding is indicated by a Mucosae or Organs Grade of ≥1, or Skin Grade of ≥2
*This differs from the published definition (Rodeghiero et al, 2009) which requires 2 platelet 
measurements 1 day apart to define no response or loss of response. In the current protocol 
platelet count assessments are not as frequently planned (unless unscheduled measurements are 
performed), thus it was deemed appropriate to modify the definition above to take into account 
the schedule of assessments in this study. 
As a result the following clinical response variables are not in complete accordance with the 
guideline:

Duration of Clinical Response

Duration of Complete Clinical Response

No Clinical Response
REDACTED COPY 
UT
PY
UT
it
CO
it. Thi
OPY
. Thi
platelet
D CO
platelet
m the B
TED
m the B
alculat
DACT
alculat
ble
RED
ble:
ED
:
il
R
il
pport any marketing authorization application and any extensions or variations thereof.
let 
va
let 
defined
ons 
defined
Respon
nsio
Respon
l
e
l Resp
exte
Resp
nse to t
ny e
nse to t
unt <10
d an
unt <10
severa
and
severa
i
.
o
.
atelet co
licat
atelet co
t least 
ppli
t least 
is
n
is mus
n ap
mus
et count
ation
et count
Baselin
izat
Baselin
tion rul
utho
tion rul
ll be as
keting
ll be as
re
a
re are a
ark
are a
vailabl
ma
vailabl
ndicated
t any
ndicated
cannot be used to su
ing is in
supp
ing is in
m the
d to
m the pu
o 
pu
1 day a
used
1 day a
nt asse
be us
nt asse
ed), thu
ot be
ed), thu
hedule 
nnot
hedule 
This document 
s a resu
nt ca
s a resu
guide
ment
guide



UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 41 of 128
All response variables described above will be listed by dose arm and subject and summarized 
by dose arm and visit where appropriate. The responder rates will be tabulated as described in 
Section 8.1.3.3. Moreover the change in category of bleeding from Baseline will also be 
presented in shift table at all post-Baseline visits by dose arm. Summary tabulations for Clinical 
Response by dose arm will be repeated according to past intravenous immunoglobulin 
medication (Yes/No) and the number of past ITP therapies (≤2/>2). All analyses described in this 
section will be performed for the FAS.
In case rescue medications are taken, only the data up to (not including) the start date of rescue 
medication will be utilized for the summary tables. Listings will contain all the data but a 
footnote will be included indicating the patients for which some data has been excluded from the 
summary tables. In case of partial dates, the imputation rules for partial dates described in 
Section 4.2.7 will be applied.
8.2.2
Patient reported outcomes
8.2.2.1
NFI-MS
The NFI-MS was developed in multiple sclerosis and consists of 23 items in four subscales:

Physical (8 items)

Cognitive (4 items)

Relief by diurnal sleep or rest (6 items)

Abnormal nocturnal sleep and sleepiness (5 items)
Each item is answered using a 4-point Likert scale according to the following:

0 = Strongly disagree

1 = Disagree

2 = Agree

3 = Strongly agree
Within each subscale a summary score is calculated by adding up the responses to each item, i.e., 
the summary score for the physical subscale ranges from 0 to 24. In addition, an overall 
summary score (ranging from 0 to 30) is calculated using specified items from the Physical and 
Cognitive subscales. The individual items and further detail regarding the scoring algorithm are 
presented in Section 13.2. A listing with the questionnaire glossary will be described.
The individual NFI-MS item results and calculated summary scores (for each subscale and for 
the Physical/Cognitive subscales) will be listed by dose arm and visit including changes from 
Baseline (Day 1, predose). Descriptive summaries (including n, arithmetic mean, median, SD, 
minimum and maximum) will be presented by dose arm and visit for both absolute values and 
changes from Baseline. Summaries will be presented for both the FAS and PPS.
Mean and change from Baseline values will be plotted over time by dose arm with all dose arms 
overlaid on the same plot, for both the FAS and PPS. Separate plots will be presented for each 
individual subscale and the Physical/Cognitive overall score.
REDACTED COPY 
5 item
ED C
5 item
kert sca
ACT
kert sca
e used to support any marketing authorization application and any extensions or variations thereof.
ue 
a
ue 
d from 
ns o
d from 
bed in
sion
bed in
items in
and
items in
ms)
iza
ms)
ale acc
thor
ale acc
mmary
port 
mmary
the phy
upp
the phy
ging fro
to su
ging fro
les. 
d t
les. Th
to
Th
ection
sed
ection
nt cannot b
dual N
be 
dual N
ysical/C
not b
ysical/C
eline (D
ann
eline (D
minimum
nt ca
minimum
This documen
chang
men
chang
M
m
M


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 42 of 128
9
PHARMACOKINETICS AND PHARMACODYNAMICS 
9.1
Pharmacokinetics
Due to the blood sampling regimen there will be no calculation of PK parameters using standard 
methods eg, noncompartmental analysis. Population PK analysis may be conducted and will be 
described in a separate Data Analysis Plan and reported outside the CSR.
The actual blood sampling timepoints for UCB7665 concentration will be obtained relative to the 
start time of the first infusion. No time deviations will be calculated as the blood sampling is not 
scheduled at a specified timepoint at each visit.
Individual concentrations of UCB7665 will be listed by dose arm for the SS and will include the
actual sampling time in days relative to the first dose. The planned dose in mg will be calculated 
based on the body weight at Screening and the dose arm, and included in the listing. The actual 
dose administered will be calculated based on the planned dose and the percent of planned dose 
administered as follows:
Actual dose (mg) = Planned dose (mg)*Percent of planned dose administered
The percent of planned dose administered is calculated as described in Section 10.1. The actual 
dose will also be included in the concentration listing.
Individual concentrations will be summarized by dose arm and scheduled sampling day for the 
PK-PPS using n, arithmetic mean, median, SD, minimum, maximum, geoMean and 95% CI, 
geoCV (assuming log-normally distributed data).
For each subject, individual concentration versus time (day) profiles will be presented 
graphically in linear and semi-logarithmic scale. Individual plasma concentration versus time 
(day) profiles will also be displayed for each dose arm with all subjects within each dose arm 
overlaid on the same plot (linear and semi-logarithmic scale).
Geometric mean profiles of UCB7665 with corresponding lower and upper limit of the 95% CI 
(linear scale plot only) will also be presented with all dose arms overlaid on the same plot.
All figures will include the LLOQ on the semi-logarithmic plots.
The following rules will apply for PK data listings and summaries:

Values below the LLOQ will be reported as BLQ in the listings

Descriptive statistics of concentrations will be calculated if at most 1/3rd of the individual 
data points are missing or are not quantifiable (<LLOQ). Values that are BLQ will be 
replaced by the numerical value of the LLOQ/2 in this instance. However if n≤3, then only n, 
minimum and maximum will be presented. The other descriptive statistics will be left blank.

If no subjects have data, only n=0 will be presented. The other descriptive statistics will be 
left blank.
The 95% CI for the geoMean will be calculated by obtaining the lower and upper 95% CI for 
the arithmetic mean on the log-transformed data and back-transforming to obtain the 
respective values for the geoMean

The 95% CI lower and 95% CI upper should be left blank if the SD (or equivalently, the 
geoCV) is 0
REDACTED COPY
e arm
OPY 
e arm
inimum
COP
inimum
a).
ED
a).
versus
ACTE
versus
mic sca
DAC
mic sca
for eac
RED
for eac
sem
R
sem
d to support any marketing authorization application and any extensions or variations thereof.
he
a
he
not 
vari
not 
in
o
include
ons 
clude
be calc
nsio
be calc
ting.
xten
ting. Th
n
Th
ent of p
y ex
ent of p
dminist
and 
dminist
ed in
tion
ed in S
m and sc
appl
m and sc
m, max
on ap
m, max
s time (
horiz
s time (
ale. Ind
autho
ale. Ind
ch dose
g au
ch dose
mi
eti
mi-
tin
-loga
ting
loga
665 wit
mark
665 wit
be pres
y ma
be pres
LLOQ o
rt any
LLOQ o
apply 
ppo
apply 
e LLO
to su
e LLO
annot be use
statisti
sed 
statisti
nts are m
e use
nts are m
ed by
t be 
ed by t
nimum 
not 
nimum 
This document ca
If no 
t can
If no 
lef
nt 
lef


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 43 of 128

The geoCV will be calculated using the following formula where SD is the standard 
deviation from the log-transformed data
geoCV (%) = sqrt[(exp (SD^2) – 1)] x 100
The above summaries will be repeated separately for the subjects in the PK/PD substudy sample, 
in the event of very few subjects (<5 subjects) only listings will be provided.
Further analyses and summaries relating to the population PK analyses and PK/PD analyses will 
be described in a separate SAP and reported separately.
9.2
Pharmacodynamics
The analysis of the PD data will be performed on the FAS with the exception of the total IgG and 
IgG subclasses, which will be analyzed on the PD-PPS. All listings will be presented for the SS.
The above summaries will be repeated separately for the subjects in the PK/PD substudy sample, 
in the event of very few subjects (<5 subjects) only listings will be provided.
9.2.1
ITP-specific autoantibodies
The following ITP-specific autoantibodies will be measured using the indirect MAIPA method 
and pre-chloroquine minus post chloroquine treated scores for PIFT
The results will be expressed in the form of the OD value and for indirect PIFT method using the 
following categories: 0 = negative; 0.5 = week positive; 1 = positive; 2 = positive; 3 = strong 
positive; 4 = strong positive.
ITP-specific autoantibodies (OD value and PIFT categories) will be listed by dose arm and 
timepoint. OD values that are ALD will be displayed as such in the listings.
Descriptive summaries (including n, arithmetic mean, median, SD, minimum and maximum)
will be presented by dose arm and visit for absolute values only. Any values that are ALD will 
be handled as described in Section 4.2.3 for the calculation of the descriptive statistics.
Mean values will be plotted over time by dose arm with all dose arms overlaid on the same plot
and separate plots for each variable. In addition, combined individual (spaghetti) plots will be 
plotted over time by dose arm for each variable (absolute values only). All subjects within each 
dose arm will be overlaid on the same plot.
In order to evaluate the relationship between changes in platelet count and total IgG, IgG 
subclasses and ITP-specific autoantibodies the following figures will be presented:

Spaghetti plot of individual ITP-specific autoantibodies and platelet counts (measured by 
ACM Global Central Laboratory) will be displayed graphically over time (Day 1 to Day 85 
for Dose Arm 1; Day 1 to Day 71 for Dose Arm 2; Day 1 to Day 64 for Dose Arm 3 and Day 
1 to Day 57 for Dose Arms 4 and 5) for each subject (linear scale). The ITP-specific 
autoantibodies
and platelet counts will be overlaid on the 
same plot (discrete y-axes) with separate plots for each subject (4 lines per plot)
REDACTED COPY 
of the
DACT
of the
5 = we
REDA
5 = we
sed to support any marketing authorization application and any extensions or variations thereof.
total Ig
ions
total Ig
nted f
ensio
nted for
sio
or
fo
f
sio
fo
f
D subs
ext
D subs
ed.
an
ed.
the ind
ion a
the ind
PIFT
catio
PIFT
e OD v
utho
e OD v
eek pos
g au
eek pos
ue
ar
ue and
rke
and
D will 
ma
D will 
uding n
t any
uding n
arm an
port 
arm an
in
p
in Sec
ppo
Sec
e plotte
to s
e plotte
ts for e
ed t
ts for e
This document cannot be u
ime by
use
ime by
will be 
be u
will be 
er to
not
er to ev
ot
ev
classes
can
classes

e

Sp
nt
Sp


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 44 of 128

A scatter plot of platelet counts (measured by ACM Global Central Laboratory) versus 
ITP-specific autoantibodies measured at the same visit will be presented in linear scale, with 
separate plots for each dose arm and for each variable 
All subjects and visits will be included on the same plot for each dose arm

Individual ITP-specific autoantibodies and total IgG (from ACM Global Central Laboratory)
will be displayed graphically over time (Day 1 to Day 85 for Dose Arm 1; Day 1 to Day 71 
for Dose Arm 2; Day 1 to Day 64 for Dose Arm 3 and Day 1 to Day 57 for Dose Arms 4 and 
5) for each subject (linear scale). The ITP-specific autoantibodies 
and total IgG will be overlaid on the same plot (discrete y-axes) with separate plots 
for each subject (4 lines per plot). These plots will be repeated for each of the IgG subclasses.
The plots versus time will include 2 y-axes with the ITP-specific autoantibodies on the left hand 
y-axis and the platelet counts (or total IgG and IgG subclasses) on the right hand y-axis. Only 
patients with positive ITP-specific autoantibodies will be described. 
All analyses described in this section will be performed on the FAS.
9.2.2
Total IgG and IgG subclasses
Total IgG concentrations (measured by ACM Global Central Laboratory) and IgG subclasses
will be listed by dose arm and visit including changes from Baseline and percentage changes 
from Baseline. Descriptive summaries (including n, arithmetic mean, median, SD, minimum and 
maximum) will be presented by dose arm and visit for absolute values, changes from Baseline 
and percentage changes from Baseline. The maximum decrease from Baseline in total IgG 
(absolute and percentage decrease) will be reported in the listing and summarized for each dose 
arm based on the results obtained from ACM Global Central Laboratory. Summary tabulations 
(for total IgG only) by dose arm will be repeated for the subgroups defined in Section 4.8.
In the event that a decrease from Baseline in total IgG is not observed in a given subject, the 
maximum decrease will be reported as the smallest increase from Baseline.
Mean, median, median change from Baseline and mean and median percentage change from 
Baseline values in total IgG (measured by ACM Global Central Laboratory) will be plotted over 
time by dose arm with all dose arms overlaid on the same plot. Additional figures will be 
presented in conjunction with the ADA results as described in Section 9.3.4 as well as figures in 
conjunction with the platelet results as described in Section 8.1.1.
Finally, a separate figure will be presented by subject showing the individual total IgG results 
from ACM Global Central Laboratory.
Any values that are BLQ or ALQ will be handled as described in Section 4.2.3.
All analyses described in this section will be performed on the PD-PPS. In case rescue 
medications are taken, only the IgG data up to the start date of rescue medication will be utilized 
for the summary tables. Listings will contain all the data but a footnote will be included 
indicating the patients for which some data has been excluded from the summary tables. In case 
of partial dates, the imputation rules for partial dates described in Section 4.2.7 will be applied.
REDACTED COPY
arithm
OPY 
arithm
for a
COP
for a
ximum
ED C
ximum
eporte
CTED
eporte
CM G
ACT
CM G
e repe
REDA
e repe
elin
R
elin
to support any marketing authorization application and any extensions or variations thereof.
d 
a
d 
te plots
or v
te plots
subclas
ns o
subclas
n the le
nsio
n the le
d y
xte
d y-
te
-axi
en
axi
borator
ation
borator
aseline
lica
aseline
metic m
appl
metic m
bsolut
on ap
bsolut
m decr
atio
m decr
ed in th
oriza
ed in th
Glob
tho
Global C
o
al C
eated fo
aut
eated fo
ne in to
eting
ne in to
as the s
arke
as the s
rom Ba
y ma
rom Ba
measur
any
measur
dose arm
ort a
dose arm
n with t
ppo
n with t
platele
o sup
platele
t cannot be used
te figur
ed to
te figur
lobal C
use
lobal C
s 
t b
s that 
t be 
that 
nalyses
nno
nalyses
edicatio
t can
edicatio
This documen
for the
ent 
for the
indi
me
indi
va


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 45 of 128
9.3
Other immunological variables
The analysis of the immunological data will be performed on the FAS. All listings will be 
presented for the SS.
9.3.1
Serum immunoglobulins and lymphocytes
Serum immunoglobulins (IgA, IgE and IgM) will be listed by dose arm and visit including 
changes from Baseline. Descriptive summaries (including n, arithmetic mean, median, SD, 
minimum and maximum) will be presented by dose arm and visit for both absolute values and 
changes from Baseline. The listing and summary tabulation will be repeated for B- and 
T-lymphocytes.
Mean and mean change from Baseline values will be plotted over time by dose arm with all dose 
arms overlaid on the same plot and separate plots for each variable (IgA, IgE, IgM, B- and 
T-lymphocytes).
Similar plots will be presented by dose arm for the mean and mean change from Baseline values 
in IgA, IgE, IgM and total IgG only. Separate plots will be presented for each dose arm with all 
variables overlaid on the same plot.
In addition, individual immunoglobulin (IgA, IgE, IgM and total IgG) values will be graphically 
displayed over time with all variables overlaid on the same plot and separate plots for each 
subject. 
For all overlaid plots for the immunoglobulin variables, discrete y-axes may be used for 
applicable variables to accommodate changes in the scale of measurement.
Any values are that BLQ or ALQ will be handled as described in Section 4.2.4.
All analyses described in this section will be performed on the FAS.
9.3.2
Serum and plasma complement levels
Serum (C3 and C4) and plasma (C3a and C5a) complement variables will be listed by dose arm 
and visit including changes from Baseline. Descriptive summaries (including n, arithmetic mean, 
median, SD, minimum and maximum) will be presented by dose arm and visit for both absolute 
values and changes from Baseline.
Mean and mean change from Baseline values will be plotted over time by dose arm with all dose 
arms overlaid on the same plot and separate plots for each variable.
Any values are that BLQ or ALQ will be handled as described in Section 4.2.4.
All analyses described in this section will be performed on the FAS.
9.3.3
Serum biomarkers
Serum safety biomarkers 
and BAFF will be listed by dose arm and timepoint including changes 
from Baseline. Descriptive summaries (including n, arithmetic mean, median, SD, minimum and 
maximum) will be presented by dose arm and timepoint for both absolute values and changes 
from Baseline.
REDACTED COPY 
am
Y
am
ariable
D CO
ariable
s in th
TED
s in th
e hand
DAC
e hand
will 
RED
will 
any marketing authorization application and any extensions or variations thereof.
d d 
m with a
nsion
m with a
M, B
xtens
M, B-
n
-
ge from
d any
ge from
for each
and 
for each
al
c
al IgG)
catio
IgG)
plot and
pplic
plot and
es
at
es, disc
ation
, disc
he scale
riza
he scale
dled as 
utho
dled as 
be perf
ng a
be perf
comp
rketi
comp
C3a and
ma
C3a and
m Base
any 
m Base
ent cannot be used to support
maxim
rt an
maxim
Baseli
ppor
Baseli
nge from
o sup
nge from
he sa
d to
he sam
 
m
re that B
use
re that B
ses des
t be
ses des
erum
nt ca
erum
This documen
a
fro
m
fro
men


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 46 of 128
Mean and mean change from Baseline values will be plotted over time by dose arm with all dose 
arms overlaid on the same plot and separate plots for each variable.
Any values are that BLQ or ALQ will be handled as described in Section 4.2.4.
All analyses described in this section will be performed on the FAS.
9.3.4
Anti-drug antibodies
Immunological variables will be analyzed for all subjects in the SS. Anti-UCB7665 antibody 
data will be summarized at each scheduled visit, and the rate of ADA positive subjects will be 
calculated.
A calibrator screening assay measures ADA as relative mass units (RMU) in units/mL. A cut 
point will be determined by the bioanalytical laboratory that will be used to determine the status 
of ADA as above the cut point (ACP) or below the cut point (BCP). The RMU result from the 
calibrator screening assay will be used to report ADA levels.
For any ADA levels that are ACP, a further confirmatory assay will be performed, the results of 
which will be determined as either ‘confirmed positive’ (CP) or ‘not confirmed positive’ (NCP). 
The results for the ADA measurements will be listed by treatment group and time point based on 
the SS, including the screening assay, confirmatory assay and level in units/mL. 
The following definitions will be applied:

An ADA status of positive will be concluded for any subject with an ADA level that is ACP 
and CP at any time point 

An ADA status of negative will be concluded for any subject with an ADA level that is either 
BCP or ACP and NCP at any time point

A subject will be classified as having ADA positivity at Baseline if the Day 1, predose result 
is ACP and CP

A subject will be classified as having treatment-emergent ADA positivity when meeting one 
of the following criteria:

The Baseline result is either BCP or ACP and NCP, and at least one post-Baseline time 
point is ACP and CP

The Baseline result is positive (ACP and CP) and at least one post-Baseline measurement 
shows a pre-defined fold increase in units/mL from the Baseline value (the fold increase 
from Baseline required to meet this criterion will be defined with the development of the 
assay and will be included in the TFLs)

A subject will be classified as overall positive if at least one post-Baseline measurement is 
ACP and CP (this includes subject who have negative results at Baseline)

A subject will be classified as overall negative if at all post-Baseline visits the ADA status is 
negative (this includes subjects who have positive [ACP and CP] results at Baseline)

Inconclusive: pre-ADA negative or pre-ADA positive subjects with negative ADA samples 
post baseline for which time matched drug levels are above the demonstrated drug tolerance 
characteristics of the ADA screening assay at one or more sampling time points
REDACTED COPY 
d for a
D CO
d for a
onclud
DACT
onclud
point
REDA
point
in
R
in
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
be 
v
be 
L. A cu
ions
L. A cu
mine the
ensio
mine the
result f
exten
result f
perform
d an
perform
confirm
and
confirm
nt group
ation
nt group
level in
licat
level in
any sub
ation
any sub
ded for 
utho
ded for 
g
ng ADA
keting
ng ADA
as havin
ny m
as havin
ult is ei
ppor
ult is ei
and CP
supp
and CP
ine res
d to
ine res
a pre
used
a pre-
e
-d
d
d
m Basel
be us
m Basel
ssay an
ot be
ssay an
A subje
ann
A subje
ACP
nt ca
ACP

me



UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 47 of 128

Missing: relevant samples are missing
The ADA status (positive/negative) will be summarized as a categorical endpoint (number and 
percentage of subjects) for all time points and overall, based on the SS. 
In addition, the first occurrence of treatment-emergent ADA positivity (based on the definitions 
above) will be summarized (number and percentage of subjects) at each post-Baseline visit, 
based on the SS. This tabulation will count the number of subjects at each post-Baseline visit 
who fulfill at least one of the above defined criteria for treatment-emergent positivity; subjects 
will be counted in the numerator based on the earliest visit at which one of these criteria is 
fulfilled. At other visits, subjects will be counted in the denominator (assuming a measurement is 
available). For all tabulations, percentages will be based on the number of observations at each 
visit.
A separate listing will be presented (based on the SS) showing the UCB7665 concentrations and 
ADA measurements in the same output in adjacent columns. The listing will include the 
UCB7665 concentration, ADA status (ACP or BCP) and confirmatory assay results if applicable 
(NCP or CP), together with the units/mL for results that are CP. In addition the time since the 
previous administration of IMP will be reported (in days).
Finally, individual subject plots (based on the SS) will be presented displaying the ADA 
units/mL and UCB7665 concentrations overlaid on the same figure. The figure will also show 
the timing and dose of each administration of UCB7665 received during the study.
The rules for handling values that are BLQ in the UCB7665 concentration data are described in 
Section 4.2.5 For the ADA data, any negative results for which there are no units/mL available at 
a specific visit will be substituted with 0.001 for the purpose of the figure.
9.3.5
Cytokines
Cytokines will be obtained at Baseline in all subjects and at subsequent visits only in subjects 
experiencing severe infusion reactions (or due to DMC’s or sponsor’s request). Only for subjects 
for whom additional measurements were obtained the results of the cytokine assessments will be 
listed by dose arm and timepoint including changes from Baseline. 
If appropriate (i.e., sufficient data are available), summaries will be presented by dose arm and 
timepoint for both absolute values and changes from baseline. Depending on the availability of 
data, it may be also decided to summarize the data overall without stratification by dose arm.
A minimum of 5 subjects per dose arm with any post-dose cytokine measurements will be 
required in order to produce summaries by dose arm. Similarly, a minimum of 5 subjects across 
all dose arms with any post-dose cytokine measurements will be required to produce the 
summaries without stratification by dose arm. 
The cytokines to be measured are presented in Section 13.4.
All analyses described in this section will be performed on the FAS.
10
SAFETY ANALYSES
All safety analyses will be presented using the SS. Listing will be presented by dose arm and 
subject; tabulations will be presented by dose arm and overall (AE data only), with the lowest 
dose per kg presented first and continuing in ascending order.
REDACTED COPY
e sam
PY 
e sam
7665 r
OPY
7665 r
he UC
ED C
he UC
ve resu
CTED
ve resu
001 fo
DACT
001 fo
R
ot be used to support any marketing authorization application and any extensions or variations thereof.
rement 
s or v
rement 
ns at ea
ons 
ns at ea
oncent
exte
oncent
ll includ
ny e
ll includ
ssay res
d any
ssay res
dition t
and 
dition t
ented d
icati
ented d
e figure
pplic
e figure
receive
n app
receive
CB7665
atio
CB7665
ults for
oriza
ults for
or the p
thor
or the p
in all s
ketin
in all s
ons
mar
ons (or 
arke
(or 
nts wer
y ma
nts wer
oint
an
oint inc
ny
inc
ent dat
port
ent dat
lute va
upp
lute va
decide
to su
decide
5 subje
sed 
5 subje
r
e
rder to
e use
der to
rms wit
t be 
rms wit
This document canno
ries wi
not 
ries wi
e cytok
t can
e cytok
All an
ment
All an
1
m
1


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 48 of 128
10.1
Extent of exposure
All drug administration details (including date, start and stop time of infusion, location of 
infusion site, interruptions, discontinuations [including reasons] and volume delivered) will be 
listed. The duration of the infusion, in minutes, will also be calculated.
The percent of planned dose administered will be calculated based on the actual volume 
delivered as follows:
Percent of Planned Dose Administered (%) = [100*(Actual volume/Planned volume)]
For all subjects the planned volume is 10mL.
The overall exposure to UCB7665 will be calculated in days as follows and listed for each 
subject:
Total exposure (days) = (Date of last dose – Date of first dose) + 1
The planned dose regimens are as follows:

Subjects in Dose Arm 1 will receive 5 sc doses of UCB7665 4mg/kg at 1-week intervals

Subjects in Dose Arm 2 will receive 3 sc doses of UCB7665 7mg/kg at 1-week intervals

Subjects in Dose Arm 3 will receive 2 sc doses of UCB7665 10mg/kg at 1-week intervals

Subjects in Dose Arm 4 will receive 1 sc dose of UCB7665 15mg/kg 

Subjects in Dose Arm 5 will receive 1 sc doses of UCB7665 20mg/kg 
The DMC may decide to modify the dosing regimen following review of emerging safety data. 
In this case the modified dose regimen will be considered as a new dose arm for the study.
10.2
Adverse events
Adverse events will be recorded from the time of informed consent until study completion. All 
AEs will be coded (Section 3.8) and will be categorized by relationship to UCB7665.
In addition, AEs will be classified according to the CTCAE Version 4.03 for severity. For any 
AEs where it is not possible to provide a CTCAE grading, the events will be assessed using a 
standard intensity classification (mild, moderate and severe). For the purpose of the tabulations 
all CTCAE severity classifications will be mapped to a mild/moderate/severe grade as described 
in the below sections. Bleeding events classified as Grade 1 or Grade 2 (based on CTCAE) will 
not be reported as AEs as these will be assessed and reported as part of the ITP-BAT 
assessments. Bleeding events classified as Grade 3 or higher, based on CTCAE, will be reported 
as AEs.
A TEAE is defined as any event that was not present prior the first administration of UCB7665
or any unresolved event already present before the first administration of UCB7665 that worsens 
in intensity following exposure to treatment. Adverse events starting before the first 
administration of UCB7665 or after 8 weeks following the final dose of UCB7665 will not be 
considered as TEAEs. Such events will be listed only.
Where dates are missing or partially missing, AEs will be assumed to be treatment-emergent. 
Handling of missing dates/times for classification of AEs as TEAEs is described in Section 4.2.7.
REDACTED COPY 
UC
Y
UC
of UC
COPY
of UC
oses o
ED C
oses o
g regi
ACTE
g regi
will be
EDAC
will be
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
r each
ions
r each
) + 1
ext
) + 1
/kg at 
and
/kg at 
7mg/kg
ation
7mg/kg
665 
plic
665 10
ca
10
CB7665
n ap
CB7665
of UCB
zatio
of UCB
imen fo
thori
imen fo
e consi
auth
e consi
m the ti
arke
m the ti
nd wil
ma
nd wil
ified ac
t any
ified ac
le to pr
port 
le to pr
ificatio
uppo
ificatio
classifi
o sup
classifi
ons.
d to
ons. Bl
o 
Bl
d as AE
used
d as AE
s. Bleed
be us
s. Bleed
EAE is 
anno
EAE is 
r any un
nt ca
r any un
in inte
ment
in inte
adm
m
adm


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 49 of 128
The following rules will be used to assign a TEAE to a study period:

A TEAE will be assigned to the Dosing Period for the tabulations if the start date/time of the 
event is at the time of or after the first administration of UCB7665 until 7 days after the final 
dose; for the purpose of the analysis this will be calculated as the start date/time of the final 
infusion plus 168 hours;

A TEAE will be assigned to the Observation Period for the tabulations if the start date/time 
of the event is greater than 7 days after the final dose until 8 weeks following the final dose; 
events starting later than 8 weeks following the final dose of UCB7665 are not considered as 
TEAEs.
Adverse events with missing start date/times will be handled as described in Section 4.2.7 for 
this classification.
The number and percentage of subjects who experience TEAEs will be summarized for each
dose arm and overall. The following summaries will be presented:

Incidence of TEAEs (overview including number and percentage of subjects with any 
TEAEs, serious TEAEs, discontinuations due to TEAEs, TEAEs leading to permanent 
withdrawal of UCB7665, related TEAEs, TEAEs with CTCAE Grade 3 and above [or rated 
as ‘severe’ for events with no CTCAE classification], and deaths; event counts will also be 
included)

Incidence of TEAEs (overview as described above) during the Dosing Period

Incidence of TEAEs by SOC, HLT and PT

Incidence of TEAEs during the Dosing Period by SOC, HLT and PT

Incidence of serious TEAEs by SOC, HLT and PT

Incidence of non-serious TEAEs by SOC, HLT and PT

Incidence of AEs of special interest by SOC, HLT and PT

Incidence of AEs of interest by SOC, HLT and PT

Incidence of TEAEs by relationship, SOC, HLT and PT 

Incidence of serious TEAEs by relationship, SOC, HLT and PT

Incidence of non-serious TEAEs by relationship, SOC, HLT and PT

Incidence of fatal TEAEs by relationship, SOC, HLT and PT

Incidence of TEAEs by maximum relationship, SOC, HLT and PT

Incidence of TEAEs by maximum intensity (mild, moderate and severe), SOC, HLT and PT

Incidence of non-serious TEAEs above threshold of 5% of subjects by SOC and PT

Incidence of non-serious TEAEs above threshold of 5% of subjects by relationship, SOC and 
PT

Discontinuation due to AEs
REDACTED COPY 
]
Y
]
above
D CO
above
PT
CTE
PT
ing Pe
DAC
ing Pe
OC, 
RE
OC, 
annot be used to support any marketing authorization application and any extensions or variations thereof.
e;
ar
e;
ed as
var
ed as
4.2.7
ions
4.2.7 f
s
f
marized
y ext
marized
of subje
and 
of subje
Es leadi
on a
Es leadi
AE Gra
atio
AE Gra
d deaths
plica
d deaths
)
ti
) durin
tion 
durin
eriod by
auth
eriod by
HLT a
ting 
HLT a
by SO
arke
by SO
interest
y m
interest
rest 
t a
rest by
an
by
s by rel
uppo
s by rel
ious TE
to su
ious TE
f non
sed
f non-
nce of f
be u
nce of f
cidence
nnot 
cidence
This document ca
Incid
t can
Incid

me

In
n
In


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 50 of 128
Summary tables will contain counts of subjects, percentages of subjects in parentheses and the 
number of events where applicable. A subject who has multiple events in the same SOC, HLT
and PT will be counted only once in the subject counts but all events will be included.
In summaries including relationship to UCB7665, the following relationship categories will be 
included:

Related

Not related
Subjects who experience the same event multiple times will be included in the most related 
category for tabulations by maximum relationship. Events with missing relationship will be 
considered as ‘Related’ to the UCB7665 for summary purposes but shown as missing in the data 
listings.
In summaries including intensity, the CTCAE categories will be summarized according to the 
following categories:

Grade 1: Mild

Grade 2: Moderate

Grade 3: Severe

Grade 4: Severe

Grade 5: Severe
These will be tabulated together with the AEs that were not classified according to CTCAE 
criteria i.e., all Grade 1 AEs as per CTCAE criteria will be included in the ‘mild’ category 
together with those AEs classified as mild as per the ‘standard’ intensity classification.
Subjects who experience the same event multiple times will be included in the most severe 
category for tabulations by maximum intensity. Events with missing intensity will be considered 
as ‘Severe’ for summary purposes. All data will be presented as recorded in the database for the 
listings. 
Adverse event summaries will be ordered by alphabetical SOC, alphabetical HLT within SOC 
and decreasing frequency of PT in the overall column for tables including event counts. For 
tables including only number and percentage of subjects, summaries will be ordered by 
alphabetical SOC, alphabetical HLT within SOC and decreasing incidence of PT within SOC in 
the overall column.
A listing of all AEs will be presented by subject and dose arm. The listing will include the onset 
date/time and outcome date/time of the event (including relative days), the AE duration, days 
since first dose of UCB7665, days since most recent dose of UCB7665, pattern of event, 
severity/intensity, relationship, action taken and outcome. In addition the listing will flag AEs 
that led to discontinuation, TEAEs, AEs of interest, AEs of special interest, infusion reactions, 
SAEs, Sampson criteria and CTCAE grade.
10.3
Clinical laboratory evaluations
Laboratory data (chemistry [excluding follicle stimulating hormone, FSH], hematology, 
coagulation and urinalysis) and changes from Baseline (if applicable) for numeric variables will 
REDACTED COPY 
AEs th
ACT
AEs th
CAE c
EDA
CAE c
mild
RE
mild
o support any marketing authorization application and any extensions or variations thereof.
ed 
o
ed 
will be
ons 
will be
ng in th
nsio
ng in th
d
n
d accor
ny ex
accor
hat wer
thor
hat wer
criteria
auth
criteria
d as per
ing a
d as per
ent mu
rket
ent mu
um int
mar
um int
ses. All
ny m
ses. All
es will 
ppo
es will 
ncy of
sup
ncy of
This document cannot be used t
nly num
d to s
nly num
OC
se
OC, alph
sed 
, alph
olumn.
use
olumn.
g of all 
ot be
g of all 
ime an
nno
ime an
ce first
can
ce first
severit
ent c
severit
that
me
that
S


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 51 of 128
be listed by dose arm and visit. Any laboratory measurements that are BLQ or ALQ will be 
handled as described in Section 4.2.2. Values outside the reference range for the numeric 
variables will be flagged in the listings and in addition, results considered as markedly abnormal 
laboratory results (CTCAE Grade 3 and above) will be listed separately. The reference ranges 
will also be reported in the listings.
Chemistry [excluding FSH], hematology and coagulation variables will be summarized by dose 
arm at each visit, for both absolute values and changes from Baseline.
Laboratory variables will be grouped according to the laboratory function panel (Table 10-1) and 
categorized as normal, high or low, if applicable, based on the reference range supplied by the 
analytical laboratory. For selected variables that are identified in Table 10-1, the change in 
category from Baseline will be presented in shift tables at all post-Baseline visits.
Table 10‒1: Clinical laboratory measurements
Category
Panel
Variable
Serology
Serology
HIV, HBsAg, anti-HBs, anti-HBc, anti-HCV
Hematology
Red blood cell
RBC counta, hemoglobina, hematocrit
Platelet
Plateletab
White blood cell
WBC counta
White blood cell 
differential
Absolute counts: ANCa, basophilsa, eosinophilsa, 
ALCa, monocytesa
Percentages: neutrophils/leukocytesa, 
basophils/leukocytesa, eosinophils/leukocytesa, 
lymphocytes/leukocytesa, monocytes/leukocytesa.
Coagulation
Coagulation
INRa, prothrombin timea, aPTTa, fibrinogena
Chemistry
Electrolytes
Sodiuma, chloridea, potassiuma
Minerals
Calciuma, phosphatea, magnesiuma
Kidney function
BUNa, creatininea
Proteins
Total proteina, albumina, α1-globulina, α2-globulina, 
β-globulina, gamma globulina.
For all parameters except total protein, both absolute 
and percentage values will be reported as part of the 
serum protein electrophoresis.
Liver function
ASTa, ALTa, GGTa, ALPa, LDHa, total bilirubina, 
direct bilirubin (if indicated)
Lipids
Total cholesterola, triglyceridesa
Hormones
FSH
Other
hsCRPa, amylasea
Urinalysis
Dipstick
pHa, protein, glucose, ketones, urobilinogen, bilirubin, 
blood, nitrite, leucocytes
REDACTED COPY 
count
OPY
count
Y
bsolut
D CO
bsolut
ALC
ED 
ALC
P
T
P
O
CT
R
ument cannot be used to support any marketing authorization application and any extensions or variations thereof.
) and 
var
) and 
by the
or v
by the
ge in
ons
ge in
y e
anti
and
anti-
nd
-HB
d 
HB
d a
obin
tion
obina
n
a, h
 
, h
a
tio
pl
e coun
tion
e coun
, mon
izat
, mon
Percenta
thori
Percenta
basop
auth
basop
lym
au
lym
n a
g a
ng
rke
m
ney fun
ort 
ney fun
a
Protein
upp
Protein
po
to
b
ca
en
This docum
um
u


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 52 of 128
Category
Panel
Variable
Quantitative
Albumin, creatinine
Urine sedimentc
RBC, WBC. epithelial cells, casts, crystals, yeast, 
bacteria, amorphous urates, amorphous phosphates
Pregnancy test
Urine HCGd, serum HCGe
Other
HbA1c
ALC=absolute lymphocyte count; ALP=alkaline phosphatase; ALT=alanine aminotransferase; ANC=absolute 
neutrophil count; anti-HBc=hepatitis B core antibody; anti-HBs=hepatitis B surface antibody; anti-HCV=hepatitis C 
virus antibody; aPTT=activated partial thromboplastin time; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; FSH=follicle stimulating hormone; GGT=gamma-glutamyltransferase; HbA1c=glycosylated hemoglobin; 
HBsAg=hepatitis B surface antigen; HCG=human chorionic gonadotropin; HIV=human immunodeficiency virus; 
hsCRP=high sensitivity C-reactive protein; INR=International Normalized Ratio; LDH=lactate dehydrogenase; 
RBC=red blood cell; TB=tuberculosis; WBC=white blood cell.
a Shift tables will be presented for these variables. 
b Only platelet results measured at the local laboratory will be included in the safety outputs. Measurements 
obtained at the central laboratory will be reported as part of the efficacy analyses.
c If indicated, based on results of urine dipstick.
d Urine pregnancy test will be performed predose on dosing days and at the End-of-Study Visit
e Serum pregnancy test is done at Visit 1 (Screening) and to confirm results of positive urine test if applicable.
The number and percentage of subjects with markedly abnormal laboratory results (CTCAE 
Grade 3 and above) will be tabulated by dose arm and laboratory variable at each visit. The 
criteria for identifying abnormal laboratory results are detailed in Section 13.5. 
Figures of mean and mean change from Baseline will be plotted over time by dose arm for all 
quantitative laboratory variables (with the exception of any variables measured only at Screening 
and/or Baseline, eg serology, HbA1c and FSH), with all dose arms overlaid on the same plot.
The reference range for each variable (male and female, if applicable) will be included on the 
plot for absolute values. For the differential WBC counts, figures will be presented based on 
percentage values only.
Any additional laboratory variables not included in the outputs described previously (including 
pregnancy testing, FSH and serology) will be listed separately.
Finally, in order to provide a comparison between the platelet counts measured locally and 
centrally, a separate listing will be presented including only the observed platelet counts from 
each laboratory at each visit where both measurements are obtained. Difference between 
laboratories will also be presented.
10.3.1
Potential drug-induced liver injury
Subjects who meet any of the following criteria at a given timepoint will be listed:

Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) increase ≥5xupper 
limit of normal (ULN)

ALT or AST increase ≥3xULN and total bilirubin ≥2xULN

ALT or AST increase ≥3xULN who exhibit temporally associated symptoms of hepatitis or 
hypersensitivity.
ACTED COPY
ly abn
OPY 
ly abn
m and 
COP
m and l
OP
l
ults ar
ED C
ults ar
aseline
ACTE
aseline
RED
he exc
EDAC
he exc
and F
RED
and F
(m
R
(m
thorization application and any extensions or variations thereof.
riati
a
epatitis C
or v
epatitis C
od urea
ns o
od urea
d hemog
ions
d hemog
eficienc
nsio
eficienc
dehydro
xten
dehydro
utputs. M
d an
utputs. M
nd
ati
nd-
tio
-of
tion
of-
o
-f-f
o
f-f S
n
S
ts of pos
licat
ts of pos
normal 
app
normal 
laborat
ion a
laborat
re deta
zatio
re deta
e will b
thori
e will b
not be used to support any marketing au
ception
auth
ception
FSH),
ng a
FSH),
male an
keting
male an
ere
ark
erentia
arke
ntia
riables 
t any
riables 
nd serol
port 
nd serol
ovide a
supp
ovide a
e listing
to s
e listing
at each
ed t
at each
will also
use
will also
P
This document can
ects wh
anno
ects wh
Ala
nt c
Ala
l
n
l


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 53 of 128

ALT or AST increase ≥3xULN (and ≥2xBaseline) and <5xULN, with total bilirubin 
<2xULN

ALT or AST increase ≥5xULN (and ≥2xBaseline), with total bilirubin <2xULN and no 
eosinophilia (i.e., ≤5%), with no fever, rash, or symptoms of hepatitis

Alkaline phosphatase (ALP) ≥2xULN
A summary of subjects who met the criteria for potential drug-induced liver injury (PDILI) will 
be presented together with any additional relevant data collected, if applicable.
10.4
Vital signs, physical findings, and other observations related to 
safety
10.4.1
Vital signs
The following vital signs measurements will be obtained:

Pulse rate

Systolic and diastolic blood pressure

Temperature 

Respiratory rate
A by-subject listing of all vital sign measurements and change from Baseline will be presented 
by dose arm and timepoint. The listing will include a flag for measurements identified as 
treatment-emergent markedly abnormal (TEMA)/potentially clinically significant (PCS) as 
calculated by the criteria outlined in Table 10‒2.
Descriptive statistics will be reported for all vital sign measurements. Measured values and 
changes from Baseline will be summarized by vital signs variable and timepoint for each dose 
arm. 
Figures of mean change from Baseline will be presented for each variable by dose arm. All dose 
arms will be overlaid on the same plot.
The number and percentage of subjects with TEMA/PCS vital sign values will be summarized by 
dose arm at each timepoint.
Table 10‒2: TEMA/PCS criteria for vital signs
Variable
Unit
Low
High
Systolic blood pressure
mmHg
Value <90 and ≥20 
decrease from Baseline
Value >180 and ≥15
increase from baseline
Diastolic blood pressure
mmHg
Value <50 and ≥15 
decrease from Baseline
Value >105 and ≥15 
increase from Baseline
Note: The change in measurement (increase or decrease) will be calculated relative to the value obtained at Baseline.
aBoth conditions must be satisfied for a measurement to be considered PCS.
Repeated and unscheduled measurements will be handled as described in Section 4.3.
REDACTED COPY 
and c
COP
and c
lude a 
ED C
lude a 
MA)/p
CTED
MA)/p
e
A
e 10
ACT
10‒
C
‒2
T
2
for al
RED
for al
ariz
R
ariz
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
ated to
or v
ated to
change 
on ap
change 
a flag fo
atio
a flag fo
potenti
oriza
potenti
2
t
2.
th
.
ll vital 
g au
ll vital 
zed by 
eting
zed by 
seline w
y ma
seline w
ame plo
any
ame plo
ge of su
port 
ge of su
point.
upp
point.
MA/PC
to s
MA/PC
ed
ood pre
t be 
ood pre
u
astolic b
can
astolic b
nn
en
Note
me
Note
a
m
aB
m
B


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 54 of 128
10.4.2
Electrocardiograms 
All standard 12-lead ECG recordings will be taken in triplicate with the subject resting in the 
supine position for at least 15 minutes and before obtaining any blood samples. The following 
variables will be reported:

Heart rate

RR interval

PQ/PR interval

QRS duration

QT interval

QT corrected for heart rate using Fridericia’s formula (QTcF = QT/RR0.33)
The individual measurements and the mean of the triplicate measurements will be reported in the 
by-subject listings. The listing will also include the change from Baseline and percentage change 
from Baseline (based on the mean of the triplicate measurements at each timepoint). TEMA/PCS 
ECG values will be flagged in the listing.
Measured values, changes, and percentage changes from Baseline will be summarized by dose 
arm at each timepoint and by ECG variable (based on the mean of the triplicate values at each 
visit). Mean change from Baseline and percentage change from Baseline in QTcF will be 
displayed graphically over time by dose arm, with all dose arms overlaid on the same plot.
The following cut-points in QTcF (raw data and change from Baseline) based on the mean of the 
triplicate data will be summarized categorically (number and percentage of subjects) by dose arm
at each visit.
For raw data:

<450msec

≥450 to <480msec

≥480 to <500msec

≥500msec
Change from Baseline in QTcF:

<30msec

≥30 to <60msec

≥60 msec
ECG findings for the individual triplicate measurements will be listed separately.
Repeated and unscheduled measurements will be handled as described in Section 4.3.
The number and percentage of subjects with TEMA/PCS ECG values will be summarized by 
dose arm at each visit.
REDACTED COPY 
the
PY
the
chang
COP
chang
ith all
D C
ith all
a and c
CTE
a and c
oricall
DAC
oricall
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
will be
any 
will be
ne and 
nd a
ne and 
each tim
and
each tim
eline w
plica
eline w
mean o
appl
mean o
ge from
on ap
ge from
l dose a
ation
l dose a
change
horiz
change
ly (num
utho
ly (num
eline in
d to
eline in
o <60m
ot be
o <60m
≥60 ms
ann
≥60 ms
ECG fi
ent c
ECG fi
Re
me
Re


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 55 of 128
Table 10‒3: TEMA/PCS criteria for ECG
Variable
Criteria
QT corrected for heart rate using 
Fridericia’s formula (QTcF)
≥501ms
OR
≥60ms compared to baseline
PR prolongation
≥210ms and ≥10ms change from 
baseline
10.4.3
Other safety variables
Body weight will be listed by subject and visit. Subjects with abnormalities in the physical 
examination will be listed including details of the abnormality.
11
OTHER ANALYSES 
Subjects who experience severe headaches will complete a headache questionnaire followed by a 
neurological assessment (including fundoscopy). This will be performed daily until resolution. 
Additionally, a computed tomography (CT) or magnetic resonance imaging (MRI) scan, and 
lumbar puncture (LP) for CSF collection may be performed if indicated at the discretion of the 
Investigator.
The neurological assessment will include general appearance and, if indicated, assessments of 
cranial nerves, motor system examination, reflexes, coordination and fundoscopy. Each 
parameter within each body system (with the exception of fundoscopy) will be assessed as 
normal, abnormal not clinically significant or abnormal clinically significant. For the fundoscopy 
assessment, the result will be assessed as normal or abnormal, and the specific abnormalities will 
be documented in the CRF.
The results of the CT scan (or MRI) will be reported including the date and time of the 
assessment and the evaluation (normal, abnormal not clinically significant, or abnormal 
clinically significant).
The assessments to be performed from the CSF collection will include the following biomarkers:

Assessment of CSF/serum albumin quotients

Assessment of CSF/serum IgG quotients

Labile mediators such as the prostanoids

Soluble intercellular adhesion molecule-1 (ICAM-1) and histamine


Transforming growth factor-beta (TGFβ)

IL-10/CSF/serum IL-10 quotients
Symptoms and frequency of severe headache questionnaire glossary will be listed. The results of 
the headache questionnaire, neurological examination and any additional tests performed
REDACTED COPY 
appear
COP
appear
xes, co
D CO
xes, co
e excep
TED
e excep
nt or ab
ACT
nt or ab
as nor
EDA
as nor
not be used to support any marketing authorization application and any extensions or variations thereof.
hysical
sion
hysical
estionn
d an
estionn
med da
and
med da
e imagi
tion a
e imagi
ndicate
catio
ndicate
rance a
on ap
rance a
oordin
ation
oordin
ption o
riza
ption o
bnorma
thor
bnorma
rmal or
auth
rmal or
will be 
rket
will be 
rmal, a
mar
rmal, a
ormed 
ort a
ormed 
F/serum
upp
F/serum
CSF/se
d to s
CSF/se
diators 
used
diators 
e
b
e inter
be 
inter
This document can

e

T
nt
T

nno
t can


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 56 of 128
(CT/MRI scan, fundoscopy and LP for CSF collection) will be listed for each subject. No 
summary tabulations will be provided for these assessments.
There will be an exit interview performed for all subjects at the end of the study. The results of 
the exit interview will be reported to UCB and not included in the TFLs as part of the CSR.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


UCB
28 Jan 2019
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 57 of 128
12
REFERENCES
Robak T, Salama A, Kovaleva L, Vyhovska Y, Davies SV, Mazzucconi MG, et al. Efficacy and 
safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and 
adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227-36.
Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, et al.
Standardization of bleeding assessment in immune thrombocytopenia: report from the
International Working Group. Blood. 2013;121(14):2596-606.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization 
of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults 
and children: report from an international working group. Blood. 2009; 113(11):2386-93.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
zation
or va
zation
of adu
ns o
of adu
6
s
6-
io
-93.
ion
93.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 76 of 128
14
AMENDMENTS TO THE STATISTICAL ANALYSIS PLAN
14.1
Amendment 1
14.1.1
Rationale for the amendment
This SAP was amended following global protocol amendment 3 dated 15 February 2017 and 
local protocol amendments 3.5 (Georgia and Bulgaria) dated 23 August 2017 and 3.6 (Moldova) 
dated 7 September 2017. The main changes were to include three additional cohorts and a non-
mandatory genomic substudy. Other changes were made in line with the protocol amendment 
and all changes are detailed in the sections below.
The list of abbreviations was updated as required and a few other minor formatting updates were 
made.
All of the changes that were made in previous version of the SAP amendment 1 that are still 
applicable to the current version will be included in this section. 
14.1.2
List of changes
Specific changes
Change #1
Introduction (Section 1)
This SAP is based upon, and assumes familiarity, with the following documents:

Final Protocol: 09 November 2015

Protocol Amendment 0.1 (Moldova): 18 November 2015

Protocol Amendment 0.2 (Germany): 12 January 2016

Protocol Amendment 0.3 (Poland): 23 May 2016

Protocol Amendment 0.4 (Romania): 11 August 2016

Protocol Amendment 1 (Global): 19 May 2016

Protocol Amendment 1.1 (Moldova): 23 May 2016

Protocol Amendment 1.3 (Poland): 09 June 2016
Has been changed to:
This SAP is based upon, and assumes familiarity, with the following documents:

Final Protocol: 09 November 2015

Protocol Amendment 0.1 (Moldova): 18 November 2015

Protocol Amendment 0.2 (Germany): 12 January 2016

Protocol Amendment 0.3 (Poland): 23 May 2016

Protocol Amendment 0.4 (Romania): 11 August 2016

Protocol Amendment 1 (Global): 19 May 2016
REDACTED COPY 
with 
CO
with 
 18 N
DAC
 18 N
any): 1
RED
any): 1
t be used to support any marketing authorization application and any extensions or variations thereof.
nt 
v
nt 
pdates w
ons 
pdates w
1 that a
exte
1 that a
the fol
ion a
the fol
Novemb
utho
Novemb
12 Janu
ng a
12 Janu
): 23 M
rketi
): 23 M
mania)
y ma
mania)
Global)
t any
Global)
t 1.1 (M
ppor
t 1.1 (M
ment 1
o sup
ment 1
ged to:
ed t
ged to:
based 
be us
based 
This document cannot
l Proto
ot b
l Proto
Protoc
can
Protoc

e

Pr
nt 
Pr



UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 77 of 128

Protocol Amendment 1.1 (Moldova): 23 May 2016

Protocol Amendment 1.3 (Poland): 09 June 2016

Protocol Amendment 2.0 (Global; not implemented): 21 October 2016

Protocol Amendment 3.0 (Global): 15 February 20117

Protocol Amendment 3.1 (Moldova): 08 March 2017

Protocol Amendment 3.3 (Poland): 07 March 2017

Ptoeocol Amendment 3.4 (Romania): 10 March 2017

Protocol Amendment 3.5 (Georgia and Bulgaria): 23 August 2017

Protocol Amendment 3.6 (Moldova): 07 September 2017
Change #2
Introduction (Section 1)
If a future protocol amendment necessitates a substantial change to the statistical analysis of the 
study data, this SAP will be amended accordingly. In addition, if analysis definitions have to be 
modified or updated prior to database lock, a SAP amendment will be required. If, after database 
lock, additional analyses are required to supplement the planned analyses described in this SAP, 
these changes will be described in the CSR together with the associated rationale. The content of 
this SAP is compatible with the International Council for Harmonisation (ICH)/Food and Drug 
Administration (FDA) E9 Guidance documents.
Has been changed to:
If a future protocol amendment necessitates a substantial change to the statistical analysis of the 
study data, this SAP amendment will be updated accordingly. In addition, if analysis definitions 
have to be modified or updated prior to database lock, a further SAP amendment will be 
required. If, after database lock, additional analyses are required to supplement the planned 
analyses described in this SAP, these changes will be described in the CSR together with the 
associated rationale. The content of this SAP is compatible with the International Council for 
Harmonisation (ICH)/Food and Drug Administration (FDA) E9 Guidance documents.
Change #3
Exploratory objectives (Section 2.1.3)
The following objectives have been added:

To evaluate the genomic components of ITP to understand the molecular etiology, 
progression, and treatment of the disease, applicable only for subjects consenting to
participate in the optional genomic analyses substudy

REDACTED COPY
he pl
PY 
he pl
er with
COP
er with
ouncil
ED C
ouncil
nts.
CTE
nts.
ssitate
RE
ssitate
b
R
b
marketing authorization application and any extensions or variations thereof.
the sta
n an
the sta
f analys
ation
f analys
t will b
plica
t will b
anned a
appl
anned a
h the a
on ap
h the a
l for H
ation
l for H
es a su
ing a
es a su
be upda
ketin
be upda
r to dat
arke
r to dat
t be used to support any 
addition
y ma
addition
P, these
any
P, these
ontent o
ort a
ontent o
ood and
ppo
ood and
bjective
sed 
bjective
ng obje
be us
ng obje
This document canno
evaluat
not b
evaluat
progres
ann
progres
parti
nt ca
parti

me



UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 78 of 128
Change #4
Other safety variables (Section 2.2.1.2)
The other safety variables are:

Vital sign values and change from Baseline (systolic and diastolic blood pressure, 
temperature, pulse rate, respiratory rate and body weight) to each visit in the Dosing Period 
and in the Observation Period up to Day 85 in the 4mg/kg dose arm and up to Day 71 in the 
7mg/kg dose arm. Body weight is measured only at Screening and Day 85 or Day 71 in the 
4mg/kg and 7 mg/kg dose arm respectively

12-lead electrocardiogram (ECG) parameters and change from Baseline to each dosing visit 
in the Dosing Period and to Day 36 and Day 85 in the Observation Period in the 4mg/kg dose 
arm, and at Day 22 and Day 71 in the Observation Period in the 7mg/kg dose arm

Laboratory values and change from Baseline (hematology including coagulation parameters, 
clinical chemistry, and urinalysis) to each visit in the Dosing Period and in the Observation 
Period up to Day 85 in the 4mg/kg dose arm and up to Day 71 in the 7mg/kg dose arm

TEAEs leading to withdrawal of investigational medicinal product (IMP)
Has been changed to:
The other safety variables are:

Vital sign values and change from Baseline (systolic and diastolic blood pressure, 
temperature, pulse rate and respiratory rate) to each visit in the Dosing Period and in the 
Observation Period up to Day 85 in Dose Arm 1 (4mg/kg once weekly [QWK]), up to Day 
71 in Dose Arm 2 (7mg/kg QWK), up to Day 64 in Dose Arm 3 (10mg/kg QWK) and up to 
Day 57 in Dose Arms 4 (15mg/kg) and 5 (20mg/kg). Body weight is measured only at 
Screening and at the corresponding EOS visit as outlined in the protocol

12-lead electrocardiogram (ECG) parameters and change from Baseline to each dosing visit 
in the Dosing Period and to Day 36 and Day 85 in the Observation Period in Dose Arm 1, to 
Day 22 and Day 71 in the Observation Period in Dose Arms 2, to Day 15 and Day 64 in Dose 
Arm 3 and to Day 8 and Day 57 in Dose Arms 4 and 5

Laboratory values and change from Baseline (hematology including coagulation parameters, 
clinical chemistry, and urinalysis) to each visit in the Dosing Period and in the Observation 
Period up to the corresponding EOS visit as outlined in the protocol

Values and change from Baseline in concentrations of total protein, albumin, α-globulin, and 
β-globulin to each visit in the Dosing Period and in the Observation Period up to Day 85 in 
Dose Arm 1, up to Day 71 in Dose Arm 2, up to Day 64 in Dose Arm 3 and up to Day 57 in 
Dose Arm 4 and 5

TEAEs leading to withdrawal of UCB7665

Change from Baseline in serum biomarkers 
 to each visit in the Dosing Period and up to Day 71 in the 
REDACTED COPY 
(systo
D C
(systo
ate) to 
TED
ate) to 
ose A
ACT
ose A
up to 
EDA
up to 
g) an
RE
g) an
t be used to support any marketing authorization application and any extensions or variations thereof.
he
a
he
osing v
ons 
osing v
e 4mg/k
nsio
e 4mg/k
e arm
xtens
e arm
agulatio
ny e
agulatio
and in t
d any
and in t
he 7mg
and 
he 7mg
oduct (I
tion 
oduct (I
olic and
ation
olic and
each v
riza
each v
Arm 1 (4
thor
Arm 1 (4
o Day 6
aut
o Day 6
nd 5 (20
ing a
nd 5 (20
g EOS 
ketin
g EOS 
CG) par
mar
CG) par
Day 3
ny m
Day 3
e Obse
rt an
e Obse
nd Day
port
nd Day
s and c
sup
s and c
stry, an
d to 
stry, an
o
s
o the co
sed 
the co
and ch
be u
and ch
This document canno
obulin 
ot b
obulin 
Dose Ar
anno
Dose Ar
Dose
t ca
Dose

me

T
n
T


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 79 of 128
Observation Period in Dose Arm 1, up to Day 57 in the Observation Period in Dose Arm 2, 
up to the last visit prior to the corresponding EOS visit as outlined in the protocol
Change #5
Efficacy variables (Section 2.2.2)

Baseline-corrected area under the effect curve (AUEC) for platelet count calculated from 
Baseline to the end of study visit (Day 85 in the Observation Period in the 4mg/kg dose arm 
and Day 71 in the Observation Period in the 7mg/kg dose arm)

Assessment of ITP bleeding score over time at Baseline and at each dosing visit in the 
Dosing Period and to Day 36, Day 50, Day 64 and Day 85 in the Observation Period in the 
4mg/kg dose arm, and to Day 22, Day 36, Day 50 and Day 71 in the Observation Period in 
the 7mg/kg dose arm

Value and change from Baseline in Neurological Fatigue Index for Multiple Sclerosis 
(NFI-MS) summary score to Day 36, Day 50, Day 64 and Day 85 in the Observation Period 
in the 4mg/kg dose arm and to Day 22, Day 36, Day 50 and Day 71 in the Observation 
Period in the 7mg/kg dose arm
Has been changed to:

Baseline-corrected area under the effect curve (AUEC) for platelet count calculated from 
Baseline to the end of study visit (Day 85 in the Observation Period in Dose Arm 1, Day 71 
in the Observation Period in Dose Arm 2, Day 64 in the Observation Period in Dose Arm 3 
and Day 57 in Observation Period in Dose Arms 4 and 5)

Assessment of ITP bleeding score over time at Baseline and at each dosing visit in the 
Dosing Period and to Day 36, Day 50, Day 64 and Day 85 in the Observation Period in Dose 
Arm 1, to Day 22, Day 36, Day 50 and Day 71 in the Observation Period in Dose Arm 2, to 
Day 15, Day 29, Day 43 and Day 64 in the Observation Period in Dose Arm 3 and to Day 8, 
Day 22, Day 36 and Day 57 in the Observation Period in Dose Arms 4 and 5

Value and change from Baseline in Neurological Fatigue Index for Multiple Sclerosis 
(NFI-MS) summary score to Day 36, Day 50, Day 64 and Day 85 in the Observation Period 
in Dose Arm 1, to Day 22, Day 36, Day 50 and Day 71 in the Observation Period in Dose 
Arm 2, to Day 15, Day 29, Day 43 and Day 64 in the Observation Period in Dose Arm 3 and 
to Day 8, Day 22, Day 36 and Day 57 in the Observation Period in Dose Arms 4 and 5
Change #6
Efficacy variables (Section 2.2.2)
Some variables have been re-ordered to align with the order in the protocol.
REDACTED COPY
UEC
PY 
UEC
he Obs
COP
he Obs
Day 64
ED C
Day 64
se Arm
CTED
se Arm
ver tim
DAC
ver tim
y 50, D
RED
y 50, D
0 a
R
0 a
ng authorization application and any extensions or variations thereof.
e
od in th
ons 
od in th
on Perio
nsio
on Perio
tiple Sc
ny e
tiple Sc
the Ob
d any
the Ob
1 in the
and 
1 in the
) for pla
appl
) for pla
servatio
on ap
servatio
4 in the
atio
4 in the
ms 4 an
oriza
ms 4 an
me at B
autho
me at B
Day 64
g au
Day 64
upport any market
and Day
eting
and Day
y 64 in 
arke
y 64 in 
n the O
ma
n the O
aseline
any
aseline
ore to D
ort a
ore to D
Day 22,
uppo
Day 22,
not be used to s
5, Day 
o sup
5, Day 
22, Da
d to 
22, Da
variab
t be
variab
This document canno
v
n
variab
nno
ariab


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 80 of 128
Change #7
Pharmacokinetic variable (Section 2.2.3.1)

Plasma concentration of UCB7665 over time, at each visit during the Dosing Period and 3 
and 7 days following the last dose of UCB7665
Has been changed to:

Plasma concentration of UCB7665 over time, at each visit during the Dosing Period and 3 
and 7 days following the last dose of UCB7665 in each dose arm
Change #8
Pharmacokinetic variable (Section 2.2.3.1)
The following bullet point has been added at the end of this section:

Additional blood samples for the optional PK/PD substudy (early blood sampling) will be 
drawn at Visit 2 (predose and 4 hours after end of infusion on Day 1), Visit 2a (24 and 36 
[optional] hours after the start of Day 1 UCB7665 infusion) and Visit 2b (48 hours after the 
start of Day 1 UCB7665 infusion).
Change #9
Pharmacodynamic variables (Section 2.2.3.2)

Value and change from Baseline (absolute and percentage) in total IgG concentrations 
(measured by ACM Global Central Laboratory) to each visit in the Dosing Period and in the 
Observation Period up to Day 85 in the 4mg/kg dose arm and up to Day 71 in the 7mg/kg 
dose arm

Value and change from Baseline in total and endogenous IgG (measured via IgG depletion 
assay by LGC) to each visit in the Dosing Period and to Day 32, Day 36, Day 43, Day 57, 
Day 71 and Day 85 in the Observation Period in the 4mg/kg dose arm, and to Day 18, Day 
22, Day 29, Day 43, Day 57 and Day 71 in the Observation Period in the 7mg/kg dose arm

ITP-specific autoantibodies in serum 
 over time, 
measured at Day 1, Day 36 and Day 85 in the 4mg/kg dose arm and at Day 1, Day 22 and 
Day 71 in the 7mg/kg dose arm

Change from Baseline in IgG subclass concentrations (measured by ACM Global Central 
Laboratory) to each visit in the Dosing Period and in the Observation Period up to Day 85 in 
the 4mg/kg dose arm and up to Day 71 in the 7mg/kg dose arm
Has been changed to:

Value and change from Baseline (absolute and percentage) in total IgG concentrations 
(measured by ACM Global Central Laboratory) to each visit in the Dosing Period and in the 
Observation Period up to Day 85 in Dose Arm 1, up to Day 71 in Dose Arm 2, up to Day 64 
in Dose Arm 3 and up to Day 57 in Dose Arms 4 and 5

Value and change from Baseline in total IgG (measured via IgG depletion assay by LGC) to 
each visit in the Dosing Period and to Day 32, Day 36, Day 43, Day 57, Day 71 and Day 85 
in the Observation Period in Dose Arm 1, to Day 18, Day 22, Day 29, Day 43, Day 57 and 
REDACTED COPY 
nd per
D CO
nd per
ratory)
TED
ratory)
e 4mg
ACT
e 4mg
in to
RE
in to
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
d sampl
ny e
d sampl
), Visit
d an
), Visit
Visit 2b
and
Visit 2b
rcentag
ation
rcentag
y) to eac
rizat
y) to eac
g/kg do
thori
g/kg do
otal and
ting 
otal and
 Dosin
rketi
 Dosin
ervation
mark
ervation
 and D
ny m
 and D
dies in 
ort a
dies in 
Day 36 
ppor
Day 36 
g/kg do
supp
g/kg do
Baselin
d to
Baselin
y) to ea
used
y) to ea
g/kg do
be u
g/kg do
en cha
not 
en cha
Value
can
Value
(me
nt c
(me


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 81 of 128
Day 71 in the Observation Period in Dose Arm 2, to Day 11, Day 15, Day 22, Day 36, Day 
50 and Day 64 in Dose Arm 3 and to Day 4, Day 8, Day 15, Day 29, Day 43 and Day 57 in 
Dose Arms 4 and 5

ITP-specific autoantibodies in serum 
 over time, 
measured at Day 1, Day 36 and Day 85 in Dose Arm 1, at Day 1, Day 22 and Day 71 in Dose 
Arm 2, at Day 1, Day 15, and Day 64 in Dose Arm 3 and at Day 1, Day 8 and Day 57 in 
Dose Arms 4 and 5

Change from Baseline in IgG subclass concentrations (measured by ACM Global Central 
Laboratory) to each visit in the Dosing Period and in the Observation Period up to Day 85 in 
Dose Arm 1 and up to Day 71 in Dose Arm 2, up to Day 64 in Dose Arm 3 and up to Day 57 
in Dose Arms 4 and 5
Change #10
Other immunological variables (Section 2.2.4)

Change from Baseline in serum immunoglobulin concentrations (total IgA, IgE, and IgM) to 
the last visit in the Dosing Period and to Day 36 and Day 71 in the Observation Period in the 
4mg/kg dose arm, and to Day 22 and Day 57 in the Observation Period in the 7mg/kg dose 
arm

Change from Baseline in B- and T-lymphocyte concentrations to each visit in the Dosing 
Period and in the Observation Period up to Day 85 in the 4mg/kg dose arm and up to Day 71 
in the 7mg/kg dose arm

Change from Baseline in serum (C3 and C4) and plasma (C3a and C5a) complement levels 
to Day 15 (Dosing Period) and to Day 32 and Day 57 in the Observation Period in the 
4mg/kg dose arm, and to Day 15 (Dosing Period) and to Day 18 and Day 43 in the 
Observation Period in the 7mg/kg dose arm

Change from Baseline in serum biomarkers 
to each visit in the Dosing Period and to Day 32, Day 36, Day 43, 
Day 50, Day 57, Day 64 and Day 71 in the Observation Period in the 4mg/kg dose arm, and 
to Day 18, Day 22, Day 29, Day 36, Day 43, Day 50 and Day 57 in the Observation Period in 
the 7mg/kg dose arm

Change from Baseline in serum biomarkers 
 to each visit in the Dosing Period in both the 4mg/kg dose arm and the 
7mg/kg dose arm

Value and change from Baseline in ADA relative mass units (RMU) to each visit in the 
Dosing Period and to Day 32, Day 36, Day 43, Day 57, Day 71 and Day 85 in the 
Observation Period in the 4mg/kg dose arm, and to Day 18, Day 22, Day 29, Day 43, Day 57 
and Day 71 in the Observation Period in the 7mg/kg dose arm

Anti-drug antibody screening status (positive/negative) at each of the visits described above. 
For ADA screening positive results the confirmatory ADA result will be reported as either 
confirmed positive (CP) or not confirmed positive (NCP)
REDACTED COPY 
conce
OPY
conce
Day 85
D CO
Day 85
and C4
DACT
and C4
Day 32
REDA
Day 32
(Dos
RE
(Dos
ort any marketing authorization application and any extensions or variations thereof.
ral
r v
ral
ay 85 i
s or 
ay 85 i
p to Da
ons 
p to Da
total IgA
and 
total IgA
the Ob
on a
the Ob
tion Pe
atio
tion Pe
entratio
n app
entratio
5 in the
tion 
5 in the
4) and p
utho
4) and p
2 and D
aut
2 and D
sing Pe
ting 
sing Pe
dose a
keti
dose a
m biom
ma
m biom
each v
any m
each v
4 and D
rt an
4 and D
This document cannot be used to supp
Day 29, 
ppor
Day 29, 
rm
su
rm
Baselin
d to 
Baselin
to 
sed
to 
dose ar
be us
dose ar
ue and 
not b
ue and 
Dosing 
anno
Dosing 
Obse
nt ca
Obse
an
nt
an

use


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 82 of 128

Change from Baseline in cytokines over time. Cytokines will be measured at all visits in both 
dose arms for subjects who experience infusion reactions only

Change from Baseline in serum B cell activating factor (BAFF) levels to each dosing visit in 
the Dosing Period and to Day 43 and Day 71 in the Observation Period in the 4mg/kg dose 
arm, and to Day 29 and Day 57 in the Observation Period in the 7mg/kg dose arm
Has been changed to:

Change from Baseline in serum immunoglobulin concentrations (total IgA, IgE, and IgM) to 
the last visit in the Dosing Period and to Day 36 and Day 71 in the Observation Period in 
Dose Arm 1, to Day 22 and Day 57 in the Observation Period in Dose Arm 2, to Day 15 and 
Day 50 in the Observation Period in Dose Arm 3 and to Day 8 and Day 43 in the Observation 
Period in Dose Arms 4 and 5

Change from Baseline in serum (C3 and C4) and plasma (C3a and C5a) complement levels 
to Day 15 (Dosing Period) and to Day 32 and Day 57 in the Observation Period in Dose 
Arm 1, to Day 15 (Dosing Period) and to Day 18 and Day 43 in the Observation Period in 
Dose Arm 2, to Day 11 and Day 36 in Observation Period in Dose Arm 3 and to Day 4 and 
Day 29 in Observation Period in Dose Arms 4 and 5

Change from Baseline in exploratory biomarkers relating to mechanism of action, disease 
activity, treatment response, and clinical outcome

Value and change from Baseline in ADA relative mass units (RMU) to each visit in the 
Dosing Period and to Day 32, Day 36, Day 43, Day 57, Day 71 and Day 85 in the 
Observation Period in Dose Arm 1, and to Day 18, Day 22, Day 29, Day 43, Day 57 and 
Day 71 in the Observation Period in Dose Arm 2, to Day 11, Day 15, Day 22, Day 36, Day 
50 and Day 64 in Dose Arm 3 and to Day 4, Day 8, Day 15, Day 29, Day 43 and Day 57 in 
Dose Arms 4 and 5

Anti-drug antibody screening status (positive/negative) at each of the visits described above. 
For ADA screening positive results the confirmatory ADA result will be reported as either 
confirmed positive (CP) or not confirmed positive (NCP)

Change from Baseline in cytokines over time. Cytokines will be measured at all visits in all
dose arms for subjects who experience infusion reactions only. Further description of the 
cytokines variables can be found in Appendix 13.4. Additional exploratory biomarkers may 
be investigated if needed using the samples already available.

Change from Baseline in serum B cell activating factor (BAFF) levels to each dosing visit in 
the Dosing Period and to Day 43 and Day 71 in the Observation Period in Dose Arm 1, to 
Day 29 and Day 57 in the Observation Period in Dose Arm 2, to Day 22 and Day 50 in the 
Observation Period in Dose Arm 3 and to Day 15 and Day 43 in the Observation Period in 
Dose Arms 4 and 5

Change from Baseline in B- and T-lymphocyte concentrations to each visit in the Dosing 
Period and in the Observation Period up to Day 85 in Dose Arm 1, up to Day 71 in Dose 
Arm 2, up to Day 64 in Dose Arm 3 and up to Day 57 in Dose Arms 4 and 5
REDACTED COPY 
la
Y
la
e
O
e
at
D
ative m
D CO
ive m
ay 43, 
TED 
ay 43, 
d to D
ACTE
d to D
Dose
EDAC
Dose
d to D
RED
d to D
ot be used to support any marketing authorization application and any extensions or variations thereof.
) to
vari
) to
d in
or
d in
ay 15 a
ns o
ay 15 a
e Obser
sion
e Obser
comple
y ex
comple
on Peri
any 
on Peri
Obser
nd a
Obser
se
n
se Arm
an
Arm
to mec
plica
to mec
mass u
tion
mass u
Day 57
rizat
Day 57
Day 18,
thori
Day 18,
e Arm 
auth
e Arm 
Day 4, D
ng a
Day 4, D
tatus (p
mark
tatus (p
 results
ny m
 results
or not c
t any
or not c
ne in cy
ppor
ne in cy
jects
sup
jects w
pp
w
ables ca
to s
ables ca
ted if n
sed t
ted if n
from B
be us
from B
Dosing 
ot be
Dosing 
This document cann
ay 29 a
nno
ay 29 a
Obser
can
Obser
Do
nt c
Do

m



UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 83 of 128
Change #11
Other immunological variables (Section 2.2.4)
One item has been re-ordered to align with the order in the protocol.
Change #12
Other immunological variables (Section 2.2.4)
The following paragraph has been removed since it is already mentioned within the section:
Cytokine samples will be taken at Baseline for all subjects and at subsequent visits only if the 
subject experiences infusion reactions.
Change #13
Study design and conduct (Section 2.3)
This is a Phase 2, multicenter, open-label, multiple-dose 2-dose-arm study to evaluate the safety, 
tolerability, and efficacy of UCB7665 in subjects with primary persistent or chronic ITP. The 2 
dose arms will be as follows:

Dose Arm 1: UCB7665 4mg/kg sc (5 doses at an interval of 1 week)

Dose Arm 2: UCB7665 7mg/kg sc (3 doses at an interval of 1 week)
The maximum duration of the study per subject is approximately 16 weeks, consisting of a 
Screening Period (1 to 28 days), a Dosing Period of 2 or 4 weeks, and an Observation Period of 8 
weeks.
A data monitoring committee (DMC) will monitor emergent safety data during the study. The 
first 6 subjects in the study will receive UCB7665 4mg/kg. These subjects in Dose Arm 1 will 
not be randomized. While recruitment is still ongoing safety data for the first 3 subjects up to 7 
days after the final dose of the third subject will be reviewed by the DMC. 
During a second DMC meeting, all available safety data up to the cut off date defined as 7 days 
after the final dose of the sixth subject will be reviewed. During these reviews recruitment in the 
dose arm will not be stopped. Following this review, the DMC will make a decision on whether 
to open Dose Arm 2 for enrollment. Once the DMC has approved the opening of Dose Arm 2 for 
enrollment, subjects will subsequently be randomized to 1 of the 2 dose arms using interactive 
voice/web response system (IXRS). If the new dose arm will be initiated and if the UCB7665 
4mg/kg will be continued, new subjects will be randomized to 1 of the 2 dose arms in an 
allocation ratio of 1:1 (once 15 subjects are in the 4mg/kg group, the remaining subjects will not 
be randomized; these subjects will be allocated to the 7mg/kg group).
At least 4 interim analyses will be performed. Based on the interim analysis the DMC will assess 
the safety of UCB7665, determine whether to initiate the UCB7665 7mg/kg dose arm and may 
decide to adapt the dose regimen.
The analyses and TFLs required for the interim analyses are described in a separate interim SAP.
REDACTED COPY
nterv
PY 
nterv
appro
COP
appro
od of 2
ED C
od of 2
ill mo
DAC
ill mo
ve UC
RED
ve UC
t is
R
t is
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
f the
or v
f the
y to eva
any 
y to eva
nt or ch
nd a
nt or ch
1 week
atio
1 week
al of 1 w
pplic
al of 1 w
oximate
on a
oximate
2 or 4 w
atio
or 4 w
onitor e
autho
onitor e
CB7665
g au
CB7665
s still o
eting
s still o
subject 
arke
subject 
all ava
y ma
all ava
h subje
any
h subje
ed. Fol
ort a
ed. Fol
enrollm
uppo
enrollm
will su
o sup
will su
se syste
d to 
se syste
contin
sed 
contin
atio of 1
e us
atio of 1
mized; 
t be
mized; 
ast 4 in
anno
ast 4 in
e safety
t ca
e safety
decide
ment 
decide
Th
m
Th


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 84 of 128
Has been changed to:
This is a Phase 2, multicenter, open-label, multiple-dose, multiple-arm study to evaluate the 
safety, tolerability, and efficacy of UCB7665 in subjects with primary persistent or chronic ITP. 
The 5 dose arms will be as follows:

Dose Arm 1 (15 subjects): UCB7665 4mg/kg sc (5 doses at an interval of 1 week)

Dose Arm 2 (15 subjects): UCB7665 7mg/kg sc (3 doses at an interval of 1 week)

Dose Arm 3 (6 to 12 subjects): UCB7665 10mg/kg sc (2 doses at intervals of 1 week)

Dose Arm 4 (6 to 12 subjects): UCB7665 15mg/kg sc (1 dose)

Dose Arm 5 (6 to 12 subjects): UCB7665 20mg/kg sc (1 dose)
The maximum duration of the study per subject is approximately 16 weeks, consisting of a 
Screening Period (1 to 28 days), a Dosing Period of 1 to 4 weeks, and an Observation Period of 8 
weeks.
A data monitoring committee (DMC) will monitor emergent safety data during the study. The 
first 6 subjects in the study will receive UCB7665 4mg/kg. These subjects in Dose Arm 1 will 
not be randomized. While recruitment is still ongoing safety data for the first 3 subjects up to 7 
days after the final dose of the third subject in Dose Arm 1 will be reviewed by the DMC. 
During a second DMC meeting, all available safety data up to the cut off date defined as 7 days 
after the final dose of the sixth subject in Dose Arm 1 will be reviewed. During these reviews 
recruitment in the dose arm will not be stopped. Following this review, the DMC will make a 
decision on whether to open Dose Arm 2 for enrollment. Once the DMC has advocated the 
initiation of Dose Arm 2, the subsequent subjects will be randomly assigned in 1:1 ratio to either 
Dose Arm 1 or Dose Arm 2 using an interactive voice/web response system (IXRS). Once 15 
subjects are enrolled in Dose Arm 1, the remaining subjects will enrolled in Dose Arm 2.
After the safety data review of at least 6 subjects in Dose Arm 2 is done, the DMC will make a 
recommendation on whether to open Dose Arm 3 for enrollment. Once the DMC has advocated 
the initiation of Dose Arm 3 and the enrollment of 15 subjects in Dose Arm 2 has been 
completed, the subsequent subjects will be assigned to Dose Arm 3 only. After every third 
subject has been enrolled, the DMC will review all available safety data up to cut off date 
defined as 7 days after the dosing. Depending on the emerging safety data of 6 subjects in Dose 
Arm 3, the DMC will recommend whether to open Dose Arm 4 for enrollment or to include 
additional subjects in Dose Arm 3. A maximum of 12 subjects may be enrolled in Dose Arm 3.
Once the DMC has advocated the initiation of Dose Arm 4, the enrollment of Dose Arm 3 will 
be closed and all subsequent subjects will be assigned to Dose Arm 4. After every third subject is 
enrolled, the DMC will review all available safety data up to the cutoff date defined as 7 days 
after the dosing. Depending on the emerging safety data of 6 subjects in Dose Arm 4, the DMC 
will recommend to include additional subjects in Dose Arm 4 or not. A maximum of 12 subjects 
may be enrolled in Dose Arm 4. The DMC will recommend to open Dose Arm 5 for enrollment 
in a subsequent meeting, if applicable. 
Once the DMC has advocated the initiation of Dose Arm 5, the enrollment of Dose Arm 4 will 
be closed and all subsequent subjects will be assigned to Dose Arm 5. After every third subject is 
REDACTED COPY 
rm 1
Y
rm 1
y data 
COP
y data 
Arm 1
D C
Arm 1
ed. Fo
TED
ed. Fo
for en
ACT
for en
nt subj
EDA
nt subj
inter
RE
inter
cannot be used to support any marketing authorization application and any extensions or variations thereof.
nsisting
exte
nsisting
bservati
ny ex
bservati
ata dur
and
ata dur
subjec
tion 
subjec
ata for t
icatio
ata for t
will be 
pplic
will be 
a up to t
on ap
a up to t
1 will b
ation
1 will b
ollowin
riza
ollowin
nrollme
thor
nrollme
bjects w
aut
bjects w
ractive
ing a
ractive
he rema
ketin
he rema
east 6 s
mar
east 6 s
open D
ny m
open D
and th
rt any
and th
nt subje
port
nt subje
led, the
supp
led, the
fter the 
to su
fter the 
C will re
ed to
C will re
bjects in
use
bjects in
DMC h
t be 
DMC h
sed and
not 
sed and
olled, th
cann
olled, th
This document
after the
nt ca
after the
will r
men
will r
m
m
m


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 85 of 128
enrolled, the DMC will review all available safety data up to the cutoff date defined as 7 days 
after the dosing. Depending on the emerging safety data of 6 subjects in Dose Arm 5, the DMC 
will recommend to include additional subjects in Dose Arm 5. A maximum of 12 subjects may 
be enrolled in Dose Arm 5.
At least 11 interim analyses will be performed. Based on the interim analyses the DMC will 
assess the safety of UCB7665, determine whether to initiate subsequent dose arms and may 
decide to adapt the dose regimen. The analyses and TFLs required for the interim analyses are 
described in a separate interim SAP.
During this study, subjects will also have the option of providing additional informed consent for 
exploratory DNA and RNA analyses. Participation in this additional portion of the study is 
optional and does not preclude subject’s eligibility for participation in the main study. The 
additional genomic samples must not be collected if the subject has not consented to participate 
in this exploratory genomic substudy. Any results from this analysis will be reported separately 
and will not form a part of the main CSR. Thus, these analyses are not described further in this 
SAP.
During this study, subjects from Bulgaria, Georgia and Moldova who are enrolled in Dose Arm 
3, 4 or 5, will also have the option of providing additional informed consent for a PK/PD 
substudy (early blood sampling) at selected study sites. Participation in this additional portion of 
the study is optional and does not preclude subject’s eligibility for participation in the main 
study. The additional PK/PD blood samples must not be collected if the subject has not 
consented to participate in this exploratory substudy.
Change #14
Determination of sample size (Section 2.4, first paragraph)
The sample size of 15 subjects, in each dose arm, is mainly based on the efficacy objective of the 
study. In addition, the inclusion of 15 subjects in each dose arm will ensure that sufficient data 
are available to form conclusions about the safety of administering UCB7665.
Has been changed to:
The sample size of 15 subjects in Dose Arms 1 and 2, is mainly based on the efficacy objective 
of the study. In addition, the inclusion of 15 subjects in Dose Arms 1 and 2 will ensure that 
sufficient data are available to form conclusions about the safety of administering UCB7665. 
Based on the safety data from Dose Arms 1 and 2, the sample size of 6 to 12 subjects in Dose 
Arms 3, 4 and 5 were judged to be sufficient in order to explore subjects’ safety and IgG 
reductions under different dose regimens and is not based on a formal sample size calculation
Change #15
General presentation of summaries and analyses (Section 3.1, last paragraph)
In the event that the number of infusions in the planned dose arms (3x7mg/kg and 5x4mg/kg) are 
modified following review by the DMC, the data will be summarized based on the actual dose 
arms completing the study. For example, if the 5x4mg/kg dose arm is modified such that some 
subjects receive only 4 infusions, then the data will be summarized separately for this new dose 
regimen.
In the TFLs the dose arms will be displayed as follows where applicable:
REDACTED COPY
eligib
OPY 
eligib
not be
COP
not be
study.
ED C
study.
n 2.
EDA
n 2.4,
DA
4,
ch d
R
ch d
annot be used to support any marketing authorization application and any extensions or variations thereof.
nsent fo
or v
nsent fo
udy is
ons
udy is
dy. The
nsio
dy. The
ed to pa
xten
ed to pa
reported
y ext
reported
cribed 
any 
cribed 
ho are 
n a
ho are 
med con
atio
med con
cipation
plica
cipation
bility fo
app
bility fo
e collec
on a
e collec
, first p
aut
, first p
dose ar
eting
dose ar
5 subjec
arket
5 subjec
abou
mar
about t
ar
t t
bjects in
port 
bjects in
n, the i
upp
n, the i
vailabl
to su
vailabl
ety data
ed to
ety data
5 were
used
5 were
under d
be u
under d
ge #1
nnot
ge #15
t 
5
This document c
eneral 
t can
eneral 
In the
men
In the
m
m
m


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 86 of 128

UCB7665 5x4mg/kg

UCB7665 3x7mg/kg
If additional dose arms are initiated during the study these will be displayed similarly. For 
example, if the 5x4 mg/kg dose arm is modified such that some subjects receive only 4 infusions 
this dose arm will be displayed as UCB7665 4x4mg/kg in the TFLs.
Has been changed to:
In the event that the number of planned infusions in the dose arms are modified following review 
by the DMC, the data will be summarized based on the actual dose arms completing the study. 
For example, if the 5x4mg/kg QWK dose arm is modified such that some subjects receive only 4 
infusions, then the data will be summarized separately for this new dose regimen.
In the TFLs the dose arms will be displayed as follows where applicable:

UCB7665 5x4mg/kg QWK

UCB7665 3x7mg/kg QWK

UCB7665 2x10mg/kg QWK

UCB7665 1x15mg/kg

UCB7665 1x20mg/kg
If additional dose arms are initiated during the study these will be displayed similarly. For 
example, if the 5x4mg/kg QWK dose arm is modified such that some subjects receive only 4 
infusions this dose arm will be displayed as UCB7665 4x4mg/kg QWK in the TFLs.
Data listings containing all documented data and all derived data will be generated.
Change #16
Study periods (Section 3.2.1.2)

Dosing Period: Up to 4 weeks; during the Dosing Period subjects will receive weekly doses 
of IMP (5 doses of 4mg/kg in Dose Arm 1 and 3 doses of 7mg/kg in Dose Arm 2). The dose 
regimen may be adapted following review by the DMC;

Observation Period: 8 weeks; a visit will be scheduled 3 days after the final dose and weekly 
thereafter to collect safety and efficacy data.
Has been changed to:

Dosing Period: 1 to 4 weeks; during the Dosing Period subjects will receive weekly doses of 
UCB7665 (5 doses of 4mg/kg [QWK] in Dose Arm 1, 3 doses of 7mg/kg [QWK] in Dose 
Arm 2, 2 doses of 10mg/kg [QWK] in Dose Arm 3, 1 dose of 15mg/kg in Dose Arm 4 and 1 
dose of 20mg/kg in Dose Arm 5). The dose regimen may be adapted following review by the 
DMC

Observation Period: 8 weeks; a visit will be scheduled 3 days after the final dose (or only 
dose administration for Dose Arms 4 and 5) and weekly thereafter to collect safety and 
efficacy data
REDACTED COPY 
tudy t
D CO
tudy t
modif
TED
modif
as UC
ACT
as UC
ed dat
REDA
ed dat
sed to support any marketing authorization application and any extensions or variations thereof.
eview
var
eview
study.
or v
study.
eive on
ons 
eive on
these w
ation
these w
fied su
riza
fied su
CB7665
thor
CB7665
ta and a
g au
ta and a
eks; du
any 
eks; du
/kg in D
ort a
/kg in D
pted fol
ppor
pted fol
iod: 8 w
o sup
iod: 8 w
collect s
d to
collect s
annot be u
anged 
use
anged 
ng Peri
ot be
ng Peri
CB766
nnot
CB766
This document ca
Arm 2
can
Arm 2
dos
nt c
dos


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 87 of 128
Change #17
Definition of Baseline values (section 3.3)
Table 14‒1: Definition of Baseline
Measurement
Definition of Baseline
Safety data:

Clinical chemistry (including proteins)

Hematology (including platelets measured 
locally)

Coagulation

Urinalysis

Vital signs

12-lead ECG

Predose Day 1 or if missing the Screening 
valuea
Efficacy variables:

Platelets (measured by ACM Global 
Central Laboratory)

ITP bleeding scale

NFI-MS

Platelets: Predose Day 1 or if missing the 
Screening value

ITP bleeding scale: Predose Day 1 or if 
missing the Screening assessment

NFI-MS: Predose Day 1
Pharmacodynamic variables:

Total IgG

IgG subclasses

Total IgG: Predose Day 1 or if missing the 
Screening value

IgG subclasses: Predose Day 1 or if 
missing the Screening value

ITP-specific autoantibodies: Predose Day 1
Immunological variables:

Immunoglobulins (IgA, IgE and IgM)

B- and T-lymphocytes

Serum (C3 and C4) and plasma 
complement (C3a and C5a)

ADA

Serum biomarkers 

Serum BAFF

Cytokines

Predose Day 1 (except B- and T-
lymphocytes)

B- and T-lymphocytes: Predose Day 1 or if 
missing the Screening value
ADA=anti-drug antibody; BAFF= B cell activating factor; ECG=electrocardiogram; Ig=immunoglobulin; 
ITP=primary immune thrombocytopenia; NFI-MS= Neurological Fatigue Index for Multiple Sclerosis;
REDACTED COPY 

P

N
Y
N
CO
ED
ting authorization application and any extensions or variations thereof.
ati
dose Da
and 
dose Da
value
n a
value
eeding s
atio
eeding s
sing the
plica
sing the
NFI
ap
NFI-
app
-MS
pp
MS
a

t

To
on
To
n
uth
ed to support any marketi
and IgM
ma
and IgM
and plas
ort a
and plas
and C5
ppo
and C5
markers
d to
markers
eti
nt cannot be us
um BAF
be u
um BAF
Cytokin
not b
Cytokin
no
=anti
ann
=anti-dr
n
dr
P=prima
t ca
P=prima
This documen
used
ent 


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 88 of 128
Has been changed to:
Table 14‒1: Definition of Baseline
Measurement
Definition of Baseline
Safety data:

Clinical chemistry (including proteins)

Hematology (including platelets measured 
locally)

Coagulation

Urinalysis

Vital signs

12-lead ECG

Serum safety biomarkers 

Predose Day 1 or if missing the Screening 
valuea
Efficacy variables:

Platelets (measured by ACM Global 
Central Laboratory)

ITP bleeding scale

NFI-MS

Platelets: Predose Day 1 or if missing the 
Screening value

ITP bleeding scale: Predose Day 1 or if 
missing the Screening assessment

NFI-MS: Predose Day 1
Pharmacodynamic variables:

Total IgG

IgG subclasses


ITP-specific autoantibodies in serum 

Total IgG: Predose Day 1 or if missing the 
Screening value

IgG subclasses: Predose Day 1 or if 
missing the Screening value


ITP-specific autoantibodies: Predose Day 1
Immunological variables:

Immunoglobulins (IgA, IgE and IgM)

B- and T-lymphocytes

Serum (C3 and C4) and plasma 
complement (C3a and C5a)

ADA

Serum BAFF

Cytokines, if applicable (as outlined in the 
protocol)

Predose Day 1 (except B- and T-
lymphocytes)

B- and T-lymphocytes: Predose Day 1 or if 
missing the Screening value
ADA=anti-drug antibody; BAFF= B cell activating factor; ECG=electrocardiogram; Ig=immunoglobulin; 
ITP=primary immune thrombocytopenia; NFI-MS= Neurological Fatigue Index for Multiple Sclerosis;
REDACTED COPY 
I
Y 
I
ED
ED
ED
ED
ED
ED
zation application and any extensions or variations thereof.
ati
 Predos
tion 
 Predos
ning va
icati
ning va
P
p
P bleed
ppli
bleed
missin
n ap
missin

t

NF
on
NF
a
uthoriza

marketing auth
serum 
mark
serum 
za
uth
t cannot be used to support any 
(IgA, Ig
ppor
(IgA, Ig
hocytes
sup
hocytes
and C4
d to 
and C4
men
sed
ment (C3
ed 
t (C3
erum B
ot be
erum B
Cyto
anno
Cyto
pr
an
pr
This document 
ny
nt
ADA=
ent
ADA=
ITP
me
ITP
y m


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 89 of 128
Change #18
Full Analysis Set (Section 3.5.3)
The analysis of the PD (excluding total IgG, IgG subclasses and IgG depletion assay), efficacy 
and immunologic variables will be performed on the FAS. Efficacy analyses will be repeated for 
the PPS where stated in the SAP.
Has been changed to:
The analysis of the PD (excluding total IgG, IgG subclasses and IgG depletion assay), efficacy 
and immunologic variables will be performed on the FAS. Efficacy analyses will be repeated for 
the pharmacodynamics per protocol set (PD-PPS) where stated in the SAP.
Change #19
Pharmacodynamic Per Protocol Set (section 3.5.6)
The Pharmacodynamic Per Protocol Set (PD-PPS) is a subset of the FAS, consisting of those 
subjects who had no important protocol deviations potentially affecting the serum concentration 
of total IgG, as confirmed during a pre-analysis review of the data prior to database lock. 
The PD-PPS will be used for the analysis of the total IgG, IgG subclasses and IgG depletion 
assay.
Has been changed to:
The Pharmacodynamic Per Protocol Set (PD-PPS) is a subset of the FAS, consisting of those 
subjects who had no important protocol deviations potentially affecting the serum concentration 
of total IgG, as confirmed during a pre-analysis review of the data prior to database lock. 
Protocol deviations may not necessarily lead to total exclusion of a subject from the PD-PPS but 
may lead to exclusion of specific data.
The PD-PPS will be used for the analysis of the total IgG, IgG subclasses and IgG depletion 
assay.
Change #20
Treatment assignment and treatment groups (Section 3.6)
Treatment (dose arm) assignment for the SS, FAS, PK-PPS, PD-PPS and the PPS will be 
according to the actual treatment regimen received.
In the event that the number of infusions in the planned dose arms (3x7mg/kg and 5x4mg/kg) are 
modified following review by the DMC, the data will be summarized based on the actual dose 
arms completing the study. For example, if the 5x4mg/kg dose arm is modified such that some 
subjects receive only 4 infusions, then the data will be summarized separately for this new dose 
regimen.
Has been changed to:
Treatment (dose arm) assignment for the SS, FAS, PK-PPS, PD-PPS and the PPS will be 
according to the actual planned treatment regimen (reflecting the potential DMC decisions).
In the event that the number of planned infusions in the dose arms are modified following review 
by the DMC, the data will be summarized based on the actual dose arms completing the study.
REDACTED COPY 
PS) is
ED C
PS) is
iations
CTED
iations
nalysis
DACT
nalysis
ly lead
REDA
ly lead
a.
R
a.
o support any marketing authorization application and any extensions or variations thereof.
acy 
va
acy 
ated fo
or v
ated fo
consis
any
consis
g the se
nd a
g the se
rior to 
n an
rior to 
subclas
catio
subclas
s a subs
atio
s a subs
s poten
oriza
s poten
s review
utho
s review
d to tot
g aut
d to tot
alysis o
arke
alysis o
and tre
port
and tre
) assign
sup
) assign
ent cannot be used t
ctual tr
d to s
ctual tr
hat the n
used
hat the n
ollowin
be u
ollowin
mpletin
ot b
mpletin
cts rece
anno
cts rece
gimen.
t can
gimen.
This documen
Has 
men
Has 
T


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 90 of 128
For example, if the weekly 5x4mg/kg QWK dose arm is modified such that some subjects 
receive only 4 infusions, then the data will be summarized separately for this new dose regimen.
Change #21
Changes to protocol-defined analyses (Section 3.9)
All text was deleted with the exception of the final paragraph.
Change #22
Pharmacodynamic data (section 4.2.3)
Measurements BLQ are not anticipated in the PD data (total IgG [measured by ACM Global 
Central Laboratory, IgG subclasses and total IgG [via IgG depletion assay from LGC]). In the 
event that any BLQ measurements are received, these will be discussed at the DEM.
Has been changed to:
Measurements BLQ are not anticipated in the PD data (total IgG [measured by ACM Global 
Central Laboratory] and IgG subclasses). In the event that any BLQ measurements are received, 
these will be discussed at the DEM.
Change #23
Dates and times (Section 4.2.7)
Partial dates may be imputed for the following reasons:

Classification of AEs as treatment-emergent

Classification of medications as prior or concomitant
Has been changed to:
Partial dates may be imputed for the following reasons:

Classification of AEs as treatment-emergent

Classification of medications as past, prior or concomitant
Change #24
Handling of repeat and unscheduled measurements
All repeated and unscheduled measurements will be presented in the listings, where applicable. 
The following general rules will apply to all repeated and unscheduled measurements:

For repeated measurements obtained prior to the first dose of UCB7665 the latest value 
(which may be scheduled or unscheduled) will be used in the calculation of descriptive 
statistics;

For repeated measurements obtained at the designated Baseline visit, the latest value (which 
may be scheduled or unscheduled) will be defined as the Baseline provided that this occurred 
prior to the first dose of UCB7665;

For repeated measurements obtained at any timepoint after the first dose of UCB7665, the 
first value of any repeated measurements will be used in the calculation of changes from 
REDACTED COPY 
easons
D CO
easons
gent
CTED
gent
or or co
DAC
or or co
d to support any marketing authorization application and any extensions or variations thereof.
Global
ns o
Global
C]). In 
sion
C]). In 
EM.
ten
EM.
red by 
d any
red by 
measure
and
measure
s:
ti
s:
oncom
autho
oncom
followi
rket
followi
ment
ma
ment-
a
tions as
rt any
tions as
and u
to su
and u
This document cannot be use
d unsch
ed t
d unsch
g gener
use
g gener
epeated
ot be
epeated
which m
nnot
which m
statist
can
statist

e

F
nt
F


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 91 of 128
Baseline and for the descriptive statistics. Unscheduled and repeated measurements will not 
be included in the descriptive statistics at timepoints after the first dose of UCB7665.
The above rules are not applicable for the determination of the response variables for the platelet 
measurements; both scheduled and unscheduled measurements may be used in the calculation of 
response, time to response and duration of response (Section 8.1.1).
Has been changed to:
All repeated and unscheduled measurements will be presented in the listings, where applicable. 
The following general rules will apply to all repeated and unscheduled measurements:

For repeated and unscheduled measurements obtained prior to the first dose of UCB7665 the 
latest value (which may be scheduled or unscheduled) will be used in the calculation of 
descriptive statistics;

For repeated and unscheduled measurements obtained at the designated Baseline visit, the 
latest value (which may be scheduled or unscheduled) will be defined as the Baseline 
provided that this occurred prior to the first dose of UCB7665;

For repeated measurements obtained at any timepoint after the first dose of UCB7665, the 
first value of any repeated measurements will be used in the calculation of changes from 
Baseline and for the descriptive statistics. Unscheduled and repeated measurements will not 
be included in the descriptive statistics at timepoints after the first dose of UCB7665, 
however they may be included in any summaries for abnormal measurements.
The above rules are not applicable for the determination of the response variables for the platelet 
measurements; both scheduled and unscheduled measurements may be used in the calculation of 
response, time to response and duration of response (Section 8.1.1).
Change #25
Interim analyses and data monitoring (Section 4.4)
For the sequential adaptive design in this study, at least 4 interim analyses will be performed. 
Safety data from the interim analyses will be reviewed by the DMC to monitor the safety, to 
adapt the dose regimen, and to decide when and if the UCB7665 7mg/kg dose arm should be 
opened.
Has been changed to:
For the sequential adaptive design in this study, at least 11 interim analyses will be performed. 
Safety data from the interim analyses will be reviewed by the DMC to monitor the safety, to 
adapt the dose regimen, and to decide when and if the UCB7665 7mg/kg weekly group (Dose 
Arm 2), UCB7665 10mg/kg weekly group (Dose Arm 3), UCB7665 15mg/kg group (Dose Arm 
4) and UCB7665 20mg/kg group (Dose Arm 5) should be opened. . 
Change #26
Examination of subgroups (Section 4.8)
The following subgroups will be defined within each dose arm:

Use of corticosteroid medication: Present
REDACTED COPY
duled
PY 
duled
oints a
OPY
oints a
aries fo
D CO
aries fo
termin
CTED
termin
eduled
ACT
eduled
n of re
EDA
n of re
keting authorization application and any extensions or variations thereof.
le.
a
le.
B7665
ons o
B7665
lation o
nsion
lation o
Baselin
ny ex
Baselin
d as the
d any
d as the
e first d
tion 
e first d
e calcu
icatio
e calcu
and rep
pplic
and rep
after th
n app
after th
for abno
tion 
for abno
nation 
oriza
nation 
d meas
thor
d meas
esponse
aut
esponse
ot be used to support any ma
ring (S
marke
ring (S
gn in th
ny m
gn in th
analys
t any
analys
nd to d
port 
nd to d
d to:
d to
d to:
ntial ada
used
ntial ada
from th
be us
from th
e dose r
ot be
e dose r
This document can
2), UCB
nno
2), UCB
and UC
t can
and UC
Chan
ment
Chan
E
m
E


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 92 of 128

Use of corticosteroid medication: Absent
Only medication classified as either ‘prior and concomitant’ or ‘concomitant’ will be considered. 
Past use of corticosteroids (not ongoing after dosing) will not be considered for this 
classification. The list of applicable Anatomical Therapeutic Chemical (ATC) codes in order to 
identify the presence/absence of corticosteroids is provided in Section 13.1.
The descriptive summaries for platelets and total IgG will be presented for the subgroups above. 
Subgroup analyses will only be presented if the number of subjects in each subgroup is greater 
than or equal to 5 (n≥5) in each stratum.
Has been changed to:
The following subgroups will be defined within each dose arm:

Use of corticosteroid medication: Present

Use of corticosteroid medication: Absent

Responder at the end of previous ITP treatment: No

Responder at the end of previous ITP treatment: Yes
Only medication classified as either ‘prior and concomitant’ or ‘concomitant’ will be considered. 
Past use of corticosteroids (not ongoing after dosing) will not be considered for this 
classification. The list of applicable Anatomical Therapeutic Chemical (ATC) codes in order to 
identify the presence/absence of corticosteroids is provided in Section 13.1.
The descriptive summaries for platelets and total IgG will be presented for the subgroups above. 
Change #27
Subject disposition (Section 5.1, second paragraph)
The listing of subject disposition will include the date of informed consent, date of 
randomization (if applicable), date and time of first and last dose of UCB7665, date of premature 
termination and primary reason (if applicable) and date of final contact. 
The listing of study discontinuation will include the reason for discontinuation and the number of 
days on UCB7665.
The number of days on IMP will be calculated as follows:
Number of days on IMP= [(Date of Last Dose Received) – (Date of First Dose Received)] + 1
Has been changed to:
The listing of subject disposition will include the date of informed consent, date of genomic 
consent (if applicable), date of randomization (if applicable), date and time of first and last dose 
of UCB7665 (if applicable), date of premature termination and primary reason (if applicable) and 
date of final contact. 
The listing of study discontinuation will include the reason for discontinuation and the number of 
days on UCB7665.
The number of days on UCB7665 will be calculated as follows:
REDACTED COPY
will 
PY 
will 
herape
COP
herape
is pro
D C
is pro
d to
CT
d total 
CTE
tal 
cond
RE
cond
t any marketing authorization application and any extensions or variations thereof.
or ‘conc
licat
or ‘conc
not be c
appl
not be c
eutic C
on ap
eutic C
ovided 
ation
ovided 
IgG w
horiz
IgG w
d para
ting
d para
ll inclu
arke
ll inclu
e and t
ma
e and t
n (if ap
any 
n (if ap
cannot be used to suppo
ntinuati
port 
ntinuati
s on IM
to s
s on IM
s on IM
sed
s on IM
change
be u
change
ting of
not 
ting of
sent (if
cann
sent (if
This document
of UCB
nt ca
of UCB
date 
men
date 
T


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 93 of 128
Number of days on UCB7665= [(Date of Last Dose Received) – (Date of First Dose Received)] 
+ 1
Change #28
Other Baseline characteristics (Section 6.2, 4th bullet point)

ITP-specific autoantibodies 
 expressed in terms of optical 
density (OD)
Has been changed to:

ITP-specific autoantibodies 
 expressed in terms of optical 
density (OD) for MAIPA analysis and pre-chloroquine minus post chloroquine treated scores 
for PIFT
Change #29
Efficacy analyses (Section 8)
The following sentence has been added at the end of this section:
Treatment (dose arm) assignment for efficacy analysis will be according to the actual treatment 
regimen.
Change #30
Platelets (Section 8.1)
The following sentence has been added at the end of this section:
In case rescue medications were taken, only the platelet data up to the time point where the 
rescue medication was taken will be utilized.
Change #31
Definition of variables (Section 8.1.1, 13th bullet)

Baseline-corrected AUEC for platelet count calculated from Baseline to the end of study visit 
(Day 85 in the Observation Period in the 4mg/kg dose arm and Day 71 in the Observation 
Period in the 7mg/kg dose arm)
Has been changed to:

Baseline-corrected AUEC for platelet count calculated from Baseline to the end of study visit 
for each of the defined dose arms.
Change #32
Definition of variables (Section 8.1.1, last bullet)

The Baseline-corrected AUEC will be calculated according to the following rules:

The AUEC will be calculated according to the linear trapezoidal rule using protocol 
scheduled visits

Unscheduled visits will not be included in the calculation
REDACTED COPY 
at the 
DAC
at the 
n, on
RE
n, on
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
of opti
s or
of opti
reated s
ions
reated s
cording
tion
cording
end of
utho
end of
nly the 
ing a
nly the 
ilized.
ketin
ilized.
ion 8.1
any 
ion 8.1
UEC fo
port 
UEC fo
ervatio
upp
ervatio
mg/kg d
to su
mg/kg d
ged to
sed 
ged to
e
b
e-
e
-corre
be u
corre
ach of 
ot be
ach of 
nge #
ann
nge #3
Definit
ent c
Definit

m



UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 94 of 128

No imputation of any missing data will be performed

To account for differences in the timing of Baseline samples for each subject the Baseline 
measurement will be considered as time zero in the calculation

The units of the AUEC will be 109/L*day

The measurements at Baseline and at the last visit must be available

A minimum of 10 out of 14 measurements must be available for the calculation in the 
5x4mg/kg dose arm; a minimum of 8 out of 12 measurements must be available for the 
calculation in the 3x7mg/kg dose arm. These include the Baseline and measurement at 
the last visit

The AUEC will not be calculated in the case of early withdrawal from the study
Has been changed to:

The Baseline-corrected AUEC will be calculated according to the following rules:

The AUEC will be calculated according to the linear trapezoidal rule using protocol 
scheduled visits

Unscheduled visits will not be included in the calculation

No imputation of any missing data will be performed

To account for differences in the timing of Baseline samples for each subject the Baseline 
measurement will be considered as time zero in the calculation

The units of the AUEC will be 109/L*day

The measurements at Baseline and at the last visit must be available

A minimum of 10 out of 14 measurements must be available for the calculation in Dose 
Arm 1; a minimum of 8 out of 12 measurements must be available for the calculation in 
Dose Arm 2; a minimum of 7 out of 11 must be available for the calculation in Dose Arm 
3; a minimum of 5 out of 9 must be available for the calculation in Dose Arms 4 and 5. 
These include the Baseline and measurement at the last visit

The AUEC will not be calculated in the case of early withdrawal from the study
Change #33
Presentation of results (Section 8.1.2)
Individual platelet and total IgG (including IgG subclasses, measured by ACM Global Central 
Laboratory) concentrations will be displayed graphically over time (Day 1 to Day 85 for the 
4mg/kg dose arm and Day 1 to Day 71 for the 7mg/kg dose arm) for each subject (linear scale). 
The platelet and total IgG concentrations will be overlaid on the same plot (discrete y-axes) with 
separate plots for each subject (2 lines per plot). Additional plots will be presented with the 
platelet and IgG subclasses overlaid on the same figure (5 lines per plot). All plots will include a 
vertical reference line to indicate when the last dose was administered for each subject.
REDACTED COPY 
erform
OPY
erform
g of Ba
ED C
g of Ba
me ze
TED
me ze
0
D
09
DA
9/L*
DAC
/L*
e and
RE
e and
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
the
r va
the
ent at 
s or 
ent at 
e study
tens
e study
lowing
d any
lowing
idal rul
n an
idal rul
ion
lic
ion
med
n ap
med
aseline
atio
aseline
ero in
riza
ero in t
a
t
day
auth
day
d at the
ing 
d at the
measure
rke
measure
ut of 12
mar
ut of 12
m of 7 
ny m
m of 7 
ut of 9 
rt an
ut of 9 
Baseli
por
Baseli
will not 
o sup
will not 
n of re
e us
n of re
ual plate
ot b
ual plate
ratory) 
anno
ratory) 
mg/kg d
t can
mg/kg d
The pl
ent 
The pl
se
m
sep
e
p


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 95 of 128
Has been changed to:
Individual platelet and total IgG (including IgG subclasses, measured by ACM Global Central 
Laboratory) concentrations will be displayed graphically over time (Day 1 to Day 85 for Dose 
Arm 1; Day 1 to Day 71 for Dose Arm 2; Day 1 to Day 64 for Dose Arm 3 and Day 1 to Day 57 
for Dose Arms 4 and 5) for each subject (linear scale). The platelet and total IgG concentrations 
will be overlaid on the same plot (discrete y-axes) with separate plots for each subject (2 lines 
per plot). Additional plots will be presented with the platelet and IgG subclasses overlaid on the 
same figure (5 lines per plot). All plots will include a vertical reference line to indicate when the 
last dose was administered for each subject.
Change #34
Analysis of time to responder (Section 8.1.3.2)
The point estimate for the median number of days to response with 95% CIs will be given if 
estimable. Further a summary including the number and percent of censored subjects, the 
number of responders and total subjects by dose arm and in total will be given.
Has been changed to:
The point estimate for the median number of days to response with 90% CIs will be given if 
estimable. Further a summary including the number and percent of censored subjects, the 
number of responders and total subjects by dose arm and in total will be given.
Change #35
Pharmacokinetics (Section 9.1)
The following paragraphs have been added at the end of this section:
The above summaries will be repeated separately for the subjects in the PK/PD substudy sample, 
in the event of very few subjects (<10 subjects) only listings will be provided.
Further analyses and summaries relating to the population PK analyses and PK/PD analyses will 
described in a separate SAP and reported separately.
Change #36
Pharmacodynamics (Section 9.2)
The following paragraph has been added at the end of this section:
The above summaries will be repeated separately for the subjects in the PK/PD substudy sample, 
in the event of very few subjects (<5 subjects) only listings will be provided.
Change #37
ITP-specific autoantibodies (Section 9.2.1)
In order to evaluate the relationship between changes in platelet count and total IgG, IgG 
subclasses and ITP-specific autoantibodies the following figures will be presented:

Individual ITP-specific autoantibodies and platelet counts (measured by ACM Global Central 
Laboratory) will be displayed graphically over time (Day 1 to Day 85 for the 4mg/kg dose 
REDACTED COPY 
d p
Y
d p
m and i
OPY
m and i
adde
RE
adde
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
the
vari
the
will be 
ext
will be 
ed subj
any 
ed subj
e given
nd a
e given
with
cati
with 90
tio
90
cent of 
pplic
cent of 
in total
app
in total
ed at th
ing 
ed at th
ed 
ar
ed sepa
rke
sepa
(<10 su
ma
(<10 su
ies rela
t any
ies rela
P and r
ort a
P and r
ics
d to
ics (Se
to 
(Se
g paragr
used
g paragr
summ
be 
summ
event o
not 
event o
hange #
t can
hange #
ITP
ment
ITP
In
m
In


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 96 of 128
arm and Day 1 to Day 71 for the 7mg/kg dose arm) for each subject (linear scale). The 
ITP-specific autoantibodies 
 and platelet counts will be 
overlaid on the same plot (discrete y-axes) with separate plots for each subject (4 lines per 
plot) 

A scatter plot of platelet counts (measured by ACM Global Central Laboratory) versus 
ITP-specific autoantibodies measured at the same timepoint will be presented in linear scale, 
with separate plots for each dose arm and for each variable 
 All subjects and timepoints will be included on the same plot for each dose arm

Individual ITP-specific autoantibodies and total IgG (from ACM Global Central Laboratory) 
will be displayed graphically over time (Day 1 to Day 85 for the 4mg/kg dose arm and Day 1 
to Day 71 for the 7mg/kg dose arm) for each subject (linear scale). The ITP-specific 
autoantibodies 
 and total IgG will be overlaid on the same 
plot (discrete y-axes) with separate plots for each subject (4 lines per plot). These plots will 
be repeated for each of the IgG subclasses.
Has been changed to:
In order to evaluate the relationship between changes in platelet count and total IgG, IgG 
subclasses and ITP-specific autoantibodies the following figures will be presented:

Individual ITP-specific autoantibodies and platelet counts (measured by ACM Global Central
Laboratory) will be displayed graphically over time (Day 1 to Day 85 for Dose Arm 1; Day 1 
to Day 71 for Dose Arm 2; Day 1 to Day 64 for Dose Arm 3 and Day 1 to Day 57 for Dose 
Arms 4 and 5) for each subject (linear scale). The ITP-specific autoantibodies 
and platelet counts will be overlaid on the same plot (discrete y-
axes) with separate plots for each subject (4 lines per plot) 

A scatter plot of platelet counts (measured by ACM Global Central Laboratory) versus 
ITP-specific autoantibodies measured at the same timepoint will be presented in linear scale, 
with separate plots for each dose arm and for each variable 
. All subjects and timepoints will be included on the same plot for each dose arm

Individual ITP-specific autoantibodies and total IgG (from ACM Global Central Laboratory)
will be displayed graphically over time (Day 1 to Day 85 for Dose Arm 1; Day 1 to Day 71 
for Dose Arm 2; Day 1 to Day 64 for Dose Arm 3 and Day 1 to Day 57 for Dose Arms 4 and 
5) for each subject (linear scale). The ITP-specific autoantibodies 
and total IgG will be overlaid on the same plot (discrete y-axes) with separate plots 
for each subject (4 lines per plot). These plots will be repeated for each of the IgG subclasses.
Change #38
Serum biomarkers (
 BAFF) will 
be listed by dose arm and timepoint including changes from Baseline. Descriptive summaries 
(including n, arithmetic mean, median, SD, minimum and maximum) will be presented by dose 
arm and timepoint for both absolute values and changes from Baseline.
Has been changed to:
Serum safety biomarkers 
 and BAFF will be listed by dose arm and timepoint including changes 
REDACTED COPY
et cou
OPY 
et cou
r time 
COP
r time 
4 for D
ED C
4 for D
cale). T
CTED
cale). T
count
DACT
count
subjec
REDA
subjec
mea
R
mea
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
m
v
m
oratory
s or 
oratory
m and D
ons 
m and D
ecific 
nsio
ecific 
erlaid o
xten
erlaid o
t). Thes
y ex
t). Thes
ount an
tion 
ount an
es will 
icati
es will 
unts (m
app
unts (m
(
o
(Day 1
on a
Day 1
Dose A
atio
Dose A
The
oriz
The IT
za
IT
ts
ut
ts will b
utho
will b
ct
g
ct (4 lin
g aut
(4 lin
easured
keting
easured
sured a
arke
sured a
ose arm
ma
ose arm
timepo
any 
timepo
c autoa
port 
c autoa
raphica
uppo
raphica
Day 1 
o sup
Day 1 
bject (l
d to 
bject (l
nd 
se
nd tota
sed
tota
h subjec
be us
h subjec
e #3
not
e #38
t b
8
um bio
can
um bio
be liste
ent c
be liste
(incl
men
(incl
ar
m
ar


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 97 of 128
from Baseline. Descriptive summaries (including n, arithmetic mean, median, SD, minimum and 
maximum) will be presented by dose arm and timepoint for both absolute values and changes 
from Baseline.
Change #39Anti-drug antibodies (Section 9.3.4)
Full section has been updated with the following text:
Immunological variables will be analyzed for all subjects in the SS. Anti-UCB7665 antibody 
data will be summarized at each scheduled visit, and the rate of ADA positive subjects will be 
calculated.
A calibrator screening assay measures ADA as relative mass units (RMU) in units/mL. A cut 
point will be determined by the bioanalytical laboratory that will be used to determine the status 
of ADA as above the cut point (ACP) or below the cut point (BCP). The RMU result from the 
calibrator screening assay will be used to report ADA levels.
For any ADA levels that are ACP, a further confirmatory assay will be performed, the results of 
which will be determined as either ‘confirmed positive’ (CP) or ‘not confirmed positive’ (NCP). 
The results for the ADA measurements will be listed by treatment group and time point based on 
the SS, including the screening assay, confirmatory assay and level in units/mL. 
The following definitions will be applied:

An ADA status of positive will be concluded for any subject with an ADA level that is ACP 
and CP at any time point 

An ADA status of negative will be concluded for any subject with an ADA level that is either 
BCP or ACP and NCP at any time point

A subject will be classified as having ADA positivity at Baseline if the Day 1, predose result 
is ACP and CP

A subject will be classified as having treatment-emergent ADA positivity when meeting one 
of the following criteria:

The Baseline result is either BCP or ACP and NCP, and at least one post-Baseline time 
point is ACP and CP

The Baseline result is positive (ACP and CP) and at least one post-Baseline measurement 
shows a pre-defined fold increase in units/mL from the Baseline value (the fold increase 
from Baseline required to meet this criteria will be defined with the development of the 
assay and will be included in the TFLs)

A subject will be classified as overall positive if at least one post-Baseline measurement is 
ACP and CP (this includes subject who have negative results at Baseline)

A subject will be classified as overall negative if at all post-Baseline visits the ADA status is 
negative (this includes subjects who have positive [ACP and CP] results at Baseline)

Inconclusive: pre-ADA negative or pre-ADA positive subjects with negative ADA samples 
post baseline for which time matched drug levels are above the demonstrated drug tolerance 
characteristics of the ADA screening assay at one or more sampling time points
REDACTED COPY 
for an
CO
for an
nclude
ACT
nclude
point
EDA
point
ving
RE
ving
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
e e 
L. A cut
ons o
L. A cut
ine the 
nsion
ine the 
esult fr
tens
esult fr
erforme
d any
erforme
onfirm
and a
onfirm
gro
ion
group 
n a
up 
evel in 
catio
evel in 
ny subj
ion a
ny subj
ed for a
thori
ed for a
g ADA
ting
g ADA
s havin
y ma
s havin
lt is eith
port 
lt is eith
nd CP
upp
nd CP
ne resu
d to s
ne resu
pre
sed
pre-
ed
-de
d t
de
Baselin
e use
Baselin
say and
t be 
say and
subjec
nno
subjec
ACP 
t can
ACP 

me

A
n
A


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 98 of 128

Missing: relevant samples are missing
The ADA status (positive/negative) will be summarized as a categorical endpoint (number and 
percentage of subjects) for all time points and overall, based on the SS. 
In addition, the first occurrence of treatment-emergent ADA positivity (based on the definitions 
above) will be summarized (number and percentage of subjects) at each post-Baseline visit, 
based on the SS. This tabulation will count the number of subjects at each post-Baseline visit 
who fulfill at least one of the above defined criteria for treatment-emergent positivity; subjects 
will be counted in the numerator based on the earliest visit at which one of these criteria is 
fulfilled. At other visits, subjects will be counted in the denominator (assuming a measurement is 
available). For all tabulations, percentages will be based on the number of observations at each 
visit.
A separate listing will be presented (based on the SS) showing the UCB7665 concentrations and 
ADA measurements in the same output in adjacent columns. The listing will include the 
UCB7665 concentration, ADA status (ACP or BCP) and confirmatory assay results if applicable 
(NCP or CP), together with the units/mL for results that are CP. In addition the time since the 
previous administration of IMP will be reported (in days).
Finally, individual subject plots (based on the SS) will be presented displaying the ADA 
units/mL and UCB7665 concentrations overlaid on the same figure. The figure will also show 
the timing and dose of each administration of UCB7665 received during the study.
The rules for handling values that are BLQ in the UCB7665 concentration data are described in 
Section 4.2.5 For the ADA data, any negative results for which there are no units/mL available at 
a specific visit will be substituted with 0.001 for the purpose of the figure.
Change #40
Extent of exposure (Section 10.1)
The planned dose regimens are as follows:

Subjects in Dose Arm 1 will receive 5 sc doses of UCB7665 4mg/kg at 1-week intervals

Subjects in Dose Arm 2 will receive 3 sc doses of UCB7665 7mg/kg at 1-week intervals
Has been changed to:
The planned dose regimens are as follows:

Subjects in Dose Arm 1 will receive 5 sc doses of UCB7665 4mg/kg at 1-week intervals

Subjects in Dose Arm 2 will receive 3 sc doses of UCB7665 7mg/kg at 1-week intervals

Subjects in Dose Arm 3 will receive 2 sc doses of UCB7665 10mg/kg at 1-week intervals

Subjects in Dose Arm 4 will receive 1 sc dose of UCB7665 15mg/kg 

Subjects in Dose Arm 5 will receive 1 sc doses of UCB7665 20mg/kg 
REDACTED COPY
e sam
PY 
e sam
7665 r
OPY
7665 r
he UC
ED C
he UC
ve resu
CTED
ve resu
001 fo
DACT
001 fo
arketing authorization application and any extensions or variations thereof.
rement 
s or v
rement 
ns at ea
ons 
ns at ea
oncent
exte
oncent
ll includ
ny e
ll includ
ssay res
d any
ssay res
dition t
and 
dition t
ented d
icati
ented d
e figure
pplic
e figure
receive
n app
receive
CB7665
atio
CB7665
ults for
oriza
ults for
or the p
thor
or the p
not be used to support any m
follow
mar
follow
ill rece
any 
ill rece
2 will 
port 
2 will 
o:
o:
e regim
d to
e regim
in Dose
use
in Dose
ects in 
ot be
ects in 
This document can
Subject
ann
Subject
Sub
nt c
Sub

m



UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 99 of 128
Change #35
Adverse events (Section 10.2)
In addition, AEs will be classified according to the CTCAE Version 4.03 for severity. For any 
AEs where it is not possible to provide a CTCAE grading, the events will be assessed using a 
standard intensity classification (mild, moderate and severe). For the purpose of the tabulations 
all CTCAE severity classifications will be mapped to a mild/moderate/severe grade as described 
in the below sections.
Has been changed to:
In addition, AEs will be classified according to the CTCAE Version 4.03 for severity. For any 
AEs where it is not possible to provide a CTCAE grading, the events will be assessed using a 
standard intensity classification (mild, moderate and severe). For the purpose of the tabulations 
all CTCAE severity classifications will be mapped to a mild/moderate/severe grade as described 
in the below sections. Bleeding events classified as Grade 1 or Grade 2 (based on CTCAE) will 
not be reported as AEs as these will be assessed and reported as part of the ITP-BAT 
assessments. Bleeding events classified as Grade 3 or higher, based on CTCAE, will be reported 
as AEs.
Change #36
Potential drug-induced liver injury (Section 10.3.1)
Subjects who meet any of the following criteria at a given timepoint will be listed:

Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) increase ≥5 x upper 
limit of normal (ULN) 

Alanine aminotransferase or AST increase ≥3 x ULN and total bilirubin ≥2 x ULN

Alanine aminotransferase or AST increase ≥3 x ULN (and ≥2 x Baseline) and <5 x ULN, 
with total bilirubin <2 x ULN

Alanine aminotransferase or AST increase ≥5 x ULN (and ≥2 x Baseline), with total bilirubin 
<2 x ULN

Alanine aminotransferase or AST increase ≥8 x ULN

Alkaline phosphatase (ALP) ≥2 x ULN
Has been changed to:
Subjects who meet any of the following criteria at a given timepoint will be listed:

Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) increase ≥5 x upper 
limit of normal (ULN) 

ALT or AST increase ≥3 x ULN and total bilirubin ≥2 x ULN

ALT or AST increase ≥3 x ULN who exhibit temporally associated symptoms of hepatitis or 
hypersensitivity.

ALT or AST increase ≥3 x ULN (and ≥2 x Baseline) and <5 x ULN, with total bilirubin <2 x 
ULN
REDACTED COPY 
.1)
OP
.1)
at a g
D CO
at a g
artate 
CTE
artate 
T incre
RED
T incre
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
For an
ons o
For an
ed usin
nsion
ed usin
the tab
tens
the tab
grade 
ext
grade 
ased on
any 
ased on
the ITP
nd a
the ITP
on CTC
and
on CTC
given ti
ation
given ti
amino
horiz
amino
ease ≥
ng a
ease ≥
increa
rket
increa
or AST
any 
or AST
ferase 
upp
ferase 
phatase 
d to s
phatase 
nged to
used
nged to
who me
be u
who me
lanine a
nnot
lanine a
limit o
can
limit o

e

A
nt
A



UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 100 of 128

ALT or AST increase ≥5 x ULN (and ≥2 x Baseline), with total bilirubin <2 x ULN and no 
eosinophilia (i.e., ≤5%), with no fever, rash, or symptoms of hepatitis

Alkaline phosphatase (ALP) ≥2 x ULN

Change #37
Treatment group assignment for the TFLs (Section 13.6)
Treatment Label
TFL group
UCB7665 5x4mg/kg
UCB7665 3x7mg/kg
All Subjects
Subject disposition
X
X
X
Protocol deviations
X
X
X
Demographics
X
X
X
Baseline 
characteristics
X
X
Medical history
X
X
X
Prior and concomitant 
medications
X
X
X
Adverse events
X
X
X
Safety measurements 
(including safety 
laboratory tests, vital 
signs and ECG)
X
X
Efficacy (platelets, 
ITP bleeding score, 
NFI-MS)
X
X
PK
X
X
PD (ITP-specific 
autoantibodies, total 
IgG,IgG subclasses 
and IgG depletion 
assay)
X
X
Immunological 
(serum 
immunoglobulins, B-
and T-lymphocytes, 
serum and plasma 
complement, serum 
biomarkers, ADA and 
cytokines)
X
X
REDACTED COPY 
X
D C
X
OP
D 
ED
t be used to support any marketing authorization application and any extensions or variations thereof.
titi
ati
va
o
sio
xte
ny
nd
a
at
a
X
ori
X
at
uth
eti
an
l
t
l
ses
ed
ses
etion
use
etion
X
upp
X
po
s
ument cannot b
nologic
nnot 
nologic
rum
can
rum
mmuno
nt c
mmuno
and T
men
and T
se
m
se
This docum
t b
um


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 101 of 128
Has been changed to:
Treatment Labela
TFL group
UCB7665 
5x4mg/k
g weekly
(Dose 
Arm 1)
UCB7665 
3x7mg/kg 
weekly 
(Dose 
Arm 2)
UCB7665 
2x10mg/kg 
weekly
(Dose Arm 
3)
UCB7665 
1x15mg/kg 
(Dose Arm 
4)
UCB7665 
1x20mg/kg 
(Dose Arm 
5)
All 
Subject
s
Subject disposition
X
X
X
X
X
X
Protocol deviations
X
X
X
X
X
X
Demographics
X
X
X
X
X
X
Baseline 
characteristics
X
X
X
X
X
Medical history
X
X
X
X
X
X
Prior and concomitant 
medications
X
X
X
X
X
X
Adverse events
X
X
X
X
X
X
Safety measurements 
(including safety 
laboratory tests, vital 
signs and ECG)
X
X
X
X
X
Efficacy (platelets, 
ITP bleeding score, 
NFI-MS)
X
X
X
X
X
PK
X
X
X
X
X
PD (ITP-specific 
autoantibodies, total 
IgG,IgG subclasses 
and IgG depletion 
assay)
X
X
X
X
X
Immunological (serum 
immunoglobulins, B-
and T-lymphocytes, 
serum and plasma 
complement, serum 
biomarkers, ADA and 
cytokines)
X
X
X
X
X
ACTED COPY 
Y
TE
REDAC
AC
horization application and any extensions or variations thereof.
iat
ar
X
ns
X
or
o
X
o
X
on
io
en
X
d a
X
ny
nd
nd
nd
nd
nd
X
pli
X
at
X
pp
X
pp
a
nt cannot be used to support any marketing autho
X
uth
X
ho
au
X
a
X
ket
m
X
m
X
ma
s
y m
serum 
ed to
serum 
lins, B
used
lins, B
hocytes
be us
hocytes
nd plasm
t be
nd plasm
lement,
nnot
lement,
marker
cann
marker
cytokin
nt ca
cytokin
This documen
o s
en


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 102 of 128
14.2
Amendment 2
14.2.1
Rationale for the amendment
The second SAP amended has been developed to include some requirements observed during the 
study Dry Run as well as to include the ad-hoc outputs which were not part of the initial SAP. 
Updates made in the CRF are also described here. Few other minor formatting updates were 
made.
14.2.2
List of changes
Specific changes
Change #1
General along the document
In some places, “timepoint” has been changed to “visit” to make the text more appropriate to 
how the data is collected; hence “timpoint” is now only referring to a “moment of time” within a 
visit or to a general moment during the study conduction.
Change #2
Definition of Baseline values (Section 3.3)
Baseline will be the last available predose value prior to the first infusion of UCB7665, or if 
missing, the Screening values. 
Measurement-specific Baseline timepoints (based on the planned measurements) are presented in 
Table 3‒1.
REDACTED COPY
r to th
OPY 
r to th
ased o
TED 
ased o
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
re appr
y ex
re appr
oment o
any
oment o
he first 
app
he first 
on the
izat
on the


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 103 of 128
Table 14‒1: Definition of Baseline
Measurement
Definition of Baseline
Safety data:

Clinical chemistry (including proteins)

Hematology (including platelets measured 
locally)

Coagulation

Urinalysis

Vital signs

12-lead ECG

Serum safety biomarkers 

Predose Day 1 or if missing the Screening 
valuea
Efficacy variables:

Platelets (measured by ACM Global 
Central Laboratory)

ITP bleeding scale

NFI-MS

Platelets: Predose Day 1 or if missing the 
Screening value

ITP bleeding scale: Predose Day 1 or if 
missing the Screening assessment

NFI-MS: Predose Day 1
Pharmacodynamic variables:

Total IgG

IgG subclasses


ITP-specific autoantibodies in serum 

Total IgG: Predose Day 1 or if missing the 
Screening value

IgG subclasses: Predose Day 1 or if 
missing the Screening value

ITP-specific autoantibodies: Predose Day 1
Immunological variables:

Immunoglobulins (IgA, IgE and IgM)

B- and T-lymphocytes

Serum (C3 and C4) and plasma 
complement (C3a and C5a)

ADA

Serum BAFF

Cytokines, if applicable (as outlined in the 
protocol)

Predose Day 1 (except B- and T-
lymphocytes)

B- and T-lymphocytes: Predose Day 1 or if 
missing the Screening value
If the Screening value is to be used as Baseline (i.e., predose Day 1 is missing), the highest value 
for the platelet count obtained from the 2 measurements at Screening will be used as the 
Baseline.
REDACTED COPY 

OP

N
Y
N
R
CO
ED
arketing authorization application and any extensions or variations thereof.
ati
dose Da
and
dose Da
value
on a
value
eeding s
catio
eeding s
sing the
plica
sing the
NFI
ap
NFI-
ap
-M
pp
M
d a
m 
et
m 

at

To
o
To
n 
uth
nnot be used to support any ma
 IgE an
t any
 IgE an
tes
po
tes
C4) and
supp
C4) and
(C3a an
to su
(C3a an
m BAFF
us
m BAFF
ytokine
t be
ytokine
protoc
not 
protoc
This document cann
a
nn
f the Sc
t ca
f the Sc
for th
ment
for th
Ba
m
Ba
eting
ark


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 104 of 128
Has been changed to:
Baseline will be the last available predose value prior to the first infusion of UCB7665, or if 
missing, the latest no missing value prior to Baseline (screening value or unscheduled visit 
value). 
Measurement-specific Baseline timepoints (based on the scheduled or unscheduled 
measurements) are presented in Table 3‒1.
Table 14‒1: Definition of Baseline
Measurement
Definition of Baseline
Safety data:

Clinical chemistry (including proteins)

Hematology (including platelets measured 
locally)

Coagulation

Urinalysis

Vital signs

12-lead ECG

Serum safety biomarkers

Predose Day 1 or if missing the latest no 
missing value prior to Day 1
Efficacy variables:

Platelets (measured by ACM Global 
Central Laboratory)

ITP bleeding scale

NFI-MS

Platelets: Predose Day 1 or if missing the 
latest no missing value prior to Day 1

ITP bleeding scale: Predose Day 1 or if 
missing the latest no missing value prior to 
Day 1

NFI-MS: Predose Day 1
Pharmacodynamic variables:

Total IgG

IgG subclasses


ITP-specific autoantibodies in serum 

Total IgG: Predose Day 1 or if missing the 
latest no missing value prior to Day 1

IgG subclasses: Predose Day 1 or if 
missing the latest no missing value prior to 
Day 1

ITP-specific autoantibodies: Predose Day 1
Immunological variables:

Immunoglobulins (IgA, IgE and IgM)

B- and T-lymphocytes

Serum (C3 and C4) and plasma 
complement (C3a and C5a)

ADA

Serum BAFF

Cytokines, if applicable (as outlined in the 
protocol)

Predose Day 1 (except B- and T-
lymphocytes)

B- and T-lymphocytes: Predose Day 1 or if 
missing the latest no missing value prior to 
Day 1
REDACTED COPY 
ED
al
ED
al
ED
ED
ED
ED
sed to support any marketing authorization application and any extensions or variations thereof.
v
he lates
sions
he lates
1
e
1
s

za
uth
ific auto
ed t
ific auto
y m
ument cannot be u
ogical v
t be
ogical v
Immu
nno
Immu

c

B
a
B

n

This docum
e u
um
use


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 105 of 128
If the latest non missing value prior to Baseline is to be used as Baseline (i.e., predose Day 1 is 
missing), the highest value for the platelet count obtained from the last 2 non missing 
measurements prior to Baseline will be used as the Baseline.
Change #3
Electrocardiograma data (Section 4.2.6)
For the ECG data, all calculations of changes from Baseline and descriptive statistics will be 
based on the mean of the triplicate assessments at each timepoint. In the event that there are not 3 
available measurements at a given timepoint, the mean will be calculated based on the number of 
measurements for which data is provided.
Has been changed to:
For the ECG data, all calculations of changes from Baseline and descriptive statistics will be 
based on the mean of the triplicate assessments at each visit. In the event that there are not 3 
available measurements at a given visit, the mean will be calculated based on the number of 
measurements for which data is provided (variables analyzed will be those described in Section 
10.4.2).
Change #4
Examination of subgroups (Section 4.8)
The following subgroups will be defined within each dose arm:

Use of corticosteroid medication: Present

Use of corticosteroid medication: Absent

Responder at the end of previous ITP treatment: No

Responder at the end of previous ITP treatment: Yes
Only medication classified as either ‘prior and concomitant’ or ‘concomitant’ and medical 
procedure will be considered for ITP treatment. Responder categories will be defined taking into 
account the last valid value reported (either Yes or No) for each patient. Past use of 
corticosteroids (not ongoing after dosing) will not be considered for this classification. The list of 
applicable Anatomical Therapeutic Chemical (ATC) codes in order to identify the 
presence/absence of corticosteroids is provided in Section 13.1.
Has been changed to:
The following subgroups will be defined within each dose arm:

Use of corticosteroid medication: Present/Absent

Responder at the end of previous ITP treatment: No/Yes/Unknown

Previous intravenous immunoglobulin (IVIg) therapy: Yes/No 

Number of previous ITP therapies: ≤2/>2
Only medication classified as either ‘prior and concomitant’ or ‘concomitant’ and medical 
procedure will be considered for ITP treatment. Responder categories will be defined taking into 
account the last reported ITP treatment value (either Yes or No) for each patient. If this value is 
REDACTED COPY 
ach do
COP
ach do
sent
DAC
sent
ITP t
RED
ITP t
any marketing authorization application and any extensions or variations thereof.
not 3 
aria
not 3 
mber of
or va
mber of
tistics w
exten
tistics w
at there 
y ex
at there 
d on th
d any
d on th
hose de
and a
hose de
ose arm
ion a
ose arm
treatme
ng a
treatme
ITP tre
rketi
ITP tre
her ‘prio
ma
her ‘prio
or ITP 
any 
or ITP 
ot be used to support
reporte
rt a
reporte
oing aft
ppor
oing aft
l Thera
supp
l Thera
of cortic
to s
of cortic
nged to
used
nged to
wing sub
be u
wing sub
This document cann
e of co
not
e of co
Resp
t ca
Resp

me

P
n
P


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 106 of 128
unknown, the second-last reported ITP treatment value will be used, then the third-last, and so 
on, until a known response is provided. The Unknown responder category will only be 
considered in cases where the investigator has never reported a category (Yes or No) for any of 
the previous ITP treatments. Past use of corticosteroids (not ongoing after dosing) will not be 
considered for this classification. The list of applicable Anatomical Therapeutic Chemical (ATC) 
codes in order to identify the presence/absence of corticosteroids is provided in Section 13.1.
Change #5
Demographics (Section 6.1)
All Baseline demographic characteristics (with the exception of year of birth) will be 
summarized by dose arm and overall for the SS. 
Has been changed to:
All Baseline demographic characteristics (with the exception of year of birth) will be 
summarized by dose arm and overall for the SS. Number and percentage of patients with a BMI 
equal or higher than 30 will also be summarized by dose arm.
Change #6
Other Baseline characteristics (Section 6.2)
Baseline disease characteristics will be listed and summarized by dose arm for the SS including 
the following:

Duration of disease

Karnofsky Performance Scale Index

ITP bleeding scale (skin, visible mucosae and organs, with gradation of severity [SMOG])

ITP-specific autoantibodies 
 expressed in terms of optical 
density (OD) for MAIPA analysis and pre-chloroquine minus post chloroquine treated scores 
for PIFT

Immunological variables (IgG [including total IgG and IgG subclasses measured by ACM 
Global Central Laboratory], IgM, IgA, IgE and lymphocytes [B and T])

Serum (C3 and C4) and plasma complement levels (C3a and C5a)

Platelet count (measured by ACM Global Central Laboratory)
Has been changed to:
Baseline disease characteristics will be listed and summarized by dose arm for the SS including 
the following:

Duration of disease

Karnofsky Performance Scale Index

ITP bleeding scale (skin, visible mucosae and organs, with gradation of severity [SMOG])
REDACTED COPY
mmari
OPY 
mmari
mucos
RED
mucos
eting authorization application and any extensions or variations thereof.
h) will b
y ex
h) will b
of patie
d any
of patie
ized by
app
ized by
sae and
ng a
sae and
t be used to support any mark
ysis and
mark
ysis and
s
o
s (IgG 
ort a
(IgG 
ratory],
ppor
ratory],
C4) and
o sup
C4) and
nt (mea
ed t
nt (mea
hanged
be us
hanged
This document canno
e disea
not b
e disea
ollowin
anno
ollowin
Dur
nt c
Dur

m

rket


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 107 of 128

ITP-specific autoantibodies 
 expressed in terms of optical 
density (OD) for MAIPA analysis and pre-chloroquine minus post chloroquine treated scores 
for PIFT

Immunological variables (IgG [including total IgG and IgG subclasses measured by ACM 
Global Central Laboratory], IgM, IgA, IgE and lymphocytes [B and T])

Serum (C3 and C4) and plasma complement levels (C3a and C5a)

Platelet count (measured by ACM Global Central Laboratory)

Number of prior ITP medications received

Number of prior ITP medications received categorized

Prior ITP medications received by preferred term

Medical history of splenectomy (MedDRA v20.2, Preferred Term=”Splenectomy”)
Change #7
Measurements of treatment compliance (Section 7)
The study medication will be administered and monitored by the investigator or designee. The 
measured plasma concentrations will provide information regarding compliance. Any dosing 
deviations (eg, incomplete infusion volume administered, infusion temporarily interrupted, 
infusion discontinued) will be discussed at the DEM and any actions taken regarding the 
analyses will be documented accordingly and discussed in the CSR.
Has been changed to:
The study medication will be administered and monitored by the investigator or designee. The 
measured plasma concentrations will provide information regarding compliance. Any dosing 
deviations (eg, incomplete infusion volume administered, infusion discontinued) will be 
discussed at the DEM and any actions taken regarding the analyses will be documented 
accordingly and discussed in the CSR.
Change #8
Platelets (Section 8.1)
All efficacy analyses are based on platelet count measured by ACM Global Central Laboratory. 
Measurements of platelet count obtained by the local laboratory will be listed and summarized as 
part of the safety laboratory data. These are not included in the analyses described in the sections 
below. All tabulations and mean figures will be presented for both the FAS and the PPS unless 
otherwise stated. Individual figures will be presented for the FAS only. In case rescue 
medications are taken, only the platelet data up to the time point where the rescue medication is 
taken will be utilized.
Has been changed to:
All efficacy analyses are based on platelet count measured by ACM Global Central Laboratory. 
Measurements of platelet count obtained by the local laboratory will be listed and summarized as 
part of the safety laboratory data. These are not included in the analyses described in the sections 
below. All tabulations and mean figures will be presented for both the FAS and the PPS unless 
REDACTED COPY 
ion 
Y
ion 
tered,
OPY
tered,
EM an
D CO
EM an
discus
TED 
discus
tered 
RED
tered 
pro
R
pro
nnot be used to support any marketing authorization application and any extensions or variations thereof.
enectom
ny e
enectom
he inve
icatio
he inve
egardin
pplic
egardin
,
n
, infusi
n app
infusi
nd any
tion 
nd any
ssed in
izati
ssed in
and mo
g au
and mo
ovide in
eting
ovide in
olume 
rket
olume 
ions tak
mar
ions tak
e CSR
ny m
e CSR
es are b
to s
es are b
of plate
sed t
of plate
fety lab
use
fety lab
l tabula
t be 
l tabula
se stat
not 
se stat
This document ca
ication
cann
ication
ken w
t ca
ken w
Has
me
Has


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 108 of 128
otherwise stated. Median figures and individual figures will be presented for the FAS only. In 
case rescue medications are taken, only the platelet data up to the time point where the rescue 
medication is taken will be utilized for the summary tables. Listings will contain all the data but 
a footnote will be included indicating the patients for which some data has been excluded from 
the summary tables.
Change #9
Presentation of results (Section 8.1.2)
The individual platelet measurements will be listed by dose arm and timepoint including changes 
from Baseline (Day 1, predose). Descriptive summaries (including n, arithmetic mean, median, 
SD, minimum and maximum) will be presented by dose arm and scheduled timepoint for both 
absolute values and changes from Baseline. Summary tabulations by dose arm will be repeated 
for the subgroups defined in Section 4.8 (based on the FAS only).
Has been changed to:
The individual platelet measurements will be listed by dose arm and visit including changes from 
Baseline (Day 1, pre-dose). Descriptive summaries (including n, arithmetic mean, median, SD, 
minimum and maximum) will be presented by dose arm and scheduled visit for both absolute 
values and changes from Baseline based on the FAS only. Summary tabulations by dose arm will 
be repeated for the subgroups defined in Section 4.8 (based on the FAS only too).
Change #10
Presentation of results (Section 8.1.2)
Mean and mean change from Baseline platelet values will be plotted versus scheduled visit by 
dose arm with all dose arms overlaid on the same plot. Similar plots will be provided for 
response rate over time (response, complete response and platelet count ≥50x109/L). 
Individual platelet and total IgG (including IgG subclasses, measured by ACM Global Central 
Laboratory) concentrations will be displayed graphically over time (Day 1 to Day 85 for Dose 
Arm 1; Day 1 to Day 71 for Dose Arm 2; Day 1 to Day 64 for Dose Arm 3 and Day 1 to Day 57 
for Dose Arms 4 and 5) for each subject (linear scale). The platelet and total IgG concentrations 
will be overlaid on the same plot (discrete y-axes) with separate plots for each subject (2 lines 
per plot). Additional plots will be presented with the platelet and IgG subclasses overlaid on the 
same figure (5 lines per plot). All plots will include a vertical reference line to indicate when the 
last dose was administered for each subject.
Has been changed to:
Mean and mean change from Baseline platelet values will be plotted versus scheduled visit by 
dose arm with all dose arms overlaid on the same plot. Similar plots will be provided for 
response rate over time (response, complete response and platelet count ≥50x109/L). Mean 
median, mean change and median change from Baseline total IgG results will be plotted over 
time by dose arm with all dose arms overlaid on the same plot.
Individual platelet and total IgG (including IgG subclasses, measured by ACM Global Central 
Laboratory) concentrations will be displayed graphically over time (Day 1 to Day 85 for Dose 
Arm 1; Day 1 to Day 71 for Dose Arm 2; Day 1 to Day 64 for Dose Arm 3 and Day 1 to Day 57 
for Dose Arms 4 and 5) for each subject (linear scale). The platelet and total IgG concentrations 
REDACTED COPY
y
(base
PY 
(base
atelet 
DAC
atelet 
on the
REDA
on the
mpl
RE
mpl
y marketing authorization application and any extensions or variations thereof.
hanges
or va
hanges
median
ns or
median
nt for b
sions
nt for b
ll be re
ensi
ll be re
isit incl
and a
isit incl
ithmeti
n an
ithmeti
eduled 
ation
eduled 
mmary
plica
mmary
d on the
appl
d on the
t values
utho
t values
e same 
g au
e same 
lete res
ting
lete res
cluding
arke
cluding
be displ
y ma
be displ
t be used to support an
ose Arm
any 
ose Arm
each su
ort a
each su
ame plo
ppor
ame plo
plots w
supp
plots w
s per p
d to s
s per p
dminist
sed t
dminist
hanged
be u
hanged
nt canno
nd mea
not b
nd mea
arm w
ann
arm w
esponse
nt ca
esponse
This documen
media
ment
media
tim
m
tim


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 109 of 128
will be overlaid on the same plot (discrete y-axes) with separate plots for each subject (2 lines 
per plot). Additional plots will be presented with the platelet and IgG subclasses overlaid on the 
same figure (5 lines per plot). All plots will include a vertical reference line to indicate when the 
last dose was administered for each subject. The mean (and median in a separate plot) change 
from baseline in platelet and the mean (median) change from baseline in total IgG concentrations 
will be overlaid on the same plot (discrete y-axes) with separate plots for each dose arm (2 lines 
per plot).
Change #11
Analysis of responder rate (Section 8.1.3.3)
The following paragraphs have been added at the end of this subsection:
Moreover, for responder rate, summary tabulations by dose arm will be repeated according to 
previous intravenous immunoglobulin therapy (Yes/No) and the number of previous medications 
(≤2/>2). Percentage of days without bleeding will also be described by dose arm for each type of 
response (response, complete response and platelet Count >=50x10/L). Percentage of days 
without bleeding is calculated using the following formula:
((N of visits with a SMOG score – N of these visits where bleeding occurred) / N of visits with a 
SMOG score) x 100
In case rescue medications are taken, only the data up to the start date of rescue medication will 
be utilized for the summary tables. Listings will contain all the data but a footnote will be 
included indicating the patients for which some data has been excluded from the summary tables. 
In case of partial dates, the imputation rules for partial dates described in Section 4.2.7 will be 
applied.
Change #12
IPT bleeding score and platelet response (Section 8.2.1.1)
All response variables described above will be listed by dose arm and subject and summarized 
by dose arm and visit where appropriate. The responder rates will be tabulated as described in 
Section 8.1.3.3. All analyses described in this section will be performed for the FAS.
Has been changed to:
All response variables described above will be listed by dose arm and subject and summarized 
by dose arm and visit where appropriate. The responder rates will be tabulated as described in 
Section 8.1.3.3. Moreover the change in category of bleeding from Baseline will also be 
presented in shift table at all post-Baseline timepoints by dose arm. Summary tabulations for 
Clinical Response by dose arm will be repeated according to previous intravenous 
immunoglobulin therapy (Yes/No) and the number of previous medications (≤2/>2). All analyses 
described in this section will be performed for the FAS.
In case rescue medications are taken, only the data up to the start date of rescue medication will 
be utilized for the summary tables. Listings will contain all the data but a footnote will be 
included indicating the patients for which some data has been excluded from the summary tables.
In case of partial dates, the imputation rules for partial dates described in Section 4.2.7 will be 
applied.
REDACTED COPY 
up to th
OPY
up to th
contain
CO
contain
me data
ED C
me data
s for p
CTE
s for p
support any marketing authorization application and any extensions or variations thereof.
accord
tens
accord
revious
ext
revious
se arm 
any 
se arm 
Percen
d a
Percen
ing occ
ation
ing occ
the star
app
the star
n all th
tion 
n all th
a has be
izatio
a has be
partial d
horiz
partial d
ponse (
rket
ponse (
above w
y ma
above w
ppropri
any 
ppropri
s descr
ort a
s descr
t be used to
bles des
to s
bles des
d visit w
ed t
d visit w
3. Mor
use
. Mor
in shift
be u
in shift
This document canno
l Respo
not b
l Respo
munoglo
ann
munoglo
escribe
nt ca
escribe
In ca
men
In ca
b
m
b


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 110 of 128
Change #13
Pharmacokinetics (Section 9.1)
The following sentence has been removed from this section:
If applicable, a separate listing of UCB7665 concentrations in the cerebrospinal fluid (CSF) will 
be presented by dose arm. These data will not be summarized.
Change #14
ITP-specific autoantibodies (Section 9.2.1)
The results will be expressed in the form of the OD value.
ITP-specific autoantibodies (OD value ) will be listed by dose arm and timepoint. Values that are 
ALD will be displayed as such in the listings.
Has been changed to:
The results will be expressed in the form of the OD value and for indirect PIFT method using the 
following categories: 0 = negative; 0.5 = week positive; 1 = positive; 2 = positive; 3 = strong 
positive; 4 = strong positive.
ITP-specific autoantibodies (OD value and PIFT categories) will be listed by dose arm and 
timepoint. OD values that are ALD will be displayed as such in the listings.
Change #15
ITP-specific autoantibodies (Section 9.2.1)
The following sentence has been added at the end of this section:
Only patients with positive ITP-specific autoantibodies will be described.
Change #16
Total IgG and IgG subclasses (Section 9.2.2)
Mean and mean percentage change from Baseline values in total IgG (measured by ACM Global 
Central Laboratory) will be plotted over time by dose arm with all dose arms overlaid on the 
same plot. Additional figures will be presented in conjunction with the ADA results as described 
in Section 9.3.4 as well as figures in conjunction with the platelet results as described in 
Section 8.1.1.
Finally, a separate figure will be presented by subject showing the individual total IgG results 
from ACM Global Central Laboratory.
Any values that are BLQ or ALQ will be handled as described in Section 4.2.32.
All analyses described in this section will be performed on the PD-PPS. In case rescue 
medications are taken, only the IgG data up to the timepoint where the rescue medication is 
taken will be utilized for the summary tables. Listings will contain all the data but a footnote will 
be included indicating the patients for which some data has been excluded from the summary 
tables.
Has been changed to:
REDACTED COPY
as su
OPY 
as su
)
C
)
at the 
DAC
at the 
ific
RE
ific au
E
au
port any marketing authorization application and any extensions or variations thereof.
Values
nsio
Values
ect PIFT
nd a
ect PIFT
; 2 = po
n an
; 2 = po
will be 
plica
will be 
uch in th
app
uch in th
end of
utho
end of
utoanti
ng a
utoanti
Section
y ma
Section
hange 
t any
hange 
e plotte
port 
e plotte
This document cannot be used to sup
igures w
uppo
igures w
well as f
o sup
well as f
arate fi
use
arate fi
M Globa
be u
M Globa
alues th
nnot
alues th
ll analy
t ca
ll analy
medic
ment 
medic
tak
me
tak


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 111 of 128
Mean, median, median change from Baseline and mean and median percentage change from 
Baseline values in total IgG (measured by ACM Global Central Laboratory) will be plotted over 
time by dose arm with all dose arms overlaid on the same plot. Additional figures will be 
presented in conjunction with the ADA results as described in Section 9.3.4 as well as figures in 
conjunction with the platelet results as described in Section 8.1.1.
Finally, a separate figure will be presented by subject showing the individual total IgG results 
from ACM Global Central Laboratory.
Any values that are BLQ or ALQ will be handled as described in Section 4.2.3.
All analyses described in this section will be performed on the PD-PPS. In case rescue 
medications are taken, only the IgG data up to the start date of rescue medication will be utilized 
for the summary tables. Listings will contain all the data but a footnote will be included 
indicating the patients for which some data has been excluded from the summary tables. In case 
of partial dates, the imputation rules for partial dates described in Section 4.2.7 will be applied.
Change #17
Adverse events (Section 10.2)
In addition the listing will flag AEs that led to discontinuation, TEAEs, AEs of interest, AEs of 
special interest, infusion reactions and SAEs.
Has been changed to:
In addition the listing will flag AEs that led to discontinuation, TEAEs, AEs of interest, AEs of 
special interest, infusion reactions, SAEs, Sampson criteria and CTCAE grade.
Change #18
Clinical laboratory evaluations (Section 10.3)
Values outside the reference range for the numeric variables will be flagged in the listings and in 
addition, will be listed separately. The reference ranges will also be reported in the listings.
Has been changed to:
Values outside the reference range for the numeric variables will be flagged in the listings and in 
addition, results considered as markedly abnormal laboratory results (CTCAE Grade 3 and 
above) will be listed separately. The reference ranges will also be reported in the listings.
Change #19
Vital signs (Section 10.4.1)
Table 10-2 has been updated as follows:
Variable
Unit
Low
High
Systolic blood pressure
mmHg
Value <90 and ≥20 
decrease from Baseline
Value >180 and ≥15 
increase from baseline
Diastolic blood pressure
mmHg
Value <50 and ≥15 
decrease from Baseline
Value >105 and ≥15 
increase from Baseline
Change #20
REDACTED COPY 
discon
ED C
discon
ampso
CTE
ampso
ctio
RE
ctio
support any marketing authorization application and any extensions or variations thereof.
ll be 
sion
ll be ut
ns
ut
cluded 
ensi
cluded 
ary tabl
exte
ary tabl
2.7
y
2.7 wil
y e
wil
TEAEs
catio
TEAEs
ntinuat
zatio
ntinuat
on crite
horiz
on crite
n 10.
ting
n 10.3
g
3
or the n
arke
or the n
The re
ma
The re
nce ran
port
nce ran
dered a
supp
dered a
nt cannot be used to
d separ
to su
d separ
(Secti
be u
(Secti
0
n
0-
o
-2 ha
not 
2 ha
riable
t ca
riable
n
ument 
Systo
men
Systo
This docum nt
um


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 112 of 128
Electrocardiograms (Section 10.4.2)
The following sentence has been added at the end of this subsection:
The number and percentage of subjects with TEMA/PCS ECG values will be summarized by 
dose arm at each timepoint.
Change #21
Electrocardiograms (Section 10.4.2)

QT corrected for heart rate using Fridericia’s formula (QTcF)
The individual measurements and the mean of the triplicate measurements will be reported in the 
by-subject listings. The listing will also include the change from Baseline and percentage change 
from Baseline (based on the mean of the triplicate measurements at each timepoint) and will be 
presented by dose arm and timepoint.
Has been changed to:

QT corrected for heart rate using Fridericia’s formula (QTcF = QT/RR0.33)
The individual measurements and the mean of the triplicate measurements will be reported in the 
by-subject listings. The listing will also include the change from Baseline and percentage change 
from Baseline (based on the mean of the triplicate measurements at each timepoint). TEMA/PCS 
ECG values will be flagged in the listing.
Change #22
Electrocardiograms (Section 10.4.2)
The following table has been added:
Variable
Criteria
QT corrected for heart rate using 
Fridericia’s formula (QTcF)
≥501ms
OR
≥60ms compared to baseline
PR prolongation
≥210ms and ≥10ms change from 
baseline
Change #23
Classification of markedly abnormal laboratory values based in CTCAE grades (Section 
13.5)
Table 13-2 has been updated as follows:
Category
Panel
Variable
Criteria (CTCAE aGrade 3 and 
above)
Hematology
Red blood cell
Hemoglobin (Decrease)
<8g/dL (<80g/L)
REDACTED COPY
asure
PY 
asure
RE
annot be used to support any marketing authorization application and any extensions or variations thereof.
orted in
ns o
orted in
entage c
sion
entage c
int) and
tens
int) and
T/RR
and
T/RR0.3
d
0.3
uremen
tion
uremen
m Bas
licat
m Bas
ments a
ppli
ments a
ng
using
mark
using 
cF)
y m
cF)
ke
rt
s
on of m
e use
on of m
13
nn
13-
n
-
This document ca
2 h
no
2 h
Categor
nt c
Categor
ca
m
H
m
um


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 113 of 128
Category
Panel
Variable
Criteria (CTCAE aGrade 3 and 
above)
Hemoglobin (Increase)
>4g/dL (>40g/L) above ULN 
OR
>4g/dL (>40g/L) above 
baseline if baseline is > ULN
White blood cell
WBC count (Decrease)
<2000/mm^3 
(<2.0x10^9/L)
WBC count (Increase)
>20,000/mm^3 
White blood cell 
differential
ALC (Decrease)
<500/mm^3 
(<0.5x10^9/L)
ALC (Increase)
>20,000/mm^3 
(>20x10^9/L)
ANC
<1000/mm^3 
(<1.0x10^9/L)
Chemistry
Liver Function
ALT
>5.0xULN
ALP
>5.0xULN
AST
>5.0xULN
Total bilirubin
>3.0xULN
GGT
>5.0xULN
Kidney Function
Creatinine
>3.0xbaseline value 
OR 
>3.0xULN
Creatinine (Acute 
kidney injury)
>3xbaseline value
OR
>4xULN
Creatinine 
phosphokinase
>5xULN
eGFR or CrCI
≤29ml/min/1.73m^2
Minerals
Calcium (Decrease)
corrected <7mg/dL 
(<1.75mmol/L); ionized <0.9 
mmol/L
Calcium (Increase)
corrected >13.5mg/dL 
(>3.1mmol/L); ionized 
>1.8mmol/L
Magnesium (Decrease)
<0.4mmol/L (<0.9mg/dL)
Magnesium (Increase)
>1.23mmol/L (>3mg/dL)
Phosphate
<0.6mmol/L (<2mg/dL)
Metabolic
Glucose (Decrease)
<2.2mmol/L (<40mg/dl)
REDACTED COPY 
Y
ubin
CO
ubin
OP
D C
atinin
CTE
atinin
TED
R
C
R
C
RE
R
arketing authorization application and any extensions or variations thereof.
ati
v
L)
ex
L)
sio
mm^3 
ny e
mm^3 
10^9/L
d any
10^9/L
ex
00/mm
and 
00/mm
(<1.0x1
on a
(<1.0x1
d a
>5.0
atio
>5.0
on
ca
>
a
>
ca
ca
ca
p
a
tio
e
h
e
iza
Creatin
eting
Creatin
kidn
rket
kidn
g 
This document cannot be used to support any mar
ar
ny
po
Miner
to s
Miner
s
se
be
nt
um
um
um
um


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 114 of 128
Category
Panel
Variable
Criteria (CTCAE aGrade 3 and 
above)
Glucose (Increase)
>250mmol/L (>13.9mg/dl)
Electrolytes
Potassium (Decrease)
<3.0mmol/L
Potassium (Increase)
>6.0mmol/L
Sodium (Decrease)
<130mmol/L
Sodium (Increase)
>155mmol/L
Lipids
Total cholesterol
>10.34mmol/L (>400mg/dL)
Triglycerides
>5.7mmol/L (>500mg/dL)
Proteins
Albumin
<20g/L (<2g/dL)
Other
Amylase
>2.0xULN
14.3
Amendment 3
14.3.1
Rationale for the amendment
Various updates were suggested prior to and during the Data Evaluation Meeting in December 
2018.
14.3.2
List of changes
Change #1
Front page
SAP amendment 3 has been added:
Final SAP
07 Oct 2016
SAP Amendment 1 14 Nov 2017
SAP Amendment 2
14 May 2018
SAP Amendment 3
24 Jan 2019
Change #2
List of Abbreviations
The following abbreviations have been added:-
IVIg
intravenous immunoglobulin
TPO-R
thrombopoietin-receptor
Change #3
Introduction (4th paragraph)
If a future protocol amendment necessitates a substantial change to the statistical analysis of the 
study data, this SAP amendment will be updated accordingly. In addition, if analysis definitions 
have to be modified or updated prior to database lock, a further SAP amendment will be 
REDACTED COPY 
e D
Y
e D
d to support any marketing authorization application and any extensions or variations thereof.
ititi
ati
ar
00mg/d
ns o
00mg/d
o
500mg/
nsio
500mg/
io
g/dL)
exte
g/dL)
ten
LN
an
LN
y e
d a
a Evalu
pplic
a Evalu
17
m
17
2018
ny 
2018
n 2019
rt a
n 2019
ons
to
ons
nt cannot be use
abbrev
sed
abbrev
TPO
ann
TPO-
n
-R
n
R
This documen
Chan
ment
Chan
In
m
In


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 115 of 128
required. If, after database lock, additional analyses are required to supplement the planned
analyses described in this SAP, these changes will be described in the CSR together with the 
associated rationale. The content of this SAP is compatible with the International Council for 
Harmonisation (ICH)/Food and Drug Administration (FDA) E9 Guidance documents.
Has been changed to:
If a future protocol amendment necessitates a substantial change to the statistical analysis of the 
study data, this SAP amendment will be updated accordingly. In addition, if analysis definitions 
have to be modified or updated prior to database lock, a further SAP amendment will be 
required.
This SAP amendment 3 is due to various updates and clarifications of the analysis definitions 
suggested prior to and during the Data Evaluation Meeting 3 part 1 in December 2018.
If, after database lock, additional analyses are required to supplement the planned analyses 
described in this SAP, these changes will be described in the CSR together with the associated 
rationale. The content of this SAP is compatible with the International Council for 
Harmonisation (ICH)/Food and Drug Administration (FDA) E9 Guidance documents.
Change #4
Table 3-1 (Definition of Baseline)
The following footnote has been removed:
Error! Reference source not found.
Platelets measured locally are not measured at 
Screening.
Change #5
Full Analysis Set (Section 3.5.3)
The following paragraph has been added:
Platelet data for subjects who have taken rescue medications (based on medical review and 
defined in Section 8.1.4) will only be utilized in the summary tables up to the start of these 
rescue medications.
Change #6
Per Protocol Set (Section 3.5.4)
The Per Protocol Set (PPS) is a subset of the FAS, consisting of those subjects who had received 
all foreseen sc infusions, had a platelet count measurement (measured by ACM Global Central 
Laboratory) during the Observation Period, and no important protocol deviations that may 
potentially affect the platelet count as confirmed during a pre-analysis review of the data prior to 
database lock. Protocol deviations may not necessarily lead to total exclusion of a subject from 
the PPS but may lead to exclusion of specific data and/or timepoints from the analysis.
Has been changed to:
The Per Protocol Set (PPS) is a subset of the FAS, consisting of those subjects who had received 
all foreseen sc infusions, had a platelet count measurement (measured by ACM Global Central 
Laboratory) during the Observation Period, and no important protocol deviations that may 
potentially affect the platelet count as confirmed during a pre-analysis review of the data prior to 
REDACTED COPY 
lets m
ED C
lets m
marketing authorization application and any extensions or variations thereof.
ns 
ri
ns 
efinitio
sions
efinitio
2018
ensi
2018.
s
.
nned an
ext
nned an
r with t
any 
r with t
Cou
nd a
Council
d a
ncil
dance d
and
dance d
measure
zatio
measure
dded:
arke
dded:
nt cannot be used to support any 
ve take
y m
ve take
only b
t any
only b
(Sectio
d to 
(Sectio
col Set
used
col Set
n sc infu
be u
n sc infu
ory) du
ot b
ory) du
ntially a
anno
ntially a
tabase 
t can
tabase 
This documen
the PP
ent 
the PP
H
m
H


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 116 of 128
database lock. Protocol deviations may not necessarily lead to total exclusion of a subject from 
the PPS but may lead to exclusion of specific data and/or timepoints from the analysis.
Platelet data for subjects who have taken prohibited medications potentially affecting platelet 
counts such as PLEX, dexamethasone or rituximab (based on medical review) will only be 
utilised in the summary tables up to the start of these medications.
Change #7
Dates and times (Section 4.2.7, final bullet on partial stop dates)

If the stop date is completely unknown, do not impute the stop date
Has been changed to:

If the stop date is completely unknown, do not impute the stop date, except for ITP 
medications where end date is missing and ongoing is ticked as ‘no’, which will be imputed 
as “Past” medications.
Change #8
Examination of Subgroups (Section 4.8)
The following subgroups will be defined within each dose arm:

Use of corticosteroid medication: Present/Absent

Responder at the end of previous ITP treatment: No/Yes/Unknown

Previous tintravenous immunoglobulin (IVIG)  therapy: Yes/No 

Number of previous ITP therapies: ≤2/>2
Only medication classified as either ‘prior and concomitant’ or ‘concomitant’ and medical 
procedure will be considered for ITP treatment. Responder categories will be defined taking into 
account the last reported ITP treatment value (either Yes or No) for each patient. If this value is 
unknown, the second-last reported ITP treatment value will be used, then the third-last, and so 
on, until a known response is provided. The Unknown responder category will only be 
considered in cases where the investigator has never reported a category (Yes or No) for any of 
the previous ITP treatments. Past use of corticosteroids (not ongoing after dosing) will not be 
considered for this classification. The list of applicable Anatomical Therapeutic Chemical (ATC) 
codes in order to identify the presence/absence of corticosteroids is provided in Section 13.1.
The descriptive summaries for platelets and total IgG will be presented for the subgroups above. 
Has been changed to:
The following subgroups will be defined within each dose arm:

Concomitant corticosteroid medication: Yes/No
Concomitant medication is defined in Section 6.4.4. The list of applicable Anatomical 
Therapeutic Chemical (ATC) codes to be utilized as corticosteroids is provided in
Section 13.1.

Responder at the end of past ITP therapy: No/Yes/Unknown
REDACTED COPY 
ent: N
D CO
ent: N
(IVIG)
CTE
(IVIG)
≤2/>2
EDAC
≤2/>2
prio
RE
prio
rt any marketing authorization application and any extensions or variations thereof.
or ITP
tens
or ITP
ch
e
ch will 
exte
will 
m:
li
m:
No/Yes/
ation
No/Yes/
G)  thera
oriza
G)  thera
or and c
ting 
or and c
treatme
rketi
treatme
ment va
mark
ment va
ed ITP
ny m
ed ITP
provid
t any
provid
be used to suppo
the inv
port 
the inv
ments.
uppo
ments. P
po
P
lassific
o sup
lassific
identify
d to
identify
ve sum
use
ve sum
This document cannot 
n chan
ot be
n chan
followi
anno
followi
Con
nt c
Con


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 117 of 128
Responder categories will be defined utilizing the value (either Yes or No) for the last 
reported ITP therapy for each patient. If this value is unknown, the second-last reported ITP 
therapy value will be used, then the third-last, and so on, until a known response is provided. 
The Unknown responder category will only be considered in cases where the investigator has 
never reported a category (Yes or No) for any of the past ITP therapies. For the ‘Response’ 
definition, the CRF entries will be utilized.
The past ITP therapy is defined as procedure history related to ITP or past medication related 
to ITP, where past medication is defined in Section 6.4.1. For ‘related to ITP’ CRF entries 
will be utilized.
The corticosteroid medication given more than 3 months prior to screening was routinely not 
recorded and cannot be considered. Thus, some patients with an unknown response might 
have had a known response.

Past intravenous immunoglobulin (IVIg) medication: Yes/No
Past medication is defined in Section 6.4.1. The ATC Therapeutic Subgroup code (Level 2) 
‘IMMUNE SERA AND IMMUNOGLOBULINS’ will be utilized.

Number of past ITP therapies: ≤2/>2
The past ITP therapy is defined as procedure history related to ITP or past medication related 
to ITP, where past medication is defined in Section 6.4.1. For ‘related to ITP’ CRF entries 
will be utilized.
The corticosteroid medication given more than 3 months prior to screening was routinely not 
recorded and cannot be considered. Thus, some patients might have had 1 more past ITP 
therapy than utilized for subgroup determination.
The descriptive summaries for platelets and total IgG will be presented for the subgroups above. 
Change #9
Past, prior and concomitant medications (Section 6.4)
Past, prior and concomitant medications will be summarized for the SS by dose arm and for all 
subjects by WHODD Anatomical Main Group [Level 1], Therapeutic Subgroup [Level 2] and 
PT. 
Separate tabulations will be presented for the following:

Past medications

Prior and concomitant medications

Concomitant medications
All medications will be listed and will include coding information, reported term, dose per intake 
and unit, frequency, formulation, route of administration, indication, category (past/prior and 
concomitant/concomitant) and start and end date (or ongoing, if applicable).
Has been changed to:
Past, prior, baseline and concomitant medications
DACTED COPY 
ry re
Y
ry re
ion
OPY
ion 6.
PY
6.
e than
TED
e than
hus, so
ACT
hus, so
RED
determ
EDA
determ
ets a
R
ets a
uthorization application and any extensions or variations thereof.
d 
a
d 
s
outinely
ons 
outinely
onse m
nsio
onse m
Subgrou
nd a
Subgrou
d.
a
d.
ated to 
pplic
ated to 
4.1
a
4.1. Fo
app
. Fo
n 3 mon
riza
n 3 mon
ome pa
thor
ome pa
not be used to support any marketing a
minatio
aut
minatio
and tot
eting
and tot
medicat
ny m
medicat
medic
ort a
medic
natomic
ppor
natomic
ons will
d to
ons will
cations
use
cations
and co
t be
and co
This document can
Concom
anno
Concom
All
nt
All med
nt c
med
and 
men
and 
co
m
co


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 118 of 128
Past, prior, baseline and concomitant medications will be summarized for the SS by dose arm 
and for all subjects by WHODD Anatomical Main Group [Level 1], Therapeutic Subgroup 
[Level 2] and PT.
All medications will be listed and will include coding information, reported term, dose per intake 
and unit, frequency, formulation, route of administration, indication, category (past/prior and 
concomitant/concomitant) and start and end date (or ongoing, if applicable).
Change #10
This section has been added:-
Baseline Medication (Section 6.4.3)
Baseline medications will include any medications that started prior to dosing and continued 
after (classified as prior and concomitant medications).
Change #11
Concomitant medication definition (Section 6.4.4)
Concomitant medications will include any medication that has been taken at least once (after the 
first administration of UCB7665) during the Dosing Period and/or the Observation Period.
Any medication that started prior to the first administration of UCB7665 and continued after 
dosing will be classified as prior and concomitant. Any medication that started after the first 
administration of UCB7665 will be classified as concomitant only.
Any medications with missing dates and/or times will be handled as described in Section 4.2.7 in 
order to classify them as prior and/or concomitant.
Has been changed to:
Concomitant medications will include any medication that has been taken at least once (after the 
first administration of UCB7665) during the Dosing Period and/or the Observation Period.
This includes medications that started prior to the dosing and continued after (classified as prior 
and concomitant medications) as well as any medication that started after the first administration 
of UCB7665 (classified as concomitant).
Any medications with missing dates and/or times will be handled as described in Section 4.2.7 in 
order to classify them as prior and/or concomitant.
Change #12
Platelets (Section 8.1)
All efficacy analyses are based on platelet count measured by ACM Global Central Laboratory. 
Measurements of platelet count obtained by the local laboratory will be listed and summarized as 
part of the safety laboratory data. These are not included in the analyses described in the sections 
below. All tabulations and mean figures will be presented for both the FAS and the PPS unless 
otherwise stated. Median figures and individual figures will be presented for the FAS only. In 
case rescue medications are taken, only the platelet data up to the start date of rescue medication  
will be utilized for the summary tables. Listings will contain all the data but a footnote will be 
included indicating the patients for which some data has been excluded from the summary tables.
REDACTED COPY
ation
PY 
ation
Any m
COPY
Any m
conco
D CO
conco
times 
CTED
times 
comit
DACT
comit
o support any marketing authorization application and any extensions or variations thereof.
contin
ensio
contin
n taken
on a
n taken
/or the 
catio
/or the 
of UCB
pplic
of UCB
medicat
n ap
medicat
omitan
tion
omitan
will be
oriza
will be
tant.
utho
tant.
any m
ketin
any m
uring th
mark
uring th
started 
ny m
started 
s) as w
rt an
s) as w
s conco
port
s conco
h missi
sup
h missi
This document cannot be used t
hem as 
d to s
hem as 
(Sectio
t be 
(Sectio
fficacy 
nno
fficacy 
easurem
t can
easurem
part of
ent c
part of
belo
me
belo


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 119 of 128
In case of partial dates, the imputation rules for partial dates described in Section 4.2.7 will be 
applied.
Has been changed to:
All efficacy analyses are based on platelet count measured by ACM Global Central Laboratory. 
Measurements of platelet count obtained by the local laboratory will be listed and summarized as 
part of the safety laboratory data. These are not included in the analyses described in the sections 
below. All tabulations and mean figures will be presented for both the FAS and the PPS unless 
otherwise stated. Median figures and individual figures will be presented for the FAS only. In 
case rescue medications are taken, only the platelet data up to the start date of rescue medication 
will be utilized for the summary tables (refer to Section 8.1.4). In case prohibited medications 
affecting platelets are taken, only the platelet data up to the start date of prohibited medication 
will be utilized for the summary tables for the PPS (refer to Section 3.4). Listings will contain all 
the data but a footnote will be included indicating the patients for which some data has been 
excluded from the summary tables. In case of partial dates, the imputation rules for partial dates 
described in Section 4.2.7 will be applied.
Change #13
Definition of Variables (Section 8.1.1)
The main efficacy variable is defined as the following: 

Maximum Increase from Baseline: the Maximum Increase from Baseline (Day 1, predose) is 
defined as the highest positive change from Baseline during the study. In the event that the 
platelet count was to decrease during the study the Maximum Increase from Baseline may be 
negative and would correspond to the smallest decrease from the Baseline value
The following additional variables will be defined for the platelet count, the calculation rules for 
which are provided in the section immediately below:

Response: a Response is defined as a platelet count ≥30x109/L and at least 2-fold increase 
from the Baseline value, by visit, and at any timepoint during the study

Time to Response: the time to Response is defined as the time from starting treatment 
(Day 1) to achievement of Response

Duration of Response: the duration of Response is defined as the time between achievement 
of a Response to the first time a loss of Response occurred (defined as platelet count <30 x 
109/L or less than 2-fold increase from Baseline)

Complete Response: a Complete Response is defined as a platelet count ≥100x109/L, by 
visit, and at any timepoint during the study

Time to Complete Response: the time to Complete Response is defined as the time from 
starting treatment (Day 1) to achievement of Complete Response

Duration of Complete Response: the duration of Complete Response is defined as the time 
between achievement of a Complete Response to the first time a loss of Complete Response 
occurred (defined as platelet count <100x109/L)

Platelet Count ≥50x109/L, by visit, and at any timepoint during the study
REDACTED COPY 
g:
P
g:
mum I
D CO
mum I
m Base
ED C
m Base
he stud
CTE
he stud
e sma
DAC
e sma
ill be
RE
ill be
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
In
v
In
dication
or v
dication
dication
ons 
dication
medica
nsio
medica
gs will 
xten
gs will 
e data h
y ext
e data h
rules f
any 
rules f
Increas
tion 
Increas
eline d
izatio
eline d
dy the 
horiz
dy the M
allest de
autho
allest de
e define
ing a
e define
e
k
ediatel
ketin
diatel
ed as a
mar
ed as a
visit, a
ny m
visit, a
time to
ort a
time to
ment of R
ppo
ment of R
ponse: 
to su
ponse: 
e to the
ed to
e to the
ss than
used
ss than
plete Re
t be 
plete Re
it, and 
not 
it, and 
Time
t can
Time
sta
nt 
sta

m



UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 120 of 128

Time to Platelet Count ≥50x109/L: the time to Platelet Count ≥50x109/L is defined as the 
time from starting treatment (Day 1) to achievement of Platelet Count ≥50x109/L

Duration of Platelet Count ≥50x109/L: the duration of a Platelet Count ≥50x109/L is defined 
as the time between achievement of a Platelet Count ≥50x109/L to the first time the platelet 
count is <50x109/L

Maximum: the maximum value for platelet count over all visits in the study

Value and change from Baseline in platelet count over time

Baseline-corrected AUEC for platelet count calculated from Baseline to the end of study visit 
for each of the defined dose arms.
For all the above response variables the following rules will apply:

The time to response (including Complete Response, Response and Platelet Count 
≥50x109/L) is defined as the first time that a given response is achieved during the study. 
Thus, in the event that the platelet count was to increase above the threshold level, decrease 
below the threshold level, and subsequently increase again the time to response would be to 
the first time the definition of response was achieved. The time to response will be calculated 
in days and presented to 1 decimal place in the listings.
Time to response (days) = Date/time of first response – Date/time of first dose of UCB7665

The duration of response (including Complete Response, Response and Platelet Count 
≥50x109/L) will be defined as the duration of the first time the response was achieved to loss 
of first response. The duration of response will be calculated in days and presented to 1 
decimal place in the listings.
Duration of response (days) = Date/time of loss of first response – Date/time of first response
If the platelet value meets the criterion for a specific response for a second time (following a 
loss of initial response), the second response period will be added to the overall duration of 
response. This rule will be applied for any subsequent ‘response periods’. For subject in 
whom the response is maintained until the end of the study the duration of response will be 
calculated using the date of the end of study visit as the ‘end of response date’. Any such 
cases will be flagged in the data listings

Both scheduled and unscheduled measurements may be included in the calculation of a 
response, time to response or duration of response

The Baseline-corrected AUEC will be calculated according to the following rules:

The AUEC will be calculated according to the linear trapezoidal rule using protocol 
scheduled visits

Unscheduled visits will not be included in the calculation

No imputation of any missing data will be performed

To account for differences in the timing of Baseline samples for each subject the Baseline 
measurement will be considered as time zero in the calculation

The units of the AUEC will be 109/L*day
REDACTED COPY 
onse
OPY
onse
te Resp
D CO
te Resp
n of th
TED 
n of th
nse w
ACTE
nse w
te/tim
RE
te/tim
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
tudy vi
s or 
tudy vi
let Cou
y ext
let Cou
d durin
any 
d durin
hresho
nd a
hresho
me to r
n an
me to r
me to re
tion 
me to re
Date/
app
Date/
sponse,
tion 
sponse,
he first 
izat
he first 
will be c
horiz
will be c
me of l
ting 
me of l
terion f
arket
terion f
cond re
mar
cond re
applied
ny m
applied
aintain
rt an
aintain
date of t
port
date of t
ed in th
supp
ed in th
d and u
d to 
d and u
me to r
sed 
me to r
seline
be u
seline
The A
nnot 
The A
sch
ann
sch

n



UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 121 of 128

The measurements at Baseline and at the last visit must be available

A minimum of 10 out of 14 measurements must be available for the calculation in Dose 
Arm 1; a minimum of 9 out of 12 measurements must be available for the calculation in 
Dose Arm 2; a minimum of 8 out of 11 must be available for the calculation in Dose Arm 
3; a minimum of 7 out of 9 must be available for the calculation in Dose Arms 4 and 5. 
These include the Baseline and measurement at the last visit

The AUEC will not be calculated in the case of early withdrawal from the study
Has been changed to:
The main efficacy variable is defined as the following: 

Maximum Increase from Baseline: the Maximum Increase from Baseline (Day 1, predose) is 
defined as the highest positive change from Baseline during the study. In the event that the 
platelet count was to decrease during the study the Maximum Increase from Baseline may be 
negative and would correspond to the smallest decrease from the Baseline value
The following additional variables will be defined for the platelet count, the calculation rules for 
which are provided in the section immediately below:

Response: a platelet count ≥30x109/L and at least 2-fold increase from the Baseline value, by 
visit, and at any timepoint during the study

Time to Response: the first time that a given response is achieved during the study. Thus, in 
the event that the platelet count was to increase above the threshold level, decrease below the 
threshold level, and subsequently increase again the time to response would be to the first 
time the definition of response was achieved. The time to response will be calculated in days 
and presented to 1 decimal place in the listings.
Time to response (days) = Date/time of first response – Date/time of first dose of UCB7665

‘No’ or ‘Loss of’ Response: a platelet count <30x109/L OR >=30x109/L WITHOUT at least 
a 2-fold increase from the Baseline value, by visit

Duration of Response (including Complete Response, Response and Platelet Count 
≥50x109/L): the duration of the first time the response was achieved to first loss of response. 
The duration of response will be calculated in days and presented to 1 decimal place in the 
listings.
Duration of response (days) = Date/time of loss of first response – Date/time of first 
response, where “loss of first response” is defined as platelet count<30x109/L OR (platelet 
count ≥30x109/L WITHOUT at least a 2-fold increase from the Baseline value)
If the platelet value meets the criterion for a specific response for a second time (following a 
loss of initial response), the second response period will be added to the overall duration of 
response. This rule will be applied for any subsequent ‘response periods’. For subject in 
whom the response is maintained until the end of the study the duration of response will be 
calculated using the date of the end of study visit as the ‘end of response date’. Any such 
cases will be flagged in the data listings
REDACTED COPY 
Y
respon
D CO
respon
rease 
TED 
rease 
ase ag
ACTE
ase ag
achiev
DAC
achiev
in the 
RED
in the 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
y 1, pre
ensi
y 1, pre
he even
exte
he even
from Ba
ny e
from Ba
eline v
d any
eline v
unt, the
n and
unt, the
ncrease
plica
ncrease
nse is a
tion 
nse is a
above 
izati
above 
gain the
horiz
gain the
ved. Th
auth
ved. Th
e listing
ng au
e listing
me of fi
ketin
me of fi
platele
mar
platele
Baselin
ny m
Baselin
(includi
ort a
(includi
ation o
uppo
ation o
espons
o sup
espons
of respo
use
of respo
se, whe
be u
se, whe
nt ≥30x
ot b
nt ≥30x
If the p
cann
If the p
loss
nt ca
loss
r
n
r


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 122 of 128

Complete Response: a platelet count ≥100x109/L, by visit, and at any timepoint during the 
study

‘No’ or ‘Loss of’ Complete Response: a platelet count <100x109/L, by visit.

Time to Complete Response: the time from starting treatment (Day 1) to achievement of 
Complete Response

Platelet Count ≥50x109/L, by visit, and at any timepoint during the study

‘No’ or ‘Loss of’ Platelet Count ≥50x109/L: a platelet count <50x109/L, by visit.

Time to Platelet Count ≥50x109/L: the time to Platelet Count ≥50x109/L is defined as the 
time from starting treatment (Day 1) to achievement of Platelet Count ≥50x109/L

Maximum: the maximum value for platelet count over all visits in the study

Value and change from Baseline in platelet count over time

Baseline-corrected AUEC for platelet count calculated from Baseline to the end of study visit 
for each of the defined dose arms.
For all the above response variables the following rules will apply:

Both scheduled and unscheduled measurements may be included in the calculation of a 
response, time to response or duration of response

The Baseline-corrected AUEC will be calculated according to the following rules:

The AUEC will be calculated according to the linear trapezoidal rule using protocol 
scheduled visits

Unscheduled visits will not be included in the calculation

No imputation of any missing data will be performed

To account for differences in the timing of Baseline samples for each subject the Baseline 
measurement will be considered as time zero in the calculation

The units of the AUEC will be 109/L*day

The measurements at Baseline and at the last visit must be available

A minimum of 10 out of 14 measurements must be available for the calculation in Dose 
Arm 1; a minimum of 9 out of 12 measurements must be available for the calculation in 
Dose Arm 2; a minimum of 8 out of 11 must be available for the calculation in Dose Arm 
3; a minimum of 7 out of 9 must be available for the calculation in Dose Arms 4 and 5. 
These include the Baseline and measurement at the last visit

The AUEC will not be calculated in the case of early withdrawal from the study
Change #14
Analysis of Time to Response (Section 8.1.3.2)
REDACTED COPY
ay b
PY 
ay b
nse
OP
nse
ulated 
ED C
ulated 
rding t
ACTE
rding t
e inc
RE
e inc
to support any marketing authorization application and any extensions or variations thereof.
as the
s o
as the
L
ne to th
nd a
ne to th
ly:
ati
ly:
include
pplic
include
d accord
atio
d accord
to the l
horiz
to the l
luded 
ing 
luded 
g data w
arke
g data w
es in th
y m
es in th
onside
any
onside
UEC w
port
UEC w
ments a
sup
ments a
This document cannot be used
um of 
ed to
um of 
; a min
use
; a min
se Arm
be u
se Arm
3; a mi
ot b
3; a mi
Thes
anno
Thes

nt

Ch
me
Ch


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 123 of 128
The time to first response will be analyzed with the log-rank test and displayed using Kaplan-
Meier curves. Each response parameter will be considered in a separate analysis. The following 
parameters will be included in the analysis:

Time to Response: the time to Response is defined as the time from starting treatment 
(Day 1) to achievement of Response (platelet count ≥30x109/L and at least 2-fold increase 
from the Baseline value)

Time to Complete Response: the time to Complete Response is defined as the time from 
starting treatment (Day 1) to achievement of Complete Response (platelet count ≥100x109/L)

Time to Platelet Count ≥50x109/L
Kaplan-Meier curves will be presented for all three response parameters. Descriptive statistics 
will include the p-value for the log-rank test for the equality over dose arms. The point estimate 
for the median number of days to response with 90% CIs will be given if estimable. Further a 
summary including the number and percent of censored subjects, the number of responders and 
total subjects by dose arm and in total will be given.
For the purpose of the analysis subjects with no response will be censored at the end of the study 
or at the date of withdrawal.
Analyses will be performed for the FAS and repeated for the PPS.
Has been changed to:
The time to first response will be analyzed with the log-rank test and displayed using Kaplan-
Meier curves.
Kaplan-Meier curves will be presented for the variables Time to Response, Time to Complete 
Response, and Time to Platelet Count ≥50x109/L. Descriptive statistics will include the p-value 
for the log-rank test for the equality over dose arms. The point estimate for the median number of 
days to response with 90% CIs will be given if estimable. Further a summary including the 
number and percent of censored subjects, the number of responders and total subjects by dose 
arm and in total will be given.
For the purpose of the analysis subjects with no response will be censored at the end of the study 
or at the date of withdrawal.
Analyses will be performed for the FAS and repeated for the PPS.
Change #15
Analysis of responder rate (Section 8.1.3.3, 3rd paragraph)
Analyses will be performed for the FAS and repeated for the PPS. Summary tabulations by dose 
arm will be repeated for the subgroups defined in Section 4.8 (based on the FAS only).
Moreover, for responder rate, summary tabulations by dose arm will be repeated according to 
previous intravenous immunoglobulin therapy (Yes/No) and the number of previous medications 
(≤2/>2). Percentage of days without bleeding will also be described by dose arm for each type of 
response (response, complete response and platelet Count >=50x10/L). Percentage of days 
without bleeding is calculated using the following formula:
REDACTED COPY
for t
PY 
for t
th the 
ED C
th the 
for
EDA
for th
DA
th
t ≥50
RE
t ≥50
R
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
10
r v
109
v
9/L)
var
/L)
ve stati
nsio
ve stati
e point
xten
e point
mable.
y ext
mable.
ber of 
any 
ber of 
ensor
on a
ensored
a
ed
e PPS.
pplic
e PPS.
log
izat
log-
at
-ran
tio
ran
e
a
e varia
auth
varia
0x10
ing a
0x109
g a
9/L
a
/L
ver dose
ketin
ver dose
be give
arke
be give
subject
y ma
subject
alysis s
port 
alysis s
awal.
upp
awal.
erform
d to s
erform
of resp
t be 
of resp
ses wil
nnot
ses wil
m will b
can
m will b
Moreov
ent c
Moreov
prev
men
prev
(≤
m
(≤


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 124 of 128
((N of visits with a SMOG score – N of these visits where bleeding occurred) / N of visits with a 
SMOG score) x 100
Has been changed to:
Analyses will be performed for the FAS and repeated for the PPS. Summary tabulations by dose 
arm will be repeated for the subgroups defined in Section 4.8 (based on the FAS only).
Percentage of days without bleeding will also be described by dose arm for each type of response 
(response, complete response and platelet Count >=50x10/L). Percentage of days without 
bleeding is calculated using the following formula:
((N of visits with a SMOG score – N of these visits where bleeding occurred) / N of visits with a 
SMOG score) x 100
Change #16
The following section has been added:
Rescue medication definition (after medical inspection) (Section 8.1.4)
In the rescue medication section of the protocol, rescue medication is defined as platelet 
substitution or treatment with a commercially available IVIg. In addition, the prohibited 
medications PLEX, dexamethasone and rituximab will also be considered as a rescue medication 
for analysis.
Change #17
ITP bleeding score and platelet response (Section 8.2.1.1)
In addition to the platelet response variables defined in Section 8.1.1 the following variables will 
also be defined based on a combination of platelet response and information from the ITP 
bleeding score (these will be referred to as Clinical Response variables). In case rescue 
medications or prohibited medications potentially affecting platelet counts are taken, only the 
platelet data up to the start date of rescue medication will be utilized for the summary tables
(refer to Section 8.1.4):

Clinical Response: a Clinical Response is defined as a platelet count ≥30x109/L and 
<100x109/L with at least 2-fold increase from the Baseline value AND absence of bleeding, 
by visit, and at any timepoint during the study

Time to Clinical Response: the time to Clinical Response is defined as the time from starting 
treatment (Day 1) to achievement of Clinical Response

Duration of Clinical Response: the duration of Clinical Response is defined as the time 
between achievement of a Clinical Response to the first time a loss of Clinical Response 
occurred (defined as platelet count <30x109/L or less than 2-fold increase from Baseline OR 
presence of bleeding)

Complete Clinical Response: a Complete Clinical Response is defined as a platelet count 
≥100x109/L AND absence of bleeding, by visit, and at any timepoint during the study

Time to Complete Clinical Response: the time to Complete Clinical Response is defined as 
the time from starting treatment (Day 1) to achievement of Complete Clinical Response
REDACTED COPY 
Sectio
TED
Sectio
les de
DACT
les de
n of p
REDA
n of p
to a
RE
to a
pport any marketing authorization application and any extensions or variations thereof.
its with
s or
its with
.4)
d
.4)
is defin
n an
is defin
additio
ation
additio
consid
icat
consid
on 8.2.1
rizat
on 8.2.1
efined i
utho
efined i
platelet 
g aut
platelet 
as Clin
ting 
as Clin
s poten
rketi
s poten
rescue 
mark
rescue 
inical R
rt a
inical R
east 2
por
east 2
t be used to su
f
y timep
supp
y timep
cal Res
d to 
cal Res
Day
used
Day 1)
d
1)
o
b
on of C
be u
n of C
This document canno
ween ac
not b
ween ac
occurre
ann
occurre
prese
nt ca
prese

me



UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 125 of 128

Duration of Complete Clinical Response: the duration of Complete Clinical Response is 
defined as the time between achievement of a Complete Clinical Response to the first time a 
loss of Complete Clinical Response occurred (defined as platelet count <100x109/L OR 
presence of bleeding)

No Clinical Response: a platelet count <30x109/L and less than 2-fold increase from Baseline 
OR presence of bleeding, by visit, and at any timepoint during the study
For all the above response criteria, the calculation rules included in Section 8.1.1 will apply. In 
addition the following will be applicable:

The clinical response variables will be assessed only for visits for which both platelet counts 
and the ITP bleeding score are assessed (with the exception of the confirmatory platelet 
assessments which may be obtained at any visit [scheduled or unscheduled] provided that 
they meet the criteria below)

In order to define a clinical response, the platelet count must be confirmed on 2 separate 
occasions at least 7 days apart (i.e., the second assessment should be ≥168 hours after the 
first assessment). The time to response will be taken as the time to the first platelet 
assessment (obtained at the same time as the corresponding ITP bleeding score assessment). 
If the second assessment does not fulfill the required criteria for a clinical response, the 
subject will be considered as a nonresponder at the respective visits

In order to define no response or a loss of response, the platelet count must be confirmed on 
2 separate occasions within 1 to 7 days* (i.e., the second assessment should be ≥24 hours and 
≤168 hours after the first assessment). The loss of response will be taken as the point at 
which the first platelet assessment was obtained (obtained at the same time as the 
corresponding ITP bleeding score assessment). If the second assessment does not fulfill the 
required criterion for no response or loss of response, the subject will be considered as a 
responder at the respective visits

Absence of bleeding is indicated by Grade 0 for all domains of the SMOG

Presence of bleeding is indicated by a Grade of 1 or above, for at least one domain of the 
SMOG
*This differs from the published definition (Rodeghiero et al, 2009) which requires 2 platelet 
measurements 1 day apart to define no response or loss of response. In the current protocol 
platelet count assessments are not as frequently planned (unless unscheduled measurements are 
performed), thus it was deemed appropriate to modify the definition above to take into account 
the schedule of assessments in this study. 
As a result the following clinical response variables are not in complete accordance with the 
guideline:

Duration of Clinical Response

Duration of Complete Clinical Response

No Clinical Response
All response variables described above will be listed by dose arm and subject and summarized 
by dose arm and visit where appropriate. The responder rates will be tabulated as described in 
REDACTED COPY
e res
PY 
e res
ponse, 
COP
ponse, 
e., the
ED C
e., the
he los
CTE
he los
as obta
DACT
as obta
assess
REDA
assess
 or l
RE
 or l
annot be used to support any marketing authorization application and any extensions or variations thereof.
n 
a
n 
let coun
ns o
let coun
platelet
sion
platelet
rovide
tens
rovide
med on
any 
med on
e ≥168
nd a
e ≥168
to the f
n an
to the f
TP blee
tion
TP blee
ia for a
licat
ia for a
ective v
pplic
ective v
, the pla
ion a
, the pla
e secon
zatio
e secon
ss of re
oriza
ss of re
ained (
utho
ained (
sment)
g au
sment)
loss of
ting 
loss of
ted by 
y ma
ted by 
ndicated
t any
ndicated
 publis
supp
 publis
ay apart
to s
ay apart
sessme
ed t
sessme
hus it w
use
hus it w
ule of a
t be 
ule of a
esult th
nnot
esult th
This document c
deline:
can
deline:

e

D
nt
D



UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 126 of 128
Section 8.1.3.3. Moreover the change in category of bleeding from Baseline will also be 
presented in shift table at all post-Baseline visits by dose arm. Summary tabulations for Clinical 
Response by dose arm will be repeated according to past intravenous immunoglobulin 
medication (Yes/No) and the number of past ITP therapies (≤2/>2). All analyses described in this 
section will be performed for the FAS.
In case rescue medications are taken, only the data up to the start date of rescue medication  will 
be utilized for the summary tables. Listings will contain all the data but a footnote will be 
included indicating the patients for which some data has been excluded from the summary tables.
In case of partial dates, the imputation rules for partial dates described in Section 4.2.7 will be 
applied.
Has been changed to:
In addition to the platelet response variables defined in Section 8.1.1 the following variables will 
also be defined based on a combination of platelet response and information from the ITP 
bleeding score (these will be referred to as Clinical Response variables). In case rescue 
medications are taken, only the platelet data up to the start date of rescue medication will be 
utilized for the summary tables (refer to Section 8.1.4):

Clinical Response: a Clinical Response is defined as a platelet count ≥30x109/L with at least 
2-fold increase from the Baseline value AND absence of bleeding, by visit. This must be 
confirmed by a second measurement at least 5 days later (to allow for the ±2-day visit 
window), showing a platelet count ≥30x109/L and at least 2-fold increase from the Baseline.

Time to Clinical Response is defined as the time from starting treatment (Day 1) to 
achievement of Clinical Response. The will be taken as the time to the first platelet 
assessment (obtained at the same time as the corresponding ITP bleeding score assessment). 
If the second assessment does not fulfill the required criteria for a clinical response, the 
subject will be considered as a nonresponder at the respective visits.

Duration of Clinical Response: the duration of Clinical Response is defined as the time 
between achievement of a Clinical Response to the first time a loss of Clinical Response 
occurred (defined as platelet count <30x109/L or less than 2-fold increase from Baseline OR 
presence of bleeding). Refer to Section 8.1.1 in case a subject has several clinical responses 
or the clinical response is maintained until the end of the study".

Complete Clinical Response: a Complete Clinical Response is defined as a platelet count 
≥100x109/L AND absence of bleeding, by visit. This must be confirmed by a second 
measurement at least 5 days later (to allow for the ±2-day visit window), showing a platelet 
count ≥100x109/L.

Time to Complete Clinical Response: the time to Complete Clinical Response is defined as 
the time from starting treatment (Day 1) to achievement of Complete Clinical Response

Duration of Complete Clinical Response: the duration of Complete Clinical Response is 
defined as the time between achievement of a Complete Clinical Response to the first time a 
loss of Complete Clinical Response occurred (defined as platelet count <100x109/L OR 
presence of bleeding). Refer to Section 8.1.1 in case a subject has several clinical responses 
or the clinical response is maintained until the end of the study". 
REDACTED COPY
nce 
PY 
nce 
days l
OPY
days la
Y
a
L and
D CO
L and
the tim
CTED
the tim
he will
DACT
he will
ime as
REDA
ime as
t fulf
RE
t fulf
ort any marketing authorization application and any extensions or variations thereof.
bles.
varia
bles.
l be
or v
l be
wing va
exte
wing va
n from t
ny e
n from t
In case
d any
In case
cue med
and 
cue med
elet cou
icati
elet cou
f bleed
pplic
f bleed
ater
a
ater (to
app
(to
at leas
tion 
at leas
me from
oriza
me from
l b
uth
l be tak
tho
e tak
s the co
aut
s the co
fill the 
ting 
fill the 
nrespon
keti
nrespon
e: the d
ma
e: the d
Clinica
any m
Clinica
telet co
rt an
telet co
ppo
).
not be used to su
Refer
por
Refer
ponse is
supp
ponse is
nical R
d to 
nical R
L AND
sed
L AND
ement a
be us
ement a
≥
t b
≥10
t be
10
This document can
0x
be
0x
Time to
anno
Time to
the ti
nt ca
the ti

me

D
n
D


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 127 of 128

No Clinical Response or a loss of clinical response: the platelet count must be defined as a 
platelet count <30x109/L OR >=30x109/L WITHOUT at least a 2-fold increase from the 
Baseline value OR presence of bleeding, by visit. This must be confirmed by a second 
measurement 1 to 9 days* later, showing a platelet count <30x109/L OR >=30x109/L 
WITHOUT at least a 2-fold increase from the Baseline value.
For all the above response criteria, the calculation rules included in Section 8.1.1 will apply. In 
addition the following will be applicable:

The Clinical Response variables will be assessed only for visits for which both platelet 
counts and the ITP bleeding score are assessed. The last visit cannot be a clinical response as 
no confirmation after that is available.

Absence of bleeding is indicated by Grade 0 for all domains of the SMOG, or a Skin Grade 
of 0 or 1

Presence of bleeding is indicated by a Mucosae or Organs Grade of ≥1, or Skin Grade of ≥2
*This differs from the published definition (Rodeghiero et al, 2009) which requires 2 platelet 
measurements 1 day apart to define no response or loss of response. In the current protocol 
platelet count assessments are not as frequently planned (unless unscheduled measurements are 
performed), thus it was deemed appropriate to modify the definition above to take into account 
the schedule of assessments in this study. 
As a result the following clinical response variables are not in complete accordance with the 
guideline:

Duration of Clinical Response

Duration of Complete Clinical Response

No Clinical Response
All response variables described above will be listed by dose arm and subject and summarized 
by dose arm and visit where appropriate. The responder rates will be tabulated as described in 
Section 8.1.3.3. Moreover the change in category of bleeding from Baseline will also be 
presented in shift table at all post-Baseline visits by dose arm. Summary tabulations for Clinical 
Response by dose arm will be repeated according to past intravenous immunoglobulin 
medication (Yes/No) and the number of past medications (≤2/>2). All analyses described in this 
section will be performed for the FAS.
In case rescue medications are taken, only the data up to (not including) the start date of rescue 
medication will be utilized for the summary tables. Listings will contain all the data but a 
footnote will be included indicating the patients for which some data has been excluded from the 
summary tables. In case of partial dates, the imputation rules for partial dates described in 
Section 4.2.7 will be applied.
Change #18
Table 10-1 (Clinical laboratory measurements)
HbA1c has been moved from the Hematology category to the “Other” category.
REDACTED COPY 
he
Y
he
bles ar
D CO
bles ar
espons
RED
espons
be used to support any marketing authorization application and any extensions or variations thereof.
ponse a
s or 
ponse a
r a Skin
tens
r a Skin
1, or Sk
any 
1, or Sk
which re
and 
which re
e. In the
on a
e. In the
unsc
atio
unsche
o
he
finition
plica
finition
re not in
tion 
re not in
se
ng
se
above w
mar
above w
propria
ny m
propria
he chan
rt an
he chan
all pos
port
all pos
 will b
supp
 will b
o) and t
to s
o) and t
erform
ed to
erform
ue med
e us
ue med
nnot 
on will 
t be
on will 
te will 
not
te will 
This document ca
mmary t
cann
mmary t
Section
nt c
Section
Ch
me
Ch


UCB
07 Nov 20168
Statistical Analysis Plan
UCB7665
TP0001
Confidential
Page 128 of 128
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE
This document has been reviewed and approved per the Review and Approval of Clinical 
Documents Standard Operating Procedures. Signatures indicate that the final version of the SAP 
or amended SAP is released for execution.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.


Approval Signatures
Name:
tp0001-sap-amend-3
Version:
2. 0
Document Number:
CLIN-000130088
Title:
TP0001 Statistical Analysis Plan Amendment 3
Approved Date:
29 Jan 2019
Document Approvals
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 29-Jan-2019 08:30:39 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 29-Jan-2019 08:48:01 GMT+0000
OPY
Appro
OPY 
Appro
ACTED COP
OP
D C
Na
CO
Na
REDAC
AC
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
pli
ovals
appl
ovals
thorization ap
ap
ho
ame:
tion
ame:
Capac
izati
Capac
Dat
riz
Dat
rketing auth
th
rk
h
n